<SEC-DOCUMENT>0001104659-14-061061.txt : 20140814
<SEC-HEADER>0001104659-14-061061.hdr.sgml : 20140814
<ACCEPTANCE-DATETIME>20140814161524
ACCESSION NUMBER:		0001104659-14-061061
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20140630
FILED AS OF DATE:		20140814
DATE AS OF CHANGE:		20140814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGILE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001261249
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36464
		FILM NUMBER:		141042951

	BUSINESS ADDRESS:	
		STREET 1:		101 POOR FARM ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540-1715
		BUSINESS PHONE:		609-683-1880

	MAIL ADDRESS:	
		STREET 1:		101 POOR FARM ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540-1715
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a14-17045_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font></b><b>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .55in;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .55in;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number 001-36464</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">23-2936302</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of incorporation or organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">101 Poor Farm Road</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Princeton, New Jersey 08540</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address including zip code of principal executive offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(609) 683-1880</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; </font><font size="2" style="font-size:10.0pt;">Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160; See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller reporting company </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Do not check if smaller reporting company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by checkmark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were 18,592,968 shares of the registrant&#146;s common stock, $0.0001 par value, outstanding as of August&nbsp;13, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\14-17045-1\task6922459\17045-1-ba.htm',USER='108224',CD='Aug  9 07:36 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics, Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Quarterly Report On Form&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For The Quarter Ended June 30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Table of Contents</font></b><a name="TableOfContents"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PartiFinancialInformation_073951">PART&nbsp;I: FINANCIAL   INFORMATION</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_073953">Item 1. Financial   Statements</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_082921">Item 2.   Management&#146;s Discussion and Analysis of Financial Condition and Results of   Operations</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_083501">Item 3.   Quantitative and Qualitative Disclosures About Market Risk</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures__083503">Item 4. Controls   and Procedures</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PartiiOtherInformation_083605">PART&nbsp;II: OTHER   INFORMATION</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings__083608">Item 1. Legal Proceedings</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors__083610">Item 1A. Risk Factors</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_084652">Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.02%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits__084704">Item 6. Exhibits</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i<a name="PB_i_073713_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='i',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-bg.htm',USER='108698',CD='Aug 13 22:54 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This quarterly report on Form&nbsp;10-Q includes statements that are, or may be deemed, &#147;forward-looking statements.&#148; In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms &#147;believes,&#148; &#147;estimates,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;could,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;approximately&#148; or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form&nbsp;10-Q and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned development of Twirla and our other product candidates, the strength and breadth of our intellectual property, our ongoing and planned clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our development and validation of manufacturing capabilities, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form&nbsp;10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Form&nbsp;10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Form&nbsp;10-Q, they may not be predictive of results or developments in future periods.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the success and timing of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our inability to timely obtain from our third party manufacturer, Corium, sufficient quantities or quality of our product candidates or other materials required for a clinical trial;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability along with Corium to complete successfully the qualification and validation of equipment related to the expansion of Corium&#146;s manufacturing facility;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain and maintain regulatory approval of our product candidates, and the labeling under any approval we may obtain;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our plans to develop and commercialize our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-16.5pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\14-17045-1\task6922459\17045-1-bi.htm',USER='108224',CD='Aug  9 08:54 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory developments in the United States and foreign countries;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the rate and degree of market acceptance of any of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our available cash;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain additional funding;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain and maintain intellectual property protection for our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the successful development of our sales and marketing capabilities;</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the performance of third-party manufacturers; and</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to successfully implement our strategy.</font></p>
<p style="margin:0in 0in .0001pt 84.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any forward-looking statements that we make in this Form&nbsp;10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form&nbsp;10-Q. You should also read carefully the factors described in the &#147;Risk Factors&#148; section of this Form&nbsp;10-Q to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Form&nbsp;10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Form&nbsp;10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third party research, surveys and studies are reliable, we have not independently verified such data.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\14-17045-1\task6922459\17045-1-bi.htm',USER='108224',CD='Aug  9 08:54 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Part&nbsp;I &#151; Financial Information</font></b><a name="PartiFinancialInformation_073951"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160; Financial Statements</font></b><a name="Item1_FinancialStatements_073953"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Balance Sheets</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">June&nbsp;30,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,119,646</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53,494,022</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">146,704</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">661,218</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,266,350</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54,155,240</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Property and equipment, net of accumulated   depreciation of $273,092 in 2013 and $278,135 in 2014 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,963,079</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,964,777</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred financing costs, net </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">157,499</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">132,985</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,208</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,208</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,405,136</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66,271,210</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities, convertible   preferred stock and stockholders&#146; (deficit) equity</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">715,454</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,325,664</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">379,164</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">373,270</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loan payable, current portion </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,105,407</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,151,653</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant liability </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">644,478</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">452,157</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current liabilities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,844,503</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,302,744</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loan payable, long-term </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,769,528</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,619,816</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitment and contingencies</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A-1, 8%, non-cumulative convertible   preferred stock, $.0001 par value, authorized 284,743 shares; issued and   outstanding 137,787 shares at December&nbsp;31, 2013 and 0 shares at   June&nbsp;30, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">898,305</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A-2 convertible preferred stock,   $.0001 par value, authorized 99,178 shares; issued and outstanding 66,116   shares at December&nbsp;31, 2013 and 0 shares at June&nbsp;30, 2014 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">543,623</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;B, 8% non-cumulative, convertible   preferred stock, $.0001 par value, authorized&nbsp;4,510,066 shares; issued   and outstanding 4,510,066 shares at December&nbsp;31, 2013 and 0 shares at   June&nbsp;30, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44,928,382</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;C, 12% non-cumulative, convertible   preferred stock, $.0001 par value, authorized&nbsp;2,711,734 shares; issued   and outstanding 1,578,400 at December&nbsp;31, 2013 and 0 shares at   June&nbsp;30, 2014 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22,862,367</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders&#146; (deficit) equity:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock, $.0001 par value, authorized   10,000,000 shares; issued 0 shares outstanding at December&nbsp;31, 2013 and   June&nbsp;30, 2014</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock, $.0001 par value, authorized   150,000,000 shares; issued 109,321 and outstanding 103,536 shares at   December&nbsp;31, 2013 and issued 18,598,754 and outstanding 18,592,968   shares at June&nbsp;30, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">88</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,860</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in capital </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,872,723</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">169,540,281</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated deficit </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(118,314,383</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(121,193,491</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stockholders&#146; (deficit) equity </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(71,441,572</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48,348,650</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities, convertible preferred stock and   stockholders&#146; (deficit) equity </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,405,136</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66,271,210</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to unaudited financial statements.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_074250_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-fa.htm',USER='108698',CD='Aug 13 22:56 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Statements of Operations</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating   expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research   and development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,425,741</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,390,857</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,497,454</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,785,180</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General   and administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">823,329</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,103,853</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,979,977</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,157,157</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   operating expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,249,070</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,494,710</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,477,431</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,942,337</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss   from operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,249,070</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,494,710</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,477,431</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,942,337</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other   income (expense)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest   expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(378,228</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(403,488</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(756,456</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781,714</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest   income</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">259</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,432</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">137</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change   in fair value of warrants</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,160</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">179,715</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,346</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192,321</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss   before benefit from income taxes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,619,879</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,718,401</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216,109</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,531,593</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit   from income taxes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,652,485</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net   loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,619,879</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,718,401</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216,109</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,879,108</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net   loss per common share:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic   and Diluted</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(70.29</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.46</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(175.31</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.71</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average   shares outstanding:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic   and Diluted</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,499</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,000,092</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,865</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,074,734</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to unaudited financial statements.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_074834_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-fa.htm',USER='108698',CD='Aug 13 22:56 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Statements of Cash Flows</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;Months&nbsp;Ended<br>   June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash flows from operating   activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216,109</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,879,108</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to reconcile net loss to net cash used   in operating activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,159</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,043</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Noncash stock bonus </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79,509</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Noncash stock based compensation </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">836,158</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">592,345</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Noncash interest </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,164</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91,715</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair value of warrants </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16,346</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(192,321</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in operating assets and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,700</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(514,514</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable and accrued expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56,515</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,604,316</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash (used in) operating activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,187,250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,212,524</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash flows from investing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acquisition of property and equipment </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,633,503</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,741</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,633,503</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,741</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash flows from financing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from convertible bridge notes </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,000,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash paid for financing costs </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(150,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from issuance of common stock in initial   public offering, net of offering costs </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,743,641</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52,593,641</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net increase (decrease) in cash and cash   equivalents </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11,820,753</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,374,376</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents, beginning of period </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,013,754</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,119,646</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents, end of period </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,193,001</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53,494,022</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental disclosure of   noncash financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conversion of preferred stock into common stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69,232,677</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conversion of notes payable and interest into   common stock</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,020,667</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental cash flow   information</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest paid </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">690,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">690,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes to unaudited financial statements.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_075002_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-fa.htm',USER='108698',CD='Aug 13 22:56 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1. Organization and Basis of Presentation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Nature of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agile Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) was incorporated in Delaware on December&nbsp;22, 1997. The Company is engaged in research and development of transdermal patch technology for use in contraception. The Company&#146;s activities since inception have consisted principally of raising capital, and performing research and development. The Company is headquartered in Princeton, New Jersey.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is devoting substantially all of its efforts toward research and development of its transdermal patch for use in contraception, and raising capital. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies. The Company has incurred losses each year since inception. As of June&nbsp;30, 2014, the Company had an accumulated deficit of approximately $121.2&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. The Company expects to continue to incur net losses into the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basis of Presentation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying unaudited interim condensed financial statements have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;) for interim information and pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#147;SEC&#148;) for reporting on Form&nbsp;10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules&nbsp;and regulations. It is recommended that these interim condensed financial statements be read in conjunction with the financial statements and related notes that appear in the Company&#146;s final prospectus filed with the SEC on May&nbsp;22, 2014, relating to the Company&#146;s Registration Statements on Form&nbsp;S-1 (File No.&nbsp;333-194621) for the Company&#146;s initial public offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the opinion of management, the unaudited interim condensed financial statements reflects all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and six months ended June&nbsp;30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2. Summary of Significant Accounting Polices</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s complete listing of significant accounting policies are described in Note 2 to the Company&#146;s audited financial statements as of December&nbsp;31, 2013 included in the Prospectus that forms a part of the Company&#146;s Registration Statement on Form&nbsp;S-1 dated May&nbsp;22, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preparation of the Company&#146;s financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_075147_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2. Summary of Significant Accounting Polices (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amounts of assets and liabilities reported in the Company&#146;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock Split</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;5, 2014, the Company effected a 1.4-for-1 stock split of the Company&#146;s common stock. All share and per share amounts of common stock contained in the Company&#146;s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders&#146; deficit reflects the stock split by reclassifying from &#147;Additional paid-in Capital&#148; to &#147;Common Stock&#148; in an amount equal to the par value of the increased shares resulting from the stock split.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fair Value of Financial Instruments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with ASC 825, <i>Financial Instruments</i>, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note&nbsp;3).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, <i>Distinguishing Liabilities from Equity</i>. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer&#146;s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the completion of the Company&#146;s initial public offering in May&nbsp;2014, the warrants to purchase shares of Series&nbsp;A-1 and Series&nbsp;A-2 preferred stock expired unexercised and the warrants to purchase shares of Series&nbsp;C preferred stock automatically converted into warrants to purchase shares of common stock.&#160; Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock-Based Compensation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i>. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Awards for consultants are accounted for under ASC 505-50, <i>Equity Based Payments to Non-Employees</i>. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_075307_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2. Summary of Significant Accounting Polices (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net Loss Per Share</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,809,325</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock warrants </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">287,028</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common   stock warrants </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62,505</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common   stock options </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,341,731</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,750,120</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,438,084</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,812,625</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_075400_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2. Summary of Significant Accounting Polices (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following tables summarizes the Company&#146;s computation of basic and diluted net loss per share for common stockholders:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.75in;width:83.32%;">
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Numerator</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,619,879</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,718,401</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Denominator</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Denominator for basic and diluted net loss per   share </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,499</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,000,092</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per share, basic and diluted </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(70.29</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.46</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;Months&nbsp;Ended<br>   June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="bottom" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Numerator</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216,109</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,879,108</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Denominator</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" style="padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Denominator for basic and diluted net loss per   share</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,865</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,074,734</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="63%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:63.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per share, basic and diluted </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(175.31</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.71</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&nbsp;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&nbsp;2014-10.&#160; ASU No.&nbsp;2014 is effective for fiscal years beginning after December&nbsp;15, 2014, with early adoption permitted.&#160; Retrospective application is required for the elimination of incremental DSE disclosures.&#160; Prior to the issuance of ASU No.&nbsp;2014-10, the Company had met the definition of a DSE since its inception.&#160; The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&nbsp;10-Q.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3. Fair Value Measurements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ASC 820, <i>Fair Value Measurements and Disclosures</i>, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_075628_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3. Fair Value Measurements (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level&nbsp;1&nbsp;&#151; Quotes prices in active markets for identical assets and liabilities. The Company&#146;s Level&nbsp;1 assets and liabilities consist of cash and cash equivalents.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level&nbsp;2&nbsp;&#151; Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level&nbsp;2 assets or liabilities.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level&nbsp;3&nbsp;&#151; Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company&#146;s Level&nbsp;3 liabilities consist of the warrant liability.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the Company&#146;s financial instruments measured at fair value by level within the fair value hierarchy as of December&nbsp;31, 2013 and June&nbsp;30, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.75in;width:83.34%;">
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">December&nbsp;31, 2013</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,066,156</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets at fair value </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,066,156</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A-1 warrants </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">438,978</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A-2 warrants </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64,537</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;C warrants </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140,963</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities at fair value </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">644,478</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The significant assumptions used in preparing the option pricing model for valuing the Company&#146;s warrants as of December&nbsp;31, 2013 include (i)&nbsp;volatility (104.8%), (ii)&nbsp;risk free interest rate of 1.94% (estimated using treasury bonds with a 6&nbsp;year life), (iii)&nbsp;strike price ($10.00) for the Series&nbsp;A-1 and Series&nbsp;A-2 warrants and $15.00 for the Series&nbsp;C warrants, (iv)&nbsp;fair value of Series&nbsp;A-1 preferred stock ($4.17), Series&nbsp;A-2 preferred stock ($2.91) and Series&nbsp;C preferred stock ($7.63) and (v)&nbsp;expected life (six years).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_075728_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3. Fair Value Measurements (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a rollforward of the fair value of Level&nbsp;3 warrants:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beginning balance at December&nbsp;31, 2013 </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">644,478</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration of Series&nbsp;A-1 and Series&nbsp;A-2   warrants </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(493,361</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair value </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301,040</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ending balance at June&nbsp;30, 2014 </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">452,157</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.85in;width:77.34%;">
<tr>
<td width="42%" valign="bottom" style="padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53,397,077</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets at fair value </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53,397,077</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities:</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock warrants </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">452,157</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="42%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:42.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities at fair value </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">452,157</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The significant assumptions used in preparing the option pricing model for valuing the Company&#146;s warrants as of June&nbsp;30, 2014 include (i)&nbsp;volatility (104.8%), (ii)&nbsp;risk free interest rate of 1.94% (estimated using treasury bonds with a 5.5&nbsp;year life), (iii)&nbsp;strike price ($6.00) for the common stock warrants, (iv)&nbsp;fair value of common stock ($8.72) and (v)&nbsp;expected life (5.5&nbsp;years).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no transfers between Level&nbsp;1, 2 or 3 during 2013 or 2014. If the Company&#146;s estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4. Prepaid Expenses and Other Current Assets</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets consist of the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.85in;width:77.34%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">June&nbsp;30,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.3pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid insurance </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48,055</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">604,320</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.3pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">98,649</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56,898</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.3pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total prepaid expenses and other current assets </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">146,704</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">661,218</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5. Accrued Liabilities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued liabilities consist of the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.85in;width:77.34%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">June&nbsp;30,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee bonuses </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">238,941</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">254,135</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140,223</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119,135</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total accrued liabilities </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">379,164</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">373,270</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_082534_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6. Convertible Note Financing</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;28, 2014, the Company and certain of the Company&#146;s existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0&nbsp;million. The Company issued Convertible Promissory Notes (the &#147;Notes&#148;) to evidence its payment obligations with respect to the $3.0&nbsp;million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes are convertible into unregistered equity securities of the Company upon the occurrence of events stated therein. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in an underwritten public offering (see Note 8). The Notes were subordinate to the Company&#146;s term loan with Oxford Finance LLC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7. Term Loan Amendment</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In January&nbsp;2014 the Company amended its Loan Agreement with Oxford Finance whereby the interest only period was extended for three months (through April&nbsp;1, 2014). The interest only period was extended for an additional three months (through July&nbsp;1, 2014) as a result of the Company&#146;s $3.0&nbsp;million convertible note financing in which was completed in April&nbsp;2014 (see Note&nbsp;6).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The interest only period was further extended for an additional six months (through January&nbsp;1, 2015) and the maturity date of the loan was extended to July&nbsp;1, 2017 as a result of the completion of the Company&#146;s initial public offering (see Note 8). In connection with the amendment to the Loan Agreement the Company has paid Oxford Finance a total of $150,000.&#160; The $150,000 has been offset against the amount of the loan and is being amortized to interest expense.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At June&nbsp;30, 2014, the Company believes it is in compliance with the Loan Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8. Stockholders&#146; Equity</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Initial Public Offering and Related Transactions</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;23, 2014, the Company completed its initial public offering selling 9,166,667 shares of common stock at $6.00 per share.&#160; Proceeds from the Company&#146;s initial public offering, net of underwriting discounts and commissions and other offering costs were $49.7 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, each of the following occurred in connection with the completion of the Company&#146;s IPO on May&nbsp;23, 2014:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of all outstanding shares of convertible preferred stock into 8,809,325 shares of the Company&#146;s common stock</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of the aggregate principal amount of $3.0 million and accrued interest under the Company&#146;s outstanding convertible subordinated promissory notes into 503,450 shares of the Company&#146;s common stock.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;7, 2014, the Company filed an amendment to its amended and restated certificate of incorporation which, among other things, revised the automatic conversion provision relating to the Series&nbsp;C Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;A-1 Preferred Stock and Series&nbsp;A-2 Preferred Stock. Following such amendment, the Series&nbsp;C, the Series&nbsp;B, the Series&nbsp;A-1 and A-2 Preferred Stock now automatically convert into shares of common stock at the then effective conversion price upon:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_082605_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8. Stockholders&#146; Equity (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, covering the offer and sale of common stock from which the Company receives gross proceeds of at least $45,000,000 or (ii)&nbsp;the affirmative vote of the holders of at least a majority of the voting power the Series&nbsp;C Preferred Stock, the Series&nbsp;B Preferred Stock and the Series&nbsp;A-1 Preferred Stock, respectively, after first giving effect, if in conjunction with a public offering which does not meet the standards set forth in clause&nbsp;(i)&nbsp;above, to any adjustment of the conversion price for each series of preferred stock to which it would otherwise be entitled by virtue of such public offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;29, 2014, the Company filed an amended and restated certificate of incorporation (the &#147;Restated Certificate&#148;) with the Secretary of State of the State of Delaware in connection with the closing of the Company&#146;s initial public offering of shares of its common stock. The Company&#146;s board of directors (the &#147;Board&#148;) and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company&#146;s initial public offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Restated Certificate amends and restates in its entirety the Company&#146;s second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: (i)&nbsp;authorizes 150,000,000 shares of common stock; (ii)&nbsp;eliminates all references to the previously existing series of preferred stock; (iii)&nbsp;authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iv)&nbsp;provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company&#146;s stockholders; (v)&nbsp;provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (vi)&nbsp;provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and (vii)&nbsp;requires that any action instituted against the Company&#146;s officers or directors in connection with their service to the Company be brought in the State of Delaware.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Convertible Preferred Stock</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to its conversion in the IPO, the Company&#146;s convertible preferred stock was classified as temporary equity on its balance sheets instead of stockholders&#146; (deficit) in accordance with authoritative guidance for the classification and measurement or redeemable securities.&#160; Upon certain change in control events that were outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_082616_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agile Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Unaudited Financial Statements</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;30, 2014</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8. Stockholders&#146; Equity (Continued)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Stock-Based Compensation Expense</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation expense related to stock options was allocated as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">292,263</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">208,908</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125,714</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">155,331</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stock-based compensation expense </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">417,977</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">364,239</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;Months&nbsp;Ended<br>   June&nbsp;30</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">584,732</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">335,433</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">251,426</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">256,912</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stock-based compensation expense </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">836,158</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">592,345</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9. Income Taxes</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Sale of New Jersey Net Operating Losses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company received approval to sell a portion of the Company&#146;s New Jersey net operating losses (NOLs) as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other companies. On February&nbsp;27, 2014, the Company completed the sale of NOLs totaling approximately $39.1&nbsp;million for net proceeds of approximately $3.6&nbsp;million. Such proceeds are reflected as a tax benefit for six months ended June&nbsp;30, 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10. Related Party Transactions</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effective March&nbsp;17, 2014, one of the Managing Partners of SmartPharma&nbsp;LLC or SmartPharma, an entity which provides commercial and business development consulting services to the Company was appointed Chief Commercial Officer. In connection with the appointment of this individual as Chief Commercial Officer, the Company amended its consulting agreement with SmartPharma to remove this individual from the list of persons providing service under the consulting agreement. SmartPharma invoiced the Company $3,250 and $74,300 of fees for the three and six months ended June&nbsp;30, 2014.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_082821_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-fn.htm',USER='106406',CD='Aug 13 07:11 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 2.&#160; Management&#146;s Discussion and Analysis of Financial<a name="Item2_ManagementsDiscussionAndAna_082921"></a> Condition and Results of Operations</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form&nbsp;10-Q and the audited financial information and notes thereto included in the Prospectus that forms a part of our Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-194621), which was filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule&nbsp;424(b)(4)&nbsp;on May&nbsp;22, 2014 (the &#147;Prospectus&#148;).&#160; Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Dollars in tabular format are presented in thousands, except per share data, or as otherwise indicated.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a women&#146;s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products for women. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. We have developed a proprietary transdermal patch technology, called Skinfusion, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and stability and patient comfort. Our lead product candidate, Twirla, also known as AG200-15, is a once-weekly contraceptive patch currently in Phase&nbsp;3 clinical development.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception in 1997, we have devoted substantial resources to developing Twirla, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. We incurred research and development expenses of $17.4&nbsp;million, $9.2&nbsp;million, $2.4&nbsp;million and $3.8 million during the years ended December&nbsp;31, 2012 and 2013 and the three and six months ended June&nbsp;30, 2014, respectively. We anticipate that a significant portion of our operating expenses will continue to be related to research and development as we continue to develop Twirla and advance our pipeline of product candidates. To date, we have funded our operations primarily through sales of common stock, convertible preferred stock, convertible promissory notes, and a term loan. As of December&nbsp;31, 2013 and June&nbsp;30, 2014 respectively, we had $2.1&nbsp;million and $53.5 million in cash and cash equivalents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;29, 2014, we completed our initial public offering whereby we sold 9,166,667 shares of common stock, at a public offering price of $6.00 per share, before underwriting discounts and expenses.&#160; The aggregate net proceeds received by us from the offering were $49.7 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not generated any revenue and have never been profitable for any year. Our net loss was $23.9&nbsp;million, $14.3&nbsp;million, $3.7 million and $2.9 million for the years ended December&nbsp;31, 2012 and 2013 and the three and six months ended June&nbsp;30, 2014 respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and clinical trials of, and seek regulatory approval for, Twirla and any other product candidates we advance to clinical development.&#160; We will continue to invest in the Corium facility, and incur significant expenses, in order to complete the equipment qualification and validation related to the expansion of Corium&#146;s manufacturing capabilities in order to be capable of supplying projected commercial quantities of Twirla, if approved. We continue to plan the process of scaling up the commercial manufacturing capabilities for Twirla with Corium and the associated costs and timelines.&#160; We expect the validation and expansion to be completed by the end of 2016 in coordination with our planned commercialization activities.&#160; Corium is responsible for all aspects of Twirla manufacturing. If we obtain regulatory approval for Twirla, we expect to incur significant expenses in order to create an infrastructure to support the commercialization of Twirla, including sales, marketing and distribution functions. As previously disclosed, we expect to enroll the first subject in our Phase 3 clinical trial in the third quarter of 2014. We also expect that we are likely to complete the trial in the first quarter of 2016. We believe the key drivers of the timing for completion are the timelines for clinical supply, and the pace of site selection, site initiation and subject enrollment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to incur additional costs associated with operating as a public company. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_082949_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial Operations Overview</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenue. In the future, we may generate revenue from product sales, license fees, milestone payments and royalties from the sale of products developed using our intellectual property. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize Twirla and any product candidates that we may advance in the future. If we fail to complete the development of Twirla or any other product candidates we advance in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, will be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception, we have focused our resources on our research and development activities. Research and development expenses consist primarily of costs incurred for the development of Twirla and other current and future product candidates, which include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">expenses incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct our clinical trials and preclinical studies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expenses;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of acquiring, developing and manufacturing clinical trial materials, including the supply of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs associated with research, development and regulatory activities; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">administrative office space and other expenses such as insurance and supplies.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to us by our third party vendors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis, as the majority of our past and planned expenses have been and will be in support of Twirla. We expect to increase our research and development expenses for the foreseeable future as we initiate further clinical trials and continue equipment qualification and validation of our commercial manufacturing process.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, our research and development expenses have related primarily to the development of Twirla. For the three months ended June&nbsp;30, 2013 and 2014 our research and development expenses were approximately $2.4&nbsp;million and $2.4&nbsp;million, respectively. For the six months ended June&nbsp;30, 2013 and 2014 our research and development expenses were approximately $5.5 million and $3.8 million, respectively. The following table summarizes our research and development expenses by functional area.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;width:73.34%;">
<tr>
<td width="35%" valign="bottom" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.96%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended<br>   June&nbsp;30,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.96%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;months<br>   ended<br>   June&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="35%" valign="bottom" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="35%" valign="bottom" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="59%" colspan="11" valign="bottom" style="padding:0in 0in 0in 0in;width:59.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">266</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,177</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">507</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,245</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">940</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,779</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">201</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Personnel related </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">456</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">443</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">926</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">911</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturing&nbsp;&#151; commercialization </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">322</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">245</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,226</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">630</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturing </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">150</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">252</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">474</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">462</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">292</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">585</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">336</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and development expenses </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,426</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,391</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,497</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,785</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_083105_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is difficult to determine with any certainty the duration and completion costs of our currently planned or future clinical trials of Twirla and any of our other current and future product candidates we may advance, or if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, or experience issues with our manufacturing capabilities we could be required to expend significant additional financial resources and time with respect to the development of that product candidate. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#146;s commercial potential.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance and administrative functions including stock-based compensation and travel expenses. Other general and administrative expenses include facility-related costs and professional fees for legal, patent review, consulting and accounting services. General and administrative expenses are expensed as incurred.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the three months ended June&nbsp;30, 2013 and 2014, our general and administrative expenses totaled approximately $0.8&nbsp;million and $1.1&nbsp;million, respectively. For the six months ended June&nbsp;30, 2013 and 2014, our general and administrative expenses totaled approximately $2.0&nbsp;million and $2.2&nbsp;million, respectively. We anticipate that our general and administrative expenses will increase in the future with the continued research, development and potential commercialization of Twirla and any of our other product candidates, and as we operate as a public company. These increases will likely include increased legal and accounting services, stock registration and printing fees, addition of new personnel to support compliance and communication needs, increased insurance premiums, outside consultants and investor relations.</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Additionally, if in the future we believe regulatory approval of Twirla or any of our other product candidates appears likely, we anticipate that we would begin preparations for commercial operations, which would result in an increase in payroll and other expenses, especially as relates to the sales and marketing of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our discussion and analysis of financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles.&#160; The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures.&#160; On an ongoing basis, our actual results may differ significantly from our estimates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There have been no material changes to our critical accounting policies and estimates from the information provided discussed in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in the Prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_083113_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended June&nbsp;30, 2013 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months<br>   ended<br>   June&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,426</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,391</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(35</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">823</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,104</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">281</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,249</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,495</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">246</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expenses)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(378</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(403</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair value of warrants </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">180</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">173</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss before income taxes </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,620</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,718</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">98</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit from income taxes </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,620</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,718</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">98</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and development expenses.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Research and development expenses were comparable for the three months ended June&nbsp;30, 2013 ($2.4&nbsp;million) and the three months ended June&nbsp;30, 2014 ($2.4 million). Fluctuations in research and development expenses were primarily due to the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a decrease in regulatory expenses of $0.9&nbsp;million for the three months ended June&nbsp;30, 2014 as compared to the three months ended June&nbsp;30, 2013. A significant portion of the overall decrease, approximately $0.8&nbsp;million, is related to a decrease in regulatory consulting fees. Regulatory consulting fees for 2013 include professional fees associated with the review and preparation of a response to the complete response letter, or CRL, that we received from the Food&nbsp;&amp; Drug Administration, or FDA, in February&nbsp;2013. Regulatory consulting fees for 2014 relate to the preparation of the protocol for our planned additional Phase&nbsp;3 clinical trial for Twirla; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in clinical development expenses of $0.9&nbsp;million for the three months ended June&nbsp;30, 2014 as compared to the three months ended June&nbsp;30, 2013. The increase is primarily related to CRO costs associated with the start-up activities related to our planned Phase 3 clinical trial for Twirla.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and administrative expenses.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; General and administrative expenses increased by $0.3 million, or 35% from $0.8 million for the three months ended June&nbsp;30, 2013 to $1.1 million for the three months ended June&nbsp;30, 2014. This increase in general and administrative expense was primarily due to the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in professional fees of $0.2 million for the three months ended June&nbsp;30, 2014 as compared to the three months ended June&nbsp;30, 2013 primarily associated with becoming a public company; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in travel expenses of $0.1 million for the three months ended June&nbsp;30, 2014 as compared to the three months ended June&nbsp;30, 2013 associated with our initial public offering.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.9pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest expense.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Interest expense is primarily attributable to our term loan with Oxford. Interest expense also includes the accretion of the value of the common stock warrants issued to Oxford and the amortization of the deferred financing costs associated with the term loan.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Change in fair value of warrants.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Certain of our warrants to purchase our preferred stock and common stock are recorded at fair value and are subject to re-measurement at each balance sheet date. These liabilities are re-measured at each balance sheet date with the corresponding charge to earnings recorded within change in fair value of warrant liability. The fair value of the convertible preferred stock warrants and warrants to purchase common stock with non-standard anti-dilution provisions are determined using the Black-Scholes option pricing model which incorporates a number of assumptions and judgments to estimate the fair value of these warrants including the fair value per share of the underlying stock, the remaining contractual term of the warrants, risk-free interest rate, expected dividend yield, credit spread and expected volatility of the price of the underlying stock.&#160; During the three months ended June&nbsp;30, 2014, the fair value of our warrant liability changed by $0.2 million compared to three months ended June&nbsp;30, 2013 reflecting the expiration of the Series&nbsp;A-1 and Series&nbsp;A-2 preferred stock warrants of $0.5 million, offset, in part, by an increase in the value of the common stock warrants of $0.3 million primarily due to the change in the fair value of the underlying common stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_083230_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Six Months Ended June&nbsp;30, 2013 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;months<br>   ended<br>   June&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,497</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,775</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,712</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,980</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,157</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">177</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,477</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,942</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,535</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expenses)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(756</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(782</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair value of warrants </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">176</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss before income taxes </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,532</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,684</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Benefit from income taxes </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,652</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,652</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,216</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,879</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,337</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and development expenses.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Research and development expenses decreased by $1.7&nbsp;million, or 31%, from $5.5&nbsp;million for the six months ended June&nbsp;30, 2013 to $3.8&nbsp;million for the six months ended June&nbsp;30, 2014. This overall decrease in research and development expenses was primarily due to the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a decrease in regulatory expenses of $1.5&nbsp;million. A significant portion of the overall decrease, approximately $1.4&nbsp;million, is related to a decrease in regulatory consulting fees. Regulatory consulting fees for 2013 include professional fees associated with the review and preparation of a response to the CRL that we received from the FDA in February&nbsp;2013. Regulatory consulting fees for 2014 relate to the preparation of the protocol for our planned additional Phase&nbsp;3 clinical trial for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a decrease in manufacturing commercialization expenses of $0.6&nbsp;million for the six months ended June&nbsp;30, 2014 as compared to the six months ended June&nbsp;30, 2013. Payments for labor and materials decreased from approximately $0.9&nbsp;million in 2013 to zero in 2014 as the construction of the facility and receipt of equipment was principally completed during the first quarter of 2013.&#160; This decrease was partially offset by an increase in idle and other facility charges of $0.3 million;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in clinical development expenses of $0.7&nbsp;million for the six months ended June&nbsp;30, 2014 as compared to the six months ended June&nbsp;30, 2013. The increase is primarily related to CRO costs associated with the start-up activities related to our planned Phase 3 clinical trial for Twirla; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a decrease in stock-based compensation expense of $0.2&nbsp;million. This decrease was primarily the result of the completion of the vesting period for certain non-employee stock options during 2013 for which there was no comparable expense in 2014.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and administrative expenses.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; General and administrative expenses increased by $0.2 million, or 9%, from $2.0 million for the three months ended June&nbsp;30, 2013 to $2.2 million for the three months ended June&nbsp;30, 2014. This increase in general and administrative expense was primarily due to the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in professional fees of $0.1 million for the six months ended June&nbsp;30, 2014 as compared to the six months ended June&nbsp;30, 2013 primarily associated with becoming a public company; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an increase in travel expenses of $0.1 million for the six months ended June&nbsp;30, 2014 as compared to the six months ended June&nbsp;30, 2013 associated with our initial public offering.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.9pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest expense.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Interest expense is primarily attributable to our term loan with Oxford. Interest expense also includes the accretion of the value of the common stock warrants issued to Oxford and the amortization of the deferred financing costs associated with the term loan.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest income.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Interest income comprises interest income earned on cash and cash equivalents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Change in fair value of warrants.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Certain of our warrants to purchase our preferred stock and common stock are recorded at fair value and are subject to re-measurement at each balance sheet date. These liabilities are re-measured at each balance sheet date</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_083322_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with the corresponding charge to earnings recorded within change in fair value of warrant liability. The fair value of the convertible preferred stock warrants and warrants to purchase common stock with non-standard anti-dilution provisions are determined using the Black-Scholes option pricing model which incorporates a number of assumptions and judgments to estimate the fair value of these warrants including the fair value per share of the underlying stock, the remaining contractual term of the warrants, risk-free interest rate, expected dividend yield, credit spread and expected volatility of the price of the underlying stock.&#160; During the six months ended June&nbsp;30, 2014, the fair value of our warrant liability changed by $0.2 million compared to six months ended June&nbsp;30, 2013 reflecting the expiration of the Series&nbsp;A-1 and Series&nbsp;A-2 preferred stock warrants of $0.5 million, offset, in part, by an increase in the value of the common stock warrants of $0.3 million primarily due to the change in the fair value of the underlying common stock.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Benefit from income taxes.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Benefit from income taxes for the six months ended June&nbsp;30, 2014 represents the proceeds we received from the sale of New Jersey net operating losses, or NOLs, as part of the Technology and Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused state NOLs are allowed to sell these NOLs to other companies. In February&nbsp;2014, we completed the sale of New Jersey state NOLs totaling approximately $39.1&nbsp;million for net proceeds of approximately $3.6&nbsp;million. There was no comparable transaction during the six months ended June&nbsp;30, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;29, 2014, we completed our initial public offering whereby we sold 9,166,667 shares of common stock, at a public offering price of $6.00 per share, before underwriting discounts and expenses.&#160; The aggregate net proceeds received by us from the offering were $49.7 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have funded our operations since inception through the issuance of common stock, convertible preferred stock and convertible promissory notes and, to a lesser extent, through a term loan and government grants. As of June&nbsp;30, 2014, we had raised a total of $170.8&nbsp;million from such sales of our equity securities and debt instruments, as well as our term loan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At June&nbsp;30, 2014, we had cash and cash equivalents totaling $53.5&nbsp;million. We invest our cash equivalents in highly liquid, interest-bearing investment-grade and government securities in order to preserve principal.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the primary sources and uses of cash for the periods indicated:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="66%" style="border-collapse:collapse;margin-left:1.25in;width:66.66%;">
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Six&nbsp;months&nbsp;ended<br>   June&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash used in operating activities </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,187</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,213</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash used in investing activities </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,634</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash provided by financing activities </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52,594</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net (decrease) increase in cash and cash   equivalents </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11,821</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,374</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Operating Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred significant costs in the area of research and development, including CRO fees, manufacturing, regulatory and other clinical trial costs, as our primary product candidate Twirla was being developed. With the planned initiation of an additional Phase&nbsp;3 clinical trial in 2014, clinical development expenses are expected to increase as compared to 2013. Net cash used in operating activities was $7.2&nbsp;million for the six months ended June&nbsp;30, 2013 and consisted primarily of a net loss of $8.2&nbsp;million which was offset, in part, by non-cash stock based compensation expense of $0.8&nbsp;million. Net cash used in operating activities was $1.2&nbsp;million for the six months ended June&nbsp;30, 2014 and consisted primarily of a net loss of $2.9&nbsp;million which was offset, primarily, by an increase in accounts payable and accrued expenses of $1.6 million.&#160; This increase is largely timing related as certain costs associated with our initial public offering were not paid until after June&nbsp;30, 2014. The change in net loss as compared to the comparable period in 2013 was primarily the result of the receipt of $3.6&nbsp;million from the sale of a portion of our New Jersey state NOLs during the six months ended June&nbsp;30, 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Investing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities for the six months ended June&nbsp;30, 2013 and 2014 was $4.6&nbsp;million and $7 thousand, respectively. Cash used in investing activities for the six months ended June&nbsp;30, 2013 represents the acquisition of equipment to be used in the commercialization of Twirla.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_083421_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Financing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash provided by financing activities for the six months ended June&nbsp;30, 2014 was primarily derived from the proceeds received from our initial public offering of common stock in May&nbsp;2014 from which we raised a total of $49.7 million in net proceeds after deducting underwriting discounts, commissions and offering expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Funding Requirements and Other Liquidity Matters</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Twirla is still in clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seek marketing approval for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">establish a sales and marketing infrastructure to commercialize Twirla in the United States, if approved;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">continue the equipment qualification and validation related to the expansion of Corium&#146;s manufacturing facility;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seek to identify additional line extensions for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, leverage and expand our intellectual property portfolio; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that the net proceeds from our recently completed initial public offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditures requirements through the first quarter of 2016. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of Twirla, if approved, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of Twirla. Our future capital requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs, timing and outcome of regulatory review of Twirla, including for the additional Phase&nbsp;3 trial for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of the equipment qualification and validation related to the expansion of Corium&#146;s manufacturing facility;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for Twirla, if approved;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the revenue, if any, received from commercial sales of Twirla, if approved; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including Twirla, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market Twirla that we would otherwise prefer to develop and market ourselves.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_083443_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">December&nbsp;2012 Loan Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In December&nbsp;2012, we entered into a loan and security agreement with Oxford, pursuant to which we borrowed a total of $15.0&nbsp;million from Oxford. The term loan accrues interest at a fixed annual rate equal to 9.2% (three month U.S. Libor rate of 0.47% plus 8.73%).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the original term loan, interest was payable monthly and principal was due in 30 equal consecutive monthly installments which were to begin on February&nbsp;1, 2014 and end on July&nbsp;1, 2016. In addition, we were required to make a final payment of $675,000 on the original maturity date of the term loan of July&nbsp;1, 2016.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may prepay all, but not less than all, of the term loan subject to a prepayment premium of 2.0% of the outstanding principal during the first 24&nbsp;months of the term loan. From months 25 to loan maturity the prepayment premium is 0.75% of the outstanding principal. Our obligations under the term loan are secured with a blanket lien on all of our assets, excluding intellectual property assets. The term loan provides that, upon the occurrence of certain events of default, our obligations under the term loan may be automatically accelerated, whereupon our obligations shall be immediately due and payable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the term loan, we issued to Oxford warrants to purchase 62,505 shares of common stock at $6.00 per share. These warrants are exercisable for seven years from the date of issuance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We account for the warrants as a liability and carry them at fair value. These warrants are marked to market at each reporting date with a corresponding change recognized in our statements of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In January&nbsp;2014, we amended our loan agreement with Oxford whereby the interest-only period was extended for three months through April&nbsp;2014. The interest-only period was extended for an additional three months through July&nbsp;2014 as a result of the convertible note financing which we completed in April&nbsp;2014 (see below).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The interest-only period was further extended for an additional six months through January&nbsp;2015 and the maturity date of the loan was extended to July&nbsp;1, 2017 as a result of the completion of our initial public offering. In connection with the amendment to the loan agreement we paid Oxford a total of $150,000.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">April&nbsp;2014 Convertible Subordinated Note Financing</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;28, 2014, we and certain of our existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan us an aggregate of $3.0&nbsp;million. We issued Convertible Promissory Notes, referred to herein as the Notes, to evidence our payment obligations with respect to the $3.0&nbsp;million. The Notes had an interest rate of 8%, accruing daily and compounding annually.&#160; The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in our initial public offering. The Notes were subordinate to the Company&#146;s term loan with Oxford Finance LLC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&nbsp;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&nbsp;2014-10.&#160; ASU No.&nbsp;2014 is effective for fiscal years beginning after December&nbsp;15, 2014, with early adoption permitted.&#160; Retrospective application is required for the elimination of incremental DSE disclosures.&#160; Prior to the issuance of ASU No.&nbsp;2014-10, we had met the definition of a DSE since our inception.&#160; We elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&nbsp;10-Q.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual Obligations and Contingent Liabilities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the six months ended June&nbsp;30, 2014, there were no material changes to our contractual obligations and commitments described under Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in the Prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_083455_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3.&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</font></b><a name="Item3_QuantitativeAndQualitativeD_083501"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to market risks in the ordinary course of our business. These market risks are principally limited to interest rate fluctuations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We had cash and cash equivalents of $2.1&nbsp;million and $53.5&nbsp;million at December&nbsp;31, 2013 and June&nbsp;30, 2014, respectively, consisting primarily of funds in cash and money market accounts. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we do not believe an immediate 10.0% increase in interest rates would have a material effect on the fair market value of our portfolio, and accordingly we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4.&#160; Controls and Procedures.</font></b><a name="Item4_ControlsAndProcedures__083503"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Disclosure Controls and Procedures</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form&nbsp;10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules&nbsp;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes to Internal Controls Over Financial Reporting</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There has been no change in internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_083510_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ga.htm',USER='106406',CD='Aug 13 07:14 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II: OTHER INFORMATION</font></b><a name="PartiiOtherInformation_083605"></a></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160; Legal Proceedings.</font></b><a name="Item1_LegalProceedings__083608"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are not currently subject to any material legal proceedings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A.&#160; Risk Factors.</font></b><a name="Item1a_RiskFactors__083610"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should carefully consider the following risks and uncertainties. If any of the following occurs, our business, financial condition and/or operating results could be materially harmed. These factors could cause the trading price of our common stock to decline, and you could lose all or part of your investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">You should carefully consider the risk factors set forth below as well as the other information contained in this Quarterly Report and in our other public filings in evaluating our business. The risk factors set forth below with an asterisk (*) next to the title contain material changes to the description of the risk factors associated with our business previously disclosed in our final prospectus filed with the Securities and Exchange Commission on May&nbsp;22, 2014 relating to our Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-194621) for our initial public offering. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently view to be immaterial may also materially adversely affect our business, financial condition or results of operations. In these circumstances, the market price of our common stock would likely decline.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Clinical Trial Process and Regulatory Approval for Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*We have not obtained regulatory approval for any of our product candidates in the United States or any other country.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently do not have any product candidates that have gained regulatory approval for sale in the United States or any other country, and we cannot guarantee that we will ever have marketable products. Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize product candidates in a timely manner. We cannot commercialize product candidates in the United States without first obtaining regulatory approval to market each product candidate from the U.S. Food and Drug Administration, or FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. We are not currently pursuing any regulatory approvals for Twirla or any other product candidate outside the United States.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have previously conducted two Phase&nbsp;3 clinical trials for Twirla, and we filed a new drug application, or NDA, with the FDA for Twirla in April&nbsp;2012. The FDA issued a Complete Response Letter, or CRL, in February&nbsp;2013, identifying certain issues, including a request for additional clinical data, quality information and chemistry, manufacturing and controls information, which must be addressed before approval can be granted. Accordingly, we are gathering the requested information and intend to conduct an additional Phase&nbsp;3 clinical trial for Twirla, which is expected to commence enrollment during the third quarter of 2014. The FDA may also re-inspect our manufacturing partner&#146;s facilities before approval can be granted. Although we met with the FDA in October&nbsp;2013 to discuss our new Phase&nbsp;3 clinical trial and received substantial written comments from the FDA in February&nbsp;2014, we have not sought and have not obtained agreement with the FDA on a special protocol assessment regarding the new Phase&nbsp;3 trial. We cannot predict whether our additional Phase&nbsp;3 clinical trial or any future trials we may conduct will be successful or whether regulators will agree with our conclusions regarding the results of these trials or any clinical trials we have conducted to date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate in preclinical studies and well-controlled clinical trials and, with respect to approval in the United States, to the satisfaction of the FDA, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. In the United States, it is necessary to submit an NDA to obtain FDA approval. An NDA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#146;s safety and efficacy for each desired indication, although we may partially rely on public information or the FDA&#146;s prior approval of similar products. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product. The FDA may further inspect our manufacturing facilities to ensure that the facilities can manufacture our product candidates and our products, if and when approved, in compliance with the applicable regulatory requirements, as well as inspect our clinical trial sites to ensure that our studies are properly conducted. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. Upon submission of an NDA, the FDA must make an initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA, or ultimately be approved. If the application is not accepted for review or approval, the FDA may require that we conduct additional clinical or preclinical trials, or take other actions before it will reconsider our application. If the FDA requires additional studies or data, we would incur increased costs and delays in the marketing approval process, which may require us to</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_083718_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">expend more resources than we have available. In addition, the FDA may not consider any additional information to be complete or sufficient to support approval.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory authorities outside of the United States, such as in Europe and Japan and in emerging markets, also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. Seeking foreign regulatory approval could require additional non-clinical studies or clinical trials, which could be costly and time consuming. Foreign regulatory approval may include all of the risks associated with obtaining FDA approval. For all of these reasons, if we seek foreign regulatory approval for Twirla or any of our other product candidates, we may not obtain such approvals on a timely basis, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The process to develop, obtain regulatory approval for and commercialize product candidates is long, complex and costly both inside and outside of the United States, and approval is never guaranteed. Even if our product candidates were to successfully obtain approval from regulatory authorities, any such approval might significantly limit the approved indications for use, including more limited patient populations, require that precautions, contraindications or warnings be included on the product labeling, including black box warnings, require expensive and time-consuming post-approval clinical studies, risk evaluation and mitigation strategies, or REMS, or surveillance as conditions of approval, or, through the product label, the approval may limit the claims that we may make, which may impede the successful commercialization of our product candidates. Following any approval for commercial sale of our product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, will be subject to additional FDA notification, or review and approval. Also, regulatory approval for any of our product candidates may be withdrawn. If we are unable to obtain regulatory approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, our ability to market to our full target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. Furthermore, we may not be able to obtain sufficient funding or generate sufficient revenue and cash flows to continue or complete the development of any of our current or future product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Failure can occur at any stage of clinical development. If the clinical trials for Twirla or any of our current or future product candidates are unsuccessful, we could be required to abandon development.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more clinical trials can occur at any stage of testing for a variety of reasons. The outcome of preclinical testing and early clinical trials may not be predictive of the outcome of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, adverse events may occur or other risks may be discovered in our planned Phase&nbsp;3 clinical trial for Twirla that would cause us to suspend or terminate the clinical trial. In some instances, there can be significant variability in safety or efficacy results between different trials of the same product candidate due to numerous factors, including changes in or adherence to trial protocols, differences in size and type of the subject populations and the rates of dropout among clinical trial subjects. Our future clinical trial results therefore may not demonstrate safety and efficacy sufficient to obtain regulatory approval for our product candidates. For example, we received a CRL from the FDA with respect to an NDA previously filed for Twirla, in which the FDA requested, among other items, additional Phase&nbsp;3 clinical data to support the application. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trials may not be successful.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Flaws in the design of a clinical trial may not become apparent until the clinical trial is well-advanced. We have limited experience in designing contraceptive clinical trials and may be unable to design and execute clinical trials to support regulatory approval of our product candidates. In addition, clinical trials often reveal that it is not practical or feasible to continue development efforts for a product candidate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to subjects. Furthermore, regulatory agencies,&nbsp;Institutional Review Boards, or IRBs, or data safety monitoring boards may at any time order the temporary or permanent discontinuation of our clinical trials or request that we cease using certain investigators in the clinical trials if such regulatory agencies or boards believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to subjects. Since our inception, we have not voluntarily or involuntarily suspended or terminated a clinical trial due to unacceptable safety risks to subjects.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_083731_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the results of the clinical trials for our current product candidates or clinical trials for any future product candidates do not achieve the primary efficacy endpoints or demonstrate unexpected safety issues, the prospects for approval of our product candidates will be materially adversely affected. For example, in the CRL that we received from the FDA in connection with the NDA previously filed for Twirla, one of the FDA&#146;s comments was that acceptable evidence of efficacy was not demonstrated, as measured by Pearl Index, or PI. Specifically, in our two completed Phase&nbsp;3 trials, the PI was higher than that seen in registration trials for previously approved hormonal contraceptives. Most experts seem to agree that inconsistent or incorrect use is a major contributor to the increased PI seen in more recent contraceptive trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have failed to achieve similar results in later clinical trials, including longer-term trials, or have failed to obtain regulatory approval of their product candidates. Many compounds that initially showed promise in clinical trials or earlier preclinical studies have later been found to cause undesirable or unexpected adverse effects that have prevented further development of the compound. Our planned Phase&nbsp;3 trial for our primary product candidate, Twirla, may not produce the results that we expect, or the FDA may interpret the data differently than we do.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the circumstances noted above, we may experience numerous unforeseen events that could cause our clinical trials to be delayed, suspended or terminated, or which could delay or prevent our ability to receive regulatory approval for or commercialize our product candidates, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or implement a clinical hold;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate. For instance, we experienced a high withdrawal rate in our two completed Phase&nbsp;3 clinical trials for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our third party contract research organization, or CRO, or study sites may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all. For instance, investigator compliance with study procedures was an issue that we encountered in our two completed Phase&nbsp;3 clinical trials for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or amend a trial protocol;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our CRO;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may elect or be required to suspend or terminate clinical trials of our product candidates based on a finding that the subjects are being exposed to health risks, or due to other reasons;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The cost of clinical trials for our product candidates may be greater than we anticipate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There may be changes in government regulations or administrative actions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our product candidates may have undesirable adverse effects or other unexpected characteristics;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may not be able to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may not be able to demonstrate that a product candidate provides an advantage over current standards of care or future competitive therapies in development; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There may be changes in the approval policies or regulations that render our data insufficient for approval.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_083745_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we elect or are required to suspend or terminate a clinical trial for any of our product candidates, or our product candidate development is otherwise delayed, our development costs may increase, our commercial prospects will be adversely impacted, any periods during which we may have the exclusive right to commercialize our product candidates may be shortened and our ability to generate product revenues may be delayed or eliminated.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to conduct additional clinical trials in the future for Twirla and our other product candidates. Subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Size and nature of the subject population;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Proximity of subjects to clinical sites and the number of sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Effectiveness of publicity created by clinical trial sites regarding the trial;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Eligibility and exclusion criteria for the trial;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Design of the clinical trial, including factors such as frequency of required assessments, length of the study and ongoing monitoring requirements;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Competing clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Clinician and subject perceptions as to the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies, including any products that may be approved for the indications we are investigating;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subjects&#146; ability to comply with the specific instructions related to the trial protocol, proper documentation and use of the drug product. For instance, in our Phase&nbsp;3 clinical trials, there was a high rate of subject noncompliance;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Inability to obtain or maintain subject informed consents;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Risk that enrolled subjects will drop out before completion; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject&#146;s relationship with her partner.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furthermore, we plan to rely on a CRO and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we may have agreements governing their committed activities, we have limited influence over their actual performance. Additionally, the CRO and clinical trial sites may have business, regulatory, personnel or other issues that keep us from satisfactorily completing our clinical trials. Any delays or unanticipated problems during clinical trials, such as additional monitoring of clinical trial sites, slower than anticipated enrollment in our clinical trials or subjects dropping out of or being excluded from participation in our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process and harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*Regulatory approval may be substantially delayed or may not be obtained for one or all of our product candidates if regulatory authorities require additional time or studies to assess the safety and efficacy of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may be unable to initiate or complete development of our product candidates on schedule, if at all. The timing for the completion of the studies for our product candidates other than Twirla will require funding beyond the proceeds of our initial public offering. In addition, if regulatory authorities require additional time or studies to assess the safety or efficacy of Twirla, we may not have or be able to obtain adequate funding to complete the necessary steps for approval for any or all of our product candidates. Additional delays may result if the FDA, an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Studies required to demonstrate the safety and efficacy of our product candidates are time consuming, expensive and together take several years or more to complete. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Delays in regulatory approvals or rejections of applications for regulatory approval in the United States, Europe, Japan or other markets may result from many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to obtain sufficient funds required for a clinical trial;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory requests for additional analyses, reports, data, non- clinical and preclinical studies and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory questions regarding interpretations of data and results and the emergence of new information regarding our product candidates or other products;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_083842_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Clinical holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial in countries that require such approvals;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Failure to reach agreement with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to enroll or retain a sufficient number of subjects who meet the inclusion and exclusion criteria in our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to conduct our clinical trials in accordance with regulatory requirements or our clinical trial protocols;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding safety or efficacy of our product candidates during clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Failure to meet the level of statistical significance required for approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any determination that a clinical trial presents unacceptable health risks to subjects;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Lack of adequate funding to commence or continue our clinical trials due to unforeseen costs or other business decisions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to identify and maintain a sufficient number of sites, many of which may already be engaged in other clinical trial programs, including other clinical trials for the same indications targeted by our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to obtain approval from IRBs to conduct clinical trials at their respective sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to timely obtain from our third party manufacturer sufficient quantities or quality of the product candidate or other materials required for a clinical trial;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to validate our commercial manufacturing process;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be unable to obtain approval for the manufacturing processes or facilities of the third party manufacturer with whom we contract for clinical and commercial supplies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be unable to obtain agreement from the FDA on product labeling;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may have insufficient funds to pay the significant user fees required by the FDA upon the filing of an NDA; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may have difficulty in maintaining contact with subjects, resulting in incomplete data.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The lengthy and unpredictable approval process, as well as the unpredictability of future clinical trial results, may result in our failure to obtain regulatory approval to market Twirla or any of our other product candidates, which would significantly harm our business, results of operations and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes in regulatory requirements and guidance may also occur and we may need to amend clinical trial protocols submitted to applicable regulatory authorities or conduct additional studies to reflect these changes. Amendments and additional studies may require us to resubmit clinical trial protocols to Institutional Review Boards and regulatory authorities for re-examination, which may impact the costs, timing or successful completion of a clinical trial.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are required to conduct additional clinical trials or other studies with respect to any of our product candidates beyond those that we contemplated, if we are unable to successfully complete our clinical trials or other studies or if the results of these studies are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for our product candidates, we may not be able to obtain regulatory approval at all or we may obtain approval for indications that are not as broad as intended. For example, the FDA issued a CRL in response to our NDA for Twirla requesting, among other items, an additional Phase&nbsp;3 clinical study, which will delay our ability to obtain regulatory approval for that product candidate. We may also experience delays due to changes in regulatory requirements and guidance, which may require protocol amendments or the conduct of additional studies. These amendments and additional studies may require regulatory or IRB approval. The approval and conduct of these studies may delay, limit or preclude regulatory approval for our product candidates. Our product development costs will also increase if we experience delays in testing or approvals and we may not have sufficient funding to complete the testing and approval process for any of our product candidates. Significant clinical trial delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products if and when approved. If any of this occurs, our business will be materially harmed.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_083856_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our product candidates may have undesirable adverse effects, which may delay or prevent regulatory approval or, if approval is received, require our products to be taken off the market, require them to include safety warnings or otherwise limit their sales.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unforeseen adverse effects from any of our product candidates could arise either during clinical development or, if approved, after the approved product has been marketed. In the combined safety population of our completed Phase&nbsp;3 trials, there were a total of 22 serious adverse events, or SAEs, of which 16 occurred in the Twirla cohort, which had approximately 2.3 times as many subjects as the oral contraceptive comparator cohort. Three of the 16 SAEs in the Twirla cohort (0.2% of the overall Twirla safety population) were considered to be possibly related to Twirla, and included one drug overdose with Benadryl, one case of uncontrollable nausea and vomiting and one instance of deep vein thrombosis. In addition to the SAEs described above, some subjects taking Twirla experienced non-serious adverse events, such as nausea, headache, application site irritation and breast tenderness. Subjects receiving the oral contraceptive comparator also experienced non-serious adverse events such as nausea, headache and breast tenderness, though at different rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any undesirable adverse effects that may be caused by our product candidates could interrupt, delay or halt clinical trials and could result in more restrictive labeling or the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product candidates and generating revenues from their sale. Adverse effects could also impact subject recruitment or the ability or willingness of enrolled subjects to complete the trial, or result in product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, if any of our product candidates receive regulatory approval and we or others later identify undesirable adverse effects caused by the product, we could face one or more of the following consequences:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may suspend marketing of, withdraw or recall the product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory authorities may require the addition of labeling statements, such as a black box warning or a contraindication, or other labeling changes;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory authorities may withdraw their approval of the product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory authorities may seize or detain the product or seek an injunction against its manufacture or distribution;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The FDA or other regulatory authorities may issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The FDA may require the establishment or modification of a REMS or a comparable foreign authority may require the establishment or modification of a similar strategy that may, for instance, require us to issue a medication guide outlining the risks of such adverse effects for distribution to patients, or restrict distribution of the product, if and when approved, and impose burdensome implementation requirements on us;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be required to conduct additional trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be required to change the way that the product is administered;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be subject to litigation or product liability claims, fines, injunctions or criminal penalties;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory authorities may impose label changes, or additional restrictions on marketing and distribution of the product; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our reputation may suffer.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its sale.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_083913_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our development and commercialization strategy for Twirla depends, in part, on published scientific literature and the FDA&#146;s prior findings regarding the safety and efficacy of approved products containing Ethinyl Estradiol and Levonorgestrel based on data not developed by us, but upon which the FDA may rely in reviewing our NDA.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Hatch-Waxman Act added Section&nbsp;505(b)(2)&nbsp;to the Federal Food, Drug and Cosmetic Act, or FDCA. Section&nbsp;505(b)(2)&nbsp;permits the filing of an NDA where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The FDA interprets Section&nbsp;505(b)(2)&nbsp;of the FDCA, for purposes of approving an NDA, to permit the applicant to rely, in part, upon published literature or the FDA&#146;s previous findings of safety and efficacy for an approved product. The FDA may also require companies to perform additional clinical trials or measurements to support any deviation from the previously approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&nbsp;505(b)(2)&nbsp;applicant. The label, however, may require all or some of the limitations, contraindications, warnings or precautions included in the reference product&#146;s label, including a black box warning, or may require additional limitations, contraindications, warnings or precautions. We have submitted an NDA for Twirla under Section&nbsp;505(b)(2)&nbsp;and as such the NDA relied, in part, on the FDA&#146;s previous findings of safety and efficacy from investigations for approved products containing ethinyl estradiol, or EE, and levonorgestrel, or LNG and published scientific literature for which we have not received a right of reference. We received a CRL in response to our Section&nbsp;505(b)(2)&nbsp;NDA for Twirla, in which the FDA requested, among other things, that we conduct an additional Phase&nbsp;3 clinical trial. Even though we may be able to take advantage of Section&nbsp;505(b)(2)&nbsp;to support potential U.S. approval for Twirla, the FDA may require us to perform additional clinical trials or measurements to support approval over and above the clinical trials that we have already completed and the additional clinical trial we currently plan to commence during the third quarter of 2014. In addition, notwithstanding the approval of many products by the FDA pursuant to Section&nbsp;505(b)(2), over the last few years some pharmaceutical companies and others have objected to the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If the FDA changes its interpretation of Section&nbsp;505(b)(2), or if the FDA&#146;s interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section&nbsp;505(b)(2)&nbsp;NDAs that we submit. Such a result could require us to conduct additional testing and costly clinical trials, which could substantially delay or prevent the approval and launch of our product candidates, including Twirla.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Capital</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have never been profitable. Currently, we have no products approved for commercial sale, no source of revenue and we may never become profitable.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never been profitable and do not expect to be profitable in the foreseeable future. We have no products approved for commercial sale and to date have not generated any revenue from product sales. Our ability to generate revenue and become profitable depends upon our ability to successfully complete the development of and obtain the necessary regulatory approvals for our product candidates. We have been engaged in developing Twirla and our Skinfusion technology since our inception. To date, we have not generated any revenue from Twirla, and we may never be able to obtain regulatory approval for the marketing of Twirla. Further, even if we are able to gain approval for and commercialize Twirla or any other product candidate, there can be no assurance that we will generate significant revenues or ever achieve profitability. Our ability to generate product revenue depends on a number of factors, including our ability to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Successfully complete clinical development of, and receive regulatory approval for, our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Set an acceptable price for our products, if approved, and obtain adequate coverage and reimbursement from third party payors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Obtain commercial quantities of our products, if approved, at acceptable cost levels; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Successfully market and sell our products, if approved, in the United States and abroad.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, because of the numerous risks and uncertainties associated with product candidate development, we are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or other regulatory authorities to perform studies in addition to those that we currently anticipate. Even if our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of these products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to become and remain profitable depends on our ability to generate revenue. Even if we are able to generate revenues from the sale of our products, if approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or obtain additional funding, or are unable to sustain profitability on a continuing</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_083931_2639"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">* <i>We have incurred operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable future.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred losses in each year since our inception in December&nbsp;1997. Our net losses were $23.9&nbsp;million for the year ended December&nbsp;31, 2012 and $14.3&nbsp;million for the year ended December&nbsp;31, 2013. Our net losses were $3.7 million and $2.9 million for the three and six months ended June&nbsp;30, 2014. As of June&nbsp;30, 2014, we had an accumulated deficit of $121.2&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specialty pharmaceutical product development is a speculative undertaking, involves a substantial degree of risk and is a capital-intensive business. We expect to incur expenses without corresponding revenues until we are able to obtain regulatory approval and subsequently sell Twirla in significant quantities, which may not happen. We have devoted most of our financial resources to research and development, including our non-clinical development activities and clinical trials. We expect to incur increased expenses as we commence our additional Phase&nbsp;3 clinical trial for Twirla, respond to the CRL and supplement our NDA with the results of the trial, complete the qualification and validation of our commercial manufacturing process, advance our other product candidates and expand our research and development programs. To date, we have financed our operations primarily through the sale of convertible preferred stock and convertible debt. Our product candidates will require the completion of regulatory review, significant marketing efforts and substantial investment before they can provide us with any revenue.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assuming we obtain FDA approval, we expect that our expenses will increase as we prepare for the commercial launch of Twirla. As a result, we expect to continue to incur substantial losses for the foreseeable future, and these losses may increase. We are uncertain when or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and adversely affect the price of our common stock and our ability to raise capital.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern, and as a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended December&nbsp;31, 2013 with respect to this uncertainty. This going concern opinion could materially limit our ability to raise additional funds through the issuance of new debt or equity securities or otherwise. Future reports on our financial statements may include an explanatory paragraph with respect to our ability to continue as a going concern. We have incurred significant losses since our inception and have never been profitable, and it is possible we will never achieve profitability. We have devoted a majority of our resources to developing Twirla, but this product candidate cannot be marketed until regulatory approvals have been obtained. Meaningful revenues will likely not be available until and unless Twirla or any of our current or future product candidates are approved by the FDA or comparable regulatory agencies in other countries and successfully marketed, either by us or a partner, an outcome which may not occur. Based upon our currently-expected level of operating expenditures, we expect to be able to fund our operations through the first quarter of 2016. This period could be shortened if there are any significant increases in planned or actual spending on development programs or more rapid progress of development programs than anticipated. There is no assurance that other financing will be available when needed to allow us to continue as a going concern. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>If we fail to obtain the capital necessary to fund our operations, we may be unable to obtain regulatory approval of or commercialize Twirla in the United States and we could be forced to share our rights to commercialize Twirla with third parties on terms that may not be favorable to us.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We need large amounts of capital to support our development and commercialization efforts for Twirla. If we are unable to secure sufficient capital to fund our operations, we will not be able to continue these efforts and we might have to enter into strategic collaborations that could require us to share commercial rights to Twirla with third parties in ways that we currently do not intend or on terms that may not be favorable to us. Based on our current operating plans, we believe that our cash, cash equivalents and marketable securities will be sufficient to meet our anticipated operating needs through the first quarter of 2016. Our cash and cash equivalents were $53.5&nbsp;million as of June&nbsp;30, 2014. We anticipate requiring additional capital to fund operating needs thereafter. We may also need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_083953_2794"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>Our operating activities may be restricted as a result of covenants related to the outstanding indebtedness under our loan agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of June&nbsp;30, 2014, we had $15&nbsp;million of principal indebtedness outstanding under our loan and security agreement with Oxford Finance&nbsp;LLC, or Oxford. The loan agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance, and restrictions on our ability to dispose of our business or property, change our line of business, liquidate or dissolve, enter into any change in control transaction, merge or consolidate with any other entity or acquire all or substantially all the capital stock or property of another entity, incur additional indebtedness, incur certain types of liens on our property, including our intellectual property, pay any dividends or other distributions on our capital stock other than dividends payable solely in capital stock or redeem our capital stock. Our business may be adversely affected by these restrictions on our ability to operate our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term loan is secured by substantially all of our property other than our intellectual property. We are currently required to make interest-only payments through January&nbsp;2015. The term loan bears interest at a fixed rate of 9.2% per annum and matures on July&nbsp;1, 2017.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, we may be required to repay the outstanding indebtedness under the term loan if an event of default occurs under the loan agreement. Under the loan agreement, an event of default will occur if, among other things, we fail to make payments under the loan agreement; we breach any of our covenants under the loan agreement, subject to specified cure periods with respect to certain breaches; Oxford determines in good faith that we are unable to satisfy our obligations under the loan agreement as they become due and that our principal investors do not intend to fund amounts necessary to satisfy such obligations; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit Oxford to accelerate the maturity of such indebtedness or that could have a material adverse effect on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our product candidate development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Oxford could also exercise its rights as collateral agent to take possession and dispose of the collateral securing the loan for its benefit, which collateral includes all of our property other than our intellectual property. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>We will need to obtain additional financing to fund our operations and, if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our product candidates.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our operations have consumed substantial amounts of cash since inception. From our inception to June&nbsp;30, 2014, we have cumulative net cash flows used by operating activities of $108.0&nbsp;million. We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. We will need to obtain additional financing to conduct additional trials for the approval of our product candidates if requested by regulatory authorities, and to complete the development of any additional product candidates we might acquire. Moreover, our fixed expenses such as rent, interest expense and other contractual commitments are substantial and are expected to increase in the future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future funding requirements will depend on many factors, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Progress, timing, scope and costs of our clinical trials, including the ability to timely enroll subjects in our planned and potential future clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Time and cost necessary to obtain regulatory approvals that may be required by regulatory authorities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our ability to successfully commercialize our product candidates, if approved;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our ability to have commercial product successfully manufactured consistent with FDA regulations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Sales and marketing costs associated with commercializing our products, if approved, including the cost and timing of expanding our marketing and sales capabilities;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_084015_8299"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Cash requirements of any future acquisitions or the development of other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Costs of operating as a public company;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Time and cost necessary to respond to technological and market developments; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until we can generate a sufficient amount of revenue, we may finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances and marketing or distribution arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. In addition, if we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our projected operating requirements through the first quarter of 2016. We expect that these funds will not be sufficient to enable us to complete all necessary development of our product candidates other than Twirla, complete validation of our commercial manufacturing process or commercially launch Twirla or our other current product candidates. Accordingly, we will be required to obtain further funding through other public or private offerings, debt financing, collaboration or licensing arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. Our forecast of the period of time through which our financial resources will be adequate to support our operating requirements is a forward- looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on a number of assumptions that may prove to be wrong, and changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate. Our inability to obtain additional funding when we need it could seriously harm our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders or restrict our operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. The sale of additional equity or convertible debt securities could result in the issuance of additional shares of our capital stock and could result in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing research and development efforts. This could harm our business, operating results and financial condition and cause the price of our common stock to fall.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are a development stage company which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a development stage company. We were incorporated and commenced active operations in 1997. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital and developing our product candidates. We have not yet demonstrated our ability to successfully complete a Phase&nbsp;3 registration trial for, obtain regulatory approval of or manufacture on a commercial scale any of our product candidates, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, as a development stage company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a focus on product candidate development to a company capable of supporting commercial activities. We may not be successful in such a transition.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_084025_8247"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-gc.htm',USER='105340',CD='Aug  9 10:57 2014' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Relating to the Commercialization of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are substantially dependent on the commercial success of Twirla.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assuming FDA approval, Twirla will be the first product that we commercialize. Our ability to generate revenues and become profitable will depend in large part on the commercial success of Twirla. If Twirla or any other product that we commercialize in the future do not gain an adequate level of acceptance among physicians, patients and third parties, we may not generate significant product revenues or become profitable. Market acceptance of Twirla, and any other product that we commercialize, by physicians, patients and third party payors will depend on a number of factors, some of which are beyond our control, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Efficacy, safety and other potential advantages of our product candidates in relation to alternative treatments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Relative convenience and ease of administration of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Availability of adequate coverage or reimbursement of our product candidates by third parties, such as insurance companies and other payors, and by government healthcare programs, including Medicare, Medicaid and state health insurance exchanges;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Prevalence and severity of adverse events associated with our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Cost of our product candidates in relation to alternative treatments, including generic products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Extent and strength of our third-party manufacturer and supplier support;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Extent and strength of our marketing and distribution support;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Limitations or warnings contained in our product&#146;s FDA approved labeling; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory REMS or voluntary risk management plan.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, if Twirla is approved by the FDA, physicians and patients may not be immediately receptive to a transdermal contraceptive system, as opposed to a pill or any other method, and may be slow to adopt it as an accepted treatment for the prevention of pregnancy. In addition, even though we believe Twirla has significant advantages over other treatment options, because no head-to-head trials comparing Twirla to the competing approved patch product have been conducted, the prescribing information approved by the FDA may not contain claims that Twirla is safer or more effective than the currently approved patch product, or other claims that may be necessary for successful marketing of Twirla. Accordingly, we will not be permitted to promote Twirla, if approved, for any comparative advantages to the currently marketed contraceptive patch. The availability of numerous inexpensive generic forms of contraceptive products may also limit acceptance of Twirla among physicians, patients and third party payors. If Twirla does not achieve an adequate level of acceptance among physicians, patients and third party payors, we may not generate significant product revenues or become profitable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">It will be difficult for us to profitably sell Twirla, if approved, or any other product that we obtain marketing approval for in the future if coverage and reimbursement for such product is limited.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Market acceptance and sales of Twirla, if approved, or any other product that we obtain marketing approval for in the future, will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for approved medications. A primary trend in the U.S. healthcare industry is cost containment. Government authorities and these third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage or reimbursement will be available for Twirla, if approved, or any other product that we obtain marketing approval for in the future and, if coverage is available, we cannot be sure of the level of reimbursement. Reimbursement may impact the demand for, or the price of, Twirla, if approved, and any other products that we obtain marketing approval for and commercialize. Numerous generic products may be available at lower prices than branded therapy products, such as Twirla, which may also reduce the likelihood and level of reimbursement for Twirla or other products. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize Twirla, if approved, or any other product for which we obtain marketing approval.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_080056_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*If we are unable to establish effective marketing and sales capabilities for Twirla, if approved, or enter into agreements with third parties to market and sell Twirla, we may be unable to generate product revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are seeking approval for Twirla from the FDA for a contraception indication. Assuming successful completion of our additional Phase&nbsp;3 trial in the first quarter of 2016, we plan to submit a complete response to the FDA that will include additional clinical trial results and manufacturing information to our NDA in early 2016. Assuming a six-month review by the FDA, we could receive a decision late in 2016. We intend to launch Twirla as soon as possible following receipt of approval from the FDA, if granted. However, we cannot assure you that the FDA will approve Twirla or that the FDA&#146;s timeline for review will be within six months. Following our original submission of the NDA, we received a CRL from the FDA requesting, among other things, additional Phase&nbsp;3 data. Assuming timely and successful completion of this additional Phase&nbsp;3 study and other items such as timely and successful completion of validation of equipment for commercial manufacturing, and ultimate FDA approval, we expect to be ready for commercialization by the end of 2016.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At present, we have no sales personnel and a limited number of marketing personnel. We do not intend to begin to hire additional marketing personnel until shortly prior to the final submission to our NDA or establish our own sales force or engage a contract sales organization in the United States until shortly prior to FDA approval of Twirla. At the time of our anticipated commercial launch of Twirla, assuming regulatory approval by the FDA, our sales and marketing team will have worked together for only a limited period of time. We cannot guarantee that we will be successful in marketing Twirla in the United States.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to establish our own sales force or a contract sales force in a cost-effective manner or realize a positive return on this investment. In addition, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to commercialize Twirla, if approved, in the United States without strategic partners or licensees include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our inability to timely recruit and retain adequate numbers of effective sales and marketing personnel;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, or if we do not successfully enter into appropriate collaboration arrangements, we will have difficulty commercializing Twirla, which would adversely affect our business, operating results and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we intend to commercialize Twirla outside the United States, we will likely enter into collaboration agreements with pharmaceutical partners, and we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend on the success of the efforts of these third parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that we rely on, or partner with, third parties to commercialize Twirla, if approved, or any other product candidate for which we obtain marketing approval in the future, we may receive less revenue than if we commercialized these products ourselves. In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts. In the event that we are unable to partner with a third party marketing and sales organization, our ability to generate product revenues may be limited in the United States, internationally or both.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">A variety of risks associated with potential international business relationships could materially adversely affect our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may enter into agreements with third parties for the development and commercialization of Twirla and possibly other product candidates in international markets. If we do so, we would be subject to additional risks related to entering into international business relationships, including:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_080105_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Differing regulatory requirements in foreign countries including, among others, requirements relating to drug approvals, reimbursement and sales and marketing practices;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Potentially reduced protection for intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The potential for so-called parallel importing, which is when a local seller, faced with higher local prices, opts to import goods from a foreign market with lower prices, rather than buying them locally;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Unexpected changes in tariffs, trade barriers and regulatory requirements;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Economic weakness, including inflation, or political instability in foreign economies and markets;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Compliance with tax, employment, immigration and labor laws for employees traveling and working abroad;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Foreign taxes;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other risks incident to doing business in another country;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Workforce uncertainty in countries where labor unrest is more common than in the United States;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, tsunamis, hurricanes and fires.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These and other risks may materially adversely affect our ability to develop and commercialize products in international markets and may harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we receive regulatory approval for Twirla, we still may not be able to successfully commercialize it and the revenue that we generate from its sales, if any, may be limited.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The commercial success of Twirla in any indication for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the contraceptive market landscape as well as acceptance and uptake of Twirla by physicians, patients and third-party payors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risks related to the contraceptive market landscape include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The prescription contraceptive market could experience a decrease in growth or negative growth if fewer women choose to use hormonal contraception;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The perceived safety of hormonal contraceptives could be negatively affected by media reports of adverse effects and advertisements for class action lawsuits due to adverse effects;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Price pressures from third party payors, including managed care organizations and government-sponsored health systems, could limit our revenue;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The proportion of the contraceptive market comprised of generic products could continue to increase, making introduction of a branded contraceptive difficult and expensive;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Competition in the contraceptive market could increase, with the introduction of new contraceptives, including the potential of a new generic or branded competitive contraceptive patch;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Competition from generic contraceptive products could increase as additional generic contraceptives receive FDA approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Implementation of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010 or, collectively, the Affordable Care Act, or ACA, and its effect on pharmaceutical coverage, reimbursement and pricing could limit our revenue; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_080113_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Access to the prescriber universe, particularly obstetrics and gynecology physicians, could be limited, decreasing our ability to promote Twirla efficiently.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The degree of acceptance and uptake of Twirla, if approved, by physicians, patients and third-party payors will depend upon a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The level of contraceptive effectiveness of Twirla demonstrated in our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The incidence and severity of adverse effects associated with Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Limitations on use or warnings contained in FDA-approved labeling;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Acceptability to patients of the appearance and feel of Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Willingness of patients to try a new contraceptive and to use a transdermal patch as their form of contraception;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Willingness of physicians to prescribe a contraceptive patch in light of safety issues and restrictive labeling of the currently marketed contraceptive patch;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The cost of Twirla to the patient, as compared to other contraceptive products and methods;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our ability to obtain and maintain sufficient third party coverage or reimbursement for Twirla from private health insurers, government healthcare programs (including Medicare, Medicaid and 340B Clinics) and other third party payors; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The effectiveness of our or any future collaborators&#146; sales and marketing strategies.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, even if we obtain regulatory approval, the timing of an approval may reduce our ability to commercialize Twirla successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability to develop competing products. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render Twirla not commercially viable. For example, regulatory authorities may grant approval contingent on the performance of costly post- marketing clinical trials or other post-marketing commitments, including REMS, or may approve Twirla with a label that contains fewer, or more limited, indications than requested, warnings, precautions or contraindications, including black box warnings, and the label may not include the claims necessary or desirable for the successful commercialization of Twirla. Any of the foregoing scenarios could materially harm the commercial prospects for Twirla.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If Twirla is approved, but does not achieve an adequate level of acceptance by physicians, third-party payors and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate physicians, patients and third party payors on the benefits of Twirla may require significant resources and may never be successful. Even if we are able to demonstrate and maintain a competitive advantage over our competitors and become profitable, if the market for hormonal contraceptives fails to achieve expected future growth or decreases, we may not generate sufficient revenue or sustain profitability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The proportion of the contraceptive market that is made up of generic products could continue to increase, making introduction of a branded contraceptive difficult and expensive.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The proportion of the U.S. market that is made up of generic products has been increasing over time. In 2005, generic contraceptive products held 47% of prescription volume and 34% of sales and, by 2011, those values had risen to 68% and 44%, respectively. As of September&nbsp;2013, 73% of the prescription volume and 45% of sales of combined hormonal contraceptives, or CHCs, in the U.S. were generated by generic products. If this trend continues, it may be more difficult to introduce Twirla, if approved, as a branded contraceptive, at a price that will maximize our revenue and profits. Also, there may be additional marketing costs to introduce Twirla in order to overcome the trend towards generics and to gain access to reimbursement by payors. If we are unable to introduce Twirla at a price that is commensurate with that of current branded contraceptive products, or we are unable to gain reimbursement from payors for Twirla, or if patients are unwilling to pay any price differential between Twirla and a generic contraceptive, our revenues will be limited. For example, in light of the introduction of the generic version of the Ortho Evra product by Mylan&nbsp;Inc. in April&nbsp;2014, in order to be competitive and gain market share, we may increase the rebates available to commercial payors or we may provide incentives to consumers covered by non-governmental payors, such as coupons or rebates, in order to make up for the difference in the co-payment for Twirla and the generic patch product.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_080242_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Physicians, patients and payors may not adopt a new contraceptive patch due to concerns based upon the prior experience with or perception of the currently marketed contraceptive patch.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Ortho Evra</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;contraceptive patch, or Evra, was introduced in early 2002 and was the first FDA-approved contraceptive patch. The following is a brief history of the Evra market experience:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evra had rapid uptake in the contraceptive market, achieving a 10% share of the CHC market by September&nbsp;2003. The initial approved labeling for Evra indicated that it delivered a daily EE dose of 20 micrograms.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Following the approval of Evra, users of Evra began to report thrombotic and thromboembolic events to the FDA.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A pharmacokinetic study was conducted in 2005 and later published in the Journal of Clinical Pharmacology comparing Evra to an oral contraceptive, which demonstrated that Evra was delivering higher serum concentrations of EE compared to an oral contraceptive with an EE dose of 35 micrograms. A pharmacokinetic study evaluates how the body handles a given drug over time; these studies are conducted by measuring the amount of time it takes for the drug to be absorbed, distributed and eliminated throughout the body.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Johnson&nbsp;&amp; Johnson, the manufacturer of Evra, revised the Evra labeling in November&nbsp;2005 to include information that EE exposure with Evra is 60% higher than that of an oral contraceptive containing EE of 35 micrograms, based on area under the curve, a commonly-used metric for measuring EE exposure in contraceptives. This information was ultimately included in a unique black box warning and bolded warning in the Evra labeling.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The FDA held a Joint Meeting of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management on December&nbsp;9, 2011. The Committees concluded that users of Evra have an increased risk of VTE compared to users of second generation contraceptives, such as those containing LNG. The Committees, through a vote, concluded that the benefits of Evra outweighed the risks, but that the current package insert did not adequately reflect the risk/benefit profile.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A subsequent change to the labeling for Evra was implemented in August&nbsp;2012.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Evra market share declined rapidly following the labeling changes, from a peak share of 11% in 2005, to 4% by the end of 2006, to 1.4% by the end of 2013.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In April&nbsp;2014, the Evra label was revised to provide revised dosage form and strength information. However, this revision did not affect the unique black box warning and bolded warning in the Evra label.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The approval of a generic equivalent to Evra was announced by Mylan&nbsp;Inc. in April&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have conducted pharmacokinetic studies of Twirla to demonstrate that it delivers a daily EE dose of approximately 30&nbsp;micrograms, comparable to a low-dose oral contraceptive. However, because none of our completed or planned clinical trials studied or expect to study Twirla in a head-to-head comparison with Evra, if Twirla is approved by the FDA, we will not be able to make direct comparative claims regarding the safety and efficacy of Twirla as compared to Evra. While we expect Twirla, if approved, to have the same black box warning currently required for all CHCs, we cannot predict whether the FDA will require that we include information in the Twirla labeling or black box warning regarding the additional risks associated with the Evra patch. Assuming approval, if we are not able to convince physicians, patients and payors that Twirla delivers a low daily dose of EE, this may limit uptake and usage of Twirla and our revenue will be limited.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The biotechnology and pharmaceutical industries are intensely competitive. We would have significant competition with contraceptive products already in the marketplace, many of which have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have. Any new product that competes with a previously approved product may need to demonstrate compelling advantages in efficacy, convenience, tolerability or safety to be commercially successful. In addition, new products developed by others could emerge as competitors to Twirla, if approved. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_080250_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our potential competitors include large, well-established pharmaceutical companies, and specialty pharmaceutical sales and marketing companies. These companies include Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., or Merck, which markets Nuvaring</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, Actavis&nbsp;plc, or Actavis, which markets several branded and generic contraceptives including Loestrin</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;24 and LoLoestrin</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, Teva Pharmaceutical Industries&nbsp;Ltd., or Teva, which markets several branded and generic contraceptives including Gianvi</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;and Quartette</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, Bayer AG, or Bayer, which markets Beyaz</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;and Mirena</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, Johnson&nbsp;&amp; Johnson, which markets Ortho-Tri-Cyclen</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Lo and Ortho Evra</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, Pfizer&nbsp;Inc., which markets Alesse</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;and Mylan&nbsp;Inc. which markets Xulane&#153;, a generic version of Ortho Evra. Additionally, several generic manufacturers currently market and continue to introduce new generic contraceptives, including Sandoz International&nbsp;GmbH, Glenmark Pharmaceuticals&nbsp;Ltd., Lupin Pharmaceuticals,&nbsp;Inc., and Amneal Pharmaceuticals&nbsp;LLC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are other contraceptive product candidates in development that, if approved, would potentially compete with Twirla. Specifically, Bayer has a contraceptive patch recently approved in the European Union, or E.U., a patch and oral contraceptive, each in Phase&nbsp;3 clinical development in the United States. Other companies that have new contraceptive product candidates in various stages of development include Teva (oral contraceptive in Phase&nbsp;3), Merck (oral contraceptive in Phase&nbsp;3), Actavis (vaginal ring and oral contraceptive in Phase&nbsp;2) and Antares Pharma,&nbsp;Inc. (transdermal gel contraceptive in Phase&nbsp;2).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Sales of our products, if approved, may be adversely affected by the consolidation among wholesale drug distributors and the growth of large retail drug store chains.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The network through which we will sell our products, if and when approved, has undergone significant consolidation marked by mergers and acquisitions among wholesale distributors and the growth of large retail drugstore chains. As a result, a small number of large distributors control a significant share of the market. In 2012, three companies generated about 85% of all revenues from drug distribution in the United States, and in 2010, four chain pharmacy companies owned about 30% of all retail pharmacy outlets. Consolidation of drug wholesalers and retailers, as well as any increased pricing pressure that those entities face from their customers, including the U.S. government, may increase pricing pressure and place other competitive pressures on drug manufacturers, including us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and to commercialize Twirla and may affect the prices we may obtain.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for Twirla, restrict or regulate post-approval activities and affect our ability to profitably sell Twirla.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the FDA&#146;s regulations, guidance or interpretations will change, or what the impact of such changes on the potential marketing approval of Twirla, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2010, President Obama signed into law the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the healthcare industry and impose additional healthcare policy reforms. The ACA, among other things, increased the Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program for both branded and generic drugs, extended the rebate program to certain individuals enrolled in Medicaid managed care organizations, addressed new methodologies by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are line extension products and expanded the 340B drug discount program (excluding orphan drugs) to other entities. Further, the ACA imposed a significant annual tax on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may require us to modify our business practices with regard to healthcare practitioners.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Of particular relevance to our business is the ACA requirement that all health plans, with limited exceptions, cover certain preventive services for women with no cost sharing, which means no deductible, no co-insurance and no co-payments by the patient. Contraceptive methods and counseling, including all FDA-approved contraceptive methods as prescribed, are included in the ACA mandate, and this has come to be known as the &#147;contraceptive mandate.&#148; Under the ACA, payors are only required to cover one favored product within each contraceptive &#147;method&#148; without imposing any cost-sharing obligations on the patient. For example, the introduction of a generic contraceptive patch product with a price that will likely be lower than the price of Twirla makes it less clear that Twirla would have a preferred position, such as coverage without a co-insurance payment, under the ACA contraceptive mandate. Other products within the same method may also be covered, but payors are allowed to use reasonable medical management</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_080415_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">techniques, such as the application of cost-sharing obligations. An amendment was issued that provided an exemption to the contraceptive mandate for group health plans established or maintained by religious employers. However, the contraceptive mandate has remained controversial, with several legal challenges filed around the country, and the U.S. Supreme Court ruled in June&nbsp;2014 that owners of certain private companies can object to the contraceptive mandate on religious grounds. Although it is too early to determine the full effect of the contraceptive mandate and other provisions of the ACA on our business, the new law appears likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and will stay in effect through 2024 unless additional Congressional action is taken. On January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or ATRA, which among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value of our product candidates and reduce our profitability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, the recently enacted Drug Quality and Security Act imposes new obligations related to product tracking and tracing on manufacturers of pharmaceutical products. Among the requirements of this new legislation, manufacturers will be required to provide certain information regarding the drug products they produce to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. The transfer of information to subsequent product owners by manufacturers will eventually be required to be done electronically. Manufacturers will also be required to verify that purchasers of the manufacturers&#146; drug products are appropriately licensed. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, and FDA and trading partner notification responsibilities related to counterfeit, diverted, stolen and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Third party coverage and reimbursement and healthcare cost containment initiatives and treatment guidelines may constrain our future revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to successfully market Twirla and other product candidates, if approved, will depend in part on the level of coverage and reimbursement that government authorities, private health insurers and other organizations provide for Twirla or our other product candidates and contraceptives in general. Countries in which Twirla or our other product candidates are sold through reimbursement schemes under national health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price increases. In certain countries, including the United States, government-funded and private medical care plans can exert significant indirect pressure on prices. We may not be able to sell Twirla or our other product candidates profitably if adequate prices are not approved or coverage and reimbursement are unavailable or limited in scope. Increasingly, third party payors attempt to contain healthcare costs in ways that are likely to impact our development of products including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Failing to approve or challenging the prices charged for healthcare products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Introducing reimportation schemes from lower-priced jurisdictions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Limiting both coverage and the amount of reimbursement for new therapeutic products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or investigational by third party payors; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Refusing to provide coverage when an approved product is used for off-label indications.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_080419_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Manufacturing and Our Reliance on Third Parties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*We have no manufacturing capacity and anticipate continued reliance on Corium, our third party manufacturer, for the development and commercialization of our product candidates in accordance with manufacturing regulations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on Corium International,&nbsp;Inc., or Corium, our third party manufacturer, to produce clinical supplies of Twirla and our other product candidates, and we plan to continue relying on them for commercial supplies and samples of our product candidates, if approved. We do not own or operate, and have no plans to establish, any manufacturing facilities for our product candidates. We lack the resources and the capabilities to manufacture Twirla or any of our product candidates on a clinical or commercial scale. The facilities used by Corium to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after submission of an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as Current Good Manufacturing Practices, or cGMPs, for manufacture of our product candidates and our products, if and when approved. If Corium or other contract manufacturers that we may use cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturer to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities that would also require FDA approval, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Moreover, if our contract manufacturer cannot successfully manufacture materials that conform to our specifications and the strict regulatory requirements of the FDA or others, we may be subject to other regulatory enforcement action such as adverse inspectional findings, Warning Letters, Untitled Letters, recall requests, withdrawal of product or investigational approvals, clinical holds or termination, disgorgement, restitution, exclusion from federal healthcare programs product seizures and detention, consent decrees, corporate integrity agreements, criminal and civil penalties, including imprisonment, refusal to permit import or export of the product and injunction against or restriction of manufacture or distribution. If our contract manufacturer experiences issues in its manufacturing process or is unable to produce clinical supplies in adequate quantity and quality, our clinical trial could be delayed or our ability to receive regulatory approval of our product candidates could be negatively affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The machinery to produce the commercial supply of Twirla must be qualified and validated, which is time-consuming and expensive, and this machinery is located within one manufacturing site and is customized to the particular manufacturing specifications of Twirla. If Corium is unable to qualify and validate this equipment in a timely manner, our ability to launch and commercialize Twirla will be compromised. If this customized equipment malfunctions at any time during the production process, the time it may take Corium to secure replacement parts, to undertake repairs and to revalidate the equipment and process could limit our ability to meet the commercial demand for Twirla. Similar manufacturing conditions may also apply to our other product candidates. This may increase the risk that the third party manufacturer may not manufacture Twirla in accordance with the applicable regulatory requirements, that we may not have sufficient quantities of Twirla or our product candidates or that we may not have such quantities at an acceptable cost, any of which could delay, prevent, or impair the commercialization of Twirla, if approved, and the development of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we have manufacturing agreements with Corium for the clinical and commercial supply of Twirla, Corium and several of its suppliers of raw materials will be single source providers to us for a significant period of time. In particular, Corium manufactures Twirla using EE and LNG and components that it purchases from third parties, most of which are single source suppliers of the applicable material. We do not have any control over the process or timing of the acquisition of these raw materials by Corium. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we outsource all of our manufacturing processes, there is no guarantee that there will be sufficient supplies to fulfill our requirements or that we may obtain such supplies on acceptable terms. Although Corium intends to enter into agreements with critical manufacturers, component fabricators and secondary service providers to secure commercial supply of Twirla, not all of such suppliers and service providers will be under contract. Any delays in obtaining adequate supplies of our product candidates could limit our ability to meet commercial demand for Twirla.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, in the event Twirla is approved and achieves significant market share, Corium may not possess adequate manufacturing capabilities to meet market demand for Twirla. If it becomes necessary to engage an additional third party manufacturer to produce Twirla, we may need to license certain manufacturing know-how from Corium, or our commercial supply will be limited while the new third party manufacturer develops the necessary know-how to manufacture Twirla.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_080424_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reliance on a third party manufacturer subjects us to risks that would not affect us if we manufactured the product candidates ourselves, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Reliance on the third party for regulatory compliance and quality assurance;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Reduced control over the manufacturing process for our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The possible breach of the manufacturing agreements by the third party because of factors beyond our control;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The possibility of termination or nonrenewal of the agreements by the third party because of our breach of the manufacturing agreement or based on their own business priorities; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The disruption and costs associated with changing suppliers.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product candidates may compete with other products and product candidates for access to manufacturing resources and facilities. There are a limited number of manufacturers that operate under cGMP requirements and that are both capable of manufacturing for us and willing to do so. If our existing third party manufacturer, or the third parties that we may engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue to manufacture our product candidates for any reason, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we are unable to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our third party manufacturer is subject to regulatory requirements, covering manufacturing, testing, quality control and record keeping relating to our product candidates, and subject to ongoing inspections by the regulatory agencies. In addition to the above-described regulatory actions, failures by our third party manufacturer to comply with applicable regulations may result in long delays and interruptions to our manufacturing capacity while we seek to secure another third party manufacturer that meets all regulatory requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are dependent on numerous third parties in Corium&#146;s supply chain for the supply of our product candidates, and if Corium fails to maintain supply relationships with these third parties, develop new relationships with other third parties or suffers disruptions in supply, we may be unable to continue to develop our product candidates, or, assuming FDA approval, commercialize Twirla.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We, through our manufacturing partner Corium, rely on a number of third parties for the supply of active ingredients and other raw materials for the clinical supply of our product candidates and, assuming FDA approval, commercialization of Twirla. Our ability to develop our product candidates depends, in part, on Corium&#146;s ability to successfully obtain the active pharmaceutical ingredients used in our product candidates, in accordance with regulatory requirements and in sufficient quantities for clinical testing and later commercialization. If Corium fails to develop and maintain supply relationships with these third parties, we may be unable to continue to develop our product candidates or commercialize any approved products in the future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We, through Corium, also rely on certain third parties as the current sole source of the materials they supply. Although many of these materials are produced in more than one location or are available from another supplier, if any of these materials becomes unavailable to us for any reason, we likely would incur added costs and delays in identifying or qualifying replacement materials and there can be no assurance that replacements would be available to us on acceptable terms, or at all. In certain cases we may be required to get regulatory approval to use alternative suppliers, and this process of approval could delay development of our product candidates and, assuming FDA approval, commercial production of Twirla, indefinitely.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If Corium&#146;s third party suppliers fail to deliver the required quantities of sub-components and starting materials, in accordance with all regulatory requirements, and on a timely basis and at commercially reasonable prices, and we and Corium are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality, and on a timely basis, the continued development of our product candidates, and assuming FDA approval, commercialization of Twirla, would be impeded, delayed, limited or prevented, which could harm our business, results of operations, financial condition and prospects.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_080435_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If the manufacturing facilities of Corium are not maintained in a manner that is compliant with cGMP requirements, we may need to find alternative manufacturers and suppliers, which could result in supply interruptions of Twirla and our other product candidates, additional costs and lost revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corium&#146;s facilities used for the manufacture of our product candidates must be maintained in a manner compliant with cGMP requirements, including obtaining favorable inspection reports. We do not control the manufacturing process and are dependent on Corium for compliance with the FDA&#146;s requirements for manufacture of Twirla and our other product candidates. If Corium cannot successfully manufacture material components and finished products that conform to our specifications and the FDA&#146;s strict regulatory requirements, they and we may be subject to regulatory action, including adverse inspectional findings, Warning Letters, Untitled Letters, product recall requests, withdrawal of product or investigational approvals, clinical holds or termination, disgorgement, restitution, exclusion from federal healthcare programs, detentions or seizures, refusal to allow the import or export of a product, injunction against or restriction of manufacture or distribution, consent decrees, corporate integrity agreements, criminal and civil penalties, including imprisonment, and Corium may not be able to maintain FDA approval for its manufacturing facilities or acceptance of its manufacturing data in regulatory filings. If Corium&#146;s facilities cannot maintain compliance with FDA requirements, we may need to find and successfully qualify alternative manufacturing facilities, which could result in supply interruptions of Twirla and our other product candidates and substantial additional costs as a result of such delays, including costs with respect to finding alternative manufacturing facilities, and lost revenues.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with applicable regulatory requirements, we may be delayed in obtaining or ultimately not be able to obtain marketing approval for our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently rely on CROs for most aspects of our clinical trials, including trial conduct, data management, statistical analysis and electronic compilation of our NDA. We may enter into agreements with CROs to obtain additional resources and expertise in an attempt to accelerate our progress with regard to new or ongoing clinical and preclinical programs. Entering into relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, typically there is a transition period between engagement of a CRO and the time the CRO commences work. As a result, delays may occur, which may materially impact our ability to meet our desired clinical development timelines and ultimately have a material adverse impact on our operating results, financial condition or future prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As CROs are not our employees, we cannot control whether or not they devote sufficient time and resources to our clinical trials for which they are engaged to perform, and whether they comply with the applicable regulatory requirements, known as Current Good Clinical Practices, or cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development, which include requirements related to the conduct of the study, subject informed consent, and IRB approval. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. Although we may rely on third parties for the execution of our trials, we are nevertheless responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on CROs does not relieve us of our regulatory responsibilities. If we or any of our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, European Medicines Agency or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications, in addition to the additional Phase&nbsp;3 clinical trial that we are planning to conduct in response to the CRL that we received from the FDA in February&nbsp;2013. We cannot assure you that, upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product candidate materials produced under cGMP regulations. Our failure to comply with these regulations may require us to discontinue or repeat clinical trials, which would delay the regulatory approval process. If the CROs we engage do not successfully carry out their contractual duties or obligations, conduct the clinical trials in accordance with all regulatory requirements, or meet expected deadlines, or if they need to be replaced, or the quality or accuracy of the data they provide is compromised due to the failure to adhere to regulatory requirements or for other reasons, then our development programs may be extended, delayed or terminated, or we may not be able to obtain marketing approval for or successfully commercialize our product candidates. Failure to comply with clinical trial regulatory requirements may further subject us to regulatory action, including Warning Letters, Untitled Letters, adverse inspectional findings, clinical holds or termination, criminal and civil penalties, including imprisonment, injunction against manufacture or distribution and debarment. As a result, our financial results and the commercial prospects for our product candidates would be harmed and our costs would increase.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_080440_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\jms\106406\14-17045-1\task6929603\17045-1-ge.htm',USER='106406',CD='Aug 13 12:49 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may seek partnerships, collaborations and other strategic transactions to maximize the commercial potential of Twirla, our other product candidates and our proprietary technologies in the United States and territories throughout the world. We may enter into such arrangements on a selective basis depending on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for Twirla and each of our other product candidates and technologies, both in the United States and internationally. We face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters could lead to delays in the development process or commercialization of our product candidates and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision making authority.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect us financially and could harm our business reputation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to establish an effective distribution process our business may be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not currently have the infrastructure necessary for distributing pharmaceutical products. We intend to contract with third party logistics wholesalers to warehouse these products and distribute them to pharmacies. This distribution network will require significant coordination with our sales and marketing and finance organizations. Failure to secure contracts with wholesalers could negatively impact the distribution of our products, if and when approved, and failure to coordinate financial systems could negatively impact our ability to accurately report product revenue. If we are unable to effectively establish and manage the distribution process, the commercial launch and sales of our products, if and when approved, will be delayed or severely compromised and our results of operations may be harmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Regulatory Matters Following Approval</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we obtain marketing approval for Twirla or other product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, Twirla or other product candidates could be subject to labeling and other restrictions, including withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if we obtain U.S. regulatory approval of Twirla or other product candidates, the FDA may still impose significant restrictions on their indicated uses, including more limited patient populations, require that precautions, contraindications, or warnings be included on the product labeling, including black box warnings, or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase&nbsp;4 clinical trials, and post-market surveillance to monitor safety and efficacy. Claims that we may make may also be restricted through our approved labeling. Twirla and our other product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, import, export, safety surveillance, advertising, marketing promotion, recordkeeping, reporting of adverse events and other post-market information, and further development. These requirements include registration with the FDA, listing of our drug products, payment of annual fees, as well as continued compliance with cGCPs for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents. Should the inspectional findings not be resolved to the FDA&#146;s satisfaction or should the finding rise to a sufficient level, the FDA and other government authorities may issue a Warning Letter or Untitled Letter, or take other regulatory action such as a product seizure and detention, withdrawal of product approval, request for a recall, refusal to allow the import or export of the product, criminal or civil penalties, injunction against or restriction of manufacture or distribution, consent decrees, disgorgement, restitution, clinical holds or terminations, exclusion from federal healthcare programs, corporate integrity agreements, or imprisonment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA has the authority to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the information that patients must be provided, distribution or use of an approved drug, such as limiting prescribing </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_080551_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring treated patients to enroll in a registry.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to sales and marketing activities by us or any future collaborative partner, advertising and promotional materials must comply with the FDA&#146;s rules in addition to other applicable federal and local laws in the United States and similar legal requirements in other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Application holders must notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act and similar state laws, which impact, among other things, our proposed sales, marketing and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, if Twirla and our other product candidates are approved, our product labeling, advertising and promotional materials would be subject to regulatory requirements and continuing review by the FDA, Department of Justice, Department of Health and Human Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling, a practice known as off-label promotion. If we receive marketing approval for Twirla or our other product candidates, physicians may nevertheless prescribe the products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed. For example, we believe that Twirla, if approved, will have a label consistent with all other marketed hormonal contraceptive products, which include class labeling that warns of risks of certain serious conditions, including venous and arterial blood clots, such as heart attacks, thromboembolism and stroke, as well as liver tumors, gallbladder disease, and hypertension, and a black box warning regarding risks of smoking and CHC use, particularly in women over 35&nbsp;years old that smoke. However, regulatory authorities may require the inclusion of additional statements about adverse events in the label, including additional black box warnings or contraindications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute drug products through, for example, corporate integrity agreements, and debarment, suspension or exclusion from participation in federal and state healthcare programs. These false claims statutes include the federal civil False Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims, or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. Since 2004, these False Claims Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices promoting off-label drug uses involving fines that are as much as $3.0&nbsp;billion. This growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we or a regulatory agency discover previously unknown problems with a product candidate, once approved, such as adverse events of unanticipated severity or frequency, data integrity issues with regulatory filings, problems with the facility where the product is manufactured or we or our manufacturers or others working on our behalf fail to comply with applicable regulatory requirements before or after marketing approval, we may be subject to reporting obligations as well as the following administrative or judicial sanctions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Restrictions on the marketing, distribution or manufacturing of the product, withdrawal of the product from the market, or requests for product recalls;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_080557_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Issuance of Warning Letters, Cyber Letters or Untitled Letters;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Mandate modification to promotional materials and labeling or require us to provide corrective information to healthcare providers;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">FDA or regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings and other safety information about the product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Require us to enter into a consent decree or corporate integrity agreement, which can include imposition of various fines, reimbursement for inspection costs, required due dates for specific actions and penalties for noncompliance;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Clinical holds or termination;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Injunctions or the imposition of civil or criminal penalties, imprisonment, monetary fines disgorgement or restitution;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Suspension or withdrawal of regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Suspension of any ongoing clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Debarment;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exclusion from participation in federal healthcare programs or refusal of government contracts</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Product seizure or detention or refusal to permit the import or export of product.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize Twirla or our other product candidates, if approved, and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, the FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, and the sale and promotion of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if Twirla receives marketing approval by the FDA in the United States, we may never receive marketing approval for or commercialize Twirla or any other product candidates outside the United States.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to market Twirla or any other product candidate outside the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. The marketing approval process in other countries may include all of the risks associated with obtaining FDA approval in the United States, as well as other risks. For example, legislation analogous to Section&nbsp;505(b)(2) of the FDCA in the United States, which relates to the ability of an NDA applicant to use published data not developed by such applicant, may not exist in other countries. In territories where data is not freely available, we may not have the ability to commercialize our products, when and if approved, without negotiating rights from third parties to refer to their clinical data in our regulatory applications, which could require the expenditure of significant additional funds. Further, we may be unable to obtain rights to the necessary clinical data and may be required to develop our own proprietary safety and efficacy dossiers. In addition, in many countries outside the United States, it is required that a product receive pricing and reimbursement approval before the product can be commercialized. This can result in substantial delays in such countries. Further, the product labeling requirements outside the United States may be different and inconsistent with the U.S. labeling and to the detriment to the product, and therefore negatively affect the ability to market in countries outside the United States.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_080606_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process in others. In addition, we may be subject to fines, suspension or withdrawal of marketing approvals, product recalls, seizure of products, operating restrictions and criminal prosecution if we fail to comply with applicable foreign regulatory requirements. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to market to our full target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will need to obtain FDA approval of any proposed product names, and any failure or delay associated with such approval may adversely affect our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have received conditional approval from the FDA for the use of Twirla as the proprietary name for our lead product candidate, AG200-15. However, this approval is conditional upon a further and final review by the FDA at the time of NDA approval. Additionally, any name we intend to use for our other product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office, or USPTO. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our relationships with physicians, customers and payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any product candidates that we commercialize. Our arrangements with third-party payors, including government healthcare programs, and customers will expose us to broadly-applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute Twirla, if approved, and any other product candidates we commercialize. Restrictions under applicable federal and state healthcare laws and regulations include the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, impose obligations on covered healthcare providers, health plans and healthcare clearinghouses, as well as their business associates that create receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The federal physician payment transparency requirements under the ACA and applicable regulations require manufacturers of drugs, devices, biologics and medical supplies to report certain information to the Department of Health and Human Services including information related to payments and other transfers of value made to physicians and teaching hospitals and the ownership and investment interests held by physicians and their immediate family members; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45<a name="PB_45_080613_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the relevant government or regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Moreover, recent healthcare reform legislation has strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes; such that a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them. In addition, the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations are costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities conducted by our sales team in the sale of Twirla or our other product candidates, if approved, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, corporate integrity agreements, refusal of government contracts, contract debarment and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Intellectual Property Rights</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to protect our proprietary technology in the marketplace.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability and any future licensee&#146;s ability to maintain our patents and to obtain additional patent protection in the United States and other countries with respect to our proprietary technology and products. We believe we will be able to obtain, through prosecution of our pending patent applications, additional patent protection for our proprietary technology. If we are compelled to spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed. If we are unable to effectively protect the intellectual property that we own, other companies may be able to offer for sale the same or similar products containing the generically available active pharmaceutical ingredients in our product candidates, which could materially adversely affect our competitive business position and harm our business prospects. Our patents may be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of term of patent protection that we may have for our product candidates. Even if our patents are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The patent positions of pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the United States and many jurisdictions outside of the United States is not consistent. For example, in many jurisdictions the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or create uncertainty. In addition, publication of information related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these product candidates and potential products, including without limitation transdermal delivery systems and methods of using such transdermal delivery systems. Our product candidates contain generically available active pharmaceutical ingredients. As a result, composition-of-matter patents directed to the active pharmaceutical ingredients in our product candidates, which are generally believed to offer the strongest form of patent protection, are not available for our product candidates.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46<a name="PB_46_080623_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patents that we own or may license in the future do not necessarily ensure the protection of our intellectual property for a number of reasons, including without limitation the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The active pharmaceutical ingredients in our product candidates are generic and therefore our patents do not include claims directed solely to the active pharmaceutical ingredients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product candidates using the same active pharmaceutical ingredients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There can be no assurance that the term of a patent protection will be long enough for our company to realize sufficient economic value under the patents following commercialization of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We do not expect, upon approval of our NDA, to receive patent term restoration under the Hatch-Waxman Act for the seven patents that have been, or will be, submitted to the FDA for listing in the Orange Book;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our issued patents and pending patent applications that may issue as patents in the future may not prevent entry into the U.S. market or other markets of generic versions of our Twirla and AG890 product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We do not at this time own or control issued foreign patents in all markets that would prevent generic entry into some markets for our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be required to disclaim part of the term of one or more patents;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which, nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There may be other patents issued to others that will affect our freedom to operate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If our patents are challenged, a patent office or a court could determine that they are invalid or unenforceable;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">There might be changes in the law that governs patentability, validity and infringement of our patents that adversely affects the scope or enforceability of our patent rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A court could determine that a competitor&#146;s technology or product that is the same as or similar to, our product candidates does not infringe our patents; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory licensing.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we encounter delays in our development or clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors claim that our patents are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products that are the same as, similar to or otherwise competitive with our product candidates. In these circumstances, we may need to defend or assert our patents, by means including filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or government agency with jurisdiction may find our patents invalid, unenforceable or not infringed. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In that regard, third parties may challenge our patents in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47<a name="PB_47_080630_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the duration of the patent protection of our technology and potential products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire or be held invalid or unenforceable before our company can realize sufficient economic value following commercialization of our product candidates.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our intellectual property portfolio is currently comprised of issued patents and pending patent applications. If our issued patents are found to be invalid, not enforceable or not infringed by competitor products, or pending patent applications fail to issue or fail to issue with a scope that is meaningful to our product candidates, our business will be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There can be no assurance that our pending patent applications will result in issued patents in the United States or foreign jurisdictions in which such applications are pending. Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity or enforceability, or that we will obtain sufficient claim scope or term in those patents to prevent a third party from competing successfully with our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. To the extent that we have obtained or are able to obtain patents or other intellectual property rights in any foreign jurisdictions, it may be difficult for us to stop the infringement of our patents or the misappropriation of other intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the availability of certain types of patent rights and enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and product candidates, and the enforcement of intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#147;first to file&#148; system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter-partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not become effective until March&nbsp;16, 2013. However, the full impact of the Leahy-Smith Act and the courts&#146; review of any appeals to related proceedings, is in its early stages. Accordingly, the full impact that the Leahy-Smith Act will have on the operation of our business is not clear. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, as well as our ability to bring about timely favorable resolution of any disputes involving our patents and the patents of others.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48<a name="PB_48_080637_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which noncompliance can result in unenforceability, invalidity, abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in unenforceability, invalidity, abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or any future licensors fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our products, when and if approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our current or future product candidates infringe. There also could be patents that we believe we do not infringe, but that we may ultimately be found to infringe.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. There may be currently pending applications of which we are unaware that may later result in issued patents that our current or future product candidates infringe. For example, pending applications may exist that claim or can be amended to claim subject matter that our current or future product candidates infringe. Competitors may file continuing patent applications claiming priority to already issued patents in the form of continuation, divisional or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual property infringement or misappropriation. These lawsuits are costly and could adversely affect our results of operations and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate that our product candidates or methods either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover our product candidates or their use, the holders of any of these patents may be able to block our ability to commercialize our product candidates unless we acquire or obtain a license under the applicable patents or until the patents expire. We may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our product candidates or lead to prohibition of the manufacture or sale of product candidates by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Any claims by third parties that we have misappropriated their confidential information, know-how or trade secrets could have a similar negative impact on our business. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or that claim ownership of what we regard as our own intellectual property.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our employees, consultants and contractors were previously employed at or engaged by biotechnology companies or other pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. We are not aware of any threatened or pending claims related to these matters or concerning agreements with our senior management, or other of our employees, consultants and contractors, but litigation may be necessary in the future to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, or personnel or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49<a name="PB_49_080641_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105569\14-17045-1\task6922465\17045-1-gg.htm',USER='105569',CD='Aug  9 08:09 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on trade secrets to protect our proprietary technological advances and know-how, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, contractors, outside scientific collaborators, sponsored researchers and other advisors, including the third parties we rely on to manufacture our product candidates, to protect our trade secrets and other proprietary information. However, any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets. Accordingly, these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. In addition, others may independently discover our trade secrets and proprietary information. Further, the FDA, as part of its Transparency Initiative, a proposal to increase disclosure and make data more accessible to the public, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position and financial results.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Any lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming and may adversely impact the price of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may be required to initiate litigation to enforce or defend our intellectual property rights. These lawsuits can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the pharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information and trade secrets could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, our patents and patent applications could face other challenges, such as interference proceedings, opposition proceedings, reissue, inter partes review, re-examination proceedings, third-party submissions of prior art, and other forms of post-grant review. In the United States, for example, post-grant review has recently been expanded. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope or preventing the issuance of, any of our patents and patent applications subject to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would divert our management and scientific personnel&#146;s time and attention.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the market price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50<a name="PB_50_075839_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Development of Our Additional Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to develop and commercialize our current pipeline of additional product candidates, our prospects for future growth and our ability to reach or sustain profitability may be limited.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A key element of our strategy is to develop, obtain regulatory approval for and commercialize our portfolio of product candidates in addition to Twirla. To do so, we plan to utilize our proprietary transdermal delivery technology, Skinfusion, to develop additional product candidates. We may not be successful in our efforts to develop our portfolio of additional product candidates, and any product candidates we do develop may not produce commercially viable products that safely and effectively treat their indicated conditions. To date, our efforts have yielded three additional product candidates in addition to Twirla, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle, AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our development programs may initially show promise in identifying potential product leads, yet fail to produce product candidates for clinical development. In addition, identifying new treatment needs and product candidates requires substantial technical, financial and human resources on our part. If we are unable to obtain development partners or additional development program funding, or to continue to devote substantial technical and human resources to such programs, we may have to delay or abandon these programs. Any product candidate that we successfully identify may require substantial additional development efforts prior to commercial sale, including preclinical studies, extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are susceptible to the risks of failure that are inherent in pharmaceutical product development.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be unable to license or acquire suitable additional product candidates or technologies from third parties for a number of reasons.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The licensing and acquisition of pharmaceutical products is competitive. A number of more established companies are also pursuing strategies to license or acquire products. These established companies may have a competitive advantage over us due to their size, cash resources or greater clinical development and commercialization capabilities. In addition, we expect competition in acquiring product candidates to increase, which may lead to fewer suitable acquisition opportunities for us as well as higher acquisition prices.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other factors that may prevent us from licensing or otherwise acquiring suitable product candidates include the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be unable to license or acquire the relevant technology on terms that would allow us to make an appropriate return on our investment in such product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Companies that perceive us to be their competitor may be unwilling to assign or license their product rights to us;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may be unable to identify suitable products or product candidates within our areas of expertise; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We may not have sufficient funds to acquire, develop or commercialize additional product candidates or technologies.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Business Operations and Industry</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">In order to establish our sales and marketing infrastructure, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of July&nbsp;31, 2014, we had a total of 11 full-time employees, and we use third-party consultants to assist with our current sales and marketing functions. As our development and commercialization plans and strategies develop, we expect to need to expand the size of our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51<a name="PB_51_075910_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">integrate additional employees. In addition, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future financial performance and our ability to commercialize Twirla, if approved, and any other future product candidates and our ability to compete effectively will depend, in part, on our ability to effectively manage any future growth.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to compete in the highly competitive pharmaceuticals industry depends in large part upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. In order to induce valuable employees to remain with us, we have provided these employees with stock options that vest over time. The value to employees of stock options that vest over time is significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management team has expertise in many different aspects of drug development and commercialization. Competition for skilled personnel in our market is intense and competition for experienced personnel may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management, scientific and medical teams may terminate their employment with us on short notice. We have an employment agreement with only one of our employees, Alfred Altomari, our President and Chief Executive Officer. The employment agreement provides for at-will employment, which means that Mr.&nbsp;Altomari or any of our other employees could leave our employment at any time, with or without notice. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results or financial condition. In particular, we believe that the loss of the services of Mr.&nbsp;Altomari, or Dr.&nbsp;Elizabeth Garner, our Chief Medical Officer, may have a material adverse effect on our business. We do not currently carry &#147;key person&#148; insurance on the lives of members of executive management. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than those that we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate of and success with which we can develop and commercialize product candidates would be limited.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of Twirla or our other product candidates, if approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face a potential risk of product liability as a result of the clinical testing of Twirla and our other product candidates and will face an even greater risk if we commercialize Twirla or our other product candidates, if approved or any other current or future product candidate. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of the product candidate subject to such claims. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Decreased demand for Twirla or any future product candidates that we may develop;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Injury to our reputation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Withdrawal of clinical trial participants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Costs to defend any related litigation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A diversion of management&#146;s time and our resources;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Substantial monetary awards to trial participants or patients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52<a name="PB_52_075926_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Loss of revenue;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The inability to commercialize Twirla or our other product candidates, if approved;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A decline in our stock price; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exposure to adverse publicity.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have obtained limited product liability insurance coverage for our products and our clinical trials with a $10.0&nbsp;million annual aggregate coverage limit. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of product candidates we develop. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may acquire businesses or products, or form strategic alliances in the future, and we may not realize the benefits of such acquisitions or alliances.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our business is affected by macroeconomic conditions.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates, and overall economic conditions and uncertainties, including those resulting from political instability and the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass through price increases to patients. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations, if necessary.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest rates and the ability to access credit markets could also adversely affect the ability of patients, payors and distributors to purchase, pay for and effectively distribute our products if and when approved. Similarly, these macroeconomic factors could affect the ability of our current or potential future contract manufacturers, sole-source or single-source suppliers, or licensees to remain in business or otherwise manufacture or supply our product candidates. Failure by any of them to remain in business could affect our ability to manufacture product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules&nbsp;subsequently implemented by the SEC and the NASDAQ Global Market, impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure controls and internal control over financial reporting and changes in corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&nbsp;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules&nbsp;and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage as we currently have. We estimate that we will annually incur approximately $2.0&nbsp;million in expenses in response to these requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;404(a)&nbsp;of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we would expect to file with the SEC. However, for as</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53<a name="PB_53_075939_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">long as we remain an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We will remain an &#147;emerging growth company&#148; until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.0&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules&nbsp;of the SEC.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. We will incur substantial accounting expense and expend significant management efforts to comply with internal control over financial reporting requirements. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. Moreover, if we are not able to comply with these requirements in a timely manner or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline, and we could be subject to sanctions or investigations by the NASDAQ Global Market, the SEC or other regulatory authorities, which would require additional financial and management resources.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Business interruptions could delay us in the process of developing our product candidates and could disrupt our sales.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our headquarters are located in Princeton, New Jersey, and Corium, our contract manufacturer, is located in Grand Rapids, Michigan. We are vulnerable to natural disasters, such as severe storms and other events that could disrupt our or Corium&#146;s operations. We do not carry insurance for natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of system failures.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to the risk that employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors may engage in fraudulent or other illegal activity, fraud or other misconduct. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&nbsp;the law and regulations of the FDA and non-U.S. regulators, including those laws that require the reporting of true, complete and accurate information to the FDA and non-U.S. regulators, (ii)&nbsp;healthcare fraud and abuse laws and regulations in the United States and abroad and (iii)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct in violation of these laws may also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including regulatory enforcement actions, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, corporate integrity agreements,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54<a name="PB_54_075949_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments may be limited by provisions of the Internal Revenue Code, and may be subject to further limitation as a result of our initial public offering.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, contain rules&nbsp;that limit the ability of a company that undergoes an ownership change, which is generally any change in ownership of more than 50% of its stock over a three-year period, to utilize its net operating loss and tax credit carryforwards and certain built-in losses recognized in years after the ownership change. These rules&nbsp;generally operate by focusing on ownership changes involving stockholders owning, directly or indirectly, 5% or more of the stock of a company and any change in ownership arising from a new issuance of stock by the company. Generally, if an ownership change occurs, the yearly taxable income limitation on the use of net operating loss and tax credit carryforwards and certain built-in losses is equal to the product of the applicable long-term tax exempt rate and the value of the company&#146;s stock immediately before the ownership change. We may be unable to offset future taxable income, if any, with losses, or our tax liability with credits, before such losses and credits expire and therefore would incur larger federal income tax liability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, it is possible that the transactions relating to our initial public offering, either on a standalone basis or when combined with future transactions, will cause us to undergo one or more additional ownership changes. In that event, we generally would not be able to use our pre-change loss or credit carryovers or certain built-in losses prior to such ownership change to offset future taxable income in excess of the annual limitations imposed by Sections&nbsp;382 and 383.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*An active trading market for our common stock may not be sustained.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2014, we closed our initial public offering. Prior to our initial public offering, there was no public market for shares of our common stock. Although we have completed our initial public offering and shares of our common stock are listed and trading on The NASDAQ Global Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>We expect that our stock price may fluctuate significantly.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to our recently completed initial public offering, you could not buy or sell our common stock publicly. The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this quarterly report, these factors include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any delay in filing our response to the CRL received from the FDA with respect to Twirla and any adverse development or perceived adverse development with respect to the FDA&#146;s review of our response;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Adverse results in our planned Phase&nbsp;3 clinical trial for Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our failure to commercialize Twirla, if approved, or develop and commercialize additional product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Unanticipated efficacy, safety or tolerability concerns related to the use of Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory actions with respect to Twirla;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Inability to obtain adequate product supply of Twirla or inability to do so at acceptable prices;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Adverse results or delays in our clinical trials for our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Changes in laws or regulations applicable to Twirla or any future product candidates, including but not limited to clinical trial requirements for approvals;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55<a name="PB_55_080010_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Actual or anticipated fluctuations in our financial condition and operating results;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Actual or anticipated changes in our growth rate relative to our competitors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Competition from existing products or new products that may emerge;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Issuance of new or updated research or reports by securities analysts;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Fluctuations in the valuation of companies perceived by investors to be comparable to us;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Additions or departures of key management or scientific personnel;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Announcement or expectation of additional debt or equity financing efforts;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Sales of our common stock by us, our insiders or our other stockholders; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">General economic and market conditions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general, and the NASDAQ Global Market and the stock prices of pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our market price of our common stock may be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#146;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>Our existing principal stockholders, executive officers and directors own a significant percentage of our common stock and will be able to exert a significant control over matters submitted to our stockholders for approval.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of July&nbsp;31, 2014, our executive officers, directors, director nominees, holders of 5% or more of our capital stock and their respective affiliates together beneficially owned approximately 67.0% of our outstanding voting stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. As a result, these stockholders, if they acted together, could significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. These stockholders may be able to determine all matters requiring stockholder approval. The interests of these stockholders may not always coincide with our interests or the interests of other stockholders. This may also prevent or discourage unsolicited acquisition proposals or offers for our common stock that other stockholders may feel are in their best interest and our large stockholders may act in a manner that advances their best interests and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56<a name="PB_56_080026_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*<i>Future sales of shares of our common stock by existing stockholders could cause our stock price to decline.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If our existing stockholders sell, or indicate an intent to sell, substantial amounts of our common stock in the public market after the 180-day contractual lock-up and other legal restrictions on resale discussed lapse, the trading price of our common stock could decline significantly and could decline. Based on shares outstanding as of July&nbsp;31, 2014, we have outstanding 18,592,968 shares of common stock, assuming no exercise of outstanding options. Of these shares, 5,000,000 shares of common stock are freely tradable, without restriction, in the public market. Our underwriters may, in their sole discretion, permit our officers, directors, employees and current stockholders to sell shares prior to the expiration of the lock-up agreements. Moreover, a relatively small number of our stockholders own large blocks of shares. We cannot predict the effect, if any, that public sales of these shares or the availability of these shares for sale will have on the market price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After the lock-up agreements pertaining to our initial public offering expire and based on shares outstanding as of July&nbsp;31, 2014, an additional 13,592,968 shares will be eligible for sale in the public market. In addition, the 1,750,120 shares subject to outstanding options under our stock option plans and the 504,930 shares reserved for future issuance under our stock option plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. Moreover, 180&nbsp;days after the completion of our initial public offering (November&nbsp;19, 2014), holders of 8,809,317 shares of our common stock will have the right to require us to register these shares under the Securities Act of 1933, as amended, or the Securities Act, pursuant to a registration rights agreement. If our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">*We will have broad discretion in how we use the net proceeds from our recently completed initial public offering. We may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will have considerable discretion in the application of the net proceeds from our recently completed initial public offering. We intend to use the majority of the net proceeds from our recently completed initial public offering to conduct a Phase&nbsp;3 clinical trial for Twirla, obtain marketing approval and begin preparations for the U.S. commercial launch of Twirla, continue the equipment qualification and validation related to the expansion of Corium&#146;s manufacturing capabilities, develop our product pipeline, begin making principal and interest payments on our term loan with Oxford beginning in February&nbsp;2015 and for working capital and other general corporate purposes, which may include funding for the hiring of additional personnel, validation of capital equipment and the costs of operating as a public company. As a result, investors will be relying upon management&#146;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds from our recently completed initial public offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from our recently completed initial public offering in a manner that does not produce income or that loses value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are an &#147;emerging growth company&#148; and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We will remain an &#147;emerging growth company&#148; until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.0&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date we completed our initial public offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules&nbsp;of the SEC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our status as an &#147;emerging growth company&#148; under the JOBS Act may make it more difficult to raise capital as and when we need it.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because of the exemptions from various reporting requirements allowed to us as an &#147;emerging growth company&#148; we may be less attractive to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our financial accounting is not as transparent as other</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57<a name="PB_57_080039_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. Commencing with our annual report on Form&nbsp;10-K for the year ending December&nbsp;31, 2014, we will be required, under Section&nbsp;404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section&nbsp;404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of the exemption permitting us not to comply with the independent registered public accounting firm attestation requirement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our compliance with Section&nbsp;404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge, and compile the system and process documentation necessary to perform the evaluation needed to comply with Section&nbsp;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section&nbsp;404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the NASDAQ Global Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules&nbsp;and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have never paid dividends on our common stock and we do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not paid dividends on our common stock to date and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Consequently, in the foreseeable future, you will likely only experience a gain from your investment in our common stock if the price of our common stock increases.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58<a name="PB_58_080100_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The trading market for our common stock relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity analysts downgrade our common stock or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Authorize the issuance of preferred stock which can be created and issued by the board of directors without prior stockholder approval, with rights senior to those of our common stock;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Provide for a classified board of directors, with each director serving a staggered three-year term;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Prohibit our stockholders from filling board vacancies, calling special stockholder meetings or taking action by written consent;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Provide for the removal of a director only with cause and by the affirmative vote of the holders of 75% or more of the shares then entitled to vote at an election of our directors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Require advance written notice of stockholder proposals and director nominations; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Require any action instituted against our officers or directors in connection with their service to the Company to be brought in the state of Delaware.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including a merger, tender offer or proxy contest involving our company. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59<a name="PB_59_080114_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-gi.htm',USER='106406',CD='Aug 13 07:36 2014' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.&#160; Unregistered Sales of Equity Securities and Use of Proceeds.</font></b><a name="Item2_UnregisteredSalesOfEquitySe_084652"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unregistered Securities</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In April&nbsp;2014, the Company and certain of the Company&#146;s existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0&nbsp;million. The Company issued Convertible Promissory Notes (the &#147;Notes&#148;) to evidence its payment obligations with respect to the $3.0&nbsp;million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in our initial public offering, or IPO.&#160; The Notes were exempt from registration under the Securities Act of 1933 in reliance on Section&nbsp;4(a)(2)&nbsp;of the Securities Act and Regulation D promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon the closing of the IPO on May&nbsp;29, 2014, all shares of our then outstanding Series&nbsp;A-1 Preferred Stock, Series&nbsp;A-2 Preferred Stock, Series&nbsp;B Preferred Stock, and Series&nbsp;C Preferred Stock and all of our then-outstanding Notes automatically converted into an aggregate of 8,809,325 shares of common stock.&#160; Additionally, the warrants to purchase shares of Series&nbsp;A-1 and Series&nbsp;A-2 preferred stock were canceled and the warrants to purchase shares of Series&nbsp;C preferred stock automatically converted into warrants to purchase shares of common stock. The issuance of common stock and warrants in connection with these conversions qualified for exemption under Section&nbsp;3(a)(9)&nbsp;of the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the IPO, in May&nbsp;2014, we issued options exercisable for an aggregate of 63,000 shares of common stock at an exercise price of $6.00 to certain of our independent directors.&#160; In June&nbsp;2014, we issued options exercisable for an aggregate of 308,500 shares of common stock at an exercise price of $10.75 to certain of our executive officers.&#160; The options were exempt from registration under the Securities Act in reliance on Rule&nbsp;701 promulgated under Section&nbsp;3(b)&nbsp;of the Securities Act as transactions not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule&nbsp;701.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Use of Proceeds</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;29, 2014, we completed our IPO whereby we sold 9,166,667 shares of common stock, at a public offering price of $6.00 per share, before underwriting discounts and expenses.&#160; The aggregate net proceeds received by us from the offering were $49.7 million after deducting the underwriting discounts and commissions and offering expenses paid by us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of August, 2014, we have not used our net proceeds from the IPO.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There has been no material change in the planned use of proceeds from our IPO as described in our prospectus dated May&nbsp;22, 2014, filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;under the Securities Act of 1933, as amended, except that we now believe that we will use approximately $2 to $4&nbsp;million for the continuation, and not the completion, of equipment qualification and validation related to the expansion of Corium&#146;s manufacturing capabilities. This change is due primarily to our desire to maintain our cash position while we continue to plan the scale up of commercial manufacturing capabilities for Twirla with our third party manufacturer, Corium, and our intent to coordinate the commercial scale up process with our planned commercialization activities.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60<a name="PB_60_082217_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-gk.htm',USER='108698',CD='Aug 13 22:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6.&#160; Exhibits.</font></b><a name="Item6_Exhibits__084704"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61<a name="PB_61_083103_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-gk.htm',USER='108698',CD='Aug 13 22:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;14, 2014</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agile Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Alfred Altomari</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alfred Altomari</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief Executive Officer   (Principal Executive Officer)</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;14, 2014</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President and Chief Financial Officer   (Principal Financial and Accounting Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62<a name="PB_62_083109_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-gk.htm',USER='108698',CD='Aug 13 22:57 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;Index</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Document</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:8.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:87.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Amendment to Amended and Restated Certificate of Incorporation of the   Registrant filed on May&nbsp;7, 2014. (Incorporated by reference,   Exhibit&nbsp;3.2 to Company&#146;s Third Amendment of Registration Statement on   Form&nbsp;S-1, file number 333-194621, filed May&nbsp;9, 2014.)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Amendment to Amended and Restated Certificate of Incorporation of the   Registrant filed on May&nbsp;21, 2014. (Incorporated by reference,   Exhibit&nbsp;3.6 to Company&#146;s Fourth Amendment of Registration Statement on   Form&nbsp;S-1, file number 333-194621, filed May&nbsp;22, 2014.)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated Certificate of Incorporation of the Registrant. (Incorporated by   reference, Exhibit&nbsp;3.1 to Company&#146;s Current Report on Form&nbsp;8-K,   file number 001-36464, filed May&nbsp;30, 2014)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated Bylaws of the Registrant. (Incorporated by reference,   Exhibit&nbsp;3.2 to Company&#146;s Current Report on Form&nbsp;8-K, file number   001-36464, filed May&nbsp;30, 2014.)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth   Amended and Restated Registration Rights Agreement, dated as of July&nbsp;18,   2012, by and among the Registrant and the parties listed therein, as modified   by the Amendment to Registration Rights Agreement, dated as of May&nbsp;5,   2014, by and among the Registrant and the parties listed therein.   (Incorporated by reference, Exhibit&nbsp;4.2 to Company&#146;s Third Amendment of   Registration Statement on Form&nbsp;S-1, file number 333-194621, filed on   May&nbsp;9, 2014.)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Convertible Subordinated Promissory Note. (Incorporated by reference,   Exhibit&nbsp;4.4 to Company&#146;s Second Amendment of Registration Statement on   Form&nbsp;S-1, file number 333-194621, filed May&nbsp;5, 2014)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agile   Therapeutics,&nbsp;Inc. 2014 Incentive Compensation Plan and form of Stock   Option Agreement, form of Non-Employee Director Stock Option Agreement and   form of Restricted Stock Unit Issuance Agreement thereunder. (Incorporated by   reference, Exhibit&nbsp;10.4 to Company&#146;s Third Amendment of Registration   Statement on Form&nbsp;S-1, file number 333-194621, filed May&nbsp;9, 2014.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Chief Executive Officer pursuant to   Rule&nbsp;13a-14(a)/15d-14(a), as adopted pursuant to Section&nbsp;302 of the   Sarbanes-Oxley Act of 2002, dated August&nbsp;14, 2014.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Chief Financial Officer pursuant to   Rule&nbsp;13a-14(a)/15d-14(a), as adopted pursuant to Section&nbsp;302 of the   Sarbanes-Oxley Act of 2002, dated </font><font size="2" style="font-size:10.0pt;">August&nbsp;14,   2014.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Chief Executive Officer pursuant to 18 U.S.C. &#167;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, dated   </font><font size="2" style="font-size:10.0pt;">August&nbsp;14, 2014.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Chief Financial Officer pursuant to 18 U.S.C. &#167;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, dated   </font><font size="2" style="font-size:10.0pt;">August&nbsp;14, 2014.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interactive data files pursuant to Rule&nbsp;405 of Regulation S-T:   (i)&nbsp;Consolidated Balance Sheets, (ii)&nbsp;Consolidated Statements of   Operations, (iii)&nbsp;Consolidated Statements of Comprehensive Loss,   (iv)&nbsp;Consolidated Statements of Stockholders&#146; Equity,   (v)&nbsp;Consolidated Statements of Cash Flows, and (vi)&nbsp;the Notes to   Consolidated Financial Statements.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63<a name="PB_63_083219_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='63',FILE='C:\JMS\108698\14-17045-1\task6930608\17045-1-gk.htm',USER='108698',CD='Aug 13 22:57 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a14-17045_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF PERIODIC REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I,&nbsp;Alfred Altomari, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this quarterly report on Form&nbsp;10-Q of Agile Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a</font><font size="2" style="font-size:10.0pt;">)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date August&nbsp;14, 2014</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Alfred Altomari</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alfred Altomari<br>   Chief Executive Officer<br>   Principal Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_110142_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-ma.htm',USER='106406',CD='Aug 13 07:59 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a14-17045_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION&nbsp;302 OF THE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Scott M. Coiante, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this quarterly report on Form&nbsp;10-Q of Agile Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt 15.1pt;text-indent:-15.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date August&nbsp;14, 2014</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante<br>   Chief Financial Officer</font><font size="2" style="font-size:10.0pt;"><br>    </font><font size="2" style="font-size:10.0pt;">Principal Financial and Accounting   Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_110212_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\jms\106406\14-17045-1\task6929028\17045-1-mc.htm',USER='106406',CD='Aug 13 07:59 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a14-17045_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">STATEMENT OF CHIEF EXECUTIVE OFFICER OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGILE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Agile Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended June&nbsp;30, 2014 as filed with the Securities and Exchange Commission (the &#147;Report&#148;),&nbsp;I,&nbsp;Alfred Altomari, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1)&#160;&#160;&#160; The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2)&#160;&#160;&#160; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;14, 2014</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Alfred Altomari</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alfred Altomari</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Executive Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Principal Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_110242_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-me.htm',USER='105340',CD='Aug  9 11:02 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a14-17045_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">STATEMENT OF CHIEF ACCOUNTING OFFICER OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGILE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Agile Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended June&nbsp;30, 2014 as filed with the Securities and Exchange Commission (the &#147;Report&#148;),&nbsp;I, Scott M. Coiante, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1)&#160;&#160;&#160; The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2)&#160;&#160;&#160; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;14, 2014</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Principal Financial and Accounting Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_110339_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\skris\14-17045-1\task6922725\17045-1-mg.htm',USER='105340',CD='Aug  9 11:03 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>agrx-20140630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS Proton Version 4.0.2.8-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:agrx="http://www.agiletherapeutics.com/20140630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="agrx-20140630.xsd" />
  <xbrli:context id="D2014Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-04</xbrli:startDate>
      <xbrli:endDate>2014-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_M0505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_CommonStockMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_ConvertiblePreferredStockMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA18PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesA2ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesB8PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesC12PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA18PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_SeriesA2ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesB8PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesC12PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_TermLoanWithOxfordFinanceMember_1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">agrx:TermLoanWithOxfordFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0523_IPOMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-23</xbrli:startDate>
      <xbrli:endDate>2014-05-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0523_ConvertibleSubordinatedPromissoryNotes28April2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">agrx:ConvertibleSubordinatedPromissoryNotes28April2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-22</xbrli:startDate>
      <xbrli:endDate>2014-05-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0523_ConvertibleSubordinatedPromissoryNotes28April2014Member_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">agrx:ConvertibleSubordinatedPromissoryNotes28April2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-22</xbrli:startDate>
      <xbrli:endDate>2014-05-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0507_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesC12PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">agrx:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-06</xbrli:startDate>
      <xbrli:endDate>2014-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0507_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA18PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">agrx:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-06</xbrli:startDate>
      <xbrli:endDate>2014-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0529">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-29</xbrli:startDate>
      <xbrli:endDate>2014-05-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueInputsLevel3Member_SeriesA1WarrantsMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA1WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueInputsLevel3Member_SeriesCWarrantsMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesCWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueInputsLevel3Member_SeriesA2WarrantsMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA2WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesA1WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA1WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesA2WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA2WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesCWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesCWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_FairValueInputsLevel3Member_WarrantMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0507_SeriesA2ConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">agrx:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-06</xbrli:startDate>
      <xbrli:endDate>2014-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_M0227_StateAndLocalJurisdictionMember_NewJerseyDivisionOfTaxationMember_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agrx:TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_M0227_StateAndLocalJurisdictionMember_NewJerseyDivisionOfTaxationMember_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agrx:TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-27</xbrli:startDate>
      <xbrli:endDate>2014-02-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_SmartPharmaLLCMember_CommercialAndBusinessDevelopmentConsultingServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">agrx:SmartPharmaLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agrx:CommercialAndBusinessDevelopmentConsultingServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_SmartPharmaLLCMember_CommercialAndBusinessDevelopmentConsultingServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">agrx:SmartPharmaLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">agrx:CommercialAndBusinessDevelopmentConsultingServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_M0428_ConvertibleSubordinatedPromissoryNotes28April2014Member_2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">agrx:ConvertibleSubordinatedPromissoryNotes28April2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-04-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q1_M01_TermLoanWithOxfordFinanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">agrx:TermLoanWithOxfordFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M04_TermLoanWithOxfordFinanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">agrx:TermLoanWithOxfordFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0523_ConvertiblePreferredStockMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-22</xbrli:startDate>
      <xbrli:endDate>2014-05-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_M0529">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0523_TermLoanWithOxfordFinanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">agrx:TermLoanWithOxfordFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-22</xbrli:startDate>
      <xbrli:endDate>2014-05-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0507_MinimumMember_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesB8PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">agrx:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-07</xbrli:startDate>
      <xbrli:endDate>2014-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_ConvertibleSubordinatedPromissoryNotes28April2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">agrx:ConvertibleSubordinatedPromissoryNotes28April2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_M0529_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-29</xbrli:startDate>
      <xbrli:endDate>2014-05-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2_EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2_EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q2_TermLoanWithOxfordFinanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">agrx:TermLoanWithOxfordFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesA1WarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA1WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA18PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesA2WarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesA2ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesA2WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013_SeriesCWarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">agrx:SeriesCWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">agrx:SeriesC12PercentNoncumulativeConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001261249</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agrx:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Class">
    <xbrli:measure>agrx:class</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Series">
    <xbrli:measure>agrx:series</xbrli:measure>
  </xbrli:unit>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Tag1" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;1. Organization and Basis of Presentation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Nature of Operations&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Agile Therapeutics,&amp;#160;Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated in Delaware on December&amp;#160;22, 1997. The Company is engaged in research and development of transdermal patch technology for use in contraception. The Company&amp;#8217;s activities since inception have consisted principally of raising capital, and performing research and development. The Company is headquartered in Princeton, New Jersey.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company is devoting substantially all of its efforts toward research and development of its transdermal patch for use in contraception, and raising capital. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies. The Company has incurred losses each year since inception. As of June&amp;#160;30, 2014, the Company had an accumulated deficit of approximately $121.2&amp;#160;million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. The Company expects to continue to incur net losses into the foreseeable future.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Basis of Presentation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accompanying unaudited interim condensed financial statements have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim information and pursuant to the rules&amp;#160;and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for reporting on Form&amp;#160;10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules&amp;#160;and regulations. It is recommended that these interim condensed financial statements be read in conjunction with the financial statements and related notes that appear in the Company&amp;#8217;s final prospectus filed with the SEC on May&amp;#160;22, 2014, relating to the Company&amp;#8217;s Registration Statements on Form&amp;#160;S-1 (File No.&amp;#160;333-194621) for the Company&amp;#8217;s initial public offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In the opinion of management, the unaudited interim condensed financial statements reflects all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and six months ended June&amp;#160;30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag2" decimals="0" contextRef="I2014Q2" unitRef="USD">121193491</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Tag3" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2. Summary of Significant Accounting Polices&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company&amp;#8217;s complete listing of significant accounting policies are described in Note 2 to the Company&amp;#8217;s audited financial statements as of December&amp;#160;31, 2013 included in the Prospectus that forms a part of the Company&amp;#8217;s Registration Statement on Form&amp;#160;S-1 dated May&amp;#160;22, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The preparation of the Company&amp;#8217;s financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock Split&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;5, 2014, the Company effected a 1.4-for-1 stock split of the Company&amp;#8217;s common stock. All share and per share amounts of common stock contained in the Company&amp;#8217;s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders&amp;#8217; deficit reflects the stock split by reclassifying from &amp;#8220;Additional paid-in Capital&amp;#8221; to &amp;#8220;Common Stock&amp;#8221; in an amount equal to the par value of the increased shares resulting from the stock split.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In accordance with ASC 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note&amp;#160;3).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Warrants&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer&amp;#8217;s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In connection with the completion of the Company&amp;#8217;s initial public offering in May&amp;#160;2014, the warrants to purchase shares of Series&amp;#160;A-1 and Series&amp;#160;A-2 preferred stock expired unexercised and the warrants to purchase shares of Series&amp;#160;C preferred stock automatically converted into warrants to purchase shares of common stock.&amp;#160; Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Awards for consultants are accounted for under ASC 505-50, &lt;i&gt;Equity Based Payments to Non-Employees&lt;/i&gt;. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,809,325&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;287,028&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;62,505&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,341,731&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,750,120&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10,438,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,812,625&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following tables summarizes the Company&amp;#8217;s computation of basic and diluted net loss per share for common stockholders:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 83.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,619,879&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,718,401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;51,499&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,000,092&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(70.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(8,216,109&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,879,108&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;46,865&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,074,734&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(175.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 40.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In June&amp;#160;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&amp;#160;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&amp;#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&amp;#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&amp;#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&amp;#160;2014-10.&amp;#160; ASU No.&amp;#160;2014 is effective for fiscal years beginning after December&amp;#160;15, 2014, with early adoption permitted.&amp;#160; Retrospective application is required for the elimination of incremental DSE disclosures.&amp;#160; Prior to the issuance of ASU No.&amp;#160;2014-10, the Company had met the definition of a DSE since its inception.&amp;#160; The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&amp;#160;10-Q.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates id="Tag4" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The preparation of the Company&amp;#8217;s financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <agrx:StockSplitPolicyTextBlock id="Tag5" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock Split&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;5, 2014, the Company effected a 1.4-for-1 stock split of the Company&amp;#8217;s common stock. All share and per share amounts of common stock contained in the Company&amp;#8217;s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders&amp;#8217; deficit reflects the stock split by reclassifying from &amp;#8220;Additional paid-in Capital&amp;#8221; to &amp;#8220;Common Stock&amp;#8221; in an amount equal to the par value of the increased shares resulting from the stock split.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</agrx:StockSplitPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Tag6" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In accordance with ASC 825, &lt;i&gt;Financial Instruments&lt;/i&gt;, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note&amp;#160;3).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <agrx:WarrantsPolicyTextBlock id="Tag7" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Warrants&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer&amp;#8217;s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In connection with the completion of the Company&amp;#8217;s initial public offering in May&amp;#160;2014, the warrants to purchase shares of Series&amp;#160;A-1 and Series&amp;#160;A-2 preferred stock expired unexercised and the warrants to purchase shares of Series&amp;#160;C preferred stock automatically converted into warrants to purchase shares of common stock.&amp;#160; Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</agrx:WarrantsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Tag8" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Awards for consultants are accounted for under ASC 505-50, &lt;i&gt;Equity Based Payments to Non-Employees&lt;/i&gt;. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag9" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,809,325&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;287,028&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;62,505&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,341,731&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,750,120&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10,438,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,812,625&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following tables summarizes the Company&amp;#8217;s computation of basic and diluted net loss per share for common stockholders:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 83.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,619,879&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,718,401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;51,499&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,000,092&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(70.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(8,216,109&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,879,108&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;46,865&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,074,734&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(175.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Tag10" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,809,325&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;287,028&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;62,505&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,341,731&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,750,120&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10,438,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,812,625&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Tag11" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 695px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="695"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,619,879&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(3,718,401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;51,499&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8,000,092&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(70.29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.46&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Numerator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(8,216,109&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,879,108&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Denominator&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Denominator for basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;46,865&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4,074,734&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(175.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(0.71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Tag12" decimals="1" contextRef="D2014Q2_M0505" unitRef="Pure">1.4</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag13" decimals="INF" contextRef="I2014Q2_M0505" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag14" decimals="0" contextRef="D2014Q2YTD_CommonStockMember_WarrantMember" unitRef="Shares">62505</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag15" decimals="0" contextRef="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_2" unitRef="Shares">1750120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag16" decimals="0" contextRef="D2013Q2YTD" unitRef="Shares">10438084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag17" decimals="0" contextRef="D2013Q2YTD_ConvertiblePreferredStockMember" unitRef="Shares">8809325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag18" decimals="0" contextRef="D2013Q2YTD_ConvertiblePreferredStockMember_WarrantMember" unitRef="Shares">287028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag19" decimals="0" contextRef="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_2" unitRef="Shares">1341731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag20" decimals="0" contextRef="D2014Q2YTD" unitRef="Shares">1812625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag21" decimals="0" contextRef="D2013Q2" unitRef="USD">-3619879</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag22" decimals="0" contextRef="D2014Q2" unitRef="USD">-3718401</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag23" decimals="2" contextRef="D2013Q2" unitRef="USDPerShare">-70.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag24" decimals="2" contextRef="D2014Q2" unitRef="USDPerShare">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AssetsCurrent id="Tag25" decimals="0" contextRef="I2014Q2" unitRef="USD">54155240</us-gaap:AssetsCurrent>
  <us-gaap:Assets id="Tag26" decimals="0" contextRef="I2014Q2" unitRef="USD">66271210</us-gaap:Assets>
  <us-gaap:LiabilitiesCurrent id="Tag27" decimals="0" contextRef="I2014Q2" unitRef="USD">5302744</us-gaap:LiabilitiesCurrent>
  <us-gaap:StockholdersEquity id="Tag28" decimals="0" contextRef="I2014Q2" unitRef="USD">48348650</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag29" decimals="0" contextRef="I2014Q2" unitRef="USD">66271210</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag30" decimals="0" contextRef="I2014Q2" unitRef="USD">53494022</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag31" decimals="0" contextRef="I2013" unitRef="USD">146704</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag32" decimals="0" contextRef="I2013" unitRef="USD">2266350</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag33" decimals="0" contextRef="I2013" unitRef="USD">11963079</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag34" decimals="0" contextRef="I2014Q2" unitRef="USD">11964777</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet id="Tag35" decimals="0" contextRef="I2013" unitRef="USD">157499</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag36" decimals="0" contextRef="I2013" unitRef="USD">18208</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="Tag37" decimals="0" contextRef="I2013" unitRef="USD">14405136</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag38" decimals="0" contextRef="I2013" unitRef="USD">715454</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag39" decimals="0" contextRef="I2013" unitRef="USD">379164</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LoansPayableCurrent id="Tag40" decimals="0" contextRef="I2013" unitRef="USD">5105407</us-gaap:LoansPayableCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag41" decimals="0" contextRef="I2013_WarrantMember" unitRef="USD">644478</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DeferredFinanceCostsNoncurrentNet id="Tag42" decimals="0" contextRef="I2014Q2" unitRef="USD">132985</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag43" decimals="0" contextRef="I2014Q2" unitRef="USD">18208</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent id="Tag44" decimals="0" contextRef="I2013" unitRef="USD">6844503</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermLoansPayable id="Tag45" decimals="0" contextRef="I2013" unitRef="USD">9769528</us-gaap:LongTermLoansPayable>
  <us-gaap:CommitmentsAndContingencies id="Tag46" xsi:nil="true" contextRef="I2013" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies id="Tag47" xsi:nil="true" contextRef="I2014Q2" unitRef="USD" />
  <us-gaap:CommonStockValue id="Tag49" decimals="0" contextRef="I2013" unitRef="USD">88</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag50" decimals="0" contextRef="I2013" unitRef="USD">46872723</us-gaap:AdditionalPaidInCapital>
  <us-gaap:PreferredStockValue id="Tag51" xsi:nil="true" contextRef="I2014Q2" unitRef="USD" />
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag52" decimals="0" contextRef="I2013" unitRef="USD">118314383</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag53" decimals="0" contextRef="I2013" unitRef="USD">-71441572</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag54" decimals="0" contextRef="I2013" unitRef="USD">14405136</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag55" decimals="0" contextRef="I2014Q2" unitRef="USD">278135</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag56" decimals="0" contextRef="I2013" unitRef="USD">273092</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Tag57" decimals="INF" contextRef="I2014Q2" unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="Tag58" decimals="INF" contextRef="I2014Q2" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="Tag59" decimals="INF" contextRef="I2014Q2" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="Tag60" decimals="INF" contextRef="I2014Q2" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag61" decimals="INF" contextRef="I2014Q2" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag62" decimals="INF" contextRef="I2014Q2" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag63" decimals="INF" contextRef="I2014Q2" unitRef="Shares">18598754</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag64" decimals="INF" contextRef="I2014Q2" unitRef="Shares">18592968</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag68" decimals="INF" contextRef="I2013" unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="Tag69" decimals="INF" contextRef="I2013" unitRef="Shares">109321</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag70" decimals="INF" contextRef="I2013" unitRef="Shares">103536</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag71" decimals="0" contextRef="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USD">898305</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag72" decimals="0" contextRef="I2013_SeriesA2ConvertiblePreferredStockMember" unitRef="USD">543623</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag73" decimals="0" contextRef="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USD">44928382</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag74" decimals="0" contextRef="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USD">22862367</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag79" decimals="4" contextRef="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USDPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag81" decimals="4" contextRef="I2013_SeriesA2ConvertiblePreferredStockMember" unitRef="USDPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag83" decimals="4" contextRef="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USDPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag85" decimals="4" contextRef="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USDPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag87" decimals="0" contextRef="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">284743</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag89" decimals="0" contextRef="I2013_SeriesA2ConvertiblePreferredStockMember" unitRef="Shares">99178</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag91" decimals="0" contextRef="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">4510066</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag93" decimals="0" contextRef="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">2711734</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Tag94" decimals="0" contextRef="I2014Q2_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag95" decimals="0" contextRef="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">137787</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag96" decimals="0" contextRef="I2014Q2_SeriesA2ConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag97" decimals="0" contextRef="I2013_SeriesA2ConvertiblePreferredStockMember" unitRef="Shares">66116</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag98" decimals="0" contextRef="I2014Q2_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag99" decimals="0" contextRef="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">4510066</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag100" decimals="0" contextRef="I2014Q2_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag101" decimals="0" contextRef="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">1578400</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag102" decimals="0" contextRef="I2014Q2_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag103" decimals="0" contextRef="I2013_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">137787</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag104" decimals="0" contextRef="I2014Q2_SeriesA2ConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag105" decimals="0" contextRef="I2013_SeriesA2ConvertiblePreferredStockMember" unitRef="Shares">66116</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag106" decimals="0" contextRef="I2014Q2_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag107" decimals="0" contextRef="I2013_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">4510066</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag108" decimals="0" contextRef="I2014Q2_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag109" decimals="0" contextRef="I2013_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="Shares">1578400</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:OperatingExpenses id="Tag111" decimals="0" contextRef="D2014Q2" unitRef="USD">3494710</us-gaap:OperatingExpenses>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag112" decimals="0" contextRef="D2014Q2" unitRef="USD">-3718401</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag114" decimals="0" contextRef="D2014Q2" unitRef="Shares">8000092</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OperatingExpenses id="Tag115" decimals="0" contextRef="D2013Q2" unitRef="USD">3249070</us-gaap:OperatingExpenses>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Tag116" decimals="-5" contextRef="D2014Q2_M0523_IPOMember_CommonStockMember" unitRef="USD">49700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag117" decimals="0" contextRef="D2013Q2" unitRef="USD">-3619879</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag119" decimals="0" contextRef="D2013Q2" unitRef="Shares">51499</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OperatingExpenses id="Tag120" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">5942337</us-gaap:OperatingExpenses>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Tag121" decimals="INF" contextRef="D2014Q2_M0523_ConvertibleSubordinatedPromissoryNotes28April2014Member" unitRef="USD">3000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag122" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-6531593</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag124" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-2879108</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag125" decimals="2" contextRef="D2014Q2YTD" unitRef="USDPerShare">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag126" decimals="0" contextRef="D2014Q2YTD" unitRef="Shares">4074734</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OperatingExpenses id="Tag127" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">7477431</us-gaap:OperatingExpenses>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Tag128" decimals="INF" contextRef="D2014Q2_M0523_ConvertibleSubordinatedPromissoryNotes28April2014Member_CommonStockMember" unitRef="Shares">503450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag129" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-8216109</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag131" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-8216109</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag132" decimals="2" contextRef="D2013Q2YTD" unitRef="USDPerShare">-175.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag133" decimals="0" contextRef="D2014Q2_M0507_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember" unitRef="USD">45000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag134" decimals="0" contextRef="D2013Q2YTD" unitRef="Shares">46865</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag135" decimals="0" contextRef="D2014Q2_M0507_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember" unitRef="USD">45000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag137" decimals="0" contextRef="D2013Q2_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">292263</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag138" decimals="0" contextRef="D2013Q2_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">125714</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag139" decimals="0" contextRef="D2013Q2_EmployeeAndNonemployeeStockOptionsMember" unitRef="USD">417977</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag140" decimals="0" contextRef="D2014Q2_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">208908</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag141" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">3785180</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag142" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">2157157</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag143" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-5942337</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag144" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">781714</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag145" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">137</us-gaap:InvestmentIncomeInterest>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag146" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-192321</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag147" decimals="0" contextRef="D2014Q2_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">155331</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag148" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-3652485</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag149" decimals="0" contextRef="D2014Q2_EmployeeAndNonemployeeStockOptionsMember" unitRef="USD">364239</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag150" decimals="0" contextRef="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">584732</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag151" decimals="0" contextRef="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">251426</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag152" decimals="0" contextRef="D2014Q2" unitRef="USD">2390857</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag153" decimals="0" contextRef="D2014Q2" unitRef="USD">1103853</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag154" decimals="0" contextRef="D2014Q2" unitRef="USD">-3494710</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag155" decimals="0" contextRef="D2014Q2" unitRef="USD">403488</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag156" decimals="0" contextRef="D2014Q2" unitRef="USD">82</us-gaap:InvestmentIncomeInterest>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag157" decimals="0" contextRef="D2014Q2" unitRef="USD">-179715</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag158" decimals="0" contextRef="D2013Q2YTD_EmployeeAndNonemployeeStockOptionsMember" unitRef="USD">836158</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag159" decimals="0" contextRef="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_ResearchAndDevelopmentExpenseMember" unitRef="USD">335433</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag160" decimals="0" contextRef="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember_GeneralAndAdministrativeExpenseMember" unitRef="USD">256912</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag161" decimals="0" contextRef="D2014Q2YTD_EmployeeAndNonemployeeStockOptionsMember" unitRef="USD">592345</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag162" decimals="0" contextRef="D2013Q2" unitRef="USD">2425741</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag163" decimals="0" contextRef="D2013Q2" unitRef="USD">823329</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag164" decimals="0" contextRef="D2013Q2" unitRef="USD">-3249070</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag165" decimals="0" contextRef="D2013Q2" unitRef="USD">378228</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag166" decimals="0" contextRef="D2013Q2" unitRef="USD">259</us-gaap:InvestmentIncomeInterest>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag167" decimals="0" contextRef="D2013Q2" unitRef="USD">-7160</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag168" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">49743641</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Tag169" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 40.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In June&amp;#160;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&amp;#160;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&amp;#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&amp;#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&amp;#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&amp;#160;2014-10.&amp;#160; ASU No.&amp;#160;2014 is effective for fiscal years beginning after December&amp;#160;15, 2014, with early adoption permitted.&amp;#160; Retrospective application is required for the elimination of incremental DSE disclosures.&amp;#160; Prior to the issuance of ASU No.&amp;#160;2014-10, the Company had met the definition of a DSE since its inception.&amp;#160; The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&amp;#160;10-Q.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag170" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">5497454</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag171" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">1979977</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag172" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-7477431</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag173" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">756456</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag174" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">1432</us-gaap:InvestmentIncomeInterest>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag175" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-16346</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag176" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 675px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="675"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;292,263&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;208,908&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;125,714&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;155,331&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;417,977&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;364,239&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;584,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;335,433&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;251,426&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;256,912&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;836,158&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;592,345&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:Depreciation id="Tag177" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">5043</us-gaap:Depreciation>
  <us-gaap:PaidInKindInterest id="Tag178" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">91715</us-gaap:PaidInKindInterest>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag179" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">514514</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag180" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">1604316</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag181" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-1212524</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag182" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">6741</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag183" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">-6741</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromNotesPayable id="Tag184" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">3000000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:PaymentsOfFinancingCosts id="Tag185" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">150000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag186" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">52593641</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag187" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">51374376</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:InterestPaid id="Tag188" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">690000</us-gaap:InterestPaid>
  <us-gaap:Depreciation id="Tag189" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">6159</us-gaap:Depreciation>
  <us-gaap:PaidInKindInterest id="Tag190" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">46164</us-gaap:PaidInKindInterest>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag191" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-20700</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag192" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">56515</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag193" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-7187250</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag194" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">4633503</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag195" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-4633503</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag196" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">-11820753</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:InterestPaid id="Tag197" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">690000</us-gaap:InterestPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag198" decimals="0" contextRef="I2013Q2" unitRef="USD">8193001</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag199" decimals="0" contextRef="I2013" unitRef="USD">2119646</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag200" decimals="0" contextRef="I2012" unitRef="USD">20013754</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag201" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;3. Fair Value Measurements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;font style="FONT: 7pt Times New Roman;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; Quotes prices in active markets for identical assets and liabilities. The Company&amp;#8217;s Level&amp;#160;1 assets and liabilities consist of cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;font style="FONT: 7pt Times New Roman;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; Inputs other than Level&amp;#160;1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level&amp;#160;2 assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;font style="FONT: 7pt Times New Roman;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company&amp;#8217;s Level&amp;#160;3 liabilities consist of the warrant liability.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table sets forth the Company&amp;#8217;s financial instruments measured at fair value by level within the fair value hierarchy as of December&amp;#160;31, 2013 and June&amp;#160;30, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 83.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,066,156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,066,156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;A-1 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;438,978&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;A-2 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;64,537&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;C warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;140,963&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;644,478&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The significant assumptions used in preparing the option pricing model for valuing the Company&amp;#8217;s warrants as of December&amp;#160;31, 2013 include (i)&amp;#160;volatility (104.8%), (ii)&amp;#160;risk free interest rate of 1.94% (estimated using treasury bonds with a 6&amp;#160;year life), (iii)&amp;#160;strike price ($10.00) for the Series&amp;#160;A-1 and Series&amp;#160;A-2 warrants and $15.00 for the Series&amp;#160;C warrants, (iv)&amp;#160;fair value of Series&amp;#160;A-1 preferred stock ($4.17), Series&amp;#160;A-2 preferred stock ($2.91) and Series&amp;#160;C preferred stock ($7.63) and (v)&amp;#160;expected life (six years).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following is a rollforward of the fair value of Level&amp;#160;3 warrants:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Beginning balance at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;644,478&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expiration of Series&amp;#160;A-1 and Series&amp;#160;A-2 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(493,361&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;301,040&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Ending balance at June&amp;#160;30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 77.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="77%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="42%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;53,397,077&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;53,397,077&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The significant assumptions used in preparing the option pricing model for valuing the Company&amp;#8217;s warrants as of June&amp;#160;30, 2014 include (i)&amp;#160;volatility (104.8%), (ii)&amp;#160;risk free interest rate of 1.94% (estimated using treasury bonds with a 5.5&amp;#160;year life), (iii)&amp;#160;strike price ($6.00) for the common stock warrants, (iv)&amp;#160;fair value of common stock ($8.72) and (v)&amp;#160;expected life (5.5&amp;#160;years).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;There were no transfers between Level&amp;#160;1, 2 or 3 during 2013 or 2014. If the Company&amp;#8217;s estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock id="Tag202" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 685px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="685"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,066,156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,066,156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;A-1 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;438,978&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;A-2 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;64,537&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Series&amp;#160;C warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;140,963&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;644,478&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Tag203" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 662px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="662"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Beginning balance at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;644,478&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expiration of Series&amp;#160;A-1 and Series&amp;#160;A-2 warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(493,361&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;301,040&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Ending balance at June&amp;#160;30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 653px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="653"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="42%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;June&amp;#160;30, 2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;53,397,077&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total assets at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;53,397,077&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities at fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;452,157&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag204" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member" unitRef="USD">2066156</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:FairValueAssumptionsExercisePrice id="Tag205" decimals="2" contextRef="I2013_FairValueInputsLevel3Member_SeriesA1WarrantsMember_WarrantMember" unitRef="USDPerShare">10.00</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExercisePrice id="Tag206" decimals="2" contextRef="I2013_FairValueInputsLevel3Member_SeriesCWarrantsMember_WarrantMember" unitRef="USDPerShare">15.00</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:AssetsFairValueDisclosure id="Tag207" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member" unitRef="USD">2066156</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FairValueAssumptionsExercisePrice id="Tag208" decimals="2" contextRef="I2013_FairValueInputsLevel3Member_SeriesA2WarrantsMember_WarrantMember" unitRef="USDPerShare">10.00</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:SharePrice id="Tag209" decimals="2" contextRef="I2013_SeriesA2WarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesA2ConvertiblePreferredStockMember" unitRef="USDPerShare">2.91</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag210" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesA1WarrantsMember" unitRef="USD">438978</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag211" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesA2WarrantsMember" unitRef="USD">64537</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag212" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_SeriesCWarrantsMember" unitRef="USD">140963</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag213" decimals="0" contextRef="I2013_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member" unitRef="USD">644478</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag214" decimals="3" contextRef="D2013_FairValueInputsLevel3Member_WarrantMember" unitRef="Pure">1.048</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag215" decimals="4" contextRef="D2013_FairValueInputsLevel3Member_WarrantMember" unitRef="Pure">0.0194</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <agrx:TreasuryBondsTerm id="Tag216" contextRef="D2013_FairValueInputsLevel3Member_WarrantMember">P6Y</agrx:TreasuryBondsTerm>
  <us-gaap:SharePrice id="Tag217" decimals="2" contextRef="I2013_SeriesCWarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USDPerShare">7.63</us-gaap:SharePrice>
  <us-gaap:SharePrice id="Tag218" decimals="2" contextRef="I2013_SeriesA1WarrantsMember_WarrantMember_FairValueInputsLevel3Member_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" unitRef="USDPerShare">4.17</us-gaap:SharePrice>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Tag219" contextRef="D2013_FairValueInputsLevel3Member_WarrantMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag220" decimals="0" contextRef="I2013_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember" unitRef="USD">644478</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="Tag221" decimals="0" contextRef="D2014Q2YTD_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember" unitRef="USD">301040</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag222" decimals="0" contextRef="I2014Q2_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember" unitRef="USD">452157</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="Tag223" decimals="0" contextRef="I2014Q2" unitRef="USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="Tag224" decimals="0" contextRef="I2014Q2" unitRef="USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="Tag225" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="Tag226" decimals="0" contextRef="I2014Q2" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="Tag227" decimals="0" contextRef="I2014Q2" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet id="Tag228" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag229" decimals="0" contextRef="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member" unitRef="USD">53397077</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag230" decimals="3" contextRef="D2014Q2YTD_FairValueInputsLevel3Member_WarrantMember" unitRef="Pure">1.048</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag231" decimals="4" contextRef="D2014Q2YTD_FairValueInputsLevel3Member_WarrantMember" unitRef="Pure">0.0194</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:AssetsFairValueDisclosure id="Tag232" decimals="0" contextRef="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel1Member" unitRef="USD">53397077</us-gaap:AssetsFairValueDisclosure>
  <agrx:TreasuryBondsTerm id="Tag233" contextRef="D2014Q2YTD_FairValueInputsLevel3Member_WarrantMember">P5Y6M</agrx:TreasuryBondsTerm>
  <us-gaap:FairValueAssumptionsExercisePrice id="Tag234" decimals="2" contextRef="I2014Q2_FairValueInputsLevel3Member_WarrantMember_CommonStockMember" unitRef="USDPerShare">6.00</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag235" decimals="0" contextRef="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member_WarrantMember_CommonStockMember" unitRef="USD">452157</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag236" decimals="0" contextRef="I2014Q2" unitRef="USD">2325664</us-gaap:AccountsPayableCurrent>
  <us-gaap:SharePrice id="Tag237" decimals="2" contextRef="I2014Q2_FairValueInputsLevel3Member_WarrantMember_CommonStockMember" unitRef="USDPerShare">8.72</us-gaap:SharePrice>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Tag238" contextRef="D2014Q2YTD_FairValueInputsLevel3Member_WarrantMember">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag239" decimals="0" contextRef="I2014Q2_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_FairValueInputsLevel3Member" unitRef="USD">452157</us-gaap:LiabilitiesFairValueDisclosure>
  <agrx:PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock id="Tag240" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;4. Prepaid Expenses and Other Current Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Prepaid expenses and other current assets consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 652px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="652"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30,&lt;br /&gt;
2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Prepaid insurance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;48,055&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;604,320&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;98,649&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;56,898&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;146,704&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;661,218&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agrx:PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Tag241" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;5. Accrued Liabilities&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accrued liabilities consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 647px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="647"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30,&lt;br /&gt;
2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Employee bonuses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;238,941&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;254,135&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;140,223&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;119,135&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;379,164&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;373,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Tag242" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;9. Income Taxes&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Sale of New Jersey Net Operating Losses&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company received approval to sell a portion of the Company&amp;#8217;s New Jersey net operating losses (NOLs) as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other companies. On February&amp;#160;27, 2014, the Company completed the sale of NOLs totaling approximately $39.1&amp;#160;million for net proceeds of approximately $3.6&amp;#160;million. Such proceeds are reflected as a tax benefit for six months ended June&amp;#160;30, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Tag243" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;10. Related Party Transactions&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Effective March&amp;#160;17, 2014, one of the Managing Partners of SmartPharma&amp;#160;LLC or SmartPharma, an entity which provides commercial and business development consulting services to the Company was appointed Chief Commercial Officer. In connection with the appointment of this individual as Chief Commercial Officer, the Company amended its consulting agreement with SmartPharma to remove this individual from the list of persons providing service under the consulting agreement. SmartPharma invoiced the Company $3,250 and $74,300 of fees for the three and six months ended June&amp;#160;30, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Tag245" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 659px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="659"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30,&lt;br /&gt;
2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Employee bonuses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;238,941&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;254,135&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;140,223&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;119,135&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total accrued liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;379,164&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;373,270&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:PrepaidInsurance id="Tag246" decimals="0" contextRef="I2013" unitRef="USD">48055</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance id="Tag247" decimals="0" contextRef="I2014Q2" unitRef="USD">604320</us-gaap:PrepaidInsurance>
  <us-gaap:OtherAssetsCurrent id="Tag248" decimals="0" contextRef="I2013" unitRef="USD">98649</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="Tag249" decimals="0" contextRef="I2014Q2" unitRef="USD">56898</us-gaap:OtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag250" decimals="0" contextRef="I2014Q2" unitRef="USD">661218</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AccruedBonusesCurrent id="Tag251" decimals="0" contextRef="I2013" unitRef="USD">238941</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent id="Tag252" decimals="0" contextRef="I2014Q2" unitRef="USD">254135</us-gaap:AccruedBonusesCurrent>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag253" decimals="0" contextRef="D2014Q2_M0507_SeriesA2ConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_MinimumMember" unitRef="USD">45000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:LoansPayableCurrent id="Tag254" decimals="0" contextRef="I2014Q2" unitRef="USD">2151653</us-gaap:LoansPayableCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag255" decimals="0" contextRef="I2013" unitRef="USD">140223</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag256" decimals="0" contextRef="I2014Q2" unitRef="USD">119135</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag257" decimals="0" contextRef="I2014Q2" unitRef="USD">373270</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLossCarryforwards id="Tag258" decimals="-5" contextRef="I2014Q1_M0227_StateAndLocalJurisdictionMember_NewJerseyDivisionOfTaxationMember_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" unitRef="USD">39100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:ProceedsFromCollaborators id="Tag259" decimals="-5" contextRef="D2014Q1_M0227_StateAndLocalJurisdictionMember_NewJerseyDivisionOfTaxationMember_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" unitRef="USD">3600000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="Tag260" decimals="0" contextRef="D2014Q2_SmartPharmaLLCMember_CommercialAndBusinessDevelopmentConsultingServicesMember" unitRef="USD">3250</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="Tag261" decimals="0" contextRef="D2014Q2YTD_SmartPharmaLLCMember_CommercialAndBusinessDevelopmentConsultingServicesMember" unitRef="USD">74300</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag262" decimals="INF" contextRef="I2014Q2_M0428_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtDisclosureTextBlock id="Tag263" contextRef="D2014Q2YTD_TermLoanWithOxfordFinanceMember_1">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;7. Term Loan Amendment&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In January&amp;#160;2014 the Company amended its Loan Agreement with Oxford Finance whereby the interest only period was extended for three months (through April&amp;#160;1, 2014). The interest only period was extended for an additional three months (through July&amp;#160;1, 2014) as a result of the Company&amp;#8217;s $3.0&amp;#160;million convertible note financing in which was completed in April&amp;#160;2014 (see Note&amp;#160;6).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The interest only period was further extended for an additional six months (through January&amp;#160;1, 2015) and the maturity date of the loan was extended to July&amp;#160;1, 2017 as a result of the completion of the Company&amp;#8217;s initial public offering (see Note 8). In connection with the amendment to the Loan Agreement the Company has paid Oxford Finance a total of $150,000.&amp;#160; The $150,000 has been offset against the amount of the loan and is being amortized to interest expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;At June&amp;#160;30, 2014, the Company believes it is in compliance with the Loan Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag264" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;8. Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Initial Public Offering and Related Transactions&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;23, 2014, the Company completed its initial public offering selling 9,166,667 shares of common stock at $6.00 per share.&amp;#160; Proceeds from the Company&amp;#8217;s initial public offering, net of underwriting discounts and commissions and other offering costs were $49.7 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In addition, each of the following occurred in connection with the completion of the Company&amp;#8217;s IPO on May&amp;#160;23, 2014:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;font style="FONT: 7pt Times New Roman;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;the conversion of all outstanding shares of convertible preferred stock into 8,809,325 shares of the Company&amp;#8217;s common stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;font style="FONT: 7pt Times New Roman;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;the conversion of the aggregate principal amount of $3.0 million and accrued interest under the Company&amp;#8217;s outstanding convertible subordinated promissory notes into 503,450 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;7, 2014, the Company filed an amendment to its amended and restated certificate of incorporation which, among other things, revised the automatic conversion provision relating to the Series&amp;#160;C Preferred Stock, Series&amp;#160;B Preferred Stock, Series&amp;#160;A-1 Preferred Stock and Series&amp;#160;A-2 Preferred Stock. Following such amendment, the Series&amp;#160;C, the Series&amp;#160;B, the Series&amp;#160;A-1 and A-2 Preferred Stock now automatically convert into shares of common stock at the then effective conversion price upon:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(i)&amp;#160;the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, covering the offer and sale of common stock from which the Company receives gross proceeds of at least $45,000,000 or (ii)&amp;#160;the affirmative vote of the holders of at least a majority of the voting power the Series&amp;#160;C Preferred Stock, the Series&amp;#160;B Preferred Stock and the Series&amp;#160;A-1 Preferred Stock, respectively, after first giving effect, if in conjunction with a public offering which does not meet the standards set forth in clause&amp;#160;(i)&amp;#160;above, to any adjustment of the conversion price for each series of preferred stock to which it would otherwise be entitled by virtue of such public offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On May&amp;#160;29, 2014, the Company filed an amended and restated certificate of incorporation (the &amp;#8220;Restated Certificate&amp;#8221;) with the Secretary of State of the State of Delaware in connection with the closing of the Company&amp;#8217;s initial public offering of shares of its common stock. The Company&amp;#8217;s board of directors (the &amp;#8220;Board&amp;#8221;) and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company&amp;#8217;s initial public offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Restated Certificate amends and restates in its entirety the Company&amp;#8217;s second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: (i)&amp;#160;authorizes 150,000,000 shares of common stock; (ii)&amp;#160;eliminates all references to the previously existing series of preferred stock; (iii)&amp;#160;authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iv)&amp;#160;provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company&amp;#8217;s stockholders; (v)&amp;#160;provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (vi)&amp;#160;provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and (vii)&amp;#160;requires that any action instituted against the Company&amp;#8217;s officers or directors in connection with their service to the Company be brought in the State of Delaware.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible Preferred Stock&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Prior to its conversion in the IPO, the Company&amp;#8217;s convertible preferred stock was classified as temporary equity on its balance sheets instead of stockholders&amp;#8217; (deficit) in accordance with authoritative guidance for the classification and measurement or redeemable securities.&amp;#160; Upon certain change in control events that were outside of the Company&amp;#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock-Based Compensation Expense&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock-based compensation expense related to stock options was allocated as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;292,263&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;208,908&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;125,714&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;155,331&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;417,977&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;364,239&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
June&amp;#160;30&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;584,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;335,433&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;251,426&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;256,912&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;836,158&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;592,345&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <agrx:DebtInstrumentExtendedInterestOnlyPeriod1 id="Tag265" contextRef="D2014Q1_M01_TermLoanWithOxfordFinanceMember">P3M</agrx:DebtInstrumentExtendedInterestOnlyPeriod1>
  <agrx:DebtInstrumentExtendedInterestOnlyPeriod2 id="Tag266" contextRef="D2014Q2_M04_TermLoanWithOxfordFinanceMember">P3M</agrx:DebtInstrumentExtendedInterestOnlyPeriod2>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="Tag267" decimals="0" contextRef="D2014Q2YTD_TermLoanWithOxfordFinanceMember_1" unitRef="USD">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag268" decimals="INF" contextRef="D2014Q2_M0523_IPOMember_CommonStockMember" unitRef="Shares">9166667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ConversionOfStockSharesIssued1 id="Tag270" decimals="INF" contextRef="D2014Q2_M0523_ConvertiblePreferredStockMember_CommonStockMember" unitRef="Shares">8809325</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:PreferredStockSharesAuthorized id="Tag271" decimals="INF" contextRef="I2014Q2_M0529" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:LongTermLoansPayable id="Tag272" decimals="0" contextRef="I2014Q2" unitRef="USD">12619816</us-gaap:LongTermLoansPayable>
  <us-gaap:CommonStockSharesAuthorized id="Tag273" decimals="INF" contextRef="I2014Q2_M0529" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag274" decimals="0" contextRef="I2013" unitRef="USD">644478</us-gaap:DerivativeLiabilitiesCurrent>
  <agrx:DebtInstrumentExtendedInterestOnlyPeriod3 id="Tag275" contextRef="D2014Q2_M0523_TermLoanWithOxfordFinanceMember">P6M</agrx:DebtInstrumentExtendedInterestOnlyPeriod3>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="Tag276" decimals="0" contextRef="I2013" unitRef="USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="Tag277" decimals="0" contextRef="I2013" unitRef="USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="Tag278" decimals="0" contextRef="D2013" unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="Tag279" decimals="0" contextRef="I2013" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="Tag280" decimals="0" contextRef="I2013" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet id="Tag281" decimals="0" contextRef="D2013" unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="Tag282" contextRef="D2014Q2YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 640px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="640"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;June&amp;#160;30,&lt;br /&gt;
2014&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Prepaid insurance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;48,055&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;604,320&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;98,649&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;56,898&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;146,704&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;661,218&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <agrx:StockGrantedDuringPeriodSharebasedCompensationBonus id="Tag283" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">80000</agrx:StockGrantedDuringPeriodSharebasedCompensationBonus>
  <agrx:StockGrantedDuringPeriodSharebasedCompensationBonus id="Tag284" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">79509</agrx:StockGrantedDuringPeriodSharebasedCompensationBonus>
  <us-gaap:ShareBasedCompensation id="Tag285" decimals="0" contextRef="D2014Q2YTD" unitRef="USD">592345</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag286" decimals="0" contextRef="D2013Q2YTD" unitRef="USD">836158</us-gaap:ShareBasedCompensation>
  <dei:EntityRegistrantName id="Tag287" contextRef="D2014Q2YTD">AGILE THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag288" contextRef="D2014Q2YTD">0001261249</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag289" contextRef="D2014Q2YTD">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag290" contextRef="D2014Q2YTD">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag291" contextRef="D2014Q2YTD">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag292" contextRef="D2014Q2YTD">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag293" contextRef="D2014Q2YTD">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag294" contextRef="D2014Q2YTD">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="Tag295" decimals="INF" contextRef="I2014Q2SO" unitRef="Shares">18592968</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="Tag296" contextRef="D2014Q2YTD">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag297" contextRef="D2014Q2YTD">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag298" decimals="0" contextRef="D2014Q2_M0507_MinimumMember_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" unitRef="USD">45000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:DebtInstrumentFaceAmount id="Tag299" decimals="-5" contextRef="I2014Q2_M0428_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtDisclosureTextBlock id="Tag300" contextRef="D2014Q2YTD_ConvertibleSubordinatedPromissoryNotes28April2014Member">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;6. Convertible Note Financing&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On April&amp;#160;28, 2014, the Company and certain of the Company&amp;#8217;s existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0&amp;#160;million. The Company issued Convertible Promissory Notes (the &amp;#8220;Notes&amp;#8221;) to evidence its payment obligations with respect to the $3.0&amp;#160;million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes are convertible into unregistered equity securities of the Company upon the occurrence of events stated therein. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in an underwritten public offering (see Note 8). The Notes were subordinate to the Company&amp;#8217;s term loan with Oxford Finance LLC.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag301" decimals="0" contextRef="I2014Q2" unitRef="USD">452157</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:CommonStockValue id="Tag302" decimals="0" contextRef="I2014Q2" unitRef="USD">1860</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag303" decimals="0" contextRef="I2014Q2" unitRef="USD">169540281</us-gaap:AdditionalPaidInCapital>
  <us-gaap:EquityIssuancePerShareAmount decimals="INF" contextRef="D2014Q2_M0523_IPOMember_CommonStockMember" unitRef="USDPerShare">6.00</us-gaap:EquityIssuancePerShareAmount>
  <agrx:PreferredStockSharesAuthorizedNumberOfSeries decimals="0" contextRef="D2014Q2_M0529_MinimumMember" unitRef="Series">1</agrx:PreferredStockSharesAuthorizedNumberOfSeries>
  <agrx:BoardOfDirectorsNumberOfClasses decimals="INF" contextRef="D2014Q2_M0529" unitRef="Class">3</agrx:BoardOfDirectorsNumberOfClasses>
  <agrx:BoardOfDirectorsTerm contextRef="D2014Q2_M0529">P3Y</agrx:BoardOfDirectorsTerm>
  <agrx:BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders decimals="INF" contextRef="D2014Q2_M0529" unitRef="Class">1</agrx:BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders>
  <agrx:BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage decimals="2" contextRef="D2014Q2_M0529_MinimumMember" unitRef="Pure">0.75</agrx:BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage>
  <us-gaap:DeferredFinanceCostsGross decimals="0" contextRef="I2014Q2_TermLoanWithOxfordFinanceMember" unitRef="USD">150000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:EquityIssuancePerShareAmount decimals="INF" contextRef="D2014Q2_M0523_ConvertibleSubordinatedPromissoryNotes28April2014Member_CommonStockMember" unitRef="USDPerShare">6.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements decimals="0" contextRef="D2014Q2YTD_DerivativeFinancialInstrumentsLiabilitiesMember_WarrantMember" unitRef="USD">493361</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:ConversionOfStockAmountConverted1 decimals="0" contextRef="D2014Q2YTD" unitRef="USD">69232677</us-gaap:ConversionOfStockAmountConverted1>
  <agrx:DebtConversionOriginalDebtAmountAndAccruedInterest decimals="0" contextRef="D2014Q2YTD" unitRef="USD">3020667</agrx:DebtConversionOriginalDebtAmountAndAccruedInterest>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>agrx-20140630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<xsd:schema targetNamespace="http://www.agiletherapeutics.com/20140630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:agrx="http://www.agiletherapeutics.com/20140630" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="agrx-20140630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="agrx-20140630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="agrx-20140630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="agrx-20140630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/CashFlows" id="CashFlows">
        <link:definition>0030 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentation" id="DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>1010 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolices" id="DisclosureSummaryOfSignificantAccountingPolices">
        <link:definition>1020 - Disclosure - Summary of Significant Accounting Polices</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1030 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>1040 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>1050 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing" id="DisclosureConvertibleNoteFinancing">
        <link:definition>1060 - Disclosure - Convertible Note Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment" id="DisclosureTermLoanAmendment">
        <link:definition>1070 - Disclosure - Term Loan Amendment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/Disclosure-StockholdersEquity" id="Disclosure-StockholdersEquity">
        <link:definition>1080 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>1090 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>1100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>8110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" id="DisclosureSummaryOfSignificantAccountingPolicesPolices">
        <link:definition>2020 - Disclosure - Summary of Significant Accounting Polices (Polices)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesTables" id="DisclosureSummaryOfSignificantAccountingPolicesTables">
        <link:definition>3020 - Disclosure - Summary of Significant Accounting Polices (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>3030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>3040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>3050 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>3080 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" id="DisclosureOrganizationAndBasisOfPresentationDetails">
        <link:definition>4010 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails" id="DisclosureSummaryOfSignificantAccountingPolicesDetails">
        <link:definition>4020 - Disclosure - Summary of Significant Accounting Polices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2" id="DisclosureSummaryOfSignificantAccountingPolicesDetails2">
        <link:definition>4021 - Disclosure - Summary of Significant Accounting Polices (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails3" id="DisclosureSummaryOfSignificantAccountingPolicesDetails3">
        <link:definition>4022 - Disclosure - Summary of Significant Accounting Polices (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>4030 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" id="DisclosureFairValueMeasurementsDetails2">
        <link:definition>4031 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>4040 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
        <link:definition>4050 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails" id="DisclosureConvertibleNoteFinancingDetails">
        <link:definition>4060 - Disclosure - Convertible Note Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails" id="DisclosureTermLoanAmendmentDetails">
        <link:definition>4070 - Disclosure - Term Loan Amendment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>4080 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2" id="DisclosureStockholdersEquityDetails2">
        <link:definition>4081 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>4090 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>4100 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:element name="TermLoanWithOxfordFinanceMember" id="agrx_TermLoanWithOxfordFinanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentExtendedInterestOnlyPeriod1" id="agrx_DebtInstrumentExtendedInterestOnlyPeriod1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentExtendedInterestOnlyPeriod2" id="agrx_DebtInstrumentExtendedInterestOnlyPeriod2" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSubordinatedPromissoryNotes28April2014Member" id="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockSplitPolicyTextBlock" id="agrx_StockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsPolicyTextBlock" id="agrx_WarrantsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" id="agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonEmployeesStockOptionMember" id="agrx_EmployeeAndNonEmployeesStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" id="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesA2ConvertiblePreferredStockMember" id="agrx_SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" id="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" id="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesA1WarrantsMember" id="agrx_SeriesA1WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesA2WarrantsMember" id="agrx_SeriesA2WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCWarrantsMember" id="agrx_SeriesCWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TreasuryBondsTerm" id="agrx_TreasuryBondsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" id="agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedOfferingCostsCurrent" id="agrx_AccruedOfferingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="SmartPharmaLLCMember" id="agrx_SmartPharmaLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" id="agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentExtendedInterestOnlyPeriod3" id="agrx_DebtInstrumentExtendedInterestOnlyPeriod3" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncashConversionExpenses" id="agrx_NoncashConversionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockGrantedDuringPeriodSharebasedCompensationBonus" id="agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ForgivenessOfInterestAndNoteReceivable" id="agrx_ForgivenessOfInterestAndNoteReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="agrx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialAndBusinessDevelopmentConsultingServicesMember" id="agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockSharesAuthorizedNumberOfSeries" id="agrx_PreferredStockSharesAuthorizedNumberOfSeries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoardOfDirectorsNumberOfClasses" id="agrx_BoardOfDirectorsNumberOfClasses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" id="agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoardOfDirectorsTerm" id="agrx_BoardOfDirectorsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" id="agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonemployeeStockOptionsMember" id="agrx_EmployeeAndNonemployeeStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtConversionOriginalDebtAmountAndAccruedInterest" id="agrx_DebtConversionOriginalDebtAmountAndAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>agrx-20140630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="agrx-20140630.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="agrx-20140630.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="agrx-20140630.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInContinuingOperations to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_Depreciation" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:label="agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="StockGrantedDuringPeriodSharebasedCompensationBonus" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_PaidInKindInterest" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInContinuingOperations to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInContinuingOperations to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromNotesPayable" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_PaymentsOfFinancingCosts" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="calculation: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="3.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="calculation: us-gaap_Assets to us-gaap_AssetsCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: us-gaap_AssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="calculation: us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="DeferredFinanceCostsNoncurrentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="calculation: us-gaap_Assets to us-gaap_DeferredFinanceCostsNoncurrentNet" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="calculation: us-gaap_Assets to us-gaap_OtherAssetsNoncurrent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_LoansPayableCurrent" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesCurrent to us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermLoansPayable" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_LongTermLoansPayable" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_CommitmentsAndContingencies" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="calculation: us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_PreferredStockValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_CommonStockValue" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_AdditionalPaidInCapital" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="calculation: us-gaap_StockholdersEquity to us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="4.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_OperatingIncomeLoss" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:title="calculation: us-gaap_OperatingIncomeLoss to us-gaap_OperatingExpenses" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="calculation: us-gaap_OperatingExpenses to us-gaap_ResearchAndDevelopmentExpense" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="calculation: us-gaap_OperatingExpenses to us-gaap_GeneralAndAdministrativeExpense" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestExpense" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_InterestExpense" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_InvestmentIncomeInterest" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="calculation: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="4.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeTaxExpenseBenefit" use="optional" order="2.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:title="PrepaidInsurance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:title="calculation: us-gaap_PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidInsurance" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="calculation: us-gaap_PrepaidExpenseAndOtherAssetsCurrent to us-gaap_OtherAssetsCurrent" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to us-gaap_AccruedBonusesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="calculation: us-gaap_AccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="calculation: us-gaap_LiabilitiesFairValueDisclosure to us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="calculation: us-gaap_AssetsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1.0" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>agrx-20140630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_AccruedOfferingCostsCurrent" xlink:label="AccruedOfferingCostsCurrent" xlink:title="AccruedOfferingCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedOfferingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedOfferingCostsCurrent" xml:lang="en-US" id="label_AccruedOfferingCostsCurrent">Accrued Offering Costs Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedOfferingCostsCurrent" xlink:to="label_AccruedOfferingCostsCurrent" xlink:title="label_AccruedOfferingCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedOfferingCostsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedOfferingCostsCurrent_1" xml:lang="en-US" id="label_AccruedOfferingCostsCurrent_1">Accrued offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedOfferingCostsCurrent" xlink:to="label_AccruedOfferingCostsCurrent_1" xlink:title="label_AccruedOfferingCostsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_AccruedOfferingCostsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccruedOfferingCostsCurrent_2" xml:lang="en-US" id="label_AccruedOfferingCostsCurrent_2">Carrying value as of the balance sheet date of obligations incurred through that date and payable for offering costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedOfferingCostsCurrent" xlink:to="label_AccruedOfferingCostsCurrent_2" xlink:title="label_AccruedOfferingCostsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClasses" xlink:label="BoardOfDirectorsNumberOfClasses" xlink:title="BoardOfDirectorsNumberOfClasses" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClasses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BoardOfDirectorsNumberOfClasses" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClasses">Board of Directors, Number of Classes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClasses" xlink:to="label_BoardOfDirectorsNumberOfClasses" xlink:title="label_BoardOfDirectorsNumberOfClasses" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClasses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BoardOfDirectorsNumberOfClasses_1" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClasses_1">Represents the number of classes into which the board of directors is divided.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClasses" xlink:to="label_BoardOfDirectorsNumberOfClasses_1" xlink:title="label_BoardOfDirectorsNumberOfClasses_1" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClasses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BoardOfDirectorsNumberOfClasses_2" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClasses_2">Number of classes of Board</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClasses" xlink:to="label_BoardOfDirectorsNumberOfClasses_2" xlink:title="label_BoardOfDirectorsNumberOfClasses_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:label="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders">Board of Directors, Number of Classes Elected at Annual Meeting of Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:to="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_1" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_1">Represents the number of classes of board of directors elected at each annual meeting of stockholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:to="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_1" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_1" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_2" xml:lang="en-US" id="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_2">Number of classes elected at each annual meeting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:to="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_2" xlink:title="label_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:label="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xml:lang="en-US" id="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage">Board of Directors, Removal, Affirmative Shareholder Vote of Outstanding Capital Stock Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:to="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_1" xml:lang="en-US" id="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_1">Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:to="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_1" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_2" xml:lang="en-US" id="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_2">Represents the required percentage of affirmative vote of all shares of outstanding capital stock entitled to vote for the removal of a member of the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:to="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_2" xlink:title="label_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsTerm" xlink:label="BoardOfDirectorsTerm" xlink:title="BoardOfDirectorsTerm" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BoardOfDirectorsTerm" xml:lang="en-US" id="label_BoardOfDirectorsTerm">Board of Directors, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsTerm" xlink:to="label_BoardOfDirectorsTerm" xlink:title="label_BoardOfDirectorsTerm" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsTerm_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BoardOfDirectorsTerm_1" xml:lang="en-US" id="label_BoardOfDirectorsTerm_1">Represents the term of an elected member of the board of directors, as defined by an entity's charter and bylaws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsTerm" xlink:to="label_BoardOfDirectorsTerm_1" xlink:title="label_BoardOfDirectorsTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsTerm_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BoardOfDirectorsTerm_2" xml:lang="en-US" id="label_BoardOfDirectorsTerm_2">Term of Board member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsTerm" xlink:to="label_BoardOfDirectorsTerm_2" xlink:title="label_BoardOfDirectorsTerm_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:label="CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="CommercialAndBusinessDevelopmentConsultingServicesMember" />
    <link:label xlink:type="resource" xlink:label="label_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember" xml:lang="en-US" id="label_CommercialAndBusinessDevelopmentConsultingServicesMember">Commercial and Business Development Consulting Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:to="label_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember" />
    <link:label xlink:type="resource" xlink:label="label_CommercialAndBusinessDevelopmentConsultingServicesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember_1" xml:lang="en-US" id="label_CommercialAndBusinessDevelopmentConsultingServicesMember_1">Commercial and business development consulting services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:to="label_CommercialAndBusinessDevelopmentConsultingServicesMember_1" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_CommercialAndBusinessDevelopmentConsultingServicesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember_2" xml:lang="en-US" id="label_CommercialAndBusinessDevelopmentConsultingServicesMember_2">Represents an agreement with a related party which provides for the entity to receive commercial and business development consulting services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:to="label_CommercialAndBusinessDevelopmentConsultingServicesMember_2" xlink:title="label_CommercialAndBusinessDevelopmentConsultingServicesMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:label="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember">Convertible Financial Instrument Automatic Conversion Provision Completion of Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_1" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_1">Represents information pertaining to a convertible financial instrument which provides for automatic conversion upon the completion of an underwritten public offering if certain conditions are met as defined in the agreement to the financial instrument. Such conditions may include, but are not limited to, the amount of gross proceeds received and the timing of completion of the offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_1" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_2" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_2">Automatic conversion, underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_2" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_2" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_3" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_3">Automatic conversion, closing of an underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_3" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member" xml:lang="en-US" id="label_ConvertibleSubordinatedPromissoryNotes28April2014Member">Convertible Subordinated Promissory Notes 28 April 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:to="label_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_1" xml:lang="en-US" id="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_1">Convertible Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:to="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_1" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" xml:lang="en-US" id="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_2">Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder issued by the entity on April 28, 2014 pursuant to a Convertible Subordinated Note Purchase Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:to="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_2" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_3" xml:lang="en-US" id="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_3">Convertible subordinated promissory notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:to="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_3" xlink:title="label_ConvertibleSubordinatedPromissoryNotes28April2014Member_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:label="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:title="DebtConversionOriginalDebtAmountAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountAndAccruedInterest">Debt Conversion, Original Debt, Amount and Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountAndAccruedInterest_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountAndAccruedInterest_1">The amount of the original debt and accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountAndAccruedInterest_1" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmountAndAccruedInterest_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest_2" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmountAndAccruedInterest_2">Conversion of notes payable and interest into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:to="label_DebtConversionOriginalDebtAmountAndAccruedInterest_2" xlink:title="label_DebtConversionOriginalDebtAmountAndAccruedInterest_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:label="DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod1">Debt Instrument Extended Interest Only Period 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod1" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1_1" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod1_1">Extended interest only period through April 1, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod1" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod1_1" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod1_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1_2" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod1_2">Represents information pertaining to extended interest only period one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod1" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod1_2" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod1_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:label="DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod2" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod2">Debt Instrument Extended Interest Only Period 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod2" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2_1" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod2_1">Extended interest only period through July 1, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod2" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod2_1" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod2_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2_2" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod2_2">Represents information pertaining to extended interest only period two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod2" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod2_2" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod2_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:label="DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod3" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod3">Debt Instrument Extended Interest Only Period 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod3" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod3_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3_1" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod3_1">Extended interest only period through January 1, 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod3" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod3_1" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentExtendedInterestOnlyPeriod3_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3_2" xml:lang="en-US" id="label_DebtInstrumentExtendedInterestOnlyPeriod3_2">Represents information pertaining to extended interest only period three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExtendedInterestOnlyPeriod3" xlink:to="label_DebtInstrumentExtendedInterestOnlyPeriod3_2" xlink:title="label_DebtInstrumentExtendedInterestOnlyPeriod3_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember">Employee and Nonemployee Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_1" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember_1">An arrangement whereby an employee or nonemployee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Nonemployees may include, but are not limited to, consultants and outside members of the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember_1" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_2" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember_2">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember_2" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_2" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_3" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember_3">Common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember_3" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ForgivenessOfInterestAndNoteReceivable" xlink:label="ForgivenessOfInterestAndNoteReceivable" xlink:title="ForgivenessOfInterestAndNoteReceivable" />
    <link:label xlink:type="resource" xlink:label="label_ForgivenessOfInterestAndNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForgivenessOfInterestAndNoteReceivable" xml:lang="en-US" id="label_ForgivenessOfInterestAndNoteReceivable">Forgiveness of Interest and Note Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForgivenessOfInterestAndNoteReceivable" xlink:to="label_ForgivenessOfInterestAndNoteReceivable" xlink:title="label_ForgivenessOfInterestAndNoteReceivable" />
    <link:label xlink:type="resource" xlink:label="label_ForgivenessOfInterestAndNoteReceivable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ForgivenessOfInterestAndNoteReceivable_1" xml:lang="en-US" id="label_ForgivenessOfInterestAndNoteReceivable_1">Forgiveness of interest and note receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForgivenessOfInterestAndNoteReceivable" xlink:to="label_ForgivenessOfInterestAndNoteReceivable_1" xlink:title="label_ForgivenessOfInterestAndNoteReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_ForgivenessOfInterestAndNoteReceivable_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ForgivenessOfInterestAndNoteReceivable_2" xml:lang="en-US" id="label_ForgivenessOfInterestAndNoteReceivable_2">Represents the decrease in amounts of interest and note receivable indebtedness forgiven by the holder of the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForgivenessOfInterestAndNoteReceivable" xlink:to="label_ForgivenessOfInterestAndNoteReceivable_2" xlink:title="label_ForgivenessOfInterestAndNoteReceivable_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_NoncashConversionExpenses" xlink:label="NoncashConversionExpenses" xlink:title="NoncashConversionExpenses" />
    <link:label xlink:type="resource" xlink:label="label_NoncashConversionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashConversionExpenses" xml:lang="en-US" id="label_NoncashConversionExpenses">Noncash Conversion Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashConversionExpenses" xlink:to="label_NoncashConversionExpenses" xlink:title="label_NoncashConversionExpenses" />
    <link:label xlink:type="resource" xlink:label="label_NoncashConversionExpenses_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashConversionExpenses_1" xml:lang="en-US" id="label_NoncashConversionExpenses_1">Noncash conversion expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashConversionExpenses" xlink:to="label_NoncashConversionExpenses_1" xlink:title="label_NoncashConversionExpenses_1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashConversionExpenses_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncashConversionExpenses_2" xml:lang="en-US" id="label_NoncashConversionExpenses_2">Represents the amount of noncash conversion expenses incurred during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashConversionExpenses" xlink:to="label_NoncashConversionExpenses_2" xlink:title="label_NoncashConversionExpenses_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_PreferredStockSharesAuthorizedNumberOfSeries" xlink:label="PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="PreferredStockSharesAuthorizedNumberOfSeries" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorizedNumberOfSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries" xml:lang="en-US" id="label_PreferredStockSharesAuthorizedNumberOfSeries">Preferred Stock Shares Authorized Number of Series</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorizedNumberOfSeries" xlink:to="label_PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorizedNumberOfSeries_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries_1" xml:lang="en-US" id="label_PreferredStockSharesAuthorizedNumberOfSeries_1">The number of series of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorizedNumberOfSeries" xlink:to="label_PreferredStockSharesAuthorizedNumberOfSeries_1" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorizedNumberOfSeries_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries_2" xml:lang="en-US" id="label_PreferredStockSharesAuthorizedNumberOfSeries_2">Number of series of preferred stock that may be issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorizedNumberOfSeries" xlink:to="label_PreferredStockSharesAuthorizedNumberOfSeries_2" xlink:title="label_PreferredStockSharesAuthorizedNumberOfSeries_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:label="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:title="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock">Prepaid Expense and other Assets Current Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_1" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_1">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_1" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_2" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_2">Disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_2" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember">Series A 1, 8 Percent Noncumulative Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_1">Series A 1, 8%, non cumulative convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_2">Represents information pertaining to the Series A 1, 8% non cumulative convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_2" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_3" xml:lang="en-US" id="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_3">Series A-1 Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:title="label_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA1WarrantsMember" xlink:label="SeriesA1WarrantsMember" xlink:title="SeriesA1WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesA1WarrantsMember" xml:lang="en-US" id="label_SeriesA1WarrantsMember">Represents information pertaining to the Series A-1 warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA1WarrantsMember" xlink:to="label_SeriesA1WarrantsMember" xlink:title="label_SeriesA1WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA1WarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesA1WarrantsMember_1" xml:lang="en-US" id="label_SeriesA1WarrantsMember_1">Series A1 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA1WarrantsMember" xlink:to="label_SeriesA1WarrantsMember_1" xlink:title="label_SeriesA1WarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA1WarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesA1WarrantsMember_2" xml:lang="en-US" id="label_SeriesA1WarrantsMember_2">Series A-1 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA1WarrantsMember" xlink:to="label_SeriesA1WarrantsMember_2" xlink:title="label_SeriesA1WarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesA2ConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesA2ConvertiblePreferredStockMember">Series A 2, Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2ConvertiblePreferredStockMember" xlink:to="label_SeriesA2ConvertiblePreferredStockMember" xlink:title="label_SeriesA2ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2ConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesA2ConvertiblePreferredStockMember_1">Series A 2 convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2ConvertiblePreferredStockMember" xlink:to="label_SeriesA2ConvertiblePreferredStockMember_1" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2ConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesA2ConvertiblePreferredStockMember_2">Represents information pertaining to the Series A 2 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2ConvertiblePreferredStockMember" xlink:to="label_SeriesA2ConvertiblePreferredStockMember_2" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_2" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2ConvertiblePreferredStockMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_3" xml:lang="en-US" id="label_SeriesA2ConvertiblePreferredStockMember_3">Series A-2 Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2ConvertiblePreferredStockMember" xlink:to="label_SeriesA2ConvertiblePreferredStockMember_3" xlink:title="label_SeriesA2ConvertiblePreferredStockMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2WarrantsMember" xlink:label="SeriesA2WarrantsMember" xlink:title="SeriesA2WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesA2WarrantsMember" xml:lang="en-US" id="label_SeriesA2WarrantsMember">Series A2 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2WarrantsMember" xlink:to="label_SeriesA2WarrantsMember" xlink:title="label_SeriesA2WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2WarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesA2WarrantsMember_1" xml:lang="en-US" id="label_SeriesA2WarrantsMember_1">Series A-2 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2WarrantsMember" xlink:to="label_SeriesA2WarrantsMember_1" xlink:title="label_SeriesA2WarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesA2WarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesA2WarrantsMember_2" xml:lang="en-US" id="label_SeriesA2WarrantsMember_2">Represents information pertaining to the Series A-2 warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesA2WarrantsMember" xlink:to="label_SeriesA2WarrantsMember_2" xlink:title="label_SeriesA2WarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember">Series B, 8 Percent Noncumulative Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_1">Series B, 8% non cumulative, convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_2">Represents information pertaining to the Series B, 8% non cumulative, convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_2" />
    <link:label xlink:type="resource" xlink:label="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_3" xml:lang="en-US" id="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_3">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:title="label_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember">Series C, 12 Percent Noncumulative Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_1">Series C, 12% non cumulative, convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_1" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_2">Represents information pertaining to the Series C, 12% non cumulative, convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_2" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_2" />
    <link:label xlink:type="resource" xlink:label="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_3" xml:lang="en-US" id="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_3">Series C Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:to="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_3" xlink:title="label_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember_3" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesCWarrantsMember" xlink:label="SeriesCWarrantsMember" xlink:title="SeriesCWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesCWarrantsMember" xml:lang="en-US" id="label_SeriesCWarrantsMember">Series C Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCWarrantsMember" xlink:to="label_SeriesCWarrantsMember" xlink:title="label_SeriesCWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesCWarrantsMember_1" xml:lang="en-US" id="label_SeriesCWarrantsMember_1">Series C warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCWarrantsMember" xlink:to="label_SeriesCWarrantsMember_1" xlink:title="label_SeriesCWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesCWarrantsMember_2" xml:lang="en-US" id="label_SeriesCWarrantsMember_2">Represents information pertaining to the Series C warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCWarrantsMember" xlink:to="label_SeriesCWarrantsMember_2" xlink:title="label_SeriesCWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SmartPharmaLLCMember" xlink:label="SmartPharmaLLCMember" xlink:title="SmartPharmaLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_SmartPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SmartPharmaLLCMember" xml:lang="en-US" id="label_SmartPharmaLLCMember">Smart Pharma LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SmartPharmaLLCMember" xlink:to="label_SmartPharmaLLCMember" xlink:title="label_SmartPharmaLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_SmartPharmaLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SmartPharmaLLCMember_1" xml:lang="en-US" id="label_SmartPharmaLLCMember_1">SmartPharma</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SmartPharmaLLCMember" xlink:to="label_SmartPharmaLLCMember_1" xlink:title="label_SmartPharmaLLCMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SmartPharmaLLCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SmartPharmaLLCMember_2" xml:lang="en-US" id="label_SmartPharmaLLCMember_2">Represents information pertaining to the SmartPharma LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SmartPharmaLLCMember" xlink:to="label_SmartPharmaLLCMember_2" xlink:title="label_SmartPharmaLLCMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:label="StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="StockGrantedDuringPeriodSharebasedCompensationBonus" />
    <link:label xlink:type="resource" xlink:label="label_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus" xml:lang="en-US" id="label_StockGrantedDuringPeriodSharebasedCompensationBonus">Stock Granted During Period Sharebased Compensation Bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:to="label_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus" />
    <link:label xlink:type="resource" xlink:label="label_StockGrantedDuringPeriodSharebasedCompensationBonus_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus_1" xml:lang="en-US" id="label_StockGrantedDuringPeriodSharebasedCompensationBonus_1">Noncash stock bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:to="label_StockGrantedDuringPeriodSharebasedCompensationBonus_1" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus_1" />
    <link:label xlink:type="resource" xlink:label="label_StockGrantedDuringPeriodSharebasedCompensationBonus_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus_2" xml:lang="en-US" id="label_StockGrantedDuringPeriodSharebasedCompensationBonus_2">Value of stock (or other type of equity) granted during the period as a result of an equity-based incentive compensation plan. This element is not the recognition of equity-based compensation expense pursuant to FAS 123R.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:to="label_StockGrantedDuringPeriodSharebasedCompensationBonus_2" xlink:title="label_StockGrantedDuringPeriodSharebasedCompensationBonus_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_StockSplitPolicyTextBlock" xlink:label="StockSplitPolicyTextBlock" xlink:title="StockSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockSplitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockSplitPolicyTextBlock" xml:lang="en-US" id="label_StockSplitPolicyTextBlock">Stock Split Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSplitPolicyTextBlock" xlink:to="label_StockSplitPolicyTextBlock" xlink:title="label_StockSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockSplitPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockSplitPolicyTextBlock_1" xml:lang="en-US" id="label_StockSplitPolicyTextBlock_1">Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSplitPolicyTextBlock" xlink:to="label_StockSplitPolicyTextBlock_1" xlink:title="label_StockSplitPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_StockSplitPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockSplitPolicyTextBlock_2" xml:lang="en-US" id="label_StockSplitPolicyTextBlock_2">Represents disclosure of accounting policy for stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSplitPolicyTextBlock" xlink:to="label_StockSplitPolicyTextBlock_2" xlink:title="label_StockSplitPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:label="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" />
    <link:label xlink:type="resource" xlink:label="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xml:lang="en-US" id="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember">Technology Business Tax Certificate Program Sale of Unused Tax Carryforwards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:to="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" />
    <link:label xlink:type="resource" xlink:label="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_1" xml:lang="en-US" id="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_1">Sale of unused NOLs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:to="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_1" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_2" xml:lang="en-US" id="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_2">Represents information pertaining to the part of the Technology Business Tax Certificate Program which allows emerging biotechnology companies to sell their unused net operating losses (NOLs) and unused research and development credits to other companies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:to="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_2" xlink:title="label_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TermLoanWithOxfordFinanceMember" xlink:label="TermLoanWithOxfordFinanceMember" xlink:title="TermLoanWithOxfordFinanceMember" />
    <link:label xlink:type="resource" xlink:label="label_TermLoanWithOxfordFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TermLoanWithOxfordFinanceMember" xml:lang="en-US" id="label_TermLoanWithOxfordFinanceMember">Term Loan with Oxford Finance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanWithOxfordFinanceMember" xlink:to="label_TermLoanWithOxfordFinanceMember" xlink:title="label_TermLoanWithOxfordFinanceMember" />
    <link:label xlink:type="resource" xlink:label="label_TermLoanWithOxfordFinanceMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TermLoanWithOxfordFinanceMember_1" xml:lang="en-US" id="label_TermLoanWithOxfordFinanceMember_1">Term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanWithOxfordFinanceMember" xlink:to="label_TermLoanWithOxfordFinanceMember_1" xlink:title="label_TermLoanWithOxfordFinanceMember_1" />
    <link:label xlink:type="resource" xlink:label="label_TermLoanWithOxfordFinanceMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TermLoanWithOxfordFinanceMember_2" xml:lang="en-US" id="label_TermLoanWithOxfordFinanceMember_2">Represents information pertaining to term loan with Oxford Finance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanWithOxfordFinanceMember" xlink:to="label_TermLoanWithOxfordFinanceMember_2" xlink:title="label_TermLoanWithOxfordFinanceMember_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TreasuryBondsTerm" xlink:label="TreasuryBondsTerm" xlink:title="TreasuryBondsTerm" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryBondsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TreasuryBondsTerm" xml:lang="en-US" id="label_TreasuryBondsTerm">Treasury Bonds Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryBondsTerm" xlink:to="label_TreasuryBondsTerm" xlink:title="label_TreasuryBondsTerm" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryBondsTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TreasuryBondsTerm_1" xml:lang="en-US" id="label_TreasuryBondsTerm_1">Life of treasury bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryBondsTerm" xlink:to="label_TreasuryBondsTerm_1" xlink:title="label_TreasuryBondsTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryBondsTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TreasuryBondsTerm_2" xml:lang="en-US" id="label_TreasuryBondsTerm_2">Term of the treasury bonds, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryBondsTerm" xlink:to="label_TreasuryBondsTerm_2" xlink:title="label_TreasuryBondsTerm_2" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_WarrantsPolicyTextBlock" xlink:label="WarrantsPolicyTextBlock" xlink:title="WarrantsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsPolicyTextBlock" xml:lang="en-US" id="label_WarrantsPolicyTextBlock">Warrants Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsPolicyTextBlock" xlink:to="label_WarrantsPolicyTextBlock" xlink:title="label_WarrantsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsPolicyTextBlock_1" xml:lang="en-US" id="label_WarrantsPolicyTextBlock_1">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsPolicyTextBlock" xlink:to="label_WarrantsPolicyTextBlock_1" xlink:title="label_WarrantsPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsPolicyTextBlock_2" xml:lang="en-US" id="label_WarrantsPolicyTextBlock_2">Represents disclosure of accounting policy for warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsPolicyTextBlock" xlink:to="label_WarrantsPolicyTextBlock_2" xlink:title="label_WarrantsPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">Summary of Significant Accounting Polices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent_1" xml:lang="en-US" id="label_AccountsPayableCurrent_1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent_1" xlink:title="label_AccountsPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedBonusesCurrent" xml:lang="en-US" id="label_AccruedBonusesCurrent">Employee bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="label_AccruedBonusesCurrent" xlink:title="label_AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedBonusesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedBonusesCurrent_1" xml:lang="en-US" id="label_AccruedBonusesCurrent_1">Accrued Bonuses, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="label_AccruedBonusesCurrent_1" xlink:title="label_AccruedBonusesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US" id="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent" xlink:title="label_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_1">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_1" xlink:title="label_AccruedLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AccruedLiabilitiesCurrent_2" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_2">Total accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_2" xlink:title="label_AccruedLiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="label_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital_1" xml:lang="en-US" id="label_AdditionalPaidInCapital_1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital_1" xlink:title="label_AdditionalPaidInCapital_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense" xlink:title="label_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_1">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_1" xlink:title="label_AllocatedShareBasedCompensationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="label_AntidilutiveSecuritiesNameDomain" xlink:title="label_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="label_ArrangementsAndNonarrangementTransactionsMember">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="label_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label_Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets_1" xml:lang="en-US" id="label_Assets_1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_1" xlink:title="label_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract_1" xml:lang="en-US" id="label_AssetsAbstract_1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_1" xlink:title="label_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent_1" xml:lang="en-US" id="label_AssetsCurrent_1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_1" xlink:title="label_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_AssetsCurrentAbstract_1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_1" xlink:title="label_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsFairValueDisclosure" xml:lang="en-US" id="label_AssetsFairValueDisclosure">Total assets at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="label_AssetsFairValueDisclosure" xlink:title="label_AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsFairValueDisclosure_1" xml:lang="en-US" id="label_AssetsFairValueDisclosure_1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="label_AssetsFairValueDisclosure_1" xlink:title="label_AssetsFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsFairValueDisclosureAbstract" xml:lang="en-US" id="label_AssetsFairValueDisclosureAbstract">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="label_AssetsFairValueDisclosureAbstract" xlink:title="label_AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsFairValueDisclosureAbstract_1" xml:lang="en-US" id="label_AssetsFairValueDisclosureAbstract_1">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="label_AssetsFairValueDisclosureAbstract_1" xlink:title="label_AssetsFairValueDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardTypeAxis" xml:lang="en-US" id="label_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="label_AwardTypeAxis" xlink:title="label_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">Cash and cash equivalents, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_1" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure_1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure_1" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">Supplemental disclosure of noncash financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockDomain" xml:lang="en-US" id="label_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain" xlink:title="label_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockLineItems" xml:lang="en-US" id="label_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems" xlink:title="label_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfStockLineItems_1" xml:lang="en-US" id="label_ClassOfStockLineItems_1">Stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems_1" xlink:title="label_ClassOfStockLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="label_ClassOfWarrantOrRightAxis" xlink:title="label_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain" xlink:title="label_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitment and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_CommitmentsAndContingencies_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_1" xlink:title="label_CommitmentsAndContingencies_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember_1" xml:lang="en-US" id="label_CommonStockMember_1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_1" xlink:title="label_CommonStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1" xml:lang="en-US" id="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1" xlink:title="label_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Par value of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_1" xlink:title="label_CommonStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="label_CommonStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_1" xlink:title="label_CommonStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesAuthorized_2" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Authorized shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="label_CommonStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued_1" xml:lang="en-US" id="label_CommonStockSharesIssued_1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_1" xlink:title="label_CommonStockSharesIssued_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_CommonStockSharesOutstanding_1">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_1" xlink:title="label_CommonStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common stock, $.0001 par value, authorized 150,000,000 shares; issued 109,321 and outstanding 103,536 shares at December 31, 2013 and issued 18,598,754 and outstanding 18,592,968 shares at June 30, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue_1" xml:lang="en-US" id="label_CommonStockValue_1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_1" xlink:title="label_CommonStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1">Conversion of Stock, Amount Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1" xlink:title="label_ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockAmountConverted1_1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1_1">Conversion of preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1_1" xlink:title="label_ConversionOfStockAmountConverted1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis" xml:lang="en-US" id="label_ConversionOfStockByUniqueDescriptionAxis">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="label_ConversionOfStockByUniqueDescriptionAxis" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockNameDomain" xml:lang="en-US" id="label_ConversionOfStockNameDomain">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="label_ConversionOfStockNameDomain" xlink:title="label_ConversionOfStockNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockSharesIssued1" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1">Number of common shares into which convertible preferred stock was converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1" xlink:title="label_ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockSharesIssued1_1" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1_1">Conversion of Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1_1" xlink:title="label_ConversionOfStockSharesIssued1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotesPayableMember" xml:lang="en-US" id="label_ConvertibleNotesPayableMember">Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="label_ConvertibleNotesPayableMember" xlink:title="label_ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotesPayableMember_1" xml:lang="en-US" id="label_ConvertibleNotesPayableMember_1">Convertible Notes Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="label_ConvertibleNotesPayableMember_1" xlink:title="label_ConvertibleNotesPayableMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableMember_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertibleNotesPayableMember_2" xml:lang="en-US" id="label_ConvertibleNotesPayableMember_2">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="label_ConvertibleNotesPayableMember_2" xlink:title="label_ConvertibleNotesPayableMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePreferredStockMember" xml:lang="en-US" id="label_ConvertiblePreferredStockMember">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="label_ConvertiblePreferredStockMember" xlink:title="label_ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_ConvertiblePreferredStockMember_1">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="label_ConvertiblePreferredStockMember_1" xlink:title="label_ConvertiblePreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionByUniqueDescriptionAxis" xml:lang="en-US" id="label_DebtConversionByUniqueDescriptionAxis">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="label_DebtConversionByUniqueDescriptionAxis" xlink:title="label_DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1">Number of common shares into which convertible promissory notes were converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1_1">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_2" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1_2">Number of common shares into which convertible promissory notes and accrued interest converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1_2" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionNameDomain" xml:lang="en-US" id="label_DebtConversionNameDomain">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionNameDomain" xlink:to="label_DebtConversionNameDomain" xlink:title="label_DebtConversionNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1">Aggregate principal amount converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1" xlink:title="label_DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmount1_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_1">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_1" xlink:title="label_DebtConversionOriginalDebtAmount1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock">Term Loan Amendment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock" xlink:title="label_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtDisclosureTextBlock_1" xml:lang="en-US" id="label_DebtDisclosureTextBlock_1">Convertible Note Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock_1" xlink:title="label_DebtDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureTextBlock_2" xml:lang="en-US" id="label_DebtDisclosureTextBlock_2">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock_2" xlink:title="label_DebtDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentAxis" xml:lang="en-US" id="label_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="label_DebtInstrumentAxis" xlink:title="label_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xml:lang="en-US" id="label_DebtInstrumentConvertibleNumberOfEquityInstruments">Number of common stock issued upon conversion of notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="label_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount">Aggregate amount of loan borrowed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount" xlink:title="label_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentFaceAmount_1" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_1" xlink:title="label_DebtInstrumentFaceAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtInstrumentFaceAmount_2" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_2">Face amount of notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_2" xlink:title="label_DebtInstrumentFaceAmount_2" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_3" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_DebtInstrumentFaceAmount_3" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_3">Aggregate principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_3" xlink:title="label_DebtInstrumentFaceAmount_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage_1">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems">Term loan amendment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems" xlink:title="label_DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentLineItems_1" xml:lang="en-US" id="label_DebtInstrumentLineItems_1">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems_1" xlink:title="label_DebtInstrumentLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtInstrumentLineItems_2" xml:lang="en-US" id="label_DebtInstrumentLineItems_2">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems_2" xlink:title="label_DebtInstrumentLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentNameDomain" xml:lang="en-US" id="label_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain" xlink:title="label_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTable" xml:lang="en-US" id="label_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="label_DebtInstrumentTable" xlink:title="label_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US" id="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">Schedule of prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xml:lang="en-US" id="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsGross" xml:lang="en-US" id="label_DeferredFinanceCostsGross">Deferred Finance Costs, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross" xlink:title="label_DeferredFinanceCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsGross_1" xml:lang="en-US" id="label_DeferredFinanceCostsGross_1">Amount offset against loan to be amortized to interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross_1" xlink:title="label_DeferredFinanceCostsGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="DeferredFinanceCostsNoncurrentNet" xlink:title="DeferredFinanceCostsNoncurrentNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US" id="label_DeferredFinanceCostsNoncurrentNet">Deferred financing costs, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNoncurrentNet" xlink:to="label_DeferredFinanceCostsNoncurrentNet" xlink:title="label_DeferredFinanceCostsNoncurrentNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNoncurrentNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsNoncurrentNet_1" xml:lang="en-US" id="label_DeferredFinanceCostsNoncurrentNet_1">Deferred Finance Costs, Noncurrent, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNoncurrentNet" xlink:to="label_DeferredFinanceCostsNoncurrentNet_1" xlink:title="label_DeferredFinanceCostsNoncurrentNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="DeferredOfferingCosts" xlink:title="DeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredOfferingCosts" xml:lang="en-US" id="label_DeferredOfferingCosts">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredOfferingCosts" xlink:to="label_DeferredOfferingCosts" xlink:title="label_DeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_DeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredOfferingCosts_1" xml:lang="en-US" id="label_DeferredOfferingCosts_1">Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredOfferingCosts" xlink:to="label_DeferredOfferingCosts_1" xlink:title="label_DeferredOfferingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Depreciation" xml:lang="en-US" id="label_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation" xlink:title="label_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Depreciation_1" xml:lang="en-US" id="label_Depreciation_1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation_1" xlink:title="label_Depreciation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeByNatureAxis" xml:lang="en-US" id="label_DerivativeByNatureAxis">Derivative, by Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeByNatureAxis" xlink:to="label_DerivativeByNatureAxis" xlink:title="label_DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeFinancialInstrumentsLiabilitiesMember" xml:lang="en-US" id="label_DerivativeFinancialInstrumentsLiabilitiesMember">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="label_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="label_DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeFinancialInstrumentsLiabilitiesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeFinancialInstrumentsLiabilitiesMember_1" xml:lang="en-US" id="label_DerivativeFinancialInstrumentsLiabilitiesMember_1">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="label_DerivativeFinancialInstrumentsLiabilitiesMember_1" xlink:title="label_DerivativeFinancialInstrumentsLiabilitiesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent" xlink:title="label_DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilitiesCurrent_1" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_1">Derivative Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_1" xlink:title="label_DerivativeLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DerivativeLiabilitiesCurrent_2" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_2">Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_2" xlink:title="label_DerivativeLiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeNameDomain" xml:lang="en-US" id="label_DerivativeNameDomain">Derivative, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeNameDomain" xlink:to="label_DerivativeNameDomain" xlink:title="label_DerivativeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:label xlink:type="resource" xlink:label="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US" id="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:label xlink:type="resource" xlink:label="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_1" xml:lang="en-US" id="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_1">Development Stage Enterprise, Deficit Accumulated During Development Stage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_1" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_1" />
    <link:label xlink:type="resource" xlink:label="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" xml:lang="en-US" id="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract" xlink:title="label_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareAbstract_1" xml:lang="en-US" id="label_EarningsPerShareAbstract_1">Net loss per common share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract_1" xlink:title="label_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Basic and Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_1">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_1" xlink:title="label_EarningsPerShareBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted_2" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label_EarningsPerShareBasicAndDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock" xlink:title="label_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock_1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock_1" xlink:title="label_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeStockOptionMember">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember" xlink:title="label_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeStockOptionMember_1" xml:lang="en-US" id="label_EmployeeStockOptionMember_1">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember_1" xlink:title="label_EmployeeStockOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_EquityIssuancePerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIssuancePerShareAmount" xml:lang="en-US" id="label_EquityIssuancePerShareAmount">Development Stage Entities, Equity Issuance, Per Share Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="label_EquityIssuancePerShareAmount" xlink:title="label_EquityIssuancePerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_EquityIssuancePerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityIssuancePerShareAmount_1" xml:lang="en-US" id="label_EquityIssuancePerShareAmount_1">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="label_EquityIssuancePerShareAmount_1" xlink:title="label_EquityIssuancePerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember">Measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember_1" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember_1">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember_1" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants" xlink:title="label_FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueAdjustmentOfWarrants_1" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants_1">Change in fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants_1" xlink:title="label_FairValueAdjustmentOfWarrants_1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueAdjustmentOfWarrants_2" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants_2">Change in fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants_2" xlink:title="label_FairValueAdjustmentOfWarrants_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">Schedule of the Company's financial instruments measured at fair value by level within the fair value hierarchy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount">Asset transfers out of Level 1 into Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount">Asset transfers out of Level 2 into Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="FairValueAssumptionsExercisePrice" xlink:title="FairValueAssumptionsExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExercisePrice" xml:lang="en-US" id="label_FairValueAssumptionsExercisePrice">Strike price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExercisePrice" xlink:to="label_FairValueAssumptionsExercisePrice" xlink:title="label_FairValueAssumptionsExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExercisePrice_1" xml:lang="en-US" id="label_FairValueAssumptionsExercisePrice_1">Fair Value Assumptions, Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExercisePrice" xlink:to="label_FairValueAssumptionsExercisePrice_1" xlink:title="label_FairValueAssumptionsExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedTerm" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm" xlink:title="label_FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedTerm_1" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm_1">Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm_1" xlink:title="label_FairValueAssumptionsExpectedTerm_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate">Volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate_1">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate_1" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate">Risk free interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate_1">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate_1" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByLiabilityClassAxis" xml:lang="en-US" id="label_FairValueByLiabilityClassAxis">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByLiabilityClassAxis" xlink:to="label_FairValueByLiabilityClassAxis" xlink:title="label_FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementBasisAxis" xml:lang="en-US" id="label_FairValueByMeasurementBasisAxis">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="label_FairValueByMeasurementBasisAxis" xlink:title="label_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="label_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosureItemAmountsDomain" xml:lang="en-US" id="label_FairValueDisclosureItemAmountsDomain">Fair Value Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="label_FairValueDisclosureItemAmountsDomain" xlink:title="label_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_1" xlink:title="label_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="label_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member_1" xml:lang="en-US" id="label_FairValueInputsLevel1Member_1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member_1" xlink:title="label_FairValueInputsLevel1Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member" xlink:title="label_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel2Member_1" xml:lang="en-US" id="label_FairValueInputsLevel2Member_1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member_1" xlink:title="label_FairValueInputsLevel2Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member" xlink:title="label_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel3Member_1" xml:lang="en-US" id="label_FairValueInputsLevel3Member_1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_1" xlink:title="label_FairValueInputsLevel3Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">Liability transfers out of Level 1 into Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_1" xml:lang="en-US" id="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_1">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_1" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">Liability transfers out of Level 2 into Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1" xml:lang="en-US" id="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">Rollforward of the fair value of Level 3 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">Fair value of Level 3 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Schedule of rollforward of the fair value of Level 3 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="label_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="label_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember_1" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_1">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_1" xlink:title="label_FairValueMeasurementsRecurringMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">Asset transfers into (out of) Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1">Expiration of Series A-1 and Series A-2 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">Liability transfers into (out of) Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">Balance at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1">Balance at the end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfFinancialInstrumentsPolicy_1" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:title="label_FairValueOfFinancialInstrumentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt">Gains (Losses) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt_1">Loss on extinguishment of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_1" xlink:title="label_GeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember" xlink:title="label_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember_1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember_1" xlink:title="label_GeneralAndAdministrativeExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1">Loss before benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationAxis" xml:lang="en-US" id="label_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="label_IncomeStatementLocationAxis" xlink:title="label_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationDomain" xml:lang="en-US" id="label_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain" xlink:title="label_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="label_IncomeTaxAuthorityAxis" xlink:title="label_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="label_IncomeTaxAuthorityDomain" xlink:title="label_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityNameAxis">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="label_IncomeTaxAuthorityNameAxis" xlink:title="label_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityNameDomain">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="label_IncomeTaxAuthorityNameDomain" xlink:title="label_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="label_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_1" xlink:title="label_IncomeTaxDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxesPaid" xml:lang="en-US" id="label_IncomeTaxesPaid">Income Taxes Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="label_IncomeTaxesPaid" xlink:title="label_IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxesPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxesPaid_1" xml:lang="en-US" id="label_IncomeTaxesPaid_1">Income taxes paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="label_IncomeTaxesPaid_1" xlink:title="label_IncomeTaxesPaid_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="label_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncomeTaxExpenseBenefit_1" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_1">Benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_1" xlink:title="label_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_1">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets">Increase (Decrease) in Other Operating Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets_1">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets_1" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense" xlink:title="label_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpense_1" xml:lang="en-US" id="label_InterestExpense_1">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_1" xlink:title="label_InterestExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid" xlink:title="label_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPaid_1" xml:lang="en-US" id="label_InterestPaid_1">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid_1" xlink:title="label_InterestPaid_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentIncomeInterest" xml:lang="en-US" id="label_InvestmentIncomeInterest">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest" xlink:title="label_InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentIncomeInterest_1" xml:lang="en-US" id="label_InvestmentIncomeInterest_1">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest_1" xlink:title="label_InvestmentIncomeInterest_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="IPOMember" xlink:title="IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IPOMember" xml:lang="en-US" id="label_IPOMember">Initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember" xlink:title="label_IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IPOMember_1" xml:lang="en-US" id="label_IPOMember_1">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember_1" xlink:title="label_IPOMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Total liabilities, convertible preferred stock and stockholders' (deficit) equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_1" xlink:title="label_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">Liabilities, convertible preferred stock and stockholders' (deficit) equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent_1" xml:lang="en-US" id="label_LiabilitiesCurrent_1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_1" xlink:title="label_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_1" xlink:title="label_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosure">Total liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="label_LiabilitiesFairValueDisclosure" xlink:title="label_LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesFairValueDisclosure_1" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosure_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="label_LiabilitiesFairValueDisclosure_1" xlink:title="label_LiabilitiesFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosureAbstract">Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="label_LiabilitiesFairValueDisclosureAbstract" xlink:title="label_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesFairValueDisclosureAbstract_1" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosureAbstract_1">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="label_LiabilitiesFairValueDisclosureAbstract_1" xlink:title="label_LiabilitiesFairValueDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LoansPayableCurrent" xml:lang="en-US" id="label_LoansPayableCurrent">Loan payable, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="label_LoansPayableCurrent" xlink:title="label_LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LoansPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LoansPayableCurrent_1" xml:lang="en-US" id="label_LoansPayableCurrent_1">Loans Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="label_LoansPayableCurrent_1" xlink:title="label_LoansPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:label="LongTermDebtOtherDisclosuresAbstract" xlink:title="LongTermDebtOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtOtherDisclosuresAbstract" xml:lang="en-US" id="label_LongTermDebtOtherDisclosuresAbstract">Term Loan Amendment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtOtherDisclosuresAbstract" xlink:to="label_LongTermDebtOtherDisclosuresAbstract" xlink:title="label_LongTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeAxis" xml:lang="en-US" id="label_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="label_LongtermDebtTypeAxis" xlink:title="label_LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeDomain" xml:lang="en-US" id="label_LongtermDebtTypeDomain">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain" xlink:title="label_LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:label xlink:type="resource" xlink:label="label_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermLoansPayable" xml:lang="en-US" id="label_LongTermLoansPayable">Loan payable, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansPayable" xlink:to="label_LongTermLoansPayable" xlink:title="label_LongTermLoansPayable" />
    <link:label xlink:type="resource" xlink:label="label_LongTermLoansPayable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermLoansPayable_1" xml:lang="en-US" id="label_LongTermLoansPayable_1">Loans Payable, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansPayable" xlink:to="label_LongTermLoansPayable_1" xlink:title="label_LongTermLoansPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember" xlink:title="label_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinimumMember_1" xml:lang="en-US" id="label_MinimumMember_1">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_1" xlink:title="label_MinimumMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations_1">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net cash (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="label_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss_1" xml:lang="en-US" id="label_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_1" xlink:title="label_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLoss_2" xml:lang="en-US" id="label_NetIncomeLoss_2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_2" xlink:title="label_NetIncomeLoss_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">Numerator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="NewJerseyDivisionOfTaxationMember" xlink:title="NewJerseyDivisionOfTaxationMember" />
    <link:label xlink:type="resource" xlink:label="label_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NewJerseyDivisionOfTaxationMember" xml:lang="en-US" id="label_NewJerseyDivisionOfTaxationMember">New Jersey</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewJerseyDivisionOfTaxationMember" xlink:to="label_NewJerseyDivisionOfTaxationMember" xlink:title="label_NewJerseyDivisionOfTaxationMember" />
    <link:label xlink:type="resource" xlink:label="label_NewJerseyDivisionOfTaxationMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewJerseyDivisionOfTaxationMember_1" xml:lang="en-US" id="label_NewJerseyDivisionOfTaxationMember_1">New Jersey Division of Taxation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewJerseyDivisionOfTaxationMember" xlink:to="label_NewJerseyDivisionOfTaxationMember_1" xlink:title="label_NewJerseyDivisionOfTaxationMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense" xlink:title="label_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NonoperatingIncomeExpense_1" xml:lang="en-US" id="label_NonoperatingIncomeExpense_1">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense_1" xlink:title="label_NonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract">Other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract" xlink:title="label_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract_1">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract_1" xlink:title="label_NonoperatingIncomeExpenseAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesPayableAbstract" xml:lang="en-US" id="label_NotesPayableAbstract">Convertible Note Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableAbstract" xlink:to="label_NotesPayableAbstract" xlink:title="label_NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses" xlink:title="label_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpenses_1" xml:lang="en-US" id="label_OperatingExpenses_1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses_1" xlink:title="label_OperatingExpenses_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract" xlink:title="label_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpensesAbstract_1" xml:lang="en-US" id="label_OperatingExpensesAbstract_1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract_1" xlink:title="label_OperatingExpensesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss_1" xml:lang="en-US" id="label_OperatingIncomeLoss_1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_1" xlink:title="label_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwards" xml:lang="en-US" id="label_OperatingLossCarryforwards">NOLs sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards" xlink:title="label_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwards_1" xml:lang="en-US" id="label_OperatingLossCarryforwards_1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards_1" xlink:title="label_OperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="label_OperatingLossCarryforwardsLineItems">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="label_OperatingLossCarryforwardsLineItems" xlink:title="label_OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsLineItems_1" xml:lang="en-US" id="label_OperatingLossCarryforwardsLineItems_1">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="label_OperatingLossCarryforwardsLineItems_1" xlink:title="label_OperatingLossCarryforwardsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsTable" xml:lang="en-US" id="label_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="label_OperatingLossCarryforwardsTable" xlink:title="label_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent" xlink:title="label_OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent_1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent_1" xlink:title="label_OtherAccruedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsCurrent" xml:lang="en-US" id="label_OtherAssetsCurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="label_OtherAssetsCurrent" xlink:title="label_OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsCurrent_1" xml:lang="en-US" id="label_OtherAssetsCurrent_1">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="label_OtherAssetsCurrent_1" xlink:title="label_OtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent" xlink:title="label_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrent_1" xml:lang="en-US" id="label_OtherAssetsNoncurrent_1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent_1" xlink:title="label_OtherAssetsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense" xlink:title="label_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNonoperatingIncomeExpense_1" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense_1">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense_1" xlink:title="label_OtherNonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="label_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaidInKindInterest" xml:lang="en-US" id="label_PaidInKindInterest">Paid-in-Kind Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="label_PaidInKindInterest" xlink:title="label_PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="label_PaidInKindInterest_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaidInKindInterest_1" xml:lang="en-US" id="label_PaidInKindInterest_1">Noncash interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="label_PaidInKindInterest_1" xlink:title="label_PaidInKindInterest_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfDebtIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfDebtIssuanceCosts">Total amount paid to Oxford finance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="label_PaymentsOfDebtIssuanceCosts" xlink:title="label_PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDebtIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfDebtIssuanceCosts_1" xml:lang="en-US" id="label_PaymentsOfDebtIssuanceCosts_1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="label_PaymentsOfDebtIssuanceCosts_1" xlink:title="label_PaymentsOfDebtIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfFinancingCosts" xml:lang="en-US" id="label_PaymentsOfFinancingCosts">Payments of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts" xlink:title="label_PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsOfFinancingCosts_1" xml:lang="en-US" id="label_PaymentsOfFinancingCosts_1">Cash paid for financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts_1" xlink:title="label_PaymentsOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts" xlink:title="label_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts_1">Cash paid for offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts_1" xlink:title="label_PaymentsOfStockIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_1">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US" id="label_PreferredStockDividendsAndOtherAdjustments">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="label_PreferredStockDividendsAndOtherAdjustments" xlink:title="label_PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsAndOtherAdjustments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockDividendsAndOtherAdjustments_1" xml:lang="en-US" id="label_PreferredStockDividendsAndOtherAdjustments_1">Deemed dividend / beneficial conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="label_PreferredStockDividendsAndOtherAdjustments_1" xlink:title="label_PreferredStockDividendsAndOtherAdjustments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare" xlink:title="label_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_1">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_1" xlink:title="label_PreferredStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_2">Par value of preferred stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_2" xlink:title="label_PreferredStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="label_PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized_1" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_1">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_1" xlink:title="label_PreferredStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockSharesAuthorized_2" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_2">Authorized shares of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_2" xlink:title="label_PreferredStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued">Preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued" xlink:title="label_PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesIssued_1" xml:lang="en-US" id="label_PreferredStockSharesIssued_1">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_1" xlink:title="label_PreferredStockSharesIssued_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding">Preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding" xlink:title="label_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesOutstanding_1" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_1">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_1" xlink:title="label_PreferredStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue">Preferred stock, $.0001 par value, authorized 10,000,000 shares; issued 0 shares outstanding at December 31, 2013 and June 30, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue" xlink:title="label_PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockValue_1" xml:lang="en-US" id="label_PreferredStockValue_1">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue_1" xlink:title="label_PreferredStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_2" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrentAbstract">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="PrepaidInsurance" xlink:title="PrepaidInsurance" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidInsurance" xml:lang="en-US" id="label_PrepaidInsurance">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidInsurance" xlink:to="label_PrepaidInsurance" xlink:title="label_PrepaidInsurance" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidInsurance_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidInsurance_1" xml:lang="en-US" id="label_PrepaidInsurance_1">Prepaid Insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidInsurance" xlink:to="label_PrepaidInsurance_1" xlink:title="label_PrepaidInsurance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromCollaborators" xml:lang="en-US" id="label_ProceedsFromCollaborators">Net proceeds from sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCollaborators" xlink:to="label_ProceedsFromCollaborators" xlink:title="label_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCollaborators_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromCollaborators_1" xml:lang="en-US" id="label_ProceedsFromCollaborators_1">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCollaborators" xlink:to="label_ProceedsFromCollaborators_1" xlink:title="label_ProceedsFromCollaborators_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering">Gross proceeds from underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering_1" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering_1">Proceeds from Issuance Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering_1" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering_2" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering_2">Proceeds from issuance of common stock in initial public offering, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering_2" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock" xlink:title="label_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock_1">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock_1" xlink:title="label_ProceedsFromIssuanceOfCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt">Proceeds from Issuance of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt_1">Proceeds from issuance of term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt_1" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1">Proceeds from issuance of preferred stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromNotesPayable" xml:lang="en-US" id="label_ProceedsFromNotesPayable">Proceeds from convertible bridge notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable" xlink:title="label_ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromNotesPayable_1" xml:lang="en-US" id="label_ProceedsFromNotesPayable_1">Proceeds from Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable_1" xlink:title="label_ProceedsFromNotesPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property and equipment, net of accumulated depreciation of $273,092 in 2013 and $278,135 in 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_1" xlink:title="label_PropertyPlantAndEquipmentNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="label_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="label_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyDomain" xml:lang="en-US" id="label_RelatedPartyDomain">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="label_RelatedPartyDomain" xlink:title="label_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAxis" xml:lang="en-US" id="label_RelatedPartyTransactionAxis">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="label_RelatedPartyTransactionAxis" xlink:title="label_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionDomain" xml:lang="en-US" id="label_RelatedPartyTransactionDomain">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="label_RelatedPartyTransactionDomain" xlink:title="label_RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US" id="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">Fees invoiced by the related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US" id="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" xlink:title="label_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionLineItems" xml:lang="en-US" id="label_RelatedPartyTransactionLineItems">Related party transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="label_RelatedPartyTransactionLineItems" xlink:title="label_RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionLineItems_1" xml:lang="en-US" id="label_RelatedPartyTransactionLineItems_1">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="label_RelatedPartyTransactionLineItems_1" xlink:title="label_RelatedPartyTransactionLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsAbstract" xml:lang="en-US" id="label_RelatedPartyTransactionsAbstract">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="label_RelatedPartyTransactionsAbstract" xlink:title="label_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_RelatedPartyTransactionsByRelatedPartyAxis">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="label_RelatedPartyTransactionsDisclosureTextBlock">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US" id="label_RelatedPartyTransactionsDisclosureTextBlock_1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_RelatedPartyTransactionsDisclosureTextBlock_1" xlink:title="label_RelatedPartyTransactionsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_1" xlink:title="label_ResearchAndDevelopmentExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember" xlink:title="label_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember_1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember_1" xlink:title="label_ResearchAndDevelopmentExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentInProcess" xml:lang="en-US" id="label_ResearchAndDevelopmentInProcess">Research and Development in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="label_ResearchAndDevelopmentInProcess" xlink:title="label_ResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentInProcess_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentInProcess_1" xml:lang="en-US" id="label_ResearchAndDevelopmentInProcess_1">Noncash research and development and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="label_ResearchAndDevelopmentInProcess_1" xlink:title="label_ResearchAndDevelopmentInProcess_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US" id="label_SaleOfStockConsiderationReceivedOnTransaction">Proceeds from initial public offering, net of underwriting discounts and commissions and other offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="label_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockConsiderationReceivedOnTransaction_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_1" xml:lang="en-US" id="label_SaleOfStockConsiderationReceivedOnTransaction_1">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="label_SaleOfStockConsiderationReceivedOnTransaction_1" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="label_SaleOfStockNameOfTransactionDomain">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="label_SaleOfStockNameOfTransactionDomain" xlink:title="label_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfAccruedLiabilitiesTableTextBlock">Schedule of accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Schedule of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US" id="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">Summary of computation of basic and diluted net loss per share for common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of stock-based compensation expense related to stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShortTermDebtTable" xml:lang="en-US" id="label_ScheduleOfShortTermDebtTable">Schedule of Short-term Debt [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShortTermDebtTable" xlink:to="label_ScheduleOfShortTermDebtTable" xlink:title="label_ScheduleOfShortTermDebtTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockByClassTable" xml:lang="en-US" id="label_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="label_ScheduleOfStockByClassTable" xlink:title="label_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="label_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SegmentGeographicalDomain" xml:lang="en-US" id="label_SegmentGeographicalDomain">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentGeographicalDomain" xlink:to="label_SegmentGeographicalDomain" xlink:title="label_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation_1" xml:lang="en-US" id="label_ShareBasedCompensation_1">Noncash stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_1" xlink:title="label_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharePrice" xml:lang="en-US" id="label_SharePrice">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice" xlink:title="label_SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharePrice_1" xml:lang="en-US" id="label_SharePrice_1">Stock fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice_1" xlink:title="label_SharePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShortTermDebtLineItems" xml:lang="en-US" id="label_ShortTermDebtLineItems">Convertible note financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtLineItems" xlink:to="label_ShortTermDebtLineItems" xlink:title="label_ShortTermDebtLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermDebtLineItems_1" xml:lang="en-US" id="label_ShortTermDebtLineItems_1">Short-term Debt [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtLineItems" xlink:to="label_ShortTermDebtLineItems_1" xlink:title="label_ShortTermDebtLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtLineItems_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShortTermDebtLineItems_2" xml:lang="en-US" id="label_ShortTermDebtLineItems_2">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtLineItems" xlink:to="label_ShortTermDebtLineItems_2" xlink:title="label_ShortTermDebtLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermDebtTypeAxis" xml:lang="en-US" id="label_ShortTermDebtTypeAxis">Short-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtTypeAxis" xlink:to="label_ShortTermDebtTypeAxis" xlink:title="label_ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermDebtTypeDomain" xml:lang="en-US" id="label_ShortTermDebtTypeDomain">Short-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtTypeDomain" xlink:to="label_ShortTermDebtTypeDomain" xlink:title="label_ShortTermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Polices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="label_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock_1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock_1" xlink:title="label_SignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StateAndLocalJurisdictionMember" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember" xlink:title="label_StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StateAndLocalJurisdictionMember_1" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember_1">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember_1" xlink:title="label_StateAndLocalJurisdictionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementClassOfStockAxis" xml:lang="en-US" id="label_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="label_StatementClassOfStockAxis" xlink:title="label_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementGeographicalAxis" xml:lang="en-US" id="label_StatementGeographicalAxis">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementGeographicalAxis" xlink:to="label_StatementGeographicalAxis" xlink:title="label_StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems_1" xml:lang="en-US" id="label_StatementLineItems_1">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems_1" xlink:title="label_StatementLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Total stockholders' (deficit) equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity_1" xml:lang="en-US" id="label_StockholdersEquity_1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_1" xlink:title="label_StockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' (deficit) equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_StockholdersEquityAbstract_1">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_1" xlink:title="label_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock_1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1">Stock split conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssued1" xml:lang="en-US" id="label_StockIssued1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="label_StockIssued1" xlink:title="label_StockIssued1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Number of shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="label_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_SubsequentEventsTextBlock_1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_1" xlink:title="label_SubsequentEventsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="label_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="label_SubsidiarySaleOfStockAxis" xlink:title="label_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract" xlink:title="label_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract_1">Supplemental cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract_1" xlink:title="label_SupplementalCashFlowInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:title="TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US" id="label_TemporaryEquityAccretionToRedemptionValueAdjustment">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:title="label_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionToRedemptionValueAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityAccretionToRedemptionValueAdjustment_1" xml:lang="en-US" id="label_TemporaryEquityAccretionToRedemptionValueAdjustment_1">Accretion of interest on shares subject to mandatory redemption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityAccretionToRedemptionValueAdjustment_1" xlink:title="label_TemporaryEquityAccretionToRedemptionValueAdjustment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_1" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_1">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_1" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityParOrStatedValuePerShare_1" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare_1">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare_1" xlink:title="label_TemporaryEquityParOrStatedValuePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized">Convertible preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized" xlink:title="label_TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesAuthorized_1" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized_1">Temporary Equity, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized_1" xlink:title="label_TemporaryEquitySharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesIssued" xml:lang="en-US" id="label_TemporaryEquitySharesIssued">Convertible preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued" xlink:title="label_TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesIssued_1" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_1">Temporary Equity, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_1" xlink:title="label_TemporaryEquitySharesIssued_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding">Convertible preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding" xlink:title="label_TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesOutstanding_1" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding_1">Temporary Equity, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding_1" xlink:title="label_TemporaryEquitySharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="label_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TypeOfArrangementAxis" xml:lang="en-US" id="label_TypeOfArrangementAxis">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="label_TypeOfArrangementAxis" xlink:title="label_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates" xlink:title="label_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UseOfEstimates_1" xml:lang="en-US" id="label_UseOfEstimates_1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates_1" xlink:title="label_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="label_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember_1" xml:lang="en-US" id="label_WarrantMember_1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_1" xlink:title="label_WarrantMember_1" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WarrantMember_2" xml:lang="en-US" id="label_WarrantMember_2">Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_2" xlink:title="label_WarrantMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="label_WarrantsAndRightsNoteDisclosureAbstract">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="label_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="label_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding">Denominator for diluted net (loss) income per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding_1">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Basic and Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2">Denominator for basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingAbstract">Denominator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract_1" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingAbstract_1">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingAbstract_1" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingAbstract_2">Weighted-average shares outstanding:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label_AmendmentDescription" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label_EntityWellKnownSeasonedIssuer" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>agrx-20140630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureConvertibleNoteFinancingDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureTermLoanAmendmentDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsTables" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails3" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesDetails3" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesTables" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesTables" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesPolices" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureStockholdersEquityDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureStockholdersEquityTables" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureConvertibleNoteFinancing" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DocumentDocumentandEntityInformation" xlink:type="simple" xlink:href="agrx-20140630.xsd#DocumentDocumentandEntityInformation" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="agrx-20140630.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="agrx-20140630.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/Disclosure-StockholdersEquity" xlink:type="simple" xlink:href="agrx-20140630.xsd#Disclosure-StockholdersEquity" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurements" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilities" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureAccruedLiabilities" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactions" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureRelatedPartyTransactions" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSubsequentEvents" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="agrx-20140630.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="agrx-20140630.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureOrganizationAndBasisOfPresentation" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolices" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolices" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureTermLoanAmendment" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" xlink:title="Presentation : us-gaap_NotesPayableAbstract to us-gaap_ScheduleOfShortTermDebtTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShortTermDebtTable to us-gaap_ShortTermDebtTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:title="Presentation : us-gaap_ShortTermDebtTypeAxis to us-gaap_ShortTermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Presentation : us-gaap_ShortTermDebtTypeDomain to agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_ScheduleOfShortTermDebtTable to us-gaap_StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShortTermDebtTable to us-gaap_ShortTermDebtLineItems" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_ShortTermDebtLineItems to us-gaap_DebtInstrumentFaceAmount" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_ShortTermDebtLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="Presentation : us-gaap_ShortTermDebtLineItems to us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="presentation: ShortTermDebtLineItems to EquityIssuancePerShareAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="presentation: ScheduleOfShortTermDebtTable to DebtConversionByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain_3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="presentation: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" priority="1" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtConversionNameDomain" xlink:to="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="presentation: DebtConversionNameDomain to ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_StatementEquityComponentsAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to us-gaap_WarrantMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeAndNonemployeeStockOptionsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeAndNonemployeeStockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="Presentation : us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:title="Presentation : us-gaap_ShortTermDebtTypeAxis to us-gaap_ShortTermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Presentation : us-gaap_ShortTermDebtTypeDomain to agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:label="us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:title="LongTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="Presentation : us-gaap_LongTermDebtOtherDisclosuresAbstract to us-gaap_DebtInstrumentTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Presentation : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TermLoanWithOxfordFinanceMember" xlink:label="agrx_TermLoanWithOxfordFinanceMember" xlink:title="TermLoanWithOxfordFinanceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="agrx_TermLoanWithOxfordFinanceMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to agrx_TermLoanWithOxfordFinanceMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_ShortTermDebtTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentLineItems" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:label="agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to agrx_DebtInstrumentExtendedInterestOnlyPeriod1" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:label="agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to agrx_DebtInstrumentExtendedInterestOnlyPeriod2" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentFaceAmount" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:label="agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to agrx_DebtInstrumentExtendedInterestOnlyPeriod3" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DeferredFinanceCostsGross" xlink:title="presentation: DebtInstrumentLineItems to DeferredFinanceCostsGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Presentation : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Presentation : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByMeasurementBasisAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:title="Presentation : us-gaap_FairValueByMeasurementBasisAxis to us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:title="Presentation : us-gaap_FairValueDisclosureItemAmountsDomain to us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DerivativeByNatureAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_DerivativeByNatureAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" xlink:title="Presentation : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_DerivativeNameDomain to us-gaap_WarrantMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA1WarrantsMember" xlink:label="agrx_SeriesA1WarrantsMember" xlink:title="SeriesA1WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="agrx_SeriesA1WarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to agrx_SeriesA1WarrantsMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2WarrantsMember" xlink:label="agrx_SeriesA2WarrantsMember" xlink:title="SeriesA2WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="agrx_SeriesA2WarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to agrx_SeriesA2WarrantsMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesCWarrantsMember" xlink:label="agrx_SeriesCWarrantsMember" xlink:title="SeriesCWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="agrx_SeriesCWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to agrx_SeriesCWarrantsMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_StatementClassOfStockAxis" use="optional" order="6.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_StatementEquityComponentsAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_AssetsFairValueDisclosureAbstract" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="Presentation : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:title="Presentation : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_AssetsFairValueDisclosure" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_LiabilitiesFairValueDisclosureAbstract" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" xlink:title="Presentation : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_LiabilitiesFairValueDisclosure" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to us-gaap_FairValueAssumptionsExpectedVolatilityRate" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to us-gaap_FairValueAssumptionsRiskFreeInterestRate" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TreasuryBondsTerm" xlink:label="agrx_TreasuryBondsTerm" xlink:title="TreasuryBondsTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="agrx_TreasuryBondsTerm" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to agrx_TreasuryBondsTerm" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" xlink:title="FairValueAssumptionsExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExercisePrice" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to us-gaap_FairValueAssumptionsExercisePrice" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_SharePrice" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to us-gaap_SharePrice" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" xlink:title="Presentation : us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to us-gaap_FairValueAssumptionsExpectedTerm" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:title="Presentation : us-gaap_DebtConversionByUniqueDescriptionAxis to us-gaap_DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Presentation : us-gaap_DebtConversionNameDomain to agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Presentation : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="IPOMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:title="Presentation : us-gaap_ConversionOfStockByUniqueDescriptionAxis to us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ConversionOfStockNameDomain to us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="3.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_StatementClassOfStockAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_StatementScenarioAxis" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:label="agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_RangeAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MinimumMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_ClassOfStockLineItems" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SaleOfStockConsiderationReceivedOnTransaction" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ConversionOfStockSharesIssued1" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_DebtConversionOriginalDebtAmount1" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesAuthorized" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesAuthorized" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="presentation: ClassOfStockLineItems to EquityIssuancePerShareAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_PreferredStockSharesAuthorizedNumberOfSeries" xlink:label="PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="PreferredStockSharesAuthorizedNumberOfSeries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="presentation: ClassOfStockLineItems to PreferredStockSharesAuthorizedNumberOfSeries" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClasses" xlink:label="BoardOfDirectorsNumberOfClasses" xlink:title="BoardOfDirectorsNumberOfClasses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsNumberOfClasses" xlink:title="presentation: ClassOfStockLineItems to BoardOfDirectorsNumberOfClasses" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsTerm" xlink:label="BoardOfDirectorsTerm" xlink:title="BoardOfDirectorsTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsTerm" xlink:title="presentation: ClassOfStockLineItems to BoardOfDirectorsTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:label="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="presentation: ClassOfStockLineItems to BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:label="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="presentation: ClassOfStockLineItems to BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_OperatingLossCarryforwardsTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_IncomeTaxAuthorityAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityDomain to us-gaap_StateAndLocalJurisdictionMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_IncomeTaxAuthorityNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityNameAxis to us-gaap_IncomeTaxAuthorityNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="us-gaap_NewJerseyDivisionOfTaxationMember" xlink:title="NewJerseyDivisionOfTaxationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_NewJerseyDivisionOfTaxationMember" xlink:title="Presentation : us-gaap_IncomeTaxAuthorityNameDomain to us-gaap_NewJerseyDivisionOfTaxationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_TypeOfArrangementAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:label="agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsLineItems" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwards" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Presentation : us-gaap_OperatingLossCarryforwardsLineItems to us-gaap_ProceedsFromCollaborators" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" xlink:title="Presentation : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_DerivativeNameDomain to us-gaap_WarrantMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_FairValueByLiabilityClassAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="Presentation : us-gaap_FairValueByLiabilityClassAxis to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_DerivativeByNatureAxis" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_DerivativeByNatureAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:title="PrepaidInsurance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidInsurance" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_OtherAssetsCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedBonusesCurrent" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesCurrent" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_AccruedOfferingCostsCurrent" xlink:label="agrx_AccruedOfferingCostsCurrent" xlink:title="AccruedOfferingCostsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="agrx_AccruedOfferingCostsCurrent" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to agrx_AccruedOfferingCostsCurrent" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SmartPharmaLLCMember" xlink:label="agrx_SmartPharmaLLCMember" xlink:title="SmartPharmaLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="agrx_SmartPharmaLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to agrx_SmartPharmaLLCMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:label="agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="CommercialAndBusinessDevelopmentConsultingServicesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" xlink:title="Presentation : us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_RelatedPartyTransactionLineItems" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="Presentation : us-gaap_RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="Presentation : us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Presentation : us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerShareBasicAndDiluted" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_StockSplitPolicyTextBlock" xlink:label="agrx_StockSplitPolicyTextBlock" xlink:title="StockSplitPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="agrx_StockSplitPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to agrx_StockSplitPolicyTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueOfFinancialInstrumentsPolicy" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_WarrantsPolicyTextBlock" xlink:label="agrx_WarrantsPolicyTextBlock" xlink:title="WarrantsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="agrx_WarrantsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to agrx_WarrantsPolicyTextBlock" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_AwardTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_EmployeeStockOptionMember" use="optional" order="1.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeAndNonemployeeStockOptionsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeAndNonemployeeStockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" xlink:title="Presentation : us-gaap_NotesPayableAbstract to us-gaap_ScheduleOfShortTermDebtTable" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShortTermDebtTable to us-gaap_ShortTermDebtTypeAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:title="Presentation : us-gaap_ShortTermDebtTypeAxis to us-gaap_ShortTermDebtTypeDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Presentation : us-gaap_ShortTermDebtTypeDomain to agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShortTermDebtTable to us-gaap_ShortTermDebtLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_ShortTermDebtLineItems to us-gaap_DebtDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DocumentDocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DocumentAndEntityInformationAbstract" xlink:label="agrx_DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_DocumentType" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_AmendmentDescription" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityWellKnownSeasonedIssuer" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityVoluntaryFilers" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityCurrentReportingStatus" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityPublicFloat" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="agrx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : agrx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" use="optional" order="150.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_Depreciation" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:label="agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="StockGrantedDuringPeriodSharebasedCompensationBonus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to agrx_StockGrantedDuringPeriodSharebasedCompensationBonus" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_PaidInKindInterest" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_NoncashConversionExpenses" xlink:label="agrx_NoncashConversionExpenses" xlink:title="NoncashConversionExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="agrx_NoncashConversionExpenses" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to agrx_NoncashConversionExpenses" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ForgivenessOfInterestAndNoteReceivable" xlink:label="agrx_ForgivenessOfInterestAndNoteReceivable" xlink:title="ForgivenessOfInterestAndNoteReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="agrx_ForgivenessOfInterestAndNoteReceivable" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to agrx_ForgivenessOfInterestAndNoteReceivable" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromNotesPayable" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsOfFinancingCosts" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromIssuanceOfLongTermDebt" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInContinuingOperations" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_1" xlink:title="CashAndCashEquivalentsAtCarryingValue_1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_InterestPaid" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_IncomeTaxesPaid" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfStockAmountConverted1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to ConversionOfStockAmountConverted1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:label="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:title="DebtConversionOriginalDebtAmountAndAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="DebtConversionOriginalDebtAmountAndAccruedInterest" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to DebtConversionOriginalDebtAmountAndAccruedInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingExpensesAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_OperatingExpenses" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_InterestExpense" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_InvestmentIncomeInterest" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeTaxExpenseBenefit" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareAbstract" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareAbstract to us-gaap_EarningsPerShareBasicAndDiluted" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:title="TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_PreferredStockDividendsAndOtherAdjustments" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:label="agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:title="PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" xlink:title="Presentation : us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract to agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/Disclosure-StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="Presentation : us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" xlink:title="Presentation : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_DerivativeNameDomain to us-gaap_WarrantMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_StatementTable" use="optional" order="10.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeByNatureAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_DerivativeByNatureAxis" use="optional" order="10.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AssetsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="DeferredFinanceCostsNoncurrentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DeferredFinanceCostsNoncurrentNet" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_OtherAssetsNoncurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:title="DeferredOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DeferredOfferingCosts" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableCurrent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LoansPayableCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLoansPayable" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LongTermLoansPayable" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_CommitmentsAndContingencies" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_PreferredStockValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapital" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquity" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_StatementTable" use="optional" order="10.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_TemporaryEquityParOrStatedValuePerShare" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_TemporaryEquitySharesAuthorized" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_TemporaryEquitySharesIssued" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_TemporaryEquitySharesOutstanding" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockParOrStatedValuePerShare" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesAuthorized" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesIssued" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesOutstanding" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesAuthorized" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesIssued" use="optional" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesOutstanding" use="optional" order="130.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolices">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SignificantAccountingPoliciesTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:label="us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:title="LongTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="Presentation : us-gaap_LongTermDebtOtherDisclosuresAbstract to us-gaap_DebtInstrumentTable" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Presentation : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TermLoanWithOxfordFinanceMember" xlink:label="agrx_TermLoanWithOxfordFinanceMember" xlink:title="TermLoanWithOxfordFinanceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="agrx_TermLoanWithOxfordFinanceMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to agrx_TermLoanWithOxfordFinanceMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>agrx-20140630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureStockholdersEquityDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureConvertibleNoteFinancingDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureSummaryOfSignificantAccountingPolicesDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureTermLoanAmendmentDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureFairValueMeasurementsDetails2" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureConvertibleNoteFinancing" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment" xlink:type="simple" xlink:href="agrx-20140630.xsd#DisclosureTermLoanAmendment" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="agrx-20140630.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.agiletherapeutics.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="agrx-20140630.xsd#BalanceSheetParenthetical" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to loc_us-gaap_IncomeStatementLocationAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="loc_us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationAxis to loc_us-gaap_IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_1" xlink:title="IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_1" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationAxis to loc_us-gaap_IncomeStatementLocationDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : loc_us-gaap_IncomeStatementLocationDomain to loc_us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to loc_us-gaap_AwardTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="Definition : loc_us-gaap_AwardTypeAxis to loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:title="Definition : loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to loc_us-gaap_EmployeeStockOptionMember" use="optional" order="1.1" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeAndNonemployeeStockOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeAndNonemployeeStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to loc_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_ScheduleOfShortTermDebtTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShortTermDebtTable to loc_us-gaap_ShortTermDebtTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeAxis to loc_us-gaap_ShortTermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeDomain to loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShortTermDebtTable to loc_us-gaap_StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="DebtConversionByUniqueDescriptionAxis" xlink:title="definition: ScheduleOfShortTermDebtTable to DebtConversionByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_2" xlink:title="DebtConversionNameDomain_3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_2" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" priority="1" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtConversionNameDomain" xlink:to="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="definition: DebtConversionNameDomain to ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_DebtInstrumentFaceAmount" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="definition: ShortTermDebtLineItems to EquityIssuancePerShareAmount" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to loc_us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to loc_us-gaap_StatementEquityComponentsAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to loc_us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_1" xlink:title="AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_1" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to loc_us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesNameDomain to loc_us-gaap_WarrantMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeAndNonemployeeStockOptionsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeAndNonemployeeStockOptionsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Definition : loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaap_DebtConversionNameDomain" xlink:title="Definition : loc_us-gaap_DebtConversionByUniqueDescriptionAxis to loc_us-gaap_DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain_3" xlink:title="DebtConversionNameDomain_3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain_3" xlink:title="Definition : loc_us-gaap_DebtConversionByUniqueDescriptionAxis to loc_us-gaap_DebtConversionNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Definition : loc_us-gaap_DebtConversionNameDomain to loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Definition : loc_us-gaap_SubsidiarySaleOfStockAxis to loc_us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_1" xlink:title="SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_1" xlink:title="Definition : loc_us-gaap_SubsidiarySaleOfStockAxis to loc_us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" xlink:title="IPOMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaap_IPOMember" xlink:title="Definition : loc_us-gaap_SaleOfStockNameOfTransactionDomain to loc_us-gaap_IPOMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaap_ConversionOfStockNameDomain" xlink:title="Definition : loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis to loc_us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain_2" xlink:title="ConversionOfStockNameDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain_2" xlink:title="Definition : loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis to loc_us-gaap_ConversionOfStockNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ConversionOfStockNameDomain to loc_us-gaap_ConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="3.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_StatementClassOfStockAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_StatementScenarioAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_StatementScenarioAxis" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : loc_us-gaap_StatementScenarioAxis to loc_us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:label="loc_agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" xlink:title="Definition : loc_us-gaap_ScenarioUnspecifiedDomain to loc_agrx_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfUnderwrittenPublicOfferingMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="loc_us-gaap_RangeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfStockByClassTable to loc_us-gaap_RangeAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" xlink:title="Definition : loc_us-gaap_RangeAxis to loc_us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" xlink:title="Definition : loc_us-gaap_RangeMember to loc_us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_ConversionOfStockSharesIssued1" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_DebtConversionOriginalDebtAmount1" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_PreferredStockSharesAuthorized" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="loc_us-gaap_CommonStockSharesAuthorized" xlink:title="Definition : loc_us-gaap_ClassOfStockLineItems to loc_us-gaap_CommonStockSharesAuthorized" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="definition: ClassOfStockLineItems to EquityIssuancePerShareAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_PreferredStockSharesAuthorizedNumberOfSeries" xlink:label="PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="PreferredStockSharesAuthorizedNumberOfSeries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorizedNumberOfSeries" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesAuthorizedNumberOfSeries" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClasses" xlink:label="BoardOfDirectorsNumberOfClasses" xlink:title="BoardOfDirectorsNumberOfClasses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsNumberOfClasses" xlink:title="definition: ClassOfStockLineItems to BoardOfDirectorsNumberOfClasses" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsTerm" xlink:label="BoardOfDirectorsTerm" xlink:title="BoardOfDirectorsTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsTerm" xlink:title="definition: ClassOfStockLineItems to BoardOfDirectorsTerm" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:label="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" xlink:title="definition: ClassOfStockLineItems to BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:label="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" xlink:title="definition: ClassOfStockLineItems to BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage" order="15.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_OperatingLossCarryforwardsTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsTable to loc_us-gaap_IncomeTaxAuthorityAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityAxis to loc_us-gaap_IncomeTaxAuthorityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_1" xlink:title="IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_1" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityAxis to loc_us-gaap_IncomeTaxAuthorityDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityDomain to loc_us-gaap_StateAndLocalJurisdictionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsTable to loc_us-gaap_IncomeTaxAuthorityNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityNameAxis to loc_us-gaap_IncomeTaxAuthorityNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain_3" xlink:title="IncomeTaxAuthorityNameDomain_3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain_3" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityNameAxis to loc_us-gaap_IncomeTaxAuthorityNameDomain" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:title="NewJerseyDivisionOfTaxationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:title="Definition : loc_us-gaap_IncomeTaxAuthorityNameDomain to loc_us-gaap_NewJerseyDivisionOfTaxationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="loc_us-gaap_TypeOfArrangementAxis" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsTable to loc_us-gaap_TypeOfArrangementAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="Definition : loc_us-gaap_TypeOfArrangementAxis to loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:label="loc_agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" xlink:title="Definition : loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember to loc_agrx_TechnologyBusinessTaxCertificateProgramSaleOfUnusedTaxCarryforwardsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_OperatingLossCarryforwards" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_OperatingLossCarryforwards" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaap_ProceedsFromCollaborators" xlink:title="Definition : loc_us-gaap_OperatingLossCarryforwardsLineItems to loc_us-gaap_ProceedsFromCollaborators" use="optional" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeAxis to loc_us-gaap_ShortTermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeDomain to loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentTable" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="loc_us-gaap_DebtInstrumentAxis" xlink:title="Definition : loc_us-gaap_DebtInstrumentTable to loc_us-gaap_DebtInstrumentAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="Definition : loc_us-gaap_DebtInstrumentAxis to loc_us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TermLoanWithOxfordFinanceMember" xlink:label="loc_agrx_TermLoanWithOxfordFinanceMember" xlink:title="TermLoanWithOxfordFinanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="loc_agrx_TermLoanWithOxfordFinanceMember" xlink:title="Definition : loc_us-gaap_DebtInstrumentNameDomain to loc_agrx_TermLoanWithOxfordFinanceMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="Definition : loc_us-gaap_DebtInstrumentTable to loc_us-gaap_ShortTermDebtTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:label="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod1" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod1" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:label="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod2" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod2" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentFaceAmount" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:label="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="DebtInstrumentExtendedInterestOnlyPeriod3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod3" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_agrx_DebtInstrumentExtendedInterestOnlyPeriod3" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="DeferredFinanceCostsGross" xlink:title="definition: DebtInstrumentLineItems to DeferredFinanceCostsGross" order="7.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="loc_us-gaap_EquityComponentDomain" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_1" xlink:title="EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_1" xlink:title="Definition : loc_us-gaap_StatementEquityComponentsAxis to loc_us-gaap_EquityComponentDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:title="Definition : loc_us-gaap_EquityComponentDomain to loc_us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementFrequencyAxis to loc_us-gaap_FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementFrequencyAxis to loc_us-gaap_FairValueMeasurementFrequencyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Definition : loc_us-gaap_FairValueMeasurementFrequencyDomain to loc_us-gaap_FairValueMeasurementsRecurringMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_FairValueByMeasurementBasisAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementBasisAxis to loc_us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain_3" xlink:title="FairValueDisclosureItemAmountsDomain_3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="FairValueDisclosureItemAmountsDomain_3" xlink:title="Definition : loc_us-gaap_FairValueByMeasurementBasisAxis to loc_us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:title="Definition : loc_us-gaap_FairValueDisclosureItemAmountsDomain to loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : loc_us-gaap_FairValueByFairValueHierarchyLevelAxis to loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_4" xlink:title="FairValueMeasurementsFairValueHierarchyDomain_4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_4" xlink:title="Definition : loc_us-gaap_FairValueByFairValueHierarchyLevelAxis to loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel1Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel1Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel3Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaap_FairValueInputsLevel2Member" xlink:title="Definition : loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain to loc_us-gaap_FairValueInputsLevel2Member" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_DerivativeByNatureAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_DerivativeByNatureAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis" xlink:to="loc_us-gaap_DerivativeNameDomain" xlink:title="Definition : loc_us-gaap_DerivativeByNatureAxis to loc_us-gaap_DerivativeNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_DerivativeNameDomain to loc_us-gaap_WarrantMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Definition : loc_us-gaap_ClassOfWarrantOrRightAxis to loc_us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_5" xlink:title="ClassOfWarrantOrRightDomain_5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_5" xlink:title="Definition : loc_us-gaap_ClassOfWarrantOrRightAxis to loc_us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA1WarrantsMember" xlink:label="loc_agrx_SeriesA1WarrantsMember" xlink:title="SeriesA1WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="loc_agrx_SeriesA1WarrantsMember" xlink:title="Definition : loc_us-gaap_ClassOfWarrantOrRightDomain to loc_agrx_SeriesA1WarrantsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2WarrantsMember" xlink:label="loc_agrx_SeriesA2WarrantsMember" xlink:title="SeriesA2WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="loc_agrx_SeriesA2WarrantsMember" xlink:title="Definition : loc_us-gaap_ClassOfWarrantOrRightDomain to loc_agrx_SeriesA2WarrantsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesCWarrantsMember" xlink:label="loc_agrx_SeriesCWarrantsMember" xlink:title="SeriesCWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="loc_agrx_SeriesCWarrantsMember" xlink:title="Definition : loc_us-gaap_ClassOfWarrantOrRightDomain to loc_agrx_SeriesCWarrantsMember" use="optional" order="3.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_StatementClassOfStockAxis" use="optional" order="6.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to loc_us-gaap_StatementEquityComponentsAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_AssetsFairValueDisclosureAbstract" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="Definition : loc_us-gaap_AssetsFairValueDisclosureAbstract to loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="loc_us-gaap_AssetsFairValueDisclosure" xlink:title="Definition : loc_us-gaap_AssetsFairValueDisclosureAbstract to loc_us-gaap_AssetsFairValueDisclosure" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesFairValueDisclosureAbstract to loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:title="Definition : loc_us-gaap_LiabilitiesFairValueDisclosureAbstract to loc_us-gaap_LiabilitiesFairValueDisclosure" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TreasuryBondsTerm" xlink:label="loc_agrx_TreasuryBondsTerm" xlink:title="TreasuryBondsTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_agrx_TreasuryBondsTerm" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_agrx_TreasuryBondsTerm" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice" xlink:title="FairValueAssumptionsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_us-gaap_FairValueAssumptionsExercisePrice" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaap_SharePrice" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_us-gaap_SharePrice" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:title="Definition : loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to loc_us-gaap_FairValueAssumptionsExpectedTerm" use="optional" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis" xlink:to="loc_us-gaap_DerivativeNameDomain" xlink:title="Definition : loc_us-gaap_DerivativeByNatureAxis to loc_us-gaap_DerivativeNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_DerivativeNameDomain to loc_us-gaap_WarrantMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to loc_us-gaap_FairValueByLiabilityClassAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="Definition : loc_us-gaap_FairValueByLiabilityClassAxis to loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="Definition : loc_us-gaap_FairValueByLiabilityClassAxis to loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="DerivativeFinancialInstrumentsLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaap_DerivativeByNatureAxis" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to loc_us-gaap_DerivativeByNatureAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="Definition : loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:title="Definition : loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract to loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" use="optional" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionLineItems to loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaap_RelatedPartyDomain" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to loc_us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_1" xlink:title="RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_1" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to loc_us-gaap_RelatedPartyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SmartPharmaLLCMember" xlink:label="loc_agrx_SmartPharmaLLCMember" xlink:title="SmartPharmaLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="loc_agrx_SmartPharmaLLCMember" xlink:title="Definition : loc_us-gaap_RelatedPartyDomain to loc_agrx_SmartPharmaLLCMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to loc_us-gaap_RelatedPartyTransactionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionAxis to loc_us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionAxis to loc_us-gaap_RelatedPartyTransactionDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:label="loc_agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="CommercialAndBusinessDevelopmentConsultingServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="loc_agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionDomain to loc_agrx_CommercialAndBusinessDevelopmentConsultingServicesMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="Definition : loc_us-gaap_RelatedPartyTransactionLineItems to loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" use="optional" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_ScheduleOfShortTermDebtTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis" xlink:title="Definition : loc_us-gaap_ScheduleOfShortTermDebtTable to loc_us-gaap_ShortTermDebtTypeAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeAxis to loc_us-gaap_ShortTermDebtTypeDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain_1" xlink:title="ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="ShortTermDebtTypeDomain_1" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeAxis to loc_us-gaap_ShortTermDebtTypeDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:label="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="ConvertibleSubordinatedPromissoryNotes28April2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" xlink:title="Definition : loc_us-gaap_ShortTermDebtTypeDomain to loc_agrx_ConvertibleSubordinatedPromissoryNotes28April2014Member" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="loc_us-gaap_DebtDisclosureTextBlock" xlink:title="Definition : loc_us-gaap_ShortTermDebtLineItems to loc_us-gaap_DebtDisclosureTextBlock" use="optional" order="20.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtInstrumentTable" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtInstrumentTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="loc_us-gaap_DebtInstrumentAxis" xlink:title="Definition : loc_us-gaap_DebtInstrumentTable to loc_us-gaap_DebtInstrumentAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="loc_us-gaap_DebtInstrumentNameDomain" xlink:title="Definition : loc_us-gaap_DebtInstrumentAxis to loc_us-gaap_DebtInstrumentNameDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_1" xlink:title="DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_1" xlink:title="Definition : loc_us-gaap_DebtInstrumentAxis to loc_us-gaap_DebtInstrumentNameDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_TermLoanWithOxfordFinanceMember" xlink:label="loc_agrx_TermLoanWithOxfordFinanceMember" xlink:title="TermLoanWithOxfordFinanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="loc_agrx_TermLoanWithOxfordFinanceMember" xlink:title="Definition : loc_us-gaap_DebtInstrumentNameDomain to loc_agrx_TermLoanWithOxfordFinanceMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="loc_us-gaap_DebtDisclosureTextBlock" xlink:title="Definition : loc_us-gaap_DebtInstrumentLineItems to loc_us-gaap_DebtDisclosureTextBlock" use="optional" order="20.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis" xlink:title="DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain" xlink:title="DerivativeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis" xlink:to="loc_us-gaap_DerivativeNameDomain" xlink:title="Definition : loc_us-gaap_DerivativeByNatureAxis to loc_us-gaap_DerivativeNameDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="DerivativeNameDomain_1" xlink:title="DerivativeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis" xlink:to="DerivativeNameDomain_1" xlink:title="Definition : loc_us-gaap_DerivativeByNatureAxis to loc_us-gaap_DerivativeNameDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain" xlink:to="loc_us-gaap_WarrantMember" xlink:title="Definition : loc_us-gaap_DerivativeNameDomain to loc_us-gaap_WarrantMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_DerivativeByNatureAxis" xlink:title="Definition : loc_us-gaap_StatementTable to loc_us-gaap_DerivativeByNatureAxis" use="optional" order="10.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:title="Definition : loc_us-gaap_StatementTable to loc_us-gaap_StatementClassOfStockAxis" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_AssetsAbstract" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_AssetsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_AssetsCurrentAbstract" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_AssetsCurrentAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Definition : loc_us-gaap_AssetsCurrentAbstract to loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Definition : loc_us-gaap_AssetsCurrentAbstract to loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_AssetsCurrent" xlink:title="Definition : loc_us-gaap_AssetsCurrentAbstract to loc_us-gaap_AssetsCurrent" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="DeferredFinanceCostsNoncurrentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_DeferredFinanceCostsNoncurrentNet" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_Assets" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_Assets" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:title="DeferredOfferingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredOfferingCosts" xlink:title="Definition : loc_us-gaap_AssetsAbstract to loc_us-gaap_DeferredOfferingCosts" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_LiabilitiesCurrentAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesCurrentAbstract to loc_us-gaap_AccountsPayableCurrent" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesCurrentAbstract to loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LoansPayableCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesCurrentAbstract to loc_us-gaap_LoansPayableCurrent" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesCurrentAbstract to loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LiabilitiesCurrent" xlink:title="Definition : loc_us-gaap_LiabilitiesCurrentAbstract to loc_us-gaap_LiabilitiesCurrent" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_LongTermLoansPayable" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_LongTermLoansPayable" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_CommitmentsAndContingencies" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_CommitmentsAndContingencies" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_StockholdersEquityAbstract" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_StockholdersEquityAbstract" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_PreferredStockValue" xlink:title="Definition : loc_us-gaap_StockholdersEquityAbstract to loc_us-gaap_PreferredStockValue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_CommonStockValue" xlink:title="Definition : loc_us-gaap_StockholdersEquityAbstract to loc_us-gaap_CommonStockValue" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_AdditionalPaidInCapital" xlink:title="Definition : loc_us-gaap_StockholdersEquityAbstract to loc_us-gaap_AdditionalPaidInCapital" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="Definition : loc_us-gaap_StockholdersEquityAbstract to loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_StockholdersEquity" xlink:title="Definition : loc_us-gaap_StockholdersEquityAbstract to loc_us-gaap_StockholdersEquity" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Definition : loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract to loc_us-gaap_LiabilitiesAndStockholdersEquity" use="optional" order="60.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.agiletherapeutics.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:title="Definition : loc_us-gaap_StatementClassOfStockAxis to loc_us-gaap_ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesC12PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesB8PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA18PercentNoncumulativeConvertiblePreferredStockMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="agrx-20140630.xsd#agrx_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="SeriesA2ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_agrx_SeriesA2ConvertiblePreferredStockMember" xlink:title="Definition : loc_us-gaap_ClassOfStockDomain to loc_agrx_SeriesA2ConvertiblePreferredStockMember" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:title="Definition : loc_us-gaap_StatementTable to loc_us-gaap_StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_TemporaryEquitySharesAuthorized" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_TemporaryEquitySharesIssued" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_TemporaryEquitySharesOutstanding" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_PreferredStockParOrStatedValuePerShare" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_PreferredStockSharesAuthorized" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesIssued" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_PreferredStockSharesIssued" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_PreferredStockSharesOutstanding" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_CommonStockParOrStatedValuePerShare" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CommonStockSharesAuthorized" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_CommonStockSharesAuthorized" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CommonStockSharesIssued" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_CommonStockSharesIssued" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CommonStockSharesOutstanding" xlink:title="Definition : loc_us-gaap_StatementLineItems to loc_us-gaap_CommonStockSharesOutstanding" use="optional" order="140.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`=?[]DX`$``+H6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-UNVC`8AL\G[1XBGT[$
MV-FZMB+T8#^'&]+8!;CQ!XE(;,MV.[C[.8&B"E$J5*2^)T00^WL?K.B1\D[N
MUEV;/9(/C34E$_F8960JJQNS+-G?^<_1-<M"5$:KUAHJV88"NYM^_#"9;QR%
M+.TVH61UC.Z6\U#5U*F06T<FW5E8WZF8OOHE=ZI:J25Q.1Y?\<J:2":.8C^#
M32??::$>VIC]6*>?MR2>VL"R;]N%?5;)E'-M4ZF82/FCT0<IHUU"GG8.:T+=
MN/`I83!^-*&_\W+`;M_O=#2^T93-E(^_5)<P^+KE_ZQ?W5N[RD\/.4)I%XNF
M(FVKARZ=0!Z<)Z5#312[-A^N>:<:\\1](G]8'/AP$1<&Z?_?,/A,#@G"48!P
M?`;A^`+"<07"\16$XQJ$XP:$0XQ10%",*E"4*E"<*E"D*E"L*E"T*E"\*E#$
M*E#,*E',*E',*E',*E',*E',*E',*E',*E',*E',*E',6J"8M4`Q:X%BU@+%
MK`6*68OW,FM,S2#QX?/MC^DPYI5J*L1-2^'"KY/;H:\EU\J3_A-]ZE`O#O!\
M]BF.U##.O'4A=:V>SC^%IS*UWSUR:1#YV-"^3CU62^X34T][?N!!+TI]$ZQ)
M'\GF0_,\_0\``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?
M<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````",DL].PS`,QN](
MO$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4
M'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR
MBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'
MJC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB
M8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%
M#U1?````__\#`%!+`P04``8`"````"$`Z,')Y]\!``"K%0``&@`(`7AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````O)C+3L,P$$7W2/Q#Y#UU9P;*0Z1L$!);'A]@)6Y3
MT2:1;1[]>ZP*4BK!91/-)I(=U;FZ,[TGD^N;C\VZ>/,AKKJV-#29FL*W55>O
MVF5IGI_N3BY,$9-K:[?N6E^:K8_F9GY\=/W@UR[E'\5FU<<BG]+&TC0I]5?6
MQJKQ&Q<G7>_;?&?1A8U+>1F6MG?5BUMZR]/IS(:?9YCYP9G%?5V:<%^3F.)I
MV^='_W]XMUBL*G_;5:\;WZ9?GF'?N_`2&^]3/M2%I4^E&;:BW=TAF63-QOXA
M)_NA*^<"R>&9LAR>03FD+8>0'#E5EB.G2,ZYLIIS)(9860TQE*-M#D%W^$S9
M'3Y#[HAV"`H,01DU!&/C@J\?4\C,B=GVKUP^V$;F:#<R[F/M0"8<R)GGJKCB
M*2S5I;:<2R1'FU805MJ-`_N&U*V!WK`VR!F"7+0C1V#FR*CLC&F[SB_Y^QS>
MK='?2)N5$)6DK8:@'-8F-T-R\ZCD'D:G?;<,6U_3%,/Q148-O92G3K^7LEO:
MW16&"VDSDB`C29N1!!DIVB006"QM$$`.:%<*%HJTK2'H#6LSDB$C>51&#BFW
M3YMAZSOXX'PIVIDC,'-$&YH"H:D-*<RH7&/-[X\#O^W!)];Y)P```/__`P!0
M2P,$%``&``@````A`%:@;WJ``P``.@L```\```!X;"]W;W)K8F]O:RYX;6R4
MEEUOFS`4AN\G[3\@[E>^DJZMFE3]BA:I:ZLE:R\M%YQ@%6QFFR79K]\!&G+`
M:=1>)0;.ZW/>\_C`^<4ZSYR_3&DNQ<@-CGS782*6"1?+D?M[/OEVXCK:4)'0
M3`HV<C=,NQ?CKU_.5U*]ODCYZH"`T",W-:8X\SP=IRRG^D@63,"=A50Y-;!4
M2T\7BM%$IXR9//-"WS_V<LJ%VRB<J8]HR,6"Q^Q&QF7.A&E$%,NH@?1UR@OM
MCL\7/&-/344.+8I[FD/>Z\QU,JK-;<(-2T;N$)9RQ3H75%E<E3R#NZ>1'[G>
MN"WR43D)6]`R,W,H;ZL.?H6#,#RNGJRL>.)LI7=!U=)9/W.1R%7U*%B[:5<1
M)+"J;SWSQ*1PW_?]]MH/QI>IV5X$>0_IUP["/O6O(^KRMHX0Z!2Y%8:;#9F*
MQGTNH865ZU.H+'`==<;ACYHF094X5KFB&14Q([/J:8VB0A05'HXBCU1!:U)F
M>$S!]';G"&G4YN*=9X8:,%883>2"/!1,-2U%\0,4/^CGT(V_ICHE$^@OK@',
M;2L?]N,?U)(*_J_>M/;PBFI>Y_*H@'A4Q3&2J3O?*:/,<ZHV50TSOA0<8*7"
MD,LXEJ4P6.8[DOG>SV9"N2)/-"L9^<FH+E5C#8Z'8]E6<]*/AYP+R@&$-9Q"
MS71=T0/T1)'K4F&94R1SVI>!M%7)$G+'Z0O/N.$=)P;`<YM"X/>#KZ6`L6+X
M2\;(O32,3+@`N&"NH/T''1PM'N=,Y>1.4D$N@8VDX@,'8RH#"\N9D?%K*K,$
M1@&Y_5/"D<#!&,?`XG$*,S!G9$[7W9HQA(%%X:]J$H%A<`3@_,T5%9K&]6C"
M.V,0`XO$V4&$P*_V0`TPBL$G603O=D(8QN"C-((YT%M\-@88RN"35'8JPU@&
M'^'23F:(\839VQMU>^C8HX'Q#"T\#P\-7%"(485%/YF#/0=2VU:%&%M8?$H(
MX-T)89)#B^3#%`+!.R&,<VCA_,XH(S?,4(Y?#_`:W8V3YIU:[_'V@CNLT_$:
MTQQ:-!^>C?A8A!AG6/2\WC,=WZK"9R+$*,.B)_+^E*RTD,U#3%!DX;QG4NY)
M9HCIB2R>]YV)ID^XHB$F)[)9ML?N-A."W8TZN5@DXP&\C4=V1)TD+'S?'\0]
M6ZO/L/8E!@MHCU=C!]]7\/D2PX=?]5-].=6>>]O/WO%_````__\#`%!+`P04
M``8`"````"$`@Q)LW!`%``!.$P``&````'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;)28VXZC.!"&[U?:=T#<=\!@,$1)1LVA=T>:E5:K/5S3Q$E0!QP!?9BW
MWS(F@7+2A&Z->CKDX[=_5[DHO/KV41Z--UXWA:C6)EG8IL&K7&R+:K\V__G[
MZ2$PC:;-JFUV%!5?FS]Y8W[;_/K+ZEW4+\V!\]8`A:I9FX>V/2TMJ\D/O,R:
MA3CQ"K[9B;K,6OA8[ZWF5/-LV]U4'BW'MGVKS(K*5`K+>HZ&V.V*G"<B?RUY
MU2J1FA^S%N;?'(I3<U8K\SER95:_O)X><E&>0.*Y.!;MST[4-,I\^7U?B3I[
M/H+O#T*S_*S=?;B2+XN\%HW8M0N0L]1$KSV'5FB!TF:U+<"!7':CYKNU^4B6
M*0E,:[/J%NC?@K\WH[^-YB#>?ZN+[8^BXK#:$"<9@6<A7B3Z?2LOP<W6U=U/
M703^K(TMWV6OQ_8O\?X[+_:'%L+M@2-I;+G]F?`FAQ4%F87C2:5<'&$"\-LH
M"YD:L"+91_?_>[%M#VO3]1>$VC[0QC-OVJ="*II&_MJTHOQ/,:174AI.KP%W
M]!H$+DW?;*EY=+:2K,TVJUJ\&Y`K,%1SRF3FD24(GOVHX2\./S,(SJ3(HU19
MF\PT8/(-1.5MP\C*>H.%S'LDNH$X&(G/B%PV*9N<+PRRFFIZ)F3,P-'%%BS(
MV-;M\)QG+V$Y^_.XD;H`VA<[^E2O">9B-\DUHHFDU\1(!-EQOV)'PI!7H]DS
MBN<6*82.$(V([Q+)72*=(I`]F,C\:$EX;<+:78+#/,V>0H(N$1TWM`./82)&
M!'4\1K7,2L:$RP*/!#;62,>$1T-&O6$1D3W85_/M25BSY^.!(X7XG3U";#?P
MM-R+QT3@N*X38HED##C$8_`/$^F8("$+0S80R)W_%7<2UMP-LMVFCQ2BW+DT
MI(QH"Q\CPJ&AS30B&1->2&$%M%'2,<$H8]0=$@#9@Z(V/W@2UNP%>%TCA2A[
M#[?]8>2F083<=HB028NR.1D]`Z:+I82UZJ(E5Z00V!Z7'3ILC"[&\5TBN4ND
M4P2*8/@5>Q+&$=3W?:20/H+4=FF@Q3A&!!0/Q]&(!!$L((QH2Y1BPO.I-Y0!
M9(]`$S,_?!VM&1PR7^W`GJ%=@0FTIU:,OG4\+?@)^II<[;O^Z[YX47=0QZ;D
M@WUV3A+5!HR?"?JTHY[I!V8AE#R\,V-$,.+K105]3T+'=;2%2S'AN_2SD,DG
M_WQWJD]`[K2"'\D.$/+V7%88":BMS2[6&)^$`;N*'M+Q/9=XH396BG4"A_C$
M'G1P&&4+,-^H:AB046U;1&2JJ5#%Y3Z2](A:+M?W'!IHV9!.JF"3LA&8;U*U
M#<BD-G9$QJW%@WL[FIBY'4W$.!!N8FN5*,5C34=3]@3SC:H.`N)U>0P$PW[H
M*XUB8)H71@MX+-^N(+,GD.0^DDXB.)JR,YAO4O41*)I:JQ$1Q81=.7VP%Z.J
MT"<L`AB\.H;VZ$=;M$37TU^U4@P0YBT^:VZ(;!+FFU4M!8JHEDY1IS@9KO@^
MDMQ'TDD$1U1V"O--JKX"172H;GW:*D:5CT"&*AR>8WU,QXA':*AI)'!*,51L
M:D.#YFJI+P\R1H@?^$.=4`;5,85ZGR]YO><Q/QX;(Q>O\@C"A82[7+T<CSPZ
M\CU7NQZ1);Q]7U]/Y'&*O&Y=;H#3C%.VYW]D];ZH&N/(=S"4O6"P36MU'J(^
MM.+4G2X\BQ8.,KH_#W!NQ>&]WEX`O!.B/7^0`UQ.PC;_`P``__\#`%!+`P04
M``8`"````"$`@].X>]D"``!N"```&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6R4EEUOFS`4AN\G[3]8OB_?@20*J9I4W2JMTC3MX]H!$ZP"1K;3M/]^
MQW9@A70HN6D#><_KY[P^F*QN7^L*O5`A&6]2[#L>1K3)>,Z:?8I__7RXF6,D
M%6ER4O&&IOB-2GR[_OQI=>3B69:4*@0.C4QQJ52[=%V9E;0FTN$M;>";@HN:
M*+@4>U>V@I+<%-65&WA>[-:$-=@Z+,4E'KPH6$;O>7:H::.LB:`54<`O2];*
MSJW.+K&KB7@^M#<9KUNPV+&*J3=CBE&=+1_W#1=D5T'?KWY$LL[;7)S9URP3
M7/)".6#G6M#SGA?NP@6G]2IGT(&.'0E:I/C.7VX7V%VO3#Z_&3W*=Y^1+/GQ
MBV#Y-]90"!NV26_`CO-G+7W,]2TH=L^J'\P&?!<HIP4Y5.H'/WZE;%\JV.T9
M-*3[6N9O]U1F$"C8.,%,.V6\`@#XBVJF)P,"(:_F_Y'EJDQQ&#NSQ`M]D*,=
ME>J!:4N,LH-4O/YC1?[)RIH$)Y,0Z$_?)TX4S)+Y!2ZN)3(-WA-%UBO!CPB&
M!M:4+=$CZ"_!67<60CX?=P8MZ9H[761*02UA-U[6H1^OW!>(,#MI-N>:((Z&
MFFVGT=D#3P\%K5X/I8O&4,EPP8W5Q`O#'/G)/!@*MA^9S'O-`!+2>@\YG9@6
M:S@]&SK"37<#]1$&_CB>:<T`)KH&1HL',-V-=S#QK._:`&\[S7BO8(`OCT&+
M8<#POX5"?S%<:&,UL%R?S#B7*<4@E?@:-BU.,0Q`OVX8>",VJYEBLXJY?2CZ
MZ@%5<@V5%H^I_-[7SI+53%%91>(9+,_Q_C/2^G4U.@PB"'MZM'71F'#T6&VL
M)C;+S[PPFHV"W5K!QRT,PEL,$:?1M'B,%H["LQJ[8:,S#%XINGZ*RKXR[(G:
MDCU](F+/&HDJ6L`8>4X"\0G[PK`7BK?FD-IQ!0>]^5C">YW"F>`Y("XX5]V%
M?M3Z7PKKOP```/__`P!02P,$%``&``@````A`/>K1PJ(`@``;08``!D```!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&ULC%5=;]L@%'V?M/]@\5YC_)$Z49RJ
M2=5MTB9-TSZ>"<8QJFTL($W[[W>!Q*F3:O-+@.3<PSGG`EG>O;1-\,R5%K(K
M$`DC%/".R5)TNP+]^OEXDZ-`&]J5M)$=+]`KU^AN]?'#\B#5DZXY-P$P=+I`
MM3']`F/-:MY2'<J>=_!+)55+#2S5#NM><5JZHK;!<13-<$M%ASS#0DWAD%4E
M&'^0;-_RSG@2Q1MJ0+^N1:]/;"V;0M=2];3O;YAL>Z#8BD:85T>*@I8MONPZ
MJ>BV`=\O)*7LQ.T65_2M8$IJ69D0Z+`7>NUYCN<8F%;+4H`#&WN@>%6@>[+8
M9`BOEBZ?WX(?])MYH&MY^*1$^55T',*&-MD&;*5\LM`OI?T*BO%5]:-KP'<5
ME+RB^\;\D(?/7.QJ`]W.P)#UM2A?'[AF$"C0A+&3P60#`N`S:(4]&1`(?7'C
M092F+E`2AWF6I;/\%FBV7)M'83E1P/;:R/:/1Q&K:F")CRPP'ED(3"<6)\=B
M&(?B,,XSDLU`\G]8L/?CXGF@AJZ62AX".'(@6/?4'F"R`.;W\P`+%GMOP:X$
MG&KHX?,J(=D2/T/P[(A97V/B,6+S#F(V0##H&L1!.-/%63"T!06#N#C*!UYG
M8.TQZ1M,.D9L_H48:8.-IFNSX`(!]UD;(>.=UQZ3NUCC+"7)1;*;$2#)Y^F9
M8:0,[$U79L$7RJ)S-WQJ'C-SR@B97RL;`=(HCI/!VT@9'-/IRBSX0AFY.$IK
MC_&9);=)?!L-&SOI\*18DA-@3F;G?GME_L7P5Z*G._Z-JIWH=-#P"GH5A?9V
M*_]>^(61O;L"6VG@FKMI#<\ZA_L1A0"NI#2GA7V1AC^*U5\```#__P,`4$L#
M!!0`!@`(````(0`"OZ*BBP(``($&```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;)257V^;,!3%WR?M.UA^+P8"A$0A59NJ6Z55FJ;]>7:,"58!(]MI
MVF^_:SNA)*FZ["7@<.[)[YZ+G<7U2]N@9ZZTD%V!HR#$B'=,EJ+;%/C7S_NK
M'"-M:%?21G:\P*]<X^OEYT^+G51/NN;<('#H=(%K8_HY(9K5O*4ZD#WOX$DE
M54L-+-6&Z%YQ6KJBMB%Q&&:DI:+#WF&N+O&05248OY-LV_+.>!/%&VJ`7]>B
MUP>WEEUBUU+UM.VOF&Q[L%B+1IA79XI1R^8/FTXJNFZ@[Y<HH>S@[19G]JU@
M2FI9F0#LB`<][WE&9@2<EHM20`<V=J1X5>";:+Y*,5DN7#Z_!=_IT3W2M=Q]
M4:+\)CH.8<.8[`#64CY9Z4-IOX)B<E9][P;P7:&25W3;F!]R]Y6+36U@VBDT
M9/N:EZ]W7#,(%&R"V&$PV0``?*)6V#<#`J$O[KH3I:D+/,F"=!I.(I"C-=?F
M7EA+C-A6&]G^\:+(0@TF\=X$KGN3"&XO+)[LB^$Z%`=QGD9I]F\$XMMQZ=Q1
M0Y<+)7<(WC@`UCVU[V\T!V<;RP3"?3\6:,76W-@B5PIJ#:-\7DZB9$&>(7^V
MU]R>:^)CQ>H=139("/`-D!#2_T/:(F@&HP$2=MS@[QJY]9IDI#EI8_61XH@1
M?FC,^'&`5EQ@\!ZQI2=L7I.[>+,PF<0G\*NQ(,G#],W@"`RZNQS,BD_!WH;B
M0_.:S(&E63[+C\%7X^>S/$MFP_,C+M@V8Z[+WCQ;=,HW'?P]G]?L@\NB.#H%
M'`NB))N&;T/WA/X4\?NDIQO^2-5&=!HUO(*!A<$4')0_0_S"R-[MA[4TL/?=
M;0U'/8?-$@8@KJ0TAX4]I88_C^5?````__\#`%!+`P04``8`"````"$`&!(=
M#9P#``#4#```&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R4EUUOVC`4
MAN\G[3]$N2^)2?@44)54W2IMTC3MX]HD!JPF<62;TO[[G1.'+#8II3=`\.N7
MQ^?8QX?%[4N1>\],*B[*I4\&H>^Q,A49+W=+__>OAYNI[RE-RXSFHF1+_Y4I
M_W;U^=/B*.23VC.F/7`HU=+?:UW-@T"E>U90-1`5*V%D*V1!-3S*7:`JR6A6
M3RKR8!B&XZ"@O/2-PUQ>XR&V6YZR>Y$>"E9J8R)93C7PJSVOU,FM2*^Q*ZA\
M.E0WJ2@JL-CPG.O7VM3WBG3^N"N%I)L<UOU"8IJ>O.N',_N"IU(HL=4#L`L,
MZ/F:9\$L`*?5(N.P`@R[)]EVZ=^1>4)&?K!:U`'ZP]E1=3Y[:B^.7R3/OO&2
M0;0A3YB!C1!/*'W,\"N8')S-?J@S\$-Z&=O20ZY_BN-7QG=[#>D>P8IP8?/L
M]9ZI%"(*-H-AC9&*'`#@U2LX;@V("'VIWX\\T_NE'XT'HTD8$9![&Z;T`T=+
MWTL/2HOBKQ$1A&I-AHT)O#<F9#2(AZ/)]",N4>,"[R>7\=4N@5E7':9[JNEJ
M(<71@[T'Y*JBN)/)')Q/\3&K:2/V5L!@D6ARARY+?^)[$`L%67Y>12%9!,^0
MF;31K(T&7EN-HTC.%</)N'4)@+C%AE!VL?O3>:)#,=)A3A!W;;[HH@S;GZD5
M28_B#1((VO4D*(8MU(E!%#H_O3::N*.)';A+"BM*8-)EP^1&<(0N1PLG+7T(
M0)NG*(QL@K713.M,A_98TC]F<<'1^3@73G*YG,BLC2;NY>H?L[C&-M?E.*'8
MY1G9L5@;33]/_YC%`P?JXW'"22[7_[UK#H#1]'/UCUE<>#LZ1>/]?8637*Z)
M$R^CZ>?J'[.X9C;7Y?RAV.69.CQ&T\_3/V;Q$#ALW4!=!JK5+M',(6I$<,C:
MX^D<@N2BQ.;#BOOA1!)3IZTJ1IPJL&Y$%SF-3[_$YL1RW.%\)XZF>%L5C#AW
MS9H8T;@N%>,XCB=.[I-&<0T>%N0.WG5UEI@R;F.ZET$C,I@W\2R*QLY*DD9R
M#2=HNISOA!'5]G8D,[?`$2,R?'#GA[&S$9)&<0V><RV\@]=S'Q#WGL)6#]9@
M+JIX-"0CI^)@\XF*2WBFN31=4\'DCB4LSY67B@,VC@1V4/MMV]3>#>NVM!V`
MGK*B._:=RATOE9>S+4P-!Q/X=6FZ4O.@157W9!NAH9NL/^[AWP.#KB4<@'@K
MA#X]8-_;_A]9_0,``/__`P!02P,$%``&``@````A``VS$2;_!@``[R4``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULG)IMCZ)($,??7W+?@?!^59X4
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MA_3E7/]5O/Z6Y<=3#>6.X(S4B3WLOW_,JAUD%,+,_$A%VA5G$`"/SB570P,R
MDG[3SZ_YOCZMW6`YBU:+P`/<><ZJ^E.N0KK.[J6JB\M_"'DF%`;Q31!X-D&\
MY<R/(R]:3H@2F"CPW$8)_6@56VB9XWGI-'U,Z_3IL2Q>'1A[H+RZI6HD>P\0
M^9X?/)LF8V\E##*E@GQ04=;NRG4@%Q54^>N3OXH>YU^A,CO#;)"!QX;Q*+'M
M$_YJV3!S4-S(AE1V90^7\ZY.P4J=*J^2N\$WNE+\YFLTL1T@WE`"2;-7HF`8
M0MT<Q#Q/R(0=)F3B)()D"8+8:U/PVH43;^KCKU;TFS?(+'6%P\CW(@9LN\`R
M#,-5W$0@RF#RV"M3,%7F!6TUL*3(P-<WZGG6)()H6T[1IN"QBB(C:9,(H@VF
MF'W>%$SSUJ\H,I(V)+#F4DF5978ZB3PE%<REM4,%2XJ,)$TB2-H2JDUUN1#&
M@ZQ1'41+ZZ^29CBC1F0DC1)!-'I@;O8)U#3+8+Q@Z@RT6N@)"\N<D.5X*Q%4
MG6K.UN7UL)639A*S=K\Q4*,N"1?=/^^7=[PK3SF"JE?]W%X]=G^JGFG9>`AU
M2^_'`2W`=A!J&Q/5J-JZO48T`:J16XG7=XH!C4/06QKA="=H5#0?H[QQ>PAU
M\]A^.9JQB-`<JB;?R:'=1%<+PM&9;B!1I[7%>),\1M,\C\QY-P8*]51G2=XV
M'P[9(\W@)(?Q!BPF9CUF8R!4%L]6<`G4^>M)E1R)2F6.HXH=0!.5N[HW8#TQ
M;^L&$HMM;3[>#[F//FK,?@PDZK0V('^2`6EZ;%`:2-+7(.JJP6L=C)3:9^YC
M5VI]%).8M-^`#FX@42*ZV3!"=2I3F-Q_?+02Z,/-XK6_TC#0L`CLDR)"=:J>
MW]$I3QD?'8)Z#9_E!A+UW9U&E3J<>6T+H^(@1E><9;'54;S8?,GA(R2*E!"J
M\X?,1EWQCYJ-@42=UF;C3S(;3;,\QFVES*21+EC,8+PCXKQF;F-9Z@'72?CZ
MS)=\Q$B4$%KJ`:L9OX#PT2)&YK7D(T:GA%"=S&I&YC5:P\B\EOS#Z+LC^L;/
M+&EG'1&GO+D[KV5QFF;C,&'KZXV!I'DB(E3?@,F,%SE`<Y"+;"!1I[7)!,QD
M1O*(YD*+S.>S#@G7Q!T'XHOP!M'SN;W2H"E4';[C*W;S.4!?(!(3]OT;`XD2
M,<XP0G4"PW5:E%H=-;8D"Q`:%H'S142H3F8Q(Z5&2R!Y[*W&`\DWC+X[HDJ]
MFBW;64?%,5^Q+#;Z`A&9M,-)*]@$=_-H5T1L/&Q%A.ID)C.21#2%[GSV^'7]
M)I"<PR110J@^9BXC^M`,2/[X6BQ`!N_914&0K!;\5NZ6,/YBN81?(YJ[%U3?
M)%,)^J;BQ:QX&P/)`C$0,J+`D!F+W4#41W&#:5.``]%`TFP6$9+(D!F,7&A-
MTV[C]7XL,)"HS]I80AA4W:XXHD_1-']>[T):AUR[6,3A7PPP#!+2_>7PA[Q%
M'T55^@FW/P.)6;3VEA#"3,BBHD>KC)"H3T+H*)SD*<H5697[/R(82*KRW5*&
M&CJ5-^`JX]8<#KD*;XL&$M,H&0_5.<E5PB%7X:YG(%&?M:N$DUQ%TVR:<,O8
M&$C4UW6>,(B3MWX`#)FIJ)YM4>:^N?@)OWFG0\N+61$A98Z8M\@]4=-CL]E`
M4AI%A.J;Y"D1>@%9//3*;"!1'\:Y-^TH:#LJ5<<<Q<Z9H[ZS!`M^W\Y`HDJ,
M,XQ0G<Q;1JJ,7@"/S?VZOC-'DF'@$E%$J#XX!WM/@0TUXSW;0,/),?HP#E;9
M"Q=)[TH`]]W@AI)+5AZS;78^5\ZN>%%[:CSX+:)YM]GO\\'7.W::#V"[S2T]
M9G^DY3&_5LXY.\"AB]D*'*/$#3OXHBYN>KO*<U'#1AO][PDV5F6PH6,Q`_A0
M%/7]A=H2U&S5>OH?``#__P,`4$L#!!0`!@`(````(0#.3F871P,``*@)```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)2676^;,!2&[R?M/R#N"QC"
M1Z(D51/2K=(F3=,^KAUP$JN`D>TT[;_?,0X$PY9FN6B#>?SZO.<<.)G?OY:%
M]4*XH*Q:V,CQ;(M4&<MIM5_8/W\\WB6V)22N<ERPBBSL-R+L^^7'#_,3X\_B
M0(BT0*$2"_L@93US79$=2(F%PVI2P9T=XR66<,GWKJ@YP7FSJ2Q<W_,BM\2T
MLK7"C-^BP78[FI&49<>25%*+<%)@"?&+`ZU%JU9FM\B5F#\?Z[N,E35(;&E!
MY5LC:EME-GO:5XSC;0&^7]$$9ZUV<S&2+VG&F6`[Z8"<JP,=>YZZ4Q>4EO.<
M@@.5=HN3W<)^0+--;+O+>9.?7Y2<1.^[)0[L](G3_`NM""0;RJ0*L&7L6:%/
MN5J"S>YH]V-3@&_<RLD.'POYG9T^$[H_2*AV"(:4KUG^EA*104)!QO%#I92Q
M`@*`OU9)56=`0O!K\_]$<WE8V$'DA+$7(,"M+1'RD2I)V\J.0K+RMX;064J+
M^&<1V'$60;!T?;.K`VE\I5CBY9RSDP6]`D>)&JO.0S,0;`WIXSN+_W((UI3(
M@U)9V+%M0?`"JO*R].-@[KY`*K,SLQHSL6\BZQ91B5.Z:;MPT47FEDU+J*J!
MI<X79*3OZ^\%:L-7L`J_/7>E%T#[XL<\=STFAH;3,3+PNQD3/1'#3O`_=A0,
MG=6+'H7#:FAFTF,F`X?O$NF[Q.8:8?B#0&XOEX(7-B2OJTX2FL&O-)(TK7@7
MQ"B9>(/.69M(A*9)/#554@/QX3[R$A/9&$CBHPAY%Q7#(CQ=MUM4\+"$@Z-7
MFH$`NC0,2_@ND;Y+;*X1AK_(]*?>)`&\8*\_>6J364H47O+7O`16FHF:6B8>
M?*:#YVC=)T(TF0X4TO[]B1=/XF"0J8U!1$ETZ2?#([SA^C6\S:/:9'KTX\'Y
M*\U,=;]ZSB0RVVQMW(]ANDQ5(MK/@$X-VG/B0>O#A%01G4]#<>@$%T+[U1-0
M3XJ2\#U9DZ(05L:.:KH%$&>WV@W>!U^]0`?K*S2#U_IX/85!W:R[W088E#7>
MDZ^8[VDEK(+LX"B('CJ0ZU&K+R2KF[FU91)&9//U`+^("`P,SP%XQYAL+]18
MZ'YC+?\```#__P,`4$L#!!0`!@`(````(0`%@<L=J`,``&H-```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;)1738_B.!"]K[3_(<I]2!R^$3!J:/7N
M2#O2:K4[<S:)`:N3.+)-T_WOMRH50@P][O0%B//\_*J>72Z67U^+/'@1VDA5
MKD(VB,-`E*G*9'E8A?_]^_1E%@;&\C+CN2K%*GP3)ORZ_OVWY5GI9W,4P@;`
M4)I5>+2V6D2128^BX&:@*E'"F[W2!;?PJ`^1J;3@63VIR*,DCB=1P649$L-"
M]^%0^[U,Q:-*3X4H+9%HD7,+^LU15N;"5J1]Z`JNGT_5EU05%5#L9"[M6TT:
M!D6Z^'8HE>:['.)^92.>7KCKASOZ0J9:&;6W`Z"+2.A]S/-H'@'3>IE)B`#3
M'FBQ7X4/;+%EDS!:+^L$_9#B;#J_`W-4YS^TS/Z2I8!L@T_HP$ZI9X1^RW`(
M)D=WLY]J!_[602;V_)3;?]3Y3R$/1PMVCR$B#&R1O3T*DT)&@6:0C)$I53D(
M@,^@D+@U("/\M?X^R\P>5^%P,AA/XR$#>+`3QCY)I`R#]&2L*GX2B#541)(T
M)$-0W[R'(?_DB(34<3URR]=+K<X!;!98RE0<MQY;`.$E(%J^#?%7$4)H2/*`
M+*MP&@8@WH`M+^MD,EM&+Y#*M,%L[C',16PO"'0`Y+4:(;JNQO>3?9&"8)2"
MR4=M&QH`[JNVFW7O$=-A"W&40(;Z*T$P&-Q=>#)O>4D<848=S,A%;'T(1QN0
M=+6ADZ-?;LU+MG#2*H0$7),SC5T%&\),:EO9C"639.PBM@XB'@UG\>P:AB,2
M!'5%^JU$L"MNG+@K;P@"Z[?ZKPO7&=[Z$(ZTR6>D(?@C;PGCT^9#.-K@9'73
MUL];G.2F+[GSEC`^C80@]V>S>#[LN.]HQ#NN4TG\UB+8U<9&MV>#,#YM/H2C
M;?X9;0C^R%O"^+3Y$(XV!K=0-W']S*UGN1F\=[<!-4=W.HY9<G.XMRYD.&+3
MX;4LNSJQ//<VF%$Q=RO+E9FJ7P/RI=$+<?5A&>^OCXJ^OSHS`GGU^2"N/JSD
M'7T]?:;Z#ZNT%>X=GPE$/D-YCF\+-"/`^X&X*@'35>D_Q@S1M[OPMD8WH/<7
MIR+MA;CZ/G6#8&_VX5EN0%Y]O6\1Z#Z=_/5TF6Z"#USV71=-'@E"&R&93>/D
MVH51&JFUI1:P$/H@MB+/39"J$[:M"5SR[6C;4C\DV$W=C&^PU<;QJ'T!G6[%
M#^([UP=9FB`7>Z",!U-(GJ9>F1ZLJNK&<Z<L]+CUSR/\IQ'0K<4#`.^5LI<'
M7*#]E[3^'P``__\#`%!+`P04``8`"````"$``U.>!IX#``"B#0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6R4EUV/HC`4AN\WV?]`N!\^Q:^HDU%@
M=Y/=9+/9C^L*59L!2MHZSOS[/:6*%@R@%U;PZ<LY[VGK<?'\GF?&&V:<T&)I
MNI9C&KA(:$J*_=+\\SM^FIH&%ZA(448+O#0_,#>?5Y\_+4Z4O?(#QL(`A8(O
MS8,0Y=RV>7+`.>(6+7$!W^PHRY&`2[:W><DP2JM)>69[CC.V<T0*4RG,V1`-
MNMN1!(<T.>:X$$J$X0P)B)\?2,DO:GDR1"Y'[/58/B4T+T%B2S(B/BI1T\B3
M^;=]01G:9I#WNSM"R46[NFC)YR1AE-.=L$#.5H&V<Y[9,QN45HN40`;2=H/A
MW=)\<>?QS+17B\J?OP2?^,UG@Q_HZ0LCZ7=28#`;RB0+L*7T5:+?4GD+)MNM
MV7%5@)_,2/$.'3/QBYZ^8K(_"*AV``G)O.;I1XAY`H:"C.4%4BFA&00`[T9.
MY,H`0]![-9Y(*@Y+TQ];P<3Q7<"-+>8B)E+2-)(C%S3_IR#W+*5$O+,(C&<1
M=V*-O&`R?43%/ZO`>%&!H*>!&XP?B&5T5H'QHN)9[LAY1`,RKTR!\:+A6M,@
M&(VGD^&NC,\J,%Y4P*!N2VU5GJK:(1)HM6#T9,`.@@+P$LG]Z,Y!\'YYH:Z2
M?9'PTIR8!E2.PY)\6_G>:&&_P3I*SLQ:,?!^9=RISFP4,YY5$B-W,O5T(+PC
MX@4Z$]UCQCH3MYGKDVQPH+8!#!QN@X2E#7+52U_6Z@8\K,[9<QN^;.XPGJ.'
M&PY@H@%,W,UHB<.F&)ZXA&$CW^3I>Q,]A[5B8)?47C2=Z"7"7B+J)>(N0G,`
M0KUU0!YT/AR7W3M!3EJ:X'.=I>\U5OE:,5U.]!)A+Q&U"=^;Z36)V\RU)IH7
M<`@][H6<U/#";ZSLM6(@CMJO:P35'MKT$F&;:&4:M9G&<^(N0O,"3L-;+[K7
M@X2;'KAZ%=:*F:ISTZE>.K%11(=+82\1]1)Q%Z$Y``?]K0/#=H:<U'3B>NBJ
M\U(Q'7ENVH3O^[I;89MIU#KJ)>(N0O-"MK6#?R<EW/2@$=M:,5T>]!)A+Q'U
M$K$BQM6J=`.Y*FN;-0-FN@'#%H.<U#2B\3N^5DR7$;U$V$M$O00TTS)6M3WO
M&J%Z9=4]Y9CM\09G&3<2>I1]L`L.UG?K%OW%J[KL^@MHD4NTQS\0VY."&QG>
MP53'DMT?4TVVNA"TK'JS+170'%<?#_!?"$.WX5@`[R@5EPO9QM?_KE;_`0``
M__\#`%!+`P04``8`"````"$`4DQ=XBP'```3*P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6R<FMN2HD@0AN\W8M_!X'Y4!(_1]L8HYT/$QL8>KFG%
MEA@5`^CIF;??+`J0*FU^>OJBU>2KA,H_JRB2>OKCQ_DT^!YG>9)>UHHZ'"N#
M^+)+]\GE=:W\\[?U9:$,\B*Z[*-3>HG7RL\X5_YX_OVWI_<T^Y8?X[@8D(=+
MOE:.17%=C4;Y[AB?HWR87N,+'3FDV3DJZ&?V.LJO61SMRT;GTV@R'L]&YRBY
M*-S#*NOC(ST<DEULI+NW<WPIN),L/D4%77]^3*YY[>V\Z^/N'&7?WJY?=NGY
M2BY>DE-2_"R=*H/S;N6^7M(L>CE1OW^H>K2K?9<_[MR?DUV6YNFA&)*[$;_0
M^SXO1\L1>7I^VB?4`Q;V018?ULI7=15.QLKH^:D,T+])_)ZWO@_R8_IN9\D^
M2"XQ19MT8@J\I.DWAKI[9J+&H[O65JG`G]E@'Q^BMU/Q5_KNQ,GKL2"YI]0C
MUK'5_J<1YSN**+D93J;,TRX]T070_\$Y8:E!$8E^E)_OR;XXKA5M-IS.QYI*
M^.`ES@LK82Z5P>XM+]+S?QQ2*U?<R:1RHM'55\>G0WTRG2\^XT6OO-!G[44=
MJOIX]HDKH6LNNT.?M0_J^&*J3C_C958'A;I=N?F%J*AU6-B7RLV$7/<,JDK1
MY-*TPKH<+J93?;:80W%&7.@R;XRHB)Z?LO1]0(.1^I1?(S:TU14[1YTQ7-\F
MASY*(<H=YN4K<[-6YLJ`LB.GO/_^K&FSI]%WRM5=Q6PX0_\;9C+3169[SZ@B
M8=0$2UYV:I,;VJ>^<VO53-W(E@V.;'!E@R<;?-D0R(:P91A1O)N@4P8(07\\
M/.O8,IK%MK[X#3?,EF6<=76^6(@QVM8M6I$6":,BU(]<F.@<E@S,)+EM!#@(
M<!'@R<!B(G;31T"`@+`#$"2EH2-(RL:11O-WM[2LE2`M-U#>-&-$T^9BI[9R
M(Z,R\%FX'!./W$A)8CU@]+%X*OL1(\78><1HHA_W$2,-?>\1,Q7]^#V8X)Z9
M2I<<WB.:?DM?05>Z_?R"KJR5H"LWW!3:RH11&6Z(6;=IY\)2#(CU@-&E&=/N
MP3@]&+<'X]5,/5?YM>'6B<E,4C7HP83=C"`9W0P%R;J'(*,%J;CAIL-6)HS*
M<$-,N8U5&V[=UC1I`-H]&*<'X_9@O)II=)$-@6P(6P8AO+1F^41X&4TS87M"
MTZ4);<,94KB9]*2Y80L)`Q(F)"Q(V)!P(.%"PH.$#XD`$F$7(0A.2ZM/",[H
MM4*WS49,39<R?\.9+L$A84#"A(0%"1L2#B1<2'B0\"$10"+DQ*Q<\BW5&?W=
M!J(@.*L&M)\)NB=01DN"3Z3[_X8S78)#PH"$"0D+$C8D'$BXD/`@X7-B48IU
M6YJ43SP!;!T^;BV(O)1$9@M6G>;\;K%9*TEL75J3;#C3)38D#$B8D+`@84/"
M@80+"0\2/B0"2(2<X`FC+^=C]M<L%@7E57HL$<9W/^G+9I+VT]LIRM3<5%"7
M^!@Q,&)BQ,*(C1$'(RY&/(SX%<+GY^E8T^7@!MA)V(F(6<"*$^U9OF<6\)J&
M<'^?2D\<&Y5#G5D`$0-[,3%B8<3&B(,1%R,>1GR,!!7"$V6Q&"^UB?1$%79Z
M$=.`%3C::=`]_[/BI7P#D!^O-Q74*3_WTX$8V(N)$0LC-D8<C+@8\2J$"Z>5
M,[0T?_K82X"1L!,1Y6>ED+;\_>I6K%)\EP;RHJ^".C3>5DASU]*UF5R^,+`;
M$R.6>*;IH^#;/1BG!^/V8+R*Z0B.CY$`(V$G(N8"78R0"V`J8+B\'I`>W#<J
MASJZN:T0/BI4+HPT+(P>C(E/96'$QHB#$1<C'D9\C`08"3L1,0%8R:<]&8`$
MX!4B<2D@W8DV[.TC94EG`G"D2H!J:-YE0`_(Q">S,&)CQ,&(BQ$/(SY&`HR$
MG8B8`JPJU$Z!GO<#7DP24T%Z;-VH716G\O%ABQ$#(V:#L/>0TMK4:@[>"E32
MI&5CQ,&(BQ$/(SY&`HR$G8B8`*Q*U$X`,`?PHI(H_*VL5#T4UK6I\KUP\U!:
M25X?_%`/0X6(B1$+(S9&'(RX&/$PXF,DP$C8B8C"LYK1)X3G)291>+G.J]Y7
MJK2I5"[:/H"D`6E@Q,2(A1$;(PY&7(QX&/$Q$F`D[$3$!&`5I'8"])SZ>>%)
M2(29=/?>J'7]ZL&,O&T.=LP`=?L/$1-[L3!B8\3!B(L1#R,^1@*,A)V(D`"T
M,>T^`7!)N&PF/0?,I+ONIH*ZEH$8,3!B5LA\7%;.Q\.YM""UL`\;(PY&7(QX
M&/$Q$F"$[3G\>!7.DX#O*>1[P\YQ]AIOX],I'^S2-[9?4*=P-M9F+^/7<@^A
M9#=ICV/Y:ERR;R<K>I5.+Z`ENS%9T1MULH^:`[0E\1J]QF&4O2:7?'"*#W0)
M3$MED/%-C?Q'D5[+'6PO:4&;$<NO1]I\&M.VL/&0X$.:%O4/=H)F.^OS_P``
M`/__`P!02P,$%``&``@````A`'N&?4R1`P``0@P``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULE)9=;Z,X%(;O5YK_@+AO^(80):F:0'='FI56HYF=
M:P><Q"I@9#M-^^_W&`>"81;:FR:XCU^?]YR#<]:/;V5AO&+&":TVIK.P30-7
M&<U)==J8/W\\/RQ-@PM4Y:B@%=Z8[YB;C]LO?ZROE+WP,\;"`(6*;\RS$/7*
MLGAVQB7B"UKC"OYSI*Q$`A[9R>(UPRAO-I6%Y=IV:)6(5*926+&/:-#CD60X
MH=FEQ)50(@P72$#\_$QJWJJ5V4?D2L1>+O5#1LL:)`ZD(.*]$36-,EM]/564
MH4,!OM\<'V6M=O,PDB])QBBG1[$`.4L%.O8<6[$%2MMU3L"!3+O!\'%C/CFK
MU+%-:[MN$O0OP5?>^V[P,[W^R4C^C508L@UUDA4X4/HBT:^Y7(+-UFCW<U.!
M?YB1XR.Z%.([O?Z%R>DLH-P!.)+&5OE[@GD&&069A1M(I8P6$`#\-4HB6P,R
M@MZ:SRO)Q7EC>N$BB&S/`=PX8"Z>B90TC>S"!2U_*<BY22D1]R8".VXB#BQ-
M;[94((VO!`FT73-Z-:!9X"A>(]EZS@H$6T/J^,[B_SD$:U+D2:ILS,@T('@.
M97G=>J&[MEXAE=F-V8V9:(#L6T0F3NHF[<)=U]%5TY:050-+G2_(2-_7[PO4
MAB]A&7Y[[DXM@';G9QCJF(@\/;1DC`Q$TC'1$]'L>)^Q(V'HK'[T7JP'MU.,
MWV-\G=C/$LDLD4X1FC\(I%\NV88>O)W399.;-B8D\5XE?]`?.\4L;SWIN\-$
M[/N`[T1Q%.EY2/I`$+N>'^A`V@>67N@$RP[0/,+KU?<X[4W"NK=H<.Y.(7!Z
M9W]8PEDBF272*4*S%W[&GH3G6E0Q4_YFB6262*<(S1_<;OWR?:Q%Y2:]C.ZH
M1143-BWJVLO8OO=/<PON-2!VW7!XT_0!SPM\;P"D?2!8^I%WOXDTCW).Z?T:
M3+>HA'5O4=AU?A/Y3B%3)9PEDEDBG2(T>_%G[$EXKD45,^5OEDAFB72*T/S!
MZ*/5[V,]VNS2"SENTAND+E(G"#QO<-/N=<(-(F=P'24:X09A[-S;L.D7.;O)
MI*M3W,#QW7M'*:=J-%,C3(G9">]Q47`CHQ<Y=GGP$G6KW4CXY,I?]L'ZSEG!
MO#%>3^0(*=>M;@-,<#4ZX;\1.Y&*&P4^PE'V(H*KD:D94#T(6C<#U8$*F-V:
MKV>8U3%,,O8"X".EHGV0!W33__8_````__\#`%!+`P04``8`"````"$`7Z;H
M)S<&``"^&P``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)R976^C.!2&
M[U?:_X"X;X(_@:KI:,AH=D?:E5:K_;BFA#1HDA`!G<[\^SWFN#$VQ(6]:9+F
M]>'Q.?9Y37CX\/UT#+Z535O5YTU(5E$8E.>BWE7GYTWX]U^?[Y(P:+O\O,N/
M];G<A#_*-OSP^/-/#Z]U\[4]E&470(1SNPD/77>Y7Z_;XE">\G957\HS?+.O
MFU/>P<?F>=U>FC+?]8-.QS6-(KD^Y=4YQ`CWS9P8]7Y?%>6GNG@YE><.@S3E
M,>^`OSU4E_8MVJF8$^Z4-U]?+G=%?;I`B*?J6'4_^J!A<"KNOSR?ZR9_.L*\
MOQ.>%V^Q^P^C\*>J:.JVWG<K"+=&T/&<TW6ZADB/#[L*9J#2'C3E?A-^)/=;
MEH;KQX<^0?]4Y6L[>!^TA_KUEZ;:_5:=2\@VU$E5X*FNORKIEYWZ%PQ>CT9_
M[BOP1Q/LRGW^<NS^K%]_+:OG0P?E%C`C-;'[W8]/95M`1B',B@H5J:B/``!_
M@U.EE@9D)/_>O[Y6N^ZP"9E<B3AB!.3!4]EVGRL5,@R*E[:K3_^BB.A0&(3J
M(/"J@Q!X.W,PTX/A]3IX11-!A'P?88W3Z;/S*>_RQX>F?@U@R0%P>\G5`B;W
M$'DZ'9`'I?VHQ/T0F&D+-?SV2,7#^ANDO="2;$)B*[83"GF5K`'KR@:YF<^F
MQ%"4,#!L\35LCY^AA`\DW%9L?0H+#:XS'TV)-R'$-FB)?>$,)4F?4\%XRB-*
M;<EV**&$I)+?2!M,<,BF5CJ#_>(OK1KD,*8V0(82V3-*22AQ)K$="@B7<632
M:R4/-LP0T`^FQ#88BQPPE""8X$0(RAW)=BBA5$HFC,)BDS:;2AZ'P7Y&-<AA
M)`XC2I"Q+UX<.\MSZTI8%)L26)"Q#>F'4V('SEE:&4HT'*-IXNSJK240,4]O
M@"FWG-U-E-@!8T[64*+!$AJY*^[V]U:^TB582NQ@F76,C00EB"4EC6$OF.74
M2[9#">$\$H3=V*X$]N;\I/5JN\\QIUJ9UL!VO#8<9P9;K\3*'5GF$-C=A[UN
M,&_,7A]Q$V+Z**-"RA$>AD%)3`071F'3J8X]>\4IMW5KZ^S"3&OPTBQF-'9+
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MO1X3Z79!_3WOCX/)C65(%YE'KW:PG`:2:8W&@AT`)^7$V4M;2\1E$M.8FAS;
M"5QD('1L(-Q,72<.-4AX!T<#DL*!?H1HJTC""&?)+<A%1D+'1L+=3JTU",D3
MQA,Y.!'C;K8T=S&<8J"?F[9@IQ'6\[!=S[OIH&J477"7(M,:)+UQV+(T_M.6
MNE7^'Z!C?Q%.1;,^,MPM#'O4==/JC&*8:8F=ST7^0M$7ANUQ="C4FNEK:SP,
M,RVQ\1;9"QW;BS#K2.^:">MPLX<27`E)FK#(]%:;;I&W4/06V(]7;W$/59G6
M3&=&)P_#3$ML/,=;_&<'BE[@KZW/+S2>3V+AJ=\*ACO$C]>KG2WLUE9KIE.#
M>%J"M16<R5O]FCF.,J_1]*,<2O?\H#5>2KPMF9;8253M??;QE:$9>&NL-=/7
MUDG$,-,2&T]9Q'P\I7:R-ZHQ:J:OK?%0HCV'IS1AB0EC\T&<(=_,*JM1#J=I
M$3U$QE#CY?1);$S'3-[9*MC](0O71C/JTLSG$#J-/HF-M\A$&'9_JP^:\NCL
M^1Q"XZ$$JTQI`CM9FD.<S;?(1=B$BS@W2)G6>*OK,QH;;Y&-,.S__NKZ/$*G
MSR>Q\1;9"#Q;<?<&<P^%6N/-'H;!'ZHG[]_Q"0P^8[CDS^7O>?-<G=O@6.YA
MV4>K&)9O@\]?\$-77_IG"D]U!\]-^K<'>$Y6P@.':`7B?5UW;Q_4$Y[KD[?'
M_P```/__`P!02P,$%``&``@````A`/RQ#@+'!```%!8``!@```!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R<F%V/ZC80AN\K]3]$N5\2)^0+`4<'MML>J96J
MJA_7(1B(EL0HR2Z[_[YCCR&Q$[*&<P'D^/7P>#SCE_7\VT=QM-YI5>>L7-AD
MXMH6+3.VS<O]PO[G[Y>GV+;J)BVWZ9&5=&%_TMK^MOSYI_F95:_U@=+&@@AE
MO;`/37.:.4Z='6B1UA-VHB6,[%A5I`T\5GNG/E4TW8I)Q='Q7#=TBC0O;8PP
MJTQBL-TNS^@SR]X*6C88I*+'M`'^^I"?ZDNT(C,)5Z35Z]OI*6/%"4)L\F/>
M?(J@ME5DLQ_[DE7IY@CK_B#3-+O$%@^]\$6>5:QFNV8"X1P$[:\Y<1('(BWG
MVQQ6P--N572WL+^3V=IW;6<Y%PGZ-Z?GNO/9J@_L_&N5;W_/2PK9AGWB.[!A
M[)5+?VSY?\%DIS?[1>S`GY6UI;OT[=C\Q<Z_T7Q_:&"[`U@17]AL^_E,ZPPR
M"F$F7L`C9>P(`/!J%3DO#<A(^B'>S_FV.2QL/YP$D>L3D%L;6C<O.0]I6]E;
MW;#B/Q01&0J#>#((O,L@!#X:3O;E9'B_3IYX<4""\&L$!Y<CLO.<-NER7K&S
M!24'P/4IY05,9A!Y.!V0!Z[]SL5B"JRTACU\7P;1W'F'M&=2LNI+/%6Q'E"$
M5XD#6%<VR(TY&Q<O;'AMV>)K6(&_0DDLP+TH)GZ@"M:JP'>3EET!@T1UP7@M
M0>U^D3P^20-,U.]?H201@.27IZDZO,;A:6>)K4+A`TF7;WQ3N5CE"EWUBU<H
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MA-PXISW-1LQR)V:I[=MK#ZD9QI.#V!YC>`_9B#=@(YK/KJ1F;&M')<KF>OPD
MO]M&Q"PUBST;D9I13#,;\1ZR$3%+8VPK'#M9:D89NS8R#0C<6=PJ2`C33>6X
MCWA<K>'I?2(U-PH1`V`ACH,]9"3\+VH-L-\I8T8B`Y@`:DYBV,H#CJ+_;/7&
M[`*/P5&)VBL/.8IGX"A2,UJ'9H[B/>0H8I96C+U>0;L89>PZBA<1$OGMX:6F
M\BY/\0P\16IN]$K74T@0Q5.W_4VD@/%+C&X3FY6BF*7FK]<K4C,,*`?ECZY!
M0+S7PYNK4[JG?Z35/B]KZTAW<.'@3B+HQ0IO]?"A82=Q4[5A#=S&B8\'N'VE
M<(WE3D"\8ZRY//![P^M][O)_````__\#`%!+`P04``8`"````"$`!I$\KR<N
M``#+FP``%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W;;AS)F>?O%]AW2`@R
M1`%%B@>1DCS=&E"4U".O6J)%RHVY3%8ER>JNDRNK)-'PA1]B;P;8!?06>Z]'
M\9/L[_]%1&9D9%:Q)+<;"ZPQ8UNLBL,7W_D44=_]^Z?Q*/M0S,OA=/+]G;V=
MW3M9,>E/!\/)U?=WWI^_W'Y\)RL7^620CZ:3XOL[-T5YY]^?_O?_]EU9+C+F
M3LKO[UPO%K/?/WA0]J^+<5[N3&?%A&\NI_-QON#/^=6#<C8O\D%Y712+\>C!
M_N[NT8-Q/IS<R?K3Y63!O@\/]NYDR\GPS\OBQ'UT\.CAG:??E<.GWRV>/I_V
ME^-BLLB`(WLQ60P7-]FKB=L`N+][L'CZW0,-=<./LA^GD\5UR=!!,4B__<-R
MLI,=[/:R_=V]A^F7Q\NKG6SOH/O+>^EH#\J[XFI8+N8Y`+[)QT4ZZM[Q#Z]>
MO\C._^/%N^/3%^_/7YV<9:_>G*3#_&(GG'.>CSC?H/B4_8_B)AUW;W=W=V__
M:&__X9/TJPI/YS>S-AA[N]M_7#GCM)@/IT+N('N>+UJ3CT'_P$CP<I1?I:O<
MN\Q'96O.R7(^YS#9RV'9YT#_6>3SE>O?V][>V]\^V$M7#DCQ2[TK9M/Y`M[,
MSA;Y8EFFP^_]9]'ZS"_Q<C@JYMD)9[N:SMM(?3.=;.?]?L$@A@P`FG^ERP=H
MIN/Q=`((T_XOO>SL.I\79?9VN3`Y`;AT6D66&!,OX>D6K/>Z>#*=[DG5O<`?
M]]/=G^6C?-(O@!/I*[.M]V?/L[OWTU'/BSY2L6>,?Y!^&2B9ER5+_+[U=5Y>
MFVCV]8_BS\OAAWP$Y5O'.YT7LWPXR(I/J(@2I$F>IXMK"-/W%'9;I#N<3Q=P
MT/HQIW,4SQS-H$4%Q$S\VLLFQ2*;7F80=SE>CHRX@P)]U!_F"Y2'OKN[_^B@
MM_MD/QM.I!4.;`D^?-S;.SCT'[94Q?/BLH#!!]GE<`*"Q93]:;DH;<?T`&_M
MD.L.U_U=P/QHF%\,1\/%L&BC_[AO6K3,9OE-?C%JR2'?SY?`&;">PO9ZFD_"
MW%Z%9!.TMF[]*9^;H@L`M22I2:HP#+C7;XMUN=I>%/-Q.NP$81LN*NW?1[.#
M:FQ4QY+WOGS^\CE=P,3T>CH:8.3N95N#XG+8'R[N&XLL;EK,#(]ZNI9.ON_N
M2.&"H'D&6R^+7I8O%]?3^?`OX'1OM\>W^D]6FA[XMVQ8EL)V^"";UHHARQ<9
M@E:,+^#X(&S&;!BE8J51$@I@U(W@.5P)T-[ND][!_IZ3N0BFO=V#WN'!D8=_
M-8C^7'N/>X=/'O<>'3YLKZ2O]GM/CAY'BZT]V?%@`$]/)PBW%,,V\M?/9T.$
M/:4B3!R)KY$P'>(XS["TDMS=<R(N10"F$_RAQ1!)RE`3,3/8B;]N@S/L*HKN
M.$.U/OX=N@%"^I,,/Q3K-DM!/5D-5SJTVG3_:S;PLYX)T`3.M5A9L?M)+]O;
M_X<6\KHF73\U:*?87]R]8C'$S;B_RL`U&:C6_^GJ+?FO!#_;@CT'T]$HGZ-K
MD6"3^)8E;2U0JXM;]W(R=NNP2*6D8YNZXFMA;\Y>#7AS7#?4S3%K05XI<+U:
M[6Z(_352$BON-MK6P+#J?&NFK#FN/-="]JR4Z_$61C(_9*5G=K!Q--/RV_SB
M>";!]K?,W;NBQ"_O._]M4'PH1E/SFU($_5!,`'1D&C`?C(<3BW@6Z+!TI%/#
M\L4X5[1U.N[UM"RSR_ETG/FQTTG+1W!NTY"`=%QD6_X0+8E[-<%Q*(A'_8!T
MI^I[MU#Z]<EUCD,A-^\R'WHC+])\=*Y."R@#_*(@_"RR"]!R.5RX<W@X%_FG
MMK?S;-.!;W!71Z`FA3)\;IH'?)A'()>C1=)G>3GL&Z&>#T=+!3.;*:Z?BN'5
M-<.W<^Q?#D:<1Q,[,!ONY2:VZ-3D_!,%"R]'TX\K.=]&7-J(F$_@J;P/YYDW
MG*+I>/#SLC1WL<P6TPPW?XJKB"E7&""\ZE/]VV*590EV('S-K?7*K;,^CZ*&
M=%O"1UO0G(/L8CIIQW;)D%Q;0T=%0J8`5BTY]-R=?N_8MDS`MPC-B!\Y-:VC
MI"&#$^M;X@1QH!URRZ/M?B?>6G"*SA$5AZC-TC1#C>MTSG&?^*TTUU"2..L,
M[=))%7R!JIOLE/)8'<RMAHY(LU\4`Z^]8G_Q8CX<(#B3Z:*M`6PG"W_1'&G0
MF)ZEN84,D,7PX"*(OH(3T1Y-O!C*?UY>C!#[Z24.*VJWBGO#!TPD.$WWJ7`&
MBC\,R99E%S<1;*MQH(GH.])Z)9IY4+A_W1=$QB,*PNT?:](!AI&N@3WTZM5P
M,I'Y$/DM-Y6"OF8VN:K5\\Z6L]G(##!8&Y";0BLL4>5LA'-N,&_"!,[14-K4
MMDH"!81VVB!5"WKSYL/TB1@FQ.`FC$'J0>@M*S7.X\!'93)O97[T5;"7XL84
ML+?SJWPR_(O+C8@X,B?FJN#8EK@MG<IJ;R?[MHEO2.,YY'MGI<,+.+Z2`C\G
M393/BB5N?MG[\OG5A(35%FY_]O>__:\3]&@^N?G[W_[W?<RV=&)_.B>#8=D>
M6/)Y,<HQYQ!9_W8!^)?/^_N$*$^>/-K1VIE?@_B=#/@5]L\L@\[<Y1^)Z$KY
MEJ05QA*_?($3M2CZUY/I:'J%$"'D*"(3"'(6\[Q?S!3J-C;[^]_^BR189<RR
M$L`UQ8_-KC'%L-$$"LB.SY#L_G"6CT8WVG^>HR,1$1\RX]]"+H1%A-?GJV!O
M@*#S7I.<__,RG\N-LE.?:J-B,9WTLC?%Q^P/I$Z*FYV451*LX3U.3:^7RPNE
M0J66`)3_$K!#_-WB$M#XW\448@Q6PA>&M_&["JGNZ`D^FL>\ABT0LXS4D3Q3
MP^9TL.PO`.-#,5D6<@P&?.'$K\PXQ<\%7_-QGDV6EK,1TH?E+WPY'`^)`_4E
MN2#(S#<ND0FW<&C.CQV0>4>8BK(GFHZ6`U&%Y"/ZB026<>,OQ0W?#?!F!DN2
MZ#V6*]!*EV0XEB.E^_@6QD?N^(?[LG;2M:OL03$GF2E<+TLE`&4O=3*_V@SE
M8L3`[^'8@#R]6%!]R?(Z^^)9B!']HBSS^8V&72[A)X.GN:5(66]A"EQ^#&49
M:4-SU<#-E;*Z`0%M6H`0I7P'YI1QS")'?F[`7BH$.]FQJ1\EDKY\#H4;AZ@@
ML]?Y`+(E.5Y+$@E%^0QH/PVI1A7@Z.[>_M[._I?/$'`D>5S'U6(:9PPD%QR[
M#E6$(&,7A'*<SX>LO+B>3Y=7:`%(6)ELH:<D'1Z86O0"2\Y1A`A:=84-S[;*
MHLC>0+[L\7U"X3EY=?X]&Z%+J@!2\V,79-:T1#V*>Q-3L2/2O'"$X,'.;0\4
M&R@%=67Y7-$:[FS22?$4;*2CL@6R[:3$2%<YU,:BC-"ID4_T96%,>+G4MBWT
M;F1.SEDK)ZUM6EU"LYSD2(^DU@SC<"R`$"(YT=Y:YR-)70BM37->%`69;14=
MQ&AX-H+1\TPO^SA$=)<4%;6R)-2VG`_,T]*7]O?2\LU"OE3OB-,Z#6*JC8+1
MS`%E2[_'%V,CBW.(:C!,[W?.=K(?CH]/S31)?07X(_ML-)DMYW+R3-\(S/F2
MO;Y\%KGFQ94*%S"K"8*^/2N0'@N`;/*+3WT7Q'*X,:PG.0RV\>S%2;4YJ/#U
M,P:\Q$Q\^:RJ("(&LN=B@-$-N3[2G](/*8B7T^D"%2K]5'E-$U5YA0NGX(Q`
MW12IZ-"!Z`I-SN(9W6H"@[4I-0#3V1&6RB4:HQM-.]DK]&4)YB1N4K=29&3?
MP9W99"S=[3QT`16PC.(,@/EY.<%0@S=C#1&AD_$<P2`76PI92(\V1@=)M[&4
M9GH>-/.O5?`?YM-2PK:4PADQM]H%^LEM^3&_<1Z+2H0]`!-'(!E>\N(50SW:
MH#5F]-HBT/QL>R_;4H43Y;*#3CTXV-Y[\O!H?^^^N2TIA"O44TNT7[G#36=,
M`&(T[SB?8`>UN]/77RW&*+.1J2!Y$7D=VR.]UT/(+Y_.L:!HC4$12AKC:HLF
MZ3.R*<LSBYQ90=JD9\SY85H07!>-X#3)-S-.'>>#PBE.%L5JFY1&EB*L@'U`
MGYM!&'[*L`+J47#,V31N_EB+RAS+NLA+Z$-S=O7PUEF+L&_8Z7()NBY=W=UL
M*D?'/\:BFREP1VC1[VPYQI*9:WDVO)H,,:!22#Y9(,R>3HDQVZ'M_D[VS7//
M$W%`8-&R*)D1/J_VY+!E!(W,0M#)@D8NDKA@4)3]^?#"*2"SF?M=LA',2+?L
M&N7J`*$JT<7*39QR6DNK23=X'P.&LM56;-:8VR528OW2E+`$4L[$H"GF+0J]
M=Y[F"S`C;Z85S@N9<#9@F+D(C!*#TGEPI^%T"K76F.J12O[R6:8+R2(;`XM%
MXBS4CO-?BDRI'`/%^)HB]G)L84Y0>Z0CY$,#5SX6W:2398,<G?1Y)T`2DH8#
M8*K4"9D_379!Z@'?B26;0/R\'%Q5"N\:+J)6JP84>3,4X^1X:_D/.&U3U*US
MVUN0D]2]*$9#/%_'7\IT4*B4>XVKA&\KV/O#.<4\W`X6+5O4$C7"J>%B5^&W
MO:/<7`L?,;$N?.^&=4X!!V#'J&11G_*.T"H=8,ZTUQ)!7\$7"M]!O,0E-\+P
M!UY1$WT1)F(MNS17:SHG-X//!#D04+B%%193I]PCR10,[->HG89T>L_YOMLB
M7S,#:E&2,OV607>N:K*HSM`9CEMV2W[,@C`*G#H]C*H8#2R<@F`6F+AHK3IQ
MBV9GEE<[F]%K\5W25O;6&^%#UQW6C$`(;6%T(3?;VWFX#0(0:>?DEUJL2Q3[
M42@`Z*AL2YP;F:%:^,O+#>2,)YA'CI?&EBN<"OS553XQ^)&KC.\LP\#&@4D0
MZRM9F'FQF$\M,8&(>QEV+GYT)B>.+MFO\S7`8P4'G6E%USJA07=W?3]%.&#B
M?(J_;0]?P\='0K>[6*[R!JI!F4,N3(SY'\&ZP\L;&0VC-?YW1X/!B6LPP">6
M$G/)(T5D1GE]"CH52QK:U24"$KV3A5ZM#R(8L`N6`27$<UU@CO$J"!(X6]SV
M4J[(G]15(M2\=(U$[/=J0C_ATI18DPOGM$.J[?+WY8P@\/L["%E9S#\4=Y[B
M?$E6XO#E^.PD>[P/N[HUF*O_/^6_A@_HE?R+SD+OY>X=_NJ3M3*=-F;5/7TR
M?XF#XH:<#\=H066"WDUQZ?3M94[\?.-7T`</;.'%TS6'B`#X)VW>BT(3L^51
M12_VZ?(+!7ZUY1G6^#;MZ"W>0`JP@(@$('/3>0HH\(S4^N.EKJ&B>R90SC5%
MYHE`9B3^U)@@NP$7!<6#&B<HL'ZB'9H2R^[^.8.E3QER*,4"P'5]LDH-X+[?
M]WP%?J,NV)H0T>GB1)17K<V\,Q]:LUADH5#$&(P(#.G:RC3,JMP*D4L-G[2(
MA0,P>$FWU,*:N[*)I7M;<O!39ZF5\ZQ@]G-DS]O)$*2S.S22-Q`,C?!-5$UD
MC-=$`J"@.UED():CP.D:?)PVD\1WR,[#QW0)_Y:R\]RYO)2^KJ5"7M=-?TZA
MO<`/6_B.NW^^,*&842`@`>1Y!]"%LIV"T_..%$,(_:+^,M.,,I8Y3`,3HS-=
M)AQ>5.J+-F>X&UII'C6L*^>Z\@&>8B"?*5LUULTM9A8\.*I.Z2H8OB*?3+[$
M9%YC<4HM=G!N&BQZX?HG+;C1`/&#\U2SR\*8TOD;XURFQ(YKKI;U?K#*-*/U
M=2$A9G($II)**@/(U=&.WLF[@,V<.3+156P0).JFZ<6.\2O)D\E?QA>N!0A[
M$#%S/9L<K^T#LLS11L,0!+'S>#HH1LYWA^7I:!!RXQ4CW>5*)&:Z0-E<V%BB
MII1@XJ3.(X9.C:Z+H/#,<Y!IDLFJH]Q.'8110MH(P9N)$Q96C.>3!#JX%V8C
M[HIT@_9W21!+@&A6IZ0[IA!PKJ'MR^=C7#&YSO7?^RWO%#^:$&>`;P\[DDZ7
M;QK<[0VW.6DM2@,5]M+ZTK"57N^P,*F$Z6W`@Z,J3TP@EOWD5:2CL#*X"CL&
MJJ.HU.+SN?@Q,/L'ZD*BY5;E@K,?-!],/TXR<M3@@E$4JT2"^TZ]-[@U\*H%
MUXR>%]N>3VDC5J*^3B0ZS[&ET<V;VB;9RW%%W.XNAV_0\*:Q.X('L4>7$G]$
MP^IOJL3CTVX;&CH0\%MH[_-:KER2G[*513=.<3B#F:/,I7_K`I>7'S@&!3F:
MWA0*@.$!L5S]B<N/3X@_G;3`4&2&FNYR4YM)8/W:6`%7=5#.`_\GX@^DA$8N
MG[KUGE8(4FRV)SV][B[&MX6\L#+-196(@;:S[[9=F28")CAA2+OI4E,E:?-3
M'09+E6C(,^HNOVQG9WTB$W#2J7ZK[577JY=0-5'9RD`!0U;/@G<+&C],1Z@)
MPD1_>\'J+AR*-/78F0MO\6I73CB:$(6C54H:-Z2[(!EVQRR6%!D+&MS1''7>
ME-AUV2,7JJBSMY;.+NQ/<99L'3.+-.5`1D(.4=O)OM-(LMZ7ES*2,D:$1115
MS*K71<:DQ;O#8JS6!\<HX8%C69V8+"M:CV,HE>$R@B!`C.*2,_)<#G</MVF'
M_TV%_X5S3)S>.PT\"F'>(#TO@CRU?,I_4C@$I4GZ-@CL\T50'XYS/!/C$Z8B
M!?P+38"+Z;;]"S,?&(`:!@E7\Z%#"Y?G`!@;"2$<A+\ZR+IXJG8AZYL\A9G.
M%"L['-27]D`9[4L3QEF7'@L[;2$^)WM'-=S@Q=^R8KF83$)93<@7"]*_RT6(
MM#AU93]]*B%4`#]Z6<]"HV.M_,(L%\W';JQX2QNZ$Q/^^.IAD#_GM6I46,-T
MK>26,`]W";D+_9@5T+_%*:MVSDU..1LMG2?JDSZHOJI07/<1A!.VL32@*NDI
MXQ!%[D9*S/)4M;9=R/5<SF_P8=3&)O,RO-P&E0K,X,HQ0?=T`,9>@D^"@!DM
M%N;;&S`,Z,!@8!)<FK77%=9^67EEIA<K!JH^-E";5M2"XU0)5[C"[ZL06-9%
M6^50-;'XI+80J2XU0HN_HF/(\*PY\$71S\G*:A9!MB?81\MX8@8BIY!\GG=E
M\0>IT)/"K5J$UZS_$:-B()5<:FUE"F?*/"F=W'+]SCG%)=<DIA^-%4P@=6]0
M2U!4UR%CP;H-519SUL6V7P5CM&X0T.&#=V-+_=*>QVOY]<[+_58S;:C=I1KM
M[W_[G^E')U'J`00J:(3VCI]"E-&>4RNRB@_7#O+^73K&&O-;'[:))6=%A4"R
M7$X7G.`A6'?=?ZG59#Q#R8;8;2-&2I6B5\<M1)ZK/OKE\X]6&/WR^87*]BF\
M;\B*4MR:MN[FWDU';AWTCO:>]!X_>I)^TVI,9ZC"A(>[K?O'SXL)K0=DK=H;
M1E^9<&R"BA22-RUSUR&;Z:2M1[L[^ZU#;>WN/#Q*AYX-/]V"SZW'O?V]HQZ7
M`].Y6_O"'=\\;GVS]^APIWU7&P@>M1#XCH:RI(8\GTX(07T+4[HV&0,G3Z[-
M0<JB3F0>U[7?,Q_\EMFSJ6+@K9?'9\]H/W:7+X_/WKO6!JVRS25-WRY`0<^H
MZ1D;@Z-<E/1LCJ&J+K\@D6K?`W`\<A);\^SYV0OK$+)J(Q]3W:":+IW]`Q52
MQ>?OK2BH%@2=]VHY'*@HV--,YZ:&G+*<8A<^$[+B)RN,(>4?I:?C)&V5+9-#
MIG"ID7Q#LI1?D,5#93E#4&>UJTQ-*0"/!8J\*3QU=S(=>>..3:6N4>4^-4E'
M)-6`"UET9=UD7B3E+O-=X!KAOM&G1NHGZEJ-LD6N>V)"_'*#"$C7JBX[$*I]
MSVOX1)92RQ5\07BGCJX)NCOJ"`C]FW5GIS>FA)D!0B'@A<BIC$8S,V<$^D@S
MH-;5-61`QWY&[9]LCYF-B56G/SQ572R:7^+KT'XB!8P7E'*A42'F3%'#V6W5
MW(3`J&=#APU-\&[ANC%ACZ*.$Q"+PRF)XF>X?94!DL.E=BEM^$Z5/&LMTA[>
MA3?US>853VIOCID%`8&E)!7QF<4]=>.7L=0I%73+C6JJ1"]<4DA/WJR5JEL3
M#\\V5&E/-QC<?KGQ*$Q%<"E1J[A?)SEG$V^*@--56Y$E.S9K<1QM:[APN5R@
M<@X/:QGWA-/!:`9Q)'[1R93&^Z#6`'!:(0ADB%%0SQ51#/6V[Q^7UCO-^'?6
MW%`W=EAW7:KC7M95OQ]=]M?8)QUV@/N[R<@U0;,5`'_C$'@%S*8C*'#XZQ:^
M=>6?GP>C).@[@YPS$^6!KH>X$M2';N*LD5JT1C(%%F\,)W@[4!WR.]TFOKD<
MSLE1+3[">ZBE$`!*>UTH,V(.KW>X,]*J"W(2]3>N$D*4S:ZTDB@_"A/[[&J4
MKN\,HPVW5C64ZC#98;Z+OA5+N"90EXHSO[ER<$G^%R@`IZ:Q`%:GD+JU&TE`
M$*H8<:4BVY*M^(3TV)*85Y=7XR]W#T$+C)6PRP<?"#@PFNJH\7F#H%.JK4)6
M6;ULLD(4JPLI+MM:95*4P$6Q^"@=[]>8(5B4-V8NV>-4AL>59,92>\IG67PA
MG(<]I.<-`R)1E;MNUE#UE=/DX,6759@$!VP;!T34R&I>L57!`%U%B\I%=GRR
MCIRH+TA6+S/.Z4BOYBN.@\=J-@%%XCR3&ER6]M"8I_Q@ERET788I"Z\!S271
M%)XI9DO?%Y%V>?KE_SCEU"&NCW[5[@$]X!'_W\IM?]VNA>Z6BNRU]``MTE\^
M$\ME?UQ:.Z^)@M76?'^,8U67FR03BY>A;C/C>D>_B"<=B>*`*NRQ8H)3+T@8
MW&&7N\3D]H\Z,@V=9U"GJO__BVR?N>,ALKUR@N2*F@COI")KK2!JN2,I[[S7
M`3Y^?X%V0L6I]=;]1?.:3^3_6=R`'Z-LJ=>/C@7"U2#/`$R/Z&^:#TV'*Q;8
MA@&AX&H27VFM&BC!0"NN#`8=/A2S_<TVDJ'1(`\*00)%'68TKV&9X5);L-)Q
MXB9]L`&3FN.$9^SY=#_,:9ZKPUK]BP,_'S@.?!^9_Z#7*RJ77$=U_;!0DPJ0
M>@S`+1B/Z2FI=PZ(]TA9!T+JYD`<MT)62+H,+;BNS>F:VZ"!36MSZ@MVQA:-
MKH.(+Q(:QQZX5>H]3QPT.-S\(:>PM)1/:U5#PC7"6%DMGIY'OGT<E\@U0L*,
M69W?PQ&[^R+\4(11R$)<7:.63?6.$6Z'%G'9*_[00G60;`:8V,F^]A?2ZD#/
MI;._)=D9:_LZ.*^K<CA,+@K`DUO$/H<80A;(:@W>]>IT7W$`04L='E9]Z\)$
M2$^ZB+%U@&!_TN@CR/N*SP_2S]N[IR..NU^/<^^%!$T4(R!=X'7=#]7*'=:]
M'7N!Y5K=\?68_5O'G*P<X>"-=7J#:BG0XNPX6Q'+IWG_$):`$T<W%$XZ"\M2
MZ.+=,"AFJI`Y1O97\`'NNLH,/`1R_\OGJ-B\M;?[<.?Q[[A<N#745[K<2EJ+
M$,C4"RD?+AF3<X*[]G:>//P=;["4KM\_.,RADJ,W+P;TWMFUN>SHRV>[=C(:
M7A9N<:U.3^N0*P/F0&5;=_?4"5S?.*JIT^[6J4\(0]_=.V2BF3@IF#"OIIA.
M\X'](EGA`&&<NH%`>"/WOG7WX<[>(R"M!^UW#-K?><(5*0E5&-?N^=FZ^VCG
MZ,"-VA(4JKA:D5_(X$HG5W^$FS)T;=8E4+%*73A!#5*DQR>'])R?Z-+?4FIH
MZTH%!Q2U).-9E;`(K:KPZ^W2^D(-456>/YRWJY4J[)QR_M;#)P>]@Z-62OC$
M1:GP?4V@="ZY?W%Z!'%3C:7CUW_[V\M@$QZDZ;>5O\.=PTTD\*@A@/VH8EYI
MOVY9:@S=NOMXY]'^:HZO@.EF>8)PJS3B\80<A%*?+@T0K!/&2U[10>8+S"0_
M#_2!DJ!<]G22$>O$H*>4X[Q">H+>K%E.\A1Y$D@;D%#JX:%!Z3Q2B.&Z7'V?
M4*D:=`[!>EB?A$HEC\I\6%8G9`W)3%3=+[I8NVZJNZKB'97(8(R"PU3KB5.9
M"YY1143K9U3?LO@\._'U!V=K4RD!5=\\-TST#20NLG6!2RAZ>!N>.("51FMI
MIH822F&M)"C](@""`P6AR!2G`PP3Z8?.:L\\YFX]1#J=RI.UQ4<N2#KD$&K?
M/BH,B?V'C1$6&HC<`U,=U__LF5PX.&WA3V$]B>K0;XAC0XT-E;N5?E>VRJ6M
M$>GRSXN+UNVI=%*]93K[2!V!=8M^$[YT\-M)=HQ#099FGSY/5Q-!$JI"@8QU
MW]]G]P:TH28^^5NF<$;L$?@2-4J`B)EY'Z\I]>DJ$/>+Y&8)Q^IP(P,@1WZX
MX"T%>\;4O3DUG9,S)A-$_<%W^^:-,YTM">'12=;29`<\#9WNQU>X7Y;;I.^E
M>A'`Q7Z6>PC-3+D&6O)8+SM8F.-/AH>2Y5=\32N]^6YW#W9VZP<OXC#.JC:L
M$B/\E+(FQ1Q>R;:W)V@C%D*Y*"5`2WM+`#5(B81<EZ_3^&[,J#'>NX(TB<C[
M\7HSZP#$%B7)0/"C%P>$LLCKU).IQL_2WX-<5XZ,HG0AJ(U9GU)DA"ZH23N7
M6\[GY=5-9.^X6L/U<@)&(+<11=DSW2"H6W*:W)$M9V2C=?"I#`)%78[*$.(Q
M]1U:U`CR56$:^C=]_-8P7)#`ZCAK&\$/>8#WX6']7G!RD0YO[:X,M<IZOB7.
M<8,>.N(8I`"<5:HONS@/FXF>;5R?EEG9DH>0Z_'V9!B.&*@'F\7\(SGMA=[,
M:#XFUGB(),:S6[)FYK!R+&+@>TQ=E2TL.'C["7]6[ZOKT>PB>_WZI!62GFN&
MO4I=/SN_91]JF98ZJK[Y+KFPV;%..N01IVGOEHYZ15-"#I?-;U`S>!Q-84-8
M:50Q7\(!74EPUX&Y4#8OB.S%6A5_3"<PMLLPX'E!UD]008LJ[',)?7K1]%P`
MLN@>F?%:S[W8_O"^H\IF"TH]5'[)BN7_L!QQV+"ZJ;P,R:3O-L0A,8T;<JV4
M=25Y$UD7G_5`6.&UFGG[2+&N^DM%5EI<Z(TNMQUUATDK#WJYI,<,06E@L'E@
M16`I-BORNA,?.F]6-**_0B^MT,;GE:D^=.P<$PH1C%'VJ`MC_KR^UJUU8ARN
MNO92(8-'@'!UNV_4T*'G?Y_!ZX*$$Z/-+*%K_F,BBCG2JTX4M!PAMKTC'LKN
MX6^;>Z'ZG.OUQLQPR1=]K?7]C5FO1PU%TM7$L1?H2!3UF#RG79T$QHJ`WA5K
M*8'C19*Y,O<Y8(PE_=U\=\T2!C+L#DVI^,H\VD5JI[*HK3W.U'WJ[>F][(69
MA%3V'^^XF\%^F*XC=P]\Y1]B/'6Z\RVWIMV-,'#PSG=;G^NJF*MTMK)3>#+N
M>M-!EQ\3R0KF9Q6OE`5O6H%JVK:.CGI'1X_"C0N(P@IU/VO;J(C46/[H8<N(
M9];=RZI>FJPLB-EJ*OWNO0=OK_VS1''<T'R:TD6!=Q\^V7F4K7J;"^X/F@O_
M2A>1/+=5048PUZ934$1?>??LU>G;^K$=3X@D;OG_N:XAEG#:/;Q<:?YQ>MO3
MTI"Q%4B\:TG_-'O<>VP_27`8,6G*<S'3.LF,ZP;_(H4,;2"%Z>#*[<<']#T:
MM5Z6F0ZR97YTRU$U&39M?A(U_<;MVC%9J3#680PW"D/8(*,O)061V\[M.A)[
M#1W3>/$T*,9'77K1/98E`Q];0.5U[`-\"^D?Q106:RD4M'>-7&`$BOP[H3+*
MYID0;Z`F>78(..5[H<Q*W3#F3B6+&8[#K<Y8%#B]NW7)T!%I4U;PECBD3D^4
M>\$F*"0TPU-GFY^M_DH)UV2>G2BL>KR]GWZO6Q.A^]Y5JP-JG`D-4T^:?_*[
M#SI=^#9D>CLVH#CY43^"TK[;ZFA>^GLA;9NC#?@/347VIHC*X)$Z<6&+`J]$
MY2Z>6N%"L]4^)N2B]R%Z97*Z@I8X?F9LO:4+`WURNZK_^9MC#@>$?*Y7]+AO
M#N_>DP.L05]7H8RT0&+6RVA1<K]'`,7*RC4'.U]72WIQ@CNL#XM7!.G*U/,0
MWN+J/%Q]HA!(N/?PL/I5&?Q_5YK1(CS:,[2&7_!&YZYMJL]#2B!>),=S_5D]
M2M65=]_K.YL2M35(W<&9#@OZZ9(OGUO<:8>.1W0PJ40F=)TJ]>DZ6%WG'&]#
M"(F.('0NJ\]4?/`S7>'6!.:K2&D4ZK`YF*);T#!437T/*22TB]"$Y7Q"R,0M
M$ZTXTO68+Y^-=RB%?R"GBTSJ';0HHPO.=)06&RKR,@^CA.3LR+A9);_NQ@:+
M.9#P05VCG2F-CV@*M6JH$XAJOCVQ]&$X7[A'7DPBDY.U'-.@\O:?W*[SODK%
MA53.NZ`03VJ%:)F=RG7FA4F:W,-S<-*>0H%1/?Q1O:KLR-=VM6I9U;S8HJQR
M8-FBUA[2XK%,N1@W7N;">O^9Y/IS2+M5R2J[%F!'D@$P@@4Q@8ZAO]>>AE5;
MI`#L0DJD-@CWV,FYLY!6/T)%:V=($T6*:</#MJA^O@H&,V7.<_:6S/K/A!\Q
M&71J/&UJWCJ9+2JR7V\%$=7*=CJ$=Z&ERTK^'DU%O;/ZU9@R\U%D]/-8J9K\
M-Z_=JLYL]B;C:H*FE!M-G.[9J8AF-*22<46!K)1,6S6%)?UA+($B^Z%:B_D&
M+?'6$SV^HN/OE;B+!;R&9&#I?WTFQUU"00[XD4S5I0AU*?N;YA`PJ@.;A\!V
ML!KKBD?<)#2%W6B%"<UC<ND>NZ/`8)-'%-S5E:4M[<MMJZTOR%OAF=@`[6HS
M=*A:%L"=])#OE6=74V@N86KJ4UAD1LJPL;0`?AOZ>@OAQ[)7;,1=%I2L?[K4
MW4V4M-C7E9QTV;`@F!*O8`0?'?XN@-8P7!JC+C:\B.W8+ZW51GC+VBGIYO%J
MI0QNS(36K_E"/2'"T.5S--4YA04Q5).(=K**DLY_HH(G&VW7)Z*O,'(BDHKZ
M]'LI^\'C4C"*AO3I"M9+?N2B_?.>/'>&C19N:24=48F4*=5K;K)YGFA-(@G1
M@"@8??4Q]#_+W#FS&BH5LAA1WB96J#@UVAI--X_XJ%N_ZV4G_Q"`%U*_DICN
MPK*4"]EA'?$LM1DMY7<2)0U/*T-[I@Q-FI(Y#==.G(&H8B"_%S&\(T5\,&??
MNW_531G7YIT@7I&>T6-)!<37"8@.M%GH1_#O,0JA>B`8'HNIH1Q1_3N#0$68
M19Q4IZ:\B@0G\H##7;&JHR7`HM=>V5BDC7O>(0TQ1'C-JJY@*(/S?L8$"&CO
M-\.*_H>-.#VW@$:A>F$:R'+WDB#J.$'2$HQI3GP9;<3O\W*O35#1"&M>+QSL
MGS_2&F&?IM#U8@?5&#ZB]:RBM9-77P>WF\U"N8[J^AE;+&/,T?'&3"B,IWSC
MQG-/$P'H$]Z&-VD0/?U;"HS0C2]A9P>,OTEK.7D$<0I%)#RK>N7I8[0,JDWN
M>J/&;Y0"]LH]M73>]<-13Y3S!5I^`*/KZS,?>]0_T\`[?8OPLV*H=[VZT%$I
M1B8]L3FUOQKBG"&TC,Y/)A&]@Q08#S8):@Y&M*-NX]>/$>O]!BS7UINWKTOR
MZ'I?KGX5][S^A8QGX?8@!\M.:C^4>';*RRUCE![7ZC&DYD&?`W&TY0M8C7Q#
MGTZF^MKFL?MAS@6UP/<J9YGJ065K-?*%W!SF0AU=14-BI^J'.L0)]B,-SI0N
M^>DF=A3P)GG^;_PNFK;TA@O2&+?<NCHP8^?$9PJ[/?\(?_"ZA0+V&V'FROB&
MB;`EOYK"$\#%Q=S7ECI3'`+0E4DD.R'8-``M8:\C&>GJGS@X>++#I06?136]
M(A*!"9?>A9KIA!U:]D+6E<><.6@U6B=#2(,7P5'U0"M*WO_T&?HH*JD45K>J
MNC=<AT[*\"$??@IGW&3KLN(T"5;9\]M'OZC2"C^*6!2P*HR:8^9<G1_U*KFP
MI@7Y-1#SZ\_H,UZ<DKD8YU\^4Y64!8P^P^&MKLVZH`_\J`3N0A0]@H3@B#G"
ME=,FE[@W:[2IMYF59QO$4%:H\@VR$_,)^,[_N$=&/4&6>74%R+D5I'HL86'W
M$NL?%I$8KEJR82RK@,';5E7\C,&:1<T(,](6SO.#W_%OHDVK1RWTEK?L`R7.
M$DR(M\!=A(TH^8)@MS:E!E.3AQT^3,&%"]H"^NX>]/8IHHL"=Q\][!U0,&?#
M2[U>Y8JHRCRILU4COI9?SS9]&3W;\D^DMZK47['$N6X0MMMN>'B*9_I<JBGV
M?/_?>T`C%??H[%)FO]+[$>DN+]6(]R=[3/?'Z%IMMK4!/J59/2?=@V&L.4$"
M+0_//\0;?##L?]RDK@APM$F7?@IN3,[-VGQI?US5:WNZ:4O@1MB8_8IM<AMM
M&.H045=<"UT=M=J-UK[-&4-Y=7M]*02;_<!9MO6<M-EPA.NS]?[L>7;W']$$
MMRVUF_WHVD)>R.JF`,MZ$`X8`M+OSNSA)?=Z-AHWE)$L*9Z.Q4RZIXJ=BU\O
M2F9CDU]$CL3_+'JWX;A^S<,KS0IWV7X+:^VG4E(PCTF%U3]K5,=%N/??_LB2
M3NA2"RV(8O1F?ZT>Z$S!.ED3[*R>]0TXX]+!"HYKXZ[CF9D-B;E2R][&JWO[
M:YDU=-;>I/BS%G!4WQI<14SUZUZOP1:LTKA_JI]LW)+G)M]&3]VTV.3=BCLU
MZV>]UF4115W^I31WOR;%S;U#=Y<D._(=3:T!1VY`^OF+^%)*^F4;XR`_YO9T
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MN5S+<[HMQJEU]3`+_2B58*WF_617,E)F25?N]Q7!TVU.#CYM>D^H<FI72D7L
M(;Y16X=KCE=ZY-9@XA5=H^Z'3$LRG)_L.;LS]=^H7SGOD5=Q/XL`MN?6F&"5
MI$M^E2#%^O&,Y%*X1)-^&8,X$8A52W<Z\KCJ0*O[SJP7F%:QN;*CZ817C3L?
MZ[TB7G^\(*T+]_1];.-:C8SG75K.!3.AT).TI"GW$V)-YE!2)2_E9[0A<WAT
M74F;13H==PEN)Z$A/ORN;8H=&M-W,G^?_V'ZI6WG&JU#BU<ZY$6X25`==QK=
M-6A<)LA\MW^ZQ+V#%<[E9FNK+7[5TB_Y$2/UVRU=TG("9[6,P8:[N/L9?J/#
MUAE6.<BN8.-!"&]A^<9XQ^.M^X7'`5Z]=EY54HT,V"5JGZRVNM$]A<P"<5\`
M#SWHM_.,E0C3I7ZDJV:\'*<?E^8>IY]Z/7JK0T=-Q?7Y>3E1MRF=<'5KSRUM
M>"OV?7:;/UOI^5;_XXH5.QH5TY&Q%EO;NYI.#+W]2=]6.JQ)2U<Z3L?4*LRE
M%?P-O'38::C56`Y]1;O4K]5ZGVY>P_AM:M9*RRO5ZE>O'H(P2V01RJCD8C>,
MVBJ[MCZM_N>5<WYH=F(:PI<J'ZZX#9=BRU<=]9M@GJ38)U*H/G0TJ#>:$Y#=
MU?-0(\V)LVQ@L@<>%7Y6HV$IW;9>Q10(SA_+6!M2.M),2_B2U+?L;CH&PV`O
M6:2?MW=9WX*4SC_N:'/]JIX?%7RL)$4&GS-473R\9[@N4],47W?+IU+%%M78
M"/_+'_A;W?G=N%Q?3<?YLQZ87E3$I@'<5^^CHO/J52-';W.OCN(R7IVO@J:(
M=ETY?XU`4J3?ABF=IWQB6N]OC5$!7;=-6U_$E6@3-I6TTU&K*\0-E-95P9YE
MJ+ZA#KL*X7'%T64)OF'Q5<>:6>';6F=67`=[J<IE5>GT;8:A5&'3Z[4?E.7B
MZ?\5````__\#`%!+`P04``8`"````"$`'X:P$VH,```_<@``#0```'AL+W-T
M>6QE<RYX;6S476V/XL@1_AXI_\'R)E%.RBQ@S`!SPYP69IRLM)F<;B=*I%P4
M&3`SSOB%&+,[<U'^>ZK:;]7XK6T,/7OH=L#054\]55U=W6[;US^\N([RQ0IV
MMN_-U,'[OJI8WLI?V][C3/WK@W$Q495=:'IKT_$]:Z:^6COUAYM?_^IZ%[XZ
MUN<GRPH5$.'M9NI3&&ZO>KW=ZLERS=U[?VMY\,W&#UPSA(_!8V^W#2QSO<-&
MKM/3^OW+GFO:GAI)N')7(D)<,WC>;R]6OKLU0WMI.W;XRF2IBKNZ^OCH^8&Y
M=`#JRT`W5XEL]B$GWK57@;_S-^%[$-?S-QM[9>513GO3'DBZN?;VKN&&.V7E
M[[UPIFKI(27ZYN-ZIEZJ2F3RPE\#B-_]9^^'W_\F^O/N#^_>]?_UW??_^,E:
M__/GW^>_^_D[M9>H(3+!!]4RW_<KQ<+7D>1>;,'-]<;WB"$ZT(1L73U[_E?/
MP.\@&,`\_-G-]>X7Y8OIP)$!PEOYCA\H(7@9[&-'/-.UHE\L3,=>!C;^;&.Z
MMO,:'=;P``N,^'>N#6["@[U(PWGU+!%-8M,$87`V#?$(M<D%DTP\6&V3^>\"
MFSA=HWI=Q_#'Z6)65-O5F:Y\7.0X/$97ZBNB)WA<SE3#@!PRZ/>15NJP$RF;
M+OJ@[VS*+D=GLVQH#(UQIY9QL9CW&RH<&EU26:/0^#"^/1N=W2LKLRY.P^?J
M`=CANF71AJY;T;_'!K[.$2=G'M!.XS$FE4OZK.MEN?'!=JV=<F]]57[R7=-#
M8NF@QG[-C<E<X'4OGG-_]^*+(JO8T4<1DZ\ACJ4]`3Y&#W7D4.;7'3C<=IRT
MB!WJ6.;!D9MKJ*=#*_`,^*#$[Q]>MU#D>5#Z(XY>]+N:7S\&YNM`8Z6.6(.=
M[]AK1/&X8*5E/+0O+N^,Q1W32Y")HB@1:AB+\0F$WLVGB^Z1+J;3KH5J!KPZ
M%OIAA*^.A1KPWZ(S3N,^KW<%,I6GA#9.!?OOQ]/I=#*XG$PF4WTXT'5&\C*.
M:-M;6R\6S@X[HRF/8`0(IL/)]%(#('U]PE2=%<$0`(Q'H\EH,-5T^)\EP=,C
MZ)K3D2K;JP2!)*\2!)*\RF8CO0XR?]Q38&%&<E\E""1YE2"0Y%56SW3HU;%T
MKQ($DKQ*$$CR*JM_._0J+'A*[JL$@22O$@22O-I9\1EGX*ETKQ($DKQ*$)S;
MJ\FT:G%W9[`5E7QE5EX?LYD<S!V7?K"&LT7)*9#!&.9MT;&;:\?:A#!+#.S'
M)_P;^EOX=^F'(9Q;N;E>V^:C[YD.O.TE+9*_%2WA[!.<:)JIX9.]>@9EW%PX
MPANI.)6&-!/I6.'K8[T_UD?:932)ZDBU:ZWMO9NW+M5=&"M`(W);;SCAT$N5
MQ.&0+;#UT`NQ^P1;,%<S3PLV@)A(0D*P11<V9HO-HC:2%F(VD@:"-I(6HC9"
MURGJ7`F3:W\/)SX/'6P8DWX_6M<3U5,MD``OB)AB$*1-GL_:)@6,UK9I:BOD
MEUS?F&OX8FL&!9;6M,C;6=.@P,J:%J(V\G&3>)<3GBXG8'HN0'+`-_?S=C!`
M4=0PP7.0!+,UDTZS_($AW6@1-*&`UY,8G<"IL;4`3DV+=IY.X-382N!`;#0K
M%Q(5-?B[4"%NA2"H*E+C2@D*KY7E.)^Q%/K[)JV^8)'QYOIE0W:*P/8=W$J!
M&U'P+:SDQV^C2BOZ`.R6-=)*&RGF=NN\WN_=I148;$\/4\&.XAF#[-.<E8C9
MYP^._>BY%ELF52,Q/P9^:*U"MN>(G?0IPS,LP3.(!8G@.48_;(PI)!%X$N;C
M&/VP#%>H'WB1JA^"2UA_E_&`NZOBH`87T*"NPM,E`EAL21"`$V0@P-U@,0<0
MGC(0P"0V00`!FB$`.!51<4P_&)!L!C&0J03]IU().2:QDE-Y0BO+TB_HK[#2
MX-+O4323?`N!GM$,'RH`'*6R+,7*2C'$[=#3,@K@0P4%!HRZW0QY@[*<+XT0
MDG0!0\8(I($J1KJ+2I)S06<&H)J1>8=U"`D*3$6R(0`<*1"((P:2QE]8<4S3
M\D#2"$RC0=(03"%P8_`9^P3U!#="2L(`>*3T"A*0W(AQ1AH(!%D9DD2#)BM%
M4@RR<F3F"DU6BB009&5(Z@E9*9)BD)4CB2MDI4@"`1B1DB&I)V2E2(I!5H[,
M7#&4E2()!%D9DGAB>.(4V:/+IM$B*ED_';=;/U5>-K4+J8.R21/X/6D>S9ZB
MF2/X@LVER%0:K[\SD[53Y<D/[%]@DHG7X:U@,=4*5+QN,[17],C7P-P^6"\P
M%8W.^+ULRM=Z`4FROG$8C#S"4DR9?EA85Y4FRCOGYP@LQQ-1:SF;U-<NS!]$
M!K^X71LAM2!P<4<V!N0ZQM!Y"'341;#GRJ8)!DGI&*BK8,`4RQ4&,(?)IR:;
MU<8J58YDQ`O><)@K8/A$=0+EB$-(]RF2I`8\BFD_@>6=*R_JGDWB`*=3A6S@
MBEQ5(,SCA<#:J#P6X8!$ZO!PYE6%T&!KI8WPX8846@'D1F`%MS9$G1'W=%15
M`M35I\!=ZV4R,C7@L'A\Y+M""V;9QIV&U<P9'7\DO$XR*.TH1P=BB?.K@8KX
MOC0E4_AOC4Y1/"*LY1.C"&VMTN61L/FL`_<9.4CH(KCYKGY2*[`JB$O$;V!4
M(L4;SW/-N,D3*M2;CDX&A%DZ$G#)(!\>?,X7=GWMN'16-&VRDE`6:-6;A$EL
M`[N$5SXZZ]S,AZ<PWK9./P`'S(M7=,+@3D8F,"X.M[2K-^&.%I5<]ZV!4JJ<
M<A/E&0JG9;G+(1O`F8HJEEJY,5FLHV";%.0<PK;<255.'=>*C;*)7ULV3@8(
M-T6\N0`Z2%PU,=XRJU)*16M!<%]:1<$8M8G760[PPIF[*DK/B/?;'VQ/FI./
M=#N7YW"]O,KKK3)Q"X`8HL<M_S7)O`-2J7-TP(<J-DJ'S$;*R1J&5.5\_Z\Q
MG>_^I430]"0^1V$W,:Q<.:-S%!YW?N[-3U)XX,+Q7.O1DB15!^[M3K#/3C&-
ME18I@^+MI!]1/&>*73@%5I5O6L8N-4246+%PSN']%L.Y^TS7*<DY>,TY%DK/
MHJ`!3U(]EG:YNB0LG'8[#%TN)^0!BK`J'W:K#G=2V"+AD`MA?DCN-#S%$E<.
MD8C[SYA^S\5JQ7I.='>WJM.7I=T_QVX+?U<@B^YZE$,FYOG<-/SM>OZDL\8*
M?NNWL)4B.\E*7HN1"7?";X0FD(*A65O_OX$>&]TQ(]<OSH5,>(F1;LH3WXPF
MTD^%1I($9[9S,3E2ZV0L&Y+B1SC"BH&70JT'`6LT"8@W3Q_;"`Q;?\F-%/C;
M**0;A16\638\W*/_6^5"^;!"GZ0GT'"!9KFW';@Y'>X`QDW<J_T.[L$TCP[&
MVVZK9*4KQ!J,$U06#`A-98&$:)JFX<9^@@N6<IK*2L>C(5A+9,$])AK+2A?O
MAO".RH*RL2FNM-(<\MR/!+G7B_S(+E`B?(')(KBHK,R/P!RQ$4UN*BOS(SB.
MR@*3F\K*_`@(B2P=E#25E?D1O$!E0;@UE97Z40?'$5DC0>XO"_W(QRI>32""
MB\K*_,C'ZE`P5JFLS(]\K*+)37%E?@2IA"\=OF@J*_,CGR=TP3Q!;<S\R',_
M$N3^,*/R$:\)1GPD)?,=O",<X6*G"$>1E,QK?)0/!:,\DI+YBX]O73"^(RF9
MIT`>L4B'+\0M2GTTY-G5!=F=F^MD9.$#!L<9$1CP&*C5WH''<_GX<"]VM0SN
MYB`&X;8I(4E/UNI96<#-CU)!?'_`851$T-W+UC$],_2#5P6OD$G%\4X?"8K[
MH^^G'/$2-/@H`NA/\"@T>,J:`KS$@SA'$%943<2D?8&G!R^7;R(&6D=H^/C#
M*783,=`Z$L,G5:R?1,1\]+;[U$-\+L6A6T3$)]M[MM9\Y/!90@.0(I+NK7T8
MF&G\\5U*$R3F'F^9E<K@4T3TV)/D_EYQ_7D/=\A*2,2)"ND[6/V+`/_+/B0T
M8BLB!*?.(D(>[!#N*9ET8DX$PA(2X<-5:ZF(@XPB*.-O9N!A;^&Z[D&,EEB4
M70,(U?_Z);M]&N,]Q(<%LANKI?,!(&IM;<R]$SZD7\[4[/V?V=U:(9CB7_UH
M?_%#)F*F9N\_X6UPH1?#7A](-Y]V<&M5^*OL`WNF_O=N/I[>WAG:Q:0_GUSH
M0VMT,1W-;R]&^F)^>VM,^UI_\3^@#)^L>`6/YCOBR87L"8MP%>!`O]HY\'S#
M(#8V!O\Y.S93R8<(/KOW)<"&"P@2(WJ[],F/-_\'``#__P,`4$L#!!0`!@`(
M````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;
M-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7
M`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA
M0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD
M$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T
M]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;
M`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG
M6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&M
MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3Q
MS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5
MJEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;
M^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;G
MUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M
M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQ
MC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=
M8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"
M2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$
M'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<
M?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O
M<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3
MJ2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^K
MT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.
M'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI
M:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?7
M85;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&Q
MMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[
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MX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0U
MG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO
M]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_
M7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`
MB\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX
M@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C
M:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`
MY+<<S=*MOP```/__`P!02P,$%``&``@````A`-*J\E&5`@``>08``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&ULC)5=;]L@%(;O)^T_(.YK_)'4:12G
M:E)EJ[1*T[2/:X*QC6J,!>3KW^]@&M=)MB@WCC$O+\\Y'$YFCWM9HRW71J@F
MPU$08L0;IG+1E!G^]7-U-\'(6-KDM%8-S_"!&_PX__QIME/ZS52<6P0.C<EP
M96T[)<2PBDMJ`M7R!F8*I26U,-0E,:WF-.\6R9K$87A/)!4-]@Y3?8N'*@K!
M^+-B&\D;ZTTTKZD%?E.)UAS=)+O%3E+]MFGOF)(M6*Q%+>RA,\5(LNE+V2A-
MUS7$O8]&E!V]N\&%O11,*Z,*&X`=\:"7,3^0!P).\UDN(`*7=J1YD>&G:+H<
M8S*?=?GY+?C.#-Z1J=3NBQ;Y-]%P2#8<DSN`M5)O3OJ2NT^PF%RL7G4'\%VC
MG!=T4]L?:O>5B[*R<-IC",C%-<T/S]PP2"C8!'&'P50-`/!$4KC*@(30??>[
M$[FM,IS<!^,T3"*0HS4W=B6<)49L8ZR2?[PH<E"]2?QND@#]^_PX&,7C='*#
M"_%$78#/U-+Y3*L=@J*!/4U+70E&4W!VD8V`R7/TL?XO5,!S)D_.)<,I1K#<
MP/%LYTD:SL@6<LK>-0NO@6>O2>-3R?)2$O4*`L`]->1B2/WO<SC".;&#<\ET
MM`O_84AR#G)-<0("*1N"'--W'<@MRC#LT6<B23\"]8Q>,QIH1GTJ.L7RFN*$
M$4R&C-?9G!C*<[!O<GY,"Z^YQG9-<<(&I78[FQ.?YRTYS<K":R:^!N/Q61%"
MDW`6?CH=)>''O,?R+<#?$,EUR9>\K@UB:N.N=P2V_=>^\SS%7?/H)^#FM[3D
MKU27HC&HY@4L#8,4]M:^=_B!56UW_];*PIWO7BMH\1Q*-`Q`7"AECP/7G?H_
MC?E?````__\#`%!+`P04``8`"````"$`TX1(GHP"```4!P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6R4E5^/HC`4Q=\WV>_0]'U`0%").!EGXNXD
MN\EFLW^>:RG22"EIJ\Y\^[VE:A`-Z[R(U=/3WSVW+?/'-U&A/5.:RSK#@3?"
MB-54YKS>9/CWK]7#%"-M2)V32M8LP^],X\?%YT_S@U1;73)F$#C4.L.E,4WJ
M^YJ63!#MR8;5\$\AE2`&AFKCZT8QDK>31.6'HU'B"\)K[!Q2=8^'+`I.V8ND
M.\%JXTP4JX@!?EWR1I_<!+W'3A"UW34/5(H&+-:\XN:]-<5(T/1U4TM%UA74
M_1:,"3UYMX,K>\&IDEH6Q@,[WX%>USSS9SXX+>8YAPIL[$BQ(L-/0?J<8'\Q
M;_/YP]E!=[XC7<K#%\7S;[QF$#:TR39@+>762E]S^Q-,]J]FK]H&_%`H9P79
M5>:G/'QE?%,:Z'8,!=FZTOS]A6D*@8*-%\;6B<H*`.`3"6YW!@1"WMKG@>>F
MS'"4>/%D%`4@1VNFS8I;2XSH3ALI_CI1<+1R)N'1!)Y'DR#VQF$\F7[$)3JZ
MP//D$GKA-`[BY/\LOJNKC>F%&+*8*WE`L/6`7#?$;N0@!6>;3P0IW\X'@K%S
MGNRD=BJH-?1TOXB2:.[OH1'TJ%E>:\)D?*EY/FEL!X'G#`5!=:&&8:RX#]-;
M:'E+$_=@AC47?!!4E^^^T.RD#,,JG="22X:ETXP[FEXEST.*"T8PZ3(.9VC%
MT/C.NE$RZ;$YS1#;D.*"#8[._6Q6W,]MVF-SFB$VIYBYS3KS@K/!!5CR$3`K
M[H/-SK[M25DZS7%9K]=NN/BLPVULQ^4N-G=B&[)AWXG:\%JCBA6PC4;>!.I2
M[EIS`R.;]C"LI8'KJ/U:PMN'P;$=>2`NI#2G@3UVY_?9XA\```#__P,`4$L#
M!!0`!@`(````(0#X5FXUGP,``%(,```8````>&PO=V]R:W-H965T<R]S:&5E
M=#$N>&ULE)?;CJ,X$(;O1]IW0+X?P.0<A8P:6KT[TJPTFCU=.^`D5@-F;:?3
M_?9;Q@2PZ>S0-TD(?_[Z7.4RE=V7U[+P7JB0C%<QPGZ(/%IE/&?5*49__?GT
M>8T\J4B5DX)7-$9O5*(O^U\^[:Y</,LSI<H#ATK&Z*Q4O0T"F9UI2:3/:UK!
MG2,7)5%P*4Z!K`4E>?.CL@BB,%P&)6$5,@Y;,<6#'X\LHX\\NY2T4L9$T((H
MX)=G5LN;6YE-L2N)>+[4GS->UF!Q8`53;XTI\LIL^_54<4$.!:S[%<])=O-N
M+D;V)<L$E_RH?+`+#.AXS9M@$X#3?I<S6(%.NR?H,48/>)OB.0KVNR9!?S-Z
ME8//GCSSZZ^"Y=]812';4"=%#G_0@F:*YE`YY.F*'#A_UC_]"E^%$$0V`AU$
M_GL+\Q#I*$$79OCY%O*I*=MWX>7T2"Z%^L&OOU%V.BN(M(`TZ&QL\[='*C,H
M`\3RHX5VS7@!%O#JE4SO)T@C>35T+%?G&,V6_F(5SC#(O0.5ZHEI2^1E%ZEX
M^8\1X=;*F$2M";Q?S?UHYJ]PN)FMIIO,6A-X;TUPY,^CQ6H]`24PRVHR]D@4
MV>\$OWJP7P%<UD3O?KP%Y_?3`OG0V@<MCM$*"A<C";5YV8>[X`6RG[6*Q"C@
MM5-@6Y'>%+J`P-"!0&ZF@VBQ!M'UTF2)^6(8-W+BCA6S3F&!0!:F@V@Q;(G!
M>MV,&,5\H)AW<1OV]/\4%AF83"?3XAC!JKM*+.RXB5$,R9:V(ATK>G:+#';Q
M=#(MMLE6=MS$*(9D:UN1CA5WR)8?(=-BFVQCQTV,8DB&G8*G8\D=-.BCZ4G3
M8AL-.YV5&,FBZ<LY7D<NF+D_9+\#IA^8D\\$+7;`G-9+C&08&/>]9WI@++G#
MMOD(FQ8[;+VM.3B,Q&)S^B0=2WH3JPLP/-*F)ZY1.W1.`R:MQL)SFB5]1W./
M3Y^]DPN+S4D]/$&PTX9)J['XG)9)W]'<X]-G](!//ZMGD-.?/)3,R3[D=+=^
M@HUFR-DSF!W82I9-^^#U8A-MEOUR[3KK$WO`^1,^<[Y;?&[KXO$S('*Z*'U'
MTZ_!YH-U?H!/J^U]&#GMF<!8IS7#_$5]\#:!8TTO,7QF8C/S1TG%B::T**27
M\8N>P#"DOONV&RG;6:^[`<-934[T=R).K))>08_PT]#7@Y0PXYVY4+QNIIL#
M5S"6-1_/,+M3F!9"'\1'SM7M0L\BW;^!_7\```#__P,`4$L#!!0`!@`(````
M(0`,-**=R0(``'T'```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)15
M76^;,!1]G[3_8/F]$$@@:112M67=*FW2-.WCV3$F6,48V4[3_OM=VX$&VJ79
M"\;VN8=SCZ\OJZLG4:-'IC2738:C8((1:Z@L>+/-\*^?=Q<+C+0A34%JV;`,
M/S.-K]8?/ZSV4CWHBC&#@*'1&:Z,:9=AJ&G%!-&!;%D#.Z54@AB8JFVH6\5(
MX8)$'<:321H*PAOL&9;J'`Y9EIRR7-*=8(WQ)(K5Q(!^7?%6=VR"GD,GB'K8
MM1=4BA8H-KSFYMF18B3H\G[;2$4V->3]%,T([;C=Y!6]X%1)+4L3`%WHA;[.
M^3*\#(%IO2HX9&!M1XJ5&;Z.EGF"P_7*^?.;L[T^>D>ZDOO/BA=?></`;#@F
M>P`;*1\L]+ZP2Q`<OHJ^<P?P7:&"E617FQ]R_X7Q;67@M!-(R.:U+)YSIBD8
M"C1![&1068,`>"+!;66`(>3)C7M>F"K#TS1(YI-I!'"T8=K<<4N)$=UI(\4?
M#XJLJ)XD/I#`>"")DF`6)_/%_[!,#RPP=BQ`>*:$V2$8QCXXB!=)E*3O)Q)Z
M4YS'.3%DO5)RCZ!N(6W=$GL+HB4P=^9Z*WJ[_^4V.&1)KBU+AN<8@9$:*N1Q
M':?35?@(QTH/F!N/@><19C;$W'88:[TESH\60E#<RP;;CF6_70N=.@NVZCK6
M&[^07CJELVB>CG5XP$#K4&G^!B+M(0.I<-CG2[5@*-"!24G/ZSRY\1@XK-[(
ML?QW$?DIQ$`]?.9\]1:<8;"F5Q:G+ZYX]1XS<]9'P5AYM_O",$+DIQ`#Y7"Y
MCY7;RIY"\SE=*C9HG,%\Y+_'^.*)/EV,!-Z>WH9.:;_P1K07[]N@OZ*"J2V[
M976M$94[V^(BL*U?[;OO=>P::+\!W:\E6_:-J"UO-*I9":&38`Z?5KY_^HF1
MK6L`&VF@[[G7"GYS#"[>)`!P*:7I)K9#]S_.]5\```#__P,`4$L#!!0`!@`(
M````(0!KG5J8'P<``&\=```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;*Q976^C.!1]7VG_`^)]DIBO)"C):!(^I5UIM9K=?::$)*A)B("V,_]^K[$-
MMB^=IIUY*<WQ]<'G^MH^P.KSM\O9>"[JIJRN:Y-,9J917/-J7UZ/:_.?K]&G
MA6DT;7;=9^?J6JS-[T5C?M[\_MOJI:H?FU-1M`8P7)NU>6K;FS^=-OFIN&3-
MI+H55V@Y5/4E:^%G?9PVM[K(]EVGRWEJS6;>])*55Y,Q^/4]'-7A4.9%4.5/
ME^+:,I*Z.&<MC+\YE;=&L%WR>^@N6?WX=/N45Y<;4#R4Y[+]WI&:QB7WT^.U
MJK.',^C^1IPL%]S=#T1_*?.Z:JI#.P&Z*1LHUKR<+J?`M%GM2U!`TV[4Q6%M
M?B%^:A%SNEEU"?JW+%X:Z7^C.54O<5WN_RBO!60;YHG.P$-5/=+0=$\AZ#Q%
MO:-N!OZJC7UQR)[.[=_52U*4QU,+T^V"(BK,WW\/BB:'C`+-Q'(I4UZ=80#P
MU[B4M#0@(]FW[OI2[MO3VK2]B3N?V03"C8>B::.24II&_M2TU>4_%M0IZDDL
M3@)70>*\F\3A)'#E)&2R<%W'6\SO'PE$=G+@RDG>KV;..>#Z\8'`^NH&`M?W
M#F3*IJB;\2!KL\VJKEX,6$8P"<TMHXN2^$O3$%/-)J:?_-?F'B:=DGRA+&L3
MQ,&T-E"PSQO+FZVFSU!D.8_9XABB1NQ$!*TH2AOH0*@#D0[$.I#H0"H!4TA"
MGPDHM%^0"<I",R$T;`4@I4:3+2)$ET`'0AV(="#6@40'4@E09-N_1#9E@64N
M%X#EJ3JW+,:!M=A7B:.&[/J0/A<("1$2(21&2(*05$:4C,``?T$A4!985)#V
M7JWE:16_94$_3$D?TJ<$(2%"(H3$"$D0DLJ(DA+8^N24C!\$8C.@P9UR,>(M
M0QRO7Q4[A`0("1$2(21&2(*05$845=Y[5-%@515#9%4("1`2(B1"2(R0!"&I
MC"BJ8!>^?ZYHL*J*(38[U^DNO./(,'L!1^#2US9Q+74MAWV0*(,((3%"$H2D
M'.ENKPBE=A,=71-ZL+>G,G_<5C`XV.Q'BM6&(XH=7)1#U<\063]')/T,H69F
MT.^XFOX^J->/D!@A"4)2AMA8/QS7/ZV?<JCZ.6(/:Y4C3H\$#+$7[*2?$5N3
MWK?WTCDR<,1]3.<69D0["I*^77"D#"$=AU((!!RNG(F1&8>Y$E/>1:N:.61+
MHD74``4<\H:E$6(HPAUC')5@*%4ZJOJH99$J_0U]S.#`R2,RMR4<@CVC+]BY
M5J\[$31XEX!#MGR($5>;J5!TY.6PM"Q/*XA(A`S<\5W<B>@H2FVQG"W48DM%
M2,>MYHUZ'BEOS-R^<X>@)[BV1#AD0=D-Z=3<SD[TDPN(4;GS;MW`P]!<K_J0
M]X(0,7D1)HJ'*+IXB.O:MN8LDB%$$*4*D9HHZH5^.E',4,%=Q!VWA$-RW5F.
M-M2=B!HT!QRRY0R/%!ZC=^EV_KQQR'PYGZO%$6'N^"[NA$=Q;MMS+'NI<J<*
MMYI/:J1^D,^OU>VUHTG>J)@=4Q+*(&6CXE%RG3'(&:`0=DU:Q1(4<0A4B/F*
M<52"H53IJ.JF5DO2_<9&Q8R9HH]!\NE+7SS`R-GYQQ\+.03.H%]_1-]S0M%Q
M**L(0S&&$@RE`L*',*$^3)+\L3V&F3DE$PQ2,L$AR8AT=U^;;SB1(4K,=(2A
M&$,)AE(.C=@10HW:3V>"N3TE$QP:ZG37W0I6T&`G`@Z][DF&@"$)C-D>:.(A
MZA5;,@0(FI1#;#3J>J#>34K)&^N!.3U%.S=_LG8>-4`!89!B3!`4\2AEO:.H
M!'.E2D=5'[5D]^OC!DX^(#@$E=VO9&Q,>-"PD`/"H+>,">_(S(.[<.:V]I`2
M<2*80C&=\5W<B>C(N&W;=6S-]*0BI.-6\D:=@YRW#VT:'8GJ8SGT8V,B^DD%
MQ"%N3"R7./K+FW`($8F*,%$\1'7+Q_661,MX,H0(HE0A4A.E.=^/)0H;8FO$
M$&-C(J*&X@@X](8QX5'</"QLC[B::XTP=WP7=Z)RNTO+UI\\Z;>!SK)*A<?>
M];,WOY>B/A:[XGQNC+QZHN_Q81UM5CW,/C)L71_>G,`<Z;CGP[L'C,,NY(>P
M5>"6&%KHOH);`FOFT\K"+5!)/BT5W`(?/[YT.X@^+O@HTGU!T'$+/I:,\&QM
M'UX!CO`[P#]*Y/CP@@QWV!+7W\*QB%MVT+(;;0F@A?H,W"<@'K2,L8$)`85C
M+7#X0>J[V=;$PWD&;&,M\#0+?<82#(^KT&>L)2`6]!E+)CR10)^QEH`XT&<L
M;^`VH<]8RW;N;\?*93?W=V-X`")'-4+=C<6G<Q_>JHSD?NF'RQ$\7OKP.@+B
MIWUZX7/7+3L6?V;UL;PVQKDXP#*:=8^6-?M@QGZTW.D_5"U\Z.I,_PD^;!;P
M7FTV`1M[J*I6_*`WZ#^5;OX'``#__P,`4$L#!!0`!@`(````(0#!U&`\G0(`
M`-@&```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)1576^;,!1]G[3_
M8/F]&$B3M"BD2E=UF[1)T[2/9\=<P"K&R'::]M_O&B>,I-U$7Q"^')]S[O7U
M977SI!KR",9*W>8TB6)*H!6ZD&V5TY\_[B^N*+&.MP5O=`LY?09+;];OWZWV
MVCS8&L`19&AM3FOGNHPQ*VI0W$:Z@Q:_E-HH[G!I*F8[`[SH-ZF&I7&\8(K+
ME@:&S$SAT&4I!=QIL5/0ND!BH.$._=M:=O;(IL04.L7-PZZ[$%IU2+&5C73/
M/2DE2F2?JU8;OFTP[Z?DDHLC=[]X0:^D,-KJTD5(QX+1ESE?LVN&3.M5(3$#
M7W9BH,SI)LENKRA;K_KZ_)*PMZ-W8FN]_VAD\46V@,7&8_('L-7ZP4,_%SZ$
MF]F+W??]`7PSI("2[QKW7>\_@:QJAZ<]QX1\7EGQ?`=68$&1)DKGGDGH!@W@
MDRCI.P,+PI]RFJ*P+%R=T]DBFB_C68)PL@7K[J6GI$3LK-/J=P`EO:G`U5N[
MXXZO5T;O"1XWHFW'??,D&1(?/06&P>6_3*([3[+Q+#E=4H+Z%@O[N$Z3V8H]
M8C7$`7,;,/@<,,F`8.AFL(0VQI9>+\]1V8.]LB^7MW(;`F.9]'69V5MD/+BO
M_&`^32X'WJ`<,)>C!/\B3A)$R/0$/1A/>L2:)O,SY8"9H(Q],EW9@[$ML*"C
MI!=GT@$T07KQ%FD/[J6'8SU$\-*-S"P',R?UQ3Z<GJ4'GTH=(N'>C!O3S^&S
MNS*+%]$2:_#_)O4;3S4.D9,V3:[.T@F3)%Q7!::"#]`TE@B]\U,BQ7LV1(<!
MMDG]53B/S[--/]C8\`$'2\<K^,I-)5M+&BB1,NYS,6$TA873'3K'\:(=CI3^
MM<8_".!5BR-,O-3:'1<HS(9_TOH/````__\#`%!+`P04``8`"````"$`BN(O
MC#T%``":$P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLF%V/JD@0
MAN\WV?]`N#\B7RI$/1E%/I+=9+/9CVL&6R4CM@%FG/GW6TW3V-W%3CR[<S.,
MC]6OU%L%7;#\_EZ=C3=2-R6]K$Q[,C4-<BGHOKP<5^:??\3?%J;1M/EEGY_I
MA:S,#]*8W]<__[2\T?JE.1'2&J!P:5;FJ6VOH64UQ8E4>3.A5W*!;PZTKO(6
M/M9'J[G6)-]WBZJSY4RG,ZO*RXO)%<+Z$0UZ.)0%B6CQ6I%+RT5J<LY;./_F
M5%X;H585C\A5>?WR>OU6T.H*$L_EN6P_.E'3J(HP.UYHG3^?(>]WV\L+H=U]
M0/)56=2TH8=V`G(6/U&<<V`%%BBME_L2,F"V&S4YK,PG.\QLU[36R\Z@OTIR
M:Z3_C>9$;TE=[G\I+P3<ACJQ"CQ3^L)"LSU#L-A"J^.N`K_5QIX<\M=S^SN]
MI:0\GEHHMP\9L<3"_4=$F@(<!9F)XS.E@I[A!."O496L-<"1_+T[WLI]>X+_
MYA//\><+&^*-9]*T<<DT3:-X;5I:_=U']5I<Q>E5X-BK.-.)[4UG/Z#A]1IP
M%!H39^';?B?RR8_#:78IP+%?N)`R^&3AO%\(QWZA/5GXOC=;S!]/'2ZD[M?A
MV(O,)OY\ZCY@G\5KT94VRMM\O:SIS8#K!<QNKCF[^NPP,`U14Y[*4.5_*S)4
MEXD\,965"<E!^1KHS+>U,UTLK3?HIJ*/V>`86XW8B@C6.DPVTL%.![$.$AVD
M.L@D8($)@Q/04%_@!%-A3H@<-@)(UFAIBPBQ)-+!3@>Q#A(=I#K()*"D[7Y)
MVDQE9<+?3QJ`QWAPT0U!GF;%$#)X@<@.D1B1!)$4D4PFBB-P@E_0"$P%+BJP
M?<@67Q,\Z%-+AI#!$D1VB,2()(BDB&0R42R!>Y1LR?@=7]P,6'"7N3CC#2<>
M'"0O`JWV0Y!8%B&R0R1&)$$D1223B9+H[$<29<%JHIQXL^'RWR(2(;)#)$8D
M021%)).)DA7<F!\O'PM6L^($LI+*9T^U\@U!0_D0V2$2(Y(@DB*2R41)E(V:
MTF[V>9^R8#513N3R(1(ALD,D1B1!)$4DDXF2%>S+CV?%@M6L.''Y2,;VU6U/
M[FT:]02,E:Y05RWQ;@@2)8Z14#+$R$+:;3X=@H10)@LIN=LPILK)\P%EPJ:F
M]E06+QL*)PQ;^DBI71A$^O&$B:BF=+JP8TFN""39TB,8+?E,8^N6W`-$*C&6
M2>Y1O8QNR#U`R&2*C&H)FV`>[G*;SSNP$0GIC4#J!8VFL7[A?9:)^H6NO*G9
MOI;,KH^:,?]A$'07@:=IQ^(,[MK)0]JIINU[MNNK79HIVJIQ;`:2C/MOO<0'
M*<5/CASH,NGJF:GGM66C`&O"[@FMGV\Y\N>=4_`0XSBHP8804;X8"R4]$D)V
M@&Q)[R%"*%.$5*?8</2_G>(3%OR*^,4-)-]YH':>HSO51]V[(^H7NK+%(YW'
M%_J\\]QY8,^TYHS%&=RUDX>TTSYJT':=N;8%LH?O+KM.F_O)'Z;Y$U=%ZB/9
MDO.Y,0KZRAZ4H6/6RP'SI_C-+(2-'!S3^3R$?6^$+T+8.3#/`G@;T#W0:T*1
M[80[7A3M&VBCD/4)%H-7"T]C?,->.8S$;YP0'CBPSL8-8>[&_,D+G\`]_,7&
M"V$J'>%^"$/<"`_"S6C6VR#<CGX1!2%L;%@ILJ=@TYB!<1"RFSQ>D@0A;&TC
M'*12OL(:+(<W(]?\2'[-ZV-Y:8PS.4!#3+N-K>;O5OB'EEZ[#>Z9MO!*I/OW
M!._`".SCTPGL@@=*6_$!?MH:WJJM_P$``/__`P!02P,$%``&``@````A`/A]
MX8E"!0``01,``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RLF-N.HS@0
MAN]7VG=`W$\(!$A`249-"`=I5EJM=G:O:>(DJ`..@#Z]_98Q)MC%1)G5W#2=
M+^4?ZJ]R;+/^^E%>M#=2-P6M-KHYF^L:J7)Z**K31O_^=_1EI6M-FU6'[$(K
MLM$_2:-_W?[^V_J=UB_-F9!6`X6JV>CGMKWZAM'D9U)FS8Q>207?'&E=9BU\
MK$]&<ZU)=N@&E1?#FL]=H\R*2N<*?OV(!CT>BYR$-'\M2=5RD9I<LA:>OSD7
MUT:HE?DC<F56O[Q>O^2TO(+$<W$IVL].5-?*W$]/%:VSYPOD_6':62ZTNP](
MOBSRFC;TV,Y`SN`/BG/V#,\`I>WZ4$`&S':M)L>-_F3ZJ;G0C>VZ,^B?@KPW
MH_^UYDS?X[HX?"LJ`FY#G5@%GBE]8:'I@2$8;*#145>!/VOM0([9ZZ7]B[XG
MI#B=6RBW`QFQQ/S#9TB:'!P%F9GE,*6<7N`!X*]6%JPUP)'L8Z-;<./BT)XW
M^L*=.<OYPH1P[9DT;50P25W+7YN6EO_R(+.7XB)V+P+77L2:62O'=%PF<F<@
M?-O=':[]P-7,MISEJKO[G8'+?B!<^X'F;.4XMKM:/O[8,`>ZN\.U%WDX=8/;
MV%4ES-ILNZ[INP:M#D8UUXQ-'-/W=$V4@Z<R%.A']8'",)$GIK+1(3FPOH&F
M>MO"M%H;;]`(>1\3X!A3CMB)"%9U)ANJ8*^"2`6Q"A(5I"-@@`F#$]!1O\`)
MIL*<$#D$`HRL4=(6$6)(J(*]"B(5Q"I(5)".@)3V`J>]@%D]/1]%O=D@F'EW
MZ\UC;)AC0U/82N9#R)`Z(GM$(D1B1!)$TC&1#(`'_`5U9RHPA\#E(5L\!7C0
M74N&D,$21/:(1(C$B"2(I&,B60(_26-+[O<""^XR%T\<<&+#9>2%.MF'(#$L
M1&2/2(1(C$B"2#HF4J+NSR3*@N5$.;'=8;;O$`D1V2,2(1(CDB"2CHF4%?P.
M/UX^%BQGQ0ED-2Z?I4S=(6@H'R)[1")$8D021-(QD1)EF\+1XG6_3UFPG"@G
MX_(A$B*R1R1")$8D020=$RDK6(8?SXH%RUEQXMJWIN1D<6O3L"=@[&B&+N02
M[X<@4>(("<5#S%A(^9E/AB`AE/:DV^!)N9NP](R3Y_N1&=LDM><B?PDH/#"L
MX!.E7L"^H]^-,!'9E$YWHX]=Z='8EA[!)I!O84S5DEN`2"7",O$MJI=1#;D%
M")E4R$Q8PC8L#W>YR;<WL!`)Z4`@>4([<K5W(NJV=0E[M!@O:J:C)+/OHUSF
M_]O67LT=13K"TO%#THDL[<[MA:7L*E-)6VXEMN,9^?;_6HEOFR0[.;*@R4:3
MQU7M[`=V1ZE^-\N1L^R,\E:N[<F#]FS[`(T+$:)X48_XD:S3B6]1S'#'77DK
M62>Y10B=5-*1?6([(\4GRV6GKY^9<GQ[!7<1=PS@D;M9*+?=4G[4G8BZI1SV
MB.U"!X,GVH[+.[SM3-M=SI7.C+!V_)!VTD?UVJYK6J9B,3LC=]EUS\W]Y&=>
M?KHJ27TB.W*Y-%I.7]EY%OIENQXP/VP'K@^K.#BF\J4/B]X$7_FP;&">>G!H
M[\[=BE!H6C[K*CP$NLAG?8*_@3<`3U,\8&\&)N(#RX?#!=8)%CYLNC%_LOTG
M<`]_$=@^;$DGN./##FZ">WXPF?7.\W>37X2>#ZL:5@K-.=@T96#D^>P7'@^)
M/1_6M0D.4@D?80S%@!<8U^Q$_LCJ4U$UVH4<H2'FW:I6\U<@_$-+K]WJ]DQ;
M>'71_7N&5U4$SL+S&<S'(Z6M^`"W-H:77]O_````__\#`%!+`P04``8`"```
M`"$`>R%\TFH.```/30``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*R<
M77,:.Q*&[[=J_P/%_3',%P8J]E;,?,]LU=;6V=UK@K%-Q1@7D.2<?[^MD312
MZU4FD).;$#_J?IEIM:26&/CPCS_VKZ.OV^-I=WB[&P<WT_%H^[8Y/.[>GN_&
M__D]_VT^'IW.Z[?']>OA;7LW_G-[&O_C_N]_^_#M</Q\>MENSR-2>#O=C5_.
MY_?E9'+:O&SWZ]/-X7W[1BU/A^-^?:8_C\^3T_MQNW[LG/:ODW`ZG4WVZ]W;
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M%%PA$BD1>M4BT4T<)K?S3F7@[6/E2:_*TWKW`3^ZP>[6Z56_8W`S3Y)X-K\E
M-N`Y4Y[TJCP3<[\#?K?*CUZONE(:K-V5TJOR"Z@[YTF0=-TT\(X+Y4FO^AXO
MC&I`J2@S0^2D[/;+XAKT.47_49XA=<[`908ZA<1_+KO0B4SD;ERDZ_/Z_L/Q
M\&U$DPV]Z>E]+::N8"GD](B0;]^/D>\-$1H;0N6CD+D;4T]1^I]H7'^]#VZG
M'R9?:2QNE,V#QX9;K+2%&'A"-G5!YH+<!84+2A=4+JA=T+B@M<"$`M='CP+V
M*Z(G9$3T]'T_:&#"&3JATA;:)75!YH+<!84+2A=4+JA=T+B@M0`+%<U4OR)4
M0N9N3/\.))JTB6D0]4:Q$[[>I(\?D`Q(#J0`4@*I@-1`&B"M35@@Z;9^12"%
M#`UZZJX^2#ADI=%@)'N3/I)`,B`YD`)(":0"4@-I@+0V89&D98M%TE\%Z"E.
M6'<!TS?Z($E,+U8(`R?3>B/ME@+)@.1`"B`ED`I(#:0!TMJ$Q8<6["OB(ZQY
M?"2)9_V\M@*2`LF`Y$`*("60"D@-I`'2VH0%@]:V*X(AK'DP)*%@V,GBSNJ]
M49\L0#(@.9`"2`FD`E(#:8"T-F'Q$5LDNY`8'DS"FL='$CM9@*1`,B`YD`)(
M":0"4@-I@+0V8<&@`I(%0U15(56]NJR[N*X20CQ.DCAY%#F33F_4YQ&0#$@.
MI`!2`JF`U$`:(*U-6.A$)<UB-YQ(G3F/D$)V*B%*$66(<D0%HA)1A:A&U"!J
M&>*1$57HY4-,;"R<W%%H1BW6BN761L:JSQY$&:(<48&H1%0AJA$UB%J&>+!$
M'7I%L&392N60ON<'41I1_&8&K1"EB#)$.:("48FH0E0C:A"U#/'(B,K2CLQ/
M3TZ!K%'IK4S0)'(R+'&F)^5(5MHQ190ARA$5B$I$%:(:48.H98C'4=25=AQ_
M,%'),I0%2R*688#2`%"&*$=4("H158AJ1`VBEB$>&5%17A$968"RR$CDI-',
M3:/>RJ01H$R<[XEQ;)(M1U0@*A%5B&I$#:*6(1XL47%>$2Q9H+)@2<32"%`:
M`,H0Y8@*1"6B"E&-J$'4,L0C(VK-*R(C2U,6F;Y:M=>[6S>->BN31H"R`%".
MJ$!4(JH0U8@:1"U#/%BB%KTB6+)T9<&RJ]GN^&T5`$H198AR1`6B$E&%J$;4
M(&H9XI$1I>85D9&5*8M,7ZS::31WTZBW,FD$*`L`Y8@*1"6B"E&-J$'4,L2"
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M"B$^L*,:,Z8:H8]AZ"X0RHC6<!-"Y4?K;.\7),Z&/-/JB^Z#M7`ZF]%'F7SD
MYRA>:+=!\5)9):S[8T>^0OGZ(OGF(OF6R?,N$]7[7^\RN0=@72:1D_9.Z%=B
MOA6'*';:*T>[KSU]IJP&^PS$"_5^X:!XJ:U8SV*?@7RM'0?E&VTU*-\J*QD:
MWF=BJS'49[\?WK^W5))J/U?)'0OK-(7XQ.X>+XAY7W2:/=`DBKO'0[JE.%-6
M%LK1L4"K$E&%CC5:-8A:YLB#2'W$@OB#B5V8TSV;R?A!)!&AA)WVS9V1O5)6
M+,.5%G/$64E:B:7)S%UN$N8H7V@T*%\JJV'Y2FN9\5EK-"C?:/F@FU/C:+ZX
M=>;K5@MUVKQO:&1<TS?"W.D;B=B"$<S=G6FH'.U$EBBAA>/[4<^4(UGII29'
MK<)8#6B5QDIK5:A5:RLQ?+_>S^(D<FZF,19:IV4Z/,)BFS0TA5Q6;<O-%AL4
M$CF#PNGZ5:@<35JE"B5LZG'3/3-6^B9SU"J,U6#@U:6:ST\KU*JUUFT7>'H6
M;3%S:K?&F.B+:ID0BWSD[@!_JD;J5'C*:\0".'=V,"MM9:6\0N+%I#Q,1\J*
MGAZTK-S^R5&^N$B^O$B^0OGZ(OE&RXN=HA@^<0S3$=/F7493W>!@N6R]C82,
MTV<2V9MY966A%%&&*$=4("H158AJ1`VBEB$>,7>+^=.?@42X^U2((F1EXL+9
M7J^,E1Z4*:(,48ZH0%0BJA#5B!I$+4,\CM?M/B/<?2IDI=,*48HH0Y0C*A"5
MB"I$-:(&4<L0CXS8V=D+V'#Y%LF-H+U2*>2DD7.RLC)6)HW4IM*L&QE:Y8@*
M1"6B"E&-J$'4,L2#)78J5P1+;6RL6C>2B*41H!2M,D0YH@)1B:A"5"-J$+4,
M\<B(?<L5D1'FSA2N$)^-W+.P2%G9RZY$8O`/+;O*<?[=A2MGVOSNQ!;"OKMN
M&IZ)9^]]QZC6WC!26Q0[!23BE=W"J856VM&J[!1*J-PR-[IP3@(R8Z4'6JZU
M^$[#;+#XO8K"W;W7(+GR_#A2.P+[OB7B6XF%NR?6CG8'2\?9M.NZ:!I,8V>1
MRI07F9B;5E?0"?$[%/7J7[]#57K;=R@1/ZI9F#C+#ZOHT+;+?;MGE2-EANE9
MK!RE52)3.$["(''V+CG39C=-QP?#-WU9[=7)\(&KD#VE(4H198AR1`6B$E&%
MJ$;4(&H9XA'[4;5ZT=8NQF)5(Y,`*XW,/CA52$PQ)B=NG6U(9JSZQ$>MPEA9
M6O!!BK'26A5JU<;*UG*6^\98::V6:?%(NU7N<`U"!_GNXJ&0.*4RP5HXHV.E
M':VY12'[@Q1$.3H6:%4BJM"Q1JL&4<L<>;"N*V5C+&45XM/4W%V`M*/)TE0A
MNC;=J1FB'!T+M"H15>A8HU6#J&6./%AN=?M3AP3B>P5.M:(06\S@@Q3M9^>;
MJGEI<3*)"C.]5I>'\DD4+6ZGMTXVYZA>:+]!]5)9_>"3%)2O+Y)O+I)OF3SO
M,U$/_^7E67S;P>TSB9R\=^JGE7:T\UXY#B_/RI%.K,31R/<Z35V642^TWZ!Z
MJ:U8U[K'1A5>?*T=!^4;;34HWS)YWFFBO![JM`O+"U6EFQGF0>PK14>RJ7WN
MEHW:RAYJTI$6>#-;`<K1L5#(<BP15>A8HU6#J&6./(C41X-!O*SB$"I.B281
MWW+$[F&RF,R$H\G-5*$?'"8;*QWI'+4*8V5-?6X&E\9*:U6H56LK>9CL*X4;
M8Z*%6B;$(T]Y_PLB+U2<R"O$L]>IXE:QLK*S5R)QF#JT4$BK'QPFHWRAT+!\
MJ:R&Y2N4KR^2;[2\/$SV]6++M'F7B=W0+YAQU&[,GG$DHG&J,V<5`TH198AR
M1`6B$E&%J$;4(&H98A$3"SY$[*>^[=,I\4172$QN)E\7[A1CK'1H4T09HAQ1
M@:A$5"&J$36(6H9X'-V-X?!V1<RZSJR@D)UAB%)$&:(<48&H1%0AJA$UB%J&
M>&2NV\B)><6-C$1.&KGSI7*TXI<BRA#EB`I$):(*48VH021^)43<H[Q4&2SY
MJQ_RUPWVV^/S=K5]?3V--H<OXA<]9F)-Z['\N9&')-2_-^*V1/%2'%C3<(*6
MA%JZ'P=Q6^+I4IQ[>'SB!;5T#Q6Z/@GYT)#P^"3BMU"Z+RVX/L%\*9YW]O@$
M]#[T<*^G):3WH0K=TQ+1^]`G9;X6B@X=__I:(FKIZAFX-O*1GV)`"_G(&@A:
M*-;T;1+/^P04:_KJA*]E1BW=2@)JM]32K?AN"[EX/<C!:T]A]D:9@NR-<4`Q
MIJ_O^:Z68DS?5<,6J@27&=5/V$)UW5)4;=A"5=I2E&'80C^?\]';7^+M/?8/
MU%E>>]&]'ON/\?(C#3Q\XP?J06\'4O_YNH^./.BV?6]!9QITV[X6.K2@V_:U
MI/&,U'Q=2WL.4O.UT*:"U'PM:41=0D?[>)=I-*<67TK0J2)=@2_$=$9(5^!K
MH1,_N@)?2QJ'I.:+,QV/D9JOA<Z_2,W7DH9TU?2D#=X//0"T%(_W8`L]SK,4
M#^Q@"ST'0VJ^]*>G6DC-UT+/J)":KX6>(28U7Y_20\*DYFNAIX!)S=>2AI0'
M=%:)5TV/\9&:KX6>TR,U7PL]<D]JOOZA!^A)S=="C\.3FJ^%'BTG-5__T+/C
MI.9KH8?#2:UKF?1S&?T<U?OZ>?O/]?%Y]W8:O6Z?:'&;=A\C'>4/6LD_SNH9
MRT^',_T2%165]-L^],-C6_I9G:GX(OK3X7#6?U#`)OU/F=W_'P``__\#`%!+
M`P04``8`"````"$`C[0;`ZL/```650``&````'AL+W=O<FMS:&5E=',O<VAE
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MSC]5UW9:GU]^_#`DZ+^KY?=M]M]GV\?U=[U9W?]C];*D;%.=7`4^K]=?G:F]
M=XB<+\%;#17XU^;L?OFP^/:T^_?ZNUFNOCSNJ-PM1>0"N[[_LUMN[RBCU,W%
MN'4]W:V?Z`3H_\^>5VYH4$86?]R<C^G`J_O=X\UY/;EHIZ.Z(O.SS\OM3JU<
ME^=G=]^VN_7S_[Q1%;KRG=2A$_H;.AG7%U4SFK@^#O@UP8_^1K_Q,7[4ZW#2
M]#?Z51?-N)W.AK,^<,1)\*2_P;.ZNIBU;3.930^?ZS1XTM_@V5Q,J]%5_88?
M3;3A7.GOB>=Z%3SI;_"L#Y[JI2_M,%*ZQ6[Q\<-F_?V,IA\5;_NZ<).YNJ;.
MXA#Q:=H/FA^-&1HLKI-/KI>;<PJ?AL.6!OKO'RG9'RY_I\%Y%VQN"S;<8AXM
MW$ATW782]!(H";0$1@*;@4M*PCX3-,K_@DRX7EPF8@RW$:34C$78T2*Z=!+T
M$B@)M`1&`IL!%C;-2QEV32M->8V(]79.M!H<K+>W:6C^[@=%(R+?F^Q#!](#
M44`T$`/$YH0E@$Y0)L`MDB?.`-<+S2'*\CY:G`+>Z&!*]B;[E`#I@2@@&H@!
M8G/"4D+AYRDY/!:<\1!Y/.-;3QKZD^5B(FJ_-XIN'9`>B`*B@1@@-B<L4%KJ
MCP_4&?-`/6DF^]D^!](!Z8$H(!J(`6)SPJ*B=3B/RJWIX_:"DG#BF';]\(`]
MH8#SRDY%9?=&^\H"Z8$H(!J(`6)SPG+@-&QV73L\A)TQ#]23O+)`.B`]$`5$
M`S%`;$Y85'2%/CXJ9\RC\D1,S)DHW]YH7SX@/1`%1`,Q0&Q.6*`578*.CW2P
MYJ$&E%<048>H1Z00:40&D66(Q^=42#8^WSU'*R]GZ,(3RW4;D)BE5Z+,R2HZ
M=HAZ1`J11F00689X-IPXR;)Q>+:ZBZP8V`&Q:GNK#'5HU2-2B#0B@\@RQ.-S
MXB.+SU6[GKF;KE.7Y,K+&#I4K-IM0+S<]4B6.^B?=*WJDF/LJT>D$&E$!I%E
MB*?#"8\L'6^4V\L4%G)0+BF8>06H0]0C4H@T(H/(,L3C<WKC^/B\.F'Q><07
MZKJ2)=U;Q?IU3KC2U"#'B'I$"I%&9!!9AGC(3HP<'[*7+BSD7,T,=W_S"E"'
MJ$>D$&E$!I%EB,?GA$86WT_,8"]96.Q[%9/)JEK>)E9[JUC;#E&/2"'2B`PB
MRQ!/AU,H63K>F,%>S["0<XD3R@VHJP#UB!0BC<@@L@SQ^)PP.3X^+V-8?'ME
MDY>TEC-X;Y5*"JBO`"E$&I%!9!EB(8]/4ER#-5=<`647W#FB#E&/2"'2B`PB
MRQ"/[Z]27&-47`&)2[#<[4A6^VHCZA$I1!J10609XMDX27&-47$%Q*J-B@NM
M>D0*D49D$%F&>'Q"<1U>H,:HJ@(2)15[FO-DE4H*0JM'*X5((S*(+$,\Y)-4
MU1A554"LI*BJT*I'I!!I1`:198C'Y[3-T6NRT];B)B$@H:KDOE2R2B5%5856
M"I%&9!!9AGC()ZFJ,:JJ@%A)456A58]((=*(#"++$(^OH*I:6EY/W*<:HZ0*
M2$Q?N5.5K%*M067U:*40:40&D66(Y\)IG>.'MU=&N>08@UB:(^H0]8@4(HW(
M(+(,\?B<BLGB>[^"'GL]Q&(/$HG&=MIRKN7.5G#,9D.'J$>D$&E$!I%EB*7#
M/6/)TW'X`C58<[D54!;,'%&'J$>D$&E$!I%EB,<GY-8;\:&FJCT2J[7<Q4I6
M^QF,J$>D$&E$!I%EB(=\DJ:J45,%Q$J*F@JM>D0*D49D$%F&>'Q"4[D9_([5
MND:Q%1!?K1NYA96L4JU1;*&50J01&426(9Z+D\16C6(K(%9K%%MHU2-2B#0B
M@\@RQ.,38LO5^EW/D&K480&):LO=K625JAUT6-KVZ]%*(=*(#"++$,_&23JL
M1AT6$*LVZC"TZA$I1!J10609XO$)'?;&8HURJPZJB0J4KK^-W,%*5JFD>\>(
M>K12B#0B@\@RQ$,^26[5*+<"8B4%!=:A58]((=*(#"++$(^O(+<F]45Z(>GH
M=WMJE%L!B1DL=[>25:QMAZA'I!!I1`:198BEHSE);@W67&X%E)<;48>H1Z00
M:40&D66(QR?DUKO7ZP:56$"BVG)W*UGMJXVH1Z00:40&D66(9^,D)=:@$@N(
M51N5&%KUB!0BC<@@L@SQ^`I*K&J'R;U[7-U]O5W3*DR%+*SC-;V=Y]_9:U"'
M132\D^IWY2-J]D^4NH#<MD6VV(NML3Y9Q?&@$&G6/8]1*"PWHD^/$867>_O*
M;0SE,0:4QQA0.[S,.!Y58G'K8S?)1T6T]Q%31$>#P8<'ZY1-=G-<*!RE>U\Y
MKX/R&V!WF^2BRF^`6WG]C4;I[<0NHMD0YVQ&[ZS*%S?[:)/<5$1T:<B&@-A*
MT]%J<.3QGB2HW,HC]O("<MO]V0G(_9WHF&K=1<?*%W8V'8W%-D&/7BIZT1J0
M'0[B#><Y'(['>Y+`:E!@1937MVK$F<^C5:I4%]'!2O71*CFJB/S(H+>U1V*&
MZVA1**\05^^;NZBY&H]$U>6>0+#*9G@7'=WJ1^\FUTTUE8_3>W13PFW:CJJQ
MN"O5S(T7O2#!3E_!4'TU`;&QT(KSFD>K5-(N(-IB'[(P:NK9:"86J1[]E/"C
M%^EI./!'F9JYL32T0GK)P?#;^O5'%ZMLS1MZ(;OLQ9>`:&[&*\P<48>H1Z00
M:40&D66(QRTDV>$UW6VDB#4N(+?VI$6GE??)R2IFH4/4(U*(-"*#R#+$0SY)
M=[6HNP)B)47=A58](H5((S*(+$,\/J&[WB@I"JS6(]IIB,6:1Y1&<1<170:R
MPHNK>9^L8E\*D49D$-F(AI/@(3LAE"D3.7N/DIIM4%/YY/6(92*@/!,>O2$U
M0_=DE3*Q=XQ(HY5!9`.BO1)RY)D0&NU]F4#IU@:41,H\HB0NNX#HAM^MW05!
MF@QBQ`J[T<DJ=".6?Y,,8C>6=<-3X@1/-CC>F`_.6BSA'KDGA-E(%UI[W@;'
M[%(6$-WPQ]/L$2ETU&AE$%GFR$,62NY]HP`%7NL1DS8S<9&=!Z-<V40_OE:(
MJO;1BO13EF?1O8K=TZ4HLY(J-_9U\(@F6O$C"H%NWSHB3[U3?]EHDZD_4DAX
M#<F$A$=B%$IQW0;'?!1Z1-LR:10"4NBH`\H<#2++''DJ"M)R/!E>*#Y^`Z!%
M:1D0&X55*P5V=$PK5A<0;<FX=:6MFBOAU">+F"N%_>ADY?J9C>A_5^+"9Y)-
M[,FRGEBF)B7U2;]BI2'N=DKBF#D^:T.'?!6+B*UB$RG(HU4V?@)R3U&S"2<G
M;[1BTW(B=*"*5NP6M963-UH=/**)5OR(H@XV6OWHB+P.3M_^].2=N%Y$\CVB
M1W5Q-,RC54)=0+3=%*UZ1`H=-5H91)8Y\KB=?,WB/GR)G'BQFR].`>5"*:),
M*$7$%N6)N)#VR2IF02'2B`PB&Q$*I8E0R7*=/DHR#IV(2J-X#E9>K0T;EEU`
M;TC&9)4RX;O/5*1&*X/(!E20C!.G0K/BOR\37LJR,1%0&LWSX5"4KTPR!O1C
MR9@,4A)\S_1@."*=K'X@&9-!]+$!^;/A\T&HZ#?F`\KEB4?B8BU&^CQ8T1OL
M\9RZ@'+)B$BAHT8K@\@R1QZRDZ\_/0J"!LYNH28>L8LU2,9@E$O&Z,?6BA:N
M.J%WTC/IVC015BIVSZX4>-4)?1T\HHGGQ8\H1*I]ZX@\]73$0ZF/E_\W1J'K
M1:Q%'HE1*"7C)#CFH]"C3/GUP2I#"ATU6AE$ECGR5#AA*D;AR9)QXM4M6XL\
M8J,0)6-T3"M6%U"0C/21C8DH=9\LXB16V(].5FY]:D;39EJ+86J23>S)LIYX
MI@KBNOHIR8A">Q(038QL=H%D#%;Y^/'H+<D8K-BTG`@QJ,))N#>^TDG@Y#WF
MB";VQ8\H[_>BU8^.R.HP+4GW["GG<9-WZ(5/WH#R749$':(>D4*D$1E$EB$>
MMU.TV4P]O#A-G;6(SR/W^"W5=2(7I^!(5G%.=(AZ1`J11F00689XR">IY"FJ
MY(!82;U5ACJTZA$I1!J10609XO$5)/'LZCT_`*;O14&Y/:)`\W*+^^]Y<&3I
MV#O&$="CE4*D$1E$[M-6[E3]$7TZ_*>J_`>(GI>;+\OY\NEI>W:W_N8^0S4;
MT>[!'OMO9-U.1_21K&&#!5K<Y[.&CTU!RYA:!J4$+77\Y)9LJ:?7[G4QR@2T
MS*AE5FRYHI9A"U+Z-'36_H(.+736=,TK'*>ALZ9W/@HM-?G0>\>E%O*A];O4
M0I'ZFV)Y!G5#+8/`AY:66H;U`%HFU#+<ZLF6,?GX>R9H(1\22(5S&U.NZ9<0
MI1;*-?V&H-1"N:;7Z0LM->6:KH>%EHI\Z!>/A98Q^9!D*;50KNEW<Z46RC7]
MXJS40KFF'V:56BC7]+RUT%*1CU?E,F\5^?@[)VBA7--OL$N]4:[IY8]2"^7:
MWP9!;Y1K^@ELP8=<BM4AAZ(]I;F8Y8JR3-_`*!RAHBS3]R!*+91EKR_%^9)@
MO':2$'U(`EX[B8<M](6]3\6*N<,7[&]=B4O<3:8"_]1<?Z)E#@]\2S4LEITJ
M6"P@U:]4/MIFH8;2$;I)0^DH'8/NV"D=I1:Z!R:?TO'I)I=\2BW=9$H^I>%`
MMR3D4VJA[>!KM^&+>:$-WFNW@8LMM$5'QRD5A?;@Z#BEEEO*SFTQ.W-JF1=;
M.FIQ^UFE,ZBII9CKEO)&C\'0AQZH43REEJZ=D$^IIO0,BGQ*+5U+0YQV_4O'
MH2%>;*'7\:[=FW7H<]O6U[?T/!-;Z*'S];S80L^>Z3BEWKJ61E71AYX>TZ`N
M'>>VI06`WI#`,[AM:0;2BP2E%AKQ]`B>6B[W*P!]E?)U\67YS\7FR^IE>_:T
M?""Y,!I>>-SX[UKZ?^S"NR2?USOZ'B6I8OJB(7U_=$D?$QRY/?^']7H7_^$.
ML/^BZ<?_`P``__\#`%!+`P04``8`"````"$`]%\I[$H#``!M"P``&````'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;)Q6VXZ;,!!]K]1_0+POQ.0>)5EEN]JV
M4BM552_/#IA@+6!D.YO=O^^,35AN44A?DC`9G^,S-V9]_YJES@N3BHM\XQ)O
MY#HL#T7$\\/&_?WKZ6[A.DK3/**IR-G&?6/*O=]^_+`^"?FL$L:T`PBYVKB)
MUL7*]U68L(PJ3Q0LAW]B(3.JX5$>?%5(1B-S*$O]8#2:^1GEN6L15G((AHAC
M'K)'$1XSEFL+(EE*-=Q?);Q09[0L'`*74?E\+.Y"D14`L><IUV\&U'6R</7U
MD`M)]RGH?B43&IZQS4,'/N.A%$K$V@,XWUZTJWGI+WU`VJXC#@HP[(YD\<;=
MD=4#6;K^=FT"](>SDZK]=E0B3I\EC[[QG$&T(4^8@;T0S^CZ-4(3'/8[IY],
M!GY()V(Q/:;ZISA]8?R0:$CW%!2AL%7T]LA4"!$%&"^8(E(H4K@`?#H9Q]*`
MB-!7\WWBD4XV[GCJ+:;3R6PQ!Y@]4_J)(Z;KA$>E1?;7>I$2RZ($)0I\GU%F
MWG0^&A,@O0+BVQL9@8]4T^U:BI,#50.4JJ!8@V0%P/V*0`KZ[M!YX\Y=!^ZJ
M(`TO6T)F:_\%0A>6/@_6!S[??2H/'T@K9F`;SHS.R(RQQ:L\6$.=)NBG&=]"
M@\Z0G/KE.P*MSZ3F,^EG!I?A`M$9<@"RWN/6H;9.`ZBA'H93H[.AKH);6J!/
M:I>9]ZN<W4*%SDVJTF(JO5$>4&7#):!S$[>T-"4L^B7@F![<`^C<I"HM70G+
M)JZ9&L$"1\25/L.#38[24J]W0I;]<@B('J['>#?)SJ:N(H+=70L52@K&9NI=
MD61.MF@0#$P-4<'H@JB;Q@7V42N"9U./J-:(,'D:!1Z.YBOST,X"@*Y:AY2F
MIBAR0=1-(X)4,^*=K33UB,(>KF7JBI"RX^M"2E.C@X(+0Y;<-`6,=ZL6+LX!
MTAH$IN069$`7F9,MFG(L-+,SOI"=F^8"Z0Z&LZDG._\]&F#-Z51VWW`(VB\E
MN]S8=W_&Y(%]8FFJG%`<<7$)X&U>6:NE:F?JH6V?K'9VV?*K?V#9*>B!?:?R
MP'/EI"P&S)'I(&G7)?N@10$)@65%:-ARS,\$UEH&;_21!P47"Z'/#U#D?K4H
M;_\!``#__P,`4$L#!!0`!@`(````(0`ZS5'U>@4``%,6```8````>&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULG%C;CJ-&$'V/E']`O-MT-W?+]FI@-,E*B11%
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M*W]MVJK\%T%4AL(@3`9Q@;V\#F]-W^P@D2ZOQZS-MNNZ>K>@6>!1S243K4=7
M$/":$#Z^3_&K#"$U$>1!1-G8H6T!^0;*\K:-R=IY`R5S"4G&$*HCTBM"%`#8
M]10A.97B;:VO3`18,!':"VH)O@&Q>VK,>.X8$;H]1&,"`LUG(L!07^7!L9%Q
M@A!/@7C]@SOVZ11"HP9!YE,3X(T->?>:1+[^X`0A45?+!8O"F))(AZ0:)&(T
MH"3N(1HYZ&V5G&@RF-(OIN9:27&3H9]1N00AP*//P]1O"J%1#'2*TTTFP+I^
M\=`QV'8("3K]?.(9EU/U<D#]+W2#@5)UFR8EP`8I0XT$(4@J(O#3EPN[3;T>
MQOY7Y11NINR,:5H";-`R>PTA4JN8N9X!2%5`Y()>0RMJ18SO(2;`!K%`UR-!
M"!*+:4A-7NIU+Z#!H+=&BT*OSQ>L0^O$(K/Q)0:9+2AHQHS=DAJ0P/6&['1V
M8N\JY9PWG12WM;;>0D,^B9F:STF(3E.LZ?MIXG)75QT;A@U'E2)&BNE3#_[I
MF:0:A)%0F1R=I-C7]Y/$+:^2C(<.ER01@R1I`!N%#O7$Z:4JQ`]\I5UUDF)Q
M*R2GYY?BFM?(C11$S+4=&7R:82,)-4Q(HY#YP_[1"1I^\0."8Z.@2GVD?%-&
M(.6;@NC\[C(+.G8+2HQI321(*AB$G@%(=8`7N*Y/!E/1Z=UE&W3L&Y2,]HWJ
M#(M;]#3`-+V[[(/B[H?6[CV>*HG+ZB((.JP'C=IO"J++9[C(S'TXMA-*#!()
M50W#%09L-FHJ(;=3T7BRNURE0^NN0HGA9XD$7>?8O\%/0N;PN^$K'LS8]#0S
M]!5UW5!B;+I$@I"G%X>>&XP&1F+F$!7[7]F'\PK.Q%VFH*8#2A`2]9D?WR**
M@>80%0O^?J)H"[JBIKTPS3NH"Y*&ANJIAEE0&H$1^E_L(`;I_`^JXBY34]-L
MNM`;&S5EE,:!\LD&5[D.(03R\8=9U*=(;/W[-46OT#2E@YOA5A)?Z2$;67S7
MBSW"C,6::IB(QK`4ALVO$S5,9V:7HOEHZY,.3Y!$$72[`Z6B4Q"=I^$^,WG>
M<"%JB)4PU60"\:$W"(V)2R7F=BXZ4<.'9A)%']$K/PR!%!1!6'F7,!($(YZS
M_8@9?O2#_8D6HQ=\Z'W)#T&W19(%GX)H.HIO\NH$3?/KT,:(*Q]4D9\$X>E#
M$-^PH2D$LL,S/#SK*GE]X"D_G1HKKU[%^1R#+^;]N_W9X0,3YT;&^PF<*78'
M<$Y_`8[T+MF!_Y[5A^+<6">^AY!D&<+`UW@HB"_:ZM*=L#U7+1SF=7\>X?"6
MP[D460)X7U7M]84X]>J/@[?_`0``__\#`%!+`P04``8`"````"$`#@,)Y4`"
M```'!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R,E%N/VC`0A=\K
M]3]8?M\8)\`"(JP6$.U*K515O3P;QR$6<1S9YK+_OF,;4A!HQ4L2D^//Y\P,
MF;X<58WVPEBIFQS3I(>1:+@N9+/)\>]?JZ<11M:QIF"U;D2.WX7%+[//GZ8'
M;;:V$L(A(#0VQY5S[800RRNAF$UT*QIX4VJCF(.EV1#;&L&*L$G5).WUAD0Q
MV>!(F)A'&+HL)1=+S7=*-"Y"C*B9`_^VDJT]TQ1_!*>8V>[:)ZY5"XBUK*5[
M#U",%)^\;1IMV+J&W$?:9_S,#HL;O)+<:*M+EP".1*.WF<=D3(`TFQ82$OBR
M(R/*'+_2R2+#9#8-]?DCQ<%>/"-;Z<,7(XMOLA%0;&B3;\!:ZZV7OA7^)]A,
M;G:O0@-^&%2(DNUJ]U,?O@JYJ1QT>P"!?*Y)\;X4ED-!`9.D`T_BN@8#<$5*
M^LF`@K!CN!]DX:H<9\-D\-S+*,C16EBWDAZ)$=]9I]7?**(G5(2D)T@&[D_O
MTT<A)!H*^9;,L=G4Z`."F8$C;<O\!-()@'VP#,IS/Q@D\GM>_::P%=06FK&?
MI<-T2O9007[2S.]HKA6+.XIA)R'@KS,)R2]-?FS.BR$$1ITY2O]S0X!YU/0O
M-/WNY*!8?*2X\@8'/>[-BW,,[,Y;?W1]\#Q*1J&J-*5TG/7']%H#D^XQ)PT=
M9;2?C;).$^W%68Z];ME&?&=F(QN+:E'"X;WD&0;/Q$F."Z?;T-.U=C"!X;&"
M#XZ`AO<2$)=:N_/"_U>Z3]CL'P```/__`P!02P,$%``&``@````A`,@)7R?I
M`@``J`@``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULE%9;;YLP%'Z?
MM/]@^;T8R*4-"JG25=TJ;=(T[?+L@`E6`2/;:=I_OW,PH9"D+7WA<OC\?3XW
M'Y;73V5!'H4V4E4Q#3R?$E$E*I75-J9_?M]=7%%B+*]27JA*Q/19&'J]^OQI
MN5?ZP>1"6`(,E8EI;FT=,6:27)3<>*H6%7S)E"ZYA5>]9:;6@J?-HK)@H>_/
M6<EE11U#I,=PJ"R3B;A5R:X4E74D6A3<POY-+FMS8"N3,70EUP^[^B)190T4
M&UE(^]R04E(FT?VV4IIO"O#[*9CRY,#=O)S0ES+1RJC,>D#'W$9/?5ZP!0.F
MU3*5X`&&G6B1Q70=1#=!2-EJV03HKQ1[TWLF)E?[KUJFWV4E(-J0)\S`1JD'
MA-ZG:(+%[&3U79.!GYJD(N.[POY2^V]";G,+Z9Z!1^A8E#[?"I-`1('&"V?(
ME*@"-@!74DHL#8@(?VKN>YG:/*:3B1=,_3F@R488>R>1D9)D9ZPJ_SE,T#(Y
MCK#E@/N!8^[-+OU)\#X)<_MIW+OEEJ^66NT)U`Q(FIIC!081$)_W!QQ![!K!
M,;VD!/9J(`F/JS!8+-DC!"YI,3<.`]<.$W0(!J*=,JB-5T8P*F-D<2LWSM"7
M"<_+3#XB@^"8`G>W^3#T.UZG[##3'F;:(08.`F2\@PB&HNBQAL&LXW7*#C-"
M&6IJO#*"(?M#IU]RYJ0=:(3T_"/2"&ZDN[2V%NC/7@9>R2S4X7@O$3R4:BU-
MCPWRAF=VKR6:5@^OL*_?:0]<.-1H+8,R#2==6@>RBZ'LVYV(X*%4:SEU)X!@
MGO@SA2V]K=`L&TH<3$-W7JG^`%!]V7?4$'VDUIK.>(3-?Y2A<#XB05CDQRJM
M:>C32^>Y%+FYX`[.4NBM^"**PI!$[?#,#^$H[*S=/%HWX^C8/HO6;DZQ[@O,
MB9IOQ0^NM[(RI!`9</K>)=2;=I/&O5A50X1@7"@+(Z)YS.&/0,!QZ'L`SI2R
MAQ><9=T_QNH_````__\#`%!+`P04``8`"````"$`/9UY+*`"``!)!P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R455UOFS`4?9^T_V#YO1@(21<4
M4J6KNE7:I&G:Q[-C#%C!&-E.T_[[76/"0I-U](6/R_$Y]]QK7U8W3[)&CUP;
MH9H,1T&($6^8RD539OCGC_NK#Q@92YN<UJKA&7[F!M^LW[];'93>F8ISBX"A
M,1FNK&U30@RKN*0F4"UOX$NAM*067G5)3*LYS;M%LB9Q&"Z(I*+!GB'54SA4
M40C&[Q3;2]Y83Z)Y32WD;RK1FB.;9%/H)-6[?7O%E&R!8BMJ89\[4HPD2Q_*
M1FFZK<'W4Y10=N3N7L[HI6!:&578`.B(3_3<\Y(L"3"M5[D`!Z[L2/,BPYLH
MO5UBLEYU]?DE^,&</"-3J<,G+?(OHN%0;&B3:\!6J9V#/N0N!(O)V>K[K@'?
M-,IY0?>U_:X.G[DH*PO=GH,AYRO-G^^X85!0H`GBN6-BJH8$X(JD<#L#"D*?
MNOM!Y+:"IUD0)>$"T&C+C;T7CA$CMC=6R=\]IF?R'''/`?>>8[8(YM?A+/H_
M"?'Y=/;NJ*7KE58'!%L&)$U+W0:,4B"^[`>,..S&@3-\C1'D:J`'C^LXB5?D
M$0K'>LRMQ\!UP$0#@H#HH`QJTY4=V"F[RKI4;GW@5.9O(B.9V5MD'#C#<!V2
M/S?H,<D))KEL$"#3#3HP]`!LO2+M01.D85--EW;@3GHH;A^!4W*2S.RRR\5;
MI!QX+-5'HN[TG6X/V&73+3CPF+>/C"W\HU%N1D\^`PX\ENHCYQ:68]YN9BRA
MPZ\?,K=J+-!'1IL]F;]HAQ]=_FQ+KDO^D=>U04SMW5B*X;0.T6%B;F)7]I?Q
M)-UTDY0,'V"2M;3D7ZDN16-0S0N@#(-KV"?:ST+_8E4+F<-`4Q:&6/=8P2^+
MPX$-`P`72MGC"PB3X2>X_@,``/__`P!02P,$%``&``@````A`+C/Y[O?!```
M<Q$``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULK%C;CJLV%'VOU']`
MO)]P#P0E.9J$<)%.I:KJY9DA3H(&<`3,9.;ONVUC@FTZRE'G)4X6V\M>:V]\
MR?K[>UUI;ZCM2MQL=&MAZAIJ"GPLF_-&_^O/^%N@:UV?-\>\P@W:Z!^HT[]O
M?_UE?</M2W=!J->`H>DV^J7OKZ%A=,4%U7FWP%?4P),3;NN\AY_MV>BN+<J/
MM%-=&;9I+HTZ+QN=,83M(QSX="H+%.'BM49-STA:5.4]S+^[E->.L]7%(W1U
MWKZ\7K\5N+X"Q7-9E?T')=6UN@BS<X/;_+D"W>^6FQ><F_Y0Z.NR:'&'3_T"
MZ`PV457SRE@9P+1='TM00&S76G3:Z$]6F%F6;FS7U*"_2W3K)M^U[H)O25L>
M?Y0-`K<A3R0#SQB_D-#L2"#H;"B]8YJ!WUOMB$[Y:]7_@6\I*L^7'M+M@2(B
M+#Q^1*@KP%&@6=@>82IP!1.`3ZTN26F`(_D[;6_EL;]L=!M*XQEU?5P2*ETK
M7KL>U_^PAU3)V-D>.D/+.YL+RS67,-2C'.[``2WG6-B!9WF4Y)/!80@Z<VB'
MCL'"M3T_L,CHGW3TAX[0#AVM1>!Y[C+P'Y\VF$1'AW8@62X\WW3HX)_;9[`4
MT(Q&>9]OURV^:?":@-G=-2<OG16N=(VGDDD9D_M?N86D$I(GPK+101RDKX."
M?-O:7K`VWJ"(BB%FI\988L2>1Y"*(;21#!QD():!1`92&<@F@`$FC$Y`07V!
M$X2%.,$U[#@PL4:2S2-XET@&#C(0RT`B`ZD,9!-`D.U\B6S"LM'A\UX`IEP`
M+,:%EVX,<B4KQI#1"P4Y*$BL((F"I`J231'!$9C@%Q0"88&7"FP?U=K>2M2[
M8T&?6C*&C)8HR$%!8@5)%"15D&R*");`&C6U9'ZAYXL!":;*^8QW#'&7XUNQ
M5Y!(00X*$BM(HB"I@F131%"U_!E5)%A4Q9"I*@6)%.2@(+&")`J2*D@V1015
ML`H_GBL2+*IBB,/V;;(*[P?DGKUH0*"YU[;IB+5]&(-X&<0*43+&3(FD12$=
M@SA1-B42M),3IK*;+<@6VU_*XF6'8;ZP_L_4KP.[%MO+"(=H"4.FE@S(Q!*&
MP"F`;GZF);LQ/N<B8H4C&6,&#MF(\3GGR*8<@A&PE4^-F!%,I\H4DV!1\8!`
MC=T3;,G;]1!TW^LBACC3-<_R)!4'%K0DAL,QP0E6KD0<*\3)(\2I2.RYEN.)
M)9E-B06[+#@#3_UBQZ"?+!Q*(OHX0#;0WXTTE^*T]KRC,ZZ/T0!Y/G4)CK>V
M+5?4/8270ZP2)?<H8K=EK117TGL()\H$(M$I<GSZOZ\87$[DBN.06'*V[-30
M<5)S0T=G:K%:=$.4QZK.\5?64JK+F,_@SIT\Q)W*W([MF^*\R6V,"J;<S$]V
MNV)G\1JU9[1'5=5I!7XE-R<K@,2/,+O6[98AK/J0(PG/_!`6`A6'(@H/D$GU
M"51%2-*N/H&KXY,]@^_(E7(.MT,X6:H\.R>$`Y:*/[GA$YBA/MBY(1P_9G`O
MA`U\!O?#W9SHO1_NY_#(#V%'4GFB(#S,Q<=^""NT&I_X(6Q(,W@0IC3>&+,#
M5]YK?D:_Y>VY;#JM0B=(K$D7E99=FMF/'E\AX7!YQ3U<>NG7"_RY@6#O-1>P
M=9TP[OD/&-@8_R[9_@L``/__`P!02P,$%``&``@````A`*984Y[<!```(Q$`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK%C9CJ,X%'T?:?X!\=YA
M7V(E:840%FE&&HVZ9YXIXB2H`$=`;7\_UQ@(MIE22NJ7HCB^/OB<>[UE\_V]
M*I57W+0%J;>JL=)5!=<Y.17U9:O^_!%]\U6E[;+ZE)6DQEOU`[?J]]WOOVW>
M2//<7C'N%&"HVZUZ[;H;TK0VO^(J:U?DAFMH.9.FRCIX;2Y:>VMP=NH[5:5F
MZKJK55E1JXP!-8]PD/.YR'%(\I<*UQTC:7"9=3#^]EK<VI&MRA^AJ[+F^>7V
M+2?5#2B>BK+H/GI25:ERE%YJTF1/)>A^-^PL'[G[%XF^*O*&M.3<K8!.8P.5
M-:^UM09,N\VI``74=J7!YZVZ-U!J&*JVV_0&_5/@MW;VO])>R5O<%*<_BAJ#
MVY`GFH$G0IYI:'JB$'36I-Y1GX&_&N6$S]E+V?U-WA)<7*X=I-L!1508.GV$
MN,W!4:!9F0YERDD)`X"_2E70T@!'LO>M:L*'BU-WW:J6NW(\W3(@7'G";1<5
ME%)5\I>V(]6_+*A7-)'8`PD\!Q)S9?J.X;B4Y)..T-I_'9Y#1W]EFX[G]U__
MI*,W=(3GT-%8^8YCN[[W^+!A#O1?A^=`\K!TC=G89R7,NFRW:<B;`J4.1K6W
MC$X<`ZU594P'DS(EZ/_R`XFA)'O*LE5!'%C?0E&][DS'W6BO4`CY$!/(,08?
M<1@C:-8I;2@"1Q&(1"`6@40$TAF@@0F3$U!1O\`)RD*=&#4$(S"S1I`]1HQ=
M0A$XBD`D`K$()"*0S@!.MB7+MF!6+\_',=^T$\R\>;YUG9<5L!@;YMA4%#8?
M<IA")ND2<I202$)B"4DD))TCG`$PP%^0=\H"<PA<GM3"NL#K#5C0IY9,(9,E
M$G*4D$A"8@E))"2=(YPEL"3-+?F\%FAPKWP<<<`0VYTFP4%"0@DY2D@D(;&$
M)!*2SA%.E?L553285\60N2H)"27D*"&1A,02DDA(.D<X5;#H/IXK&LRK8HAK
MWW/%$.N>O7!`X'&O;=WB:_LX!8UE$$E$\10S)Q(6A60*&HG2`>F/`YQV>BB4
M-J\5W5&[:Y$_!P3&"\O]0OU:L$FQK8MR\)8P9&X)0^:6,`1."_U>IQNB&U/[
M*"*2..(I9N`0C9C:1XYTX)"-@)U[;L2"X'ZH3#$-YA4/"-38+,$.G^##$'3?
MVD*&6/,USW`$%4<6Y%+#7W>VKSL";R3QQH_P)AROJ]N6*6Q`Z9R8*QL#]K>Y
M7>S0\\6ZZ4EX&P?(!/J9C\(YZ#!VM*8I%PZ0X_4FK7W77O/F'^\18S%$,D]\
MCZ)F.ZZ_]GF>Y!XQ\J0<#^\3/2H)\\MTZ;G\"_,++A-BN8T07V_"9GD8HV8%
M-T#T?#(9+%?<$.6PDC-LU].%HHQD[O@A[H3G=EW#-`2+Z>VI%]R/F_G);D/L
MW%WAYH(/N"Q;)2<O]*9C^)#V"6;7L,!%L.1#C@0\]1"L`C(.)81HD<@M4!2(
MIEUN@:O>WES``WH%7,)-!*=(F2>P$)RN9'QOHSV8(3<$-H*SQP+N(-B]%W`/
M!4NB#QXZ+.&AAV`[DGE"'QV7XB,/P?(LQ\<>@MUH`?=1TL=K4W;@BGK++OC/
MK+D4=:N4^`R)U?LEI6&77/;2D1LD'"ZJI(/+:?_O%7Z,P'#;T5<PK\Z$=.,+
M?%B;?M[8_0<``/__`P!02P,$%``&``@````A`+6Q01)#"P``"C@``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3,N>&ULK)O;;N,X$H;O%]AW,'P_L77R"4D&
ML261!&:!Q6)V]]KM*(G1L178[D[WVV]1)"46?XUC9_LF3CX6*ZHJ'GY1\NWO
M/W:O@^_5X;BM]W?#Z&8\'%3[3?VXW3_?#?_]9_G;;#@XGM;[Q_5KO:_NAC^K
MX_#W^[__[?:]/GP]OE35:4`>]L>[X<OI]+88C8Z;EVJW/M[4;]6>6I[JPVY]
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M3?U*%T`_![NM'AJ4D?6/YO-]^WAZH=_F-_$LB[()V0^^5,=3N=4^AX/-M^.I
MWOW76EE?QDMLO="G]9),;K+I.(FTDS,=$]N1/FW'.+V91N-Y,CW?,;4=Z=-V
M/&]/K4V<]&GMH^E%_VAB.]+G=5<XM1WI\Z(KI!G97"%]7G>%<]N1/B^ZPI$9
M`LV(RM>G]?WMH7X?T#2E&A_?UGK21PMRYH:2*5\[N/YJ;-&@TDX>M)>[(45-
MH^9($^+[?1Q/;D??:1!OK,T2;2)NL7(6>L1JMWD(BA"4(1`AD"%0'AA1$MI,
MT#C^!9G07G0F7`Q+![S4!&$["]<E#T$1@C($(@0R!,H#+&R:A;\@;.WE;D@_
MSPP`8Y/2[&V-TB`5K4F;"R`%D!*(`"*!*)^PC-`%_H*,:"\TJ2CM;;0X)XS1
MV92T)FU*@!1`2B`"B`2B?,)20BNHGY+^C<8M!MJXB=Q=\=*0E#Z\7$R#VK=&
MKEL.I`!2`A%`)!#E$Q8HK?B7!ZJ->:"&F+V_6<)60'(@!9`2B``B@2B?L*AH
M8;X\*FW,HS)D0NZ]\LV"\K5&;?F`%$!*(`*(!*)\P@+5"M?;S<Z/4VW,`S7$
M+Q^0'$@!I`0B@$@@RB<L*MJ7_:CT'AUG-S2&K]REM1\>L"$4L%_9>5#9UJBM
M+)`"2`E$`)%`E$]8#B)2R7X2SI>VL>:A6N07%U&.J$!4(A*()"+%$(]/RY*+
MAVYD1`SM+JXF2XMX+9-Q4,O.RG7,$16(2D0"D42D&.(A:TER><A&P+"0#6(E
M!93K+9B&O6=5("H1"402D6*(QZ<5QN7Q&3U"[EQEEI%!$RIVM_`FH)I;*]<Q
M[SHZ5"`J$0E$$I%BB(>L%807\J>7JLA($98-@X)LQ.$`;ZU<Z+GU11T=*A"5
MB`0BB4@QQ+.A98:7C0_6+"-*6,@&3;K;B96^SZ?1[*$<48&H1"00242*(1Z?
M%AQ>?+K:R4R?.5R[,T5&NK#8#0K6LR0L=VOE:IM;7VR^@U6)5@*11*08XNG0
MLL1+QP?E-B*&A6QUS:P=J*L(4(ZH0%0B$H@D(L40CT\+%"\^7>Z,UJ8K54AD
M=`X+O)4^_D(7WAS:CEYA<T0%HA*10"01*89X+K10\7+Q0:V-K&$A^TK'W"I$
M@')$!:(2D4`D$2F&6'QQ(+<^/[4;3UR*611,[2R8VIU5.[41%8A*1`*11*08
MXNFX2IW%J,XL\L;N"E&.J$!4(A*()"+%$(]/:R1O..MRS^A,^/J5/#9JRQ_J
M%@7E#HX'5YU55VY4;FA5(A*()"+%$$_'5<HM1N5F$2NWL?)0CE8%HA*10"01
M*89X?(%,.[]ZQ:C%+.)'`DEXHM-9=26U\JQY.M(L>P5:E8@$(HE(,<1#UKK)
M&^$?A&Q4%AO%!GGU6^GIP>\L<D0%HA*10"01*89X?%KB>/']'PNV$4LL]E8_
M^?MS>`(4MU9=N0$5:%4B$H@D(L403\=56BQ&+681*[>Q\E".5@6B$I%`)!$I
MAGA\@1;[8#BCY(H-"F9P>/33674E;3LZ5*!5B4@@DH@40SSDJR17C)++(J]^
M*T0YH@)1B4@@DH@40RR^))!<YTO:6'-991'%Y\W2-#P!ZJQ<_7)$!:(2D4`D
M$2F&>,A7R:H$995%?DD1Y8@*1"4B@4@B4@SQ^`)9]4%)43HE!B7F*;Y^)KIR
MJ-M!<X=H?6K/B:(L.!DI.BM7^!*10"01*8>:B^`A!]))[T-1=J.?[)]>MINO
MRUJ#WN?)"3TX;B3!0X**RB*6"6.5^)DP2&^372;2X,ZBL+[(JLM$V]$A@582
MD7+7U9.)0&1]+A.HO1*+DO;J5PZE+<HM2F;F:?PX"DY.BL[`15PZU+D1#K5N
M@IMRV1DX-\HB.A<CQ`>'%DR>2/E@/AAYY0L1*K]67)1T]]]6%M&9I$.Y19.N
MO@6B$CL*M)*(%.O(X]-RY_+XC#AB\5GD+^'38/BN:,#K)-!!31>Q07I:=N,^
M"VI5N(ZVF'-Z'AV,BM*9=+Z%1>=]2]?1#939?!SH0^5,&M\\;X%:^]Q401&7
M&*3OZ]NT3,,;3VO$!I#IETV;R4/O,TTCR&5KXHI0HB-AD7.494EX?"\[$^=(
M,4<\48'L^URB4`W2,M$,*7_<Q6GXI,%9=8,CMTAO\6V&(QQXQGVF5_CO]VDT
MG4^#>\42?8N+?$MK97TGDS1.`A6KF&^>ST!3AOG\LW[[J]V*=H]VNT*MF1C$
M%BIKY2]4!J4=*FQ'#Y46>0-4H)5$I%A'%G=ZE=9LK"D/WJ,IBV@I=*-VY9"W
M'3M$<Z4;'>&:4W16SE>)2""2B)1#N!VG@=8,2WV1,&F<!)DPJI1EPB(_$P9]
M($RL>U^8(!*()")E$2VZE%5>_$"5?BX3*%93B[K1O'*H4Q2Y130GF]<$49AT
M!MUP,)Y)6#@D.BOK)EB@96?@^BB+>H0)3;<K-N[&.A@%5HOZL1OD3=O<=O2%
M":+2N>]\";22B!3KR$L>:-'SPDN_CZ8%AC_?+?(W"!`FKI^W/UAT7CP4KJ,9
M$]DLG2;!W4OI3#K?XB+?TG4TOI,D2Y-`]"AG@L)$O[+F"[K/3174L8U?>HO'
MWS9!F%@C-H",*ZLGXBQ*P]=L"]N+3-RX+]&1Z*R:Z9--YE&0<=F9.$>*.>(#
M3`M03_E^+E%&Q;)Q9Y$_[E"8Z"./0!%;]($PL596/,R2290%JK5$W^(BWY+[
MSN9Q$MZ(ZB\)=-=M\FE>^C>O:.^JPW.UJEY?CX--_4V_T-\4OL7FVP;+>+[0
MQTI4I;`E&2_TZ4M?"WU%@<XM>EKBA+PU2T_H+4ZII5F"H26CED8*0,N$6IHM
M"%JFU-(,4FB944OS##QLB:B/N>V!%NI#3VM[XHDH._2<LZ<EINS0#.QKH>S0
MP[*^EIA:FG41KH#ZT+M./7TBZF/&-/2A7)OI#2V4:[-/00OEFE[)Z/L_E&MZ
M.Z&GA;KT]J`.O?:4YM[*4))[<TPI[LUP1!FF5][PBF@G7!2T76$+;74+O;=A
M2YYFU*<O#EK-J$]?"WT3YZ&_6G1A/?]CJ<O;QZE0?=?TD"X>:!+CQ2ZI?KU3
M)1TOEB3-L`?IY\6JMR6G%JUUL4^>1M32YXV$,%U`7PL),$IC7Y"DJ<A;7PN=
MJ"ST$0I>`1V9+/09";;DR93Z]`TCNBNF/GTM>3*G/GU#B>YXJ$]?RS*)%TMS
MGQ5,%3HJ7:QZ6^C$E+SU1TK#K[</G7G2&.@;!'361E?=5VTZ/B-O3<NHO3CZ
M)M;;^KGZQ_KPO-T?!Z_5$RWLX^:$]&"^RV7^.-E[SR_UB;Z"17*,OIU#W[FK
MZ!!XK%_^?:KKD_N#TC]JO\5W_S\```#__P,`4$L#!!0`!@`(````(0`9N24"
MR@H``!<S```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*Q;77/J.!)]
MWZK]#Q3O$["Q^7`EF0KXV]ZJK:F9W6="G(2Z@%-`;N[]]]-M299:[3@D<U]"
M..H^MDZWI)9LKG__L=\-OE?'T[8^W`R=J_%P4!TV]</V\'0S_.O/^+?Y<'`Z
MKP\/ZUU]J&Z&/ZO3\/?;?__K^JT^?CL]5]5Y``R'T\WP^7Q^"4:CT^:YVJ]/
M5_5+=8"6Q_JX7Y_AZ_%I='HY5NN'QFF_&[GC\72T7V\/0\$0'"_AJ!\?MYLJ
MK#>O^^IP%B3':K<^P_V?GK<O)\6VWUQ"MU\?O[V^_+:I]R]`<;_=;<\_&]+A
M8+\)LJ=#?5S?[Z#?/QQOO5'<S1=&O]]NCO6I?CQ?`=U(W"CO\V*T&`'3[?7#
M%GJ`L@^.U>/-\,X)RHD['-U>-P+];UN]G8S_!Z?G^BTY;A_*[:$"M2%.&('[
MNOZ&IMD#0N`\8MYQ$X'_'@</U>/Z=7?^HWY+J^W3\QG"[4./L&/!P\^P.FU`
M4:"Y<GUDVM0[N`'X.]AO,35`D?6/FZ$+%]X^G)]OAI/IE3\;3QPP']Q7IW.\
M1<KA8/-Z.M?[_PLC1U()$D^2P*<D<:[FON]-Y[/+2<"RN1/XE"3SJYDS7DP^
MP3&5'/#9WLAG.S.3'/`I.=PK=^X[_A05Z5$!AE33`?B4CA/=@1X_!X+>..(_
M[6U_6C]'A1+_D307AW(DTJ+)LG!]7M]>'^NW`0Q=X#J]K'$B<`('DD3EE^A/
MFW'O)1QD&K+<(<W-$"2%7#K!*/E^Z_J3Z]%WR.R-M%ER&X=:K)0%IC'2AC80
MV4!L`XD-I#:0V4!N`X4-E`8P`N%:]4"P7Z$>TJ!ZJM]+!1AR6E(I"^42VD!D
M`[$-)#:0VD!F`[D-%#90&@"1:O)KI$(:F,.,1'-F8ZK-4MAX,%NUV>A1DU5K
MTNK'D(@A,4,2AJ0,R1B2,Z1@2&DB1$CHUJ_(.:2!00_A:D5R?4NFI3#J5;(U
M:95D2,20F"$)0U*&9`S)&5(PI#01HB1,]T3)[C5537%HW0BF.KH4B#=MQ^V*
M(2%#(H;$#$D8DC(D8TC.D((AI8D0,6!)_808:$W%$(@I!D-"AD0,B1F2,"1E
M2,:0G"$%0TH3(6+`0D;$$*OB%58JY^?MYMNR%C531\9,8/43:R*24(TD,M$)
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M)B$Z@_MT+*RP-,69S1QH`O*:(Q,Q1TDK`XJY8\*M4@YEW#'G5@6'2N)(1<0R
MWA2Q?[&#,-BSN81\$%I/+G-K9*^4HT["4$'$D<]*XHHN**OI[22,%9>F3Q34
M2Y]*JW[Z3'%I^EQ!O?2%HG>:.=6;S!<S:[XN%5'#36.#&X-/Q$;L(R#6>O:1
M6PLR$.<S.Y&EHYG(`O+AXWW5(Z>U4E>,)60,BD1;]7"EVDIQ99PK5U98?GV_
MG7K^Q.I,H2T43TEXJ,*XVS`5_MJT+_8L1'@!68/""OT*STEQ!M%I%4K()U./
MG>Z1ME*=C#E7HJUZA9>WJG>)&>?*%=>L$=[QQHNI5;$5VD3=5$F(J/*XM?GG
MRB.+52-)B`@XM_8G*T=:F2DOH`FI4/AT)*S\#Z8C1I_(*_;3I]*JGS[C=Y]?
M1%\H>MP#XO#Q/#X=F;=.0P:S2&_(+EQOD::)F<Y*U[<6UR5,(&C5>[*C;53"
MA1R*.!1S*.%0RJ&,0SF'"@Z5!**J0OE#5/U@`49S*^,%9)YL.`P*.11Q*.90
MPJ&40QF'<@X5'"H)1)7!#98Y17R@C-R/F<N?W+3IJ6WE,"CD4,2AF$,)AU(.
M91S*.51PJ"00409W$Y]0IC&G.:,@&.QZ?5_89Q3*RI@E)01/%`U'-DLJQ_F[
M\TRL3!INVCLHJ4CO<%%VI_CX\)VGBNHHQD5/JZ,"H@OQPEJZ5LK16(@EY$.^
M&`I9&[=(6ZDI*%9<M##4]3#M*VX8S!S_4@&"U:O=;P&1HP)G8<VR*^5H!E@X
M3L=-Z"9C9^Q99W*1]`(3W6EY!QW1M#<87^LAWW>X<F-`UNN%UKG9?JVDE5EB
M*4=2%/,4%O2^2&'/=QW?*C5CPDW#BH5Q7U@O6RI=45^;A:6$S,F>0R&'(@[%
M'$HXE'(HXU#.H8)#)8&H8EB%]BEVT8DV3A'V0)"0'MHK964<:DL(/_1H9Z?:
MVDHGOJ377(FV,KC8P;:V4ER9A&"[HJ!<6YE<]MFVME*.)>&B2F.!9RK=OZSB
M,;8MJ8#H`??"&ATKY6C.+<+1/.*65@84<\>$6Z4<RKACSJT*#I7$D8IEU[P?
MB-76MBH02U=`N-SIS)JS!4@ZZBP-I:-YWLVA6$+&_)9PJY1#&7?,N57!H9(X
M4K'L4O9K4SVO<%U9SH)(K8;LW%L:0:6MM`^5'[BW?OP,55F),U1_,EG,QC,K
MFV/.GBB_7O946GUP\,WI\XOHBXOH2T)/8X;UL#D;?"UFHJHF"Y6`K+RWZJ>5
M*QW-O)>.9K`[@B:M^H/&V!-Y04SB]U,B558DM/8I3,9O/E>.O?2%LNJE+PD]
M"1H>(O0&[;+RHJ&AY;*"8*+6\LSMLE%9&4--0L8Q=\2AF#LFW"KE4,8=<VY5
M<*@DCE3$KFV&XW_R&?J$;SDD1+<<GGWVIQR-S%>.1'P[ZR)MI>:YF',EVLH(
MI,V5:BO%E7&N7%F)L[^N4KC0)HJH)$14>=PL_.,Y![>@5F&B("(@._M35F;V
M"BY,%IWV;$L@'?L/YV).GTBHGSZ]B#[C]/E%](6B%V=_75'$]X0;21ME1,C$
M>[_BC<Q]=7RJ5M5N=QILZE=\I]?#W5$+BQ>.E],`WEN!-+#P.V<6W,$5>`L<
M]@5X0M;5,H>6>6?+`EJ:=R6LZRQ=+\"-!F<+)TZ`PX>WP'`)<##P%DC^`+.;
MM\"+U7?=O8$;Z[!?NG!;7?@$7M#NP.^\X`[.:_F%E]"_KNXM_0#>GN+V4$D&
M$2QXO`5*Q0!K0]X"M6"`Q1]O"2=C$+'9^EO"PU0.(G:UP%P-(G:UA"Z$!$Y,
M.J[CNM#2)5CH^M#2U5/8>D%_NEI@(P7]Z6H)W2FP=>D,NPY@ZVJ!;06P=;6$
MCA?@8S'>'W@,%J2=+?!0*\#'5MP'G@8!6]==P[,=8.MJ@2<UP-;5$BX">&.&
M7R59!/!.#,?S10!OO7`\="`RHM2S,P!:\+DU]X'GU'!772TA)&=7GB60FEUX
M#HG9A8?S`-Z7XE=.Y@&\$<7Q?![`.T^`C]I.P,\27M9/U7_6QZ?MX33858\P
MQ8V;@N`H?M@@OISE>P7W]1E^D``%%+R5#C]`J>"%\/$5G`<\UO59?<$+M#]I
MN?T;``#__P,`4$L#!!0`!@`(````(0"4U8N<J@\``-U2```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;*R<76_CNA&&[POT/P2Y/XEE28YC;+:()9$4
MT`)%<=I>>Q-GU]@D#FSO[CG_OD.1%#GS<ATGW5XT9Q_.C#3##[VB9'WXVQ]/
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MW&\H`UOVL]WZX>;\MECTL^OSRX\?A@+]9[/^L4_^^VS_9?M#[S;W?]\\KZG:
MU$^V!SYMMU^M:7]O$3E?@K<:>N"?N[/[]</JV^/A7]L?9KWY_.5`W5U31C:Q
MQ?V?[7I_1Q6E,!?3VD:ZVS[2"=#_GSUM[-"@BJS^N#F?TH$W]X<O-^?E[**^
MFI0%F9]]6N\/:F-#GI_=?=L?MD__=4:%#^6"E#X(_?5!IN5%44UF-L81O\K[
MT=_@-SW%CZ(.)TU_@U]Q44WKJ_EPUD>../.>]-=[%M<7\[JN9O.KX^=ZY3WI
MK_>L+JZ*R77YBA]-M.%<Z>\;S_7:>])?[UD>/=5+U[7#2&E7A]7'#[OMCS.:
M?M1Y^Y>5G<S%@H*%(>+*-`Z:GXT9&BPVR*V-<G-.Z=-PV--`__YQ6EU_N/Q.
M@_/.VRS1IN`63;"P(]&&;27H)%`2:`F,!'T"+JD(8R5HE/^"2M@HMA(AAV4`
M26E$VL$BN+02=!(H";0$1H(^`2QMFI<R[9)6FOP:$?K;.M%JD/0W32Z>UM+9
M5#1_QT%1<9-F-!E3!](!44`T$`.D3PDK`)V@+(!=)-\X`VP4FD-4Y3';8CKG
M^2Z=T=&2C"9C28!T0!00#<0`Z5/"2D+IIR4Y/A:L\9!Y...E(Q7]^7DMFM$H
MN+5`.B`*B`9B@/0I88G24G]ZHM:8)^I(-1MG>P.D!=(!44`T$`.D3PG+BM;A
M-"N[ID_K"RK"&\>TC<,3=H023GM6+/3-:#3V+)`.B`*B@1@@?4I8#:R&3:YK
MQX>P->:).I+V+)`62`=$`=%`#)`^)2PKND*G6=F>+>=6O+VU:VT@GK$CO&O+
M"5_`FM%H[%H@'1`%1`,Q0/J4L"(4='F257C'BCV$&6J0#.92:)*EMSJZ9D>;
ML2R(.D0*D49D$/4,\>)8>7/RP"^<&*++5CCSI4=\]99E::)5<&P1=8@4(HW(
M(.H9XBE;:7-ZRDX(L90=2F>[O9#3!$E0BZA#I!!I1`91SQ#/STJ7)+_WS_K"
MB2`Z5.BUI4=BWD_%O(]6P;%%U"%2B#0B@ZAGB)?#RA91CO=,?Z=^;-FC2BE+
MGOBR&#52M)(J-MK$XHQN`75HI1!I1`91SQ`OCI4Z27&.7_=LV<1EP",Q_459
MFF@5\FL1=8@4(HW((.H9XBE;'71ZRDXUL2F0"JGAQK,I`+6(.D0*D49D$/4,
M\?RLQDGR>[><*YQ88JF/^BD.[Z*$`3Y:Q=X&U/GPR9*I$&E$!E'/$*^&U49)
M-5X9X$Y)L913<>5[&U!;`.H0*40:D4'4,\3SL[+G]/R<2&+YC;HI[5)Q<]X4
MHU7L4D`=6BE$&I%!U#/$4I[^&CTWA`$]-Q,+NK<ZJN>BS5@<1!TBA4@C,HAZ
MAGAQWJ3GIJCG/!(+NBA+$ZUBRBX6.0;4H95"I!$91#U#/&6KO4Z>`E.GU-(I
MX%&R$C6(6D0=(H5((S*(>H9X?AD]5U.QWWAW/D4QYY$0<U=\"C31*G1LBZA#
MI!!I1`91SQ"OA1!SQY?SZ:C9PIDO/6)][<57W)9IT:I#I!!I1`91SQ#/3^BQ
M]VMW>Y,OM)I'HKO%IF,3K4+16D0=(H5((S*(>H9X.816L^6PRNZM0W\4<>DU
M3NQ#+:=>Q-%P&!6^E#;1)A9G=`NH0RN%2",RB'J&>'&LICI]W7,*C*U[7I11
M0<>$BU*4I9F.5B&_%E&'2"'2B`RBGB&>LI59IZ?L1!E+&71:,P74(NH0*40:
MD4'4,\3SLYHJR<^.]_<L]4Z:L<1'M9;T=27WZZ:C5>QK0!U:*40:D4'4,\1J
M89\JI;4XOM0/UGR'TJ-TJ4?4(NH0*40:D4'4,\3S$TKMW?=I)8HXC_A*7XF]
MRB9:C;V-J$.D$&E$!E'/$*^&$''O7.G+4=VEPUQL3RV]U5%1'VUB<5QP<@NH
M0RN%2",RB'J&>'&$`GQE*J#0*QWBHKX296FB5<BO1=0A4H@T(H.H9XBG_":A
M5Z+0\XC-?A1Z:-4A4H@T(H.H9XCGEQ%ZL_(BO@!R\KL4)0H]C\3TEYMRT2IV
MMXN5%*U#*X5((S*(>H9X.830>V6$CWHNG/FR]"HLBO@&48NH0Z00:40&4<\0
MST]HM?<O]BCC2B_0J`)1QE52N4:K4+,648=((=*(#**>(5Z--\FX$F6<1\DX
M;1"UB#I$"I%&9!#U#/'\K&82,JZHA\E]^+*Y^[K<4D?153LSRDMZ&\J](U4Z
MX96*N(#*\0+4!!2O2:U']JXJ&0]B1Z^+5F$\*$2:A6<Y5D*>N0OV&W,<@G#5
M%E"28T!)C@'5[N6Q22$6MRX81!\5T.@CIH@.!H,/3U9HM4S'4;E#SU4HR`)*
MYV@MK[_!*+X-U@8T'_*<S^D=0?GB5!=LHIL*B(90,@3$)IX.5H,CSU>HL5?R
M'457&$K+RB&[3YF<@-Q9\E;T["XXML&Q<!T[OYK(MZ(Z]%+!BXZ:'`[R]><Y
M'([G^R:!5:'`"BCMWZ*26RO!*O94&]#1GNJ"5714`;F106_'3L0,U\$BT[U"
M7+UO[J+FLH*:]IQ$K\L-!6_%>MT[VM7O^T=ZHE1<R5<(.G13X7C>[:J>%%-Q
M2ZN9&^_TC`1[\RIM);789@N(C85:G%<3K&*7MA[1[N!0A4E5SB=SL4AUZ*>$
M'[VX3,.!;^)JYL;+0.=Y[&+U^_;E9Q>K=,VS4<1*[E!ZD;:*E*P2U"+J$"E$
M&I%!U#/$\Q:2[)4U#G57E=-=M;S)CE9QC1L=`^K02B'2B`RBGB&>\IMT5X6Z
MRR,J:CCS!E&+J$.D$&E$!E'/$,]/Z*Y7NA0%5N40W:?$_#R**;?!BKHQ7FWD
MU;R+5B&60J01&41]0,-)L)3K7R'#AB!\\GJ45B*@I!(>O2(UH]58"40:D4'4
M>T1W6A2+5T)HM'==U.QFJUC&`HHBI0DHBLO6([HG&'[-@((T&L0B^(/%,#I:
M^3!B^3?1((3I/:*7?*`D5O`D]R''YT/MY5'RMI=']AE$,M*%UFZ"8W(I\XAN
M'\)I=H@4.FJT,HAZYLA'@5!R[QL%*/!JAYBTF8N+;..-4F43_/A:(7JU"U:T
MXB9U%N%5"$_#)K&2*C?$.GI$$ZSX$85`[U\[(B_]*ZKR-"%1HZST2(Q"*:Z#
M8SH*72RZKXNC$)!"1^U1XF@0]<R1ER(C+:>SX<7KTS<`:I26'K%16-128`?'
MN&*U'M$=GUU7ZJ*Z%DY=M`BU4AA'1RL;9SZA_UV+VU@3;4*DGD7BE;**,%FB
MAOE*OQJD(6YW2L*8>4/5G,1,MTUJC]@J-I."/%BEX\<YVF<XR82#R>NMV+2<
M"1VH?'B[R9_$@LE[RA%-B,6/*/JA#U8_.R+O!ZM)93\D6U:A(UZYA-@H0D@X
M1#O]830TM;>*J/6(;EF#58=(H:-&*X.H9XX\[S=)XAHEL4=,*#DKIU'<+Q.#
M%64>>W\F+J1=M`I54(@T(H.H#R@CE(1*?M\E$L5SC>(YH%0R.JO7).-H%2L!
M2/OP%"M8&40].PG6^;-?(9Z'('S,!Q1'<Q-0U'JM1S^7C-$@I*<"BF%T0*/R
M%.N3B08A3.]11C+.K"9-UH'C\WVP%KG;`+0'Q!;;6HST)C@FBZU'J61$I-!1
MHY5!U#-'/@J$2G[7?)BA>/:(7:Q!,@:_.%3:X,?6BEKT:A>LF(";"2L5PK,K
M12VO.B'6T2.:8,6/*$1J_]H1>>E?4>NG775F*-<]$J-02L;@F(Y"%RM1?IVW
M2I!"1XU6!E'/''DI,NKYS9)QAN+9(S8*43(&QW08>J7L)"-]U&`FNKKS3B0J
MP\*B,(Z.5E8R5I.KZDK^8L!$FQ"I9Y%XI3+BNOA_).,,A79`;!4#R1BLTO'C
M8KTB&;VC?1TFD0-B6JI@]3,!-T@+':R.BE03K/@1Y?U>L/K9$7D_6*V:7"KD
MNGGBY'6*E_1Z6@HQ4Y<S9V4W\\>"B;6NB39A$+6(.D0*D49D$/4,\=I8B9O4
MYI7+J+46EU&'[+;]F'`Q$V5I9J-53!E0AU8*D49D$/4,\92MZCT]9:>1T]NT
MF4/IYC*B%E&'2"'2B`RBGB&>G]6?27YVN,^OW_-C:OJ&#W2W0_9I1=+=XAZ]
M\8Y)A5I$'2*%2",RB.SGANRINB.Z<KC/![F/PCRM=Y_7S?KQ<7]VM_UF/PTT
MG](.PXC]=XMFL\4M1:(Q*EIH7M,GC8:[`VBYHI9A8866.;7,L]&NPP>2A,]M
M.:4S&&X31`N]"[BP;]YESJTLJ66X(()/12V#!(>6FEKRQZ%,W1TA^%"F]*Y,
M[@PH4[H]R+14%,UUBHQ6431Z`H0^MU/J!;KB8`N]^;ZP[YGG6B@:O8Z=:Z%S
MHQ>9<RW4"_1:;Z:EG%`^PV:</.N2/FV5/;?;Z61QZV[PI`^UV!]"98XSI6CT
M>Z%<"_4V_=(FUT*]3;\[R;50;],SV5P+]7;VW&Z+:G%+OV#+^%"+_3UNKH6B
MT8\;<BW4/_2#SUP+]0_]^#'70OU#/QO,M5#_Y,^-@F5C4:AL)`J4R_&VH#YS
MF^"RSZC%?HP@=U;49_2;_5P+]9F[3D`TZK/L<=I9M;#R%*.1'%U8N8DM]'6U
MV^S(L">6L5_:H93C=MG(\%L:$KEJ+6E`Y,YG2<,A.QIH,.3&`NWXD$/N"+33
M0-7(59TV#Z@:N99V5I!/+F^ZWR:?7$L[*\DGESO='9%/KH5VIA=V[QG[@_::
M%W8O&5MHMY!\<B.5M@/))]>RI.HLL]5IJ*7)MK348K?6<F=P32W96M=4-WHB
MAS[T;(]\<BUM/26?W%BBQV'DDVMI:QKA]``B=QP:X=D6>C-P85_R0Y]E=4W5
MR8V#AEJ:;`L]!E_89]48K:UI5&5]Z$$VC='<<985C5YZLD_1+L=I3A\7?%E]
M7O]CM?N\>=Z?/:X?2&%,AG<,=^[SA.X?!_^*RJ?M@3XK2$*:/DQ'GY%<TS?A
M)O91PL-V>PC_L`<8/TSY\7\```#__P,`4$L#!!0`!@`(````(0"<I=C5AP(`
M`(<&```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)1576^;,!1]G[3_
M8/F]&`A-&A12)8NZ55JE:=K'LV,,6,$8V4[3_OM=8X*2)NKH"\27XW/NN;[7
M6=R_R!H]<VV$:C(<!2%&O&$J%TV9X=^_'F[N,#*6-CFM5<,S_,H-OE]^_K0X
M*+TS%><6`4-C,EQ9VZ:$&%9Q24V@6M[`ET)I22TL=4E,JSG-NTVR)G$83HFD
MHL&>(=5C.%11",8WBNTE;ZPGT;RF%O(WE6C-D4VR,722ZMV^O6%*MD"Q%;6P
MKQTI1I*ECV6C--W6X/LE2B@[<G>+"WHIF%9&%38`.N(3O?0\)W,"3,M%+L"!
M*SO2O,CP*DK7,TR6BZX^?P0_F)/?R%3J\%6+_+MH.!0;CLD=P%:IG8,^YBX$
MF\G%[H?N`'YHE/."[FO[4QV^<5%6%D[[%@PY7VG^NN&&04&!)HAO'1-3-20`
M3R2%ZPPH"'WIW@>1VRK#<1+,HG`^F0'+EAO[(!PE1FQOK))_/2CJJ3Q)W)/`
MNR>93(/;63B)0/,_),0GU/G;4$N7"ZT."'H&)$U+70=&*1!?-P1.'';EP!F>
M802Y&CB$YV6<3!?D&2K'>LS:8^`Y8*(!04!T4`:U\<H.[)1=:5TJ:Q\XE8FO
MRTP^(N/`&8;GD/RE08])3C#)=66`C#?HP'`&8.L=:0\:(0W],%[:@3OIH;A]
M!,;D))G9=9?3CT@Y\+E4'^DZ_:P]H,M.+703-X?RO-^A;M>Y0!\YZY3D[HT7
M/_A^,"37)?_"Z]H@IO9NJ&-H]2$ZW#>KV'7CVWB2KKHN)<,'N`=:6O(GJDO1
M&%3S`BC#P`V^]C>)7UC50N8PR,K"#=#]K.#"Y]#M80#@0BE[7(`P&?Y"EO\`
M``#__P,`4$L#!!0`!@`(````(0"*'L8YT`D``'\K```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;*Q:VV[C.!)]7V#_P?#[V+K:CI%D$.L.S`*+Q>S,
ML^,HB=&V95A*I_OO]U`D)19+L9WTSL.H<UA59!T6R2-:M[__V.]&W\M3O:T.
M=V-WXHQ'Y6%3/6T/+W?C__Z9_K88C^IF?7A:[ZI#>3?^6=;CW^__^8_;]^KT
MK7XMRV:$"(?Z;OS:-,?E=%IO7LO]NIY4Q_*`EN?JM%\W^//T,JV/IW+]U#KM
M=U//<6;3_7I[&,L(R],U,:KGY^VFC*O-V[X\-#+(J=RM&XR_?MT>:QUMO[DF
MW'Y]^O9V_&U3[8\(\;C=;9N?;=#Q:+]9%B^'ZK1^W"'O'VZPWNC8[1\L_'Z[
M.55U]=Q,$&XJ!\ISOIG>3!'I_O9IBPP$[:-3^7PW?G"7A>^/I_>W+4%_;<OW
MVOCWJ'ZMWK/3]NF/[:$$VY@G,0./5?5-F!9/`H+SE'FG[0S\^S1Z*I_7;[OF
M/]5[7FY?7AM,=XB,1&++IY]Q66_`*,),O%!$VE0[#`#_'^VWHC3`R/K'W=A#
MQ]NGYO5N[,\FX=SQ79B/'LNZ2;<BY'BT>:N;:O^W-')5*!G$5T'P5$'<FXFW
M"-UP)J*<\0R4)Y[:<W&=)^*V`\=3>\XG<]>Y\>?GNYPI1SRUHY'QF;'.E2.>
MRM&?+,(PF"TN](BUU@X53]WC=4.]48YX=CV>HW4J)[>ME7C=K.]O3]7["`L0
MTU<?UV(YNTL$TT4BD^W*YJ.J0;F((`\BRMT8Z:,@:I3Z]WLO=&ZGWU&>&V6S
MXC8NM8BTA:A%$3:V@<0&4AO(;""W@<(`IB"A8P)U_G]@0D013.@<5AHPJ+'2
MUA;:);:!Q`92&\AL(+>!P@!(VEB9=MH^]IKA74+/MW#"?F#,-S8%FM9*V@18
MOUU1!-0DZDRZU!F2,"1E2,:0G"&%B1`",$";`+%-?G(%B"A80V"YR]8+K0)?
M2:.SE'0F'24,21B2,B1C2,Z0PD0()4C?IL0+)Y\G1<1I2=')K"028(?M:'(#
MNRPZ(^T6,R1A2,J0C"$Y0PH3(1Q@B"8'Y]>#,*:)2@2)ZAPBAL0,21B2,B1C
M2,Z0PD1(5MBBS:SD=C\1IU3SNMU\6U68%FR0`]GZV-;E9B]BT&05THJ9UB92
M2-"E'TM$'/K&S%M[1M(9:=92AF1F:)*;$*[L*/MD;B(&S4TA1FX*,7)32"A/
M/L?UZ3Z7,(_4]K"60&9ZD"1Q1IM)#DP4*-8S)8QI-@I!?72S$'ITM)&RZ<^P
M6"&+-K_%`DK*WNT3YI0J!(^N*S>8T;XRTXWDZ>(,NC[1UIIFJB`/<8S^Y[3_
M2#OVTQMK1U?.YF+N>`OJE7"O5'N9!P!/ESC2?(4L,:KW_,2Z4L3@N-$+9:4A
M<VK=P!IYI*V,R=70V8E*M%7OF&I(E@7TO&,MYTQ;M$XT72%'C'2_M!&)T]:J
M;P59LWY#YR_2CN:LRUB>V.:^W[M^X,Y]Z_A.N%NJ^U-N\]!Q/4OX9L2-LB!$
MR2^S()4->NEK04&D%FQ!'KG*JI_26$%>(%EP`G_A+*R]*>%^J>6W<#V4`R4]
M(VZ4!B%$SM#P9W7$VAX\E8S-SI5R1K#=+7C/WMQ6RNJL!NMM-*,QAQ(.I1S*
M.)1SJ"`0Y48(%(.;"_N"E#.D%B1D*A$A;[%N#"CF4,*AE$,9AW(.%02B^0FI
M<GU^PMK:YR5D)!.Y#(HYE'`HY5#&H9Q#!8%H?D*N7)^?$C?F6I:0+Z]HQ&MQ
MY"JH%Y>QAM#2%;]K%W_26^G"3CF4<2CG4*&A=A`T92%>C)2_MK<K!60R(2'"
MA(),)B1T06BZG57/!(,R;I5SJ%"0/\"$D#>_S(322"83"NK/K\A5D*%*%>3+
M\]GCLK0WZ$E@8;+>JKW7<5SK/,A[`QVF4!"V-4"D.,3);%)R?C]KK>EZ5Y"'
M-6Y4NJ6X(^UHG&T*\F^Z<S+A4,H=,VZ5<Z@@CC1E2]I]:3UX7/$I2'3<,;&P
M3MU(^_6E$FL_NE=8LYIH*ZR*+KH;6N%3'1ZC,ZQLE:]CG>TQUU:T1TNQ%Y=Z
MI-1?D)G7*0N/ZTP%655HJVWM:%:AC!6T=_?MNW*BK`PHY8X9M\HY5!!'2L6`
MUO1FXNK_$Z_^D,?V^:L@4H5N:"MN[6B6H8P5R/>LT`UN+*=$.<%";RPICY/U
M5F)_6CCX[\9ZI<U[&QVI()$H4T-R%#\$**)TS5Q_80(YS5A3$-G%9M:;0Z0=
MS?J1CN**UEAP;/$J*[(L9];[3*K"^Z9BQ@\SEF[75F=[S+45[=&:AT);?=0C
MG0<A4\^<GGHB+APA4NR:DEC4/%2D_/%-WE<I".\HND!B!04]E'`HY8X9M\HY
M5!!'FK>0KT;>%_*38I?D)R%3*(F-2J1L""4-D4UY9AVD26^EB4DYE'$HYU"A
M(2Z4/`S"3/EK1Z0(8HD%"1$F%&0R(2$Q(_V:"JRC+FG'B)]#>R&><BCC4,ZA
M0D$#DM$3*M28_*\Q(:4LJ0D%]=4<M5V!+T,R*NACR=@;].4@(_M]F*RW^D`R
M]@8Z3*&@(<DH-*E!R87UH!2L(9<]"8GRZ^<WM"H]4E9XK]%CBA5$)*.,94`I
M=\RX8\ZA@CB2+4!L[V;*7ZJ"-@A=#PHBAS63C-JO+Y58^V&A&`S:IXZV0D'T
M5C/+*M7AR4G!3AT=ZVR/N;:B/5HKM[C4(Z4>XSI'_76GCB^B6-Q+R*I"6S)J
M1Z,*%63HPX1#*7?,N%7.H8(X4BJ$5C46GJC"3TM&H2YL)B1$JI!+1NUHEJ%T
M5)(1GU?,K*E.E),I&7F<K+<2^U/@S(.Y;Y5IWMOH[:`@D2A3`^+:_17)"&W"
M6%,0V<689-2.9OU(1[$*^F496ODFRE%40V\UL\1@JJTP$;T57[S7])CK6+1'
M^WU/6WW4HYP'^164_+)E7YY>RJC<[>K1IGH37SBU!=/!^O.K8/F`X)A=JP5W
MQ$MQ(SO4$J*E%0#,9X:65E-8+;'O+459\F@HPZ4H,]Z"3\,>AO`5/AEK7X:L
M/E;>$M]W\#@K'Y^8#>`/2%U*73L0,A],''D/IHVLAY*&U,.(VAJT>HB]Q3+!
M6<\'"]6PS`=;<`[#I[VWL:+AH(7/4$OLNZ!]B"QLBZ!]J"7V?/0S1!A>,M'/
M4`M>$^`SQ`W>`^`SU+(".ZM!=B*T1(,M,5J$IN:\Q=X<+8-<N^`-5W'<!Y=Z
M2W%OQUMBST$^[>T$X]I!/T,ML8<2Q\T#CX9;"_@,M<3S)7[;YQXK=[Y<X4:5
MM^#:>QD-MN#V&]D,18M=U-2@#^ZOL9;:?J9=HOC\\;A^*?^U/KUL#_5H5SYC
M\W#:3PA.\@-*^4>C?I!ZK!I\^(AC'A_.X4/7$I?SCK@G>*ZJ1O^!1*;=I[/W
M_P,``/__`P!02P,$%``&``@````A`,FHFCHS`0``0`(``!$`"`%D;V-0<F]P
M<R]C;W)E+GAM;""B!`$HH``!````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````)R1T4K#,!2&[P7?H>2^3=L-V4*;@<JN'`A.%.]B<K8%FS3D1+N]O5G7
M546OO`S_GR_?.:D6>],D'^!1M[8F19:3!*QLE;;;FCRNE^F,)!B$5:)I+=3D
M`$@6_/*BDH[)UL.];QWXH`&32++(I*O)+@3'*$6Y`R,PBPT;PTWKC0CQZ+?4
M"?DFMD#+/+^B!H)0(@AZ!*9N))(!J>2(=.^^Z0%*4FC`@`U(BZR@7]T`WN"?
M%_KD6]/H<'!QID'W.UO)4SBV]ZC'8M=U63?I-:)_09]7=P_]J*FVQUU)(/RX
MGT9@6,55;C2HZP/?O_HF0=Q5]'=6*=G;,>E!!%!)?(^=[,[)T^3F=KTDO,R+
M:9K/TF*Z+G,VF;-R_E+1<VNXST>@&03^33P#>._]\\_Y)P```/__`P!02P,$
M%``&``@````A`.QB3.GJ`@``:PD``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($
M`2B@``$`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````G%;?3]LP$'Z?
MM/^ARCND4)@FE`9!H0*)K=42V*-U.-?&PK$SV^E:_OI=DK6DX.:!-__X[OS=
M?7>VH\MU(0<K-%9H-0Y.CH?!`!77F5#+<?"83H^^!P/K0&4@M<)QL$$;7,9?
MOT1SHTLT3J`=D`MEQT'N7'D1AI;G6(`]IFU%.PMM"G`T-<M0+Q:"XXWF58'*
MA:?#X;<0UPY5AME1N7,8M!XO5NZS3C/-:W[V*=V41#B.KLI2"@Z.HHQ_"&ZT
MU0LWN%USE%'8W8R(78*\,L)MXF$4=J=1PD'BA!S'"Y`6H_!M(;I#J),V!V%L
M'*W<Q0JYTV9@Q2NE[308/(/%FLXX6($1H!S1JF'MI!G+TCH3_];FQ>:(SD8A
M`=K%9MC%=L?B+!Z=-P@:[2-K#RT3VMCGF`HGT<X6<S#.0WETWN7<L&@9MX2V
M*C*J#7:K'.6+W:M6;:&[S'<Q7(,$Q9$E'X([`&%$C0HE1T?:D5`[6)VXED;B
MP&%=39;I!9M1238B[Z7N`'@"-F=3J?_ZP3.S!"5>&W=-D-=@17/*W*#?)*F*
M`LRF9I*(I1)4[:0SN^)<5\IY^4^I7M@3R`K9#P1;F388+Y;.+4%0MM?46A9M
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M]&/HK$7AVR\I_@<``/__`P!02P$"+0`4``8`"````"$`'7^_9.`!``"Z%@``
M$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`
M!@`(````(0"U53`C]0```$P"```+`````````````````!D$``!?<F5L<R\N
M<F5L<U!+`0(M`!0`!@`(````(0#HP<GGWP$``*L5```:````````````````
M`#\'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(````
M(0!6H&]Z@`,``#H+```/`````````````````%X*``!X;"]W;W)K8F]O:RYX
M;6Q02P$"+0`4``8`"````"$`@Q)LW!`%``!.$P``&``````````````````+
M#@``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`BT`%``&``@````A`(/3
MN'O9`@``;@@``!D`````````````````41,``'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"+0`4``8`"````"$`]ZM'"H@"``!M!@``&0``````````
M``````!A%@``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(
M````(0`"OZ*BBP(``($&```9`````````````````"`9``!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`!@2'0V<`P``U`P``!D`
M````````````````XAL``'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M+0`4``8`"````"$`#;,1)O\&``#O)0``&0````````````````"U'P``>&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#.3F871P,`
M`*@)```9`````````````````.LF``!X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L!`BT`%``&``@````A``6!RQVH`P``:@T``!D`````````````````
M:2H``'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`
M`U.>!IX#``"B#0``&0````````````````!(+@``>&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0!23%WB+`<``!,K```9````````
M`````````!TR``!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`BT`%``&
M``@````A`'N&?4R1`P``0@P``!D`````````````````@#D``'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`7Z;H)S<&``"^&P``
M&`````````````````!(/0``>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M`BT`%``&``@````A`/RQ#@+'!```%!8``!@`````````````````M4,``'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0`&D3RO)RX`
M`,N;```4`````````````````+)(``!X;"]S:&%R9613=')I;F=S+GAM;%!+
M`0(M`!0`!@`(````(0`?AK`3:@P``#]R```-``````````````````MW``!X
M;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,`````
M````````````H(,``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"```
M`"$`TJKR494"``!Y!@``&0````````````````!EB@``>&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+`0(M`!0`!@`(````(0#3A$B>C`(``!0'```9````
M`````````````#&-``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`
M%``&``@````A`/A6;C6?`P``4@P``!@`````````````````](\``'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0`,-**=R0(``'T'
M```9`````````````````,F3``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L!`BT`%``&``@````A`&N=6I@?!P``;QT``!D`````````````````R98`
M`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`P=1@
M/)T"``#8!@``&0`````````````````?G@``>&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+`0(M`!0`!@`(````(0"*XB^,/04``)H3```9````````````
M`````/.@``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@`
M```A`/A]X8E"!0``01,``!@`````````````````9Z8``'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0![(7S2:@X```]-```8````
M`````````````-^K``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4
M``8`"````"$`C[0;`ZL/```650``&`````````````````!_N@``>&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`/1?*>Q*`P``;0L`
M`!@`````````````````8,H``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+
M`0(M`!0`!@`(````(0`ZS5'U>@4``%,6```8`````````````````.#-``!X
M;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`#@,)Y4`"
M```'!0``&0````````````````"0TP``>&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;%!+`0(M`!0`!@`(````(0#("5\GZ0(``*@(```9````````````````
M``?6``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A
M`#V=>2R@`@``20<``!D`````````````````)]D``'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`N,_GN]\$``!S$0``&0``````
M``````````#^VP``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`
M!@`(````(0"F6%.>W`0``",1```9`````````````````!3A``!X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`+6Q01)#"P``"C@`
M`!D`````````````````)^8``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"+0`4``8`"````"$`&;DE`LH*```7,P``&0````````````````"A\0``
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0"4U8N<
MJ@\``-U2```9`````````````````*+\``!X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L!`BT`%``&``@````A`)REV-6'`@``AP8``!D`````````````
M````@PP!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"```
M`"$`BA[&.=`)``!_*P``&0````````````````!!#P$`>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0#)J)HZ,P$``$`"```1````
M`````````````$@9`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````
M(0#L8DSIZ@(``&L)```0`````````````````+(;`0!D;V-0<F]P<R]A<'`N
9>&UL4$L%!@`````L`"P`Y@L``-(?`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 2) (Stock options, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 364,239<span></span></td>
        <td class="nump">$ 417,977<span></span></td>
        <td class="nump">$ 592,345<span></span></td>
        <td class="nump">$ 836,158<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">208,908<span></span></td>
        <td class="nump">292,263<span></span></td>
        <td class="nump">335,433<span></span></td>
        <td class="nump">584,732<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 155,331<span></span></td>
        <td class="nump">$ 125,714<span></span></td>
        <td class="nump">$ 256,912<span></span></td>
        <td class="nump">$ 251,426<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (3,718,401)<span></span></td>
        <td class="num">$ (3,619,879)<span></span></td>
        <td class="num">$ (2,879,108)<span></span></td>
        <td class="num">$ (8,216,109)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for basic and diluted net loss per share</a></td>
        <td class="nump">8,000,092<span></span></td>
        <td class="nump">51,499<span></span></td>
        <td class="nump">4,074,734<span></span></td>
        <td class="nump">46,865<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.46)<span></span></td>
        <td class="num">$ (70.29)<span></span></td>
        <td class="num">$ (0.71)<span></span></td>
        <td class="num">$ (175.31)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">4. Prepaid Expenses and Other Current Assets</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Prepaid expenses and other current assets consist of the following:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 652px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="652">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December&#160;31,<br />
2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30,<br />
2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Prepaid insurance</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48,055</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">604,320</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">98,649</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,898</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total prepaid expenses and other current assets</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">146,704</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">661,218</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_PrepaidExpenseAndOtherAssetsCurrentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U
M93<T8S%A,3`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T
M-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%L86YC95]3:&5E
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"86QA
M;F-E7U-H965T<U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]O9E]/<&5R871I;VYS/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT
M<U]O9E]#87-H7T9L;W=S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]"87-I<U]O9E]0<F5S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3
M:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N=',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F5P86ED7T5X<&5N<V5S
M7V%N9%]/=&AE<E]#=7(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!8V-R=65D7TQI86)I;&ET:65S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]N=F5R=&EB;&5?3F]T95]&:6YA;F-I
M;F<\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y497)M
M7TQO86Y?06UE;F1M96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A
M;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF
M:6-A;G1?06-C;W5N=#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<U]486)L97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F5P86ED7T5X<&5N
M<V5S7V%N9%]/=&AE<E]#=7(Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^06-C<G5E9%],:6%B:6QI=&EE<U]486)L97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?
M17%U:71Y7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?0F%S:7-?;V9?4')E<S$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I
M9VYI9FEC86YT7T%C8V]U;G0S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?
M;V9?4VEG;FEF:6-A;G1?06-C;W5N=#4\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<U]$971A
M:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER
M7U9A;'5E7TUE87-U<F5M96YT<U]$971A:6PQ/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4')E<&%I9%]%>'!E;G-E<U]A;F1?3W1H
M97)?0W5R,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D%C8W)U961?3&EA8FEL:71I97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G9E<G1I8FQE7TYO=&5?1FEN86YC
M:6YG7T1E=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E1E<FU?3&]A;E]!;65N9&UE;G1?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?1&5T
M86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T
M;V-K:&]L9&5R<U]%<75I='E?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7T1E=&%I;',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A
M<G1Y7U1R86YS86-T:6]N<U]$970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S4N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C
M9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T
M-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET
M>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D%U9RX@,3,L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO
M;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=!1TE,12!42$5205!%551)0U,@24Y#/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E
M;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,#`P,3(V,3(T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<Q,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6X@,S`L#0H)
M"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F]N+6%C8V5L97)A
M=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-3DR
M+#DV.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E
M<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U
M8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W
M-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!
M1D)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)A;&%N8V4@4VAE971S("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-3,L-#DT+#`R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPQ,3DL-C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N
M9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C8Q+#(Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T-BPW,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L,34U+#(T,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,C8V+#,U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T(&]F(&%C8W5M
M=6QA=&5D(&1E<')E8VEA=&EO;B!O9B`D,C<S+#`Y,B!I;B`R,#$S(&%N9"`D
M,C<X+#$S-2!I;B`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,2PY-C0L-S<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L.38S+#`W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@9FEN86YC:6YG(&-O
M<W1S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,BPY
M.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-3<L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L,C<Q+#(Q,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0P-2PQ,S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,R-2PV-C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,34L
M-#4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-S,L,C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S<Y+#$V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]A;B!P87EA8FQE+"!C=7)R96YT
M('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34Q
M+#8U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,3`U+#0P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0U,BPQ-3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#0L-#<X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R
M<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PS,#(L-S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPX-#0L-3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N('!A>6%B;&4L(&QO;F<M=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-C$Y+#@Q-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL
M-S8Y+#4R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6ET;65N="!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R`H9&5F:6-I="D@97%U:71Y
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:RP@)"XP,#`Q('!A<B!V86QU92P@875T:&]R:7IE
M9"`Q,"PP,#`L,#`P('-H87)E<SL@:7-S=65D(#`@<VAA<F5S(&]U='-T86YD
M:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!*=6YE(#,P+"`R,#$T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"`D+C`P,#$@<&%R('9A;'5E+"!A=71H;W)I>F5D(#$U
M,"PP,#`L,#`P('-H87)E<SL@:7-S=65D(#$P.2PS,C$@86YD(&]U='-T86YD
M:6YG(#$P,RPU,S8@<VAA<F5S(&%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!I
M<W-U960@,3@L-3DX+#<U-"!A;F0@;W5T<W1A;F1I;F<@,3@L-3DR+#DV."!S
M:&%R97,@870@2G5N92`S,"P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PX-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V.2PU-#`L,C@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L
M.#<R+#<R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3(Q+#$Y,RPT.3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$X+#,Q-"PS.#,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@<W1O8VMH;VQD97)S)R`H9&5F:6-I="D@97%U:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT."PS-#@L-C4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S$L-#0Q+#4W,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!L:6%B:6QI=&EE<RP@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M(&%N9"!S=&]C:VAO;&1E<G,G("AD969I8VET*2!E<75I='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#(W,2PR,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT,#4L,3,V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M97)I97,@02`Q+"`X)2P@;F]N(&-U;75L871I=F4@8V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@Y."PS,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-E<FEE<R!!(#(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T,RPV,C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E<FEE<R!"+"`X)2!N;VX@8W5M=6QA=&EV92P@8V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0T+#DR."PS.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E<FEE<R!#+"`Q,B4@;F]N(&-U;75L871I=F4L(&-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,BPX-C(L,S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I
M;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V-#0L-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U
M93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X
M,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE
M970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14M604<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,C<X+#$S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<S+#`Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&%U=&AO<FEZ960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M+#4Y."PW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#DL,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PU.3(L.38X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#4S
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5R:65S($$@,2P@."4L(&YO;B!C=6UU;&%T:79E(&-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E
M("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K+"!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@T+#<T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<L-S@W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,W+#<X-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@
M,B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O
M8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:RP@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDY+#$W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-BPQ,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPQ,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E<FEE<R!"+"`X)2!N;VX@8W5M=6QA=&EV92P@8V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#4Q,"PP-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@:7-S=65D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,3`L,#8V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,3`L,#8V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@
M0RP@,3(E(&YO;B!C=6UU;&%T:79E+"!C;VYV97)T:6)L92!P<F5F97)R960@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@875T:&]R
M:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S$Q+#<S
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4W."PT,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE('!R969E<G)E9"!S=&]C:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4W."PT,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A
M,C4Q7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%24-!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L,SDP+#@U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,BPT,C4L-S0Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#<X-2PQ.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-#DW
M+#0U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,3`S+#@U,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R,RPS,CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$U-RPQ-3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DW.2PY-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#DT+#<Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C0Y+#`W,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.30R
M+#,S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L-#<W+#0S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#DT+#<Q,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#(T.2PP-S`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PY
M-#(L,S,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#<L-#<W+#0S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC;VUE("AE>'!E
M;G-E*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#`S+#0X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S-S@L,C(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<X,2PW,30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S4V+#0U-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W.2PW,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$V
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y,BPS,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-BPS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&)E9F]R92!B96YE9FET(&9R;VT@:6YC
M;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#<Q
M."PT,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,RPV,3DL.#<Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#8L-3,Q+#4Y,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#(Q-BPQ,#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96YE9FET
M(&9R;VT@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-C4R+#0X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@S+#<Q."PT,#$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#8Q.2PX-SDI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#@W
M.2PQ,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@X+#(Q-BPQ,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S('!E<B!C;VUM
M;VX@<VAA<F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"87-I8R!A;F0@1&EL=71E9"`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-#8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@W,"XR.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q-S4N,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D+6%V
M97)A9V4@<VAA<F5S(&]U='-T86YD:6YG.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD($1I;'5T960@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M,#`P+#`Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4Q+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,#<T+#<S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#@V-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U8V8X,V%?8V)D,5\T,V%E7V$R
M-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,"]7;W)K<VAE
M971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U0T%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C=&EV:71I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#@W.2PQ,#@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@X+#(Q-BPQ,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL
M92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#$U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]N8V%S:"!S=&]C:R!B;VYU<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL-3`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYC87-H
M('-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3DR+#,T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@S-BPQ-3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;F-A<V@@:6YT97)E<W0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ+#<Q-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#$V-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$Y,BPS,C$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38L,S0V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,30L-3$T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#<P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,#0L,S$V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L-3$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@*'5S960@:6XI(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(Q,BPU,C0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPQ.#<L,C4P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T:6YG(&%C=&EV:71I97,\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W%U
M:7-I=&EO;B!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#<T,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#8S,RPU,#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-BPW-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV,S,L-3`S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&-O;G9E<G1I8FQE(&)R:61G92!N;W1E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!F:6YA
M;F-I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U
M,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@:6X@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<L(&YE="!O9B!O9F9E<FEN
M9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL-S0S
M+#8T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L-3DS+#8T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@:6YC<F5A<V4@*&1E8W)E87-E*2!I;B!C87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,2PS-S0L,S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3$L.#(P+#<U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,3$Y+#8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+#`Q,RPW-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',L(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4S+#0Y-"PP,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$Y,RPP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P
M<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@;F]N8V%S:"!F:6YA;F-I;F<@86-T
M:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G-I;VX@;V8@<')E9F5R<F5D('-T;V-K(&EN=&\@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PR
M,S(L-C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!N;W1E<R!P87EA8FQE(&%N9"!I;G1E
M<F5S="!I;G1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPP,C`L-C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@8V%S
M:"!F;&]W(&EN9F]R;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%I9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V.3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q
M7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P
M+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@0F%S:7,@;V8@4')E
M<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!"87-I<R!O9B!0<F5S96YT
M871I;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]R9V%N:7IA=&EO;B!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXQ+B!/
M<F=A;FEZ871I;VX@86YD($)A<VES(&]F(%!R97-E;G1A=&EO;CPO9F]N=#X\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#(^3F%T=7)E(&]F($]P97)A=&EO;G,\+V9O;G0^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!9VEL92!4:&5R87!E
M=71I8W,L)B,Q-C`[26YC+B`H=&AE("8C.#(R,#M#;VUP86YY)B,X,C(Q.RD@
M=V%S(&EN8V]R<&]R871E9"!I;B!$96QA=V%R92!O;B!$96-E;6)E<B8C,38P
M.S(R+"`Q.3DW+B!4:&4@0V]M<&%N>2!I<R!E;F=A9V5D(&EN(')E<V5A<F-H
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M/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
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M:6]N+B!!<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,30L('1H92!#;VUP86YY(&AA
M9"!A;B!A8V-U;75L871E9"!D969I8VET(&]F(&%P<')O>&EM871E;'D@)#$R
M,2XR)B,Q-C`[;6EL;&EO;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE
M($-O;7!A;GD@:&%S(&9I;F%N8V5D(&ET<R!O<&5R871I;VYS('1O(&1A=&4@
M<')I;6%R:6QY('1H<F]U9V@@=&AE(&ES<W5A;F-E(&%N9"!S86QE(&]F(&ET
M<R!C;VUM;VX@<W1O8VL@:6X@:71S(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG
M("AS964@3F]T92`X*2P@<')I=F%T92!P;&%C96UE;G1S(&]F(&ET<R!C;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VLL('9E;G1U<F4@;&]A;G,L(&%N9"!N
M;VXM9&EL=71I=F4@9W)A;G0@9G5N9&EN9RX@5&AE($-O;7!A;GD@97AP96-T
M<R!T;R!C;VYT:6YU92!T;R!I;F-U<B!N970@;&]S<V5S(&EN=&\@=&AE(&9O
M<F5S965A8FQE(&9U='5R92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY"
M87-I<R!O9B!0<F5S96YT871I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
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M("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@:6YF;W)M
M871I;VX@86YD('!U<G-U86YT('1O('1H92!R=6QE<R8C,38P.V%N9"!R96=U
M;&%T:6]N<R!O9B!T:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES
M<VEO;B`H=&AE("8C.#(R,#M314,F(S@R,C$[*2!F;W(@<F5P;W)T:6YG(&]N
M($9O<FTF(S$V,#LQ,"U1+B!!8V-O<F1I;F=L>2P@8V5R=&%I;B!I;F9O<FUA
M=&EO;B!A;F0@9F]O=&YO=&4@9&ES8VQO<W5R92!N;W)M86QL>2!I;F-L=61E
M9"!I;B!F:6YA;F-I86P@<W1A=&5M96YT<R!P<F5P87)E9"!I;B!A8V-O<F1A
M;F-E('=I=&@@52Y3+B!'04%0(&AA=F4@8F5E;B!C;VYD96YS960@;W(@;VUI
M='1E9"!P=7)S=6%N="!T;R!S=6-H(')U;&5S)B,Q-C`[86YD(')E9W5L871I
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M,#LR,BP@,C`Q-"P@<F5L871I;F<@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!2
M96=I<W1R871I;VX@4W1A=&5M96YT<R!O;B!&;W)M)B,Q-C`[4RTQ("A&:6QE
M($YO+B8C,38P.S,S,RTQ.30V,C$I(&9O<B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
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M;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,30@87)E(&YO="!N96-E<W-A<FEL>2!I
M;F1I8V%T:79E(&]F('1H92!O<&5R871I;F<@<F5S=6QT<R!F;W(@=&AE(&9U
M;&P@9FES8V%L('EE87(@;W(@86YY(&9U='5R92!P97)I;V0N/"]F;VYT/CPO
M<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A
M95]A,C4Q7S0W-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-E<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8V5S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^,BX@4W5M;6%R>2!O9B!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC97,\+V9O;G0^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
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M87,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,R!I;F-L=61E9"!I;B!T:&4@
M4')O<W!E8W1U<R!T:&%T(&9O<FUS(&$@<&%R="!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(%)E9VES=')A=&EO;B!3=&%T96UE;G0@;VX@1F]R;28C,38P.U,M
M,2!D871E9"!-87DF(S$V,#LR,BP@,C`Q-"X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^57-E(&]F($5S=&EM
M871E<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E1H92!P<F5P87)A=&EO;B!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET
M:"!5+E,N)B,Q-C`[1T%!4"!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4@
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
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M<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#(^4W1O8VL@4W!L:70\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY/;B!-87DF(S$V,#LU+"`R
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M;'5E(&]F("0P+C`P,#$@<&5R('-H87)E+B!!8V-O<F1I;F=L>2P@=&AE('-T
M;V-K:&]L9&5R<R8C.#(Q-SL@9&5F:6-I="!R969L96-T<R!T:&4@<W1O8VL@
M<W!L:70@8GD@<F5C;&%S<VEF>6EN9R!F<F]M("8C.#(R,#M!9&1I=&EO;F%L
M('!A:60M:6X@0V%P:71A;"8C.#(R,3L@=&\@)B,X,C(P.T-O;6UO;B!3=&]C
M:R8C.#(R,3L@:6X@86X@86UO=6YT(&5Q=6%L('1O('1H92!P87(@=F%L=64@
M;V8@=&AE(&EN8W)E87-E9"!S:&%R97,@<F5S=6QT:6YG(&9R;VT@=&AE('-T
M;V-K('-P;&ET+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D9A:7(@5F%L
M=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]F;VYT/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^26X@86-C;W)D
M86YC92!W:71H($%30R`X,C4L(#QI/D9I;F%N8VEA;"!);G-T<G5M96YT<SPO
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M9F%I<B!V86QU92`H<V5E($YO=&4F(S$V,#LS*2X\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^1FEN86YC:6%L(&EN<W1R=6UE;G1S+"!I;F-L=61I;F<@86-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<RP@87)E(&-A
M<G)I960@870@8V]S="P@=VAI8V@@87!P<F]X:6UA=&5S(&9A:7(@=F%L=64@
M9VEV96X@=&AE:7(@<VAO<G0M=&5R;2!N871U<F4N/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#(^5V%R<F%N=',\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!A8V-O
M=6YT<R!F;W(@:71S('=A<G)A;G1S('1O('!U<F-H87-E(')E9&5E;6%B;&4@
M8V]N=F5R=&EB;&4@<W1O8VL@:6X@86-C;W)D86YC92!W:71H($%30R`T.#`L
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M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@8V]M<&QE=&EO;B!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&EN($UA
M>28C,38P.S(P,30L('1H92!W87)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@
M;V8@4V5R:65S)B,Q-C`[02TQ(&%N9"!397)I97,F(S$V,#M!+3(@<')E9F5R
M<F5D('-T;V-K(&5X<&ER960@=6YE>&5R8VES960@86YD('1H92!W87)R86YT
M<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@4V5R:65S)B,Q-C`[0R!P<F5F97)R
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M(&5A8V@@<F5P;W)T:6YG('!E<FEO9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V9O;G0^/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@0V]M
M<&%N>2!A8V-O=6YT<R!F;W(@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&EN
M(&%C8V]R9&%N8V4@=VET:"!!4T,@-S$X+"`\:3Y#;VUP96YS871I;VXM4W1O
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M86P@<&%I9"UI;B!C87!I=&%L+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07=A<F1S(&9O<B!C;VYS=6QT86YT
M<R!A<F4@86-C;W5N=&5D(&9O<B!U;F1E<B!!4T,@-3`U+34P+"`\:3Y%<75I
M='D@0F%S960@4&%Y;65N=',@=&\@3F]N+45M<&QO>65E<SPO:3XN($%N>2!C
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O(&-O;G-U;'1A;G1S(&ES
M(&UA<FME9"UT;RUM87)K970@;W9E<B!T:&4@87!P;&EC86)L92!V97-T:6YG
M('!E<FEO9"!A<R!T:&5Y('9E<W0N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/DYE="!,;W-S(%!E<B!3:&%R
M93PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
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M('!E<FEO9',@<')E<V5N=&5D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M7
M24142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93LG(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`W,"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R-BXU)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(V)2!C;VQS<&%N/3-$,SX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/DIU;F4F(S$V,#LS,#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/C(P,30\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#<P
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^."PX,#DL,S(U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<P)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-S`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@=V%R<F%N=',\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C(X-RPP,C@\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^0V]M;6]N('-T;V-K('=A<G)A;G1S/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF
M(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXV,BPU,#4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^0V]M;6]N('-T;V-K(&]P=&EO;G,\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ
M+#,T,2PW,S$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXQ+#<U,"PQ,C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W
M,"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,3`L-#,X+#`X-#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T
M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#@Q,BPV,C4\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&5S('-U;6UA<FEZ97,@=&AE
M($-O;7!A;GDF(S@R,3<[<R!C;VUP=71A=&EO;B!O9B!B87-I8R!A;F0@9&EL
M=71E9"!N970@;&]S<R!P97(@<VAA<F4@9F]R(&-O;6UO;B!S=&]C:VAO;&1E
M<G,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL
M969T.U=)1%1(.B`X,RXS,B4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($U!4D=)3BU,1494.B`P+C<U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X,R4^#0H-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,S$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E(&-O
M;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5&AR964F
M(S$V,#M-;VYT:',F(S$V,#M%;F1E9#QB<B`O/@T*2G5N928C,38P.S,P/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY.
M=6UE<F%T;W(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DYE="!L
M;W-S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#,L-C$Y+#@W.3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,2XQ,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B@S+#<Q."PT,#$\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#$N,3(U<'0[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D1E;F]M:6YA=&]R
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY$96YO;6EN871O<B!F
M;W(@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
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M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXU,2PT.3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C@L,#`P+#`Y,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY.970@;&]S<R!P97(@<VAA<F4L(&)A<VEC(&%N9"!D:6QU=&5D
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X
M="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@W,"XR.3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,2XQ,C5P=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH
M,"XT-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,2XQ,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S
M+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S,2XX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S,24@8V]L<W!A;CTS1#4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3Y3:7@F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#QB<B`O/@T*2G5N928C
M,38P.S,P/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
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M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^3G5M97)A=&]R/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY.970@;&]S<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,#8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B@X+#(Q-BPQ,#D\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#$N,3(U<'0[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXH,BPX-SDL,3`X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V
M,R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY$96YO;6EN871O<CPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^1&5N;VUI;F%T;W(@9F]R(&)A<VEC(&%N
M9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^-#8L.#8U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#`W-"PW,S0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3F5T
M(&QO<W,@<&5R('-H87)E+"!B87-I8R!A;F0@9&EL=71E9#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,BXR-7!T(&1O
M=6)L93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXH,3<U+C,Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C(U<'0[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#`N-S$\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N,C5P
M=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,CY296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO9F]N=#X\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`T,"XU<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY);B!*=6YE)B,Q-C`[,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG
M(%-T86YD87)D<R!";V%R9"`H1D%30BD@:7-S=65D($%352!.;RXF(S$V,#LR
M,#$T+3$P+"!W:&EC:"!E;&EM:6YA=&5S('1H92!C;VYC97!T(&]F(&$@9&5V
M96QO<&UE;G0@<W1A9V4@96YT:71Y+"!O<B!$4T4L(&EN(&ET<R!E;G1I<F5T
M>2!F<F]M($=!05`N)B,Q-C`[(%5N9&5R(&-U<G)E;G0@9W5I9&%N8V4L($13
M17,@87)E(')E<75I<F5D('1O(')E<&]R="!I;F-R96UE;G1A;"!I;F9O<FUA
M=&EO;BP@:6YC;'5D:6YG(&EN8V5P=&EO;BUT;RUD871E(&9I;F%N8VEA;"!I
M;F9O<FUA=&EO;BP@:6X@=&AE:7(@9FEN86YC:6%L('-T871E;65N=',N)B,Q
M-C`[($$@1%-%(&ES(&%N(&5N=&ET>2!D979O=&EN9R!S=6)S=&%N=&EA;&QY
M(&%L;"!O9B!I=',@969F;W)T<R!T;R!E<W1A8FQI<VAI;F<@82!N97<@8G5S
M:6YE<W,@86YD(&9O<B!W:&EC:"!E:71H97(@<&QA;FYE9"!P<FEN8VEP86P@
M;W!E<F%T:6]N<R!H879E(&YO="!Y970@8V]M;65N8V5D(&]R(&AA=F4@8V]M
M;65N8V5D(&)U="!T:&5R92!H87,@8F5E;B!N;R!S:6=N:69I8V%N="!R979E
M;G5E(&=E;F5R871E9"!F<F]M('1H870@8G5S:6YE<W,N)B,Q-C`[($5N=&ET
M:65S(&-L87-S:69I960@87,@1%-%<R!W:6QL(&YO(&QO;F=E<B!B92!S=6)J
M96-T('1O('1H97-E(&EN8W)E;65N=&%L(')E<&]R=&EN9R!R97%U:7)E;65N
M=',@869T97(@861O<'1I;F<@05-5($YO+B8C,38P.S(P,30M,3`N)B,Q-C`[
M($%352!.;RXF(S$V,#LR,#$T(&ES(&5F9F5C=&EV92!F;W(@9FES8V%L('EE
M87)S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B8C,38P.S$U+"`R,#$T+"!W
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M;F-E(&ET<R!I;F-E<'1I;VXN)B,Q-C`[(%1H92!#;VUP86YY(&5L96-T960@
M=&\@861O<'0@=&AI<R!!4U4@96%R;'DL(&%N9"!T:&5R969O<F4@:70@:&%S
M(&5L:6UI;F%T960@=&AE(&EN8W)E;65N=&%L(&1I<V-L;W-U<F5S('!R979I
M;W5S;'D@<F5Q=6ER960@;V8@1%-%<RP@8F5G:6YN:6YG('=I=&@@=&AI<R!1
M=6%R=&5R;'D@4F5P;W)T(&]N($9O<FTF(S$V,#LQ,"U1+CPO9F]N=#X\+W`^
M#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C,35C9C@S85]C8F0Q7S0S865?
M83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-
M96%S=7)E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU
M92!-96%S=7)E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0R/C,N($9A:7(@5F%L=64@365A<W5R96UE;G1S/"]F;VYT
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
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M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D9A
M:7(@=F%L=64@:7,@9&5F:6YE9"!A<R!T:&4@97AC:&%N9V4@<')I8V4@=&AA
M="!W;W5L9"!B92!R96-E:79E9"!F;W(@86X@87-S970@;W(@<&%I9"!T;R!T
M<F%N<V9E<B!A(&QI86)I;&ET>2`H86X@97AI="!P<FEC92D@:6X@=&AE('!R
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M9F%I<B!V86QU92!A<F4@87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,Q.#,[/&9O;G0@<W1Y;&4],T0G1D].5#H@-W!T(%1I;65S
M($YE=R!2;VUA;CLG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X\+V9O;G0^(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DQE=F5L)B,Q
M-C`[,28C,38P.R8C.#(Q,CL@475O=&5S('!R:6-E<R!I;B!A8W1I=F4@;6%R
M:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,N(%1H
M92!#;VUP86YY)B,X,C$W.W,@3&5V96PF(S$V,#LQ(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@8V]N<VES="!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I
M;CL@34%21TE..B`P:6X@,&EN(#!P="`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P:6X@
M,&EN(#!P="`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG('-I>F4],T0R/B8C,3@S.SQF;VYT('-T>6QE/3-$)T9/3E0Z(#=P="!4
M:6UE<R!.97<@4F]M86X[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^/"]F;VYT/B`\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,979E
M;"8C,38P.S(F(S$V,#LF(S@R,3([($EN<'5T<R!O=&AE<B!T:&%N($QE=F5L
M)B,Q-C`[,2!T:&%T(&%R92!O8G-E<G9A8FQE+"!E:71H97(@9&ER96-T;'D@
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M,38P.S(@87-S971S(&]R(&QI86)I;&ET:65S+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN
M(#!P="`P+C<U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG('-I>F4],T0R/B8C,3@S
M.SQF;VYT('-T>6QE/3-$)T9/3E0Z(#=P="!4:6UE<R!.97<@4F]M86X[)R!S
M:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4
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M;G0@;&EA8FEL:71Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="`P+C<U:6X[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
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M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@<V5T<R!F;W)T
M:"!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!M
M96%S=7)E9"!A="!F86ER('9A;'5E(&)Y(&QE=F5L('=I=&AI;B!T:&4@9F%I
M<B!V86QU92!H:65R87)C:'D@87,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,R!A;F0@2G5N928C,38P.S,P+"`R,#$T+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@.#,N,S0E.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XW-6EN.R<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.#,E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-#8N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^3&5V96PF(S$V,#LQ/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#$^3&5V96PF(S$V,#LR/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^3&5V96PF(S$V,#LS/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-#8N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R
M/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-#8N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0V
M+C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1T;W`@=VED=&@],T0T-B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR
M+#`V-BPQ-38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#0V+C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1T;W`@=VED=&@],T0T-B4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1O=&%L(&%S<V5T<R!A="!F86ER
M('9A;'5E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
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M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
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M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+#`V-BPQ-38\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,:6%B:6QI=&EE<SH\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY397)I97,F(S$V,#M!
M+3$@=V%R<F%N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C$R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0S."PY-S@\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY397)I97,F(S$V,#M!
M+3(@=V%R<F%N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C8T+#4S-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0V+C8E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1T;W`@=VED=&@],T0T-B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/E-E<FEE<R8C,38P.T,@=V%R<F%N=',\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R
M,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C$T,"PY-C,\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A;"!L:6%B:6QI=&EE<R!A
M="!F86ER('9A;'5E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
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M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
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M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
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M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
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M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV-#0L
M-#<X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/E1H92!S:6=N:69I8V%N="!A<W-U;7!T:6]N<R!U<V5D(&EN('!R97!A<FEN
M9R!T:&4@;W!T:6]N('!R:6-I;F<@;6]D96P@9F]R('9A;'5I;F<@=&AE($-O
M;7!A;GDF(S@R,3<[<R!W87)R86YT<R!A<R!O9B!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$S(&EN8VQU9&4@*&DI)B,Q-C`[=F]L871I;&ET>2`H,3`T+C@E*2P@
M*&EI*28C,38P.W)I<VL@9G)E92!I;G1E<F5S="!R871E(&]F(#$N.30E("AE
M<W1I;6%T960@=7-I;F<@=')E87-U<GD@8F]N9',@=VET:"!A(#8F(S$V,#MY
M96%R(&QI9F4I+"`H:6EI*28C,38P.W-T<FEK92!P<FEC92`H)#$P+C`P*2!F
M;W(@=&AE(%-E<FEE<R8C,38P.T$M,2!A;F0@4V5R:65S)B,Q-C`[02TR('=A
M<G)A;G1S(&%N9"`D,34N,#`@9F]R('1H92!397)I97,F(S$V,#M#('=A<G)A
M;G1S+"`H:78I)B,Q-C`[9F%I<B!V86QU92!O9B!397)I97,F(S$V,#M!+3$@
M<')E9F5R<F5D('-T;V-K("@D-"XQ-RDL(%-E<FEE<R8C,38P.T$M,B!P<F5F
M97)R960@<W1O8VL@*"0R+CDQ*2!A;F0@4V5R:65S)B,Q-C`[0R!P<F5F97)R
M960@<W1O8VL@*"0W+C8S*2!A;F0@*'8I)B,Q-C`[97AP96-T960@;&EF92`H
M<VEX('EE87)S*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@:7,@82!R;VQL9F]R=V%R
M9"!O9B!T:&4@9F%I<B!V86QU92!O9B!,979E;"8C,38P.S,@=V%R<F%N=',Z
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T
M.U=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)
M3BU,1494.B`P+C<U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0X,"4^#0H-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X,"XV,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#@P
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M0F5G:6YN:6YG(&)A;&%N8V4@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8T
M-"PT-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X,"XV,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#@P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^17AP:7)A=&EO;B!O9B!397)I97,F(S$V,#M!+3$@86YD(%-E<FEE<R8C
M,38P.T$M,B!W87)R86YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B@T.3,L,S8Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X,"XV,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#@P
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M0VAA;F=E(&EN(&9A:7(@=F%L=64\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,S`Q+#`T,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#@P+C8R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#`E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%;F1I;F<@8F%L86YC
M92!A="!*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^-#4R+#$U-SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ
M;&5F=#M724142#H@-S<N,S0E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!-05)'24XM3$5&5#H@,"XX-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S<E/@T*#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N-#8E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DQE
M=F5L)B,Q-C`[,3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0Q/DQE=F5L)B,Q-C`[,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/DQE=F5L)B,Q-C`[,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0R+C0V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-#(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^2G5N928C,38P
M.S,P+"`R,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0R+C0V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-#(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<W-E=',Z/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-#(N-#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1T;W`@=VED=&@],T0T,B4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXU,RPS.3<L,#<W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`T,BXT-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&]T
M86P@87-S971S(&%T(&9A:7(@=F%L=64\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C4S+#,Y-RPP-S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T,BXT-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#0R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^3&EA8FEL:71I97,Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-#(N-#8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1T;W`@=VED=&@],T0T,B4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!W87)R86YT
M<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N
M-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#4R+#$U-SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0R+C0V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#(E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A
M;"!L:6%B:6QI=&EE<R!A="!F86ER('9A;'5E/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
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M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
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M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
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M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXT-3(L,34W/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!S:6=N:69I8V%N="!A<W-U
M;7!T:6]N<R!U<V5D(&EN('!R97!A<FEN9R!T:&4@;W!T:6]N('!R:6-I;F<@
M;6]D96P@9F]R('9A;'5I;F<@=&AE($-O;7!A;GDF(S@R,3<[<R!W87)R86YT
M<R!A<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,30@:6YC;'5D92`H:2DF(S$V,#MV
M;VQA=&EL:71Y("@Q,#0N."4I+"`H:6DI)B,Q-C`[<FES:R!F<F5E(&EN=&5R
M97-T(')A=&4@;V8@,2XY-"4@*&5S=&EM871E9"!U<VEN9R!T<F5A<W5R>2!B
M;VYD<R!W:71H(&$@-2XU)B,Q-C`[>65A<B!L:69E*2P@*&EI:2DF(S$V,#MS
M=')I:V4@<')I8V4@*"0V+C`P*2!F;W(@=&AE(&-O;6UO;B!S=&]C:R!W87)R
M86YT<RP@*&EV*28C,38P.V9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K("@D
M."XW,BD@86YD("AV*28C,38P.V5X<&5C=&5D(&QI9F4@*#4N-28C,38P.WEE
M87)S*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE<F4@=V5R92!N;R!T
M<F%N<V9E<G,@8F5T=V5E;B!,979E;"8C,38P.S$L(#(@;W(@,R!D=7)I;F<@
M,C`Q,R!O<B`R,#$T+B!)9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&5S=&EM871E
M<R!R96=A<F1I;F<@=&AE(&9A:7(@=F%L=64@;V8@:71S('=A<G)A;G1S(&%R
M92!I;F%C8W5R871E+"!A(&9U='5R92!A9&IU<W1M96YT('1O('1H97-E(&5S
M=&EM871E9"!F86ER('9A;'5E<R!M87D@8F4@<F5Q=6ER960N($%D9&ET:6]N
M86QL>2P@=&AE<V4@97-T:6UA=&5D(&9A:7(@=F%L=65S(&-O=6QD(&-H86YG
M92!S:6=N:69I8V%N=&QY+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?
M-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R
M<F5N="!!<W-E=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F5P86ED($5X<&5N<V5S(&%N9"!/=&AE<B!#=7)R
M96YT($%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!!
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,CXT+B!0<F5P86ED($5X<&5N<V5S(&%N9"!/=&AE<B!#=7)R96YT($%S
M<V5T<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E
M;G0@87-S971S(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9SH\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#8U,G!X.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!-05)'24XM3$5&5#H@,"XX-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C4R/@T*#0H\='(@
M<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)
M3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0
M.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^1&5C96UB97(F(S$V,#LS,2P\8G(@+SX-"C(P,3,\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y*=6YE)B,Q
M-C`[,S`L/&)R("\^#0HR,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,"XS<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY0<F5P86ED(&EN<W5R86YC93PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
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M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0X+#`U-3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
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M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8P-"PS,C`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C$N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1T;W`@=VED=&@],T0V,24^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3`N,W!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3W1H97(\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^.3@L-C0Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4V+#@Y.#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V,2XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,"XS<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A;"!P<F5P86ED(&5X
M<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,30V+#<P-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]2
M1$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C8Q+#(Q
M.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q
M7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P
M+U=O<FMS:&5E=',O4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D%C8W)U960@3&EA8FEL:71I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-R=65D
M($QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-R=65D($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^-2X@06-C<G5E9"!,:6%B
M:6QI=&EE<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D%C8W)U960@;&EA8FEL:71I97,@8V]N<VES="!O
M9B!T:&4@9F]L;&]W:6YG.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$
M)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,24=..B!L969T.R!724142#H@-C0W
M<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`P
M+C@U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0V-#<^#0H-"CQT<B!S='EL93TS1"=P861D:6YG.C`[
M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)
M3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/D1E8V5M8F5R)B,Q-C`[,S$L/&)R("\^#0HR,#$S
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^2G5N928C
M,38P.S,P+#QB<B`O/@T*,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8Q
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M16UP;&]Y964@8F]N=7-E<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C(S."PY-#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR-30L,3,U/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ-#`L,C(S
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q.2PQ,S4\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C$N
M,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1T;W`@=VED=&@],T0V,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/E1O=&%L(&%C8W)U960@;&EA8FEL:71I97,\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C,W.2PQ-C0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C,W,RPR-S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U
M8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W
M-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(
M2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYV97)T:6)L92!.;W1E($9I
M;F%N8VEN9R`H0V]N=F5R=&EB;&4@3F]T97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE($YO=&4@1FEN86YC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,CXV+B!#;VYV97)T:6)L92!.;W1E($9I;F%N
M8VEN9SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/D]N($%P<FEL)B,Q-C`[,C@L(#(P,30L('1H92!#;VUP
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M(&%G<F5E9"!T;R!L;V%N('1H92!#;VUP86YY(&%N(&%G9W)E9V%T92!O9B`D
M,RXP)B,Q-C`[;6EL;&EO;BX@5&AE($-O;7!A;GD@:7-S=65D($-O;G9E<G1I
M8FQE(%!R;VUI<W-O<GD@3F]T97,@*'1H92`F(S@R,C`[3F]T97,F(S@R,C$[
M*2!T;R!E=FED96YC92!I=',@<&%Y;65N="!O8FQI9V%T:6]N<R!W:71H(')E
M<W!E8W0@=&\@=&AE("0S+C`F(S$V,#MM:6QL:6]N+B!4:&4@3F]T97,@:&%D
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M871I8V%L;'D@8V]N=F5R=&5D(&EN=&\@-3`S+#0U,"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&%T("0V+C`P('!E<B!S:&%R92!W:&EC:"!W87,@97%U86P@
M=&\@=&AE('!U<F-H87-E('!R:6-E(&%T('=H:6-H('-H87)E<R!W97)E('-O
M;&0@=&\@=&AE('!U8FQI8R!I;B!A;B!U;F1E<G=R:71T96X@<'5B;&EC(&]F
M9F5R:6YG("AS964@3F]T92`X*2X@5&AE($YO=&5S('=E<F4@<W5B;W)D:6YA
M=&4@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!T97)M(&QO86X@=VET:"!/>&9O
M<F0@1FEN86YC92!,3$,N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U8V8X,V%?8V)D,5\T
M,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,"]7
M;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2#X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY497)M($QO86X@06UE;F1M96YT("A497)M(&QO86XI
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E<FT@
M;&]A;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y497)M($QO86X@06UE;F1M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXW+B!497)M($QO86X@06UE;F1M96YT
M/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^26X@2F%N=6%R>28C,38P.S(P,30@=&AE($-O;7!A;GD@86UE
M;F1E9"!I=',@3&]A;B!!9W)E96UE;G0@=VET:"!/>&9O<F0@1FEN86YC92!W
M:&5R96)Y('1H92!I;G1E<F5S="!O;FQY('!E<FEO9"!W87,@97AT96YD960@
M9F]R('1H<F5E(&UO;G1H<R`H=&AR;W5G:"!!<')I;"8C,38P.S$L(#(P,30I
M+B!4:&4@:6YT97)E<W0@;VYL>2!P97)I;V0@=V%S(&5X=&5N9&5D(&9O<B!A
M;B!A9&1I=&EO;F%L('1H<F5E(&UO;G1H<R`H=&AR;W5G:"!*=6QY)B,Q-C`[
M,2P@,C`Q-"D@87,@82!R97-U;'0@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R`D
M,RXP)B,Q-C`[;6EL;&EO;B!C;VYV97)T:6)L92!N;W1E(&9I;F%N8VEN9R!I
M;B!W:&EC:"!W87,@8V]M<&QE=&5D(&EN($%P<FEL)B,Q-C`[,C`Q-"`H<V5E
M($YO=&4F(S$V,#LV*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(&EN
M=&5R97-T(&]N;'D@<&5R:6]D('=A<R!F=7)T:&5R(&5X=&5N9&5D(&9O<B!A
M;B!A9&1I=&EO;F%L('-I>"!M;VYT:',@*'1H<F]U9V@@2F%N=6%R>28C,38P
M.S$L(#(P,34I(&%N9"!T:&4@;6%T=7)I='D@9&%T92!O9B!T:&4@;&]A;B!W
M87,@97AT96YD960@=&\@2G5L>28C,38P.S$L(#(P,3<@87,@82!R97-U;'0@
M;V8@=&AE(&-O;7!L971I;VX@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!I;FET
M:6%L('!U8FQI8R!O9F9E<FEN9R`H<V5E($YO=&4@."DN($EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@86UE;F1M96YT('1O('1H92!,;V%N($%G<F5E;65N="!T
M:&4@0V]M<&%N>2!H87,@<&%I9"!/>&9O<F0@1FEN86YC92!A('1O=&%L(&]F
M("0Q-3`L,#`P+B8C,38P.R!4:&4@)#$U,"PP,#`@:&%S(&)E96X@;V9F<V5T
M(&%G86EN<W0@=&AE(&%M;W5N="!O9B!T:&4@;&]A;B!A;F0@:7,@8F5I;F<@
M86UO<G1I>F5D('1O(&EN=&5R97-T(&5X<&5N<V4N/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/D%T($IU;F4F(S$V,#LS,"P@,C`Q-"P@=&AE($-O;7!A;GD@
M8F5L:65V97,@:70@:7,@:6X@8V]M<&QI86YC92!W:71H('1H92!,;V%N($%G
M<F5E;65N="X\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U
M,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXX+B!3=&]C:VAO;&1E<G,F(S@R,3<[
M($5Q=6ET>3PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQI/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^26YI=&EA
M;"!0=6)L:6,@3V9F97)I;F<@86YD(%)E;&%T960@5')A;G-A8W1I;VYS/"]F
M;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^3VX@36%Y)B,Q-C`[,C,L(#(P,30L('1H92!#;VUP86YY(&-O;7!L
M971E9"!I=',@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<@<V5L;&EN9R`Y+#$V
M-BPV-C<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@<VAA
M<F4N)B,Q-C`[(%!R;V-E961S(&9R;VT@=&AE($-O;7!A;GDF(S@R,3<[<R!I
M;FET:6%L('!U8FQI8R!O9F9E<FEN9RP@;F5T(&]F('5N9&5R=W)I=&EN9R!D
M:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS(&%N9"!O=&AE<B!O9F9E<FEN9R!C
M;W-T<R!W97)E("0T.2XW(&UI;&QI;VXN/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY);B!A9&1I=&EO;BP@96%C
M:"!O9B!T:&4@9F]L;&]W:6YG(&]C8W5R<F5D(&EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@8V]M<&QE=&EO;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS($E03R!O
M;B!-87DF(S$V,#LR,RP@,C`Q-#H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T(#`N
M-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<@<VEZ93TS
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M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P
M="`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG('-I
M>F4],T0R/B8C,3@S.SQF;VYT('-T>6QE/3-$)T9/3E0Z(#=P="!4:6UE<R!.
M97<@4F]M86X[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^/"]F;VYT/B`\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CYT:&4@8V]N=F5R
M<VEO;B!O9B!T:&4@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#,N
M,"!M:6QL:6]N(&%N9"!A8V-R=65D(&EN=&5R97-T('5N9&5R('1H92!#;VUP
M86YY)B,X,C$W.W,@;W5T<W1A;F1I;F<@8V]N=F5R=&EB;&4@<W5B;W)D:6YA
M=&5D('!R;VUI<W-O<GD@;F]T97,@:6YT;R`U,#,L-#4P('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^3VX@36%Y)B,Q-C`[-RP@,C`Q-"P@=&AE
M($-O;7!A;GD@9FEL960@86X@86UE;F1M96YT('1O(&ET<R!A;65N9&5D(&%N
M9"!R97-T871E9"!C97)T:69I8V%T92!O9B!I;F-O<G!O<F%T:6]N('=H:6-H
M+"!A;6]N9R!O=&AE<B!T:&EN9W,L(')E=FES960@=&AE(&%U=&]M871I8R!C
M;VYV97)S:6]N('!R;W9I<VEO;B!R96QA=&EN9R!T;R!T:&4@4V5R:65S)B,Q
M-C`[0R!0<F5F97)R960@4W1O8VLL(%-E<FEE<R8C,38P.T(@4')E9F5R<F5D
M(%-T;V-K+"!397)I97,F(S$V,#M!+3$@4')E9F5R<F5D(%-T;V-K(&%N9"!3
M97)I97,F(S$V,#M!+3(@4')E9F5R<F5D(%-T;V-K+B!&;VQL;W=I;F<@<W5C
M:"!A;65N9&UE;G0L('1H92!397)I97,F(S$V,#M#+"!T:&4@4V5R:65S)B,Q
M-C`[0BP@=&AE(%-E<FEE<R8C,38P.T$M,2!A;F0@02TR(%!R969E<G)E9"!3
M=&]C:R!N;W<@875T;VUA=&EC86QL>2!C;VYV97)T(&EN=&\@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!A="!T:&4@=&AE;B!E9F9E8W1I=F4@8V]N=F5R<VEO
M;B!P<FEC92!U<&]N.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*&DI)B,Q-C`[=&AE
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M87-T("0T-2PP,#`L,#`P(&]R("AI:2DF(S$V,#MT:&4@869F:7)M871I=F4@
M=F]T92!O9B!T:&4@:&]L9&5R<R!O9B!A="!L96%S="!A(&UA:F]R:71Y(&]F
M('1H92!V;W1I;F<@<&]W97(@=&AE(%-E<FEE<R8C,38P.T,@4')E9F5R<F5D
M(%-T;V-K+"!T:&4@4V5R:65S)B,Q-C`[0B!0<F5F97)R960@4W1O8VL@86YD
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M=FER='5E(&]F('-U8V@@<'5B;&EC(&]F9F5R:6YG+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3VX@36%Y)B,Q
M-C`[,CDL(#(P,30L('1H92!#;VUP86YY(&9I;&5D(&%N(&%M96YD960@86YD
M(')E<W1A=&5D(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R871I;VX@*'1H92`F
M(S@R,C`[4F5S=&%T960@0V5R=&EF:6-A=&4F(S@R,C$[*2!W:71H('1H92!3
M96-R971A<GD@;V8@4W1A=&4@;V8@=&AE(%-T871E(&]F($1E;&%W87)E(&EN
M(&-O;FYE8W1I;VX@=VET:"!T:&4@8VQO<VEN9R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&]F('-H87)E<R!O9B!I
M=',@8V]M;6]N('-T;V-K+B!4:&4@0V]M<&%N>28C.#(Q-SMS(&)O87)D(&]F
M(&1I<F5C=&]R<R`H=&AE("8C.#(R,#M";V%R9"8C.#(R,3LI(&%N9"!S=&]C
M:VAO;&1E<G,@<')E=FEO=7-L>2!A<'!R;W9E9"!T:&4@4F5S=&%T960@0V5R
M=&EF:6-A=&4@969F96-T:79E(&%S(&]F(&%N9"!C;VYT:6YG96YT('5P;VX@
M=&AE(&-L;W-I;F<@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!I;FET:6%L('!U
M8FQI8R!O9F9E<FEN9RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(%)E
M<W1A=&5D($-E<G1I9FEC871E(&%M96YD<R!A;F0@<F5S=&%T97,@:6X@:71S
M(&5N=&ER971Y('1H92!#;VUP86YY)B,X,C$W.W,@<V5C;VYD(&%M96YD960@
M86YD(')E<W1A=&5D(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R871I;VXL(&%S
M(&%M96YD960N(%1H92!297-T871E9"!#97)T:69I8V%T92P@86UO;F<@;W1H
M97(@=&AI;F=S.B`H:2DF(S$V,#MA=71H;W)I>F5S(#$U,"PP,#`L,#`P('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL[("AI:2DF(S$V,#ME;&EM:6YA=&5S(&%L
M;"!R969E<F5N8V5S('1O('1H92!P<F5V:6]U<VQY(&5X:7-T:6YG('-E<FEE
M<R!O9B!P<F5F97)R960@<W1O8VL[("AI:6DI)B,Q-C`[875T:&]R:7IE<R`Q
M,"PP,#`L,#`P('-H87)E<R!O9B!U;F1E<VEG;F%T960@<')E9F5R<F5D('-T
M;V-K('1H870@;6%Y(&)E(&ES<W5E9"!F<F]M('1I;64@=&\@=&EM92!B>2!T
M:&4@0F]A<F0@:6X@;VYE(&]R(&UO<F4@<V5R:65S.R`H:78I)B,Q-C`[<')O
M=FED97,@=&AA="!T:&4@0F]A<F0@8F4@9&EV:61E9"!I;G1O('1H<F5E(&-L
M87-S97,@=VET:"!S=&%G9V5R960@=&AR964M>65A<B!T97)M<RP@=VET:"!O
M;F4@8VQA<W,@;V8@9&ER96-T;W)S('1O(&)E(&5L96-T960@870@96%C:"!A
M;FYU86P@;65E=&EN9R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K:&]L
M9&5R<SL@*'8I)B,Q-C`[<')O=FED97,@=&AA="!D:7)E8W1O<G,@;6%Y(&]N
M;'D@8F4@<F5M;W9E9"!W:71H(&-A=7-E(&%N9"!O;FQY('5P;VX@=&AE(&%F
M9FER;6%T:79E('9O=&4@;V8@:&]L9&5R<R!O9B!A="!L96%S="`W-24@;V8@
M=&AE('9O=&EN9R!P;W=E<B!O9B!A;&P@=&AE;BUO=71S=&%N9&EN9R!S:&%R
M97,@;V8@8V%P:71A;"!S=&]C:R!O9B!T:&4@0V]M<&%N>2!E;G1I=&QE9"!T
M;R!V;W1E(&=E;F5R86QL>2!I;B!T:&4@96QE8W1I;VX@;V8@9&ER96-T;W)S
M.R`H=FDI)B,Q-C`[<')O=FED97,@=&AA="!O;FQY('1H92!";V%R9"P@=&AE
M(&-H86ER;6%N(&]F('1H92!";V%R9"P@:68@;VYE(&ES(&%P<&]I;G1E9"P@
M;W(@=&AE(&-H:65F(&5X96-U=&EV92!O9F9I8V5R(&UA>2!C86QL(&$@<W!E
M8VEA;"!M965T:6YG(&]F('-T;V-K:&]L9&5R<SL@86YD("AV:6DI)B,Q-C`[
M<F5Q=6ER97,@=&AA="!A;GD@86-T:6]N(&EN<W1I='5T960@86=A:6YS="!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&]F9FEC97)S(&]R(&1I<F5C=&]R<R!I;B!C
M;VYN96-T:6]N('=I=&@@=&AE:7(@<V5R=FEC92!T;R!T:&4@0V]M<&%N>2!B
M92!B<F]U9VAT(&EN('1H92!3=&%T92!O9B!$96QA=V%R92X\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&D^/&9O;G0@<W1Y
M;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#;VYV97)T
M:6)L92!0<F5F97)R960@4W1O8VL\+V9O;G0^/"]I/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[
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M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\:3X\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]F;VYT/CPO:3X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!S=&]C:R!O<'1I;VYS
M('=A<R!A;&QO8V%T960@87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#@P)3L@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#@P)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8R+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S,RXQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S,R4@8V]L<W!A;CTS1#4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z
M(&)O;&0[)R!S:7IE/3-$,3Y4:')E928C,38P.TUO;G1H<R8C,38P.T5N9&5D
M/&)R("\^#0I*=6YE)B,Q-C`[,S`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXT."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^
M,C`Q,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C(N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T
M;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(Y,BPR-C,\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR
M,#@L.3`X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C$R-2PW,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,34U+#,S,3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A;"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXT,3<L.3<W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
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M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O
M=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C<E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,V-"PR,SD\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S,E(&-O;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^4VEX)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\8G(@+SX-
M"DIU;F4F(S$V,#LS,#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C0X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,30\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-3@T+#<S,CPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,S-2PT,S,\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C4Q
M+#0R-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-38L.3$R/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C(N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1O=&%L('-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
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M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C@S
M-BPQ-3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-3DR+#,T-3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q
M7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C
M,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H965T
M<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>&5S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/CDN
M($EN8V]M92!487AE<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^4V%L92!O9B!.97<@2F5R<V5Y($YE
M="!/<&5R871I;F<@3&]S<V5S/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A;GD@<F5C96EV
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M;R!O=&AE<B!C;VUP86YI97,N($]N($9E8G)U87)Y)B,Q-C`[,C<L(#(P,30L
M('1H92!#;VUP86YY(&-O;7!L971E9"!T:&4@<V%L92!O9B!.3TQS('1O=&%L
M:6YG(&%P<')O>&EM871E;'D@)#,Y+C$F(S$V,#MM:6QL:6]N(&9O<B!N970@
M<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D,RXV)B,Q-C`[;6EL;&EO;BX@
M4W5C:"!P<F]C965D<R!A<F4@<F5F;&5C=&5D(&%S(&$@=&%X(&)E;F5F:70@
M9F]R('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$T+CPO9F]N
M=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q
M,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C,35C9C@S85]C8F0Q
M7S0S865?83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H965T<R]3:&5E=#$U+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E
M9"!087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T
M:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/C$P+B!296QA=&5D(%!A<G1Y
M(%1R86YS86-T:6]N<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D5F9F5C=&EV92!-87)C:"8C,38P.S$W
M+"`R,#$T+"!O;F4@;V8@=&AE($UA;F%G:6YG(%!A<G1N97)S(&]F(%-M87)T
M4&AA<FUA)B,Q-C`[3$Q#(&]R(%-M87)T4&AA<FUA+"!A;B!E;G1I='D@=VAI
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M,C4P(&%N9"`D-S0L,S`P(&]F(&9E97,@9F]R('1H92!T:')E92!A;F0@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,30N/"]F;VYT/CPO<#X-
M"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A
M,C4Q7S0W-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5(1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8V5S("A0;VQI8V5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8V5S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@
M17-T:6UA=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,CY5<V4@;V8@17-T:6UA=&5S/"]F;VYT/CPO8CX\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE('!R97!A<F%T
M:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L('-T871E;65N
M=',@:6X@8V]N9F]R;6ET>2!W:71H(%4N4RXF(S$V,#M'04%0(')E<75I<F5S
M(&UA;F%G96UE;G0@=&\@;6%K92!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS
M('1H870@869F96-T('1H92!A;6]U;G1S(')E<&]R=&5D(&EN('1H92!F:6YA
M;F-I86P@<W1A=&5M96YT<R!A;F0@86-C;VUP86YY:6YG(&YO=&5S+B!4:&4@
M0V]M<&%N>2!B87-E<R!I=',@97-T:6UA=&5S(&%N9"!J=61G;65N=',@;VX@
M:&ES=&]R:6-A;"!E>'!E<FEE;F-E(&%N9"!V87)I;W5S(&]T:&5R(&%S<W5M
M<'1I;VYS('1H870@:70@8F5L:65V97,@87)E(')E87-O;F%B;&4@=6YD97(@
M=&AE(&-I<F-U;7-T86YC97,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
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M(&9R;VT@=&AO<V4@97-T:6UA=&5S+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(%-P;&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,CY3=&]C:R!3<&QI=#PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG
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M=64@;V8@)#`N,#`P,2!P97(@<VAA<F4N($%C8V]R9&EN9VQY+"!T:&4@<W1O
M8VMH;VQD97)S)B,X,C$W.R!D969I8VET(')E9FQE8W1S('1H92!S=&]C:R!S
M<&QI="!B>2!R96-L87-S:69Y:6YG(&9R;VT@)B,X,C(P.T%D9&ET:6]N86P@
M<&%I9"UI;B!#87!I=&%L)B,X,C(Q.R!T;R`F(S@R,C`[0V]M;6]N(%-T;V-K
M)B,X,C(Q.R!I;B!A;B!A;6]U;G0@97%U86P@=&\@=&AE('!A<B!V86QU92!O
M9B!T:&4@:6YC<F5A<V5D('-H87)E<R!R97-U;'1I;F<@9G)O;2!T:&4@<W1O
M8VL@<W!L:70N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&
M:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0R/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN
M<W1R=6UE;G1S/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^26X@86-C;W)D86YC92!W:71H($%30R`X,C4L
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M97%U:79A;&5N=',@87)E(&-A<G)I960@870@9F%I<B!V86QU92`H<V5E($YO
M=&4F(S$V,#LS*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1FEN86YC:6%L
M(&EN<W1R=6UE;G1S+"!I;F-L=61I;F<@86-C;W5N=',@<&%Y86)L92!A;F0@
M86-C<G5E9"!L:6%B:6QI=&EE<RP@87)E(&-A<G)I960@870@8V]S="P@=VAI
M8V@@87!P<F]X:6UA=&5S(&9A:7(@=F%L=64@9VEV96X@=&AE:7(@<VAO<G0M
M=&5R;2!N871U<F4N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/E=A<G)A
M;G1S/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&ET<R!W87)R
M86YT<R!T;R!P=7)C:&%S92!R961E96UA8FQE(&-O;G9E<G1I8FQE('-T;V-K
M(&EN(&%C8V]R9&%N8V4@=VET:"!!4T,@-#@P+"`\:3Y$:7-T:6YG=6ES:&EN
M9R!,:6%B:6QI=&EE<R!F<F]M($5Q=6ET>3PO:3XN($%30R`T.#`@<F5Q=6ER
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M:&5R(&EN8V]M92`H97AP96YS92D@:6X@=&AE('-T871E;65N="!O9B!O<&5R
M871I;VYS+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P
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M,2!A;F0@4V5R:65S)B,Q-C`[02TR('!R969E<G)E9"!S=&]C:R!E>'!I<F5D
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM0F%S960@0V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V9O;G0^/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@0V]M
M<&%N>2!A8V-O=6YT<R!F;W(@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&EN
M(&%C8V]R9&%N8V4@=VET:"!!4T,@-S$X+"`\:3Y#;VUP96YS871I;VXM4W1O
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M86P@<&%I9"UI;B!C87!I=&%L+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07=A<F1S(&9O<B!C;VYS=6QT86YT
M<R!A<F4@86-C;W5N=&5D(&9O<B!U;F1E<B!!4T,@-3`U+34P+"`\:3Y%<75I
M='D@0F%S960@4&%Y;65N=',@=&\@3F]N+45M<&QO>65E<SPO:3XN($%N>2!C
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O(&-O;G-U;'1A;G1S(&ES
M(&UA<FME9"UT;RUM87)K970@;W9E<B!T:&4@87!P;&EC86)L92!V97-T:6YG
M('!E<FEO9"!A<R!T:&5Y('9E<W0N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,CY.970@3&]S<R!097(@4VAA<F4\+V9O;G0^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
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M;G1E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!T
M86)L92!S971S(&9O<G1H('1H92!O=71S=&%N9&EN9R!P;W1E;G1I86QL>2!D
M:6QU=&EV92!S96-U<FET:65S('1H870@:&%V92!B965N(&5X8VQU9&5D(&9R
M;VT@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T(&QO<W,@<&5R('-H
M87)E(&)E8V%U<V4@=&\@9&\@<V\@=V]U;&0@8F4@86YT:2UD:6QU=&EV92`H
M:6X@8V]M;6]N(&5Q=6EV86QE;G0@<VAA<F5S*3H\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#$P,"4[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,C8N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R-B4@
M8V]L<W!A;CTS1#,^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y*=6YE
M)B,Q-C`[,S`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-S`E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C@L
M.#`Y+#,R-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`W,"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K('=A<G)A;G1S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXR.#<L,#(X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R
M,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0W,"4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;6UO
M;B!S=&]C:R!W87)R86YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^-C(L-3`U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D-O;6UO;B!S=&]C:R!O<'1I;VYS/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PS-#$L-S,Q/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2PW-3`L,3(P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0W
M,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/E1O=&%L/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C$P+#0S."PP.#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,2PX,3(L-C(U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@
M9F]L;&]W:6YG('1A8FQE<R!S=6UM87)I>F5S('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M<'5T871I;VX@;V8@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@
M<&5R('-H87)E(&9O<B!C;VUM;VX@<W1O8VMH;VQD97)S.CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@.#,N
M,S(E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@
M,"XW-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.#,E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG.C`[
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+C@R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!C;VQS<&%N/3-$-3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E1H<F5E)B,Q-C`[36]N=&AS)B,Q
M-C`[16YD960\8G(@+SX-"DIU;F4F(S$V,#LS,#PO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^3G5M97)A=&]R/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY.970@;&]S<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N,#8E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@S+#8Q.2PX-SD\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#$N,3(U<'0[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXH,RPW,3@L-#`Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXI/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,CY$96YO;6EN871O<CPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^1&5N;VUI;F%T;W(@9F]R(&)A<VEC(&%N9"!D
M:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-3$L-#DY/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
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M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX+#`P,"PP.3(\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z
M,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3F5T(&QO
M<W,@<&5R('-H87)E+"!B87-I8R!A;F0@9&EL=71E9#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXH-S`N,CD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#$N,3(U<'0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#`N-#8\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#$N,3(U<'0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,S$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E(&-O;'-P
M86X],T0U/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^4VEX)B,Q-C`[
M36]N=&AS)B,Q-C`[16YD960\8G(@+SX-"DIU;F4F(S$V,#LS,#PO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z
M(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/C(P,30\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0R/DYU;65R871O<CPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^3F5T(&QO<W,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXH."PR,38L,3`Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#(L.#<Y+#$P
M.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,2XQ,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#(^1&5N;VUI;F%T;W(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED
M=&@],T0V,R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/D1E;F]M:6YA=&]R(&9O<B!B87-I8R!A;F0@9&EL=71E9"!N970@
M;&]S<R!P97(@<VAA<F4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0V+#@V-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^-"PP-S0L-S,T/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DYE="!L;W-S('!E<B!S:&%R
M92P@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C`V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M*#$W-2XS,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXR-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@P+C<Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C(U<'0[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^4F5C96YT($%C
M8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V9O;G0^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@-#`N-7!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^26X@2G5N928C,38P
M.S(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A
M<F0@*$9!4T(I(&ES<W5E9"!!4U4@3F\N)B,Q-C`[,C`Q-"TQ,"P@=VAI8V@@
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M:6YG($%352!.;RXF(S$V,#LR,#$T+3$P+B8C,38P.R!!4U4@3F\N)B,Q-C`[
M,C`Q-"!I<R!E9F9E8W1I=F4@9F]R(&9I<V-A;"!Y96%R<R!B96=I;FYI;F<@
M869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q-"P@=VET:"!E87)L>2!A9&]P
M=&EO;B!P97)M:71T960N)B,Q-C`[(%)E=')O<W!E8W1I=F4@87!P;&EC871I
M;VX@:7,@<F5Q=6ER960@9F]R('1H92!E;&EM:6YA=&EO;B!O9B!I;F-R96UE
M;G1A;"!$4T4@9&ES8VQO<W5R97,N)B,Q-C`[(%!R:6]R('1O('1H92!I<W-U
M86YC92!O9B!!4U4@3F\N)B,Q-C`[,C`Q-"TQ,"P@=&AE($-O;7!A;GD@:&%D
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M="!O;B!&;W)M)B,Q-C`[,3`M42X\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C
M8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q
M83$P+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8V5S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC97,\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&]U='-T86YD:6YG
M('!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@=&AA="!H879E(&)E
M96X@97AC;'5D960@9G)O;2!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N
M970@;&]S<R!P97(@<VAA<F4@8F5C875S92!T;R!D;R!S;R!W;W5L9"!B92!A
M;G1I+61I;'5T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H('1H92!O
M=71S=&%N9&EN9R!P;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S('1H
M870@:&%V92!B965N(&5X8VQU9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F
M(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&)E8V%U<V4@=&\@9&\@<V\@
M=V]U;&0@8F4@86YT:2UD:6QU=&EV92`H:6X@8V]M;6]N(&5Q=6EV86QE;G0@
M<VAA<F5S*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L
M:6=N.FQE9G0[5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/@T*#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-S`E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,C8N-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R-B4@8V]L<W!A;CTS1#,^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3Y*=6YE)B,Q-C`[,S`\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`W,"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-S`E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@
M=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C@L.#`Y+#,R-3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W,"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K('=A
M<G)A;G1S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR.#<L,#(X/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-S`E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!W87)R86YT<SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C(L-3`U/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-S`E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!O<'1I
M;VYS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,2PS-#$L-S,Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PW-3`L,3(P/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-S`E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1T;W`@=VED=&@],T0W,"4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$P+#0S."PP.#0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PX,3(L-C(U
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,24[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O
M9B!C;VUP=71A=&EO;B!O9B!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P
M97(@<VAA<F4@9F]R(&-O;6UO;B!S=&]C:VAO;&1E<G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ
M,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE
M9G0[5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#8Y-7!X.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XW-6EN.R<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M-CDU/@T*#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-
M.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[
M(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S,2XX,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M,24@8V]L<W!A;CTS1#4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y4
M:')E928C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I*=6YE)B,Q-C`[
M,S`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^3G5M97)A=&]R/"]F;VYT/CPO
M8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^3F5T(&QO<W,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXH,RPV,3DL.#<Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#,L-S$X+#0P,3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,2XQ,C5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,RXY."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D1E;F]M
M:6YA=&]R/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$
M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2
M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1&5N;VUI;F%T;W(@9F]R(&)A
M<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-3$L-#DY/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX+#`P
M,"PP.3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DYE="!L;W-S
M('!E<B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^*#<P+C(Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@P+C0V/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q+C$R-7!T.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M
M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-C,E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S$N.#(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S$E(&-O;'-P86X],T0U/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^4VEX)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\8G(@+SX-
M"DIU;F4F(S$V,#LS,#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,SPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3XR,#$T/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P
M<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8S+CDX)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C,E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#(^3G5M97)A=&]R/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^3F5T(&QO<W,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH."PR
M,38L,3`Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q+C$R-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#(L.#<Y+#$P.#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,2XQ,C5P=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D1E;F]M:6YA=&]R/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,3@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,RXY."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8S)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^1&5N;VUI;F%T;W(@9F]R(&)A<VEC(&%N9"!D
M:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-#8L.#8U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
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M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#`W-"PW,S0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C,N.3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,R4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DYE="!L;W-S('!E<B!S:&%R
M92P@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C`V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M*#$W-2XS,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXR-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXP-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@P+C<Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C(U<'0[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U
M8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W
M-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R
M1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M
M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!T:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!M96%S
M=7)E9"!A="!F86ER('9A;'5E(&)Y(&QE=F5L('=I=&AI;B!T:&4@9F%I<B!V
M86QU92!H:65R87)C:'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#8X-7!X.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-
M05)'24XM3$5&5#H@,"XW-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@U/@T*#0H\='(@<W1Y;&4]
M,T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[
M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0V+C8E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M-B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,3PO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,CPO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,SPO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#8N-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPP-C8L,34V/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C
M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-#8N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&]T86P@87-S
M971S(&%T(&9A:7(@=F%L=64\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C(L,#8V+#$U-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T-BXV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,:6%B:6QI=&EE<SH\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#8N
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^4V5R:65S)B,Q-C`[02TQ('=A<G)A;G1S
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C$R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXT,S@L.3<X/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-
M.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[
M(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0V+C8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@
M=VED=&@],T0T-B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/E-E<FEE<R8C,38P.T$M,B!W87)R86YT<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N
M-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C0L-3,W
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#0V+C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0T-B4^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E-E<FEE<R8C,38P.T,@
M=V%R<F%N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-"XT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-"4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N-#(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$T,"PY-C,\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG
M.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!
M1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-#8N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&]T86P@;&EA8FEL:71I97,@
M870@9F%I<B!V86QU93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-C0T
M+#0W.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!R;VQL9F]R=V%R9"!O9B!T:&4@9F%I<B!V86QU92!O9B!,979E
M;"`S('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`V-C)P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%2
M1TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8V,CX-"@T*/'1R('-T>6QE/3-$
M)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z
M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`X,"XV,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#@P)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0F5G:6YN:6YG
M(&)A;&%N8V4@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8T-"PT-S@\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$
M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M
M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@.#`N-C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0X,"4^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X<&ER871I;VX@;V8@4V5R
M:65S)B,Q-C`[02TQ(&%N9"!397)I97,F(S$V,#M!+3(@=V%R<F%N=',\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH-#DS+#,V,3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P
M<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@P+C8R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.#`E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY#:&%N9V4@:6X@9F%I<B!V86QU93PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS,#$L
M,#0P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN
M9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0
M041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#@P+C8R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#`E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%;F1I;F<@8F%L
M86YC92!A="!*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^-#4R+#$U-SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI
M9VXZ;&5F=#M415A4+4%,24=..B!L969T.R!724142#H@-C4S<'@[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`P+C@U:6X[)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0V-3,^#0H-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N
M-#8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0Q/DQE=F5L)B,Q-C`[,3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,CPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,SPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T,BXT-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#0R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/DIU;F4F(S$V,#LS
M,"P@,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N-#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED
M=&@],T0T,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/D%S<V5T<SH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.
M1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z
M(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N-#8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0T,B4^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU,RPS.3<L,#<W/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N-#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED
M=&@],T0T,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/E1O=&%L(&%S<V5T<R!A="!F86ER('9A;'5E/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
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M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXU,RPS.3<L,#<W/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XR-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0R+C0V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-#(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY,:6%B:6QI=&EE<SH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#(N-#8E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T
M;W`@=VED=&@],T0T,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!W87)R86YT<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q
M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-2XU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#4R+#$U-SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T
M,BXT-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#0R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^5&]T86P@;&EA8FEL:71I97,@870@9F%I<B!V
M86QU93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-"XR,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-"4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-"XR
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#4R
M+#$U-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C
M8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q
M83$P+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R97!A:60@17AP96YS97,@86YD($]T:&5R
M($-U<G)E;G0@07-S971S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A
M;F0@3W1H97(@0W5R<F5N="!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T
M.U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`V-#!P>#L@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N.#5I;CLG(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8T
M,#X-"@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XR,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D1E8V5M8F5R)B,Q-C`[,S$L/&)R
M("\^#0HR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^2G5N928C,38P.S,P+#QB<B`O/@T*,C`Q-#PO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.
M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'
M2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-C$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1T;W`@=VED=&@],T0V,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3`N,W!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^4')E<&%I9"!I;G-U<F%N8V4\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT."PP-34\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV,#0L,S(P
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8Q+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M+C-P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]T:&5R/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXR-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/CDX+#8T.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C4R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU
M-BPX.3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,24^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3`N,W!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&]T86P@
M<')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$T-BPW,#0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C8V,2PR,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U
M8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W
M-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8V-R=65D($QI86)I;&ET:65S
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@86-C
M<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,24=..B!L
M969T.R!724142#H@-C4Y<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($U!4D=)3BU,1494.B`P+C@U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V-3D^#0H-"CQT<B!S='EL
M93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,
M1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P
M>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-C$N,C(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/D1E8V5M8F5R)B,Q-C`[
M,S$L/&)R("\^#0HR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^2G5N928C,38P.S,P+#QB<B`O/@T*,C`Q-#PO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/
M5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@
M,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,2XR
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^16UP;&]Y964@8F]N=7-E<SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
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M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(S."PY-#$\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C(R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-30L,3,U/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)
M3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))
M1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8Q+C(R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ-#`L,C(S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N-3(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Q.2PQ,S4\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-C$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,24^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1O=&%L(&%C8W)U960@
M;&EA8FEL:71I97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,W.2PQ-C0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,30N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,30E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C,W,RPR-S`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q
M83$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B
M9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,"]7;W)K<VAE971S+U-H965T,C$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C
M:VAO;&1E<G,G($5Q=6ET>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U
M:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS
M92!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#8W-7!X.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XW-6EN.R<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C<U/@T*
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C0X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,R4@
M8V]L<W!A;CTS1#4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y4:')E
M928C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I*=6YE)B,Q-C`[,S`\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[
M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)
M3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C(N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q
M-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.
M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(Y,BPR-C,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#@L.3`X/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!
M1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'
M+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#8R+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY'96YE<F%L(&%N9"!A9&UI
M;FES=')A=&EV93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,C4L-S$T/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$U-2PS,S$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.
M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
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M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C<E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C0Q-RPY-S<\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,S8T+#(S.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z
M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P
M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,S)2!C;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0Q/E-I>"8C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I*=6YE)B,Q
M-C`[,S`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^,C`Q-#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A
M9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@
M=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4X-"PW,S(\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS,S4L
M-#,S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN
M9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0
M041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#8R+C0X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY'96YE<F%L(&%N
M9"!A9&UI;FES=')A=&EV93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-3$L-#(V/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C(U-BPY,3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@
M=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
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M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C<E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C@S-BPQ-3@\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^-3DR+#,T-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R
M-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P135'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A
M;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD($)A<VES(&]F(%!R97-E;G1A
M=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,3(Q+#$Y,RPT.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q."PS,30L,S@S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q
M7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P
M+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P131%04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%Y(#`U+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM;VX@<W1O8VL\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@<W!L:70@8V]N=F5R<VEO;B!R871I;SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A<B!V86QU92!O9B!C;VUM;VX@<W1O
M8VL@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q
M7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P
M+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1314044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC97,@*$1E=&%I;',@,BD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S('!E<B!S
M:&%R93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M('1H
M92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92`H
M:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX
M,3(L-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L-#,X+#`X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.
M970@;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-E8W5R:71I97,@97AC
M;'5D960@9G)O;2!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S
M<R!P97(@<VAA<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#@P.2PS,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@
M;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-E8W5R:71I97,@97AC;'5D
M960@9G)O;2!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S<R!P
M97(@<VAA<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-S4P+#$R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,S0Q+#<S,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('P@5V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DYE="!L;W-S('!E<B!S:&%R93PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE
M<R!E>&-L=61E9"!F<F]M('1H92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE
M="!L;W-S('!E<B!S:&%R92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C(L-3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K('P@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S('!E<B!S:&%R93PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I
M=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M('1H92!C86QC=6QA=&EO;B!O
M9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92`H:6X@<VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X-RPP,C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?
M-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O
M5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5D%!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-E<R`H1&5T86EL<R`S*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY.=6UE<F%T;W(\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,L-S$X+#0P,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L-C$Y+#@W.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L.#<Y
M+#$P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#@L,C$V+#$P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5N;VUI;F%T;W(\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E;F]M
M:6YA=&]R(&9O<B!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#`P+#`Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q
M+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,#<T+#<S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0V+#@V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R('-H87)E+"!B87-I
M8R!A;F0@9&EL=71E9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-#8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W,"XR.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-S$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q-S4N,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E
M7V$R-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970R-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P151/0DD^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU
M92!-96%S=7)E;65N=',@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^(#0U,BPQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@-C0T+#0W.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8T-"PT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE=F5L(#,@?"!787)R86YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@87-S=6UP
M=&EO;G,@=7-E9"!I;B!P<F5P87)I;F<@=&AE(&]P=&EO;B!P<FEC:6YG(&UO
M9&5L(&9O<B!V86QU:6YG('1H92!#;VUP86YY)W,@=V%R<F%N=',\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA=&EL
M:71Y("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#0N.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`T+C@P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4@
M*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N.30E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2XY-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI9F4@;V8@=')E87-U<GD@8F]N9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#8@;6]N=&AS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<U('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@?"!787)R
M86YT<R!\($-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@87-S=6UP=&EO;G,@=7-E
M9"!I;B!P<F5P87)I;F<@=&AE(&]P=&EO;B!P<FEC:6YG(&UO9&5L(&9O<B!V
M86QU:6YG('1H92!#;VUP86YY)W,@=V%R<F%N=',\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=')I:V4@<')I8V4@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!F86ER('9A;'5E("AI;B!D;VQL87)S('!E<B!S
M:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`X+C<R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5V96P@,R!\(%=A<G)A;G1S('P@4V5R:65S($$M,2!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF
M:6-A;G0@87-S=6UP=&EO;G,@=7-E9"!I;B!P<F5P87)I;F<@=&AE(&]P=&EO
M;B!P<FEC:6YG(&UO9&5L(&9O<B!V86QU:6YG('1H92!#;VUP86YY)W,@=V%R
M<F%N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=')I:V4@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,R!\(%=A
M<G)A;G1S('P@4V5R:65S($$M,2!W87)R86YT<R!\(%-E<FEE<R!!+3$@4')E
M9F5R<F5D(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:6=N:69I8V%N="!A<W-U;7!T:6]N<R!U<V5D(&EN('!R
M97!A<FEN9R!T:&4@;W!T:6]N('!R:6-I;F<@;6]D96P@9F]R('9A;'5I;F<@
M=&AE($-O;7!A;GDG<R!W87)R86YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&9A:7(@=F%L=64@*&EN(&1O
M;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B`T+C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,979E;"`S('P@5V%R<F%N=',@?"!397)I97,@02TR('=A
M<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:6=N:69I8V%N="!A<W-U;7!T:6]N<R!U<V5D(&EN('!R97!A<FEN
M9R!T:&4@;W!T:6]N('!R:6-I;F<@;6]D96P@9F]R('9A;'5I;F<@=&AE($-O
M;7!A;GDG<R!W87)R86YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T<FEK92!P<FEC92`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M979E;"`S('P@5V%R<F%N=',@?"!397)I97,@02TR('=A<G)A;G1S('P@4V5R
M:65S($$M,B!0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT(&%S<W5M<'1I;VYS
M('5S960@:6X@<')E<&%R:6YG('1H92!O<'1I;VX@<')I8VEN9R!M;V1E;"!F
M;W(@=F%L=6EN9R!T:&4@0V]M<&%N>2=S('=A<G)A;G1S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@9F%I<B!V
M86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#(N.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@?"!787)R86YT<R!\(%-E
M<FEE<R!#('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!A<W-U;7!T:6]N<R!U<V5D(&EN
M('!R97!A<FEN9R!T:&4@;W!T:6]N('!R:6-I;F<@;6]D96P@9F]R('9A;'5I
M;F<@=&AE($-O;7!A;GDG<R!W87)R86YT<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T<FEK92!P<FEC92`H:6X@9&]L
M;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,979E;"`S('P@5V%R<F%N=',@?"!397)I97,@0R!W87)R86YT
M<R!\(%-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@87-S=6UP
M=&EO;G,@=7-E9"!I;B!P<F5P87)I;F<@=&AE(&]P=&EO;B!P<FEC:6YG(&UO
M9&5L(&9O<B!V86QU:6YG('1H92!#;VUP86YY)W,@=V%R<F%N=',\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!F
M86ER('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@-RXV,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C=7)R:6YG('P@365A<W5R
M960@870@9F%I<B!V86QU92!\($QE=F5L(#$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,RPS.3<L,#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPP-C8L,34V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S(&%T(&9A:7(@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#,Y-RPP-S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#`V-BPQ-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8W5R<FEN9R!\($UE87-U<F5D(&%T(&9A:7(@=F%L=64@
M?"!,979E;"`S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@870@9F%I
M<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4R+#$U
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8T-"PT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8W5R<FEN9R!\($UE87-U<F5D(&%T(&9A:7(@=F%L=64@
M?"!,979E;"`S('P@5V%R<F%N=',@?"!#;VUM;VX@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4R
M+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8W5R<FEN9R!\($UE87-U<F5D(&%T(&9A:7(@=F%L=64@?"!,
M979E;"`S('P@5V%R<F%N=',@?"!397)I97,@02TQ('=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,S@L.3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296-U<G)I;F<@?"!-96%S=7)E9"!A="!F86ER('9A;'5E
M('P@3&5V96P@,R!\(%=A<G)A;G1S('P@4V5R:65S($$M,B!W87)R86YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA
M8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C0L-3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296-U<G)I;F<@?"!-96%S=7)E9"!A="!F86ER('9A
M;'5E('P@3&5V96P@,R!\(%=A<G)A;G1S('P@4V5R:65S($,@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI
M86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B`Q-#`L.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A
M,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D
M,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970R-RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P13-*044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I
M<B!686QU92!-96%S=7)E;65N=',@*$1E=&%I;',@,BD@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!V86QU92!M96%S=7)E;65N=',\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E="!T<F%N
M<V9E<G,@;W5T(&]F($QE=F5L(#$@:6YT;R!,979E;"`R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T('1R86YS9F5R<R!O
M=70@;V8@3&5V96P@,B!I;G1O($QE=F5L(#$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!<W-E="!T<F%N<V9E<G,@:6YT;R`H;W5T(&]F
M*2!,979E;"`S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&EA8FEL:71Y('1R86YS9F5R<R!O=70@;V8@3&5V96P@,2!I;G1O($QE=F5L
M(#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI
M='D@=')A;G-F97)S(&]U="!O9B!,979E;"`R(&EN=&\@3&5V96P@,3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!T<F%N
M<V9E<G,@:6YT;R`H;W5T(&]F*2!,979E;"`S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71I97,@?"!787)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F]L;&9O
M<G=A<F0@;V8@=&AE(&9A:7(@=F%L=64@;V8@3&5V96P@,R!W87)R86YT<SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M;&%N8V4@870@=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#0L-#<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!O
M9B!397)I97,@02TQ(&%N9"!397)I97,@02TR('=A<G)A;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.3,L,S8Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F
M86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#$L
M,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F%L86YC92!A="!T:&4@96YD(&]F('1H92!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#4R+#$U-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?
M-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O
M5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D-!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY0<F5P86ED($5X<&5N<V5S(&%N9"!/=&AE<B!#
M=7)R96YT($%S<V5T<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!!<W-E=',\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&EN<W5R86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`V,#0L,S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T."PP-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-BPX.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY."PV-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!P<F5P86ED(&5X<&5N
M<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-C$L,C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#8L-S`T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S
M865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O
M<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139#04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO
M>65E(&)O;G5S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C4T+#$S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C,X+#DT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q.2PQ,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#`L,C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@86-C<G5E9"!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-S,L
M,C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S-SDL,38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T
M,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970S,"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15)(04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N=F5R
M=&EB;&4@3F]T92!&:6YA;F-I;F<@*$1E=&%I;',I("A54T0@)"D\8G(^26X@
M36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`R,RP@
M,C`Q-#QB<CY#;VYV97)T:6)L92!.;W1E<SQB<CY#;VUM;VX@<W1O8VL\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`R."P@,C`Q-#QB
M<CY#;VYV97)T:6)L92!.;W1E<SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VYV97)T:6)L92!N;W1E(&9I;F%N8VEN
M9SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%G9W)E9V%T92!A;6]U;G0@;V8@;&]A;B!B;W)R;W=E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<F%T92`H87,@
M82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@8V]M;6]N('-H87)E<R!I;G1O('=H:6-H(&-O;G9E
M<G1I8FQE('!R;VUI<W-O<GD@;F]T97,@86YD(&%C8W)U960@:6YT97)E<W0@
M8V]N=F5R=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#,L
M-#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F4@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U8V8X,V%?8V)D,5\T,V%E
M7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C,6$Q,"]7;W)K
M<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,2T%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/E1E<FT@3&]A;B!!;65N9&UE;G0@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^07!R+B`R."P@,C`Q-#QB<CY#;VYV97)T:6)L92!.;W1E<SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,C,L(#(P,30\8G(^5&5R
M;2!L;V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@
M,S`L(#(P,30\8G(^5&5R;2!L;V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^5&5R;2!L;V%N/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^5&5R
M;2!L;V%N/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E1E<FT@;&]A;B!A;65N9&UE;G0\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'1E;F1E9"!I;G1E<F5S
M="!O;FQY('!E<FEO9"!T:')O=6=H($%P<FEL(#$L(#(P,30\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S(&UO;G1H<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X=&5N9&5D
M(&EN=&5R97-T(&]N;'D@<&5R:6]D('1H<F]U9V@@2G5L>2`Q+"`R,#$T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S(&UO;G1H<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86-E(&%M;W5N="!O9B!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'1E;F1E9"!I;G1E<F5S="!O;FQY
M('!E<FEO9"!T:')O=6=H($IA;G5A<GD@,2P@,C`Q-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@86UO=6YT
M('!A:60@=&\@3WAF;W)D(&9I;F%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@;V9F<V5T(&%G86EN<W0@
M;&]A;B!T;R!B92!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S$U8V8X,V%?
M8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C
M,6$Q,"]7;W)K<VAE971S+U-H965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.54%)/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A$
M971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$.3XP
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,CDL(#(P,30\8G(^8VQA<W,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,CDL(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#(Y+"`R
M,#$T/&)R/DUI;FEM=6T\8G(^<V5R:65S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA>2`P-RP@,C`Q-#QB<CY397)I97,@0R!0<F5F97)R
M960@4W1O8VL\8G(^075T;VUA=&EC(&-O;G9E<G-I;VXL(&-L;W-I;F<@;V8@
M86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9SQB<CY-:6YI;75M/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`P-RP@,C`Q-#QB
M<CY397)I97,@0B!0<F5F97)R960@4W1O8VL\8G(^075T;VUA=&EC(&-O;G9E
M<G-I;VXL(&-L;W-I;F<@;V8@86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E
M<FEN9SQB<CY-:6YI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`P-RP@,C`Q-#QB<CY397)I97,@02TQ(%!R969E<G)E9"!3=&]C
M:SQB<CY!=71O;6%T:6,@8V]N=F5R<VEO;BP@8VQO<VEN9R!O9B!A;B!U;F1E
M<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG/&)R/DUI;FEM=6T\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#`W+"`R,#$T/&)R/E-E<FEE
M<R!!+3(@4')E9F5R<F5D(%-T;V-K/&)R/D%U=&]M871I8R!C;VYV97)S:6]N
M+"!C;&]S:6YG(&]F(&%N('5N9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<\
M8G(^36EN:6UU;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87D@,C,L(#(P,30\8G(^0V]N=F5R=&EB;&4@<W5B;W)D:6YA=&5D('!R;VUI
M<W-O<GD@;F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%Y(#(S+"`R,#$T/&)R/D-O;G9E<G1I8FQE('-U8F]R9&EN871E9"!P<F]M
M:7-S;W)Y(&YO=&5S/&)R/D-O;6UO;B!S=&]C:SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87D@,C,L(#(P,30\8G(^0V]N=F5R=&EB;&4@
M<')E9F5R<F5D('-T;V-K/&)R/D-O;6UO;B!S=&]C:SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,C,L(#(P,30\8G(^26YI=&EA;"!P
M=6)L:6,@;V9F97)I;F<\8G(^0V]M;6]N('-T;V-K/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@
M97%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,38V+#8V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I;FET:6%L('!U8FQI8R!O9F9E<FEN9RP@;F5T(&]F('5N
M9&5R=W)I=&EN9R!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS(&%N9"!O=&AE
M<B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0Y+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!C;VUM;VX@
M<VAA<F5S(&EN=&\@=VAI8V@@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E
M<R!W97)E(&-O;G9E<G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3`S+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8V]M;6]N('-H87)E
M<R!I;G1O('=H:6-H(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!W87,@
M8V]N=F5R=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PX,#DL,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@
M8V]N=F5R=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!U;F1E<G=R
M:71T96X@<'5B;&EC(&]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T.2PW-#,L-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0U+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0U+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=71H;W)I>F5D('-H
M87)E<R!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^075T
M:&]R:7IE9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F('-E<FEE<R!O9B!P<F5F97)R960@<W1O8VL@=&AA
M="!M87D@8F4@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!C;&%S<V5S(&]F($)O87)D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E
M<FT@;V8@0F]A<F0@;65M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8VQA<W-E<R!E
M;&5C=&5D(&%T(&5A8V@@86YN=6%L(&UE971I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^069F:7)M871I=F4@=F]T
M92!O9B!A;&P@=&AE;BUO=71S=&%N9&EN9R!S:&%R97,@;V8@8V%P:71A;"!S
M=&]C:R!F;W(@<F5M;W9A;"!O9B!D:7)E8W1O<G,@*&%S(&$@<&5R8V5N="D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C
M,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?
M-#<T-64W-&,Q83$P+U=O<FMS:&5E=',O4VAE970S,RYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M1510044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D@*$1E=&%I;',@,BD@*%-T;V-K(&]P=&EO;G,L(%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,V-"PR,SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q-RPY
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4Y,BPS-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#@S-BPQ-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS93PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P."PY,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3(L,C8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,U+#0S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X-"PW,S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E
M;G-A=&EO;B!%>'!E;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-34L,S,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,C4L-S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R-38L.3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-3$L-#(V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S
M865?83(U,5\T-S0U93<T8S%A,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8S$U8V8X,V%?8V)D,5\T,V%E7V$R-3%?-#<T-64W-&,Q83$P+U=O
M<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135(04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS*2`H4W1A=&4L
M($YE=R!*97)S97DL(%-A;&4@;V8@=6YU<V5D($Y/3',L(%531"`D*3QB<CY)
M;B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(W+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C<L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E('P@3F5W($IE<G-E
M>2!\(%-A;&4@;V8@=6YU<V5D($Y/3',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!O<&5R871I;F<@;&]S<V5S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D],
M<R!S;VQD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.2XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@<')O8V5E9',@9G)O;2!S86QE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q7S0W-#5E-S1C
M,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C,35C9C@S85]C
M8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H965T<R]3:&5E=#,U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%5D9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2
M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R`H1&5T86EL<RD@*%-M87)T4&AA
M<FUA+"!#;VUM97)C:6%L(&%N9"!B=7-I;F5S<R!D979E;&]P;65N="!C;VYS
M=6QT:6YG('-E<G9I8V5S+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-M87)T4&AA<FUA('P@
M0V]M;65R8VEA;"!A;F0@8G5S:6YE<W,@9&5V96QO<&UE;G0@8V]N<W5L=&EN
M9R!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F5L871E9"!P87)T>2!T<F%N<V%C=&EO;G,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&965S(&EN=F]I
M8V5D(&)Y('1H92!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W-"PS,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V,Q-6-F.#-A7V-B9#%?-#-A95]A,C4Q
M7S0W-#5E-S1C,6$Q,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C
M,35C9C@S85]C8F0Q7S0S865?83(U,5\T-S0U93<T8S%A,3`O5V]R:W-H965T
M<R]F:6QE;&ES="YX;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/'AM;"!X;6QN<SIO/3-$(G5R;CIS8VAE;6%S
M+6UI8W)O<V]F="UC;VTZ;V9F:6-E.F]F9FEC92(^#0H@/&\Z36%I;D9I;&4@
M2%)E9CTS1"(N+B]7;W)K8F]O:RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,U+FAT;6PB
M+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]C,35C9C@S85]C8F0Q7S0S
8865?83(U,5\T-S0U93<T8S%A,3`M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accrued Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Employee bonuses</a></td>
        <td class="nump">$ 254,135<span></span></td>
        <td class="nump">$ 238,941<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
        <td class="nump">119,135<span></span></td>
        <td class="nump">140,223<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
        <td class="nump">$ 373,270<span></span></td>
        <td class="nump">$ 379,164<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedBonusesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
        <td class="nump">$ 604,320<span></span></td>
        <td class="nump">$ 48,055<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
        <td class="nump">56,898<span></span></td>
        <td class="nump">98,649<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
        <td class="nump">$ 661,218<span></span></td>
        <td class="nump">$ 146,704<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidInsurance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Note Financing (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Convertible Notes

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014

</div>
          <div>Convertible Notes</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible note financing</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount of loan borrowed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares into which convertible promissory notes and accrued interest converted</a></td>
        <td class="nump">503,450<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Share price (in dollars per share)</a></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermDebtLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Term Loan Amendment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 28, 2014

</div>
          <div>Convertible Notes</div>
        </th>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Term loan</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014

</div>
          <div>Term loan</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Term loan</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Term loan</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term loan amendment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod1', window );">Extended interest only period through April 1, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod2', window );">Extended interest only period through July 1, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of notes</a></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod3', window );">Extended interest only period through January 1, 2015</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Total amount paid to Oxford finance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Amount offset against loan to be amortized to interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 150,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents information pertaining to extended interest only period one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_DebtInstrumentExtendedInterestOnlyPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents information pertaining to extended interest only period two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_DebtInstrumentExtendedInterestOnlyPeriod2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_DebtInstrumentExtendedInterestOnlyPeriod3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents information pertaining to extended interest only period three.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_DebtInstrumentExtendedInterestOnlyPeriod3</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the amount as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain. Such amount is before the consideration of accumulated amortization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfDebtIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">3. Fair Value Measurements</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">ASC 820, <i>Fair Value Measurements and Disclosures</i>, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;<font style="FONT: 7pt Times New Roman;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font> <font style="FONT-SIZE: 10pt;" size="2">Level&#160;1&#160;&#8212; Quotes prices in active markets for identical assets and liabilities. The Company&#8217;s Level&#160;1 assets and liabilities consist of cash and cash equivalents.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;<font style="FONT: 7pt Times New Roman;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font> <font style="FONT-SIZE: 10pt;" size="2">Level&#160;2&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level&#160;2 assets or liabilities.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;<font style="FONT: 7pt Times New Roman;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font> <font style="FONT-SIZE: 10pt;" size="2">Level&#160;3&#160;&#8212; Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company&#8217;s Level&#160;3 liabilities consist of the warrant liability.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the Company&#8217;s financial instruments measured at fair value by level within the fair value hierarchy as of December&#160;31, 2013 and June&#160;30, 2014.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 83.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">December&#160;31, 2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,066,156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total assets at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,066,156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;A-1 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">438,978</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;A-2 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">64,537</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;C warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">140,963</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">644,478</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The significant assumptions used in preparing the option pricing model for valuing the Company&#8217;s warrants as of December&#160;31, 2013 include (i)&#160;volatility (104.8%), (ii)&#160;risk free interest rate of 1.94% (estimated using treasury bonds with a 6&#160;year life), (iii)&#160;strike price ($10.00) for the Series&#160;A-1 and Series&#160;A-2 warrants and $15.00 for the Series&#160;C warrants, (iv)&#160;fair value of Series&#160;A-1 preferred stock ($4.17), Series&#160;A-2 preferred stock ($2.91) and Series&#160;C preferred stock ($7.63) and (v)&#160;expected life (six years).</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following is a rollforward of the fair value of Level&#160;3 warrants:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Beginning balance at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">644,478</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expiration of Series&#160;A-1 and Series&#160;A-2 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(493,361</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">301,040</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Ending balance at June&#160;30, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 77.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="77%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="42%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">June&#160;30, 2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53,397,077</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total assets at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53,397,077</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The significant assumptions used in preparing the option pricing model for valuing the Company&#8217;s warrants as of June&#160;30, 2014 include (i)&#160;volatility (104.8%), (ii)&#160;risk free interest rate of 1.94% (estimated using treasury bonds with a 5.5&#160;year life), (iii)&#160;strike price ($6.00) for the common stock warrants, (iv)&#160;fair value of common stock ($8.72) and (v)&#160;expected life (5.5&#160;years).</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">There were no transfers between Level&#160;1, 2 or 3 during 2013 or 2014. If the Company&#8217;s estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENUAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="9">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 29, 2014

</div>
          <div>class</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>May 29, 2014</div>
        </th>
        <th class="th">
          <div>May 29, 2014

</div>
          <div>Minimum

</div>
          <div>series</div>
        </th>
        <th class="th">
          <div>May 07, 2014

</div>
          <div>Series C Preferred Stock

</div>
          <div>Automatic conversion, closing of an underwritten public offering

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>May 07, 2014

</div>
          <div>Series B Preferred Stock

</div>
          <div>Automatic conversion, closing of an underwritten public offering

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>May 07, 2014

</div>
          <div>Series A-1 Preferred Stock

</div>
          <div>Automatic conversion, closing of an underwritten public offering

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>May 07, 2014

</div>
          <div>Series A-2 Preferred Stock

</div>
          <div>Automatic conversion, closing of an underwritten public offering

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Convertible subordinated promissory notes</div>
        </th>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Convertible subordinated promissory notes

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Convertible preferred stock

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>May 23, 2014

</div>
          <div>Initial public offering

</div>
          <div>Common stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,166,667<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from initial public offering, net of underwriting discounts and commissions and other offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 49,700,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares into which convertible promissory notes were converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">503,450<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of common shares into which convertible preferred stock was converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,809,325<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from underwritten public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 49,743,641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 45,000,000<span></span></td>
        <td class="nump">$ 45,000,000<span></span></td>
        <td class="nump">$ 45,000,000<span></span></td>
        <td class="nump">$ 45,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Authorized shares of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_PreferredStockSharesAuthorizedNumberOfSeries', window );">Number of series of preferred stock that may be issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_BoardOfDirectorsNumberOfClasses', window );">Number of classes of Board</a></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_BoardOfDirectorsTerm', window );">Term of Board member</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders', window );">Number of classes elected at each annual meeting</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage', window );">Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_BoardOfDirectorsNumberOfClasses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of classes into which the board of directors is divided.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_BoardOfDirectorsNumberOfClasses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of classes of board of directors elected at each annual meeting of stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_BoardOfDirectorsNumberOfClassesElectedAtAnnualMeetingOfStockholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the required percentage of affirmative vote of all shares of outstanding capital stock entitled to vote for the removal of a member of the board of directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_BoardOfDirectorsRemovalAffirmativeShareholderVoteOfOutstandingCapitalStockPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_BoardOfDirectorsTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the term of an elected member of the board of directors, as defined by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_BoardOfDirectorsTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_PreferredStockSharesAuthorizedNumberOfSeries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of series of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_PreferredStockSharesAuthorizedNumberOfSeries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionOriginalDebtAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received on stock transaction after deduction of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockConsiderationReceivedOnTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAFBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 53,494,022<span></span></td>
        <td class="nump">$ 2,119,646<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">661,218<span></span></td>
        <td class="nump">146,704<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">54,155,240<span></span></td>
        <td class="nump">2,266,350<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $273,092 in 2013 and $278,135 in 2014</a></td>
        <td class="nump">11,964,777<span></span></td>
        <td class="nump">11,963,079<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred financing costs, net</a></td>
        <td class="nump">132,985<span></span></td>
        <td class="nump">157,499<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">18,208<span></span></td>
        <td class="nump">18,208<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">66,271,210<span></span></td>
        <td class="nump">14,405,136<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,325,664<span></span></td>
        <td class="nump">715,454<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">373,270<span></span></td>
        <td class="nump">379,164<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable, current portion</a></td>
        <td class="nump">2,151,653<span></span></td>
        <td class="nump">5,105,407<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
        <td class="nump">452,157<span></span></td>
        <td class="nump">644,478<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">5,302,744<span></span></td>
        <td class="nump">6,844,503<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, long-term</a></td>
        <td class="nump">12,619,816<span></span></td>
        <td class="nump">9,769,528<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitment and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value, authorized 10,000,000 shares; issued 0 shares outstanding at December 31, 2013 and June 30, 2014</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.0001 par value, authorized 150,000,000 shares; issued 109,321 and outstanding 103,536 shares at December 31, 2013 and issued 18,598,754 and outstanding 18,592,968 shares at June 30, 2014</a></td>
        <td class="nump">1,860<span></span></td>
        <td class="nump">88<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">169,540,281<span></span></td>
        <td class="nump">46,872,723<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Accumulated deficit</a></td>
        <td class="num">(121,193,491)<span></span></td>
        <td class="num">(118,314,383)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
        <td class="nump">48,348,650<span></span></td>
        <td class="num">(71,441,572)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' (deficit) equity</a></td>
        <td class="nump">66,271,210<span></span></td>
        <td class="nump">14,405,136<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A 1, 8%, non cumulative convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">898,305<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A 2 convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">543,623<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B, 8% non cumulative, convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44,928,382<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C, 12% non cumulative, convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,862,367<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 644,478<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNoncurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermLoansPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityCarryingAmountAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1. Organization and Basis of Presentation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Nature of Operations</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Agile Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware on December&#160;22, 1997. The Company is engaged in research and development of transdermal patch technology for use in contraception. The Company&#8217;s activities since inception have consisted principally of raising capital, and performing research and development. The Company is headquartered in Princeton, New Jersey.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company is devoting substantially all of its efforts toward research and development of its transdermal patch for use in contraception, and raising capital. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies. The Company has incurred losses each year since inception. As of June&#160;30, 2014, the Company had an accumulated deficit of approximately $121.2&#160;million.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. The Company expects to continue to incur net losses into the foreseeable future.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Basis of Presentation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying unaudited interim condensed financial statements have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form&#160;10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules&#160;and regulations. It is recommended that these interim condensed financial statements be read in conjunction with the financial statements and related notes that appear in the Company&#8217;s final prospectus filed with the SEC on May&#160;22, 2014, relating to the Company&#8217;s Registration Statements on Form&#160;S-1 (File No.&#160;333-194621) for the Company&#8217;s initial public offering.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In the opinion of management, the unaudited interim condensed financial statements reflects all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and six months ended June&#160;30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (SmartPharma, Commercial and business development consulting services, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">SmartPharma | Commercial and business development consulting services</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Fees invoiced by the related party</a></td>
        <td class="nump">$ 3,250<span></span></td>
        <td class="nump">$ 74,300<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Accumulated deficit</a></td>
        <td class="nump">$ 121,193,491<span></span></td>
        <td class="nump">$ 118,314,383<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 210<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4TAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Details 2)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
        <td class="nump">1,812,625<span></span></td>
        <td class="nump">10,438,084<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,809,325<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
        <td class="nump">1,750,120<span></span></td>
        <td class="nump">1,341,731<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock | Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
        <td class="nump">62,505<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible preferred stock | Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">287,028<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Polices</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Polices</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2. Summary of Significant Accounting Polices</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company&#8217;s complete listing of significant accounting policies are described in Note 2 to the Company&#8217;s audited financial statements as of December&#160;31, 2013 included in the Prospectus that forms a part of the Company&#8217;s Registration Statement on Form&#160;S-1 dated May&#160;22, 2014.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of the Company&#8217;s financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock Split</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May&#160;5, 2014, the Company effected a 1.4-for-1 stock split of the Company&#8217;s common stock. All share and per share amounts of common stock contained in the Company&#8217;s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders&#8217; deficit reflects the stock split by reclassifying from &#8220;Additional paid-in Capital&#8221; to &#8220;Common Stock&#8221; in an amount equal to the par value of the increased shares resulting from the stock split.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Fair Value of Financial Instruments</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In accordance with ASC 825, <i>Financial Instruments</i>, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note&#160;3).</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Warrants</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, <i>Distinguishing Liabilities from Equity</i>. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer&#8217;s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In connection with the completion of the Company&#8217;s initial public offering in May&#160;2014, the warrants to purchase shares of Series&#160;A-1 and Series&#160;A-2 preferred stock expired unexercised and the warrants to purchase shares of Series&#160;C preferred stock automatically converted into warrants to purchase shares of common stock.&#160; Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock-Based Compensation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i>. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Awards for consultants are accounted for under ASC 505-50, <i>Equity Based Payments to Non-Employees</i>. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Share</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,809,325</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">287,028</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">62,505</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,341,731</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,750,120</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,438,084</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,812,625</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following tables summarizes the Company&#8217;s computation of basic and diluted net loss per share for common stockholders:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 83.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,619,879</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,718,401</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">51,499</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,000,092</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(70.29</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.46</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(8,216,109</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,879,108</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">46,865</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,074,734</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(175.31</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.71</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Recent Accounting Pronouncements</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 40.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In June&#160;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&#160;2014-10.&#160; ASU No.&#160;2014 is effective for fiscal years beginning after December&#160;15, 2014, with early adoption permitted.&#160; Retrospective application is required for the elimination of incremental DSE disclosures.&#160; Prior to the issuance of ASU No.&#160;2014-10, the Company had met the definition of a DSE since its inception.&#160; The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&#160;10-Q.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKVAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="nump">$ 278,135<span></span></td>
        <td class="nump">$ 273,092<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
        <td class="nump">18,598,754<span></span></td>
        <td class="nump">109,321<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
        <td class="nump">18,592,968<span></span></td>
        <td class="nump">103,536<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A 1, 8%, non cumulative convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">284,743<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">137,787<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">137,787<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A 2 convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,178<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">66,116<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">66,116<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B, 8% non cumulative, convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,510,066<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,510,066<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,510,066<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C, 12% non cumulative, convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,711,734<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,578,400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,578,400<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 14<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (27)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Polices</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,809,325</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">287,028</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">62,505</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,341,731</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,750,120</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,438,084</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,812,625</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of computation of basic and diluted net loss per share for common stockholders</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 695px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="695">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,619,879</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,718,401</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">51,499</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,000,092</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(70.29</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.46</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(8,216,109</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,879,108</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">46,865</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,074,734</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(175.31</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.71</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 13, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">AGILE THERAPEUTICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001261249<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Non-accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,592,968<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of the Company's financial instruments measured at fair value by level within the fair value hierarchy</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 685px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="685">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">December&#160;31, 2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,066,156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total assets at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,066,156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;A-1 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">438,978</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;A-2 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">64,537</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Series&#160;C warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">140,963</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 46.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="46%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">644,478</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of rollforward of the fair value of Level 3 warrants</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 662px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="662">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Beginning balance at December&#160;31, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">644,478</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expiration of Series&#160;A-1 and Series&#160;A-2 warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(493,361</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">301,040</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="80%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Ending balance at June&#160;30, 2014</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 653px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="653">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="42%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">June&#160;30, 2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Assets:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53,397,077</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total assets at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53,397,077</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 42.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="42%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities at fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452,157</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EICAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 2,390,857<span></span></td>
        <td class="nump">$ 2,425,741<span></span></td>
        <td class="nump">$ 3,785,180<span></span></td>
        <td class="nump">$ 5,497,454<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,103,853<span></span></td>
        <td class="nump">823,329<span></span></td>
        <td class="nump">2,157,157<span></span></td>
        <td class="nump">1,979,977<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">3,494,710<span></span></td>
        <td class="nump">3,249,070<span></span></td>
        <td class="nump">5,942,337<span></span></td>
        <td class="nump">7,477,431<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(3,494,710)<span></span></td>
        <td class="num">(3,249,070)<span></span></td>
        <td class="num">(5,942,337)<span></span></td>
        <td class="num">(7,477,431)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(403,488)<span></span></td>
        <td class="num">(378,228)<span></span></td>
        <td class="num">(781,714)<span></span></td>
        <td class="num">(756,456)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">82<span></span></td>
        <td class="nump">259<span></span></td>
        <td class="nump">137<span></span></td>
        <td class="nump">1,432<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
        <td class="nump">179,715<span></span></td>
        <td class="nump">7,160<span></span></td>
        <td class="nump">192,321<span></span></td>
        <td class="nump">16,346<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before benefit from income taxes</a></td>
        <td class="num">(3,718,401)<span></span></td>
        <td class="num">(3,619,879)<span></span></td>
        <td class="num">(6,531,593)<span></span></td>
        <td class="num">(8,216,109)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,652,485<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (3,718,401)<span></span></td>
        <td class="num">$ (3,619,879)<span></span></td>
        <td class="num">$ (2,879,108)<span></span></td>
        <td class="num">$ (8,216,109)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars per share)</a></td>
        <td class="num">$ (0.46)<span></span></td>
        <td class="num">$ (70.29)<span></span></td>
        <td class="num">$ (0.71)<span></span></td>
        <td class="num">$ (175.31)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and Diluted (in shares)</a></td>
        <td class="nump">8,000,092<span></span></td>
        <td class="nump">51,499<span></span></td>
        <td class="nump">4,074,734<span></span></td>
        <td class="nump">46,865<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Term Loan Amendment (Term loan)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Term loan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Amendment</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">7. Term Loan Amendment</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In January&#160;2014 the Company amended its Loan Agreement with Oxford Finance whereby the interest only period was extended for three months (through April&#160;1, 2014). The interest only period was extended for an additional three months (through July&#160;1, 2014) as a result of the Company&#8217;s $3.0&#160;million convertible note financing in which was completed in April&#160;2014 (see Note&#160;6).</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The interest only period was further extended for an additional six months (through January&#160;1, 2015) and the maturity date of the loan was extended to July&#160;1, 2017 as a result of the completion of the Company&#8217;s initial public offering (see Note 8). In connection with the amendment to the Loan Agreement the Company has paid Oxford Finance a total of $150,000.&#160; The $150,000 has been offset against the amount of the loan and is being amortized to interest expense.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At June&#160;30, 2014, the Company believes it is in compliance with the Loan Agreement.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Note Financing (Convertible Notes)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Notes</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Note Financing</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">6. Convertible Note Financing</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On April&#160;28, 2014, the Company and certain of the Company&#8217;s existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0&#160;million. The Company issued Convertible Promissory Notes (the &#8220;Notes&#8221;) to evidence its payment obligations with respect to the $3.0&#160;million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes are convertible into unregistered equity securities of the Company upon the occurrence of events stated therein. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in an underwritten public offering (see Note 8). The Notes were subordinate to the Company&#8217;s term loan with Oxford Finance LLC.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermDebtLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>May 05, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
        <td class="nump">1.4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock (in dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 640px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="640">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December&#160;31,<br />
2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30,<br />
2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Prepaid insurance</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48,055</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">604,320</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">98,649</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,898</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10.3pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total prepaid expenses and other current assets</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">146,704</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">661,218</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">10. Related Party Transactions</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Effective March&#160;17, 2014, one of the Managing Partners of SmartPharma&#160;LLC or SmartPharma, an entity which provides commercial and business development consulting services to the Company was appointed Chief Commercial Officer. In connection with the appointment of this individual as Chief Commercial Officer, the Company amended its consulting agreement with SmartPharma to remove this individual from the list of persons providing service under the consulting agreement. SmartPharma invoiced the Company $3,250 and $74,300 of fees for the three and six months ended June&#160;30, 2014.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">8. Stockholders&#8217; Equity</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Initial Public Offering and Related Transactions</font></i></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May&#160;23, 2014, the Company completed its initial public offering selling 9,166,667 shares of common stock at $6.00 per share.&#160; Proceeds from the Company&#8217;s initial public offering, net of underwriting discounts and commissions and other offering costs were $49.7 million.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In addition, each of the following occurred in connection with the completion of the Company&#8217;s IPO on May&#160;23, 2014:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;<font style="FONT: 7pt Times New Roman;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font> <font style="FONT-SIZE: 10pt;" size="2">the conversion of all outstanding shares of convertible preferred stock into 8,809,325 shares of the Company&#8217;s common stock</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;<font style="FONT: 7pt Times New Roman;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font> <font style="FONT-SIZE: 10pt;" size="2">the conversion of the aggregate principal amount of $3.0 million and accrued interest under the Company&#8217;s outstanding convertible subordinated promissory notes into 503,450 shares of the Company&#8217;s common stock.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May&#160;7, 2014, the Company filed an amendment to its amended and restated certificate of incorporation which, among other things, revised the automatic conversion provision relating to the Series&#160;C Preferred Stock, Series&#160;B Preferred Stock, Series&#160;A-1 Preferred Stock and Series&#160;A-2 Preferred Stock. Following such amendment, the Series&#160;C, the Series&#160;B, the Series&#160;A-1 and A-2 Preferred Stock now automatically convert into shares of common stock at the then effective conversion price upon:</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(i)&#160;the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, covering the offer and sale of common stock from which the Company receives gross proceeds of at least $45,000,000 or (ii)&#160;the affirmative vote of the holders of at least a majority of the voting power the Series&#160;C Preferred Stock, the Series&#160;B Preferred Stock and the Series&#160;A-1 Preferred Stock, respectively, after first giving effect, if in conjunction with a public offering which does not meet the standards set forth in clause&#160;(i)&#160;above, to any adjustment of the conversion price for each series of preferred stock to which it would otherwise be entitled by virtue of such public offering.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May&#160;29, 2014, the Company filed an amended and restated certificate of incorporation (the &#8220;Restated Certificate&#8221;) with the Secretary of State of the State of Delaware in connection with the closing of the Company&#8217;s initial public offering of shares of its common stock. The Company&#8217;s board of directors (the &#8220;Board&#8221;) and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company&#8217;s initial public offering.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Restated Certificate amends and restates in its entirety the Company&#8217;s second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: (i)&#160;authorizes 150,000,000 shares of common stock; (ii)&#160;eliminates all references to the previously existing series of preferred stock; (iii)&#160;authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iv)&#160;provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company&#8217;s stockholders; (v)&#160;provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (vi)&#160;provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and (vii)&#160;requires that any action instituted against the Company&#8217;s officers or directors in connection with their service to the Company be brought in the State of Delaware.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible Preferred Stock</font></i></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Prior to its conversion in the IPO, the Company&#8217;s convertible preferred stock was classified as temporary equity on its balance sheets instead of stockholders&#8217; (deficit) in accordance with authoritative guidance for the classification and measurement or redeemable securities.&#160; Upon certain change in control events that were outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock-Based Compensation Expense</font></i></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock-based compensation expense related to stock options was allocated as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">292,263</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">208,908</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">125,714</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">155,331</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stock-based compensation expense</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">417,977</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">364,239</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">584,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">335,433</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">251,426</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">256,912</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stock-based compensation expense</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">836,158</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">592,345</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">9. Income Taxes</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Sale of New Jersey Net Operating Losses</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company received approval to sell a portion of the Company&#8217;s New Jersey net operating losses (NOLs) as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other companies. On February&#160;27, 2014, the Company completed the sale of NOLs totaling approximately $39.1&#160;million for net proceeds of approximately $3.6&#160;million. Such proceeds are reflected as a tax benefit for six months ended June&#160;30, 2014.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Polices)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Polices</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of the Company&#8217;s financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_StockSplitPolicyTextBlock', window );">Stock Split</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock Split</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On May&#160;5, 2014, the Company effected a 1.4-for-1 stock split of the Company&#8217;s common stock. All share and per share amounts of common stock contained in the Company&#8217;s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders&#8217; deficit reflects the stock split by reclassifying from &#8220;Additional paid-in Capital&#8221; to &#8220;Common Stock&#8221; in an amount equal to the par value of the increased shares resulting from the stock split.</font></p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Fair Value of Financial Instruments</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In accordance with ASC 825, <i>Financial Instruments</i>, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note&#160;3).</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_WarrantsPolicyTextBlock', window );">Warrants</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Warrants</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, <i>Distinguishing Liabilities from Equity</i>. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer&#8217;s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In connection with the completion of the Company&#8217;s initial public offering in May&#160;2014, the warrants to purchase shares of Series&#160;A-1 and Series&#160;A-2 preferred stock expired unexercised and the warrants to purchase shares of Series&#160;C preferred stock automatically converted into warrants to purchase shares of common stock.&#160; Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.</font></p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock-Based Compensation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i>. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Awards for consultants are accounted for under ASC 505-50, <i>Equity Based Payments to Non-Employees</i>. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Share</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</font></p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,809,325</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">287,028</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock warrants</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">62,505</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,341,731</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,750,120</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="70%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,438,084</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,812,625</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following tables summarizes the Company&#8217;s computation of basic and diluted net loss per share for common stockholders:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 83.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="83%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,619,879</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(3,718,401</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">51,499</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,000,092</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(70.29</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.46</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.82%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="31%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="63%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Numerator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(8,216,109</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,879,108</font></p></td>
<td style="PADDING-BOTTOM: 1.125pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Denominator</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Denominator for basic and diluted net loss per share</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">46,865</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,074,734</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 63.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="63%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net loss per share, basic and diluted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(175.31</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 2.25pt double; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(0.71</font></p></td>
<td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr></table>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Recent Accounting Pronouncements</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 40.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In June&#160;2014, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.&#160; Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.&#160; A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.&#160; Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No.&#160;2014-10.&#160; ASU No.&#160;2014 is effective for fiscal years beginning after December&#160;15, 2014, with early adoption permitted.&#160; Retrospective application is required for the elimination of incremental DSE disclosures.&#160; Prior to the issuance of ASU No.&#160;2014-10, the Company had met the definition of a DSE since its inception.&#160; The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with this Quarterly Report on Form&#160;10-Q.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_StockSplitPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents disclosure of accounting policy for stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_StockSplitPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_WarrantsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents disclosure of accounting policy for warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_WarrantsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5HAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details) (State, New Jersey, Sale of unused NOLs, USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 27, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 27, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">State | New Jersey | Sale of unused NOLs</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating losses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOLs sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 39.1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Net proceeds from sale</a></td>
        <td class="nump">$ 3.6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwardsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense related to stock options</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 675px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="675">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">292,263</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">208,908</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">125,714</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">155,331</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stock-based compensation expense</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">417,977</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">364,239</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended<br />
June&#160;30</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">584,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">335,433</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">251,426</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">256,912</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stock-based compensation expense</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">836,158</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">592,345</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETOBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="nump">$ 452,157<span></span></td>
        <td class="nump">$ 644,478<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">644,478<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
        <td class="nump">104.80%<span></span></td>
        <td class="nump">104.80%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
        <td class="nump">1.94%<span></span></td>
        <td class="nump">1.94%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_TreasuryBondsTerm', window );">Life of treasury bonds</a></td>
        <td class="text">5 years 6 months<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">5 years 6 months<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock fair value (in dollars per share)</a></td>
        <td class="nump">$ 8.72<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series A-1 warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series A-1 warrants | Series A-1 Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock fair value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.17<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series A-2 warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series A-2 warrants | Series A-2 Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock fair value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.91<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series C warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 | Warrants | Series C warrants | Series C Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Significant assumptions used in preparing the option pricing model for valuing the Company's warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock fair value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.63<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">53,397,077<span></span></td>
        <td class="nump">2,066,156<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
        <td class="nump">53,397,077<span></span></td>
        <td class="nump">2,066,156<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 3</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
        <td class="nump">452,157<span></span></td>
        <td class="nump">644,478<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 3 | Warrants | Common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="nump">452,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 3 | Warrants | Series A-1 warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">438,978<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 3 | Warrants | Series A-2 warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64,537<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Measured at fair value | Level 3 | Warrants | Series C warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 140,963<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_TreasuryBondsTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the treasury bonds, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_TreasuryBondsTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5CAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (2,879,108)<span></span></td>
        <td class="num">$ (8,216,109)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">5,043<span></span></td>
        <td class="nump">6,159<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_StockGrantedDuringPeriodSharebasedCompensationBonus', window );">Noncash stock bonus</a></td>
        <td class="nump">80,000<span></span></td>
        <td class="nump">79,509<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Noncash stock based compensation</a></td>
        <td class="nump">592,345<span></span></td>
        <td class="nump">836,158<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest</a></td>
        <td class="nump">91,715<span></span></td>
        <td class="nump">46,164<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
        <td class="num">(192,321)<span></span></td>
        <td class="num">(16,346)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(514,514)<span></span></td>
        <td class="nump">20,700<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,604,316<span></span></td>
        <td class="nump">56,515<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) operating activities</a></td>
        <td class="num">(1,212,524)<span></span></td>
        <td class="num">(7,187,250)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
        <td class="num">(6,741)<span></span></td>
        <td class="num">(4,633,503)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num">(6,741)<span></span></td>
        <td class="num">(4,633,503)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from convertible bridge notes</a></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Cash paid for financing costs</a></td>
        <td class="num">(150,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of offering costs</a></td>
        <td class="nump">49,743,641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">52,593,641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="nump">51,374,376<span></span></td>
        <td class="num">(11,820,753)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">2,119,646<span></span></td>
        <td class="nump">20,013,754<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">53,494,022<span></span></td>
        <td class="nump">8,193,001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock into common stock</a></td>
        <td class="nump">69,232,677<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agrx_DebtConversionOriginalDebtAmountAndAccruedInterest', window );">Conversion of notes payable and interest into common stock</a></td>
        <td class="nump">3,020,667<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">$ 690,000<span></span></td>
        <td class="nump">$ 690,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_DebtConversionOriginalDebtAmountAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt and accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_DebtConversionOriginalDebtAmountAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agrx_StockGrantedDuringPeriodSharebasedCompensationBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) granted during the period as a result of an equity-based incentive compensation plan. This element is not the recognition of equity-based compensation expense pursuant to FAS 123R.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>agrx_StockGrantedDuringPeriodSharebasedCompensationBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>agrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockAmountConverted1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for loan and debt issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">5. Accrued Liabilities</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accrued liabilities consist of the following:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 647px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="647">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December&#160;31,<br />
2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30,<br />
2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Employee bonuses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">238,941</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">254,135</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">140,223</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">119,135</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total accrued liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">379,164</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">373,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3JAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Asset transfers out of Level 1 into Level 2</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Asset transfers out of Level 2 into Level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Asset transfers into (out of) Level 3</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Liability transfers out of Level 1 into Level 2</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Liability transfers out of Level 2 into Level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Liability transfers into (out of) Level 3</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Liabilities | Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Rollforward of the fair value of Level 3 warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
        <td class="nump">644,478<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Expiration of Series A-1 and Series A-2 warrants</a></td>
        <td class="num">(493,361)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
        <td class="nump">301,040<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
        <td class="nump">$ 452,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>143</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/BalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/StatementOfIncome</Role>
      <ShortName>Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/CashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Summary of Significant Accounting Polices</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolices</Role>
      <ShortName>Summary of Significant Accounting Polices</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Convertible Note Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancing</Role>
      <ShortName>Convertible Note Financing</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Term Loan Amendment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendment</Role>
      <ShortName>Term Loan Amendment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/Disclosure-StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2020 - Disclosure - Summary of Significant Accounting Polices (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices</Role>
      <ShortName>Summary of Significant Accounting Polices (Polices)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>3020 - Disclosure - Summary of Significant Accounting Polices (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesTables</Role>
      <ShortName>Summary of Significant Accounting Polices (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>3030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>3040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>3050 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>3080 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>4010 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureOrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>4020 - Disclosure - Summary of Significant Accounting Polices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails</Role>
      <ShortName>Summary of Significant Accounting Polices (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>4021 - Disclosure - Summary of Significant Accounting Polices (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails2</Role>
      <ShortName>Summary of Significant Accounting Polices (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>4022 - Disclosure - Summary of Significant Accounting Polices (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails3</Role>
      <ShortName>Summary of Significant Accounting Polices (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>4030 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>4031 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureFairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>4040 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>4050 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>4060 - Disclosure - Convertible Note Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureConvertibleNoteFinancingDetails</Role>
      <ShortName>Convertible Note Financing (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>4070 - Disclosure - Term Loan Amendment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureTermLoanAmendmentDetails</Role>
      <ShortName>Term Loan Amendment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>4080 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>4081 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureStockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>4090 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>4100 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.agiletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">'Monetary' elements on report '4070 - Disclosure - Term Loan Amendment (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4080 - Disclosure - Stockholders' Equity (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 0010 - Statement - Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - Balance Sheets (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'May 29, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'May 05, 2014'</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 0030 - Statement - Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>agrx-20140630.xml</File>
    <File>agrx-20140630.xsd</File>
    <File>agrx-20140630_cal.xml</File>
    <File>agrx-20140630_def.xml</File>
    <File>agrx-20140630_lab.xml</File>
    <File>agrx-20140630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001104659-14-061061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-14-061061-xbrl.zip
M4$L#!!0````(`%:"#D7A4G(WL'P``*/[!P`1`!P`86=R>"TR,#$T,#8S,"YX
M;6Q55`D``Z09[5.D&>U3=7@+``$$)0X```0Y`0``[%WI<]LXLO^^5?L_8/VV
MMI(J2];A)+9S;/F<];S$]D;.S.[[,@61D(0)#PU!VM;\]:^[`?#0X4.Q+$KB
MA\G()(BCSU\WFN"'?][Y'KL1D9)A\'&K66]L,1$XH2N#_L>M1-6X<J3<^N>G
MO_[EP]]J-78<"1X+EW5'[(N((NEY[#B,AF'$8^B`U6JVX4\B$)%M>I;\+F.5
ML/,@AI%BWA?L/[_RP&5'C>;>?O94X:'SK^<==A6%,?3[BYX@VZTWZJWZGG[@
MKAMY\@#_9;"(0-%/^7%K$,?#@YV=V]O;.EZIAU%_I]5HM'=D`&,'CM@R[7D_
MNBLTYWWIB7@`<QB*)):.JCNA#\\V=QMOVPW[F">#[_>,@K>[7*6CN"*;$[54
MPJGWPYL=N$%]UQK-6KNYE5N$._:$Z?OMCKZ9-E7%U=ZV;<OFSG^^?.XX`^'S
MVOBJI0IW6\UW]]%)M[`/)'$TL_'^#MQ-&ZI:G_-AVKC'59<:FAO35CM!3+.(
MYO[^_@[=W0)>,_8!?QXH6M)7T6-TZR`>#<7'+27]H8?KHVN#2/0^;B%O:Y9S
M]3OE;K$=W9$6&R<$6;R+F70_;IU@NW^W_GM]HL=*&XD@EO'(7$NO2A>O]Z2(
M&,U'%.9ON7M\_K];GQK`BM;;9FMW_\/.^,-VJ)TI8YF1AB*2H3L^/K`SBD]`
M33Y9>C::MI?LWMA#(G!SC[RMM1O9P&[N`7LU-[2]9$@VBXKGFHHK04*M$_$4
M:M@[/TH-(U._?6F\:;Q9"9J,B]6;6F/WB6(%C[Q9D%BM$"&+PI6GR3,+%QBL
MWXY#WP^#3APZW[\(ORNBWW[E402#Z+^60+!,H$3?%^EJTQLN3.-NZ$E'FCDR
M5T([#4",ISCHQ"`[^/3I'PG,&%8Y#`/X4QW>2;7UR3:;6/V'G:E#S#6'0UB7
M*ST``C>B(YPDDK$4ZO3.\1)7N&=1Z..TDIB@SV7OE$<!H"9U):+.@$?B:#2]
M@^(*"MQZ:/:I.A8HNS8>!,6ZO:)^N/UT*K87344P#@%`^UAV/7$%J`@`NW!S
MRK*JQN%%%/,!VBU%55=1R-;,'QU[7*G+'BWP606F=`JP?,]4.G%?2;>T6QX2
MKDIX.(Z/GDK"!4;8[94@8"X$:M>:K5H[)=]SA4!$B_7P+2>P^!N.IOAH=,'C
M)!(E,,0OQ<$./`>>I[D'SLF!Z5V$@9/XB4?T6%/\>@^8P+3EP8_09$WEH[79
MHO#0\M>3ZT>541B7A+E(LI[2<=QL5>(Q)A[ST61]Y".7&,]0U9D,>.!([IW#
M*%&"2U"?)>]*CZ+>=4I3G'$9_<*]!)"D7>&(!*:(*)](F^=,7902[)8T'VZW
MOBJ,O/(8>4&[S&,24J'DC>1[A9-7%B>_B'Q42'F%D?)BZY,0*5^+R/\<\N!7
M&0\N[WIAY&I4*`PR;JZJ))R(;ISAVIP(/+#B#8>=N=*U5ONW\ZM+(P<3Q3:K
M*A>=I*ND*WDTZG!/3-W,35?]G+'/HHJ:%B6/;VJM]A/E,?_(8N0Q9Z&!CZ"Z
MH+FQ<*^BT)=*A='H(HR%:NT=#B/IX9.K+:MHP_22\?K1Z%L@_TC$B5!.)(>X
MO9\S:W.29HGBU5H7\5H?XU@"@5MSFUHRH6^\^Z$P(:\Q4[*)ATD<^M"/D\D4
MB,>-Q!_(+$_H&J5O@2NBVTC&L0BNDBZPY+('8\F@;X;Y(@/I)_YJ*]<R8Y.Y
MYMF!67`0KNE*OT!^/^=JOO*@/Y9F+DC3\FQ!X^V3;4'CW4O8@OD2JY4M6)$,
M=V4+*EOP(!C>7XE2PRD`:__I`&O_N0EYOD(5PX5]^87EHU>.%JU%UK"D._5?
M!%=)1`96?<52_)R?.U6Q!`,J+GMI\_3'B52.%^*CIG%ZYSP8)K'Z+&Z$UUQM
M%YDK9\B1Z2P2$)$&SJAHQA]#T>?T)-,G=\25'(L]G\+%!4TP_?DOX!"/G,&(
MQ&,&`2<%:'TJA,:T+[?4MM$CB[M,)<JZU@?-+1+MYY=4@X`-B2^CK[(_B*=`
MX2)+UKXLJ3S:<%PI0\F4X;C2A65YAE:E#"53AG&65-JP4E%*>YHBS<!A:Z!?
M52BS+M;I66W#\@%S99V>;)U:E76JK%-EG5X"M%76Z:G6Z;@R3I5QJHS3"Z17
M*MMTC]A4=J>R.PNU.ZNC?2</YABK9.**^)R%%`+-=>)=05*?M7ZE.D2A.D2A
M1-;3OM5:264EE>5YD]9*957156'J%<#4RZOH6OR;[!6PKH#U=&!=GK?K7]9=
M3$\/K\W+JI4[6;8[*;LU><K`97^7>`E8=B--2:4,E3(LRU.O@?I4GKC,QF=U
M]&_J>^D/G?%8O8(^CXU?[+F:<TVI>MO\&96UI&^;:P_;!`UOM4##D?6'@?LY
M=+CW<Q))Y4H'>694[D+<_@Q\%:,3J;EZV;OF=SS7XEHX@R#TPO[H*%$R$$I!
M@V,4F9YTH'.0AW[$?7WJV[<@4<+%!@"A1KTPNN61N^*E4N>!$_H"U@3*,`A!
MQL<<[P,D?D[1GYS*!??'=.%!CC[GA*Y'0^#Z(<+E/EF8PH&0SR0XR_&^K5KK
MW6*\;Z6;E6Y6NOECSC:OG8]TMOE'GOMHEXX/4[@:\,CGGS\?Y](X(D)`!1)H
MZ7R"844X)(`8!BKQ8@!)@`EOI"-67!F_"H].*@12C*Y!ZA0G55-'H_R=/!2>
M0K5G18K3)U1`O_.Q:%EB7Y*/)N:V!RO)KR1_`W<:OS1V6WMS'VR[C&.;GB>Y
M`<@FQI/>\41;!!BK<U)R$=WOUEI[BT/WS8?._U]5_F_`Z?_-!13^9EG7W4HR
MRB$9<R"IW85_%^+A//R:;`QGZ623()]Y)GKQB9=-EY=TE[:DQY^?YT1Y-8XY
M+4*"_(FE"]AN`_6N3'\I3'])](7>6UL)/2GQZU2@7)W+E2!BT=CLU9KM!1J;
MQKOB9OJ/?-3PA7;_5]7Z_>AV]%S(Y.6_TSC7-$M;;[#`&H"G;DLL\,1YS,]N
MV*>]5CA!5=*,9^'K!>M1HE7>"J)2?&;!<OP4[&TX$KA_#IY$F+_(9UQ2A&[?
M!?XJE,"J2FB8VT$XO1L"X5<\MCG$O>XQ._)8NCQ_=4'J6+&>83)'\@@^K%"Z
M;9'&[-&B_9,(1$1[9(>N#S8"@`JAJ4JX7UJX'\6)2KR?)-Z5X&ZJB&!H4$E)
M^:2D7*#_*5)2H<"2.,H2H\`5ENX*")9%ODL-!$LDX>T*");/Q;>?#@3;Y1"1
MRK^7Q/Z5U;^OL&A7SKTLPEU>YUXZ\:Y"^'+Z]Z=7QY1%2BH77Q(K6&(7O\+2
M77GYLLAWJ;U\223<EE-71<-+*1I^F:/0VH_Z,OJC/JT^3]'?J@K/FGW;_"D#
ME_1(Q4>>>C67E"Y!Y1?ZH:C'?/+Z4=_,WFSM7I7O4V^.=O_HF7:KJ<C'/ZC'
MQ\U6Y;I_[%.!E6XO6K?G$]+U4?AY2@96]I2/0^C3E5Z"'.[@"<+T<:/3.\=+
M7.&>1:&/[^(D,=<OXYSR*)!!7X&`=`8\`OF>WL&JY'!+MXU?2=T&2-UR,T])
M(+7(?>N<C`F0KT_W_B15N-MJOCN`%K8C>RO?.?8TM6?BDIK1N5DT-9FK]RMH
M>6_?0_@Y5\^P7BMC8P.X\@9489Q!^.!%XH-CC\,)E_QH<N99.+W'W'`G(@A]
M?)OMO@$?(O'XB).=VKNY=3](/4(5,QA#2NE@@_D$BI#)?7TK:O&XSJT9NHSZ
M/)!_DI7!0]!"3[HZA1VX@'$4J+>Q0.G[JRF$4MEY]M>@8$<>6!::ZC7O-[>8
MT;NOHI<'%%N?_N'%[X&F3,4C#PQQ#YK5E/Q3'#0;]<8P?D\7>MR7WNC@&@RG
M8A?BEGT-?1Z\W_I'/W[_U[]@%T/;P9?#KS^=7QRPA@ST?]`'M<-67?L#>[5/
MG%U>7-?.#K^<?_[O`1L?@M'=SOG_G1ZP)O:E+_QZ>O[3OZX/6#?TW/=;#"?\
M<:M%XS3K+$]&Q@.7T9<!6-AC>2+B/'9P(G92.^GT=H9/6AGWA^__I_FV,<^S
M+T05'6T@"2Z'J,OH<%Z2`->G_[FNG5^<G%[`_!KU-Q(6<2]1YJ=%<>&'?>D)
M=CV`10\%N&=';6?3/0^<.GL5#P33U_9:K<9[]/0\&*57FN]?LUNNF`R<,!J&
M$;ZW"W^P$^'Q6XY$Q=\.N>FLZU9KFS7W]]_5<6QF^F0@A2+H\[[N(3);K22C
M;K;9BFR*\>1$5T0^]]B0Q]`H3L_-9;TP8HD2V`?J=<0=01BB,)A=0//=>\7P
M#,8;PB1`G<#!1\TS;,!O!'8#*H(K&T9P2PZYYXUP'A&7\$"?.7PH8^YMTUQ!
MA&`*/EZ?M8:)=0\$=_](`%B(2*_^"@<2<1AL$S?UX<3U2:'\<7$JL7B.$0D(
M&.*YETPE70H>)?$!_D%>R!C$IP>4A__'(6ZZWBM"V'Q2C&;)CN;L&+N+7!R`
M%@1AS/JTA:J%)703)X9IW(@@$3`K!@Y+4%>P'%C%[P)NPV7.@H30-\J45-]1
M#L&I\`AOQH-0D7$*01<C!BN"1</Z^RB8.#;([3:*+,!QG)TKA@`X!<HQ"/!W
M`;0+"!@DW(.&J-"N[/6D@Z>("E1=Z!:I`HNFFT5".>EYI#!LHG@7+(99F>EM
M&,:"F,$"`<N&*8?=F$-OW'4E4@_N&))!"T<HQ:,1-NLE0(DI0R)OLB&07+A0
M$5-GK`<!!P/:]($8*0$F>0$$23#KP<#M*UBFX,#?$5!O7,?K[)#<W\])(#)M
M:#>V&2(!O<2L8Q?F`P;#9%H$RE4/(Q'L@0]AUG?T31V@U=^;K6:]E?4(#/5P
MN`U68N1+3V\:N\3E,/6WJ7:`B?5Y!(@*"!^%27]`#)!*)?@828/BGK!RXM!A
M;S!10G0!79.`'5$<AW0`";34)Y"P5TH(AF=)L+W7VSC0#0WH@9832,SZ3)-G
MT,IDS_00VPQTF=""%X+QT-(9A$'-QK>LCTE*$FT8LBB6$+6"PM-2T;I(8Q1(
M4D$S8BNJ,B"U%VB.P(0)TKE>@L,N27J6#M&6#E*7JC]@;[0(H10G`0=#KW$6
MX`7IHS"Y6)[C&N5"V5=IZ*,Q3%>(`(5YR%&6NZ.\6=MFMQ*\3!(SZAF="0T9
MN:1R>)/^3@)ROP8$>;`*[>S("SMH3C5XP:Z_!31%BL`4>Y6#D-_JG3K[Z?#P
MJ@`BT?/:]<@``506H0R3"+4_9D8MH@3&SGA&KEGT*?.-E@0!(K3*,DW4R>F=
M,\#C17#1>*P,=CZ.;CNGQQ.3`I(!IL!UPP-G,*]LX&:C]F_P'D0I:.`!(1VP
M&^CZQI?0"\,X0,OCIH$HF`U$'M[(^&Y-NZD<3/DVA3$I.7-\S@0"%A#Z>!I3
MD8HJ`6=X/QGK[#Q&F!()0@`!SB\>\!AI2PCI4;+7!6X!MC6`ZO<DH./.]<S)
MPDU[2,]$NU<DFM(#@WM%]VT$;!J0Q]X\A`X*#6V"%SSH(QT-^(M<_,)'Q5A$
M.WH:$AEMQ&S:"%]%WQ3%03]9>F%2-CJU)GMUAN'515C/P8IVN];<WWW;:FKI
MFC7.#!>V:>#A7/,Z'`(]@,2@V?`0UU]-T<CLR=80_+E'7ACC!N[^GJB8;H`1
M'$B,%5+-1-'7'VDLMLLPK.5@C\L(E33U3-8&93/(&P3[F)VQS@3G#;7/7:&Q
M`W0*.)V,6@XLV1X`(@F#B>0=`R`4#S"(1EV=#F?-\N)T$=+3\8%#VX9VWF8H
M'<+2^.E2$R!;#XP8K(G0-%Q';*/AB5G*_6*Z`]$(_O5A9U&IO6+B,%>IW<&P
MZ13)#DY,B1.-W0\S.'^2(+_'G["IPM86P'T'\*FG/FXUBGE#4Q:ZQ3!S25<H
M8P]!0'._O;O?S%;[X_,IKJ\C^P%]'BC`)XV7O@IQ@T2HB71G>X/2G:TZZR2^
MCZH*@IVC$\L(Q8A28C,2?K,R8(X^PA&B&O!NA'5Z\%Q&KCSZ,X)%EL2E4\&[
M&IE09-6ZSWM:4SW=ZY.1FTP6MIMDNMH%F(0C7&5^GO`!&ECHA@%4BJTA>[P/
MG^["70(A4P'#(WWQ2H==WW3FR7XI>'.41"/N@B^?!3@G!%EC7<H!QZ,,I&=+
M)K2.'XN6X-MRB`95Q^??!1.6WN3:N5*)/S19$@+"@`8=`N*,^ZB7RD0IF6[,
MQ-6%4)+`=3%'T>64@<!D:F$2OR=N/X6Z`]"?,)*(`3"G$4EA4S,W>*HL**3.
M54[,7,:`;SP)[DS;#X@-5!A0?B/!DV-I[HZ,P/]AAA?,\K*U[%G#>,,L3!4J
M)0Q'/,F[TM.!ZC@;I\E<EWL4_:F!L%W$Q<Z%?ELGUQVB-TJ`&EFVB--@5FB!
MW-!RI=,#,T4PCY,3I?O>9MTD)ECI29\L?!QJ>)YS'#B'L6P:NS75A-OZ[QI*
MG\GV!HKKS+ND%Y=8S.^$R;>-=3HSS>^$*E88H,<)H7F-9.%9SZ44.,@;)9-U
MACU=\;)%[B4,.]76L,X0Y&XC;/KE6-3_9EIV7UCYYZQ9WZV!;`$"T(*JD%+W
M>8)\'AI$#H(D*NBP.X+VKTQ)"XEK1.1<!O<K_@/)/9#OF%MEQ^#6*CEXE3[&
M=I&(HY#V.H59JL5JN35J;Z"+42:F"3WH61+(`F/O)80/_@[Q0:/1S!8ZEA5+
MQQB`)(I(Y9:5[I^D<?G8A-`802".Q2BR1UZ+=#:7M3O,MIF&7+HU(.&QWF[*
M)?-PJ<5];)_0'XR3;X4)ML"PB8&'ACX-C0H+UM&[@^X+;9FFEC8PZ0S'";NA
MF7NLEF:_6,*E\3O+WC'<#%1Y/IFZ/>P<L[T6F"(<1Q*Q9I*';F_GTL>DG91X
MTE)9R#AW,9F?3SZEG1G81=C315\N"*F!R4#WC<E>B/K^S`Q1`6ULDVW1_E]2
M=G@8H4%Q",&!HE@?JM$>3:P.RJBT;W;P!PX--]*Y.``!))J4.+^:=*LN%P>^
MWK3LY]DT!N:W^@T0`C;P$;'`H*,H$05<N3U.:41&*9#+=JU5G@7H,T@&)!IU
MP)&U6$0^"_@F[T/:UU\VPF3EX\)4U&BC#OYOH3NJ_3`!^`VN$.R'*X1/HIC?
M1$]WYZ=9P-V]1LX"GN@$5"+5`"7\<RXX(J^J/_V6F<2Z[2,+J'6,/-7\;9O`
M%)I`7)_$&&22)I$+WZ9'MU%!TNJ0;;1R$F+3.UW:@L]U/=G7AA8N0(QE5V\+
M%6SVRN`V05,V*`&WF?H\<CVATIU*L)F4<]/A+VAC5R]Z9!L@677XQ7J"]$\'
M0CX?V67G!J<-/A''GKZ8FRYN^V+-$\9@9#]T%-H%;FE\1>8!<VC6>(R*V0%3
MJ:NR78\4$N5D(GN:)50PA433TQ]&`/;@BA^ZPM,RH+=E*6V2ZS'GB70Q#V$M
MQ2C>P\H@6S2B&6J"Q%<F]'UMW9?*TGOY#91-\R3GE)(*Q-CNJY-^N>>^T&96
M.8T<WTE-`ZJIMB&+*71]>/;@(819*,Z3UUL3&0-@,"(7E@2@D9$C$7_;%,@3
MASV>Z)S;KQS1MKRQ8'IK,7RH]T(`F`W"K,?05,=2(3(Z6)^()8RF<(A4PWQ/
M2;%7Z;S0XBCFAK<0WX58+@>M8LW&U]JI%Q0WGTO2N^@UH[*NSO]DU0R/V:E;
M7S].@5_MB,*WXURZ:;/]^JPDW"S7_:ZYEW/=>3K6=()I@K3&9^=GT-?JH34P
M'&8;W.C"T>MFM;%&VS#0,.^(J;0`+[NBZY4"9@T$.1U1C.:+OBO.4A[@^W4%
M'^[\U`L+(-1L2V*,;[*Y%GK:4`[`N`ZUJ"-CGZ1B^FZH'1/=J^F2Q]QD;`#E
M&L])9DW@J]C"K7$P1[@;G65C[>2//`Z,8QUG$&)9UE1GFPZ/)<'YS#P5`W'+
M`2+6MJE5A`=N0JR*(6>.ZTBO8S"@&6GP38:R<+$835+=O"N,'>L:?(*V&SHT
M.93TF1NAD[6(/G0F9;LH@U.H']Z8+0,"04H"+96(;I#;VKREL@!."R$156_#
M?*0NNYY,'-G2[L6G@)?WT@?6QFL-0P8!H;F-Q8TQ,'*M=V10S]\TWM3>Y%&Z
M1N%,V\\K*^]`T@O01/LVIRJ@]&!49*=!:FFAERZ*3:<C<6,L^@Y2'X<U^A5G
M[(:0U3-)!Q2;S)VA&$.#$5W>A#S^!9#E<PBAQ!60AEZ%W`@/AN7`3EHRG4NP
M@]@`>'-,;3[$._3F@[6DZ0,\CB/936*;M\J#-Y.CMC6RUOHR:WTS=V2?,A@P
M%T[::BDME5E]K;6(61U8(;^>RXW5V0D"0W1_+[G*VE-6.?02'0F:W01HG);!
M9R^%S'[>I>*F'*&8*]"MT!9#YO_BB"#LJ&9`.GK37BU#Y[X`XKI`L3/<84RB
M8:@T)'=G4]"2CR+\>^O][[F9V[XLL#&-%*@PKX!K:.QQMYC2RAME!%19^3)N
MKN*#PKQRG^TOY);QP(*[PN&)SE$`V#`,NZ6MT*[(1R(WPL93L-@0,PU=4C;:
M7)W=_ZTP.0C%?3&Q!97N,V]:X'U-;W%X7GA+TDR:2#D7?%%-!^$%C7I`$BBU
ME6WY/8M`A!!>,A7.$H975,Y"TIV9)Z/-KP\6YF(-J?3S6*U8XY[L!P>>Z,7O
M?ST_N?Y_]MZUMW$<V1]^?X#S'83>76`&D#VZ2^[>&2"=I.??S^GI9#J9LSBO
M%K)$)]J1):\N27L__5-%74S;DBW;DBW''"RV'5LBB\5?7<DB_Q_R6_K;!^'C
MW;>;VV^#Z[LO7Z[N'V`:'."W/8L)3`5>)DNB;*\F\?UX9J-#7/X]0P\P__O5
M<Y/GG]]AF_E>QIR0J*`B?_J]Q&YV3-SBY_NKFYO/7W\=?+Q[?+S[C0[V@U!\
M^>7VTV/^54Z\B;07/W_+#/S2*X]W]]DW[S`V@+'__&X<)DDX+6DU2U+WYS;]
ME+@M#$@9Z@>/2*D<$)7>JR^??X5!X4E')*J17B%O-7MHGS'G8"J&#%+KAJ_T
MV!=Y!JC'C<DEXC(63"&:2*<8@I+%2)NRS*CE6=X'9=E2%_D/^;.5O3?@L_$W
MW`:,`@$_JJTS_6#OU]KL_,JTF]4M[EM=W_;`+A\,=?G84,\^1LS@N6;CFJTC
MS28K)]%K<@=L/HXNPQWN1]1?'-(<TD>`M,9-<K]-\L>KZ__Y]=O='U]OW@M_
M<1Q")I-*CHV?P%L,(9+ZR_7U[>VG3PL>)N%LF]E>BKX'66*S@H-Y_-QV"'Y=
MG\"IB5Z/H68/9WPC;=R6Q[2B:JO47)<:MHI9+:G=Q@QNH(@C3*)NT0[TF=9!
M;HF6-!)51>>0YI!^&Y`N]R`I'SH'=9WOT#JDJUV,?2%]>O]A@W-USHY!N81S
M0G5Z:"!VHF1)K<9K->0YG5I2+%.4%(L#@P.C?_;JT%CW?`W1102R%7L,N+]_
M;'75OD_(M1J'&H?:!T,1=:G[!`:/]2XRUF-L9[X9C[OP?`7MY$I/%E5-%DU5
MYFCD:.P!&DU=$F6E8BL5CV!Y!'OP;N@0#^7A8<3!^E`9*CK,DANF8Y\O5_5#
M=4JBIEJB9%7L>>$`YP`_?X"+EJR(QA&V&)Q_A)Y]Q!*60]OO<2$35H[CX=KP
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M!U4TY)%HF:/#E058')R[?BF,%GGUXUG@G"N@GDX,5T`U"@@/]=>D%O8C-U!`
M'>:T^J*#>N$^7W@"[(8$X=0+>`J,IQXN,/7`<<AQV`<<\A38Q:;`&`-,=W<V
MV0;*TV7'#XK.9>O+Z0(D71:U40O9&8Y-CLVVL6F)DB2)TDCI')XGB=O/P$;W
M.,YN>S5K8:@K;@@ZF7X\[YCFQ`GI7L0W/&^]?]YZVP1NI:_UV>QUKMN4ALII
M%]I.KJ[X>AQ7?US]7:;ZDX::<>I5OI,G_BYP,;!YA-9>`'*6)6YO9^7BC/,C
M'#D<.3U$#L^`=61<>)GT>921\G,C#JL>??"^\U,CWGSE*5>'%Z(.S\:)ZJDZ
M//34B*-XRK5IW.,<F\!%BA]4P0^J>,ON0H_W#QQCGSX_J.*,,T6]6#X[WX02
MQR''81]PV.?%NC.PX!L\G+/9VG?XHO#;6G;A=>)\P\D)9J;7FT<L49$-49;X
M015O?V,<5T!<`?5.`2EX2@XHH!9N8N<'5?3&?;[P!!@_J(*G'BXW]<!QR''8
M!QSR%-C%IL#X017GD2X[E]TVIPN0-$.TC.[O:N38Y-C<'9NB9&JBJ79_52[?
MIG]V<38_J*+_,0VOU.9YZT/RUKQ2>Z=<MVSJ0[6%$YDS7IZENN+K<5S]<?5W
MF>I/&II'47Y]SON=;"TP^V@#^@YU+W<9ZS$6V[X1K`X0KAPG3(,$XB[A/@H#
M^.R0*?Q0L0UN906N168LA4J:--1K8J7VT?`Y$)9+2[%:1!229R)\\@([<#S;
M9WGTD$#X9$=N+'P,X1_AAT]7#Q]_%+PX3HDK7#W\(7P-A\NM0>@G"J_/GO,L
M$-^CZ56@$'MP0F`VJ+=P(MB"2UZ('\Z0]S`P^XD(\,E+YJ(01L+-PZTH``^\
M)*9?1R29"Y,HG`J_7EW=,QT*?P0N!'Q.&D78T%/JN3`(B/V@A5B`*%"(R+]3
M>-\5DA`^S\(H@8:=B$XZC-4+)F$TM1,O#+!'QT\Q)L=/0"E\.4C"@0LC$"8E
M>U9>P:%Y$?,[C";),,42>H4D`>,@'LU'BBP(*9?C=`POP9>V[\]!O?K((CKV
M"70%_P+M)$:Q].)G?,$6`ICQ<1I[`8EC&N)B_CKGN@<41<+,MX,`QCV+8##>
M#`@+9UAO`63'PK/]0L"2),(<XF8GG`*Y#CP+;=!?%M^,TP0'"(Q\MF-A3$@`
MKP&DG@)OXCE`,S#UA00I$9Y(@,W#.W2BDF<[*2ED&7&+@_<`$HYOQS&T`F]`
MTW3"7CT8.[3OA\$3#&%,D#7_(DZ"'``R8K(T>=E\(D/R6:9<%^Q)`B_;;CBC
MO]6A=&EVJI[!V8(9@.X]X`DR>.+%#O0[)W:$S'CR@H!.!^WP!C3,=$RB12.R
M+@J9@+W"G`CP%DXOI2L,,%,Q]1)@&$O(-Y)$83S+^[1G,Q^X3!\'8DHL(RTH
M486`X>\(&88WB#87R/7#.(W(T@S<1QZ^3SE*11E%!M^OEV=\\CJ<SNQ@#D!P
MP1>AL``(`^Z]HG^;]AJC\%#XEE+$]O[(-$5\&&@FFY0MT"8,$\F@O!(ILBG\
M8,38)D5AJ5;<;`3,J)D1`_#)BQ>F,?"\9!P0B4`3F<FC4T/[_3VU(YA(>/Y;
MIBA@5)]`U)D)E0:_#VL,:J;C?W*]%_SK[S^E\>#)MF?O'Q:RLE"L]R',*PC!
M(WA]'_W0^?.7__XO0?A[\<X?,;F;W,:)-Z7*TW/!9MA/&N9[`W04OY')S^]N
M<'9^5_[O\>;=+]@U]%R8"*1N@'K_/<`<K0#]8F)//7_^?M5D[.R:',-<`P=P
MLDH>G,P\@W5&E_`HUAE%`U`[LZ-2I!G!RRBW%-G\$%>:&S1&`!"T3FA>*+#_
M&#XPPH?6LQ"&6`"*P.Y2"PP".+7_)&AE<LRAY(%^3J>SS&)0?6Y3;4B)LJ<(
MY3C7P2!:F26L)HPV!N"GXT"A`],#.FE)%XSM&*&.5F^)B'^E[E/6"G`$Q#0)
M(P^5,/D."M1#*T4?>[$C%'8AI,9OC7)0'6/0&V"K"K?`CL,`'5TAI2X$=5"\
MR$FG:(H=U)B;Y+Q[I[A-4!63A3HZCDD^([YGCST_,\:KTUB%N;'M4TL1/Y.B
MB62Y<9R3(&:;0TM%;/!*<BSCG(4N5<XQ5NNZ=#8R7*&[,:^'8.%5X@MIG+4M
M4@<%'1FT"9DIR:R5O7!BD0;H;T(B-`$`(.=/X=6.(M#(T"C]>X#H<]'OP0$L
MW,%P2H3$_DYBL<0PTRB.P8Z0)%QC8!Q:)XS!^P-'.DFIFQ*G/C`(WO5Q+0(&
M&Q5.4A@S0K>K:5DV$YD)L9^B[^\?<$P/X#LDU-#,2S-3F!+]@DP)989`N7$1
M5N0N$'ZSYPL*2R>4=>)((7&V(`^U`:!Y(.>B$2.G-MD>C`Y`%].G`>3@LM,%
M-RH%Y?(;JQ;8%RCN;"_8K&HJK0@-36@($A'Z=:9>,%XJU`K8L2=TG"-TH^W,
MB2:YT<K\76:,F?VAU*Z3"2UD5-H"V&-,[*34(_DK2($DR8N!#FF\'&'8B!YK
MV<<S()%$,3,LZBT['H9,$W1\XU6"4/U%)(^+J)VD6J)H0I$^7+DN];:!,3/;
M<P?`PFM[YH'K6SXD?\"A,N]<9\.B8L`^!>]"+)I-DP`^`;29\VAIP*6+335D
MSJU,I944KC*VH1[;K*N67>)/MA?]+])T-RDS%9^#.(E2"H[LW4*]&1>DWI`Q
MPO\6L[7(XC#,N0BU]SF@YCFB":#,^;UZN!8L!?0?]N-19M6RA_XL+@60P,X)
M,C<3!2;M(]CC$-P.-B54-K:4=$*7A5"'%/04>BD@W2&$@_]9:+\EITIDTCB@
M#CSTDU"+.=11S;)`U-AG3BTE;`@:(,Y<$`<_8-?P0TF+`YX.S;$D[&A^B`F!
M6#]A3YG[L:'+N]L4]Q@RGZHFD$T#YOX>3(,]IU.0.X$19C\9]UE<Y30Z@*6_
M.IM%X??<IV6F``U5D3V,G\%='B0DF@J!G0#Z=G4%&ZE'QD/\1^[_UOB'Y@4I
MT((5%Z$EV8B[1#<J'0R\BZ`(-<TLA<`&3#ZH+)>0*44_0.*%1(F'GS-S[U4K
M7<V2&*5[`T$[2%.:)Z^_,&$G]1YN06,E\X46'A9M+%(56?:A4N.*><@/CP0"
MJ&4,WZGPYKO`\%419;+,1HJH6#V(^K_GJ4=X;^Q[3YENS]8)BM$7*=(BK9O[
MIX22G'M#(KSP9$>NC[GXW&-*,$7Y).1Y6E``XVS0\^(!9&L6V`H30D4^"S&G
M=IFN9#I'JB!N3_SL2X9<<!D3F+08HUNJLK+X?DQ6\NMVJ:_FRWF7*3AV:90O
MT3#J*5^"R#&Q>%O`G/X395J>QX[`J85OIJ%+_`P#P+O@B="$%-,B8_SLN/0I
M8X%&TF[JY.F:,)_0//S^(4\J_%A8S#(B0!(7:QJ79KP^TV1?0"C;BBPV7;J9
M^61;^I`F[3&(2`%)#CP)\,G6O99CQT7@6*D;%K'3`^;BF#-MKR"<1#BO?Z^L
MY6)@@FER/@U`(B/'PSBC2"[MV.WU6N-VFH3HM3ET;2W78-3]@A:WM+X4Z#)+
M&(7%R+@>A,$@SM=)!5S%&]#MIIEHA"]>3&']0TD7:IQ8<,-7B&-!_^(*'?AA
M=!I_S/R()<%ELW3(E8@,<I%UL\S:8A4LBX)WBKYJ_(#EV.L!.?(1X[]K)D%V
M1\7_*G`_![BT#M[,/;BR*Y&8=4&.!(UD!Y1/`LNHRW8LZO*K=;Z#*5N,[\#R
M<9!E\M98FSL-+`5/F7QF*B#,%P)HL@A\"#3[08I+M2CDN;AC<`6:,YR37,Y0
MK!??4/)PZ3[74-3JD>6TR;+Q3!:Y)7`^*$$"[B08+@V`1@K9VFYI'(ND%GT[
MYQP$(%EX21O*%:07"]FO8689Z6\#(=NOL""F"!K=W'13O4IP]Q9Q!S;H0]Q]
ML4BT%\1_]&V8..'!>0Y]U(=5UK[L_D\R7UITB5.,?(H9H,P2Z?(`33J^A#Z,
MGGH3.([R>PR`LHG,':R%FX>#Q0@:M$GLN217I&-2[$7!M+R?)ZO*=UY(EH='
M]R=+68G+&*S@?OB2KP91+RSV@)<QB5YPMC/]6F(!K";Z9,@-<&5<+\G6L=<R
M=$Z6H3O"@M+)I/_JE6X20N3B!`&C[2+_D"N#'-?98AO*N2[I`YT-$[(P0,CT
MYWV!=V#I5Y#$VT(2E\*$8+X\G;FK"%/GV_F^`I8<#]<\HS\!]4DXH)^2Q73G
M>RTPMD'8+.PIPA@>F-.O=U[]W]UT+MO>6SO";0KQ/8EH6S4!^^B"["S6^GS!
M6A_@B?!0793[!BWL1UK.M%Z1C+`&[]9),\Q#0`BS[;F%IB]?L),D\L9I4N02
M6>\V7ZR@T21C'83".BS,9?%6[B0S\7:Q*2F3FFS/$Z9)"XV=B6BF(IB%%B9?
M.11N:NNN.QSE8)=1SOPT"Y7S925X.'/W7V#DX,?377P;WG?3J*`Y5R\N0;-'
MUYH6]CF)J(\_'^11#%K[R6`1ODP),-<%CGW"Q>TTFH5Q%K/45ZZ7[*,I$#:7
MLQ(S;?R163E?FL8RE$)2E_TNVO>JV2YYY<\7#(R)`^RAH0ZNZ^.+Y#LF8Q>[
M"I>&L67`8^+8:9;$`6<HG[!7N@H_)FRH]D*6=YI5U`Y6M?]*\B1-;$_)VEID
MN<7ATC(3Z+]-0M\/7RF:J232I!1N9LVR%$L2M04)-/>W6/MM!1`AQ-]"'-:!
MX0>ZDXJB>Z&><FG^\7UG?ES.JNQ]M.4#6D[PWB>3Y$-1MB!)?RLK0Z[OOGRY
MNG^`:7"`W_8L)EB5`"$5B7Y^)X%+0'RL#T>'O?P[+SNF?Q?E"=!F;NF[+5(V
MI8/+LTVIT]+7'0>D#/6#1Z1<UD4?BE'+LVX/3%`,]L`$M76F'^S]-KK>XY0W
M@_%[/KAFXYJM7CY.=!!,!VP^CBX[]!HP#FD.Z?Y!^JBW;W&3O+M);O<XI!JS
M?=KCD*[K$S@UT>LQU&SK=?75:N*\CG;M][FNVQ7QZ8Z*L$1+&HFJTOVYAQS2
M'-)'@72Y24OYT#FHZWR'DY]^TG?_H>&1Q^?F&)1+."=4IX<&8B=*EM1JO%9#
MGM.I)<4R14EIX?(5#HRW!8P^V*LW?[3O90>R%7L,N+]_;'75OD_(M1J'&H?:
M!T,1=:G[!`:/]2XRUF-L9[X9C[OP?`7MY$I/%E5-%LTV#CGG:.1H/!B-IBZ)
MLE*QE8I'L#R"/7@W=(BG,_$PHK]WS_#EJKU5IR1JJB5*5O=W>W&`<X"?PC>P
M9$4TCK#%X/PC].QC!W=']*F0"2O;IU,[@J?B30=DSM*D+$AJ5$NV6A>9URJ>
MMMC(4H>JLK'<*)^(`M!#4\_0N',-DE5>2M.M*[KG7<8K0E1S!^*)<JE=7<OZ
M9K<UJ_+0.DTDK,IL$9)^IKN<'Y\CPE0A_08=/3.G,-T&;G;9YC@2?LI&>,JR
MI>YNA7T+VZ2Y0N0*\7RNL>ZI0CQR)1/'=T?XWD@&!_KQZYNX[=[7=O?XTO?#
M<-KPD*ATBD<.A5$/U/+)[U/N8Y'()HW<B[SD;OIZQQSE2=Q?CD..PV/BL,]7
M+)^!!6^X]ZQ5T]Q6ZOQKGN'N?-VDJU#HC)?[AFKM7?3=AO*GN^7\K[OC[`03
MHPZE$\W,]G#_=&NL/ZBB(8]$RQP=KBS`XBCT-O4^*8P6>?7C6>"<*Z">3@Q7
M0#4*""\=T*06]B,W4$`=YK3ZHH-ZX3Y?>`+LA@3AU`MX"HRG'BXP]<!QR''8
M!QSR%-C%IL`8`TQW=S;9!LK39<</BLYEZ\OI`B1=%K51"]D9CDV.S;:Q:8F2
M)(G22.D<GB>)V\_`1O<XSFY[-6MAJ"MN"#J9?CSOF.;$">E>Q#<\;[U_WGK;
M!&ZEK_79['6NVY2&RFD7VDZNKOAZ'%=_7/U=IOJ3AIIQZE6^DR?^+G`QL'F$
MUEX`<I8E;F]GY>*,\R,<.1PY/40.SX!U9%QXF?1YE)'R<R,.JQY]\+[S4R/>
M?.4I5X<7H@[/QHGJJ3H\]-2(HWC*M6G<XQR;P$6*'U3!#ZIXR^Y"C_</'&.?
M/C^HXHPS1;U8/CO?A!+'(<=A'W#8Y\6Z,[#@&SR<L]G:=_BB\-M:=N%UXGS#
MR0EFIM>;1RQ1D0U1EOA!%6]_8QQ70%P!]4X!*7A*#BB@%FYBYP=5],9]OO`$
M&#^H@J<>+C?UP''(<=@''/(4V,6FP/A!%>>1+CN7W3:G"Y`T0[2,[N]JY-CD
MV-P=FZ)D:J*I=G]5+M^F?W9Q-C^HHO\Q#:_4YGGK0_+6O%)[IURW;.I#M843
MF3->GJ6ZXNMQ7/UQ]7>9ZD\:FD=1?GW.^YUL+3#[:`/Z%O3^Y'HO^-???TKC
MP9-MS][?VE$`D4M\3Z('=+7O0]]SYH^`X(]^Z/SYRW__ER#\O7CXP7DF;NJ3
MN\E5D'C4$_=>R`-QTLA+/!+??G?\U"7NIRB<7H?369K8B1<&=Y/57LKV!<\%
MM-I/LH0!<("2\XU,?GYW@Z4/ORO_]WCS[A<D'.@N.(CC'R!;WLO2$)E$OYC8
M4\^?OU_EZ-;H1AKJ").CS-_C,Q$FH>^'H":>!#HU0DR2&!.6R;.0P,]AFL0)
MA#GXP"Q,"+#9]OVY4/`:GB^8#<_;B?!LPY=C0@*!Y,P7)L!]VIAC^T[JTRD0
MPLF&1"@TX-AI3(0D!(4EQ*'P&J:^"U]#R)5X@[+W'X`U3CB=0H/DWZD'(D*0
M-=A&_./[&G@>$MGDNB%C5?8^8F1`9?.]3R;)AT('2-+?2C5[???ER]7]`TP#
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M"M_`DA71.,(6@_./T+./VPJQVJ^MJJO=6GWA(YZM<!6X-UE]T"-2NEZ@)7=3
MH+4C"+=Y,5O+N6IKC#JK3V(%EGY1'O,QTF??-Y4LY<,HA&)HZAFB=ZYC@IZV
MEC&MB272MB*6[%>%+++?96('W[3A&_/;^?A58ORRT@.W73\^1X0IB^+7E9YH
MWS;7KER[]D^[GLV)=SW5KD>NT^+X[@C?_"+2GE5O<4>@%XY`CP^;/`ST_%93
M?I0^/TJ?XY#CL.\X[//1;I?F#C3<\]?K0Z4[7Z_BY^KS&PK?PE&G%WQ#H2H:
M\@AO*3Q<6?`K4ON`<ZZ`>CHQ7`'5*"!3MD1-:F$?.+\B]6WZXA>>FN/WK?*D
MR.4F13@..0[[@$.>G.N/0W#.R3E^>>MY)/+.9;O0Z4(W71:U40MY(XY-CLVV
ML6F)DB2)TDCI')[G>GGK61G\'F<`^$VP_8^V^%6(/#U_2'J>7X6X4TK?E(;*
M:=<33ZZN^+(C5W]<_5VF^I.&FG'JQ<R3IR3YFN>)ZQ+WB&;.LF#Q[2S0G''F
MAB.'(Z>'R.&YN7.P5+R"_CPJC/GY)(<5%C]XW_GI)+PHF>M6KEO/U[WKJ6X]
M]'22H_CPM=GJXQS/P46*'XC"#T3AOL?Y[[DX1M4%/Q#EC!-BO5AR/-^\&<<A
MQV$?<-CG!<Y+<P<V^%YGL[?R\%7YM[54Q<\CX#M^3C`SO=Z]8XF*;(BRQ`]$
M>?L[$[D"X@JH=PI(P=.80`%91U%`_$"4,_3%+SPUQP]$X4F1RTV*<!QR'/8!
MASPYUQ^'X)R3<_Q`E/-(Y)W+#J73A6Z:(5I&][?$<FQR;.Z.35$R-=%4N[^D
MFQ==7'8&@!^(TO]HBY\(P-/SAZ3G^8D`.Z7T95,?JBT<<)[Q\BS5%5]VY.J/
MJ[_+5'_2T#R*\NMS1O)D2Y[91QO05_[E>B_X^>\_I?'@R;9G[Q^<9^*F/KF;
MW-I1`.%0?$^B!W2Y/Z+#?16X-YF[_8CM/`*N/_JA\^<O__U?@O#WLI$$OGH.
M?9=$\>V_4R^9?PT30K]]F/E><AT&+_"3%P;?[,0+9<%S`:'VDZR\$USB>%/;
MC['D!,+I`$7G&YG\_.X&BT]^5_[YFZ1+^CLA#;SL^_LT(N]^D8<:,X@=^U^F
M_CJ<3L.`/GUO1W?10V+#>/_7]E-2\*(D6&4)_OSUTS+)GVM(_N/AIFCIW2_2
M4)(D>4%\@^Z7Z;T*$H_&0-X+>2!.&GF)1^+;[XZ?NL3]%(53:'*6)CC48'U>
MKZ9A"F@L1J2Q(Y(JI^#_'F_^R5#Y&YF.2?3/?]A19`=)]A<S6-I)_.X70P$F
M+(;9"M5=,D)OQHC;Z<P/YX2`9'P%Y9W_11ES-\..XIP_2@5/P!N49$4Z(ZX8
M6[BB4JY4#5725$NRM#,:J]EHK/_,M$GB@3Z\C\B$1!%Q&<&HX(5E22-5.2=A
ML%IAQ58=H5BFI%AGQ)=1,[X<IB143395^7RXHDB-5&?54"U9,3H6C*\D^1PX
MX91\">/XZL7V?.K)A(Q%RUT'ZO&4@Y*W3_6RB7_WRT`UY)%ECA;CV;'S=BA7
MMD_'.N6F;&FL6W(0Y5M\R9+2)7=*:<#CA1LUH$?-+NC=TN5^]&E;Z%OC)$,?
MG@6Y)WE7<4R2^#H%=<I(V28'Y7/UM.J:K.N*QCH<;--5O9;=;;+\-=T9AF+*
MBKS6W7(_7SQ[[/E4L%>'N,D"UPU1E1138]R,]>:W!2ME]YNL7DWWFJ5JEJ%+
MFX*1VN'#_&^@9I.M:3P!VWI;"87L^!D>PW_P9PB`@7WQ57(-=GP.\*5124&@
MNDGMU\Z6-M(D16'"GR9=+E,)KL;,]MS;[S,2Q&AC[Y)G$E4*C;I)BR.-ZBJ%
MLF:8$@.G!ITU$%YUDTZNI$-1#$/5FTGN?13.P`V;W_O@;`&)R,C9%![#A;2"
M`G5G3L@C0Y58:[:IGSTHVA1ZUN`':=),T]R'IIO<0?WD!7;@D.LP3F+PSIR,
MHRQAVS3M.JMT4QLQC-K:U3)E#*063Y74;%/$Z]18BL0XU96M;U+]ZC8U7"$T
MFJ3+JK%9\5\Y#KIG\;T]1U]B542V:=^U7DU9UW0VP*QL?XV&*"5NO0U2MZG=
M-3)4<R0;RV14=[%B!T([J&&%MDVSKM&@RY*N28Q85+2^*@T1*%OTL^MYH6W5
MGK417F:.-$TS+58LZOO<4U:U;8JU2HFHRLC2NY%6;9N:K:)G9WG=,&7;E.H:
M=`Q+TW1);>Y`?0F#IT<235F(E=WOK#I'IC'2V1Q`5?/K"5LOF5(_`3P'Z`'\
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MOSHB5SO<3MSG.$X9PD9[$K:%HJR7[=3<I4F<V`'NSRU(,J1N2&*ZVGM=V)#;
MQ-O.*\+,"W5(,Y1]D::O06U#=UOH6@:9T6@UO7+90!]9)AOZU?2TA9PJE&D'
MT*2,C&H7K$6D;=<8ZO%PMC*?VY6&6JG+1JI23=9A<VENUQC5]*@ZZWHTG\='
M,IV%D1W-,Y^D2&%FJU)721)YXS3)EE&`X8S5-;<'V@\0.X.DR19,#9Y-2D-#
M:F<AG&Z^))T%"B-+9?=F[$QW6\/>ZE07PU9V'*&NJ08;C9QLA%O]\'R$']N8
M5TT;*99J*3T8]U:7/Q_WM:RT,'!%L6"Z#;.K@6_3RN:2YM.ZE=]ZA=Z0ZH.&
M:LE-A[J;S)YX5&K#4;4@IR<>J=YPI&U(9K=#K?-UK:WK%VU)XV(?DV9J]>9F
MLY?<=%1;\X%["%XQ@-%(9A/U7=`_:NKC'"IBQ9@T':)DP^AX5$T-_,'B5&+-
ME&53U=H<UK(;/VJP+MNV`$E;AE,5`C09RM;EB+8'(JNF:=7[(8>-IL&6G`-T
M0%=ST%@;[T&S8<CR-@G?E^X&NX%:UEA=S4!3RW%<S;OG:*#IQA/3FM+M:&9D
MJ:E1;&TDLFY:FM3:>"K2+K+48$W^V`:D:<YFPZB:6OKCVI(6!K:#O>_`K+0P
M@,96OB,+T\(0FIOV8QF;%@;5U/(?U^ZT,+#FKL'1+%`+HVKJ)AS9%M6.[&Z&
MUS3!U_GFW')?CBQO*]ZH6*_'G<DFNW5ZK?GEWA?5$5E9"NX/2N'I_+4PB#^2
M21B1[+E'^SN)?_,"B,F2^6?<]T%B7.Y>;B4;]F\$8C?XY04>H?N/%N-JI;3C
MB)0OL^P?!*O,B7L%.+&?R-<4<7$WH=/,S')--8;<I%:UJOH.5R_9'0K[D=$8
M>]L*22L*AU1%&TEF<^P]V%BQ384+IB_VW'SBOA&'@"2Z=\%C9`>Q[>"7"\J6
MC,Q`KZVW5M1_?KZ_RTO4UBI_UU8=1N;*`O%.Y/5`JAH4?FXO]3I;J6I0TU@A
M5;J\M..]6YG:O<(P6P4<:8JJFHW%ZH:,F;,"[B+OR0ML'[_-UHV8@PLV;_A8
MEB7&,#ZDXS!R\<A3XM[#!'MQ'$;TM()8L:YFD>?CF]5RIJ[NP]A*[NE%JTDM
M8L7$#0Q=E?61V@/IVK,(4U::':RP-G(%E(K,;@<_1B&FO%Q<6%WIN$;M4K&C
MR3@8.Q4['JB^-M8I;BP^UB136TJD=ZS#FATOL%;DHIFFQE:#[Z3#<M5#`-]Q
M$J5T'S&3X&$4VN9]1:THM(VN1&E7)%73:Y7<MO'T0.,U.R)@3>XM138@!#MC
MC;>QUG*7D1]%XRU79%;7GF_2>-G!?GOJ/)`4AQ"7S@DB%\N./D,_GNW?IV/?
M<^XF$#^SP?G&\DWVJ"3SH""=%>VL'`I(6LC:59J$4VC'64@D#.7%RT1SFN_P
MOIO\$<#LO`(4$Q(L#RCO!I#J3=-I34"AKV]N;LBO5DW+Q@+5C8??:(9EZ.T:
MECT@T^!$HR7([)>X?EN0N?+]T$%C5@@Q<9%*,+14Y^8V=\'C!D:]^6DPWTA,
M[,C!>GBF\"?OLV;GVTA1#+;LJA']AXVYP>%`S<?\*PE`*'RL"G&G,,6`&XJZ
MC:,&?]64M>..NH%=;SSJ-?C*YH@M:C_">#;6&!?:H5/D2M:(C7/V&?/&;A=#
M;9`-KG!,5-/298M1*1M[6R9L"ZH7I.T7'RLRX%]G`+.EOYH89>%E+0AJX&=4
M.7'UJ99%)ZO.>>:DKK%DO\#9M.0EE;#2_&K?A>^;45<\O""BV6F`ZY7E)DM!
M=2?+I'RRO8AN>;QR_Y5FC]]-\JIZ9EIVCG*S:9%'RE)MQ<;>#M,GVRSA3OID
M/ZN@Z^K2N6E[:)0RFLI__0B$3#P&&-N,7\U$J(:N:.RA`S4='38'VVS4+G.P
MI@X-D/#146W4QCKT?8[;V\-,Z99FJLIQA]TLD.Y8FA0=K)-Q#/N\L;:^9E43
MH"A9K`7LP#AO+**OH4N6)=72U0XL\\8J^MJUW]I%[5W-\L82^)KN-4G5V$,I
M#K/)&TO3:RA@:Z':M,=Z`VNW;HS!R9?U8QACO>'YK?O:`DLUH(_C*L4&MJUK
M6Z"JNJ8>-]@V&H1IQ[`%QD@^KA$TF@5M>T-8!\]8TX]AWHQMYJUB>X&B*;JI
MR9V:-V.;>:N@RX(@CSUUM37K9C3(M:Y;M]IM,[M:-V.?33NFI2BM63>CP4GK
MZV(YZL:\&?OLB#%!6>UEW'9/;1O[16':R-0@C)$/SA)_):_Y88/P$[01P$>'
MT+6T^Q#>FF?__TCRZS(6A(]J:?T%+^APO9?BGA"\Y6.`EW^\EZ4A7@5"OYC8
M4\^?OU^]-V3G&TG&AU]-DGWQC]OLKI5QZ+LKMY7@=B]H?,$I89E5ZY>9C)>O
M-3GD1KQ-%QIJTE"ON=&P_3M;/@?"_Y<&9$$C3KDH),]$*)=+6!X]X&J0';FQ
M\#&$?X0?/ET]?/Q1\++"D:N'/X2OX7"YM8$LB<+KL^<\"\3WZ(W*0"'V`%AS
MR"P1PHE@@\24A@,&AH>;P2<OF8M"&`DW#[>B`#SP0`W@UQ%)YL($Q$+X]>KJ
MGNE0H"LU0G'NX5/JN2@U(K80"UAI')%_I_"^*R0A?)Z%$6BYP(GHI.,A<\$D
MC*;4JF*/>+0[E6U**7PY2,*!"R,0)B5[5E[!H7D1\WN,E<,44RRA5T@2,$ZP
M@WRDR(*0<CE.Q[CLAH+NSP7X/V01'?L$NH)_@790GC;H@/@97["%`&9\G,9>
M0.*87D2)5U;G7/?PS$9AYMM!`..>@<9PO!D0%I:+]<*S_4*$($R$.4E@7J9`
MK@//0AOTE\4WXS3!`0(CG^U8&!,2P&L`J:?`FW@.T`Q,?2%!2H0G:GUQR9).
M5/)L)R6%+"-N<?!X;J'CVW$,K<`;T#2=L%</Q@[M^V'P!$,8$V3-OXB3(`>`
M##22S.1E\XD,R6<YV_U@3\#8"+8;SNAO=2A=FIVJ9W"V8`:@>W`B*(,G7NQ`
MOW/P?I`93UX0T.F@'=Z`AD'G;M&(K(M")F"O,"<"O(732^D*`[Q/=(HKC"Y+
MR#>21&$\R_NT9S-0W7:V<39>8!EI08DJ!`Q_1\@PO$&TN4"N'\8I6%ZVC_O(
MP_<I1ZDHH\C@^_7RC$^B!VH'<P""*TP)A05`&'#O%?W;M-<8A8?"MY0BMO='
MIBGBPT`SV:1L@39AF$@&Y95(D4WAAYM+H$V*PE*MN-D(F%$S(P;@DQ<O3&/@
M><DX(!*!)C*31Z>&]OM[:D<PD?#\MTQ1P*@^@:@S$RH-?A_67'N5Z?CU2ZUV
M-<_[>/5FL]SD^L$TX(.P)U=UX-AO/$VHGC1Y9(Z65B%;<^XWGO.S86=0_=ZW
M7?W[C>?P;-A\IQN:;K3EXF\\%&?#O&AJ1UDLLT'44[FJ9*CLW18[N/K,=7-%
MI$ZB%\\AU5%W'I33#2+@389@`O]#W'OPR$.7'M.\[F&;1C<>]HXNX#87%#Q0
MO)SP$)=VCW?IB4?%^\BB`;WB\+U/)LD']LI(^D5Y&[FIXTWG^066UW=?OES=
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M^^G3@N%)..O`FK6XS:)81Z/KE\Q.AYJEPZ.HOL/9?E0-N;/DJL<:]Z[RW2*N
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M,`UQ)'?OIO/,$,\,\8+,'D:=O,[IK(-=7N=TGL&VI1JBK'=_^A%75%Q1<47%
M%=7^>?R1(JJ:SK."3>*(["->E%;^M7;!9&?7V"W?EG=#9A%QO/PRTN*"NVUW
M<U???:U+FKH8`-ORRF7<MN=^#OX'9&?]_L+];MT>R::L,U=NKW6P>HVB$Q'@
MX`W)_OT<W$=D!B_=D`F)(N+FER]>!>X=WE-Z%<>$O=-PM!][9`W^QUZSN`\5
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M&VF,EC'!MMW`)["V&;WJBWP-61\=Z!.,]KL&6S-D0SN:3S#:[T+L@2*9RY-R
M<I]@M-]-VKJALRY8CSR"T7X7<P],4`"*+O7&(QCM=[>W9JBJ+JF]<0I&>]X(
MOC:.-OV"?<S#:)N=J[O:''P[R=2WCV1/^S#:9K9J-'5C^X"T`DSP'X0*1,\(
MIRL80Q3-@5IZ4?N"G$WFZG-&SBHM%@BM)#&N0*,N#Z)RDWFC5*[2J,B``/:.
M^JYI5*1-AA!I7.,CO`+.B*X=1.0GVXOHUS=>[/AAG`(JRFS"@CBYUA'Y!3,<
MKO=29%`P/S3`Y-%[61IB^H1^,;&GGC]_OYIWVCEY>5CM7[9065_\E^^!&PK(
M%2&;G]_`P`%3J%)=3X"ME`0>DDW:M,0J#75,@ATEKWOU<"V`#A,%;-3#;VJX
M03==,;"A0Z$OB(#DV(F\,?0+CHPPP09>:`//'BB[R'F>"]G*+3BA"=[;+?BX
MPS\6PHG@!;,TB47\^/KL.<]9$UX$7F/R&@IV1!"+,2C3"!L8QR1ZH6$>TH//
M^C8\F@:+7T3XVDZ$J0V]$B'%?I-0F&9C8:@;UF0X#YJ:'D_UI\6\>#',V<0+
M@#5V-FGDN_-L!T]$F$6>0S(.OH:I[R(/P=$GW@L\/`DCX#N\`ZZJ`)_1G47F
M)I$=Q.#5"K;@YR[@7/C!QM5Y+\F:_!%FFO8$?T'(-[-];&`*H:M@NR_@K=A/
M)$QCF+;H3V@<>\*GRZX6[4([T'(8`2+\>=:U[=``9TR25T*"HHV9'24>=D7A
MF]#VI@M("ZZ=D*&0>_\()Y_QH2D'$'WY&RZVP$`;?P)_/HP2^"F-0=_"X"FX
M!Q3<U6)`6P4.A!'T\I]<8#(1V(14X?$9IFS1S-3^[DW+]^%%%!]&-O(6<4RX
M2W+M459<\H>Q#U(CG1M(HWP`#$U"WP]?X_?-9*HU^1E(0Z5.@G+AVBY'#_,I
M&(9MXI.39JF5C;T73.AQS>(MU9DS@VOGTQJOBS^$RO'6#NT+SO>B77FU,TN1
ME0_"[RDFOS)ICJD4HE=.<FF+J<B"F@9'U\$]NI5BE:$,5SOL8%XV;GZ(A54:
M:AK(C`$H#0"G`YX/_9U^(`L?:!_-O@5)Y@)*'**GAZA2#='/F;H*,9^"NC98
MAU6IUUF'@7CT#1<B:"<!HX)(#HJ_1"%.L3`Q%OZ-$N"6YB43!(1]#"K6MZ,"
MLXRY\BI%!1[(:,SU:P51^(QCHTT#R$=1.`XA;(3.QW/VH9P4L&1V1D@ZCA.P
M=Y[MHVU$5RKU?0'"ORE*3&E1-PNF\`R##<)5YBG5X^/2]M:E3:V6MC_6O8@%
MDN-TECM'@%@`2I)!&E#%8A91F+G]$:$)+&@'P!J``6&*@!&Z`+UT.LO2-O8X
M3!/A.7RM\/1*!W;)2UG&_@I^F]HDM<X08=.O$'5C]Z6?VBNQ.&:<P2H2\%KS
MB<W\1Y@NRJUR5CR8CC76%8_"S")`HF(3!'TUCU.`>FPD7]D(:$.@^I(\6D5_
M>)'G(S9%&`(2'?49W4OQ_[-W;;UM&UGX?8']#X21`@F@L+Q+2KL!'-M9N'!B
M-W9;]*F@R)'-+46JO#CVO]^9(251$F^2..10.GUH+(F<RYDSWYSKG%/3_\BZ
M)&(ZH0&-61'"5'"+$KT[;Q-,$Q\=WI&.%T9!G-"W0"LB>YUJ/]_QB9HJ?+F*
MD$F7Z!(KEK,)"C)[3!X(Q$1'%W[S@DCZDU9SW?98HY0FR?O$_/6>1A-]<-$T
M^BF-6AJIHJK]L(P,N[B]N3F_N\<4MS!IS7F(%JNYB'A*=ZTPH1IK8NQ#+LD3
M(8[/Y><T`8%^3H.61LLHL>)LA282##1#/#Q30S-X2I4N"N,\-"7J>&^2TT2M
MF[MO9>T8[I#;4J&KC,?`Z\#KQ\'K.:F$P.O`ZT?)ZP?=P;MS?+RL'>D]H8RE
MUF:S8@LDV_VR8MMP:1=K51P@=;]ST!A=.UD&TEPDGNV&Y3Q=4`E\"'P(?`A\
M"'Q8*57V)^N21WLH,Y&QL5`_ZOPJBM#A7T?OZM;-$C!BI@WSA!BPGK">L)[\
MKB=#.U&?CVJNC$`*DQ/]HB@`LK,SOM_:#&M;/-PNU,;M0DR6;M=;M5I?/)YO
M%%(&DD$N/VOA-ES`)<`EP"6.%H]G7,H$,P,R<<G>@$R`3(!,K.]A!(_`:7H$
MDJO5%PEAV4#^DW<2<'7W,-LXO2,YQ!A>*ERKJCV#E>'YA.I>IP>H`*C@;%T`
M*KH69@$L`"P`+``LP'.^OTK+E>><C>:;N:BVNX"X?IM^(?2W;X%"P(?`A\"'
MP(?`A^#XZ(OC@TW@Y#T*L.2W(O+Y>WEQ"U5WL9.\F"@:LR\<JZV@044?E';8
M/K!]8/O`]H'M`]MG3R)JZF@P'K*OK`WF8O[-Q6WI"TKW^D+/S"6L#1_\&C&.
M3%(`O@.^`[X#OFN#[PQMH*O#+B4[L`2?E"7XHGNYCA=-'"ZJY0P,>3B$@3F!
M.8$Y@3G[Q9RR)@W&1L[UQV`A/#D+(<M4RFQ],#[R*7NF-'.5'L%%>%6O?%.<
M95%4+6#IP0SW#0!4<<;K`%4`50!5`%4`50!5`%7\0Y6A:0.MV\"D_KBODC])
M!=XJY;[O19A#3%=GZEBDYG6VK'D<(IN4LIX':&X&M$@S?MJGO]*RYN2KF6\C
MEY1LIH:%Q4-YA9L7CJSJ6LN.9[FQC82WSKO5K\^^:T9).>ZWLJ2)HQ_>#?`3
MV4<")_Q;F`8HK=J.PD@(S(C6]9;%L?:#\!9_Y<Q,4@4^#NE8`UHW^E68^)X=
MTBK1@BD8JR9?D4F*LT]1TEFVMS`*G+]16M_][1M9$B7I':4$H4!>2@>Y&KLL
M=(L^\$;6<4.%[:P<@F1`SYGQK)>7S^L?+^04!:1*=ACYUM]XT)HH#_',\@:U
M_;`BCN5WN9.XR'EZ*!IJ\O3;["C1RQQ99`$(486WH?,B$!J'[]B5T>9CEZU*
MG3MXH84`?\1KC!?3)LNU49@<?[-9Z7&Y[D4)XH<3JE:]<>F'Y>')M-BXU$ZQ
M\9$D&NSB7+)VXM6,.+(3?T*/CN<1KIR8KNEA)#.C$FAFK^'L*.CQJ^2PU5!.
M1]O87548MD9($/8)XRKL_&S'X8HL.V-J!JL=>'BP"5:[>ID[6,`FZD"!Q%DE
M\79YGO`2G;'K?M,/]^CK/8F3>*N-U8%JR%V"&+M`B08)]:Z:0ER@'5<2-:,B
M6$^F]T@L$*V&6QR-V-QRK%H1F/+A%N@+3JN2/)`T"61-D#59&2JN/'O#2O%+
M[*&,A4*B%@H-)$K._*MPJ6^WCM-":TC#+M(^VD@T71G(>AOY?!VH%\UX.AFY
M$89#4=5V\B2,]O4D#(?M>!(T1=0.7V5-X<G8H(K*X0D$U0A@(>*OK8"`Y*$^
MZ!2BWE'^RV[ZPLY4QPU-#H+@$9$9Z><_KI*93GS77H*R3+O9<'SF&'\FK'`:
MV!W8O6-V5X#=@=U/A]US(@J8L3M#*9PAN[=F.2J37QO.F,R7<?<S,!W&LTDO
MQ4R;;+.ZIJ8ND+K?]GU&M]27@?3Q6_:[4@F!%8$5@16!%4^0%<$SR<H^RDQP
M;,J)<$[KE;=0MHV=MMY9*%LQ(/$2S=97\SHL*2PI+"GO=J->']I<&848!7.:
MX1,-8K?('^B?V,%#1^T$KA^I;L/:/@\W/;01L,3HXDB%;_U4XSB625<'ZG@X
MD(;LPYD`FP";`)LX6SR>L:G5.[(`G`"<`)SX6CP`)W`3G+B;(+F1VZ3.@K8O
MX^;?)@DI2WT[R)BM2]EAQKQ\!+>G%!_J/<`%P`5GZP)PT;50"W@!>`%X`7@!
M_O0C\J>S48)O5@6I.@V8Z[<E&,*#^Q9"!*P(K`BL"*P(K`C>D)YY0Q@%5OJS
MF>\)2;&(%F\#[K&EXJ1O,S@-S1CX$_@3^!/X\YCX$^Y8!*LB8ZMBY\7NCU6E
MALJLX$YC&'K:;F56<+\!6@%:`5H!6@%:`5H!6@%:G09:<6"`Z(\W*_D3JMZS
MJGJ??Y-LYQ7O=5'?I^:]L5;RWLKSZ957J5][Y>V;D3A4JFO&;PVV=O'X8V+@
M``G?R?\\'Z^IZ853%(3"!$7?$?(VB\>3ZMT"7B55L&/*TJ26-_F",)\H7$\+
MV7?!/J$0H$<SL!>LOKZ,3I1E](!PHVE9,6'%`>:N:1S%^$O3_E\<1C.$21#Y
MI)40"2OV7+48"C,3\R?"7?X3.P&R1>'<MAVR`4W7?1V4OFKYL6L+5E*$,;/'
MW==R'OG1=I[)IY]_C,/WCZ8Y__`9M_H[:?32"2W7QYL&A0_X//WD8F;]^.]_
M"<+/6X\F=P&>>W8FT/$+W7#(OO6^(4P30G_\P%??"Q8?/YFA$SX0T%VV+S@V
M9B_S49$48N;WR$'^#4W_<W9)ENQ7Y<^'R[./9-QXV`N&(E-[3[CD@RR)A&?H
M%U-SYKBO'S89;$?N:V$S-5UI*"M]T"\6![4QTN<O2UFH1NFAX;ZEAW!/*>6*
M[?];4@89VX:4D?UJ(5=DOTM$"/Q-(\X$0VR@C)'!TQ5V16K0H4[+XZURH8E:
M=UD21U?EHM4:1L#KP.L=\GJK!8R`UX'7.^3U=JL7R8?'7O%9O:A/(G##X33Y
M8C*_E9`ND85F$Q1D]H!,;5AM;H6=O!J]<0@QRE\I0WPNO$"['0P\Y:\`'P(?
M`A\"'P(?5HJH_?&`'H>86J(2,),_>U=0B?-4E@:1C9F>SA/\P'K">L)Z\KN>
M#"U8<.[S:)XZNII,1ZEG05V!74C=("/S7U=`%66^=>5J]UUW<<?*0#*,@:P;
M@$M<,C?@$N#2*>)2J]E;@$R`3(!,'"T>(!/X*CBS6?395]%E52?.S:-<Y3M#
MS84NUZ7L5&2[,CP?=]T;"``J`"HX6Q>`BJXE8P`+``L`"P`+\.ESHA]SY=,_
MAKI01VF4AG#IOL5#`1\"'P(?`A\"'X)+AC.1LQV7#)OXT'L48#%RM6+G[^46
M*TQQ;CQIS/)QK%:,!DT08$Z`[0/;![8/;!_8/K!]]KV]6QT-QL,1&+*/0*O@
MRI#=EO*A=*]\],R0P]HDPZ]YY<C$#N`[X#O@.^"[-OC.T`:ZVD:1%[!1<R)-
M'I.-^J)[(9$7&P%<B,P9LO)PH@-S`G,"<P)S]HLY94T:C(V<F['!=MD[:9,K
MVR7+7%9W%8K+24)KS]1YKO)3N`A)ZY4+CK,T%K[J_/+L*>1!%`2H`J@"J`*H
M`J@"J`*H`JCJ/U09FC;0NHV_ZH]C+?F3%*5>?BHN*]Y8K?""6N3ES=)V?O/\
M28B"9]+<M3>/(_RS[UGX+9-46\^I1JY"-?*FJY$;2EO5R(V%K;1')KF1)!KL
MHAVR-KF1Q*%-[A-Z=#P/KXTP,5W3LQ"QR>U2A+%I:7+'0Y5?@9*M-'@ZDMWN
M8MFP-4*"8$485V'GTP`?TDX'5LV0I0-/(C8A2U<O<R>@8J'@3X6\)%M2DZ7;
M^/<FLF'X.G7TP_VZ>D^\Y6^UL3I0#;E+1&3G+F^04.^J*71\T,F5K,^HL-63
MZ3TB`??1IM/]:`3ZEL.?BI"9#^-P7T!?E>2!I$D@!8,4W`M[S)5G;QAC?HD]
ME#'$2-00HX&LRYG+#B[J[=875VCT:=CKUD=3D*8K`UEO(WFM`\5G3^=99^X8
M7=W-'3/:VQVCJ_USQVB*J!W.0YK"DY%%%97#P^>K\<5"7H2""H!)'NJ#^B/J
M'65_[*;:[$QUW-#D((`?$8F4?O[C*IGIQ'?M)>3+M)L;](S<U0KG&+TFK$X!
M8'=@]X[970%V!W8_'7;/"<M@QNX,97R&[-Y/(U>9,-QPOF"^P+R?+>RP#9#T
M4KP#DCU;URK6!>SWVZ_!Z%[[,L0_?H]&5_HEL"*P(K`BL.()LB)X9/D15FMZ
M9!N50IMRGB1I-"U4C6-G1^@LN+`8W9AI[#Q!$"PI+"DL*>]+RK?7^D@D`*[,
M58S":\WPB>8H6.0/]$_LX*&C=O(2CE3K8NV&@!L8VHCZ8G0[I,*WYJQQ'!"F
MJP-U/!Q(0_8Q88!-@$V`39PM'L_8U.K=50!.`$X`3GPM'H`3.#!X,U_TV8&1
M7+MM4C=&VS=N\V\MA22ROIV*S-:E[&1D7G""VR./#UL!P`7`!6?K`G#1M80,
M>`%X`7@!>`&>?HY49:X\_6PTZLS-UYW&!?;;1@TAU7V+E`)6!%8$5@16!%8$
M/PV?PF<[?AI&\:/^;.9[N"52$*7%.ZU[;$,YZ;LI3D-G!_X$_@3^!/X\)OZ$
M^SB/2.0\`7MG$D'DKJR>_(01]5O9ARJSX#5D&*[;;I59\#("6@%:`5H!6@%:
M`5H!6@%:G09:<6#-Z(^?+?ES482$?K*=9_+WSS_&X?M'TYQ_^(PUZ]^)8IV)
M,_J"S#`.D'WK?4-6'`2.]_C)#)WP-\^?A"AX)BU>>_,XPC_[GH7?HJ54'S!_
M?G)]Z^^/__Z7(/R\Z(%<57+NV>2?J]4])<M^+YW0<GW2G^#8F,W,1T72S@0;
M6<[,=,.DZ`A>:=SX-S3]S]DU*0W^U_+U=*PSTN9RM%]H1?&_KL((MQ&AV^GR
M\9QNTX>7O]"9A?36:SGY[4R(/2?I_;?[R[./BF08LFZLB%A[BNN463YP'H;Q
M;$YH&%Z]H,!R0G07.%:&(GJ6(DHI13+C5].Y)85LS^4_4D=?^G7Z,6^2=RBX
M?S(#=/91ED1)RN&7HC'O/46C@2E>[#5#_9`9)E?VE;+SL&?L7#BEO==VU`3[
M*NVS+VUD8R[CRKG4&6^M"5_XWC,*(@?C[5V`IBC`H'Q/7/;E<U;$L;R:\FH.
MZW.[Q)T\8^!^SD+_!>8XS'O+V<H2)[RKYA(Q']@V&5Q31^/A:$61LIGO0R.Y
M#S12RFED:+HZ9$<BI0<DNBBGD*Q)8T/=AT29W\O."5GEBTC;+*)IV6U4/JTZ
M9\4<61&R?_==3$;<T.LW/.H5.=:D0'6=')>5AT;1Z7`7TV-!E+11U;&0-[SJ
M:7USPK\_!PB/*4(!"J/U2:T)<EJSD\)'G3S6RF>5-[ID3N9C\/+A(:",]?K)
M]^SP`06SU<B-PP;[\<[X\^<?\SNI/'3E8<U#MU0`K"-`R@H^1TFMEZ]8LXEG
ML4MW^)X'\5#,`D;109PWWVJ!J8Y,7TLI&#4X84V4A]43+MMMZSPW;H+GZG9;
M,,@,U/[A1$];2G"XK@6'ZSKS`B1?:5O+F2G5<M7J?/GL>";NP'2OO3`*8@KZ
M:^IZE3B\C=U,9M<,`0MZ^*_I>#=^&%Y[EAO;R+[VKLS`PX^%*Z*6"6*$=[1?
ME3\?+INEK"K)DI:G8;">=JOL6B6_8<HV2U9-QV?EL!N&3?3?1&5^\.F_R@,>
M:HAQ,#R?^7%&LE6JA#9,F<VY%>BC57U6CU9)WY0+1UME6=M]M$5]L@`#VNVR
MGZ\H,S&]UM:O,[=F1UA`ALQNJ,EG1C,K5[?CFN.NYK@JX]>>XVZ3[9:@D<]Z
M(SY8+W>4AYKBE7$-X._4>JFKZG@H#8>,K/&E*JHJ5:BHJ<#1/SU5E2OTU(-G
M=IBR6M_ZKM8173CCX`H#?(6FKC;!B!_O]#^-+_44]OJ.`%6KT&O7%J/2;I=D
ML=702XU#G`"U+)QJF0#2+IOM1:MMB;N^??/<LLC1&]Z9K^2HVB+-'J(+WK:Z
M863@(;^/2D.*6F4X8L1P(W&H-&@(44<-;NG]["$UC=@J/P)#@1E[D\_KF+$I
M"MX%:&XZ-B&1%R(L8=Q&3RA(L#KEQ]5[RV"()66T8M'P(XG-L)WG1>P'B6QY
M3\)>/A#WY3P)GWD_-6>.^_IA,V)FQW":7:.T)H>'\%066-9$(26ND%(WI,5M
M*(&%!9XDE-X._9FL!P$=$D=3E@DCB3H)_VDEI&U!#92EAD^I8:742._8Q1R%
M9?](\*<"_EF8^J[K?R>9304A4H=3AP84+=XGW/R>AC5]<-$T^BD;)4:_6`14
M&;I",J;2F+6+VYN;\[M[/'D+#]B<AVA!V$4LECC2DR@J/[!1D"`)<DFZG85G
MM_R<YG'1SVDX%>XI9?(>)7T9<G%X8/WT.:.DUOUN"5U]K6N7Y3_BU$!!19AB
M\A!DNC:6Z;HSU0\^8T;E1XQ,N[E$%I4&5HNLR@/:=R#\F$R)>%TJ3Q?8!;`+
M^KL+?HD]E-D!TO8.T%K<`9`RWH+TT&S*^,$2AJBRE)<=#^M>IF=!FCAO=\)!
M]A*S["5&*P8)2XTD+(T&DJX#'`$<`1P!''4.1X:D#51%@OS)$](`2G2I'HCV
MU`?0Y?EYJ#$&;M8[TIOUQJ.!H8V!-8$UN6--W1B,QJ,N3WDPX($!;^=;'^=U
MW=Z@3\--12>I7,--17W1M&7-&`RE''<:(!4_K`Y(!4AU\DAE&/)`D3O5%OIC
M$TS^S+]3[8`HX=*`>MP(_B:(D9V)52X--98AU+@@U%@7A9260H:8V[Q_A$'%
MBWEG[];O3?BP-FPK?%@;0O@P$_F.'[LGQ$=V;1KE-#X2HH1A%\`N.)DH888[
M`/P0C/T0+"3DJ]G<]5\1PIO"B\,\M0",=Q"V=YSV.@C;X]A$IZBCP5B3`8\`
MCP"/`(^ZQR-=&\@J^[2&HW`9'(G\WU88,001=^)C/VE#3)=A(M)`47(LBL";
MP)M=\Z8\[OJ4AS!B,-_M&$1L;KNY06^&(+R35*(A"*\O&K4ZQ&>M`>'"@%2`
M5(!4?".5.E"&<(5`8R68]XSV70\9OO8L?X8>S)?2N&"%35PPEY&^8U%(B")@
MJK0;XMOYW.]-%Y&87M+&+R@(T:M`2I;<SE%@1EAY%4A)J1,)>WYX0L*%/YN;
MWJL0(`LYSU@Y-.?SP,=@($2^$"(7:XW"W`_(%>B+4.CTE61F(T4>_A1FR>EA
M<OI+<KJ4G,+;K[<WX3O!#(6Y&2R#JA^0]>1A''I\%3[%H>.A,"0L*5R0`GM3
MQR)U-^X"_S$P9T(X][W0#_`()Z\"&7FFRRN\=?V98PF7Y'9S?SZCEV+'T9,?
M.-&K*/SFV2B@/<Z3U@8"FJ'@D0QPXOC1:A@6G1N)__[N1$]"3()=;($,GF;<
MII\#%"(SL)[H=W:F3PN/SXGPLP'"1XWK?\</+^B(NP^1,$$>FI)'\-=I_NZB
M2U&X]83/:!+$9O"ZXAME.!`(&@VRQ*=ON2@B[>-OPP57DX%&1-DG4Z-+^4*O
MBG=?A3?J6)17S6*X<LFB3OV`+AE^%!\7=DB:V7Q1-+;>$X7[&!-@^1:9<8"F
M+KTCGZRS*41X)=/ITEY"YT688=9]"@6$%\06MJ+IZ#S%@O,SV37;AT09OJ^?
M!-^0BV=DWV$.3$H!F1:]VK_T8"@L&7*$!P,>MY`22:!4$K)D.@E,O)I.,0MC
M)!2^D!V^&JJ\W(98B%T`V!?3,RF*$&IY&(S(#_<S_.'NR0QFYNKUFYL+`>^!
MS&\#C!YX(T08H83O3TZRF9X=F^:>S&:DZ`JQV6&$F2RP<0UJ\(K$+L584@G+
ML1#%E"Q&?"?;<#[W'8\LZ,63@Z;DMT73MU,,L2@@P@!IS4-TF1/@(\VDK]+>
MZ'R=4,"ROH/'&).1A85-KD.5.4NVNY->RI^.VGP,$*UOD?28H0R91X!F/EZ$
MS4ZG@3^CC;MI;@X^:$+<9DJ[##4P5B]`/Z]3<:U#QWOV\3OVVKC?8&E>E^@*
MO!EJ`U622(=3A`E-X(P\&CWAYN@3C,!M!\C:J/AB/2$[=M'M=%MD?B#"=`[4
MZ;SFQNV&!H=(H8W7=ABW5MMA#,E93*QI_+B3(2VE:X\SIVDID)P%NP!V`21G
M07+6249W0'(6)$.<JG<4DB$X=HA"<A;@$>`1X!$W>`3)62<G_Y<H6]P+]I"<
M!888/I$4DK.`-[GE34C..I[C^P3,=Y"<Q1*$(>6A?THTI#ST1:.&Y"Q`*D`J
M0*H^(!4D9S6:G%4_PG0],C4M`W'MA7%@>A9:Q9\:9X*-+&=FNF$2ZI@)1KTF
M`4QG0NPYR>??[B_//FHC2==7(]ILN6Z_PXI^M5^5S9X-25,5J6[7VX4N5IV/
M=IWT>&1HXU7/VVW7[WN\^\1U8S0>U>^]1LV/Y7!T:8]U,&1%'FVM0UE_6P5%
M".]^2B(GMH8D[[HZBCH::_):"N-V^SL-0=F=*HJNR:J^TR#NTD2>SX$_NP[#
MF##Q-6[4,=T[?*`YUNUTB@(20K\<F%HRL#1V_*\ODBX-_[K';Z+P7+GPO6>2
MVH7!`2\4;B]`]GV$$>(+#5_\*_/[9\?#0\"]XRT5!3$)V3^/,?:9D6,ECX6.
M[]V1J'_RQT62#H7_NIW2;*_O@1-%R%L?>]K-%\=S9O$L^;2%*;I$_\OR5$W2
MK%/TQC>]1>;JUJ)J>RRJK,N&KJ[&E=-!WM;?`N>MP>B[,KFL28JB;J)`44?[
M#:KJ,,BAD"R/U]A^EV'5&-$>QP06.K#,L;41*VFT2)\DR:@79A"\3OW@NQG8
MX6HT:^?&>SUO.#+>?HJ"MU]D1@0+;WS+='^)`R>T'9I&DNX'+$,EB9273K*;
M;J</YHN9>6*5J+G(T\0/9+(TTR1-DEQ+]A])DB0/9$>>O]O4L;RQVXKG7@Q8
M%R2=8N+C]_P@0Z)Q&8DN>T,BHP2/UF9>*]LQ/1KIV]F,HC^<Z"G[RI*,1MFQ
MO,#Y3#+5S<W%$LX7B6&8L@NJ9%)T+Y9Y6?=I!EL!!;!H4)D257=>C(A4)BBL
M$JG8TFFHJ1(K0EVB2;0ZBJ])/#$*HV_X:;IU[#L\`?R#^;B2JXTUR>7ZZ^=<
MR,0;4%-&V:/_/B;I3_C\)\WB03IAZ`>O7_T(A<KH?!XX+GDSI5T6<N_B`)U]
ME$0I(Q#6'_?V?,OR@HW"O&",!,&,G,V$H+<O>'/;B3"#TB'+1Y@Y/!0%,FV!
MS%LX)PF?A-S;RO819@Q?_[^]:^MM6T?"[POL?R"*'J`%E-22?)';;H%<SV:W
M;7*:=!=]*A2;=G@@2SZZY+*_?F>&DD7)DF^Q$[MA']K:ELCA<#@W<C[Z[%^N
M7ZK9!V&HK8&5/"I6OTHY8:F@L#MP7/CU`S4A4IEE@>\]8+VK"/I4V@NB)QN5
MU:A8B9I6H+Z!3T$RO&&T6I0:9EF$^G:?`!06:QAHQ9U#5!$("E'9S;\2[V&Z
M%XD"`#V`[IJ%'?':WF],XQ+T<H7`?%C[;"`C`HQ`_+1@&HG-@1#@Z])X:1K>
M1$`Q:H_\^_;;V76X&RL\?5:HC]KY'B0A(5',F'>EO#F?];+4RXEOO:6":)QM
MB-821.!@?43R2$7`0_$OB%D<5$I0ITJ`>I-`;Y9("1F>L3'%9_!D&KM.9($Y
M;^OKWC/UE=73EQ:LNJYO"-%$],L+V)4H'$CC:[/5,,"!V\_'1\LO^Y[:N.8<
M!S2(>,S<H2O`8J6T(`!2@77(7(%O4#W["+%9_B>9.)E@+DW\2Q/R@[BFZKZ(
M1W#-/0'.%4A)S`A=0`J5D)HWDX+BI"];MU_C/I1J]#'U<0/&%"*+D[\26"@H
MFC.]CN8+0B-Q]IG*(66!,\FMK78O1"V'+J]^?`8F"$3IZ:5L6-GWD'I.YJ'8
M)$>'.B(#<ID-X2*VAV-K.S7KLR^NZHS9LP&4T">K,QB(W(3_XBYWVVBW.RR"
MX(T3S@NBM(#=B%!&F1NSU^U]T.9@5^4SJK[/0O8<OV0)JV5(2*V!1#3!Q"92
MU`<U0>!X--E("\1).,?T64)+38;1"R)X\`ZL`WO=[.YW6(;BM)B%V$DQ.,L=
M&(-Q%]S%\E7.+.CU,/W6ES9@VA-8S-DXNS@'EZI:YC9W6W3-X;7&OE7'XI3[
M\QE]^3`"=3R/OREICEW9V'O6@1ZG[$RA8%L9W'K^-\7K[`.K5L1U0TM!@])-
M!D)$\\"72^(HAL5%>D'1`GF<,LXV-5*E``Y9P!S#:70-VVHI+]6)DJI25G#>
M].QO9O;)$Q^"+SC$.`9B3(A#QWAF<^*=8PR;*552P-EQSHE/GL-154V\*ENJ
M1$5*+@PQKM)D&$7$D92O5L,VFJW&DM*U2FPP1[RL7+ZVV"R4O8-*=,6!\!#%
MT"_&@H3LF"9R<(YQ7FEB>@I>)?`?Q",(QYB4)VN"J0H#904M#MGE^`;F.3*@
M@5L1I:AC;K:[J<K>.-O?A$<]":B9QJ1R2S4?QA&;[*A*K]F8>N1P_B,'>V;Y
M(1KI]'-6^;E]=CJQJQ%"0TY89U037/WU8?772!@24M$QK(6[G'N@J!^R%237
M1[W#)A'<(/#F$]"_`N\)16X<^`L:\77#<CS'B;@WXFU."BE""$7)51K@<DB4
MK?4I7WF<A+@Y3DO%59D*>E-$<;H<:,G0BLHUXB7O89X(85</>J1/S:X-'E0O
MN)5-XT/4C\3:2]%."_-)GK5,"ZHK.<6UC=@P#**HB'(:,X^[H)I?-UN8B*%D
M3!"R-Z+,!'<P$"&*%PSF-LA366ED6FC,92/W3\*=S9Z"-X@]P=UDN'/7;N72
MJ%R:=:MEJDE8!&,Y(=X#J*,!B![HN1!('HI;)%!.F,'$(/6'_TQ\Q2%VIR9<
M<KL?`'?!'K$1YW)-D26CW6I,9PV"$-[&%CTWB93L3$'6W&N8:T.*S@,X[G\F
MD8(\6;$P,4=)7GU$@R<LR)+[!8U)$D7,[H+$2\.B.T$XO!)[TY.`PK<BC!.:
M5])=I9'^RF'25+3<G6\0E[)_;["=S`^Q&A^^96\IF^.3G\T/;_/P"]1"R&,W
MI)5$VW69-$P^'(-9O$/LX;H(+E=?R^:*418FID-BERKN$[NJ:>XZ`,G'5_H"
M=`\=2"ASX!`?*0R9M)J2ZT)1OA5!$H$QDX#<J9=0Q3Q%T[I2%U%"P$>M0WH6
M3-@CF?'2,LE7=:PF\8]4Z:<$,HH'JA,0UX=:WD8<)J6__`HR:!]$OB7EKHJT
M*@_S/2OJ6(F(_C^@.=U[()-7[2!]*-E![HD1Q2$1!<.D:KFOH`XK(LOOP=ZG
M6+S5NIE:KZ.MBC1T%B+PFM)`J*3H;\#\CEQ,[3,(D##NDHDVF'4B#_]-MU-I
M\>&<$8QSR$8!:`]))Q)UJ]`TP6.F]O.7H1<"));A79!NBH)Y(ZA[TCTP/\,A
M#VG5PH][#]R%2>'A"+Q^>@![IS>*J@):0\N4P:C'TL2YOH_@QVA@YZQ?58G`
M<.I'DW>)?*,=P6N>HB[W)8D]--<RFX@_3]1(E3=4Y0EU6K]5ND!I.@4][[V:
MG(H[QNQX.KO%X>9F&WA%W8.2XR'Y_4(22.Q+0_?).)$;HI8=-,+)#$O;U[MQ
M<9R3#$#Z$[A'.'E"P=8V6(H'W2-`;'X/_BRQ)Y!XV,1C#$W`B4(G3!0GLSAI
MR'`@5:4UY'\E(LQH)0=)#A#W"46<D*PHNX:5&09)2H2DYI-?;39%.$'1+D&*
M@XQ<T^YOG#%[RA3OBJUXD@T:Y5A3V2-_$7LQ%Z'`I1%DX.^9#Y\*S]G%N5$K
ML;,RJW3R`]4G6#]YWP0$E6@PP5GDM#F(*7GL]-KU:&,WNH$%%]&*X6Z_O.S4
MS<4W?0Y+1<1OD4JW!Y:XGV\-IW8JENIOF`CY6P8(G]'4D[XOKN41*,,DE"$O
M/`5CX'PDT<0G8:^Z5_0=]2SZ`RXNSAO7'V;>;1P&'N.W'#=]2!/0A@ZJ4%!D
MLQ-_]*Z!?H67D++UQ%](N_0O9$`-(\"MPH%4T5E_Q68-5=/G<5GU)/4HYI)F
M!*<"ASX:QUNZ[_0D^H!6_MZABUD_9"GW(RDIZ:G,%Z$4)!.NB0D]E0GIN169
M[$ROSI$N`$E-)&^T\+R@YZ:WS,B]O&ASVVPS<?_3DC^G\=LR&/^=53'^H9_T
MH$8]N,=:\#BL_:;S>%A^:[M@^<W'WS3PP@#)[1E,VRS6D&VK6$.MM7/]T2>8
M%@(DO\+0+Y_A+W1^,O]\@@$]D3+!*"\?7YM[PFE]"^07QBO7.E'KQ/7AK^T"
M^-J6*L3'7D+R)%B["QJ]=2!KZ"6U\)+:(+M_F;6EKS=Y&>[""G"%N^I'[!:N
M_D[X!DM",&G)T9*SA9*SJ^"[FS8N:\;+79L!6F/Z^%O-[>LU.>`GT58[!D*Y
M603)EX,&N2P?[?W.DS%R?A3YC!>Q="W#:C_%]0%ZQ>H5JU?L&E9LPS&Z#6?S
M#/\5X%.W,K>P]7[=[_(<GRR?ZX^$GQ:-W%:<BGCQ<>@VY&1W+2!=HZR:5LOH
M5"5<M6!JP7Q6P6RU#-O>_)6K.O_R8O,O\KZB:,XA/AW;Z2M!7D9(^0S3MV14
M^GPW@FQS2-LT.T:WT]&*2BLJK:BTHMI>166WFX9E=W7N;;M=?WVNY]DMDCZ=
ML1VG,[3D:,G1>:6M,BZZQF1G#L3KNKO''86_%/>ZZDX?H]<:\9?1B+OA1VVI
M.M15=WI)Z:H[776GW06=G=,Y%IUCT9*C)6?[[,].9^=>P*DO777WU(D"7<.C
M:WC6RNJ6TS0ZMJ57K%ZQ>L7NQ(JU[9;1M#=?)ZM/_FPJM[#U?IVNNMNQG.RN
M!:1KE%6K91I-JZT%4POFM@EFV^B:F_>L=?[EQ>9?=-6=+F;1Q2RZF&770UK'
M;AMF:_-`,EI1:46E%9565*MGR[N683=;.O>VB.LO_XMW)>7MO^N+6_ST\5T2
M[0U==_S^4KEQ[81N:?L:Q/Q81'@S;1+R*Q"[0P^>^?3WOS'VT1V&]^^/^75\
MYD=QF.!NX\E]3/>@GN'9(Q[%Y[[W<,%#$?1-)OH@.N[0:K=>T>UET-@W/OC'
MJV,\I/6'^?-+P_QYQ</1Y\#U_ROBF_/[01#V3X6/-[A]X:-K'K[Z=&%_^?AN
MN8Y7(-;*B6U7$6L!L<U-$&M)8K,)N7`?\/GH?$`-1'A_>X\?!1'>E)=1V'G%
M^KPG1JX7R=NIILG]<74\C]J?YBN6^$*^]OWR^-4GL]6`/[ETS""F2#6)T1G=
M\WJ<X/7$<FR7='\HK&_Z21F`HP[@[.MI'<=;EOWS[.(\I?>(+L.EOE)^Y_3+
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MXN@;7KO>`Y&B1-DWO',5%?.A&XF(NIWT\Y4KPW+F6+V%AK5>XFHXH*R8!<6K
MNXXI6[3;!:F>*VA.8Q-4/Z6T97T_5$J<8SZ[Q%426+8'TKR26W8D[VE'JP%V
M=^R*_H'?/X]O>"C7<X5GGP_7JO,D7WW"Z`&"ARP^P>AK#T.S]V9C'X,3^F+@
MCH3W\+X<U2T9\LW+\Z_A9O)UWSJKAL?TQ62'I-D8WR]S$ZVSZDVTT%/*N?H]
MGZDP&&DKA<'J5UG@JWXG8USX9BT;2!!I/WY;MSVC?&:KJD.LIJXR77:7>[_U
M/'7WOT8QW#'OD=NLU-*;!O4]*;5_;"VJ7@5Z%6SY*BBC24RO@%^D8G2C)T9V
MRGM8\_&3QWH8^_8FMKY2#Y\)'QQZS)$\P19NK?;>[2W<#94SZEW;C>W:;FC&
MFDOJE.?;J6UN\4YMTS$:K<UOU&IUI-615D=:'<V;WG:C:=A6!8J</CCRRT8`
MBU:`;:=K3RG[Y[2?+[6J9D<R+<^G2[N.T6YN'OE>BZ86S:7/A[8-I_NL%Z+J
M!)Y.X"U=039.TWAIP5A$A=\!.@"LEQ[K<FGS7L?3ND+C10;73S%].M)>QUR;
MS;;1:3S%+;Q:4VE-I365UE0KYP3;IF&9SQHM[$Y.4/XW*R:C3U.E9(\]AZH4
M%5`5Q.^AZ\<513L$M7"D("T<!GZ2UQ8Y]D+%4>63NXZLQEBU^W41/ZML@TX<
M5Q+?Z;8:W<<2/RF8P@</RP_F)+96XF^K:]E-I7*INI?E*)E5DU'/+,=NFRUG
M,4KZ7+P_\6,1/WSC0X+A\N.O[BBO27(Z]6>F#WX_^WS"KOYY\NW@XN3[U=G1
M)3O[>O3Q75VCY2Z/(/(+7>_,[_/[?_.'O$^GOD\08BQYLII=M9]22WE'QT&/
MBF>N'L;*F+KU[9N-O3]DR^JKTPU*F3OQ^\=NG+?<K1>73_C?O49[SVX4VR^T
ME'=T`+_U\?=3SQWF'9CU'0Q`3+ALN_!RWF9:W70*NLGU?G`WG*)_Q@GYO3W3
MVK--V4%=2U-3+)_[QL=!&,-2O8S=6%$'7;N^OQ\\*DQQ94OE_DZ%Q\,C(&08
MA+E`=9OUW7P-_#T7;!.\!Z_U&;6@=EQH<FI\Y:*V\R2.8M?'C%3>?6N16KK+
M\ZHZ.@?T2K?M%#@QH\]I0<VGZ!2^45A?704\$=6BD)9:J>M&RG*IHQD:Y`^K
MJANEE7*%9P!.1#\Z#8-15JQ[!BP3\`XXH:)W/@`376#]O)JJM#"OT?GY1?AB
ME(S2:M5+:(='AP[0@N<Y04J`PL2C>L'YE:Z3WV5MGT#5E-7Q'23@T4`[O;RV
M%<9U*_`_J*`]'E.YZW=09N%=*.*8^\71397/DMIOMJ8+4Q=D5[G>1BT[/'5[
MO%06U2T4<^VUZDI#FY:C\N(RP:H/8$B,/E,P$E$$*PK+\2/+.1B'PL,W4QY.
M%;K:Y='5D3D]F!DU0=!J;77YBJ0_KI9HZ=#P<<>+94JX_GQQ&DKL,X49#,?-
M4LGVA],!1NED\>-KDU:LDUKG=K7/:)IS&BW'8#CI!@.GG^'"=?T'RFSW@$\N
M$!(,U)_DFXYE=CY$C-^#6X1Z:ISI#PFSE@)5&!`9>OC^W4TP8G\E$&<,H.V(
M@:&"9P7:*0&B+^($=87KP:=;#BW@JW3ZG!Z(`^86)DX58SF+%TG8NP'7D!T,
M0TXE?&R<A*@J8@:OW]V(W@V+$O@K)8VY^&`??_0"UR\-'GZ%GX?H4@#UK^W]
M1LXP$'</B-UG5\HK@@KY"T3FZXM(C-@;["-CG]7X0-]./IL?WB(Q_%;T.>@W
M)N*(C26L`PM`R0W)VXT@@HQO&!C+,>_1T+#1&03*KF_</HY*I"77+$Q'YOQF
MT%PD.(=]%Q:RG'D8%:@@,OZN[\.\>0]J<V"L4=E,ADI3E/@A><DT:9P@2EB$
M-9)4,5J2(I:,`\GTH"?W3GI$$+]%&`L0(II:#$.Y*(R$L':18BD9<CAN9HJ0
MT(RR3'1:#=L`F\(B\C&PDQXY'E)2F1NSU^W]1H.->2B?2:7E#N24H\QF7!YG
M,@8+"*B%%U.QD@W?`2V8I^GGSZ-M`B*0]8EB!;-?@LS*OXEXJHV<M^I@99.Y
ML&<M5RU%8,5(BC))B"S)3[4;9Y\_'^W79%#J$&=J+,[R&`=V8U9Y;@T>1+-E
MF:W.,B@'%?@,5-:;D[$*+(73KH9^H*:+'1_T0:.1&KMP1?_,3U,K>?^S$AYU
M_;>[K6;#<LR<B)INBK1(B*#,60+GCSSLU/]9,Z(+$)IU\.H3+J6<UEED*)F8
MV<@C7Q/L\'P@7=F%W&"K6W2#U8B$6@'.IFF89?I62#X,W+!_/C@6(>AAL%?9
M@T<>;@%'B_)8Q1RA5\%!3`F;T\,,6A":8T:/GR[L'S5]X)N+#_+$@Z]Y_R`^
M(!OQA7/T!5*`F\S.KLX(<S%&+$+%C#%]XZ/@UO4.!@,1CDC!D`S(%_\#:OA\
MH,2EZ6*CMM.0RAUR99#5B8<Y,@G>"RR=QGZG53/D=1!9#4:0&@C*!?\>!M&,
M]94%1/.07^9@5=7VO`D-MFK8MC%]MR'4B4L>QQXU,E]!8DR8F].*R#Y23&S*
MC_^Z(68_:R+VKFVWS8TA:BACFX/^)1E]E/E_YBKY[W;7LJUVIS,#NZO<30EE
M27D^%$-@KX??RI<._/Z!]%XS^*-5:`17ID'8:2OV"01_?'=_'7KB/?X-'_\/
M4$L#!!0````(`%:"#D7BL!1S0PH``'>+```5`!P`86=R>"TR,#$T,#8S,%]C
M86PN>&UL550)``.D&>U3I!GM4W5X"P`!!"4.```$.0$``.U=W7/;-A)_[TS_
M!Y[[+,N.VUZ3B:\CVW%'<W;LL=UKWCH0"<EH*4`%0'_\]P?P0R(I``1(282<
MO,21M+O87?ZP6"[`Y<=?7^9Q\`0I0P2?'AP?'AT$$(<D0GAV>I"P`6`A0@>_
M_N?[[S[^:S`(SBD$'$;!Y#6XAI2B.`[."5T0"K@0$`P&!>%O$$-:D%XF?R'.
MDF",N1B)@QD,OOP!<!2<'1W_\G[%56$:WXWO@R]G=U>%+#G`)SQ#&&8,,<)_
M?Y#_3`"#P0M#'UCX".?@BH0I\>G!(^>+#\/A\_/SX<N$QH>$SH;OCHY.ADLN
M+87\-"C(!O*KP?&[P<GQX0N+#@+A-,S2L2T&*<B%AA7JYY."]GCXY?KJ/E5^
M@+!P$`Y77&NCY'S'[]^_'Z:_+DG%\,B@T%*T\%X09/ZC)(9W<!K(O[_?C2O<
M8(9BR!^%[Q<PX2ADAR&9#R7E\!RPQ\N8/#,Q=BJ'OR[@Z0%#\T4,B^\>*9R>
M'H`9?1$.//[QZ.>3(^F^'TK,P^ZJG(%8&G7_""%OHTV5?P,*W7,!X3G$_&8Z
M%E-I#MMHI1"R`=4N$`MCPA(*;RE<`!1]>EE`S"`;X>A&LIPGE(I!1XQ!SBX@
M!RAN=8E;#K11$T=A2!,872$P03'B"&[&((/8C:I_"1#]'X@3>`V!_"S!L!D+
MS)++1H0@#I,XC:97XG-E5/C"(8Y@5(PKU7</'^E@Q7`Q"2M#Q#*2$UJU+!\A
M#6U3P"9I?!,KU0R`Q5!:/(0Q9\4WJ0\&1\=YZ/XA__K/SY!+)6XI>4+"B+/7
MWQF,QOB<8(YP(E:_FT6^YBR='8,)C--%L:T$CKCTD1/GT#,/Y;KAV2CDZ"G%
M?W>G.0HU^]%:6-6U):R/:-7+@(;%T.*_:T"OKK(YQ9`E\WDJ;8!$)"_XIY3,
MNV&(;,F;)?L_!"T4##AI8K-6+&%"(;*0GT!\$!`:09IGI\\0S1ZY^-#CU+B`
M"PI#E&JK`;J*)'=T]2=O0>B*(F)EO`O*+#4H`Z\ZLAI&[[K#:'UUE=_\><])
M^/=O%(C;G.@BH4++6T@1B>X?`87R5B`Z)W.9!Z7ZG1&<U.-D5S&YEUM)>$M(
MW)`?MX36]MJI$7WB2V!,=3^KZZX)D6;B`LD:HK<$5B>';#F`ZG10`^]'7X!W
M*VXQQ_B_"$=IC0DRK@&=GC#WKXK@+8*MT1%;!IIJ?#7(?O(%9,O[YE'T5\)X
M5IWY`U`9PW4W/%8\N<<;:-\B"EW<LV5`-JBBQN;/OF!SC$,*1=B^@-G?,<X+
M;Q=P"BF%10&NJ+]EA3<-:+L)RR]76R%O$>8;<>B6\=]61_7$^'=Y8@S\FAFC
M,"2)F-2WX!5,8FG0>DW7>F:X"-/.##LA7\?,:.'0G<\,.QW5,^,77Y8,X:!L
M:^F*,#9Z`BB6MCP0D?C/"4YO3Q])+'1FXGX`A;49T9)[5;IUXWY+V._FN@K8
MNX/<61G?BK$:%XSQD[BGV/`^A:-0\SZ%M3!OL=]QGZ*=-W>P3V&MV-8*S)NJ
MBKRF>[L/9!3^DR"Y&4^$]OSU-A8W-6+5^B2^74@2;;7$5<"RBF+/Z"V\7?%)
M-N`X%W1;ZE>MNMCK9;$)UVMBK_'*)<(`AQL._(Y"S8'?6IBW,Z-CX&_GS1T$
M?FO%/-^'$7:%$$;L4ES,SX3#XD9%%^8;R(N@KB7S%JBN2"/.3G%!I:4VE8"M
MU<+S,Q+%2G,S75I]3IBVY-A$7LLKULG>)`3MG+)M"&JUL$A_>\T0RI-GS%@B
MS_F.L3`:Q+?))$;AS70*Y<Z[15RTXE<$R@:^-PG;EF[;82AM4,ME>?\XK%^Z
M*_%Y!X=H*P?7^YIBQGTDY3:&>I]GYRKG!]"-FM=H*@8L?^M_!M?<3.S,4,ZV
MC*$\:VHB/,\Z9*@0=['RC[R3?0*Q7+E&(H10^BJF=KK!J[GF3KRY$RUY?,%(
M'0FDF_4&".4CE9%D.8+G"*L^SU+=##7'%`?.91YAP;$'V'*WW`U95O)]K]7J
M"G&?H1Y0S2RKC-1`Z@N$-,FDK9&6*YI9HN<P*0YC9/DO3&_$/A,<9BC78\6:
M;_F00B.]SZAQ-=<2.A9B/:\,EB+C2G$-9HRTN>,T-#YCP\8L2SQH1'E^6+IT
M2$6$O_(6OPR%_%4#!UNVW(7-Y#XXP)RRZ0G7C?0H(;.^4L3!5.64:!JI/%E4
M(WB>[-?.>374#(S$1?%`0^05:`RIO)6135!1I/`ZN?X#I';LKQ$C9OH53'1T
M>X04*U/;@44GVO/T_8H`;!=-#)3%VJ.BV!=T-)O7`A=*H9XGY!>0HB=AY1.T
M#B(V+,O;.!/IOH#%P>`6J#%+]SV7)WCV`.F\#'UM1-&3+D.*BL0KF-@GM,WF
M=D]IE6-XO@;)D]TH?;Y-&ICMFLX@#O5/O5AP%/LA)LK]Q)&]\9WA9!S*\W7L
M`<YE&T#ZFIE5;.J,YC*M'W%.T23AV:,%M\"PN+66DU^$%OS[B<NNCNJ,UA8*
M>+Z86I?"&HM?S>6N?8%9HZF=<:0:P?-.`+<TWPA(=3<=*C!0KC9YURGZQXH=
M.IK-4\+##`BE4,\+0:7'Y8QG3#1DI?2I^O.^`*'!L!8H6)?H>5X]BB*4Z9;U
M-CD'"\2EHNI*H)FZJ`/JJ/8%%W9FMH"'5K#G>?(%?((Q2<\;W,M.V)]D]YL%
M1?+Q\BD*$1^%83*7SBC:@M4YM%6A30E>UHZZ"]P7F&[<>2T0O0D=+!+L0?\G
ME]>;6W_K@>#<`V&W+51R->79>=4Y^S,X)11F=`_@!;)KA`D5`"^:>XUDGZ^R
ME`S_UP(A),H>9$WK'IK@UH,&JV8MNQNYOW#9%LK$AVM4;XGA8HF,P#O5W/,;
MF67KD)4YNN-A>LKB<)B*HO^4H`^@$A>_*9.''6I=.>*FTG9?,%R\=:()P76Z
M.GY7O_>/7A-\5"C3V*;$F$*V$@LKF;XWB;B##`KOR@=/2MERKK\&%E8\N1L;
M:#V"RQH.2#N+S<`I1BG#ID&ZY\$D>_M4+'N\17.$$>,T/2Q@QI`E5^[31NH]
MP9&;U>Y(:I3O>8FP6(C-V-%0+6](:K_VCXV>$RJSOWQ*IM8T];V#PLJ.S-:&
M[NI-Y$L(Z\B^8=G.@WZ!6J>RYZ7XK[Z?>\]8[]S\O2?`M^H4KZG!]U;-%=[(
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MO=[BF_\#4$L#!!0````(`%:"#D6A1I\R-"8``/RI`@`5`!P`86=R>"TR,#$T
M,#8S,%]D968N>&UL550)``.D&>U3I!GM4W5X"P`!!"4.```$.0$``.U=67/D
M-I)^WXC]#]J>9UE'VS-MQW@G2M>,)M0MA23;\]9!%2&):Q8I@Z1:Y5^_`(NL
M(HDK08)DLE0/=G=+F<B#'X`$D$C\_1]OBW#OE=`DB*.?/QQ]=_AACT3SV`^B
MIY\_9,F^E\R#X,,__O>__^OO_[._OW=*B9<2?^]AN?>94!J$X=YI3%]BZJ6L
M@;W]_9+PGR0BM"2]R/XO2)-L[S)*F:34>R)[__G-B_R]D\.C3S]NN&I,E[>7
M=WO_.;F]*MOB`LZCIR`B*X8PB'[_B?_OP4O(WEL2_)3,G\G"NXKG.?'/'Y[3
M].6G@X-OW[Y]]_9`P^]B^G1P?'CX\6#-I:3@_]HOR?;YC_:/CO<_'GWWEO@?
M]IC3HB27#1!2DC,-:]3?/I:T1P?_^7QUERN_'T3,0=%\PR5(*?B.?OSQQX/\
MMVM2)C[0*"0TS7[KIVN&*O$/!ZM??F".WMM;N9K&(;DECWO\SU]N+VN"O*<@
M).DS^TPO)$N#>?+=/%X<<,J#LR"9AW&247*7QO/?G^/09R`X_R,+TN492;T@
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M6NE7YW>L$$,9L_.9,`HO[*I=H[&JJAZ=E]H6?ZTJO`[N@B@]\(/%04%SX(4`
MI10A91DE\OCXAUS7O#4'6K&_DXBO2?;]>.$%D4,5Q:9=Z)LWM;\@BP="72I;
M;]>!IL],*3K/'LC^VA$.]96V[A8/Y-'+0D`W;P.(LNVJQNR'013P^>&*_;,F
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M[5S-!C_QL9CX/W](:48V/XRCE(WQYV&^U&'3#'FJQJPC#`.K!?Q=RI8O7)-R
MJW/V%N@&60!7\=VUE'UV+$U8(G:T?GM`W-9YRD[3B[[-KJ/54],!L&'YK!;P
MP]%<Y]/C^:P6^?>#:-421H0S!&$P4$I]H(2E1BX07*6\J<-+2_OUR`94G'H@
M6-570JUQ96?\:&@Z'A5-MR0A[!,\SR+_C+R2,'[AFI^_\4&;?*XM^R5#E@5W
MX6801Z\XD^UH@#'6&(CBKNZP1=U*?A-W(+D8Q[+5"7C(])[Y"^:().7GX:\$
MBC\K_L+E0)ZI8K"-2]R@$"@9XR@X^^91_YY),2PXI'2%$QN_>Y^+"IV#QEU&
M-#3#B$*%N91ZT=/J4/)DN:&Y\9;\9[E=&^,B_R;THB_>@AC7&WV**W?">A&!
M8W4CAWIS3ZM_'RN[54U!84.J%\4PQA@#]*H^1'P]'J`O?3U&LZA3=J=!G(N_
M$XT[-:TG9GZF=YWK9@S.C3S-PRR1#D$0WNL('K?SF#J2ZD'9)N@U2JJ&?V'K
M"(1<,6.$_V0MGRGZ)8Z(J$TB1:8M6P.<9K9W@-66/MSXXJ>]OA`*5PU%4%*L
M88@O]T>Q9-:M1*T:*)>H0"8$4![HS+F5&\<Z1(8J:PP@_G[0^+!,Y.]#I@:9
M[@2,MU:(:<IS.<_(0RJ`1[J&UC&L(W<Y$8*DFYIJ\-P9-9N0`B,C'2V3Q?"Y
ME`DI1GLU$9E,HCH]1"9I:[(\ZL:9MUNU]++.A7K[50,B8=?(;#=@-U44*"Y@
MI8)P;N,T5`7L;VHY5/C!M<NHAX()-W8;AE)91LCTL_>G6/Q5`H>[[(')8)$#
MO_'"_!8D24R7/)Q(CC_-7F@0<G;E+H6+Y@J'MFX%09QM@DSLW%MP^-7W'[JI
M@&,,*P]25^GP/'AG:U6VYC7-@Q"^<CS3TTY[7K3P@YOY42]0/N1]/^Y.;5U3
MXRRII2\WP>0T2&9($"B:.ZT`J]4(TDD4MDOEDC"&6$S)11SE>V;&S7TE[7I.
M%'Z/8+;3?_;8SD3U-I!,2A,7DM8Q8H(/C:M)EW?&D^4O4?!'1LY(,J?!BR)%
MWXIG[4P0S^2FKS:^J.V7&V8K8/L8SQ3KJBL/UTUD4@#A2!>Q^_@"6I2V5@$"
MDB$B!7O61D=P2`[X%80?1\V`<(80P>!^,<*65S%EDQR#B6XT&6R2-W8<]^M8
MM8/K)Y.MI6'MEI=1DM*,Q[\7WIS,%KS@D292-+%4.JB<#$'<:'=N`+:XTYF!
M6@K6R7ZC;5XPCR3I+>L)^6J*GW_.V2^\)]T!E'TC4G#I&2<.-RNO.`2@7JX<
MDA]'A^1FT"Z&:>)O3,J/V9/+),F(?V2`I7U#TL#$S#Q)>';P3F>(VLC&NZ''
M5>35DEBGRG663KL0TMJ6GHIT$B"SL+:>@:9"CK[!`@P_($JCL:M`N3OUV.W&
M[W;C=[OQN]WXR>[&S]C`[@=AQJ_5WI%Y1IG!)#E_FX<9FTPNF(>YG5E:I)>>
M>S1B$T%23F7"-"I++'8LHDP]=M8L@JS)CL;`\RQ="A(R,]TT/EHNIW.@*K,_
M>_@*ZOMFCJQ29YBZL69[<E++\.$T])*$A=)\#H!&IBJ>9E0JTB$\R'0*<U7F
MCL%C@*P=%VHJ\WQ$]3"&`54MC4L*-7$9'$H(D"TFE*AI!HDF6\VKB*8H(5*4
MB$")D<VQTPUKEE!*?.AB`L0I)K_*J1$L-#2P$%89-K8KT20*%!<<!D%@3+V?
MN<--UF>O\X=-GNC()8^ZN>%D*6_`5$"I?ZEN%IQZ2>^L!P[WU4;JO[T:B/'L
M4ZXOJ&P4E%7;#W'DYPV-<5"W:E'HJ3_581T%>S*A)=I-Y$+M6`@#EC)+P\#<
MVH53!O>8B8^MQI-^%CTF\?TM@08<2G[S>*F:U+B(EM(5'FS\;L+(T5GI#"<-
M(6X74[LB4WUBQ4'!*`A:K(L_80R^P5.:,>/::?MNEM.($LOZ/C?LP_N#'Q<Z
M,@)_)2KUB\>C'TCNTN5VZ7+2$6:7+K=+E]NER_5T>5U]?:#'B^RC^02TXSOA
M&]CMOZ;V%HO]'BWX"BY,*/[>9G]E^R,03R-?V>X$*0OCQP22X]V47=4VQZ'`
M"-?=@8`4M_&ZZ8!QH$.1,KI+-]RE&_99:?..T(`DIT?'Q37N+W$TSQ99F#_I
M9I]<Z*S-LI]T:@K!$&[.273MLA;9B@Y4&!"L)Y^<8[53DS6HMFQI:DAUX;!N
M0&VIP2"!\$K#V9%[H'9KLX;4MDU-#:I.7-8-JVU5<)M2J`?K<3=<0MGK$#1S
M30YMEH[H""RS-(RU3JJV70$N*VOI)>N-*U37B'.53I:Y@A9OKZBXQ*=71,K1
M;NOJOY3ZX16#L:!><@5X=D64LSTW7+.')/`#CR[OO+6MINT*$T\)-C4=PCL2
M:C0U`0@T'U)DOBE3`*%:%LK-KXV2?*_O^O&>>E'BS;F2YB=9P,PEO@`,2#:/
MC)!I8LS6%VJPJ40+4`.(W`K,F1F$!'08"Y)S)Q#86CAA3(B->QWR\N;:F#8B
MT!1>J_P<P:K$8ER)8?:I46$4U81'103&@69SCK6>N&US1FR;J)U&0MBF'%>U
M=(Z+,`LN&N/P)&@/2MP!<*G@AR]]QQH[)NS9)_%`53!B#WLJ#QQN&DKA20(#
M+9+8J@W.;+R``5T8!K-=:1KHJ-13C1JUY"TO5@,.5]KE_W:/53H]ZB0Y!9J6
MUUV_\FC<@'/TR.-$O=R](A_<P]#R>C_@R.^[FY/(HT$,S>V3T3?S^NHT6X$@
MC=E.T5.7(T?.7\=%3J'A+U'R0N;!8T!\\YZXB6=]KJ>DP[%`T^-!..*#66W.
MH*Q*$P_XE%(P+KN@\)D.9(P;V2;,0$VMO?"A@@8<#L#W[;JDUU2"ZHL@\J)Y
MX(6;AVEF6<HT2X/Y)@Z\H?%KL'K'9O$2DM7-ZU\BIMLWIFI*HIOL(0SFUX\L
M0`^B)_`=B@&DBPNR7H4B6->9<:NXHC'<U]#,S0K=55<Z>M49XT!]ZT5/Q!`5
M"C2%VRL_GW+TIS+/1<17:5O^]?\V_M<W[E5)J*H(&&2L`L=NXM>4?6Z[863=
MIO3SHN_>T@^,ZZ.:HBOI5U6;4(VA:A^OQN(R-'+SN3XSK1?9PM@CI72%[8W?
M(8@@9-\IAAND[Y8KEF;';+2'L6OF<\?JO<:SC(<)-RQ8B/W5.XY?R+?\5_K-
M&IL&UKLW,"8$L+%+M&WCC(XYMT"1&`^N*ODN+*Q-`J927@#KELQ)\$K\ZZB2
M``-+@X2W(^:I07@GA\@.KND(3#O)&*]/[%XT'@*B_3QH#,*HF_>,QSU=$<Z=
MH:"$,:IR328..BOCNX',)`KCP4N]8US3X"E@RO&?KDI1P@<[#:]T?)/23PU=
M]BYP-XI)I6'<]KFA\9P0/^'53\M'PB^Y%[RPOG.IP9IU&X7#+?BFAKVV+NF&
M00NI<BQ^&AF+U32LU0`]R]+GF`9_;DKB2@$(85RC3D\\/:A9&-\57WI1<E#]
MB*6$J@6B`%QB6=7I8PEN=M=H3"-'L4-W."J,5FETY:"JK5H/(:V5<5:13@$]
M%L96=^*5*-&WUT]-$/VP]B7C+F*ZYC4H&M^Z#2MH'FJR3@$+'9P!PH9=^^6X
MX;@JUTGL4?_Z\2R@9,YXDE)LKK6`#R!UX04C]1108&<RZ,,;FRR_M>-LIJ;<
M>T(7A@]<)5%\U17)%#^EQ+A6WV_53OG1'(_F!K"<A^S'Q)^ELRC*O/`S(2E;
M$!5:%V]FV'5BFQ9A'1W6XA01U-UU+@8,F-@2GVV//X#XO"6+^-4+9X^/`5WD
ME=+RF6VEQJ]Q2JX?K[,T2;W(9TJ>>B]!ZH6YID65->^I66.I3Q$*!+L1,45(
M]^#<5AAWHT<)^LIQRNC/&5U&[(?DWGLCR=CO&%V_Y`>HT=-5G"2G'J7+QYA^
M8Q\B$;`BV56PX"Z0`.(8;5&LULY4^0W(:?3"V!7@;+YHW,4%ROT6@`;-W1>C
MY*VI$K<>.8IE8KHTY#?K&<K2.`HB-)G/4&@U2^5`C&\!1&DZM$H8QOP\45?C
M!3@3BQ)*N*Z_&2!A!)#=]3>Y-#-R,%]_`V)'1294,],1(LG0-H,&;.W`4!DY
M$Y-?\9M%_A43$?X[HT'B!WEBGC$)',A9O;:MHT:P##,.);)[VV`/6,!*7CS$
M*&X:0Q&OCF(=$369E`/3AG#[(B.%$_J+CC8"48Q5<@5;A$7*@F5Z4JSAD8`+
M$)*ZADFE5!B,2FF(!R5@C*1Y:]!$C#96DB'(RO*A<#/N`/2%?/LWH0E9G@6K
M"]C7CTQ?#Q0N@7D+CP+H489,YK)KMIZPQ)8\>`((13$TW3,!UX\S2OGEPOS^
MOSY4TM(7#E303#U`@ICN*C92R'+[?)`;!%643-AJX0M3;?.3RLVKQ#ADM6RI
M<+TU-X[P2H^JV*6'E."4ZM"$I+5LC,O#;F"UY!8JR+;@1Q+"&5':U34HL.DX
MM>J>S)^C.(R?EB=9$D2$%TUY.^6E=QX#U@JYH?$3]1:K^ZN_1$PGGQ-4)P=]
M+2CG`LH)W%V["&+&MH-F/("GE;"W5+I6X,FALAC'<'4HU>HP'GP.CP+,O1S&
MCW(.C_-\HGJ][#0.&9)BRF7IL&7DD=P%;-!-&UE0![@$ED:F<94T>K873PZ^
MBKUHQD9SGX_H8^=\W3W'-.5:\<N\/.0R54[6T9='<'*:\8X>F_J8*_SJ.51V
MXMJ_UW^JYA$CR&)UJ4"9+.%<425CD!?G*]4O[S(V9OA!Q$(BGPTGBR!)8KK\
M$J<D.?XT>Z%!R-G!Y5C;-"?65[5K!<&\88*,HEQJ!V_!X:>O?FJG`HK8EQNV
M*1HC3,R*(AD:CDII#"D5$DM-N;8::JF%8^?4FKZ*I,R'R3Q%GU!(DI7V$"1L
M38YLW3I#;*,FED()V>&&#BI:5-F<9DB$Z`&%-^^UKB<HP</$(H4)OL0.S>?7
M`L4^F4.4I$=+?Z_L*7=J5^NQWX+T^?J-K3W]565T=;%H&[;UKJJ!&D$P9_S2
M<6OS@>@0C]1ALJ;PDIG%V`Q98'<9GA7M#W(N4E?OO-A1N61!`R5)>AV%RU5I
M65GMMW8-2$=D+1^ZOJB,$3MZI%W8:"L4%:Z.N^)*/+P$\VTIKL#'N2YQ=8PS
M(::N_H4WEY=04GM%9)'BK$HV'5A9F^QR75L5X[8.=,<AZ6/7(4E,D`7S30<[
M'3TRP)#T$6?IYAMOF6<27#_FAA25QT[C)-6>:YJYRI--'>5T\&5O>-?A22L)
M9[WF57FR8O65:_I/&B=-'!GI-@Y4T4T#-U!#J_5.-.#0-"?64A[]'/O""^BO
M7IBQ5;C'_YUC>?2S;,@SU+K7@`'/5QMH1R[AN5;'N)6II:\5\!1H<&QBPCY:
M;&^U^?U:F<3F^*Z0A'$C'`(=*8UPH5U)A229&8P9F+DC(&7<'+E*96/CG0XE
MK5A:&M$VN'Z`4!>4MMOXEDK1E)'&G)2[QGJUEAMTPE7Q-"=;D6Z\/E!1Q3C+
MJHG+7B`A0#:_*K]1LS>8;#4/ETU10I>0B!CDF'!5=OGTZ+BH)O@ECN;9(@OS
M2H25Q*)Z$6?]&:*+-LM^TJDI!,.N!CMQ/RX#E?B7'$=V4\'MKK46K+.C3\[!
MVJW-&EC;-C4UL#IQ63>PME5AP)%U=MP-EU#V.@3-7)-#FZ4C.@+++`WC*F:]
M=S5+$I)?LKL*O(<@9'X@2;&?Y5_S5T0SRM^36MW"H^4_3[PD`!7$[45.\>$<
MMSWI;V%*$78NP^$W&#L=N1^,QL-\`.7HY=2JYB+$H35;DV:]]LG)LG(@<$')
M'QF)YJ:ZQ!;<S:ZGXT"3_><>_ZH.!G9@KUU'FG<(TA'C!I?LJ&NMMG$'R(*[
MB6T=!XX](AO<J2`+]HL9LFHME&#42=\.,`(XA)HL0!XDISJ6*&SC$"380[)N
MJI[YKR<"XX&0#;L&AR(+@D6ZS6@&&`@-;C&C4:T&!(VB>-1#8:WKY0%(JWA3
MX-3&FA7J]QYGJAR')<:LZ(=Z6*V\"<76G:MLY00>8`+8FXC6LF`.,47(J9`*
M]XKE'+]600E"K6C4(RH<B1`6H88SE`EU?"F%8"MW8`#>N$/@>9(&"X\_XK>V
M06*,,<)LTTR9N6;%BBGBA`QPS2S(]GXR8U6CCY#Y9J4'ZA'S9+G^Z[\"0MG'
M?%Y>D5<2PD-10`-B1*IE>I>!*=R-H\:G6C4Q7FZ4+A1%*UIMB!K;T>T'J'G1
M1;`0;$*V!X#N@@06&I5`6P5J55"/URU`;,7[]?LNT.7<^()?('J[^0DC9I'L
M#UQ&+UF:Y*8>P7=;U5Q-9,HH,46Z5B.@:A@UNL-J<U6IAQ*',OFH1\J*PA];
MH>XC&'4?WP/JY.X8#G4?)Y&:5U'XN!7JCL&H.WX/J).[8SC4'>M1]^GP\'#D
MV^TT>,W3HD^67[R4F6RL%:EC6/M73O1^%N9`-PV]$%>IY;8TC&MH`FM4JLD%
M6&*L3:D%C!)>;6I3RB2ID=)?;4HW./DM?R<F-<Z64KK"68W?(9@1M5\XAEL&
M@('Z3<=&PQB_?G%AH]#TFMX&3\^F>L=&GOHE51G=^YG)H,X:?C+3:(:Q))54
M7>A-:AV7#JVX)CDSEB#@LYONE#)!<,(\\<$!I:'\^@,<1IP6R?8L"$DV9H^"
M'\?E8,MKKX4*AK<4]=2-2\M-(@01$F1LD-U+UMIK!P/-U>.FE$$O%5L!0$'=
MN#*\/0#0V^L*`(*4`4>`4YOOKR"N5]C8FJ^OM];1QQ>$@/,:MGDA`2U^-/Q"
M0J,9N"+IN_AR@#J1(WX]N7;R+_BW42/WE0LD.7^SAR2EWEQ7.1W,6S[!;J9'
M,)J[0,>5Z3Z^K>O&N6</T!+C$>:IESPS._D?O".^>F'M[&QCAFZSP[:-<LT*
MYT.`=3@,F[LA+=VC?G/=I(FPQH5K@'''1&EOF_$6.LY.&W-0\]UA3",1X[A7
M&?G;3>AV#13NAC(A@-X@4WLK)XXSOT-5Q9@,OSDTK%AQRJPFAM=^S&S"&;V,
M%`&<+9&F/+@'>$*!3I@&Z@-]F62,L[7>SM8CJM5(N@60L_*&8]"99&.<T*N#
M?[;(=>,SP&>2/L=^',9/RXN8RB8&P%SOK&U)*;Z6[2'`]R`1@FO7CU^$KZ45
M&'/]9&:=O[V0>4K\7V->MY=9L;SU4FB]2U@CFEZD8D367;HA&=!%0`X$]856
MJD+PKU(18TPCT_\V2'Z_H(24C^NU@+FN"0W(Y6SO#>(`YXT+<+F"@QPHW]-\
MPEJ>Q)&?\->S58?)2L+R+7CQ]]N(,Y`O^D>32@V,>PKR(9W0>9"0&QK,[:=\
M":]VIJ_1;R,JV[IK['F]IAG&N/7NV:-&D(I$97)-Y1?;##NE`X;#5U4%C,GA
MNKA6,>W:L@(6.]L[+[=TUM@#8%4Q8RH2ZL=QCT=['7?,*ZZCF+F[+KF[+KF[
M+KF[+JF-,_1[TODF]"]1_)`0^LJ3+O.2!NS7<31G7%XQB<"?@NI!7#.><2IB
M&SX0^'THQZ+<?Q@TKT7U`6-5A-K/5S%'M`YM5`:YSFS;QI>D2N<L\^L(\$*J
M:CZQ?JJ,%M^%!M==0%T]U>B[(?J-J7:J3,DM#S*:1L/+K/8MV_TLIY*'8\4%
MZRS]36:@KP&IHBEJW^,TI=)ZUVT'Z#I?CX;NK%PBD@H)X/XZ_&>8>"\=-SUQ
MLQ%Q$40>L\$++Z.$1;?Y;FO-%X8=GI8M";N#0&X$NT3#34?*#<AVKNX_]I3;
MH][F!-H!GN?>P7+#44W(GM89=J4AD:1H=_?%J1?.LS#_ZVT<AA<Q_>91?Y@%
MAEZV^YA%)6^[1N8A=]A`7W!;MMQ4QJ(>(2I'T;\%Z;-@8E*W,:E[9#TGYFU!
M1H4^Y&F>TG`@8[MZOZ%'`EZ9<?W9ANC^<JLACX(XL!;U7H:EJ0I+_\E0?!4G
MR64T#S.?^)?1N4<C1@;:FA]*AX[C1`NYN[%C^,\[_?&DA0=0)ZZ[,?^.I.GJ
M/+(YJ/0OJ)^1HR;HO0T5@WVTC2M_VAMD".C3,ER+APXW>"TO@[L2(TGR[M[T
M=G5=^/Z`^^^"8RO`B5VH9^25A:O7YN[CU4M,]]2+DD="D]7;S/"."6I&WO$,
MK)@ZEDNPZSN4C3][K;(`N8MAUA?U\K=BP7%AP5&WCF!J1M,1U*SON",`_8FF
M(ZCUW:9]X/J,FYN_MO<+`?69?B0Z7:E)I+RWGMCK5QJWT[HV#77$5_%?Y[#/
MMBW-2>TN`'3AV7'[$5QIC"4*E&9TB0=MVS+UD%UDV-&SN'J(;8R(I/:"F_W,
M0>-$K=1^=O5W\6*O7VO",:/"//R%*VY)Z*7$O_%HH3MS$<][*&I7C%:Z0J&7
ML(,M&5Z@K`7JS.3CU5B:/Q,_"\GUH^HSG2QKOS%<>^[47EFYJ5T;HUU@!J.A
M6;G)@:^4`YI)*:&&4SMEMN:*,,QJPWUA^T;T(X24$4UJ?S?\QHY<I^P!K=1K
M=@L;M3">552U-%[O51-+8(KK`FT+^&@`:'?]%2Y;AR[,EU>-*!()A'N)<A(D
M]SG;P0=@]:B@<?W^[8*)O'GVZ,*[NCHU/'^KH2W#/"D)@B6O9B2([4P$?7W9
M2[?2IK&/#!48MXN3X('1.XR$L(0^>"\N*A2V"GN4?'H\3B(8@D8_)A_8SFFF
M24PB;T)#G3$>$FB_'MN`BE/CCI)T89'9^-'0Y#@Z.HT7"UY2W0MGD7^2)4%$
MDN2,']3$+_GSYVS49=X-HJ<[0E^#N::&A)/VRM=[6S>#+!)3CTJQ>Z_9@E(2
MP[779$*#'R^B'24DN6"?KAI>\..-*HO][&O;LGXHA;>&%_7&_62WGG2VL]Q9
M+>/P/?H1%^O+KX2F`8NBO\1I6;XE>AKM;.ON.:8IKVQ_1AY2R(F6GF']I(:<
M",'I54TU^"&5FDTXBY*1CG;D9/A<RH,FH[WJ):54HOH4229),;$=3N^TJ&X=
MDV;8\-#2RWK7A@;A)H<&1<+C-&:[`;L8HD#Q"1JI(!WB\(#'N$-AX%`!"->N
MA!X+)N#8[41(91DQ8]A]F`)J%%3"N82&#LEF@Q$N4%,'!<EQ6Y`H=Q76D>5=
M]L"$L-"21\;,74&2Q'3)X\WD^-/LA08A9S=M*G1J;KVGT+(5!(LKT\`2._<6
M''_27826*J`<P[BAFU73/8OI3IBTWS4SGX%C[6(%%3;`&4-UJ+V=HG2E$/.8
M-OI2FQMW%7O1C$TD?KX*&!/,F_JLD$6V@:,"9BG5J-UVHY%I=:VAEEHX]EK:
M]%4D/=1DGO*9*ZDD6?<4)&S/VKENGO&Y0!6Q%$O(ELPZK&AA9;-,E@C1(PKQ
MTKBN*/"M13V+%"<8WUQ4?G\M4MJ\N=B4I(<+X,W%28!&1299,*H)D2R.]6BQ
ML'0PC+A>&)=Q(#\NNGY[9%)6IRY$OP`&LA7^,5(C6%\8AX.XM?E`>(AO=L)D
MH1U,WML2M44$W&&-:A$%3VN1>N*%'-YWSX2,MRJ]2[TT#_7SAT:N'^]2YC33
MZ92)I]PT5M.-UE^KJAAC135QN;,I(<`1'YJ_46QIJWH3226JV45E(E`.ZD:0
MB`1"GJ*<!$D\"$('P,@A,>$Z(KPC-"#)Z='Q#5N@\[`DCN;9(J^R^UK-T+EA
MC1!*B9_K:+C&XJ#-<O#LU!2"*$$SH,3]N$R)1E&5^O693BHHZ@SU@M:33\[!
MVJG)&E9;MC0UJ+IP6#>DMM1`43*N%Z#.CMPCM5N;-:BV;6IJ6'7BLFY@;:N"
MX\!0C];C;L"$LM<Q:.::'-PL'=$1669ICB-)UX_&RIZ>U+X-JWVK4DZ$P$S@
MN8R:7#`1XWF,]ALI7Q]M<QXCDZ1^070"YS%&H,A()*<3<B(D:VXS0H!6#H:+
MD<?)WSQ*O2@U/ITMI2N\U?@=@@E5V_5CN&4`'(@'+8J&40X+ZRTDX8!!MR4M
MGD8T]J*O$"1(K94QWCR2$C9-&CLC2N/\9IJ^SA[S9N*5\AY1H]V>LY_&O%4C
M]Z#3U\WK,KJ]32X;1-"[#WK`U=*#FN913L1%C5OS(VIRPL)9S5\BF(OA`Y?6
ML@X#5[-=Q-__-&/+ZR@%PT!!7T.#0(,`%(I/+06$WD8E+NHBY)@0FD89I)UZ
MR?,L\OD?YW]D;%X(^=.1L_24!9C+('HR/=5NQ5^>K,)XT$!)!9+F`7P+5Q@0
MUI`LG+W")*($W@TE+U[@%U4AF!77/,FF9K8&=A;<A:=!'%.#G+T;N@$.)`__
M%`B=^G13WO3`TA\L0`!H?4[I:KR)V3(C7=Z$'C,D\OF`F==ETC\L`F%;CS`Z
M4C1H,8\I8(M;QD=Z"2B'C[/B<*K(:#Z-DS3)CT-SR.LA!.;=>-5$/QDPM;"]
M#:(`8E`.2I7I<Z.N!DI:^L*%"IK)0`9B8TN8*)IVG`#F,F`Q1BK2$&5"7UMJ
M1:=UM_)9-!PSR/4C^Y.MS?(Q"C!K2.D;,T6#9C(?'VACEQFAT;0<&I\.#\<%
M1^7M,18/Y=O)SW'(=$MX;)0N`7MVMDT4[H6S(4`5?+NWI3<Z;`3#):*,1"KJ
MP_>)S4PBRC#N&%NC18VVEAO*4`TTJ)O&?O-L/N=OER8WWI*?K`$V9+0,9=BC
M(,*%+>@^#<1B")),NS8*.5AQ0S/BB];IH:/GV:!'13=5`('L=H,AE2B4^SC\
M?CI\[-%0EQ.;C&*2H#';Z@`N4B$HXZ%-DHS5D`-A$[)=MV;@L;*^,YCTTE!N
MZEAAR>C#K<'-$&B!8V3DC:*K.'HJ2ZF48Z5VCE*3KR<I&0DNI+1;=YEM=[_B
MDLI$&>SP%VF"=)'GA$3^:1SQQV=(-&<FZS)ZS%R5IX:4E%L`+[@GG*-,*QIE
MP'1/%B\Q]>AR95B9@C1;\#7F+$UI\)"EO+/<QS>>8>9KW=:ZC)<U_Q;`M:O7
MG(.XA4(HH[96^_'@/6?D>^Y=4=E][[TM_.SWX$>._.I7H$V9MQKJ3<JC2($`
M4O8@,MNJ.;F!XD4J!.5F*(\.X@B$$A5I)82K_WJ2^#!8Z0`<H@24(?_,]X.5
M1C=>X%]&I]Y+D'JA!B`&CG*+7$4U2;C`;':`&J4@E"%\Y;'2N]1[(N=12N@+
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M#?[<G!:80:?BE(--I)XRR`RVNP.7*`CEZ;94Z\LDR>P!5>?2@:FDG#Z0I#:[
M!E$I!.71MU3CZRQ-4B_R@^C)%D425AV4:N33QY/:>M>@JDDR'V>/G@S=(M:R
M:T":,KTED58K3W1`'%2>''=_PX0[BS`+QBC%V<2#+"O+G>$*&F)]PH<G8X1E
M9M+@:)+Q%=ABQ_C11U<_XL,.++@"<FI0--W0RLYVQW@"!%9'(Q<;K%QE:1%6
M67"+=XRV)*"R]T$'E(&$*9"&YYZ:12`%X!*1-?$0"FZS&R1!@Z<C!"4L:BH;
M0R<#APHYDPR:8+:Z1(P^7#H:>8]<4!<6+$'85+B9;IAD8;5+!$$"I.\!-RF*
MG_/_/7@)83_Y?U!+`P04````"`!6@@Y%VZ&CZ4]N```FM08`%0`<`&%G<G@M
M,C`Q-#`V,S!?;&%B+GAM;%54"0`#I!GM4Z09[5-U>`L``00E#@``!#D!``#M
MO7MSW#B6+_C_1NQWP-;.C;8CTE5E:7IN5\],WI!ENZ][5);"=E7OA.-&!T4B
M)78SB6R2*5O]Z1<`WR2>Y`&)E"MBILLBSP.)\SL/@'C\Q__ZND_0`\[RF*3_
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MQ8O>[]YE9&]F56+1_>:]Z0H(?WUI`X6"1G1\-04/7,\D1%#.!A.DQD3(")X&
M%EH+V/2E,SR<V>`A(N%Q3[EX_K7^&6>3(7'VW?8RR+)'!H6'(#EB%.04'*BX
MQ^@V2%@^1?D]Q@6*:(9A;\AM$M_Q9N8H3D,F)Z+D&3G>W=/_!A5ED$;H$#P&
MMPE&.Y(-`/<]^B5G;`31))'@L.`*P[)1B)8KO%JIVI'$P6V<Q$6,<_0LHDW\
M$A?W,7V=8O2(`RH[JQ\Q\I1D^R!!Y(!9T<,T/H8)WJ!XAQ*2WN'L^?=/!.]G
M4X#R`U@.?T6"C*IY'6?4@"3+WQ_WMSB[WETF09[C?.`PAM353]%2SW);P[;,
MR^EZ)7*7U?%N.0%SD(9D@THB]K`B6Q?FI@8GEE:QZV27.+%+^?H0;Z)N,F98
M]O^`#_3WTC;D9:1L`!.6-#2@TY#\Y3X.[\L,4*,LJH6B.*=_/,1T\+!R%(6&
MEZ1Z,.!R"C&K*D)359KHFHXO6DJ\'P&*_I/S/3&LB#.O`==BV?<-JZIP=%%<
MI.DQ2'ZF)1PM!JYW'PL2_OV>)!&%BEV&MI%HEL7-)+IT+YO?Y+0:,&S(9.\T
MDF]65:!*%J*E?BD-5>(845>@UTYO!6?3P##!1P#EKNTI"]=#QDURZC5&=17]
MIZ"6PJTCX8"67$'I3?O6F_*.(K_KK=7<:5K=9BIY=9=:L/XS;H];?Q+6D6I7
M^<TSU-AQ@0)WE>P'O"</07*QV\79GF:'!_SQ/LAPJ?M74N#KW?6Q8!_[V%?0
MR^`0%T'"FW>#J2O2C'(W]$>7*B2U+HP*T/@#^:MAJV&@EID')A"%PGJYDKQ!
M'=FH(QPQZ8RG(Q]5"LKJ&;4J_`ILH%XCC70.?-.E(N\\%/1#I+,&+NNJ_--G
MQQ\?*A\,DH15[.D+TG'&G(GG-7M8N24OP_EGK*QL3+^.?Q;D*$"'4MOSWWQV
M+FX70:!_?@O\P=A9&Q=VW;/1^#K#_SC&[+/SH:'BSBQQ\-:?NU[>]VTJA?4=
M_R3->9FSE[H:AP_H<*,>EXB_CG@V1#\AWS<;JD"I<C=V^82SO6;LT261C!U*
M$M`(U=4*6[M7DLVC`F<0UL[LC5\NU#.6U`4$)E41@AO6]<1KH\/.R(*I45IN
M[GDL39LI'5U0W;`E21'>Q6FYKIFQLFC]^+L<A=3]J4B^VNCV,0F^^!:"S?%C
M6/[4I/`8<CG3V"BP!!#-_9\JQ)3QH@3+R=K8+,W5I'!IZI+L]S0#QC1WIM&K
M8TY]*<]?XP><D`,+!9<DS8\)F^C[B+.'.,3YS[RC!^B9*Z;ZU=/%S$+]W-;/
M2YLSM,N=9K+0;<O)@V?-BSK,J.5&-3OZ7`KX/^NZX&P@$BA0`-EX%6"#SA3-
M:@0\PEGM,<#X;8WQJ(/QL,5X7@GXUJ$MJ43FB%L'WL`3*K/:X0#A_8D16A;3
M5(\Q1S5;#H\"E.&$[P8\T"KYL5K7><@(6[Z9-S,<93%=KL4/,9L\":?YS<JE
MMP>.(R[OYHB#+`'3!YP5\6V"W\9ID++VO$OS(N.HOS@6A,VHA"49VVUZPX#"
M_D';?T@P<XOKW2]IA+,O65P4.+TYWB9Q6.\SD!2,2RIMRLMEE,X,:DOVS-S2
M=:&VJH+D(DW8=O2@1A%J-:%&%6IUH489:K6Q,6M7'RH5MKLQ?:FD%_50L@[^
M5X'S"<0'Z(G#!5N]=JP83&[&Z8[P;Q+4\P]4>Q"GS,EI516P6JD)*KLFJ,1M
M4!%49D$39\(VSAP/I-SC&/;"#"W]CMU(<R@C3;/E,MZAL&P2$Q;%Y>;-(,-H
MCXON[&JU@[*M(VGSV0-1H[]''X^TT1V!^^"1[0A-CA'>T**QX!I24J`DWL<%
M_[:V*>7OR9$*IRV_RPBM*^D/#S&.\KH`C7C9R:>+*6>Y$K;_B]F[^N>M7G8^
MY0`J'0LNI?P4@BCDS/F"35X]@M(![(4@S&V4T>PW;U\"R2MA\A2\_=S&VZFF
M6^*!OY_[X._G,G\/$Y)7>5Y3R_SF_4L@>R6$.IGL^GB\)5E$&TXK4-JR?9SG
M)'M\3PJ<G_WAXI#%"6/7S5Y-D3*>CK*3`A4,I[0=;,+(4KE1C+*2V9O2Z7*B
MEA5Q7G3V!\2Y$6/W;WYF$@9%,60&F&?*6@/2P%\YI[<!'-OE-\X6W9SJVX:K
M?KQJ*VT5R()_N9S>#'C4TF'?7^KJCM-B-L]T"!Y1P*:+<#4=%M)2\!8C_#6\
MI_IIO.;38B@_X##>Q?3O?QR#\M,EVRB-PV-6'1%&[1*'09(\\@^9)"V7>#_?
ML,VC?.+HT)U&HDT]8GZ&&/NKVJ/%'_+5AITOI)2G2@]_V)0IXG#,<M:(<II/
MFFA8/Z`;"I)[=G+J13V[YL_$U3JNJAULVDI;Q56=#0>M6P'OJ>?]_))W07UH
MJZ?TM[RC'SO92H,;#+W&MT4[.KO.XCO:BH0]O>`3\1=I5)T9^"ZEY0_.AT?P
M3A=0=<84`;.<>7J+YPU\)NF5^^T$<5OVMO-M>H-J-L3>;%#)R;^PU(?!ULSK
MNO`,E)'Y=I]MQH7Q"OWE=F(+(+'+AC.?>I\'>;56PS=BP&:P#2K8QA4?K1++
M@V5YK"T_8[)*,@V#_!X]HY4=6_]6/WB.BBQ(\R!D7?$]^NZF\^X[=APM;7#Y
MW3,8G43;X>0?-JGV:@T<^[3*M/$OF(<B9_4D?T#+VGWU@9B+..`L)FN?G;B.
MJTG&9M,$+>UND-_X)JH'];6SNK3+*WSS(JXYLIGY6>-?_%30[ECJFT2O>+@R
M31!L<=?.QK^I+G:H=5VGR>,-CS@O!36=%5^GE#/DF^VB5NV;7[B9JE/[H9F4
MLDSKK"NLB9MB##%R5-*CE^M[G!U8R&0[3C7+,F@#G4RVTPH`.U9A-4!KPCMA
M0"OKDN8@_W*BZV4YS_7TP:<H38SY%P(@\-2PG6((#)X9KIO$2J"2%'M01#O'
MI;SH,.9?OM8XFUAK#'^L!=\BSF?E>O-K#1B'.[.M-<Y.PZW.IKO5/*=:#&VK
MU!IG0+7&F7FM\><C?792I<8<[,TL-<X6*S7.UBHUSH!*C3.@4J/X0DZDU)B%
MRYE1<9U2XWQBJ3'\7&?!MXCS67U5GE]JJ#\?FTNQ+#7.3\.MSJ>[E?BSL'=H
M6Z74.`<J-<XM2HT@/09976W\_NG#;V:U<;Y8M7&^5K5Q#E1MG$-5&S0OGLK4
MQBQDSJLWSH'KC0I/%VGTAJ_V>]>:[^*6-B<(1ZMB+%CJ*L.(99Z_6;1J9FUA
MIDGA628"MC45_R19TJ$.X<J.8H,!,L5&$[H<SBO>[`\)><28ZGM/4ES]Q0_4
MO>:+:,7'!-JR5;_1G&V6A]BV;IZ76&B3>XJQD&U-R;VE0UO=+%%1>[*WQ1HG
M9*H-)YID$9Q!K^2RTCL?<_QJA10%6<96Z5?'6=!D79W46^./9&R15?-GG/>.
M7*]/'JL62>V.Q3'#&[;@^&_\<G""'FCV9_43PS6A-.PJ!AKP8KX8BYT1W+EU
MK3KPO1)6K=X/BM[F@0-EQ1O5X1??=_W'\'2+L#S**R@/9(OX@?-QA*MC:W-O
M3XYW[XF2@8@-^S+>"+G0RTHI@"O2$4@9Y\LM+BNOR5\`5.(QA`W[,J""W21B
MI18`5N?E4:KUZK]O!EWBR3L;=KA2_"WM&YHAV=&1U[MZ.,R;4.`//'NR=9L#
ME-HQ5;_2E&F6Y]BU;%X);JQ+[BJ&(K8=.I;>FTGOLAHO,&J)U_4>2V20:7:;
M9(8%<`4ZW6VA<B[`6*T]@%C<A1C?/9M]$Q"3U)/FS$O`#'A*VT+K;*2-;]V*
M<)AAMH&9;:_A:]NU`*0OV:X=''&T[BK-];;J:J]U-2;BVWLZQPL^:?"*ZU9S
M9KBZXGVY\ZG=PO#FZP&G.<X'N-?25;]$03?+X[3ZY]4(*O%R7Y)S;:M7W5."
MZY?K(EMO2&+<YZ9=Z,;RH%E<K64"!%BNKD'0GG6&\),!@20#*^D=`0$XSZH5
M3<'".)NVFUQ3.4C8A.,Q8S==1D=^DF]Y(R7?E4K_\F(O*0B4Q/E020^7`F_X
MIE_:RWP,SV^4S"^.Q3W)XG_BZ#V?5K[>?:2=/<J*4UBKGVC'.LMQIK1R7CJU
MU"AW*2M!VX:Z^MQ5TJ.6`;UO/A*4/.OZSB3XD#EFG6&EQ2`(_4',6C<,'.OC
M##K?I?CS*N93(1CO^2CIT,"V^G+%SRQH'W(L=^AS^KN31]5Q5L]9;MBS,[;X
MY[5;W#G1RNO[,Y?S"$GY8BMB.:^`_#!EK1C()6@=]%[@#D.L\[,WV`?7!KC?
M#"K%E9"M"-#BZ!#$455Y7:31-?OX?I'GN,@O66V:%J_CG!W@?,SP)_RU>$6E
M_WU<)LT0TA9,DX3,]=`9+9]=1$W3K736*2*W%5\]A=%9A5'RHHH9M=SH,^-'
M7,#*ZXQFPH_`@`'$MBN`&72:9483H%'-ZK,!KLM%.YR[070IYEL&L+Q2FBAL
M#1`#3Q'-:`4XCMD.[S;L5N.`^@L-AS?[8A,]!!1?_!#=,#C$19#P`7%(<CXC
M%;!+0Y.D/'&7ZX_*6T3YH65!G@=WI>QXC^O#<DG(9Z>86'9S`RJR^.ZNO'(*
M/]#&;K@[U6+96(,=XQO<!>PS#\)!QG9$Y%P-;2%),7JD#VOI*5O9G-#A#<X"
M/MT5/H8)WK#;K!*24CW_7JW7N\OP75!0!4&6/?(U@LW<6E@Y<<#[<,/7Z^6T
MDZE$-H*J9N1HHW"28[YLL5X&>!LDO+_R>XR+?^\DO*@N57G/K3]<6C,P2(O5
MB<+@RM:R%+YX^8<;3`-)6K"IQ./^F%`D/>#.J:S]PEJXFAU"5-4_\T3-"IL0
MOV)>.3NS!?*P.4OPMN1&%VQ/X!]0)0+U9/1.]A[.,?JQE!X$I`02+("V7PWX
MH*7O[(:X\0!6!O=\X'^P-)FB#OS##OP'4S6_H5ZYO'VNR/60#UPOSVZ+(_";
M[MEE)6'?2RR<9.4BT2,O$1>,<T6NYR6PZ_IG-\61DYRW&>+%RV$!]!NVE;L%
MYHJ$'Q+]A6_5*\1;=]5$@V',D`C$#\6:8;/02(?><08L]EF#>LZ72H8G^4!B
MXY$W*+&@)G6`"+N:7#\<%4BW14.WA'Z)ZG>>C0RG65M3UXZ)75@<\LNW0H6U
MV<]Z>;'V[I,VM[I`&Q.#IZ>S29-SIES]!*;G@D"S:=M`PIF!,BW,M3+:^8*S
MS>G,C1EC9.@CEN"RY%T"8B[FL8QTSL9:;W;JS/N9*&<84^=A$^Y%<.9FULA(
M[7RH39H+4F+2CT+?'2B5U8()]R*@=#))8Z1U/B:[4R]G7DZ]N$.7<D+%A!N^
M.#69.Y$0#4I/%R-EB6:8PM)^SF3(TB#YS-,QLLQR(^2:SX@L86<GU=V4:9$Q
M4S=X>34^GFAJ31GF9CID*-91D35E1F3,-&%B],RSB=&IV%!70^[G3EZ!+7::
M):F7Z"9*`G";6;\!(F5.;8#.Z:;)K2/QJ]-?Y30/G000)G!67POP#FJ'Z>UP
M@OQ.%?)*L&YCX_N<TOIH5Q8]DR6NAG@GY=/TIK@!_81"S-H[O*C6/'`/5=TW
M6>)J[N%BMFQZ2]QX1SNK]LK'.34/,*V:>YLL$7K`<_GR#&K$,T]4;\@S512`
MQ\_[%1"#GLDMT#GZ1,&UGU]NT,NS$Q_WS,0H@<0*H.E7P[V#L<^,AKAQ@,[H
MA[O`R0U_?`"]<@`T7>1ZP'<R!)K1%D?8GS`(LG<2+T9!7GB):APT7>1Z7N)B
M)#2C*8Z<I!T+7?HX%O("V:K1T'21X,,A@]4)$IK^`,;!-VN)7I`AA_7*A"%'
MZP!>KDN0V6R(;>-5"0L8V$5M/6%)PIBGM;5/ZQ&FF5A=ESI9C#"4ZJ:2G+`4
M8<QC7_OYM0YA(B:459C310C[("MN[@/:SU=7E^(<I""I4Y"09!YR%5IG)B"Q
M9`5610Q;_A25CQ%][DOV45F+F/2N06>!6Q8V\\@4V)F8YYWV^:F:599O)*3P
MIH7.-C(=EM:URC6M`.;J:V>:Z5B0Y!D)*6":88.H/[$LAJ/7_%:$\D)X?BCN
M;9#CZ)+LV<ECW`*O2'H<'MH_0T*=I*9(F.<.T]L\,\5-4JQPH`GRJDM-*RY4
MLJ&2#[6,J,N)..O*WC4#:`3`\O,-N31F89/W1/V@X.U>`\3GB]'MMPM,60$Q
M3=+BX(0N/R8V`1:?M'CY-4B._`C7$J#L]HGRK%/6C^PY_L<Q+AZ?H[LJ`G=N
M(RKO(&+WJ`?L1O9CPL]=97=,<)X7962.4S9!6AZ3U8G1!_H[OD>?[MEM\$EY
M=SS])SNDM;SH*"1W:5S?;M$3V!-3'5B+#L<L/](6LEKK[<5']/+L_,/:!=9:
MGB8ISZ9)`J[>/AZ2N+@A21P^RFX,T-)U*S$QW?SPH-(/4%5)Q&O<6\A554C\
M'2I?>G3^OMZ8Q+C?3;O1C?7AZQ.IE@DPX-,,+1!.W^BJ>D%&[\CP+G*_5-$4
MV_<G(:+>@?!!&+(3T?F=@65P8,?`E]D^9\)\R))SL:+(>#)ZN+SV"8?W*4G(
MW>.K8QZS&WP_!5\OV0?@74REX)N,T.)I_S%(\/7N%YI6<<0(V(GUU!1?@BP2
M?[4%EUMU#J#<60X'_OOFY67(YLB=&$[+MA6%:EF(TJ*.-%2)0TP>BP:EQ)*L
M*].3SP[PD"?.T.8*/'[X%&BU`]NJ!9R+5U.5RQQ+EWE_?;7RS,TI.(>D:@.5
M[XF#`%>%L`U;PD=L/GT=V%?NZGHBF[SUY3X.[U&0).1+CO`>9W=,Z&U,BE8(
MFP\*4K:*@RK+<9(P+7%6.VZ*B\Y%0K0P9G=]/6/N_)Q?[5.1L=]!G?">/XOP
M`T[(@<]*A1F.XH(++V?&&GTK5\XG$0_$E3FH?,A*/MM?D2#]2US<7W^EFJ*W
M<<JN@I+4YT;43=6MH9X9UHS:,K="UBE1A1TU[Y81($917CU6TJ"*R)ORU,SB
MQ-(L=KWL$BC`99]>UV3$\"NV&6822O.T8"$MHK1<3J$!7O#HU4U'AW%Q4D-(
M%'963_#`N)(E8RT78(K-<)`?L\=7)(URIGF85&7OZS0Z?C\/]#)],U.E0*P"
MS"/J;?T(\6>(/5P9C%+#$&U?ZKH&UH*P.4PHW<*4+$]=Q;OR`M7:J+?L[>G9
M4Y:81'3`-H5./D(%-F8]J\J/:E#;-^V&725[D_YW^G/Z^E/ZO^E_/J(R`VWX
MYQ?\-=@?V(6V-R__^_<_OSQ_38>?3;(JUS\<2,:66^R"D`^<ZQMR*3];2K$G
M:7&?EY?L%O<Q)<4IBH+'U<>D4U`E24LB.KA$5&^'4*]%T%!5#992S7("C>YY
M"4HN7.X$,IYMLW7.N^4'.OL1P\XVZSL7Y@;-9BH=UG9GF:U^==I6EN0U!;43
M2P/G.)4:>V/;KS'P9$?=;'"(TY.">D*2JGX@_W&[(+_EO_"8O[@+@L,/+'G]
M@),BKY_P=/;BQY<OSE_RA%8]_NM%8P?>*G;V\&U>9+2$&.!03UC]5A7A+!_0
MMV!>?E/*EZ-?P;;]>-SO`UKA4<!_C.]2/E6=%JAE*=,?7CD8&MB6F%O!N%/7
M!GU^$SP&MPF^2"/Z)#OBZ"H.;N,D+F@S7S?A2E;HS932=Q=[*1"^-+7M`'7%
M]!9H7=%:YK8B0QTZ+SQR,K:&[CH3I#-EK0%5J(L_YZ@'1RJKGVM65/'R`;T`
MP*CE]VATM3:P)77[#&F^9+'+8Y;10EN=I`9$XAS4$$'Z[4`S?`9I%1B[7<W2
M^M2A?.&5CPQM)G,!L6W5I`XL["CP=J7;&E@4-C>H>GG*MC:+9AWB-8,5"Z=\
MCQC.I;%*3M.&*A'-7!S+]<($*J%\)8P%'-LW^T-"'C$N-P5[4*,JS$6,>M>D
MG^!M"QBB),(M35L%*%["56_\B4^3C2R/3F+:M8-3I]:C!>`U6[G9?22=%[/G
M[0<S4UX(1[!K)XA[&*O4.HVA)"^'\Q-`,O2N21B;),$C3U26"G(ZJ8>!IA6Y
M?KBR0:C#QE6ZHQSN%M4!"-[YA"Z[:*VMI79C<^!R0J)@@LF[947GK5^EQ2P`
MJ$L,,;TC$%A]BBU($2037%_S)5;%M_W$=+(/KQP/B;^Y<0(,Q!]<E?1KYKCR
MW&\<O6:?Q\.8?Y"G_TXP^P>;?-R3K(C_R9_?9&PK4O%X0VU>T'=O_G&,^3:C
M<4H$%=MF4""Q<_T.]-?!Y&>H)BD]&D;)MB,)11U1JWL_+&J)*\0XLKT77@%8
MP<"UQ[U35/51XQ9=81O4B"N_L'4$;E`MDOZ+"2U7U39R?W,I4[@Y0\]ZV3V*
M^!ET07(3Q-&[]#(XQ+3N&B9K-56=>V54\X*&6C=$9I1J4/BTA&?;OD`'^N9%
MG**P?+>RFVE,2`S[VZSG7%@<+.HKQ%L;G,?DUN3L'=L9<?D43"Z+>W+J%</8
MWXYYP:)I_HE\P*Q3X@2_Q\6[-"1[?$5R^OPRR.]I%'Z((QR]>OPEQ[3QU_6Y
M"1=A$3\H9\X=JF@"J`L5,WW1W:^>Z\9.6J:*``X4;CM2V6[=1BZB@E$I&3UC
MLI^SUTP\JN6CVT?T[)?R!-KGJ-&"6C7H<ZUH[754+IV'+`'6!;#GG:."[LQQ
MUL!E/;9,^#V?S1J?92?QL/-WV%/V;WXP^K'TT,X1/4$C]8^_N>5<:"X"LO4*
MFX0+Q^4AUJ^&AUB_*;^-#4L5*Z:Z^#!DFA>EK%H&$75,%2JBB)F(ZH,%/W=6
M<8[[R@YOAPPRS6Z3++``KL!&D.;:YL**IYN:LKP.YH7@/I@W3Q]<LHAOS+Q>
M#$^+.(J3([LBXB,.CQE/+V^^ALF19J"WM.]8BX_E1M?KW9L@8V?WY#<XX[_I
M8L]6QPY#/*3,.@/`R)SGR)"_"R)_`+5'$0=`-&R9F!>U')0W@FC>*24AYJ3\
MZ(TP2$)^D7-Y]0AGJHZ1Y,4K+850SF2C9[1LY?_*GZ\<6D#A3IR@S05NUO<E
ML)P)UAC'KL0S;D<0:B6A-SU?Z@AC?E2+8W>WE9EZ@TJ1O_F.'EUNP'*J.?_5
MHUC`Q==X>.'C`II@Z@.UIC4CG4D?K!K]-`UT%A&5>J51\C-[O?:$\P)>`14*
M+5QP`7VG&C*OXA2_*_`>.#Z.Q,($PX[8-2/?Z->M/V3J-LE98&N5;-^/ACTG
M';G&>(4*4S)/@!;NA3]X,NSIM\>].P`.?M!G)A5QL:==#"S@4F[&03WQGN7U
M]\$>OR;[($Z-\O687)F'N^0.XLFX-2ZB1$^+K>]WF&4>O4&,"'TNR;ST48'9
M-;XG!8HITWI^PHY;O.,71;/MKN])&K1//M%_Y6S=`$G%=RE.Y*Z]R)9[GE--
M:^M,'[-6JG`Y2UG;+@-??$]97G1X4)?)%X^<B"@RT\SSK+:>^^8Y+D:#S][#
MVMFJA_-\J"<98A-G+5`!^Y*DWIK)_UH9H_W^)>+>$?Y.@-X'&R2TTG2=SPMT
M[SM>5LXV+U?V4MD2;^'+GM="K=84:H*8?!D*U@&JLQ+9&U@IEA*J+"0F`;03
MK+^;+F(=$E>&\F=MMY7-E*'!CR67O"F2@UQ$[WH!`NCP#I$>L"1O=#!+C[)*
M^6'YIT>I7W[X@L)20@HX>\&&"<-#50:T59#PY>P4"ULI`X07QZ]U6Z*L)"0T
MHG@!FJ\D>L'*B[%\0V"VQ<9E+Y*LO0U":2TQ3`UJD`5,ZR346!4F8YYAZ/&L
M4)EF9I.HY%'U\C:(LU^#Y(C;4\"%$4I!UXM20CH`."OT@U4[8ATZ7(NX>A,?
M*"C0CA*A!T;E`[)5QB3&_6[:@VZL#QO09`HF&+\;V-AKQ-]W;BTX?00H8YR$
MWK\XIZS(#.AU<0\TG1NT!ZQJ4^N:X!+#J2,OJC@3"^M=P:"Z6Q$:SH.D506H
MYE<'3<]J0UCPV,93/^K'+T$6?:):1$O-1>_J>-E_-\\!1'IF0GT@4@'J'N66
M_XG8WWZL:Q::@"A[3M41J^&,;<*_2"/V'W82&BVB^2?>XC+(LL<XO>.^,4"'
M%4_UJPUY9N'5JEWS<&RJ2HYO,PE;?M(,6ZG`_]&AW+"!3TU<!O1U7<(.%622
MT:;8P#VD0,]G,=<X$UNL*&C0Q4](P2WMTX62I!HPYET`3E9G@A]P%I/H8Q%D
MQ5Q0J4\)-Y4A!]4&W>*[.&5K8]E:Y;+E3QAIXN/%C7D70-JY/=+>I-%<G)T#
MX.Q<B3-,GWX+"#N?9P7/JD[];+DUG[+ZA)]/M6Z?LX+!=K;=7,II%0U&4[%3
M867-O0RXH.:E[!0"8*M7DHX'/![.]R\!.JN*U;?O`ZQY;Q/RY3WM0_K/=^D#
MSOGY?FGT-DZ#-.R=]:?]?``EKI,7YHF;[=$0OP8HB\QLBCH`S!*^_7@\'!*^
MV2!(4-3.6],B+RV%HETMJ7.NY_K!`02L!!HPP*9?U0D@L]WL=KCS@28W,B$;
M5(E!C1R>,QM)W<.G/?S,XY]G*)+L7+'KY=XDR//KW4=V%*IPCZ^<H,Z/`H)Y
MSB[5.--Y17(5SC@FW_)G+*'PIYYL_E-8B.C[5-M%7D#S2G)BC))&`-`KH+,K
ME'KA8'IE=,"*F&,$UBM?SGA0&TV(69EME93P%H;]BB/58&EJEO;YDWN21%3G
M[_B$2_%XNE:695H9[=HQZB]\IW-QG7V([^X+P7(,+5T_5HGH(-`LUP\2LX3B
MM6`6<+6QJWJ)2(;X:R]6=NBM.82WUO!::K\@KBH5590JF$,6CZHV.("Z>3DI
MY%/!W:<24VE9->3U1:<1&!:$/=GOXZ(^S.*2I&Q(A^E@#H]BNYZRAKV*<A[L
M]6V`J%B46A385_!MVY?E!Z/NVY51;V!88F$!\[YTA06P>3"-BDE0X+-7[>OR
M`\_30X.LME5SK!H'2<I+;N%A5M+WG9@W>#\;W4)]0/%M*%L-Y3[UMGQ47BRT
M/EK%9B':GM3U":S](&/26+"%^>KX0PU8S9B4S]>NO2984A%C1G0^1);W1]8:
M.K+G%YC<!.7G:1H'KXM[G+53YK+3@"!$C>/5!%%0KC'Y5\!&P2G-,/(X>\%^
MQM;I:!,Y[USL0@A<#<$.\L"T-K@!\#"[;%`I@D_0<R$;1,54:Y=8[<LE=;[,
M^G.,E#\.H$]TDT3ZD!-I4Z^SCP6[+X\WN3XI6I[Z=!SC#"?G@`H#NC;!YBN%
M-B.OEO)OF6L^<->D_AIV4A&_>"TB21)DG7L)5KZ#S084(C\T1)(%GVL\.<@>
M2E6SX#3.!0Q>)$,E;94#FN/YGR:6]*%;Q>D<3U8;K!YP=DMFQBC=UBHC";TJ
M>8,.3=3ZEJ*4;%.5&:</N;\L5BZ.Q3W)XG_B2)[S993C7#^FA/(A61M@<[M`
MBY&WC/@&/A(T;[SQ!JE115Z@08`!O2L<.,C)0A638##.P24%NGAB>-#G61&'
M,TPXRZM"3=.@0?-H^U=UJ_*P[G\BX-"F2A&'/RGR79X?]>FQ3R5+C345+/3[
MNEVDQ$:#!=@KGD$JC/E3SY`],)X<U4(K:VA=V-I9VNN(MS:U+-UMT+LG8'33
M'-=2^Q/"KH]%7@1I%*=WNC@F()4%LQXI+,H%K7`1UOIJ+`#?91P$.-*^\@SP
M(M/*42\'@@F#,S@XBWQ#'=/0((^!UT\/%Z8A<<#B0USL'7<RCH6BT[[&KZ%`
M;GT@G,V8Q>`(N"'Q(*+]R_<__OCCRW:BKSN?@5[^_L<-?<W^OQK%_'M5XZ&7
M/_ZT.3][R3\T=J(B?7Z^^?WYO]6#GJ!`KW'(UXJ@\Y<;1(UWSGEJ,7_8_/ZG
M/VS^Y^__=2R)O3K;_/1O?^@(^_,QQ>C\1R[H7[UQ-=GY.FK,R8A`D><@I!J=
M#C<F'X3.7TNT>58]&EI2'QQE9[DM&1!3&DIR?ELP;]+%GAS3HGQ<X.CE*$(:
MTC<A4TL_$\F&[9D+;+T:%<YUW-N6I-E+N4$E&6KHUG8`4],3:^O8=K9;S,!N
MP#32-@,\?QW!YT`#!,XR-JO(%P_$:4&\FE:$!Y(TUAKP^1-\7SW^DL;_..+7
M.`^S^,#NL15M\[1DDX5B*1NL=VE:!QR8Y=HL7$PFI-P`C3K>UJ'P8].H+3;D
M+F:&*EMF?YQM?#&\S+^D5\@K*6&]:-P&8,?I*;#PE0Z?N(IA!+[L,#6PK-PA
MI#`PH/<']MTY:FUU+R26@7]`#(M_84M<E&=#11:NT&?=MDNOZ]JKG*'@Y=B7
M^SB\9_M062$2WR9X5+5]"?+ZO7>EOQ@7<M=1X<B,Q2&:X&8_M%JF@FE<X_>7
MD_@Q00()$M."?L2T<J3EOOR>%&P7P&-`_RW9SVI`VXNS4EH`Q]"T`RS*RO7H
M_$+&N>7/?,"]SI;$JLMM.L\=`&`#HTK)1/NW8;%,H9P"523>[*R%@X<R*"IX
M'$($>J6=3M=4I)SUD9(^K;@A76&GX?$A6=[4=2_/Y[ITJ:(>)TPQ-90[J-H"
MFS0EFHR<0<C;<X;!R,,;MU#:6N08!N`PY'$)$0=I5:IF,D*&J;6A\>S8"EBP
MZ!.LC&NU2/H:WQ;MJ,CL"X(53]43ACRS',>J7?.<QU25W(',)&P9F<]?#.RP
M0":9:DK/>^)0S:?"=VE>9$=V=)9J!G4:L]#%],R`OF;:4H"RQEJQJ0MJ1=G/
MR))]G.<D>RS'"^@+SK`O<[(3D29Q8$ND3A.Q(%ZA:JP)6J'@RBJP0?+8M&N!
M4,OEU2SPLK"4U&OV0I:$)NR4R03E8`@]FQ]2V8+>(`PSMLZ7\M``FQ??9HB5
MS.'8"_&D<I*NK]"1":LAL)45.NV0^<)P3864:1S_/5I,H36CQ`\TRRB,S;X6
MKJ^S^"Y.@X0]+9<3J@<!"GHATH7T@)!7M`>\NA?K,O4$$??VXNXNPW=!P7))
MG(;Q(4A04"Z4]C)MJ,PO\1`]8HRYW.+&394M4S0#-L):NJ9#[$V]VO[I0<>H
M1I;PK1IRVV,3/^&OQ2NJ[>^"0*N@ZH17(=5LYU#H!JOMQ3K4OB#BV7["V1Y=
MD2"E2,=IQ$K']<&NLAXQ[&JS+G-A;-"-(BH=UN86K8QH+^4\;;LK`IJ$VHGM
MK8;QZMPG$V]O]K,JSW6O6F5O$7_MP8AAEN'E(V0)]:KYJQVB2S[!B0DZ66M(
M,!O'8HWS`3R2JT;N@+R$;/O0F^]B$@,1?9=J>\@39'97"%5G6+_AUSJV)&KD
MV@@0(MM,`"#R;5H,E-:ME9NZCY$XP1QMN2VT/%WA>*!/PO8#-;_)?O75<3-0
M)G'/"4B=+L83]WX;A+@<SBF=>$PF=-4N&:!#CK6#NUU/A:ES=9@ZLT[57!/U
MDH2-I6Y)EI$O/DPY*<TI\0FIX77$3LP/.9TDE6]O_6;RJ/O)E;WV9LIHGND5
MXRD9N1OSPW\8E:J9@`(ZM.)&;P.`=VERDO7E@RH9N1OKG]M8_T#RN(@?IIC_
M?)KYSU6?'DX>!.?6?>A)A?.N6C/P@9JE/&O_!E/HI45P-\2?/:.P"E(S`OJ&
M20O!*R6-4E/'48K9UF]1QISI69"C@-T7P=ZO?%O$!(Q(G,L"7_;L"Z',34&F
MU0@!,F'1UN".<6SJBW!:IF\!>T;5GDZ`)\'_*D[QNP+OU5-4(RIA6.]0`7K7
M2#=XP.YJ,'6<EJ?\*LA'LH$_7P55MI-`7F9D#:T+4[N)FGWQUI86Q$/TF;U%
M_+57D^WV1C<*:CUJ)X9W.8#M:[&W?_5E\,3M;#)8[5%[DJF4BV%59,)<!;H8
M5J4=,H!9+(85,HW+.<\6PRK-*$&VP6)8([.OA>M/[#P!):1[%$(T5Q2`0.[I
MA,1P+=@4OB7]]F-XCZ-CPJ]UO2+IW8N"55T#/.?H,R?W"LE]ZTE`+#*Q@FY%
MZ)9;MR])7N27P2$N@H0=87^3X4,01_5US1=YCHO<9/4AC+C&*>:*F^E!,+\&
M9(`SNRDJ!YTIO.?-AY(+X:\'G.;5?B;"[U0/CU0-K;(#+FEMIP:"*H&&"[#A
M5W4!N($?0#O<>4`YE*Q.`^%"-J@C9H,J01ON#%P6*H7UER7R0[H\6ISHFXM(
M![7SQ:Z>@LNER)C_AC]E)!_/X&GH!DE30`<2"J3Z83Q<)%[ON&.NUA^K=[5?
M\M=^.);<E"./T5E=2^W&]L#+_55:)H"`A>6+>FW"CCH_"N[H4#$ORNG=@J!;
MOG@A*_BU3?3O9K]U5;V</DXT(5-([U4L?$_[IZP;W^/QFCU#>D5L'-"#^XFP
M/8Z\9:C+SF?ZW&T`W=6;9%!8AM`4KSYI:FIWI8.HH&+,Y18PT`6T6M$,O/1*
MX$'*;0GIOY\B=BR"[(AO]6![O:/_I=[-FR<)L$*:05`=T(#XA5`O8/`<RM<[
M0)^CA3RIGI<QT@^(BZTV@K7*N$I*>!-#A[NQ<$L+]\):_::,:Z=K8TVX&M&N
M&*(.&0[C@)V!.(I,XU=-0.J^F@G2L9:YR.Q)5,&Q0[CM_K4V\`0=3U0=IOC]
M8,8!'H@.!)M9J8P5IV<G:3CHDZP8!;+X(6!KVU\]O@^*8X:%NX=51$UD$!/-
MA*%*\]QH(9&M0J209=L^WZ#;1U2^\F1?L=)TQ*RCC?K-`PQ71TX$2><[]U4<
MW,9)7,0X%Y[V/Y%[A'I#;B!WL&HK2-BVU6SB16:RMIU'OGB3'58$;C8%;!-E
M+`DYN$&&O5HPQ)7%1LV"&I[N\ID-ZK!Y<C_!TO"4%C?64CS('9UV79:32-)$
M(2<=9041*9`_REL!&N^%:DQ<3<"X_4N094%:H*1Z]^B+PRA,*O`.+0!,&)S!
M`#X&2W1,0\$@NM8$CQM4$3P53&C#HYC%'2Z@-PQH5$V$QUE;\#V9\"#=2:!F
M\2`M*K82R$E&:1!P"X%<*U2T,]XZ(&#H305XM6-`82T!A+4[!0PLNR1<'W!"
M#JR^_,@VC;YA2TT.69SCUW@7AW%Q$8;'_3%A6TM?']G\^Y!C!&XH@8TKS!<X
MTW&@?A%(=0G0&)5GSA:_[9"@J.1:VX/!($G@00%NWI7!#E=#@[3$)=;+>KQY
MAOA#U,K9H$H2ZOI$*0N-&']S$A68'&!C;4<Q&U3\5#I*R@\TBEQF!NW0`T#!
M;]G!%AP.C+Q:M?DFR%+:IOP&9_PVI(O;O,B"<#A?J".KND1.-LNS==KGI36%
M=+GK29FV]1MV.$YYO1SZ7+]=>>"DM2(Q[7'##G1B==`E'$HE]N9G]<=[S/8-
MY#D[EZMWM=L?3]WZDMRO(O<FL+T*\CB\2*/7<7*DH5@3WR34DC`WH@;%O:0M
M#L`_UF3N`4/>+7_`]S%6C]"S.$4129(@*WV#.\7*I]:9&E[J&VJD&/*XQ`O4
MZ,]$S62XL+@Y3IP;-`+1TT*+84`5<#E%#.RW%1-MTX%S-DBX>0F<VP8XT3<4
M?21C%`,N;_+T#4GB\%%V<(@AM21/CZA!O4C2%@=Y>JS)W'^&O-Q[KICW-&'7
M+Y^0F5CJ$VI,&/*X1(:KC"Q2,QD8LHQ<DJ'/U7^].80"&C:&J5G`M5XHW1\2
M\HCQ1YP]Q"&N0ST[[V+/=JGS%?H7"6\!N[AR]P&'Y"[E)V#@+";EN1A7DI-A
M'4FO0S6T]'D.[.:W0J0"\)8I(@2PKNU'=GG2"RX"=66@-SZ<HN`*X,0QJMSB
MPR<_`DN<#IJUF!NQQ,QEO+@=.](%6Y)ZA_DGS-M'U*6["1[YXXLO019M^FQ,
M@T=G&I^:)\IJ!7@MZ]<6+(1?'UA[A3N0M'3#?#^F@XDX,OU`D4,@WB`"C+BV
M]2O$WZ'RI2=;,/2V'#N4QNQ::C?&A_UDI-0R`04\HG/S$_YTY8UA$&;71401
M_7JQC5]"R8(R26F&%*X05M+4,4U,,P_2*KTS8YE$M`+!0HYM^1@USSU9)JPV
M&3'J89,.6QFW[_+\R$X-:KZ^BBXM-2'MH5A&"@!F=2L@,"W5H(.VA%&\I)!O
M<-B@"OTUZZ:S[L.'2RZ-+$]L+&31X<[0`IO0=8JFP:89J+$[#T/LYP<H,'3(
M,KZ&9;W@F1?Q/BCP]>YM$&>_!LD1-_]HC_X5CW$FL-;!U8IUGOM,:"6$,]FI
M5;B6C:#MSSA@?T8H*-".DJ$'1K>R<TW!"9ECOQF66`QK8)-XMCIAH,:_BU7T
M[!H#1H@X):HP6%X0YL<(?C$$RL*_I8C5TD'3JHOH;\>\8#:\WE4[_(=?PHQH
MJV[0T,[R.J-VS',RG0JY3ZDYMQVW:0F8/]4DZSJ.F8F)E25L.M8=+@S#K^D>
M%[VNB1!A<?;RGGW,0+1N;E,ZP\B7)X<12?C4\CC$">PB0+VNJ3@Y^Z9P(E[@
MI^7Q(*_R2U4NTJAW9E)9M%^G'S`[[#I.[RC!>Y)F]9]LI6(NV9/D0O0H:T.(
M!G)2N%\),,P#;I:)\P,H*LN.,C[LVVK=FP`!"&1!/`%W$Q<*O'$6J'$J>)N6
M\156?[5%^J:^AHRMJ.\>%MC,NY`4-7(Y55<RW\>1>[,/\G0<3EL7PJ@XZ?+@
M2K)@U8ELP`+A"FB1G9/?Z4F)<&6T4!56T],M$L9H!@U:,F=QHL$?E_&I4+@R
M7),*K0N^5+CR93'J*3F>PW+ARHMEJ!"_I'?G.F"M(+K+'5#NZ@&O]_O6#W5U
M<]P&N5)+]W-%YRM?OE$%LO*:YB<0O?K`!HU<(I\!EW[ZT4JV'=J=`NCX!;6U
MUMTO]F3$,VK<`O&MLQO\8WB/HV/"/Y\4]Y@OZ@W2Q]_E]>VN08+B]@*$>H`T
M6'?#]AXE;,TD^A(7]W'*175>W\<XH\'K?N4SL1VZ#WR45&]H_P8<U:=QEJ!E
M2_II?\1E6Y+XLVG_-!W0X2AKK,B7XN6*A?.7GPC_[]FG+$CS'<V&PMT&4UC%
M!8>&%3)"&;42ODC0J34.*VI!6TZ$BOHQ(D>^W(I3HY<TIQ>D^N/,JYA@!AZ9
MM]M`;XJ`Q0#H*/GI=<+@3SQ%N&G@UX(/-9P;+_;/+`='L[2B%>%5PCBK&OK2
M/F'H6!4)0\X*[J^Z5CI*&`JU=@XK%:1.&&?=A/'2/P_5@D?IH8;0FR)@,0"Z
M3!A*G3#X4R>,LS9AO#R%A.$&CA8)0R7"BX1QW)='']!!T<^XN"<12<C=XUN2
MB093!@M"9\D3I):)\L#<?=;O`4Y"4]MB%AFF2=]^C._2>!>'[$;.H)6"CNSL
MHSA%APP?`CX)PN8BRX,V^,9<]FA/(FJ8'2GG)VNB=N[3MX7D<_$M##<0+@,F
M=5W'<9$\IS?$H=\,)A([8OCD84<0]P[)R@X?UW7ZXB`&27JR7*\R]YNO.`OC
M'-^PPPX,,K.07I%Y!_3@`4+8'D>9<ZC+SL/[W-N/11;_W>=#)LRMKW0[%6",
MN=S"QF7>&"N:@1IYW-^@FA!QRJ<''8N(/.+S+.(><%C@Z!/.]D8!=TRNC+==
M<@=^,VZ-LVC;4V7K-AWF;?T72N*=EZXA,+'&,Z2@,&5R"@VW$76@9SHRU/&T
MP@PC?&J8L0JF?38O8^FO)`D*5FH_?@@*LS)6Q6@07X>,SMQ)W$+',7>D=)J/
M#<1LV[_1LX`.2%FM&^*T\++250+$R-.4X+)G7PAB2\1N@48(A!G%\PX(&<^W
M`+T)X7XLP*O`_R'.__XVP_@=N[<7YX5AV%>Q*8*^F`W<'U6M<Q3P)2KMG%$H
M9,N>HAU]S#XZ\^<H8Z>O^1[YE1A1.I\!NFR9%\&8RX@OU3<?8JIHS\''&%#-
MX6FPAT6;1:"7L:\?YE\]-O_\W_6.`_X9_.)K+#TMP(AI&.(U3##.9]0R(,?3
MZ3)P.K6(WNJ.YCWZS%[Z\AG)#`ICW[*!D!VK#SY5?XQZO$R"/%>[DIQV[$$B
M6BC'D;<#S%^$*HS<1,"Y;9XA_M`WOU#85>0.6A@8<?@`_LY6F_(4'27\5=1C
M!Q!30[F`JBU@3B!18N0&0MYMYVESBI17KJ"TL<@9#$!AR..90]`B\!]'G(:/
MQDXAY%`ZQH##@7,(V^3"08:*;)VDS]]SE.:5Q\XBMKW&852`L>!;WW':P\_9
MH2KE8MQ<>/.4#<O0=90L,+YCT"H@YU%K,O`>E0#)=EI/KK*RPL#8A<R18\/H
MDQ-IEX0K2.5.`[X>5=$*<">Q7'DM8I3M,??.&4P6<.H18,+@%>BUQ\*H:!6P
M!S\#0M4.R.\1$CUV\.^<AG(R^#<Y_\``#$8<[B`!_OE`JF0B(@8?"CHDZ+-_
MAVH`X$/W&4#&LWZ8?)<>CO5N:>$M;@:4PQ`IHH3Q!GD;(,.C4(N!*PCXMGYM
M_578<`QTK<$-Z%V9'3P$2E1,LOIP4VY)T9[BX,>E9U"@T,4^,8=7D>_,./*=
M&4>^,V<N<+9(Y#N;&/G.^I'/EU-R%#94@EQL<`-Z5V9W&?G.)D>^,Y/(=^9Q
MY)L""HO(=^9IY#LWCGSGQI'OW)D+G"\2^<XG1K[S?N0[]P_D0QLJ02XVN`&]
M*[.[C'SGDR/?N4GD._<X\DT!A47D._<I\G4VB$\ZJ-&6?Q@ES?EAG,BVO9`1
MU4*W@<<92^LL"3JE4QRMD35VTXG@G"QE68B"1W\KQ8`('6:*#M])'?2X(&)U
MZ<9&CG])R/;P1UM^71)R?0J?;7M=)J%Y!T(:2],G(2]/AK1&EMZEIYT1Z2M$
MG2>AN4=&6LC3):&3.#QR0<3:)B&_SY)4G[G/%\_^DI+;'&</[*Q]/J"CKZE)
M*%?`-C0-%Y^K5^6YUJ=(<L#ZP"..D_Z`CT_0S;2+9K#:NZL3;A]1FZVK721^
MK69T[CO*H.C271?3^A0"[F60A,>$__,#29*W)/L29)&[@*O6!Q]P9?I\";CJ
M_G`T:H%NZR)15Z)]R_[8E7_4%Z?M@N:VLV9L=.[;0<+.?<E%`#9RW\6T^NW$
M+L=U\`U=T8<5XT;)Q=5<UP9UM94?QU!?WP9U-*+/3">JE#Z=.LR;,&`QF`77
M^Q1JL:OA3>7PY==(!7S%U5'A2WP>_6J_ZJIN\Q8)PZW",NX^_5)IC'L785'F
M72X5>>=C'I8]_;8MZV+NBAOTF2E!7,O3J686]E3W-4M/U5,H4_@]N>Y*E)YX
M^/*D$N]+V.S]6F\"9MVJ14)EJ<Q9D.3BGTY\[+N'B]@H<D!72IY$/-3M!'>@
MPD%<A-YD[.!7^S5LL]SE#JEP^S&\Q]$QX8.V[)N=`#?96>W.^5PJ\LX%/1S5
M69\J`*O2;<&"_#O2X.3\U?W8SK-S%T2'KJE74.DYAI6&B@,F:NG;!!2"E(H,
MXHF"OQ<<)*<#^K4>R``)8V<UAH\%GU=NE#</FQ.AC1U*RZMP+04ON)-IVPGO
M;BJ5=HXGE]1=CM<YX]Q;K]/#1>E_IFB;),$OGVQ2M'J?N0&+R@-'+/".)VD5
MY#!7K<[2UX8"MLT##]U)9G*U%ZF!8L/H'"[@0S*=KGEH&0Z9NJ2;SD#)LTWM
MX)#2C4HTK%Z%XK_$Q?UHB)3WQTC]`16_5KW9O/(>2S<DNM&B"/@@6L"='O"W
M.THK,"VTBRT0.K?\46<K)=\[^:S<4/F\GC3U+PI!>H,R<,&[G6-=/CJ?RR0-
MU;S%?4]1"J`O5+Q@EC0?K>P=3:UR-9ONKE*JZC?_A4'O4F`\\?*FGE)^_!,=
M-U^1/'^7ALDQPM&[]$V0I91,NKAW*;V@)9"17@_BLD7_>%,FF;79=?`V:<7V
M\IXV@5T1V_GR_!0BKXU;`<=B>X]>7/MI^+5?%9AI@SUP:S=56J-X@YAJ](PI
M?XYJ]2R&U`WX+8(LYQOK0?VI5'P?<4&[D$_;N2WQ!(K<U'0]13X%>T$/>!7;
M^^U;+)1WU;J-W!U-3RI(BUS+5526N[%[=9XZLV&I]E/ISBF^"PH<+38,&S9T
M#;]F-=F;KX<X*]<*DAUUQ8PM.KQX\1(%:=3^>>;;<M^3]M!E"J6!PJ=2&3G_
MW*?4Y*8V\N[+@[(/_)O36OCSGUBO\$35)_L94.TEKH+H0I\#3\PQ/9V46OS3
MH$RSV^'+T_M$N+YO+U,AG?SGPESRP[@LH.+(2,?,LDBC8Y6X:_2[3>+M@0ZB
M2/2Q"+("OB#2M1(^Y*HU;E\%5%^(45#PO:.W^"Y.V>QLO9FT[(W3C))FKC`[
M/MIXG%--_OF=7:538NU-ZF!61]_*A3V/E3D#W\-I])O70>-N&?1XZ'EGZXXQ
M](U;VN'.9H\K<M7`HI3[F\O.!^PR^%M_\'"]>QNG-`'$0?(NS8OLR.=^;T@2
MAX^RP8`)S["X5_/`A"Z3=D'.0VKT&<06I83N]E&:DAM*U"'UQ-6-$#%V70L@
M67&ZAQ/X[)E6V4PT]6>TI'C:H)(<?:[^Z]\A(`ZPIJO4=+RKA7&VKBEG"YMP
M?IV^^5K03'.,\WO6O.O=:WP[_-AE3%_U@P']+%\S;L\\+S-1(_<O/?>6DY0+
M"7'^G!V[TZ=C_L8HUW4A<^L3:P/9]K=;V``OXS#3-P-!+#JS]PPY>(0<:M('
MG!4Q&Q.DI,`K9WT7,))$8".^]:(O3G$6)!=I=!'MXS2FF8&6_0_XS=<#3O,A
M=`VIZ\BKHY[G0&9M`2B6]9H4;J/AW58$?-E1T"-9V4,,34TL[6'7LRX1`E7_
MFJB9#!`65;L0Z1.ABNII04462/5<OH91X1$[5CQF(17DU!2K=KD/KP;'[)A)
M.-50*SLF90I^K#C=HVBA$&QT^HZI#(-P[,GI.RYQ-2U&>W``S[LT)'O,ZO&W
MM),N24H+\B.MR:\/N%P.GK_".Y+ADNY3\!7G/\<IR>+B\5U*(QG."_KK^E+>
M_.-(7_^,BWM"WSQ0$M$&IA4T5[995/.LJ+%"'\V+/,LV6!Z]EFS'MB2K-YVR
M8(-:C:A5B6ZY3E0*0J4DU!&U094HWJ`-FW'*`I)%<1IDC^6=/!OTGD8X*IT=
MT,[$U\U=-[:NX<QD12]9#_2G$D_L:IF"%$$BKXF7;K<7@:690:S"QBTM)G9Q
M40:8N`P4!5/PF^LO"^@UH;ERH?BQ"`J^5N+BEM6RX?!KE(:J5X`)J`""FU0W
M1&$C$JZ+%6.>;?,H9]\"6J3XX,ARVQ'#CC;K-U^`?,4TT<Z_^!J+1RA*2C&@
M^Y20H!:U`138`P7&X.[QU15Q\Q;5K]%G1K#R1(")765@5X#`@-XWT`NO'3"B
M50,?Y%H!HW8X`;_!M0%J3I4#>'%7@)F-=4Z@N`O`#AA+.P(MPRZ.M+IB59@T
M\,N(>M`?$P%@7J89`NP"V3J4CUAJ>-,7J'GC46B76HZ8];-1MWD$8448EY-)
M80P8O.7:H:%L'+(%3!(X>Q2H%5940%H;G@VLOB:LWP=[;!2=AX12:+>$P.`>
MM@`:WAWY-@!OV(00WR#VWM.X/;*I`N@2^^O)/0.[81P?DRH![RB>CUOA`O23
MXGJ'40E\3R.\P+X:\%M%>@4F5G"`UW$>)H1MP5).*2HIA_`74<*@7]X&(/`+
M%1A@7\#7@;X?WPC4-AQ#7&MP`WJ?`"Z[T]V$5`YQJ`N>35H!L+Q-H\8*ZIV[
MR[W&NN**8@O;FS`X0P#4TC2MCFD`8-]*.YF^I4"?O=GN!@<,Y:=(.<OZL1#G
M-T$<R<)?_^TPXM5O82#>UP6$Z4:H`8@KVE[@0NR1)R`=&&.,2Z&U)#20-K-<
M6&*8C3JRC8W7"3I\'08ZG)SY=)&DI5H_>%2+9E^5RV!D041,-0PF0RH8@(IU
M`P67D7`#G`YXNBFR7IO]K'KYW!/@2NPW!K#2T!I:%^8&WJ"JTF)M>7XJE,_+
MQZ8;7A?!QM1K1K(,!SE^C<O_ODLOPI`<V;D#P2,[<(;M$PC#[$AQ49TK$V/!
M[/<,(6T<G"1DKM_,:/GL*#I-M]+5IHC<UGSH6<WYG-U/5#.CBKO<3U/RHXZ`
MU;UU#OH(#!9`3+L"EJ%+UZE-@`8U2R\-?@\=_`85?G$9A+]I\,H3U41A'N6Q
M:@EK>G<9'.(B2.13^9:,TGPE9P3V:UT+H?.20I^-VTK%R/)/PX`J#O2YYEE_
MWLP6-0I7-42</?M"N'.<0Y1J(0#(<D5YLRN[%0.1!G8!N[DYYVDC:0/='[\%
M[!FG!I4`G])!<8^SIJW\2F[],$;%)$\#0B9H5U2T##S\BW59>9Y(A#3L,^).
M\"_)O7,Z%394#J?'E!WK`LB"GT<R53H79"RTEW@*GCR*S$.VA-FC<'V38?;E
MXC7>X2S#435C1L<=O.V&X=M&B#2<FPD!=D*;ED.'>T/=-IYI)%*6#BKFYNL`
MJ\9*E_8S,5BA3N'B$]`[3]0*&':>6(P;`0UGEGAJY-9331RZA$.7'=C.]F#Y
MF966A+!QUC(5MF(6*_?.BP_FE+QM\L[@[4QG%.J:FRF&0E4^TZ?=U@_\.`Y1
M9@NBZ4!U?T":##PPCJ4;6Z]<4U+9#Y^B_:0Q9D2U>O`0+D8;OQJ$#9`E36,M
M,`'#8`%:A["%F@\KSP0]/P*98LV9$^L`3[<.!)N9J1<3?%AC9FHH32CP8&E9
M?;9.N5RD;M@H)JC)FO@@(YN)1K7VN7%#*ET%3@G3MGU3'66W\>:`.HT-B6E_
M&W:?$YL#1R.%$GOC]Z)4N;[LU$TNC5]R\O5BV<VU\%CMT?,Z6K7/YT%U*!\"
MF1V9"B`V5!1W<<&N/3H<;Y,X1&1'AZUQ>K<R_D8]3Z2=)OOY,*8!V[S3$VA@
M&1X3;JX].0#:Q"`RE^^^7\W'.PN`+M+H8T'"O]^3)*+.5)X8.$"!*7GU2_7D
ML]!HVAJ`XT(-5,G!JV7>?F+:NXL4-KW[?`Y9-6N&<L;,)R+SCIC?H6<1WL5A
M7#Q'F(M<URV,84)L36EI%*?P@HJ!1GJFHXL?^MK2</"\>9(@D41:$S9O`[!D
MW:,MFV%`!EI[9MLZ@`+/0N5T5VJ7/%Y]*Z%:OAAM(@1MF1<!XE*AW'#MHX48
M26CW9JFM>WQ-C/I>+'3L-/*R_*0LC_,#@G%$;PB@7&:@$;:,;H4;^4%-7I7*
M]0?X3LGL#<Z'AA(A6FQ,.1FP21W$NZYD&XL.8M@&5<]/T9SZ4-0A]"CHZ(M,
M":$T",'G;TD+8$O'L1(;*+?EX>4X/*V\[<#`E@I@F]9R2UG?7?RRK]#&C,)X
MYF-%-@,)QJ'.MSKK;1!GOP;)$;='&LG#GH)X'/J$Q%`.H&@);%TF5F3D"2+6
M\=0F"@JTHY3H@9%ZXPLJ4XO\00\-,Q:'`'$0)65:IN*#1<NW<1JD85Q=^/F>
MI+OF02^0,G;$^3NGL3TE_.ACJH3)T[BJ+RL-F(SB+'S!8=`RV-)3K7"J?PEG
M+/TI14WL;^@\IB7JVNA9)BC;E[%J(5M])/:QP'6`KTE!VH\BF`1I?02(9+91
M3E&'81'%/*^1ZX0(L$+I"H<0T&_9P_H0FDTS]7@@&;M_:&6L*RQ&#+I8WUG0
MQ@6+?Q+15K8M+T2EC^LSLGR9?IQH5EEP$E.N&(G2NT\XV[_&MP7?_M5&REQ6
M-%JP-+'*A&4FOLU;-1?N1II4Z#<0L&44B,>[BSU.H[T'GF!A=S+%+A.Z>57'
M*:KF?:+*!'<9J4@ZCC$FF>T(,JWS@2^0K`;ZB&'+GKY@CQ%[OD'LC1?W%"GM
M14SZUZ"[O`&L\#XB-9$$M"!W$*DUPP+7X-XA"8L$O%[<-:2QG13`BON%#"V]
M?+G2+:,DY8F(9%".]$E`R@^15I#!DU"\OL;H,0R&3TF-Y?5Q*S78J(Y0F%5%
M"&Y<N,&31+:=;07#I_>TR_T804VUKW0,)29=+2K]'*?Q_K@7;M$2OJM^SN#=
M+(P*]0!$GJ%<.2S[E-OJSW6Q)^Y]HNPTU<^',Q%4_!@+-;00BQC5`T^V<-D8
M2Q(:1C2KQ83WN+@,\ON;C#S$$8Y>/?Z2X^A=>DG2(DZ/<7I7'1M'TN&P<0)G
MU0=6G+.@/*&-\V!NIU#N`C9RMI08,6I4DZ/;1_2,<:`X?8Y:)M1RK>M"4[!#
M9AAUNHV6@I_EKGKUXAQ;O2`X9(&:(3%N3O6+NJ?ZA0R@;+D&_P?;R/(0)+3H
M^T:0*$D$EA)\2Q/50IST[B(LXH=R$=_DS&$I3)U,C(6Y<'#+7^(DY9BWP=K[
M347K$E,C![6"-B>4KFP!JXL;TQP`1N2*;K!$ZK-IBBM_J!,D3X"'CD?L&C\(
M&@&_`7YJ[K00>J+I5/+!&U8H2'H%^F@.^\O63+=&']Z!5`"F7V]6Z@%C'"A`
M*1<(/"$/`CWZ#;!)KEV)WQ?$'&F7D"]Y>7OI4TO:KGW#21+W8I6LY">4)_0!
MC8TMA:F3M[$P%R''\I<X2=;F;;".+*:B=<FYD7.B8V-;P.JBS30'@!&YHALL
M,3:V:8HK?^B-C8^E$]#_JWW`\Q2[$MCM4JJ%T!--I7;CXHE"05*KVZI^XB];
M,]7.&1?;J@!,O;Z/BZ=B'"A`31D7GZ('+3$NGM(DUZXD&A<_M:3MVC><)'&?
MQ\7M/90`XV)+8>KD;2S,1<BQ_"5.DK5Y&ZPCBZEH77+NW!)\DN-B6\#JHLTT
M!X`1N:(;+#$NMFF**W_HC8N?'6LOZ-Q8[W>270GN=DG50NB))E.[D?%$H2#)
MU6U=/_&7K9ELYXR,;54`)E_?1\93,0X4H*:,C$_1@Y88&4]IDFM7$HV,GUK2
M=NT;3I*X+R/C\M:V*Y(+!KKC=VUJ[;Z;Z]]C/;,374^DTLDZE#SME'^C9^S)
M<W11%%E\>RS8GDE4$'03K+]!5&P9HNQ05?_`F0]Z-#20;&C'>JR2T'^?CJ7D
M4:9/`VBM,]B<.)!L:JVSD[36F5DO^!':+QZ".&$A[!.Y)/L]2;N7BKP*\CA4
M!7]S;E%Z,.&&P[1Y6Z$Q;Z39T"<,9/GH,Q9`$7N5-=(FRE@2;U`;UZ>H!8-;
MG5('Q5'-QRJCDA-U63>(,W];"#7)XV92%D6I72U@4;D9ZH:#JI_UQ!+(,ZA)
MS*2<2M4BGTZ>(V5:%0,WW36G[<M7-:;SPI-D;M\?]VS&A&0GY<K*&2D`:,Z4
MM09`5RJ#S"=;)TJ=7A;Y]&5B57##5$R>3*A^N0A#<F3SO7<W&4GI/T/,SB+.
M;T@2AX_E_W["7XM7M!E_'R6N:>Q-QK)EGQD)IK46)$=9JU8YOZ6P[0<<LG/T
M6R[49UO;GR>BB,RU[$P;+8I&N(0T02\<&,L4]$6.Q0TJ.=#GZK^,%7'>U?/.
MTCB59AI[,6NFF#^SX/CX.GZ(\YBDU[M/P5?^45%XH*8Q?9M$=/1S_=2L/3!I
M0JM+Z8H:;NYY)<WJKF1H9&)M!]L>=8L.P+!MH&@&..K`7%*AF@R1':H)/3E'
MU`5XY)%6S[=>:*61OUZ]40X]WGP]X#0?0E5+5X=2.=T\)]'IG^D:"O$*AY!R
M;;NOFK%R]?;YRMC7FI(8][II)[JQ/>S:"Z66"2!@T;"\3Y>PNVG8X9P<!?C)
MH$`6\53T_D4ZV8RZ*;TN\D%-0IJV!Z*(--`UP2/:.>[K4_((Q>R?)4:,N=PB
M!:R@-%(T`RB\H%1E4G\FE!V`QS:\^C$=3`I<W[@AC:QRDB:8BDAF>H5<ZUPW
M$$I6X5[`L+TDZ0/.BIA]16$4[2&!:T-;82YBTKT&O;4:7INUZY43#=>$2]]7
M/TKP?A9,I?H`2ER1;#E*Q]1U.=N$XRIQKSSY+S<1T?:JKG]@;0F5>,6"+4S)
M$FN[H^S-R9I1DB*%=/Z$&$E>U-+)0@Y0AM3J!QA9J'18X+<SDA@%HS]Z!F-Y
MSC0UN);:C=F=12O#X8&*3Q"]O!D+0"#`-+!Y4?,WK9+NK%-0#(,:V#8MA4[(
M0&:X[4Y$OV7_V]N@NOK1*2I#C5&KV72WB$W!HY3Q#CPQ1R<R]=;(G:9==7%(
MN5%OA0C$6G(99-GCCF1?@BR2!B(IX3`>"0AA("QM`61T$BDQ0/28;?O^^BI'
M.4DB3X`L-^`8SSICZ\D=F1P\>(DU3+%X/Y3Q3-5[_Q1@H(MN0@8/@]Q5G.)W
M!=Z;1[L1AS;L=3@<.<.H34X#85?;%/]H^?EZ^'92C.W"\F8NQ<#P!GXB0XL%
MGVO,N(^D?56S(*.+K>@S(T6<UI?!+#"2K$-OC]/#&/RI>VF]-O[VJ+6QMZ)V
MY$.]MKCRGEK)%+\I>34>PXF\=9:^O0T<10000Y[UG".["]+XGWP>XY*D=+`0
M1_R/BS2ZH>#$:<'_O-Y5GS:#Y"-]4BX[ETV*0\JL'0U&YCQWA/Q=,YT6J"D*
MUP;1L.V*X?=9LUUP.5M>W!6R<@@`Q2MQ`A<7UC_-H/,ZSD-:KQ\S+-N?Z$H\
M1"@2BE\O*BE^+<1(#KYIC@*62-G3CUTJK,.$,;TWN5+BE4^!C71=M&LYE^)C
MZ(Y,?AAR*Y7[6%<N<[5&,FI%HU8V'43XLE'T]%Q1-J!WH&:]6H,M6[\(P^R(
MHZLXN(V3\K#;8\:.2!U6#D;$=1V@(9X7@8Q:`I&C=8H4X4'-6NX86-DGS0Q*
M[+K=J@,=P@`LK>BU3$4!#_E\YTA%@CHT-/Z75$\))+*@JF5:.43F.2Z485%$
MT`N%?0(`W(LT@H6\@7`=P'OD_H0VH5&(OANU'0)L/MA0-9)L8[U.2.*/O8I"
MMO941ILAH0\1YCWM`5V0&=.,XTR7!@JK8[VPT:8GWPBR'8X*LP%_[@U4!:82
MH55J424EO%T=A*&!<$NSCH-1^^YTC:R/2GW:=0.3Z8$:9L3=4.7J>`6SE@!`
M?-HA&QK6"O`>G[=A:&EB9P^K[G6(#]!;I@Q4305*$QN?$AA4H='/4SAN@CAZ
ME_Y7G-+_I6#`^;!RDQ-4/U%$,`O?<HWS8IY0KAR^`O(M>_8B3E^PIZA^O"Z`
M%?8A^A[5=A"P)4&CDT2\C4FK`RWXE;+Q"=M3$GC$A"L&FT?^&>%Z]QK?%N_R
M_!C0?K@D>3%<*&U`V80?!>5,]&K;``)BE185EN5\U;D`P9Z=)XH.%`3L&/#K
MKSN216C'/^O@M5&NMR^Q,(1YE[J"!-3@4Z=B$B)8F*M?L^^NC`#5%(B3/`T\
M2..@DL.#@-B<+:..AF*R42@<D@&!7JP="N\CZ290'S#U4-Z\\POA$AL*X*VT
MMH[8B<T-H]Q/I=53?!<4.#))?@(U]N9O;AKF*8]FNRK9,0B$3P$"VO`V)O<@
MMO%[,LRJ/3GI*,:)2($P+V\%5*P3:C`!O("Q%_/X>T]3N\*X`N1KH6#"X`P0
MS@*A1-4T;(P#(MGM<.9=/)R+#&U<%+.L'AL_D8OP'\<XPS<9FQLL'F^HD8N+
M-'I#GQ[VX^^H]HR#N&G"".(TYBV$B:E&^O1>9""FC;=T4%U1HYI\@SC#AB]W
M;7C\\#,+T(R\SAIP]NP+P<Y1Y#94#(%`%M4Y31[7"ZD/%2V''?Z68*<)_68"
MUDL$5!;.,ASQ!,5NI(AP&N6T?>7G].AOQ[S@/V28"*P9ZT1@P3C/(ZU;.#,1
MV.A3N*&YF&U#6Y7=#35WPVKE1\NPLCO:(X9,M^5DTRR$.=@/479J(<#'<L!K
MC/<4>U%%AGY`MSC%NYAOJ`GYZ=7YZGO8EH&=+`M8"?`D"]P$V77&]]Q$OP;)
M$=_@[.-]D`T1;\<DC/YR)D`OU+4,W/\4"DT]3RJB$_)S1KBA(^L,/3`:]"Q.
M4422),AR1$L-E#..E=<Z68)$XGF&X+)C70!B8-_DS+7-11C_4M<O*^B0DF*,
M9.4>R0AQ>D09$.=XR@`S"NLJYB5`=F8#,IJ3;\G\6,:5SL;:&9O+J,,7'T7V
M@MLW&-%:8TXTBB<U!&]/?G$L[DD6_Q-'RMI!1BRL&<;$@#XF:PEXC2!09.I-
M(]9Q31`T+WWR%:F9)3ZB@849BT-PN,GN0BU3L2',YB41NGB2(#'*V"(FET!Q
MF:&%RB;CA6;D]J\RW^:"S/RD$&.2<D5,7J5:]FW1*,WV"14IMB8$=XQ^"QRE
MUD:)G2M4;..4&O,7_N%^8$XEYH6FUY,[`H#+]-G1,,7^JK3Y[LD`P2)5M@Q>
M!;WK8Y$701K%Z9U!Y!-0*\)?CQK<!01M<10(^YKLO*'+.PZ)I'WKGSN(C*WT
M"3DZ#'E<8L1EK!RJF0P15=2\?JI8L0BB`RY/(BF?05)&SQZ%,&)6%(`>T-/I
M8-14RS<%>TD_CH'_\OV//_[XLOT(TYU[02]_W-"W[/^KD=2_5V4D^K$96K68
M0$&!7N,0[V]QALY?;A`UWSG_D/_G8XK1^8_\R;_ZY#Y]9$A<1@0?!1TTB-R$
MSE:T%8*$(?+7$CC^%9;FYC6*@@WEFI&/+42NKT>OO\(K#B>SX&@CHYYC+LA-
MVP134QIH4WJ!EG];$357MO*P1_CZI>H@%R^.)K)!`YE@+ON.=PTDP.AII&H6
MCJKHRI%4T747POET'ILK),D#L0FG<S19381K+J\WU3</4F?U9O;#MQVBY+/D
M)IP^9WS)/3,3.,TK`*`[8R:TT7D8-[K_Q4;.,*1W%S=7M%5L]][SY->Y3$?;
M!/ZUO?%=FA\SMA%.['*CUWV_ZKR&<)Z1-KB:N2M:ZPLM<0/XN'[D!;#'9AFB
M5V8X&1&H^8`KU;Y<<^MU:]!WIVH_=179(ULQEI`0XRA_2W_C)5LC>$LRIFN\
M44E#UT07*=U,G&KT@\0;N0X5=&5<_`+;0_4:,12A/$A6A['.D,2XSTU[SXWE
MX4*52L$$PY?!JVOVWNO3M[\TL"GHO8AP]=$![]*XB(/DYGB;Q.%U=9:"(N(9
M\0DBH(8/S"^,V@<<(74ZS1Q'+67[IXQ=2=N/H<<TPMF7+"X*G*(#9VC.P_#'
MM\P@(_0U&[19<R^#.1>Q6:\0`'+CV-T<PE/1HY(!77\SD#,(]UK^A6`'O438
M1B\$^LZ&Z(MK])$="LE^3])J4T^<TO\K`3F(@1N4TKJ3TGMU2-`2.)5-KEKP
M>U6F7.\NN<GY=U^#\D1(KRA+!O3@/BIL#WQ"&*JQ<\0^MRSX4W<JR<KE!OXY
MD]CV2B=2P<68RRUH@,]W,-$V`SWCXD$6OI\>?BR*A!&?9T'WBJ1WGW"V9X<,
M&T5=$8,R[/89'+B0J$4N`N]`CZWO]-@5H9?1O:#>O>='7OOH/$((:+Q'`1MS
M-L?@62``C]3-09$Z!',()218_3`=%Q"RBL!#1L]"<'_)8WFG-7V`Z4OS8MA4
MB#)4ZX4X\$#3EKL(Z0:Z;1U4*U(1^@?K?.O[YRMV?ZMQ8_!I/-P2Q/-$K0#E
M!1*,41.@,:U.1(?A#H@3F;)9#M=6V<Q$F!<9[CTI<'X3/`:WR7C9CII,D*7Z
M9&#.*](.[)P#%6;.UV,:.%=Y3F(1TU?H-HNC.XQ21NZ/"PEM*G02A?5UQ$XP
MX.)CSDB^/03&$9:_1=7K4[>\00`<DJ\9XL2G,K_'@AD4+6D;ZA2D<Z&N;05,
MR%.I46)>SKB]$1X3WA0101@>]\>$GS(885IJA'%0GS#^+V?_\WSSXT]G[/M1
MLS.2/OS#YN7Y[ZN'JV^.-$`(L;&DA4V<H0HPB*IU3`-5%4R[EQ_T[S[8($KU
M5(`ACZU*EM7BZP=J4'SQ-1ZNRAP]KWY.Y_DL0(_DS\-N5YP<IBW5EO\3?69_
M_)]UL3?N:2+M)-EO7A<^/_,M\2(`]=]T(52_F0^BO@X`&#4"-4"JZ&HHO2;[
M($Y]`-.@UXFBN^2_?CU(85Y?W`0T7)9].D26E*`&F(!@'LZD&F?"3217@;HQ
M^;9ZAOA#7T`H-Q#1=ZFVA[Q`YJ<L2/,@9,6O*'OJ*058'5&"@5;2!CCTCA68
MP7C(-\!SY[4?N=K`KD*(JT%@0.\;Z+6164JK!CYXO):VPPGX+:/XF%/E`-X%
M=[F-=4Y@&/+UP%C=$>I-SVS6K/,X_TM<W'=9S%S%5IK:F<REN7`WV]\","LV
MOR76?FLL>_L6XQS%Z0.)0^K?MX^HN,<HJ]S]P&B\]&QK2.I\?R+&@62NB72H
MF3J(9C@#.IOODR:Q37M(!/^NTA6$OE!)J,?ZFT.(X0.-!M^2ZE6<XG<%WAN.
MJT;DZK38(7<1#4:M<9?8NJJL';IE;OR59R%4=-#BI0>.[:US,1E"3)F<XL1Q
M6NCKF0X396!'GQD=XH1^CE!F@,8N\/;8?(NLN>0T+5-R=63-@<[-,FV-$W_)
MC4[(TC++?<7/H#HVM<X_9.`P9?+.-UX]=M^8S^LJ&#7^(F)TXCGR%KKQ(:$^
M>V\2B!E^\O!W6E@%"ZUO:2%ES^Z=O[V.\S`A^3'#G_#7XE4RWGXQ@5/C<4).
M)RZG:*.[$8%$J[WGB>2<7$I3P43K@7J,3>!?"FF.QQ12E2!`4XXT<M1RH,^,
M!W$F3W,`-`3MQB(R"2NF@AS3WKR_2*/7^`$GA*^"J^:J1L'?@+8)]TK:F6YG
MT`Z0D*[6H_(M%>>V?LW7748MP=H>8V)>8F4%F_YTAPFXX*M3,A$298#M@*)#
M4L_0/QUP2$.FAL?/("E>;6G.81(P859GFK?)=?`T6=)IP'^*@52Z&-0:,19\
MKG&S2(#MJ)H%&Y-@BSZ7M*L7L6Z0-"4"MYR>Q>%W*=\IEX\G!XVHE?&W0^W`
MAT9M<>$]726V?M/RRCTF3E%%Y*.OC,VM\1,9/@QY7*($]``%$UV3X<)"['MJ
MJB"_1YDD1Y=;&JM%$4\+.E;AM<>U6FC]&"3X>L>/4+@D:1Y'..,[23_@$,</
M.+I..[,8`_!.XJUZQI)WEGM-:B>`J]GJE;N=G:3AJ22:0V2;T[;9J211G(?D
MF!;EY4'L0,,XS_EL7WN-ET]'F$S#()D%C3E&7@[(4+6YO5(@'+-DPA@81JL;
M8'M,J.9"]-\=OF\'D))\8RW#A^SS/MC3?^IVMI@SC/.,E`'*)S4M`G-#N1XC
MSY.Q]YW-DVTN%@87^9`92,S9UO.4$*=!%I-?TOR`PW@7XTCL(#JZVB_D=//<
M0:=_IA<HQ"O`+^7:UJ\VJ//2%^QK;4F,N]VT%U<$^#V.CLP#+\(P.^+H*@YN
MXX16I3C_Q(X_DBU-L6=L7,"<<:9/V+808O!AHU3E.L9BMC5M=4(1HT9)2[ZV
M,UG#A$PWX&13+`0TL,&!G48(G/%A00=I%3WJ,*#/G`5YLRAE&?#)A@-6`GQ(
M`&D11W%R+.A@Y2,.CQEOZINO87*,<,3V45V2_>%8\$'-]>Y-D*5Q>I??X.SC
M?9#A3X*C-]T('R<2$.%0,0#PEX)%"9@V&<41"%7]2-.1B%J1J)99WP392&5,
MM5Q$!2,NN8I._H0D2(\0A2UXCW.CX@F$/GV-#*P`/`3"ET+`OQBV-H=KW!(Q
M45SKDV.1%T$:L4\"!U+@E'UN2!Y1$ROS-E86]T&![@/Z\!;C%.%>Z&0',81!
M$K*33:OPR670]^Q;1<)O"J5A-.=A]!:'P3''J"`H(B@GZ`LY)A%]C`+:@A>U
M]J<29HTJ1#?>[4Z-9S[N8%@$V;(E77PTS`(M?KP<FIV0@^J'>H"*/*B+ANU[
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MQ.%&CZM0"E_'N?G]L.,:\#8N&%O%,[)\=%.%T[`CK]YWT1QW6Y"2%I&#!\>'
MN/<;=T'4=#CU;3BJ@R&9@P:NX*>C89V;2LC+$>#)^K1^%`FOSX,BR>Q,,_4X
M<H*,47%C)0,H'DYH-U2DLU-M$L-L)/:BD_SPIPT[.']P`J!?8[`IR!.$DND`
MGB7)`_?_>$^RXA/.]J_Q;:'V<CGIR)E%I$`^*V\%E&L*-9AXH("QYVC\_0LZ
M9-DC1N&;+RGL*W`9+1I,&'QP`#8R>O5XF02Y9K942CF&_Y@2"OVR-H"!7Z#`
M"/LCOC[T^?B39A-.X!WRI985`5\#`P/Z]6"/[]BI!'_"Y"X+#O=Q&"3B#68Z
MNAKR<KIY@-?IGPEWA7@%V*5<V^XS7_:5:4U(C'O;M//6P[5P+#8$M9*H1K2$
M:!Z<E9IG8EDF6P%D,<M6-BNQ,I#59B-FG6S49PZ,#'JLCT*%K;6[A_B4D\/C
MB>13MKML-D=*[%GLNL@R=D$TB[1T[-C2W`2/[-G%ER"+^/]\HNV[2"-VUSW;
MT"Y.YPY5*./F7!4.'!+F5[N(V;-;9AL#9BK<OOG',2X>$2?QI>IQB71-R`'U
M)Y>*/`MUU_RK)&WG.VK6E*UE9@W.;T@2A\.;7&=(4`8JC00'<<BHS<YJ!IUV
MVU"BEK?E8^`7KTZBLC0#DR86V"!RAIRE<0GVQ7>B:E!8\J^TT@^Q)2M?=]LP
M(\Z-2G;TN?JO/U]A5\*S5:VME;1N=KK)XI&[C%]T<TGU8KXK]C0`^%<M3^,T
M)5GI"8C_X0&*^[U-Y/TD_=E`]H`?O[=B30S#@Q0?G^^".$,/07+$Z%F<HH@D
M29!U-KX\/P6SJ4)%0[!B!.A\HKJ27(NL)FHB@YAH)BI5FD'P*5&@0JJ097M)
MT@><%3%;II22`J-=G`9I&*=W:\-4:3UBUM=&O>;`UG#UEU2ZK:G+*FKP8?O*
ME^N)YYE;&JUDQ"Y,?F9C<NISM\3>Q;D2:\N??;=E#T[:PF>6O>1';N(3.^,;
M<Y4THLS4TL`A=Z@7,%)U1!N"M>$8QJ@-8J^\N-!6;34Q@"7&55+Z`UW)1PHE
ME0R^0)\*E+J!(6PT82_FD<'8D\EWM07E4%9.@9L9?$$XQW=IO(O#("TN0GZ/
M`JUJ^?P%.VM1MEO,BJD&NR'3/.Q;M0QBE&&J4.$>9B*Z1TET6%#+4\[EK7YL
MK1TXR#3333+"`M`"&]28:YN++#[H40"J/)[6FWEAI_"2#9*,F=<+Y$50L.^C
M5U1%\N=C%N=1S%?K"V_]-*2N0[>.>IYCF;4%(EAK-2E\2<.[Y00K^X:A58EE
MU]MUHDLP@(57`S63L5!.<U,2_L&-$Z$NE2=7=D*C118[]5SK!DVVS(0O:*^6
MMXOF(G1TW4`IIIOO%2K]`-X@$:_Q`B'7MMP8T5[,X\/$A-:$Q+BW33MO?5R7
MJ]K8)VN2LA56*FRK:(?X%M/"8%S5#B"<2U088%W(62\>;!_[!7FE9<>P-P""
M$<?Z\._NZU!!7T8WA/V8#@;R,OU`<!>(-X#ZB&NP,\@GA$L-.$:WQM9:ZO51
M?27[F"\E&.+X"NK#KE0CU&AM*-P`MRWYMGGF"4S'AAGC4V8\.1FP"4''6&/)
M-A9L1E+\&FZ/OL1/,JAJ@#0B7#_,7.\N@_S^;4*^Y!>W>9$%82$+.`K28>@1
MDL(@6-$*("2+-1@@6L38(IL/E1@!XA2>8%MEU#'*]1`P8?`!]6_+Q5U!<D/R
MF*_OU:)?RS+V`@4+E#=H6P7F%2I-1MXA%[!]%5!V?LP8QJO?W6YC<I&/F`+%
MAG%]GZEO9U4-L40T0Z_HT\"X@4@O$.X'H@V`WN-H;O+U:R@E--08RPI[*BG7
M1ZOP8!SARR$^08Z_$6H"0J3!(3=]TFYU[<4Q-F([C.&G.*Q&;:TE`==>V%%.
MD(U`)R-H@#<FF`D^F4:C\3HI@D0U7A<(5R%Q1+[]Q#3T;CKY'7H6X5T<QL5S
MA#G5V@"5VHSH>UG;7\#6A1O*"R7;&+?9^],8MMYQ7Q19?'LL^"&P!6%',WHP
M83/%RM+QO8C0H[`D'=_H"*5A"FPLHVL!R#2C0HD-PKL#>U4`^Z-OV%:-7`PA
MH"=W!`1W$:ZG80H.+",>'054C*O78!``,0Z&70:/@N)[4F#CP"@BE@;'/C&P
M7XA:`NT9`QTVOM%C%7J';]@7FE:!?P44S%@\\X'7<1XF)#\JKNJVY5-ZAI#/
M@9,HVN>DJ)#KM/4?D923<245+#1>I4>4-?<RN')7HZ@4`L!*6L$P>M0R^+0]
M8`'4&9<V"G[/HCQ_^O&0Q$5YUD$>D_0#.^+FI5&PU[,K8[Z*W8&+ZEOK+`,H
M5=MZK$)8=<Q*SEZBL'F+,O;:1P\U0)#&48TQ.%7(HDATFS,T>N&`J,P@FVIY
M..?<H)87??@686J55M1BULTN[_+\B"-AYAB\ZF:%YM5\/QMH`?"@5J+&-VK"
M*@"7?WJ`Y&''$U6'*7Z_#\AZ?<S8]DM^#1D_;"M_C[_P5^/5!S9,8S0JF:!P
M:M`RJ'K$1*$1P%4BMN^/;&,7O]63OT*Q7UY@`@61?YA#R(YU`2"!EA-FVN;B
MZ*^#((I*VNKNR$UY[62^092AI%A];9A+@*F*`R/F]0+W\3;'_SBR74(/?&^0
M9%)=0U8'9RG9/"_2:)_I-7+I"B^1,6W;-ZA\M3+P=98CIKULV&G>0%DZ(ZZC
MDX`9;&92IQ^BGE#H,`=U[W@;KU&MFC@T-+>6VHW1P7*_4L$$F_,,/[2Z3W/)
M`!"0Y6T5_:KQ+8[B('O\&#2W_8D6=>OH.O%-0C<;ZDK]\X$N$Z^&N9AKRQYX
M=AJ"UH+$N+--^VY%6!\."5\2'"3UGJ-WZ8YD^T"UO<>.JX&\(==,![!JVUQW
M,%6F<@XS&=LN8;LE#G5H_5DG90D0,M%ZTXRQ!+Y@[Q.PT#D;:&7IT8$:OSMP
MQZ`6M]1/&U_2TL28>[6(_@GO#R2C2:9:0AB&&6:-^T0^X(B^8__^E=TN<1']
M[9@7[,<,<#Y#0M5;DR3,\LH9;9Z7`:8IECOI%'G;AJGZA+A!#1];1-MR(LY*
M7S?,Z_KQ'*@1`-O/-^72J`7-*U/U@\*7Y9L6KG0H$*>TV3@O$/VS^DJ2'V__
MAL."@7D?I!&+G8\H:R1^FR"6)*F)DGQ)6)=!ECW&Z=W%GITEV]T/\(F4NP'4
MZ<J<7YRL3/@AG=Z\O?`.;Z3;V-D-I/6N"SI0$.&,>G&YJ]$K)[9`D<R%K8$X
M6<JR<(2:,YVF&!"-+/&,*Z>:#Y6,&R\W8:Z!5K-T8R;'EV1#6W2=\5WQ$4^)
M-SCCWX?5*4;')4XL<BY(_]6U#3Z)*#0:.ZM4ABIA;-`A\/FF1%O4R%S3$&Z6
MO$N`SE&J4*J;C3EQ6J#4B&2HI"^'T6RY3;G4YFGCS"SPJ[A]"??EVI^+8W%/
MLOB?.%*'>1FU.+R/J2$]3-86^'`NT&3L4B->=?@.&D*O'$AJ=YGC:(!BR.,2
M+HX"L5#-9+2(`V])A2Z>*%;,@JN(RZ^@6BZT-`FH?4I5,*TIX3VCWP970;31
M8ND2%9\Z>/JP<-S$OFI'$(+!@-X5))P&RHZ*28A0!D@?MM-`X<$F*+8<?@7$
MZV.1%T$:Q>F=2504D*M"8X\<WAD$K7$5)/NJ+/VBRZP.EZ2E]-!'1-97.XH<
M+Z9,3E'C-(X.]4P'C3*B7C]=R-@$V`';>E&6*KC>7609-35?@R-8?:NDJ>.I
MF&:>.ZCTSO0`B6@%Z(4<6WZ!--FAS@M^"=][DKX(.L\^T7_F`;^&SH^[FM1&
M)48V,.G2U9#]2TZ;\R8OXGU0C/;IBE]6OV?X<A:(Q9H`\OY(L!R[`](M_9MA
MMGFR+A(EMB#J'E3V!:#%H'*N0*JIP5@^'9IL4UZ5_(@^5__U9A.+G3DE.7-,
MM%H<^0L/XX7P5F/AN^J'#-[-@J10#T`,&<J5([)/N:W^7#ERB+N?*'M-]?OA
M;`05-<9"#4W$8D;UP)/;?VV,)8D*(QI`@YW9&(R.B&^)L6-QV:9V.VOL=D+F
M.C/KA+5C>'Z11A_BN_LB[Q^4)]F09<G5C_MZ+@CPFK8-)`H9*-.B7"NC22U\
M&%62CH]_]&1'EBU"ANYC"2U+WO7<#;-VX>B"QLG@#I?'\USO7L?)D3[5S>1.
MY*[=SY9[GAM.:RM$Z6:M6>&;EK*VKW%*]G'*\(-V]/^CDA*EN$#/*`SSYRA.
M0[+'[;(QOIBLW'BP\@JRJ?@B,XT^SWQ+PA2L>IV@%@REO`*N6%#%@]J3PL;3
MT1M4B?JVX"FKM>VE^)9O>",[;7P5Y'%(LV;U&\S2CJ$0=?;1"G'AW88M=^+B
M>MW6?JX3:>OLG)\7F3Z[O2G\=-YO!^-YHE8`,^@&SAE-@$8U2V(CH'I?2BT$
M6KO,92!L#>`"SSM-;P0X=,_&XX3;!LK=$0,;,+0#A6\:T9*)M,G"O"S)NG6C
M;.IM(KM!&29F=^;ZJM8ZSE42U=,<72BLZ^#^^JT2,$8>:P"YJ4(6!9[C@;U:
M+QSNI@_M_9DY7ARO$ZHEF9AE,;M<A215#PC=LQ:Z+X(*NM5Y+)W5M"M?V;H"
M.NTK'YF8F35/CL/O[\C##Q&.RW*'_F-8Y=!'?[W8XS1BZ]Q>XSS,8GX"S`#P
M*I+J9XI)9CF82NN\L"^1+/<.(<.V>8HZC]<%O-)2Q*1G#3IJ:6"^38+AMS7A
MNR$4RW<P&.SJ`0)?)=(`=9RR`S?VMR<XZ_7_&&`"\P@I%H+4Y3%CAXR\C?,P
M2/X;!]D;.LH,BJ'M=635+Y&3S<*<3OL\^"FDRY$H9=I6;U#Y"K%WZ`V;XJ-O
MUX6HUHC$M,,-^V\A#+\FX7'?M*"\MN0M?39<&JZEJWZ6@FX6C+7ZY^%8)5X.
M9#G7MGY50[E\B?C;=9&LMR0Q[G33/EP%S,R=]%`>40F!W*$"A/%(-R2(N\)-
M(=SRC`#,8[%W\!U;3P)>F9DUM`L#MW0:<1FAI!F`=D`#`EFA7AC`#D7KX=KG
M:,%:A5D_:@:UQ49`51E62;DP2-F6-@DVNZ\&D"Q?@2"QJP4&@)5$/>XX80LW
M]J<?&.OU_`A:`KN("!8"TINT8*<W4K59D+Q+(_SUO_#CP.)*FNHG2&AF84RI
M=Q[89*+EJ!-S;,O'J'J.^`M$WZR+1+7%B%$'F_37LB`E^SU)RUN>-0NTS1GZ
M\%4R0&#9H$4@P%;KT:)<Q=Y`GA.5%SCY=W:"!0*&[F".&G.V91VEG,CX@`\D
M*ZAZ=CKC:.1E0MIW#@DIA%LH6P'B$#(-6E<0,S9.4$V2->]12>`%^-6V'<+>
M!`DF#(M"_6V<X.R25MYW)!.7+4**'K`'%`!X%NJ$@/%0L`Z]??H:M/PIJA_[
M`%6QD8A!K^H[:5$\WAQODSA\FY!@N%Y,^KZ'Q=Y[`"0*]$'@L"]6A\(N=8W!
M\AGB#WU`H,@P1-N7NJY9%'L?\%W,UABDQ?M@/P2%BJ2'P"$)``C%6B%P.)*L
M@^*`H49C^QBQYSX`4F(J8M*U!CVU*#)_)<DQ+8*L#,WB2E1"T\/FB`8`G!*]
M$.@<B];!<\A1X[-Y7N9N+\I+F<&(4?^:=->B&/T+3I+_2LF7]",.<I+BB!\P
M.CQ.QXBVAUDI+0!V->V`P+!<A0[+,LX:T^S]B[\S`E13E(?9KKQ.V\S$Q,H2
M-AU;XJ+;!U?T7_1A_8C^SVV08_KD_P=02P,$%`````@`5H(.10A91OHK.@``
MTAD$`!4`'`!A9W)X+3(P,30P-C,P7W!R92YX;6Q55`D``Z09[5.D&>U3=7@+
M``$$)0X```0Y`0``[7U;=^,VEN[[66O^@T_FN5)E5T\ZE=4]L^1+93SMLKS*
ME4Z?IRQ:@F1,*$+AQ57*KS\`15*\X+(!@@)(ZZ';%7$#^X(/&[>-C;_]U[=-
M>/:"X@23Z._?G7__[KLS%"W($D?KOW^7)6^"9('Q=__UG__V?_[V?]^\.;N*
M49"BY=G3[NP3BF,<AF=7)-Z2.$AI!6=OWI2$/Z,(Q27IQ^Q_<9ID9[=12CFE
MP1J=_>O7(%J>7;X[__'#H52CT.WGV\>S?UU^OBOK8@QNHC6.T+Y`B*/??V+_
M]Q0DZ.Q;@G]*%L]H$]R114[\]^^>TW3[T]NW7[]^_?[;4QQ^3^+UVXMW[]Z_
MK4H)*=A_O2G)WK"?WIQ?O'E__OVW9/G=&35:E.2\`4Q*<BIA@_KK^Y+V_.V_
M/MT]YL*_P1$U4+0XE.IP*<J=?_CPX6W^M2*E[+%$H*IJ:KVSL[W]8A*BSVAU
MQO[^\OE66/K#6T;Q-D)KUCYWP1,**=N\BG2W17__+L&;;8C*WYYCM.+7%<9Q
MHRIFVP_,MN<_,-O^>Y/#6Z"HP1J'*'VF,-FB+,6+Y/L%V>SY7.-D$9(DB]$5
MB2C24_P4HGN2HH\XHM:@0+]&:8##1*U/L(Z_47G/__+NA_?O<FDU*K>JRF.V
MV03Q;KYZQ.L(K_`BB-+98D&R**4\'TB(%R@I6%_T4TR3E54UOZ!X<T>":+9!
MT9+^+[725.):K0K_,<#Q/X,P0Y]0P/Z;<4JL*""OV2[04K+X_9F$2^JX;_[(
M<+JSHH&D6JOBW]*Q;(.^!-^0'<OSZCL::'IV9$75PZOQ):#.<0CHEQ5;5>$A
M1ML`+V^^;5&4H&06+>>LR%46QY3G+$F0'8UT^!Q=02N=1HN1517I.!5G=#*!
M@R<<XA1;\@*2:JV*_QF%;"[T$,3I[DL<1$FP8!-;.THH*Q^X)6ST'7&M5H6?
MQ^L@PG_FJPJ*WLL@P<E\16&=4/SFOUII$0TVSB:3QYM+.E3R_?&T?.]"31M=
M3XO1\54L_AQ!QXK3<>;=?5=SDGH'5L`*ZH2U'F6G8)@M`CO"DT66KV6+OT&T
MO*$P37>WT8K$FWSX,!(?5*\%!:Z"Y/EC2+X:(:16V((HCW2TS5<6\]5^P6<B
M$J>2HT_?AY^W6U;J3;>#]].!6^'P2]T!%KF#3\AM3\6/M!@:9A4TW#Z4M0TH
MZ].JIP3]D5&HW;STAW"W-@O"7@8A.[]X?$8H-1&O6=ZR0!1"5-%G1"D"P-F(
M7+I694=>S0Z]C'6Q(#C"2F#HPP_+IQY-<;>U]KFC/S1XH6\I+826)3<FJ?WS
MMUR:4IZ0+!HBA.Q4E\3<`\;\<'$5)$_Y"6.6O%D'P?8ML\-;%*9)^4MNF3?O
MSHMCW'\O?OZ-"9,\!#NVDI@])6E,QX"23\C.(?.3<"4IG10SJ_!)WKI2CATK
M+[,04>@^DSAE*+A&3VF^;!(H"2E2*"LG;2I=1]@L;AH@B!=ES?2?'7@US[$+
MBK?;W$F^63SCL$+F*B8;8',1(XWK?NSLIS,9I[.4G,$X9`FMF6Q9G<S=DYC.
M5HMH#'?`:<A)N<V^X42$&!EM"14^C7.,@-J>Z.DJ`(F,50,L?!:C0,DUV00X
M@N*D22U"2DGE'BO2MI>!A*NH""8\+E)\E+7;14AW-L%^^:TVC--9/N5!QW&V
MA**6PDE"XEWN"R]^G&UC'++BG]#F"<4M2-BHJC"C<2W^X:D%$V+53E"X[85@
M@.O'7()&:NL5BN,BSDMBR]R0+&H0-2+"7'BZ<C]OOXMT139;$K&EK6Q<A)0I
MO9Z<UCU6=<=)#=W[CI=R5GP<_L7IN-F25#IJ2FD+"PIHW*,&A`*BIZP(+C)>
M=;P(>/@XOZ)";DB4;V)SAU$E735&=KX[QX:\J0E<.0$>N/77<<"I=V)C5MUM
MWN$(W=(.`EK$=8AY<_,:D7,P]5K&B;2UN8ZK\>"#[#]&"C*FW&V4I'%^/OPQ
M6*#9AFV,"F"F(B],+R9S#S4Y=(BVKI")><6G#C!Q_=/R8TT]\VM$*$D_T^$^
M'_.7#RA>,`.N15N:^A5P82@O.%I@:MC#$E3E'/G@O1@Q>/=K:';)KEA-H^7!
M&(_/M&63VR3)T/)<`F#]2FH@UBD\,B`;VZ47F'6X\@']7A_0E,\3<0_I_<R:
MJ<=.K&G7S?7E#OL0TL8:5D0Z`E!JZ%J7_Z<S,>+D5=:W,D;O&2]WOT3XCPQ=
MHV01X[RS<+;6M,IP_9^PC'N$`=<P)C9H`4ZQ@@%RD`S4GH#J/MCPCZ149%SH
MU,F<H46O]3MP$:K:1`B(2Q<J]=I]W$_KB8[?+H#X^.W]%!#247=HC&QC3&(Z
MX%&8R-R),UMR.H_=,SJ9@0_,F4U]/);[V]M.\]#9S._'#3/32UAP.DX\'7R=
M#K[\&ZA/!U^G@R]S]+3\/4:)(K!77:`PN8S0@R#?&15MB4,Z.+Z@1[3(XOPJ
MSLVW19C1@?4CA2&#1;:'S'QU$\01524I-Q9@8<$VF70"B>U4[KR/`P#%#4`>
MP+8"+R&6D!^X;$<R'\>::OR\"H,DH1-'YA@A\S`1?7L.UJ5SCL^!$,<+`%-8
M27G(;D-`;KA85S`?T5F74CI=%A.6<R$.@7L@*F%"-%14S9#;3!JS(D[E7@+B
ML/)_**=FD(DRJ%0WIII/[1PW$B@04ZT%Z.FR:DZF%2R.,+6>]@!B(X)XL$%$
M)^;8[<E(3Q-<[O@52"9*1^!8+LN&Y/0*^MKQ6NKH/750U221'9[U<^%9EVXQ
M:8_SXH3TF*!6]B&A`47+\N&$5O<*H^-;;UJ6?SIG=2JH8NS;Q/"(;N?7((Z#
M*)4N0K@TA<5;WT:),9E^%A#5JMZ7.%G!1>&;S38D.X1FT?*>SHV+_\I[P#P7
M.N%B1;=8>1`(+C8J9!E:HQE'`,$8G-'HPU=[#K%WBHM4MJNWL\2Y\_*REJ?K
M&5$;C&WQ<J>Z=#;6T.&>=I'>4+-:MYW.ZTT0O/5^9:_/ZERMLZ6&Q:YZA)M[
M7H3G"5_?\>*2]+$279U2-)U2-)U2-)U2-!G"S5:*II%O.=V1:%V:)<]-?AAF
M5`%_.D6+QH$5\>22O"R23T+)O?;N2TR=5IL);[MKA,A!&(HON7L<\=845#+A
M$1-RD>+)>:FLP86X@)]5<JH7H\#?P+*FG,KS014Y%Q!>G0=*VEN("MWCNRX/
M,32&NRPIF!>6:Z]?<?H\_[:B3/9)N)%X_@<L4AA%2>T9!B3W^?04!Z&AN>$.
MXS+-X#&@@^Z1:UGAH[52++N_T'[01'7XH*#F.FF?C@:,AF[-[7JM\5NYA6YP
M#C;,>6M3[IMBMZY,M32/PMT#BC'IY!@R*\Q%DK2<9]CB[D7WL@4(;HV]8UUV
MOD2,]$3@11\$\E(P`,M-#H%M6PR,P`M_8DY.N2N'`J"FLOJ04S/P)U]:3T?W
MOH^C>V_HZ%RFGAG*T;5M,;"C>S^U>(F'8)>_(CE?Y28H\LE=D205+20`)<JV
MD%&.`8D&*AL[/2F/J26&WDM<[&CD.OX<DZ2;TD]!5_D_(=T84`95LYL"2@`I
M284%<GZ83-0(]TE<YY$CIQQ.IQQ.IQQ.IQQ.IQQ.0WI75UE93CD^3CD^K.T8
M/-)U)4IFYS\6#QW<DVB1;;(P8.'">AD]K-57=HA>53D'ESP1B&UC::4(L<#<
MFD\?:BNL4._"',/0HDVXJDN-")F:)C`&H9J/M?W]8?%V=7YAU9'VJZ^!3-.J
MQ@-7*\8RQ;`I<W_.%.Q,&:L=$7C,,Z1(T3IR4O=*SY($T;5QM+S#P1,.\ZM6
MQ=;0<AY]9M>O8ARM]Y>9X_(_+X,$)[+(:.OUM\W9OU[G;@*$(C*\304.1"9>
M?25@42P?]UXJ]2YWM2W3CS'Z(T/18B=91VN4;*-;5L(?W%K#(0_D8*.IX-M7
M2B[69=)YC6*>V-*-$HV2;13+2OB#8@#0>/@$FT.%3S%_+O)D?,>"O*3J==+M
M;)VB$NQUB_@#/@"*%.!3&$2%/K$`*O1U&4]KVYS?0?-Q07O0[Y22#O@U:G^0
M>KS!7F0L]P-]33(?+SAP9NPLQF$?#)C`1GE`4?'*EE/$'P`K,,:#)=P86H-\
MQ9R+."E3'T?XFR3%FR!%\U6E`T<9Z4AO4D49\Z!5U!\X0K!%K%@(OK[O2-*(
ME]"28+)S@>J?_XU13-O]>7>'7E`(FQ(`"G=G!M)"_@!ZX`D"W'2.Y@E2`7U,
M;\V=U'>UT-X=4-8A6ZN)R_J#=!@85>LVH)74,PN),,HUG%@('V<:E;2WT39+
MDUS-<]@6@KA$&XT\2G^PIX4@'@25AM#8,1!*P,4=C_-$IPDU5=]KX_,]&)_O
MIXU/OB&.@<_WUJ,XO,7GA38^+\#XO)@V/OF&.`8^+^3X_/'=NW<CA>@UBO%+
M'HARN;L/4FHH:5(M&7%UVXE/Y`\FAU@Y@4QSS)622"#)]5`/0`A(YB4F[0#0
MLR1>4H1PL:2?Q(O'@P^+X9)XG9YED;>_]:=8>%5K/[\RUD5`$7A9Z#B//^/U
MLRPSI)*^>2&%1^<<2X,.95`#'7,TD\@DN7ON%R8A]Z-D)62X]&:44X-'A32=
M\4[(38D=)W>H"A'XST<!*%OWGMI$?C:^XFJ35%.=9A?<7FK7[\O@I[B5!(:*
M@+)UYV@*4)%KVA\JG?I]V8R27RB"(D5`V+P"-`&<R/7L#9-.]4=(KCFU&2;T
MQOLQ9Y@2F?@M_(,7#\H>IYW,'[(?MJUTWK#_JQ]'J3WL<*=(H3P(#XL7P>X\
M2M=\G#":`1K"2;2-'3T$AR<CW7?:VX03DJ>XS`HN5[[`J*:?1&_J`IZ8&VW`
M7G+'?4-1+9\O"T]+.UQ!\DRMP_ZP0?@E"!OGJP<#B/:[=,N7NU_P<LY[!1RT
MI+]A!(A7RM#8*8/SGA::A5;2]>%0WSU6=$(5MX%&"2][.S,D#4+7Z*N-0?K3
M";W"Y8N`P$+.03KXQ,+(?,>>74"%]&7#TG942$W_*VHK)'GG0%VD$R7"(W4.
M?$U<<J-'E#80X!C&FQ]5PN/I3RJX8_AK(S^MY9]'#4\M.U@#J(KKM"84]8$H
MV^1:L='H$TJ?R9*$9+W[2&+>(`7-P]6W7LZFHF%]SGO"X#,4VT8_]N3%@OR^
MO%\W7.^\^;9%BQ0M_TE85D"J_^YSD$*2O<$JD/0W44&O.E8_W"LZ$\AT@%YC
M)*2JIXB$F];^"T_SSSCY_6.,4/G(D6:'D!67=`=^L=?3&0!F<]45^*+YLN85
MO5P=YT/G[I)$RX2]V\L+T!$2E:]3=[]/"Y$@*PR).Y$`KV'F@>(%3M!#C!=Z
M$PY..>D\HT$_+?R:&LK=K*(AT[2>#'Q\IHTO@W.7H`R"K'V8)D"%JA\#B77F
MTWHQ4#9SYPSZNL4`R[<IS@H,S>1ZJ2:;.4SG8<,\/O:9A%2M9!^&>7K5\/2J
MX>E50W\O5)]>-00H=WK54'@:_Y3NWZI)J$*7NU\B_$>&KE&RB'&NHS1OB$;9
MVJ/Q@#*>V`.0MT).SM7:L_P5.HU(M%47YC8`L&W&(HC8'>6N;^T]I\?LB?+`
M$1U*E@_4ECA)2+R[)RE*+GZ<;6,<LN+B>WL]JZK<M6$MGB&.GS7#HJ%``&PF
MV.C'?6IQ,:>';WFSJ=/#MZ>';T\/W[[VAV]=O-=X>OCV]3Y\:W!X<WKX=K*.
M=$(/WWKW@OBEW0E"K^H:L#:L:3RHMF$J4U`;\O;GE7);2[[V*1!;["K"R&&%
MJL6?G-B=ZHMGM,Q"5*#D<I=C1O9(,Z!$J;2,TGD'!;8?,=%<N%24L6P$&<A8
M^7@L\Y@])7B)@WCW&%1BRW9-5/0EAL1T[A$$P`/15UD$'C&W!G+$7+S$S4%(
MMBDY7WV)@RBAO8$**=V1@A<LD00HX!Y22HR0'B80(4O$M($K`#,?`7;[,)>>
M$W>^%[:J_>X>%?"&)FK-1"A0,JG#H5;YM$Z(#X<DE:/5.236+=XXWH(4<P]&
MO5'/T"#]!D$X4Q]?Y.U(KSR7!Y00`<VKTWEML,B`IGM&#V4N!9KO[U'H[>AH
MENJ>U?NZ.0/`2@=:?3=CQ#R[B#K&AJ)7F7HU1Q636*Q^0PJ0(_C)5O]M;"%O
M+G3-:I()E_/8TXAL:I8S6M>>T"S0;M\9J<1]7*`HB#&!1-OP:-N1-DV:T6)%
MHJHEG#0Y@#.%'W6?>B_A+U&R10N\PF@IWQY2T5=[U$(Z]WB1`H#H*ZN*8*KS
M:>Y&"^L_=C3J1QP%T0('X6V4I''&I)YE*14FQ8O#\/P0DQ?,_L&&DA"E^:3K
MEXC*]C7&:8JBA^PIQ(OYBDZ7<+0&!:\>@7-W_CPH4_<`5^*6$QM[O'80.E>!
MU+Q8VD&E]2>VP(Z3_QQ$:]G+K9WO14/5?O<`TUJ#O$BE?@-[K58?GY'(Q9-N
M.'`HZFWMC0?K-E^[;74\2U5;IRT!/=Y9:W["$=YD&VE[<FD*8[2^^=&F+4D)
M3!59N^X+U%NV5=/$SE%J2\\[Q9,O4EK.!8,[CYY@T3T.`:C:\^R#SV%:SY;D
MVMTF24;G7AF;$CW0B1%9YKDYDGOT-?\DWD/0*5R/X`(4<@Y(.<)(3S,`(@WO
M>/DSH<RFY01K9^ITLI]@JDQNN<]H@?`+RT1:.V17![K`Z^C&O$#*C@B[/8QB
M#&$]GM-*NM8\_B@6N&AY6-7N>_*^AY\+H&Q6"?=2N;KP>,#<RRRF:-9E.JWL
M:IW#6`A\885$@1:CA:>6VJ9P5#&95J:U9N>;QWB-J5KLU]F&9%$*<Z"2<ER?
MR:4?#PYUE;?C&;E\!DR+Y@"-#S%9(+1,/M)V81TNB!;H-L(I#L+FOK,`E=KE
MJP8"EQL/2LV-8896#7Z2K>!1HK8>';4?+F99^DQB_.<A+6`'JI!"AR:1$H\)
ME'IJ&R)1SL3:#I0GIU6U9&E`]`%*=+/3C1EW<(7-YXT2#GS$?1@MXO;A<:67
M?T!QKO)^5M*"'(2TD2E31.H_V#14K8O_TYD07/(:?7N<0>YW[S-VND2US"]\
MMU!B4A0T.+:+^H^B'J8`HDJ/0[GS_<X7F%V2(%[.5]<X1@M:)BD%SO7M(`M(
M75A02>T_?O04!D)&66F)DN,?D`!1PLD;+R,1X,&3O/#:(."H9MCR^YK*YO9F
M[%$`]";,<\G/TED494'X":&4KD0+?8M$"'J.0Z=&F'.!U3@^[/4WG!TG!6-<
M(OOXYV-`9']&&_(2A+/5"L>;/$U./H+O%?@G2=%\-<_2)`VB)57O*MCB-`AS
M'8L4.\&ZG5%E2!8"[-MA,;[.,(!I#7N''4G*[F+E_,V+ESAN(_HC^A)\0XGK
M)S@J4<1O0;>32*A+E&DE9)3.-A;FVSR6(5K?D22Y"N)XMR+Q5PI<:28H8*E"
M<R6U<Z\":45BJKY@@TO"L[[-I>3E8V!PI5NQRDUWDMA^.7&[][2(G$,'B@6B
MJ;``-0IVC40M`C;C`(STCI^*7`@:;V[X*3`@18O.#3\^'SE,?,YBD=]89.^;
M41;A_V0Q3I8X#[N37D(`EJK?(I91>X@><0H+/=W!,.KFKU`RFE:$;]<D+*V'
MUCC7+B!T6P="Y]"S,MX)%!]BS#NP\B+#$U]`S<%.F-](3NH<.P`@*&'3;_`K
M^:DQ4_+Q8M2[1U__A_F\W37>WQ:>KZB\@7+<`Y<K[`B@]Q1$XO%/UP9:6.J.
M@@!V(Q_XOE`&\]4LCMG=QOQ:NWC,D](6!A?0.`>:P4@'4;?_("?@`DY`=42L
MU(1DKQ+?4]$.O]0NS212-V982V%P[=+.D2>'$;%E&`$2N=SK^-/F>I14,5_0
MXCG*W\&^S!(<(79!]ML52\:QPK06]!"3=1QL]G>Y?HFH3$M&4.]IXFPPUBLO
M?9^]>IVCUA2,9&`;"V"N*6Z5XL6BF--:$(M'L,Y!'?@XH5-2>:10*^&\1QC,
M(/1-T7\^`>(YK5N`8I6U(0I&IM>`[*(+!,J^6+SC17;+V$W+9=:O\%R1D&*.
MQ(R7"(5*>L[]JA;=6#$(5]T&!"7<K#V!Y6DXQL<`Q_\,P@Q]0@'[[WR"5`1F
M7#B+S+A&,7[)@V8N=_=!R@[+Q;L.<N+JABR?R.'5X%(@Y9:PC+2CGE=;P(JF
M(5HZ"OHZGT?SHB^O;A_/.W_-%R6I='N$2U.8J/7-H_:7[]K*=%(V.W]GME7E
MM&82E=<^./)$$;H&*5)87$[J7ND['#SA$*<8)<6HM9RS[#Q9S.X_7P8)3GZ)
MR%."XA>V^+F-MEE*/Y-H04OE.))%NPW%IFU<:]4[[^4@:)&C65C@,&12UAV'
M?>E\'&DJ+2]WI9[[/(.2B1:H3!OF?%I_,&L;@SR<`^RE`JTE,;E`YXOG-6K[
MFZ.MM'0&?C2^]@<)$3]_>J"T=PPS;(`:0=4E>7(/-)"(Y/6QCQXFYIR<^$G#
M%I)5CF$MG>4PL+0_O6%P<',7W29&'G[(XFO"7]H#-9CFJVK'F,V`MMD<3&-$
M<OGXXJ=%.W2VSX>;LHC.(H=A\2HZTQ%:Q^6*PJI6TTJP;-%&5T&XR,+\GY])
M&'[<'W$-[P_D?.T[!Q&_*7D*Z6GHL=MN>-?!/88]@IH3/0:H'=[^BM/GCG&2
MIG62IBVK279>E\I_#,&K[3/L\IB2GU#T7Y[3&+#!AG<4?'VY7L.NGM8\Q7;_
M`$H:Q.EK\!>#\/BMG?-[,"ZORU<<I[%>G9<PB)/=>XF;:#E6'R&PT\\!CE@0
MWFVT"+,E>W?D)H@C2J;<MS@6_YX>Q8#OZ_(QKAMVS-['0/>)[I;8,=PC2BDF
M\K,!2],6.*-A_$R#T>MR+$=KLF8&P*,XCB%U,XAA_[!W"1%:!RGR9XHR2Q*4
M7^>3-\7^OE_<,`TT6M(BB[8#L%+UE+H\;`_4?HNXWNZTHM&`%U7<=_$[](+"
M\R\D_WN17]>E&B7<%S'Z5,'OHHJB_G1!FUU#W/5T+*GJ6A8DEG0IA:03/0RH
MZ7Y1Z'YNWF5454BZC+CHJ^PR0$MZT&7$DDYTE.DUR\X-5UGJ'BE[US#<K*XO
M.5Q>3Y\=M'U<=6_;2DUTGZEF]5Z33MUZ)%$SI^EG/YNZZG%P<:>5;45H`-/9
MJ&X]JKYTFI<:V]27OJ0[0QWK`_*6]X&/-DN5<ASF).0T6QVHG48Y8Q4HQO<.
M/TP[G4\>I^_NF:77G:RB1^_(V^T+!<8E%?3W`4^J^(PLGE>U&?CCG7535@QE
M95M)*RS*-]'M<0OWGJ!=<@!6`V21F4*W',[2'F63477-Z60EI$;?!GAY\VV+
MH@0Q=S9G1:ZHL2CGO8]S/*MIBEA*N!>ME%,^R3&HX8!)>$F'B2#V0+PB"15K
M_\`I_A,M"^F;8A_:7N5=;55;I8KH6YUSKVD")#*8004.4T/(YNW^OL(-.(T9
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M`IJ:+1]G/[Y[]VXRNZV?4<BN0#\$<1%:5#P;ZGH-())+,>V'%BN@I"9W-E8]
M+I[1,F.OL(J$O-PUODB>@.E55V$JPSJ<>R4P(HA=>PF\E$J<^@AH*(:/2?1A
M"DC>:M&O0-'%>06=@[4?\(@%<PE@:R18'<LZ`OD.8.G3*F)"#B"]>;S$`"\"
MM.D\/0+G*H+2,`^'".;UCQO*\N$YB#?!W=T5][D/)5TYFG))O()!]YD-J'*`
MUCZ\?"&I=%I[90*PZX]Y\$'NE8QJ[H<Q?U_H$`@,'L*$9>3(\WU@@XQD*M7U
M!C79*,;A=)0![8IL-BAFCPS-HN5EEN`()73E_X)"LF4W;:YHA\A"]N[X(XI?
M\$+PQI65N@JCFE?C*]0$XZ@E>^F!L#7LFLOP*H;F.\631-!B<E=YY]%304./
MU"+3''FXOIOJ8SP"?<M8VH^TL>O68]=0ZT7T<*Y;J[P;P&MSWDO`X%9W"$,;
MZGG].UZVQMX"33T.O7N>Y/B&SBDL2O?D1-"$JALY^A5TSDC4!9U[L=Z!`<9F
MLATIH"/(U+W6/%X'$?YS#R0ZJ6?W,.>KNL5=G^S6)60+#!+B92EN7<[YJGH"
M]Y'^LD_]H'!O5NLN(]#LU.GPVF*UGJ-RK=%-1*&[C7&"KM$*+W!*.TVVR?*A
M_3IC01#M$@)CVZNXNKK8OT+G;M4N!,F`YA:X82L*-*\\]A=\ZF[[,=ML@G@W
M7SWB=82I58*(F86E`*/V>*!ML/`B+K\N$&BVJ2APF%H*"9TY3K8[1J+'E,X;
M[C.V[45;YYGV_X0N@/:Y28KI"3P/D(TJ:QNEYE4Y=Y,`:)!![":>?`KDJ;NR
M?G),:],TM\(S":D2R<T?&4YW]R1%^:^/6SKYIF/'"_U$E?W,C'TN6FP95E,N
MN;2+.X>^%3`3:Q84=(@^4C869]K23:N;U.Q(+3>/\[G2,K?@`XISDZH'"U7)
M[I@@+C$Y_.O;:6#(@P2:>LHCG1GM^].4]CCJWJ/T-J*-A=AKB[,7:OM\>XS4
M$%NX:K9QM%#8HF=MA:&,:W'NR/3FL':LU6OZ:BS"M(9D33/807\_U'N`]K[X
M->\*L"Y@*%^/_C&U?O$KPNMG.E.9T0EYL$;-.=`\2Y,TB)8LV:I\6#"MIFA>
M_>+.NX;>0-#3/KU&`'W>T[H!+M._IO[>0T3+:QQFZ6$FK`%T=64`N,LJ<0YZ
M8Q@#NP+8@H(.H2L?M)O(Y+(V'E"^3\3;[E+HVS&E7C]1U2+O(.+24^X90)L=
MKTN(!1KV\KR#SG`3Q!'5+"GW<&"#!+!4T7!*:N?@UIOKZ&G?:VJC9&4MU)?G
MG,>SY^8^BO$U[;C58M.H:$N&1?R"'EF>_#P^[>;;(LQHP[-X6[K,W&9E<$4;
MSAI!BY89=8,;K3$8F3<;W,:]'.`0TDUK@^-@(<5@H1DF;%1;IUMIUC+:OM/'
M6I8ZB*8(I[,Z.F\H_IPF#L=1]Y>$X31)\29(D>@&(I^H4*O]<60.0ZI;+S_0
MKMF704Z4=J2*E<F5VHG&)1AQ/6Z*3S<2G&BI:X07%8=I;8U7+WO5`KMO(VJ-
M+(_LWFLO\$-:9=M/OLG+C`2-?2S1RYD!&?IRSUG@XWX-XCBHQ)5Z.`5IN6LL
MHAH)GC14-?=MPOKY:/G+2#U;.<5GKVYMV/7F_;IW6UQJN8T6U'QTJ?P0!I'<
MS_6HJ1QW36H8"6;M6:G?,L^$/1_Q_S%2Q+?7MW*WJEE*<%0Q5D]KIKW5HPJ@
M_[7RK+N3>+NO-;O$)*+_7*#:]`0&3]-JJH@[W>(C`W!/^_2,+-7ES8?X7Z>S
MI]:Y]U($NU\XVT'C7\51[*+!"DEO8WFPFU;;^MUL0[)#J,AHQI\LS,)<EOQT
MA#U:O8[R-UI1C,G^Y598MO4!>'5/#6SR<.[Q@&CCGRL,9FU1>C*IL(*3!YM"
M^I@H>Q]`764$N"L4D:2Y!90HVD%*Z1Z[@R*1F!A,F5?/HJ1UO$LE'!%JI6ER
M067DR/4F32X$4FH$ZJ3)E7`$(&F8-+FVDC`FB%K^F9TG'Q*9%(GUN`ET#4I6
MR10!)7Q%5S<SKKDA]%!VR(.KQ=&7@T([./T9170)PU+_SI8;'&$V;6'[8A"D
M:I4MF@A89GQH-3%&7[P">4[KB'+V-8B77R@7R6R22U,&>C2_.4?:T6:,,J.X
MFB.V9/+Q\02!JNS0;+W?W+K<'6@>@AW[+=?KH%RT9.<,]\$&22>30[*2'CWU
M9>&\$_&QK3R.LFI:T=YI733U$55?D7R<#%?.@^V5[,_@I!,+)7UY^B2F<X[(
M00%']&TE\O`#B-DXY1*+)T+JN1_1**7D5+U[$J&N'OQW4'2+M:"L+C9Y9!M:
ML&Z)G\Z&PC5<N)$O#.U,^.X4KZ<,Q*4]/MBJW7W?.]9B8=B&<;7<L*Z5+Q&5
MEI;6>\V+F]P=PQ3;"J(UMU;A<C$.+.2\XPW5'TA/`PIZDF5Q&TMVH)B3S];=
M.?AU?*GZ%-EA;^"`W_H<AM]0$1X>Q;5Y$.6A%P3G,-+C]3Q=L\\$G6+J29EU
MB]LLT=J95V52)'1]R'R[*A6JA+2,/^62>.`W'Y])G'Y!\>8:/:6PP#9QD8[W
MXI$Z=T#2YN*Z':7&HJR4'$Y\?\'C(.CR[QR?BM0%E9_&26FK<PDNC7.0@!J?
MZ.FJ7/UV637/#;@LQ@$3Q?F7E%H$%6].H>2-+T.)SH$2EXL4((JS(5.("!\4
MKX;PQ^R),J%C.'LQE)H*)PF)\VE3<O'C;!OCD!67O2?>JZKJ103#6OP#E/`=
M<1MV@N*M\X"X(7,9'$>X>]:PDVKC6T[,\W1^;D,;C(K&F\(:PZ)RB_;"`&6>
MY&-E^AT63*JM"@5U]>JB@,H]U.30(;J:0IP<=]]36/V0;LSEFIPL\NP1Y=\@
M6MY$U(B[VVA%XDW.T&!5+I@TE%QF'"Z"9;=VN1+KH"(]NW>"%M^OR<O;)<+[
MGDW_T>[0]*??]A)\1NL\>#-*V6ES2T\567G8R25QUG_U6X>`56WU83`KUIW%
M+`9<0.FAX8JJ$;,$+DOT[1^HG89"2=?`0X=FK("0*VL'$1T>LKG#D2!1:L$F
MWAPD\#ZW_-S^T_C:7:):W^9N5BTXQ'?1ROM-_YMH>4V74)+FYM*UVKU%,UX`
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MMJJ.#YL<QU=T8%R36+Q3Q:5J@*1%,59LR!2U`XD6!P$2'.Q:/F1/(5Y\#$G0
MWJB7TC10T/@^5@R(E;2#@$;]@O8_ZA9EX:L.[R.KWH34*]0<3*0%Q@H9#3-8
M&EBD#`6@<K(C>EB!?:2_\"8D"LK6KFB':GR8@2EL:V>TPT6`CJ-NCC:%VV_>
MPO#!H>4BI$$W=HR(E;:+D@8?`4[J.ZL.PQNN@N29CJ%?7=[7*A(\S5>5,,K;
M6NHBU5TM&:G#-.`I$^<A)B^8MMSE[I<$+6^C^1:QU%71>K9(\4O^4N$587FD
M,_I;\9%$*O/8K;R\LF&I4O>15!#PD(&M*;Q;)9:MF6+<CDP3"SV=+?\W2](\
MK<47PJZ010OJ^*BQ]JGD[DA"?P<:3O6@WH"LRD.L05@X[W^6^Q,Y:IN(;C99
MT:EQO7P07>P%`7O1WZ\1%7J!`\Y!L8RD"O:M?W+>+P9%+P%91)2Z;0#)FB'%
M=8F\&9-D3U#^S.(ET?(ZB]D;'_ET/]]`>&I?:KXD46<UUK>:>AH"W1HF#W-+
MQCUR5S"7>F(NG9\:0+0.E!)7MX?X1)/O"5I6<N3Z1;+)8E%'B.J'`%.;_`.S
M%_>H0"@1+2O$A&4[<0A>#9+5UG&#8IY<LM#9$2*X>EKW8,OYJGPS50!F4)FT
M]0(RG_;50%S'9H[0KA!1%D@\RHNFU&PQHD/4-=K_K1GJ*MCB-`@5>T7Z%:35
M2SG@@J^FAQA;TU%WT9%7%G8]PD&CJSIM@RT=+*\+58HLB;-H.6?'4[,D0<+1
MI%]EPAX%J\1Y[S)`O;3/&-A._$P+4#)YKX!)9&%WZ,.^AT1HS?)S^-='BL=C
MJTQ9T9+^$F=45!P\X3!W-.`^HE.9L(_`*IE<'S&PW<!]!";1Q+:$.,9C'N$P
M_.J-&K+"XGD7M]#D$`^PS<`(YTL@NC'R;KQ^G__('AL&R0(E(C@#2Z6R%Q%K
MU,X!?*Q%@Y[='*T4E$):Z0:#'H[=4YM0`^QSH26XRH/./0)3$I>A1V*ZR0-8
MRU`N#JTDLHG@ZL]9[D?*!+^@B/:N^:K<N\W?M$D1-13"+YP4P`8ERTU.8*'7
M@6HC$[J`.%10$=Y'._/^.<!1PFR'DCGMU\Q,&4Z>]SN^+!&<8)8"+E<T*H!^
M\EW"U':.YBH`,47=0>L4UZ])>[\XOT'"M:V&:7O0SX8+#[5JYZ,%@O:5VF(D
M!:&K>`]ZX,&#S5X"'+*QE[JRPTV^XFV2RR#!BU:7,RQ]Z%MZI2?8F?I9L/DX
MI;W.HBW5V&\Z"$QW2Q=AR5#WAPPKEP],VI4Z[U.6[@_UL^8P]X>T99K824/Q
M_BV=&<\6?V0X1M1`5.MTQQ[`S>^!TE_S33EA^)YN!558'[R@\QY@&='$AOVT
MIF.:DC9#_>`23NZLNI\Y!QEMK(XRD^Y;5NU\M/[65VJ+(Y0GRQ^>.:KW`8>8
M]QE6+N^1VI4Z[YF6YGW]K#G,O$];IJE=SV`'K&B9?*0-7G^D4#3+4Y!7;24B
M<XYER]@D!K;1&3\TY6K,UX3R>'//U.[:9;ZJK)4_FJM8J8C(6^N2+MF4,0RT
MS=$P+)3'PNS&KQ5&O;NR=,%46W0;46L%X3[?WWQ%E<*=5'K&Y3F^6E%NRL`W
MMIX#;ZX0T-X4Q9-K2/VL.<B4W^I4?](]RZJ=C];=^DIM\0ZL#XMOGO>9K^Y(
MM"Y?3-08E?@%)<-1N\"$>XN!O1P.0&W)/(K2'1+W#Z4B^?'J+%KN?T#T8_Z+
M5E^`5B;M'^I*7EV?T;:KTWZDEM:CD&+;R_9<P](6L*6[N$AG^<XCG7)OT+#1
M\9?Q/)FL!`_[OYB?KVHQ.5I#!*><=#1HT$\9ZMK6<NKC&X)9"1'VR9T+K-A_
M16Z^_/9TK6WI.,U\N=SSS.Q5K'B9XG0:QOZPN):7(&0#V(P:)(YW5/4\#9``
MR%IERQ<:865&!UX36_2$+9"EO6Q-VWVNRC2(TS'"%E3FMW,3P+)2HX&LF1U<
M@M4D/=*V?.?:-50?L^TVS$T4A*6)).^:M!.@ZI4N,Z)"2XT&M/WLT1.\8*:R
M=T]'.-<M;\*R[)<"?/)(JAPK]4_ND::)'`)24H0L&+-FII0ZDXG%7^WO[GP)
MOK'P'`F8N%2'G#W-K^.&E$Q5FZAJ\9G<_FIIB")-Q2%N.%IRMC:N<;((29+%
M2##PVJJN-GWL5YU[E&O,*RU:KGF34#54]V?>>-]^C/V@RL]2;#_/-BR3W/[G
M%"W/VT"'TI=(5M,[@ZHUZ!%]NS1QVE>2',MJ"<I85E_2[+!S\9K8,5Y394/V
MZU[V0QY#07I\\PJJMW[T*Y@$7GM;SCZ`340J(UMM(-KA:YNU<6H_]7+VZN:O
M"*^?J;>8T68(UN@^VSRAF#J4]BO(B@T(TVH*<.D7=S:`RD2M29KG%V`)_'"8
MI4BTE.E7&<!XLDJ<3QF-04,L6U"PD-*5K[ZB,I5K8K=1]MZM<G?J!Q)DU(T5
M/H?*F995II(RYZ%"3R5]H:F$SGGG5;45T5=7G%*8QZG>VR0<)M:A^+EA"[4%
M<`.5D:8*KFB=PTZ-)66V7[[B`O`)^:D3]E9\)@;!GU%$;1*RZ?ER@R/,[$%G
M^D@.0F"I,A.DBGI<0-13O@\4E9PFEJJG8Q3HD*L::L<&,96"?4#%J7MBZ00K
M#0_IXU1`ZE*VH52G<`XFD_F:4$4+,[5ZW1/S2?<D(DTURT>,%'E7H.4.^?!5
M]&."G:[ZYB`$<)K<R?I^!U4^1Q-0M2(U_)F#P1'#"=/0FGLI.?%B-&PN`/RZ
MT;'?[]^_2L*,H7C-6$5>`4Q$-E:D@=2V`SD1JXF-K:_]_6$C(%IX3%@+C48O
M`X_X.8#\L3*AA40+"5"A<DVA(!XG+K5,8`.8*H:3N[)_6&6QVW>\NTJ7:$5B
M5`L`_(0C$N-T5WO@IED+B\Q/=Y]0^DR6AW%'\O#BL25HG!,=B;/S#JBQT'+7
M).9+MJ/*/+';>Y5-"C]WB2*TPO)#6"%U.\RZ336^CJ!2M2]H.?5;N&WGUPRH
M\?"&:'N+1\-[4F5<()*IU6.+JEFKU2?E?/!)-T$<4?>=/*`XCXE1;(VJR`M[
MB\G&A"B@LN;@$C/@XVRTT>YM16%1><!2`LSY%V>GQ),$>T:!<R*&,@PZB83S
MVP_T#*HU]P_ZC.U=:?4DR^H7M-F2.(AW^T4""T1'3#OVB.:2?F/_;FUQ";Q)
MCYJ*AC2J84Q`[V\B<ZP;\9[</E$SX]XU9BENHF5"_7&^959[15:`<OT*#BT'
M+C@F3/<QB"&4=5A.[H+OZ4%0RT"V^<*G!+RF3W::9'OIKGP=W@$[7(JC_78;
MX&45@5?TUZLL9LTX2Q)$>ZS#D:$F7.5+<J%*">5K=X,:#JX07M+>-54`VT/C
M?:$8N`R[22PMU`2W`K<2YT[&I.&)9<OQAE(-N9B'ZB7/D*M8+YS7F[J+WL^A
MG?FJKBCLJ2=5[BQ0H3)EEH+87?XPKF!J-V5<7FH0/_T1L*5)?ZL(,XG)!&CD
M$H,SGKR'J:*)/J&`_?=^!>,\`.T@H.JZ)Z1(._R,2^H^ZJXFELJC@,I(U/;)
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M91"R!]L>GQ%*'1[L%)$#5V&0E`\GSKYA4322DKXZO1#2N<O071/EFFP"'`F4
M%!.6N;@Y!.Z[M+)IB(:*PH,6`9/&8T.<RF7CMKT`@T<4LUV/\Q\?4+R@4K(L
MRMDF"_-,744";_P4HF9`UR?$PG!Y808VZBM[1*^JG*-+`AABWU@"]'6%J,((
M^C'W)I&@'-<7YA"&%FVB55UJ1,#4-($Q!M5\O$D=(H7;U?F%53?:K[X&,$VK
M&@]:K1C+%,*FS"U>[QX0UY=V9P>]JFN@VK"F\8#:AJE,,6W(>V+IZJZI+5YR
MS2]W]T'*MN#$BSTY<?7P"Y_(`Q7O@PV2+O1DI!WUZB3.NYRB:8B6CH(NQ>=1
M7^CQZ[:\U+/TNL@^21;7F4MIRK=`FM\\`@"G60E,)V6['ZIN7&)M5FEO[>3)
M#=7:&T+%DTM!^$`2G+>N*N097K2]4R8MXMX87UBPB$KM!E%;P>*C\ZZCU4@$
MJ*5JOTS"JQF>W.0!]Z4N#=DT"'?PD<P@5*;+:^</.\U:1VXLZ-ZZMKTD%<MV
M(MS[G#L<H5OZ3^5I1(>P[7MJ!&-"@D@O<PC4:IS8TF9_94P5!<PE*D-56Q_]
M04H7!P2HDPHI5<V-$-%6C=YLC]M$"NR.+>0V+>C>K(L`9CXP.M!1WA7FQA\W
M*N^BIU/IQ$#$'FJ=14OVA]TC>PG"/+@AO:*KHQV.UOG5$=$!LT[9VDOF@#*>
M@$YR"[F/$:18Y-PPUN0U,8@"KE8+`*I1$GZ7?DS@-#*`$31!G+PY,!Q@`(8,
MO+(!=TRP&@)`(*B,]OVPAYBEE$]W#V&0/US.W'?^".0]$CLO=9'*YC)23W`E
M]U,:NFK.X^1U3\PE71<2[W?IT!5)TB0_*<R[E1ALX'+5>9*2?@2PT]5:&WL`
M!A/;OJ@-^P=%!:"3TM8?-NG2C`!<$.VT`26HU)N(%9L3*^F,BCN5&@4NN/(;
M[DY8>2G`IWE2Z3#G*_J7KFASCZD8L[BTK7&J13,"F$"T,QZ/6I5.+EUM,YU`
M-UF28K=4MWC1'/!BSO$'VY(WM(/19CV<U\2F[#7%87OYZ@)=//JWJZ^-+3XN
MC3;]H;P%^)SZF4`KM8IB@TM*S,^>X\^6%P!)XDPX6AM@8DZ2K#:*[;`Q(ZR5
MJD<),CF],,/5B*$&TK@OVD1,IC;(DB""^3,)93FL\BA&!B^UEKV`Q:U^8CM=
MA_`]L!N#%.D$[$_`F6GHW0MV<CX3VR0#HTYI\PD@;%A<P=$TVHVW.Q*MOZ!X
M4_?<PA%23%H-D3P2GS"EO^94:VUSM<GE-K%)&7O"!>\?'&)13?F;S6L4+5B.
M7C[T`"7*.#,9Y:B!"+>!13Q*F4YL8M=Z\:T,KIMMV,I\EJ8Q?LK2_2-$#X%D
MW#6NA_^L'Z3\J('=UUX6X6X@RL1FE]IG)N#3`:_/1?K@M^_YB`E0]<])C&:H
M/B"RF=A`%I<NH>0^*NE+S+D>W$!:PEZ943\6:3VRW)-+TK57!*4W'01DM<EF
M\_/(L*30KQ>0NG7;6\9X@J+9<HGWVCP$>'D;705;G#+5^(<9<NKR*$-$-3)H
MP;3MA3`ABXDM3*[1"PI)'KO\F`9K=!-1L;8Q3M`U6N$%3F>+(B406EYG++ZG
M74*X+VVKXFKWNG^%(\.Y=1OVZA(VI+&PHOFP[ST16C-&KOL/YR5*Z%I&N889
M'5Z5.O;"'Z_VJ>V8*Y9KAK&%FC&%'N#.4B07Q!K#Q',).//Q.OIWQ>L)V_>;
M5\^(4E`5G2=*.65O/V5O!PU!I^SMI^SMI^SMI^SMXP/F*7O[*7O[:-!ZRMY^
MRMX^.5"?LK>[WCDY928^92;F;TF>,A./-MFNX\3XIV2[#I/MCC8"N7X*AJC\
MU'LPU>B_0Y2W;K2<;0@=FO_,?Q>FDA*=]%NN_G#+T5*U_N"ZBUHRN!V-\A38
MD\6;_9Y!PJ8?@G@>YZ9<YF$_=.+[^$SQ``N65I7FATB+2XT$Z&96,,(QF-7$
M7'Y+[US)9):ESR3&?QY.U.3P%)7BP[)+/4XX*K2V`<,NBXFM?;GZWB9)I@>]
M9@D9[$K*,4..JZT]N)75>[-S."#4YEF:I$&TQ-%:!V^<8C+0-<C'C#RQWO;@
MU^`QZ4L;FG-"O<+<JQVCGQ&:VD`?FU!.%L.B_$,H<#H(*\1%Y&@G@[HZ]T4@
M="KXURDA3SH35!>0(&YD\T`=7>T@33X+_'%**%-/`H&E)'@;XQ106VL[R`-,
M`#^,%7ZUVW^:LS^-DMUKF*.?]^EK;P1'$!O11O5X+VS6U`;.^``ENB@<[5P/
MKFU?U$%G>>>C/1?I*"N=XRFH11@;V>P.IJ4=;,GG=>>C/<CH**J>U4&*B!`V
MQOF<AKYVL`:8R9W;.;IP>('L&B>+D"19C.;Q.HB*@^Y9M+P,$IS,5W53.KM3
M5A?MBD0)"?&RE+,N8"ULK&IKU>O+5NLNWSFR4Z>[=Y_ZR']`U!<*S$LJYN]#
MF%["QD8K<*MW[BGM@I4<K2D$#MF*.HT7M:RK,61<CQ=N_S';;()X-U\]XG6$
M5WC!0IOV#Q?0@>^!6G"!$F>>OR4)NPRE>!M=6:#YB@67T%W@J[`-J'PJ=ZI7
MN`R0!19R[OH`#4MZVD+@I<2<&P&V0(Z3=RAEIN,9=:K+/#C2=1KL:_24YF\M
M'H14N1&=HJTTV?(B#O--/:6W$14C4]U/D5!6&:$X%,X]A%:;$1U]!8X!PK"9
MQXG#R,L+&$U))=D[Q(1<J/#R=3A`BJS%A<"`7\3A5"^&@<?7<)J"W@<;)$UR
MHB+G(J).YADN1)E.@'J"P-%.="*N^SCI3LK!^U></L^_K2B7XK5K\9UE8)$J
MPE!![1D(.,U+C!0'P>'`K;IKK.0RL9LG38-T=H2E/J>[?\QS.7<>704T&HE$
M:MH8CNZ&N![HR4$QTQ2^.ZF@KD'+S[U"%6:(KJH@>'&/5H3U#YN"7+P<+KZP
M_WL*$D1_^?]02P,$%`````@`5H(.15IBK:28"@``:6L``!$`'`!A9W)X+3(P
M,30P-C,P+GAS9%54"0`#I!GM4Z09[5-U>`L``00E#@``!#D!``#M75]SVS82
M?[^9^PXXO5SZ(,N2DESLB=.193OC&2?R6&Z3MPY$@A*N(,``H&WUT]\")"5*
M)"'J3Q)UCGV)".PN=_>'70!+&'W_ZTO(T!.1B@I^T>J>G+80X9[P*9]>M&+5
MQLJCM/7KAW_^X_V_VFTTE`1KXJ/)''TB4E+&T%#(2$BL00!JMS/"CX03F9'>
MQ/^E6L7HEFMXD\93@KY^P=Q'EZ?==V=+KA6FVX?;,?IZ^7"7R3(ON.93RDG"
M\*+\<^7-2(B1QG)*]&<<$A5ACURT9EI'YYW.\_/S"9Y21O0,)$0DUM13)YX(
M.[W3[NO3MWTP%VLMZ236Y$;(\(H$.&8:3.??8LQH0(D/'F$D)%RO$.2ZP85<
MG8,Z*^]][I\(.847G78[7S_=C:VF&3&>RI>MM$S8)`E6N%XFDF5O>=N!WH4R
MT.'K!6V>[DTGZ<Q(N>`\#LO%^EIV]#PB'2!J`Q61U,OX8'"8+K7@#+":6*ZL
MQZK?/NVV^]V%7JQ2_W[GZQWE?^;$3S&.2J6;CA+AT",%J]#(]I0P,7BG0R?3
M/<&*++RUV56K;GHIO"`=&-VSL[..[<U(/1%S+>>KJ"GBG4S%4R?M-!;T5RW@
M9&IBIM*(LXZQO9.295P^H>4O@HX2-RD=R7)ZTV,8NFM(`PUU.)9R2`3<(\OP
MH9O#I[W@@@2`D$T!F'.A;7:P;5EK%%$>B+0)&HVCSS,T'TB`K.O/#607+47#
MB!E5;-O,AID)T786@']$DIR`HAF)\:C#..MP8%&0-:QJ=\L79R*P]`I2"D,#
MA(B(2$UA["Z'8N=@9GF8;6L6L'@Q.VJK?!)L:Q6P4$Z/V2B&)]L:!2R$?5][
MC)Q'L`"9'[\]W-:8U*QJ5\*+S9R:_0NK@6NNJ9[?0M3*T`ZO%J*0U6I1+K3*
M]%KB^>$4_D-ME/'G?YHU2"(,Y:2][ZR+6)<>*^*/^`?[>SW,4^Z4Q,6Y%DGU
M&5<':SE?VIKA<R#8+C$SZ7<\(T0G\*RTN&'H&AC&X"F2XI#R(LNL&K?7<OL]
MEF#WC``%9D4,5KLW`/+&"0AZM2+LEP:@2H`63AP%M[!]"DD"3+'9#4AO/4(6
MOQ42`1I%Z3ZHB95J*(98S6Z8>%8)!,M'M^O[;M<;,<C*:5Q?/:E3Y3&A8DE&
M<HHY_<MJ/^#^)594C8+[G#/2R7T;#A>`W61V6<J#A[Q(.]5;H0;-O-@&SQIX
MCN,PQ'(^"L9TRFD`TP'7`\_N22F?W@M&/:+6(:W'Y$:U5T`UE6I@S,E%2\$H
ME=P`6P/8&TSE[YC%Y!/!YMDFO'4@RXG<P/4+P!DIR(I!>3D-3#5@@H058>I?
MOT2$*Z(@08X,RS"69H$V4(H44:O%XP;Q=0'$5"C*I-J\:N6B5#!*)#>PUH`5
MDI:,B7]'\80R:K;:ZR"64+@A>U.`+!6!<C(:<&J`,Q3\R=0_)HQ\%IK<4`Y[
M(YA?UB&JI',#];8`5$X0,I+00E2#5PV\'HD,[P3F`YA6?#.UK`-5)'`C])\"
M0D8",B+00D8#30UHVF,MO#]G@OE$JNMO,=7S=7#*2-SPO"LN#7,B_HT2(0T^
M-?!)BA./^*4X`>6[W'B<%?!(>)%E;G"H@<,#8>8;W3V6>OXH,5?8L^6>=5`J
MZ9P(=4\+"*6"D)6$\J(:O&IMBR>*?(O!\NNGLHU3H=^%S[MNL82Q%(`2"0TL
MAZI6[%.TJ%.[Z.U3NT"OTA]-T?U@@#]B6%COAG?*ZH*[OQ_<R1L:M'>N696C
MZR)UHUF[?M5@=^A"5CF46W"ZD=VCJ-5@O5]UJQS92CHWCK4J70UB6\VCA3UX
MQ:191>=&K-Z.O8'LL%]:KXC&E!4PK,_H`O7USM]=T:M4?H/SP9:X%5!OQ>M&
M>Z]%;@/X=P*\MP_BO4V0=_>''/4:T`\->G\?T/N;0.\=`/1^`_K.^]F*5.ZD
M=4.ZQ8ZV2=0'@J^0F-W$&P`L).)-`#9I]W!5B8J`W(;5#>]>=8DF8O<J3%2`
M6TWHAK)F::(![0#'<2J@VT3N!G";PSD-COL=TZD`L)+.C5RM0SL-9'N6!:L*
M#96$;M#J%@8;U`Z!6K%:4$VY`;=B:<"%6[,<W?HX5D6@E5"XD7(?SFHBZR#'
MM"K`VD3N1&ZK0UO_%SB^[ZQ?\)"VK%X$8:^!H&$DI$:\<#.,\SJ1Y%:9.^%9
M::O77I0R=@C3*FMI+T6=@`[9W\R[]=EPETB%1DZNMKG[H]WMM;MO]]8C?_W+
M=KH(_GD/==QWRNR.DY6U$U`;+V5Q*57&ESVTET)VU&;]YI8ZFF0\YL=._G#?
ML;,[0E;6_J%4<O]-G?'+I%SAVC^6UBZ]J:.$93%/BVMOC!I]HT:)/])+JJP>
M%ZUL]_2%ZMGH)1#23_:KY!,))T0F4Y2Y8.2/C93)!27)-5'GO@@QY;>:A"8C
M@QWQ1&FJ8V/%1RGBZ*)E;_XYIT#20AAZ)4Q.%RTM8R#GE#'S<3][3F@CR`_"
M?[3O\6.9_GUPI6U79*)OP2/27N)Q_:)A5T=\>[D847K$V?S>"NSFK-R")[$W
MT2S39@>#`\S4C[:XMX/%O:.T.%=N&<<3&)0P)LT:2HJ0*B7DW-1@5._=()*4
MF2Q1&-<[2SBZ\6[W5..(46V_L,T?R8N^9-"6L]9!LV*/SMI_,KY?L(1UJU;5
M%E52'*4]N=&6%@8Q6T;?(-;"W"WD)63FLD48AT_4_!@*<_.3$3\*?H,0E<^2
M:@C6^W@"AH^"`!3A4]?P_JXO/+IHN`;MQ9R0`?<_"YX]*1L`H\@P%WQ5G^7H
MK!T#.5&#[CM(UAXT@_Y>'-H=UU.^QGTO">`FB6^-*GA@/S''ZI7>U@[8S'&D
MMEX>9`#L*.5(?3+L]@[AE%W%'*E7!MULYJS,`NL$QVI);Y,E!8(CM62XP9!"
M_]'9\2CM^9+YI>"^,EO&_`ZRV'>$.XK5@QK9.8WD_$1ZFB+_\;&X(-U5P%&N
M5]/S"-EJ;RC4PHB<R4ZJ/,:AX$1C.3^T59/D0L*+E@?9E^HR8Y/:B';%8(BE
MOI]A&>*[NV$Q!$N[CR\"B3?C@HGI_#)6E!.E'O'+T,Q0YB2FADE*3"4.QY@1
MLZXWI71#`(EE'@CYC*5?S#X'E'ET_JI;_^CO4#/I'V6&,\L7K&;++5]V;BQG
MH8/FA\:S3R;EX5RW'O+1S)?$OXI-8DI0&4,,$W--L6^VN&"5%02S4JS6*R7;
M<O]M?',CY!06KR:4S9VCR<"U^UY-'HA'Z)-Y<<X==1G^-A[(+G<>E-P3/4CU
MR(=\+?*\]=`&@^;G)C<8HB'L62AFYD^WTMQ]19X($Y$A@_A6,3.G\F&!^61.
MY9<4D'85<72I?G5_9@-9#6(]$Y+^1?S/L5%[%"1+[=4%W19L^2%`(4ZF1-:V
M^B!67@J8;T?!%97$TT*J3,$APVHUR6^D/#I;'D@HGF`D!@&UL?=$+!S)0:+?
M(16-@E&LS4+/_)]IACBB&C,+6[IUQU/B<,!AQ*?C'@9]E+3^7)^M[<+*N_=:
MIOR(87O-H)GX`TC`/,;L$R$FY4#8Y0Z2U1_:]:3]].&_6I`FZ5.N'EU,U_59
MCBX]FU7U<L$YDG1*.6:F=1":LP]@4KK1S-8?:TOR;9GW6JOLO!%=]41R)BGY
MS`^/_P-02P$"'@,4````"`!6@@Y%X5)R-[!\``"C^P<`$0`8```````!````
MI($`````86=R>"TR,#$T,#8S,"YX;6Q55`4``Z09[5-U>`L``00E#@``!#D!
M``!02P$"'@,4````"`!6@@Y%XK`4<T,*``!WBP``%0`8```````!````I('[
M?```86=R>"TR,#$T,#8S,%]C86PN>&UL550%``.D&>U3=7@+``$$)0X```0Y
M`0``4$L!`AX#%`````@`5H(.1:%&GS(T)@``_*D"`!4`&````````0```*2!
MC8<``&%G<G@M,C`Q-#`V,S!?9&5F+GAM;%54!0`#I!GM4W5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`%:"#D7;H:/I3VX``":U!@`5`!@```````$```"D
M@1"N``!A9W)X+3(P,30P-C,P7VQA8BYX;6Q55`4``Z09[5-U>`L``00E#@``
M!#D!``!02P$"'@,4````"`!6@@Y%"%E&^BLZ``#2&00`%0`8```````!````
MI(&N'`$`86=R>"TR,#$T,#8S,%]P<F4N>&UL550%``.D&>U3=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`5H(.15IBK:28"@``:6L``!$`&````````0``
M`*2!*%<!`&%G<G@M,C`Q-#`V,S`N>'-D550%``.D&>U3=7@+``$$)0X```0Y
9`0``4$L%!@`````&``8`&@(```MB`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 659px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.85in;" border="0" cellspacing="0" cellpadding="0" width="659">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="61%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December&#160;31,<br />
2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">June&#160;30,<br />
2014</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Employee bonuses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">238,941</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">254,135</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">140,223</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.52%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">119,135</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total accrued liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">379,164</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">373,270</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
